’}”g‘åŠw‘åŠw‰@ zŠÂŠí“à‰È

’}”g‘åŠw‘åŠw‰@ zŠÂŠí“à‰È §305-8575‚‚­‚ÎŽs“V‰¤‘ä1-1-1 ’}”g‘åŠwˆãŠwŒn“314 TEL 029-853-3143 FAX 029-853-3143

TOP@„@zŠÂŠí“à‰È‚̏Љî@„@Œ¤‹†”­•\‹ÆÑi‘“àŒ¤‹†”­•\j

zŠÂŠí“à‰È‚̏Љî

Œ¤‹†”­•\‹ÆÑi‘“àŒ¤‹†”­•\j

ƒŒ´’˜A‘àE‰ðàE‘¼A’˜‘„@¡ ‰p•¶˜_•¶@¡ “ú–{Œê˜_•¶

ƒŠw‰ï”­•\A‚»‚Ì‘¼„@¡ ŠCŠOŒ¤‹†”­•\@¡ ‘“àŒ¤‹†”­•\

ƒŽGŽEV•·„



@‘“àŒ¤‹†”­•\


@2016”N“xi2016”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. äï@žÄƒCŠÖŒûK•vCŽRã@•¶C‘¾“cçqCŽÂ“cNrC˜ð“c@•qC’·’Jì’q–¾C‘“cŒc‘¾C’¬–ì@‹BC•–ØŒ’ŽuCŒÜ\—’@“sC–ìãº•F,ÂÀ˜a—². Š´õƒŠ[ƒh”²‹ŽŒã‚ÉŽc‘¶‚µ‚½ánæ҂̌o‰ßŠÏŽ@‚É’…—pŒ^œ×“®Ší‚ª—L—p‚Å‚ ‚Á‚½1—áF‘æ8‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi•Ÿ‰ªj2016,2
  2. í‰ªG˜aC’Ëȕۏ²C‹g“cŒ’‘¾˜YCÂÀ˜a—²C•ˆÀ–@”V. ŽOë•Ù–DkpŽž‚̃Šƒ“ƒOŠO‚ð’ʉ߂µ‚ĐSŽºƒŠ[ƒh‚ª‘}“ü‚³‚ꂽœ–¬«S–[×“®‚Ì1—áF‘æ8‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi•Ÿ‰ªj2016,2
  3. ”~’Á@–±CˆÀ“‡—Ç‹PŽqC¬›mŽqCk@‹±ˆêCŽÂ“cNrC•–ØŒ’ŽuCŒÜ\—’@“sCŠÖŒûK•vC–ìãº•FCÂÀ˜a—². ‰^‚ªˆ«‚¢‚Å‚Í‚·‚Ü‚³‚ê‚È‚¢A’ZŠúŠÔ‚Å3“x‚ÌMechanical Fracture‚ðŒoŒ±‚µ‚½ICDAž‚ÝŠ³ŽÒ‚ւ̑Ήž‚©‚瓾‚ç‚ꂽ’mŒ©F‘æ8‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi•Ÿ‰ªj2016,2
  4. Î’Ã’qŽq,ÂÀ˜a—². ’†’ö“xQRS•‚̐S•s‘SŠ³ŽÒ‚ɑ΂·‚éCRTŒø‰ÊF‘æ8‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi•Ÿ‰ªj2016,2
  5. ”~’Á@–±CˆÀ“‡—Ç‹PŽqC¬›mŽqCk@‹±ˆêC¬ìF“ñ˜YC•–ØŒ’ŽuCŒÜ\—’@“sCŠÖŒûK•vC–ìãº•FCÂÀ˜a—². ICDì“®‚É‚æ‚é‰^“]’âŽ~ŠúŠÔ’†‚É–Æ‹–•Û—¯i’âŽ~jŽè‘±‚«‚ð‚¹‚¸‚ÉŒð’ÊŽ–ŒÌ‚ð‹N‚±‚µ‚½1—áF‘æ8‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi•Ÿ‰ªj2016,2
  6. ŽRã@•¶C•–ØŒ’ŽuCäï@žÄƒCŽÂ“cNrC‘¾“cçqC˜ð“c@•qC’·’Jì’q–¾C‘“cŒc‘¾CŽRú±@_C’¬–ì@‹BCŒÜ\—’@“sCŠÖŒûK•vC’†–±’q•¶C¬ìF“ñ˜YC–ìãº•F,ÂÀ˜a—². MarshallÃ–¬“à‚ɐS–[ƒŠ[ƒh‚ð—¯’u‚µ‚½•s®–¬Œ´«‰EŽºS‹ØÇ‚Ì1—áF‘æ8‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi•Ÿ‰ªj2016,2
  7. •ž•”@ˆ¤,ˆäì¹K,ˆä“¡—tŽq,“à“c–õl,V‹G˜N,‰äÈŒ«Ži,‰|–{‹­Žu,¬ŠÖ@çŒ,˜ð“c@•q,ÂÀ˜a—². š‹‰º—U”­«S–[•p”‚ɑ΂µ‚ÄEmpirical‚É—¼‘¤”xÃ–¬Šu—£p‚ðŽ{s‚µ‚½ˆê—áF‘æ239‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2016,2
  8. ÂÀ˜a—². ‹³ˆçƒZƒbƒVƒ‡ƒ“FzŠÂŠíf—Âɂ¨‚¯‚éƒÖ3•s–O˜aŽ‰–bŽ_‚̉”\«F‘æ239‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2016,2
  9. Hiroaki Watabe, Akira Satoh, Tomoya Hoshi, Hidetaka Nishina, Yuichi Noguchi, Kazutaka Aonuma. Impact of Heterogeneous Enhancement Detected by Multidetector Computed Tomography on Microvascular Obstruction and Left Ventricular Remodeling after Acute Myocardial InfarctionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  10. Akihiko Nogami, Keita Masuda, Takeshi Machino, Yuki Komatsu, Shinya Kowase, Kenji Kurosaki, Ahmed Talib, Kenji Kuroki, Hiro Yamasaki, Miyako Igarashi, Yukio Sekiguchi, Kazutaka Aonuma. Mapping and Ablating Ventricular Fibrillation: Trigger Elimination and/or Substrate ModificationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  11. Yoshihisa Naruse, Hiroshi Tada, Kenji Kuroki, Takeshi Machino, Hiro Yamasaki, Miyako Igarashi, Yukio Sekiguchi, Akihiko Nogami, Kazutaka Aonuma. Radiofrequency Catheter Ablation of Persistent Atrial Fibrillation Improves Parameters of Sleep-Disordered BreathingF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  12. Yoshihiro Seo, Kazutaka Aonuma. Role of Echocardiography to Evaluate Dyssynchrony and Predict CRT ResponsesF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  13. Takeshi Mitsuhashi, Akihiko Shimizu, Yukio Sekiguchi, Nobuyuki Nishii, Hiroshi Furushima, Tetsuyuki Manaka, Hisashi Yokoshiki, Tsuyoshi Kamiyama, Takashi Nitta, Ken Okumura. From JCDTR Data to JID-CAD StudyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  14. Kazutaka Aonuma. SD and Ischemic CardiomyopathyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  15. Yoshihiro Seo, Kazutaka Aonuma. Right Ventricular Dysfunction Associated with Left-sided Heart FailureF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  16. Yukio Sekiguchi. Non-pharmacological Therapy for ICD Shock ReductionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  17. Kenji Kuroki, Akihiko Nogami, Miyako Igarashi, Yuki Komatsu, Shinya Kowase, Kenji Kurosaki, Eikou Sai, Yasutoshi Shinoda, Chihiro Ota, Fumi Yamagami, Tomoaki Hasegawa, Keita Masuda, Takeshi Machino, Dongzhu Xu, Hiro Yamasaki, Nobuyuki Murakoshi, Yukio Sekiguchi, Keisuke Kuga, Kazutaka Aonuma. Combined Use of Fast-Fourier Transform Analysis and Voltage Limit Adjustment to Detect True Critical Isthmuses of Ventricular Tachycardia CircuitF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  18. Miyako Igarashi, Akihiko Nogami, Kenji Kuroki, Yukio Sekiguchi, Kazutaka Aonuma. Bipolar Radiofrequency Catheter Ablation for Refractory Ventricular Arrhythmias with Deep Intramural OriginF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  19. Kazutaka Aonuma, Yoshihiro Seo.Cutting-Edge of Three Dimensional EchocardiographyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  20. Ken Okumura, Kazutaka Aonuma, Koichiro Kumagai, Kenzo Hirao, Koichi Inoue, Masaomi Kimura, Yasushi Miyauchi, Eiki Tsushima. Japanese Anti Coagulation Regimen Exploration in Atrial Fibrillation Catheter Ablation Registry (JACRE Registry): A Prospective Multicenter Observational StudyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  21. Hirofumi Tomiyama, Takahide Kohro, Yukihito Higashi, Bonpei Takase, Toru Suzuki, Tomoko Ishizu, Shinichiro Ueda, Tsutomu Yamazaki, Tomoo Furumoto, Kazuomi Kario, Teruo Inoue, Shinji Koba, Yasuhiko Takemoto, Takuzo Hano, Masataka Sata, Yutaka Ishibashi, Koichi Node, Koji Maemura, Yusuke Ohya, Taiji Furukawa, Hiroshi Itoh. Reliability of Endothelial Function Assessment Using a Semi-automated Device across Multiple Institutions and Establishment of Normal/Reference ValuesF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  22. Keita Masuda, Tomoko Ishizu, Kazutaka Aonuma, Koichiro Niwa, Shigeru Tateno. Increased Risk of Thromboembolic Events in Adult Congenital Heart Disease Patients with Atrial TachyarrhythmiasF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  23. Kazuko Tajiri, Yasuhiro Yasutomi, Kyoko Imanaka-Yoshida, Kazuhiro Matsuo, Yusuke Tsujimura, Michiaki Hiroe, Kazutaka Aonuma. Role of Effecter Memory CD4+ T Cells in Inflammatory Dilated Cardiomyopathy: Insights from Animal StudiesF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  24. Tomoko Ishizu, Yoshihiro Seo, Yoshie Harimura, Masayoshi Yamamoto, Kenichi Obara, Akinori Sugano, Haruhiko Higuchi, Tomifumi Nakatsukasa, Isao Nishi, Kazutaka Aonuma. Right Ventricular Dysfunction Dominant Subgroup among Heart Failure with Preserved Left Ventricular Ejection Fraction; Prospective Cohort ICAS-HF RegistryF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  25. Koichi Inoue, Yuji Murakawa, Akihiko Nogami, Morio Shoda, Shigeto Naito, Koichiro Kumagai, Yasushi Miyauchi, Teiichi Yamane, Norishige Morita, Ken Okumur. Risk Assessment of Complication from Atrial Fibrillation Ablation Procedure; Insight from Updated J-CARAFF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  26. Yuji Murakawa, Akihiko Nogami, Morio Shoda, Koichi Inoue, Shigeto Naitoh, Koichiro Kumagai, Yasushi Miyauchi, Teiichi Yamane, Norishige Morita, Ken Okumura. Pericardial Effusion during and Immediately after Catheter Ablation of Atrial Fibrillation: J-CARAF StudyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  27. Kazuo Matsumoto, Ken Okumura, Yoshinori Kobayashi, Akihiko Nogami. Safety and Efficacy of Cryoballoon Ablation for the Treatment of Paroxysmal AF: Results of Post-marketing Surveillance Prospective Study in JapanF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  28. Masahiro Toyama, Shigeyuki Watanabe, Yasuhisa Kuroda, Eiji Ojima, Yuta Oishi, Yumiko Muta, Hidetaka Suzuki, Kazutaka Aonuma. Intra-Stent Thrombus Early after Stent Implantation is Associated with Cytochrome P450 2C19 GenotypesF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  29. Miyako Igarashi, Kenji Kuroki, Takeshi Machino, Keita Masuda, Tomoaki Hasegawa, Eikou Sai, Satoshi Aita, Yasutoshi Shinoda, Chihiro Ota, Fumi Yamagami, Nobuyuki Murakoshi, Yukio Sekiguchi, Keisuke Kuga, Akihiko Nogami, Kazutaka Aonuma. Left Atrial 3D Anatomical Mapping Using Three Different Directional Views of CARTOSOUND can Easily Visualize Detailed Anatomy without CT IntegrationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  30. Koichi Inoue, Yuji Murakawa, Akihiko Nogami, Morio Shoda, Shigeto Naitoh, Koichiro Kumagai, Yasushi Miyauchi, Teiichi Yamane, Norishige Morita, Ken Okumura. Update of the Current Status of Atrial Fibrillation Ablation in JapanF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  31. Yuji Murakawa, Akihiko Nogami, Morio Shoda, Koichi Inoue, Shigeto Naitoh, Koichiro Kumagai, Yasushi Miyauchi, Teiichi Yamane, Norishige Morita, Ken Okumura. Is Chronic Hemodialysis a Predictor of Periprocedural Bleeding and Ischemic Complications in Patients Undergoing Catheter Ablation for Atrial Fibrillation-JCARAF StudyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  32. Yoko Ito, Miyako Igarashi, Tomoko Ishizu, Masayuki Igawa, Ai Hattori, Satoshi Aita, Eikou Sai, Kenji Kuroki, Yukio Sekiguchi, Akihiko Nogami, Kazutaka Aonuma. Predictors of Left Atrial Stunning Just after Electrical Cardioversion in the Patients with Atrial FibrillationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  33. Shunsuke Sakai, Akira Satoh, Satoki Gen, Shunsuke Maruta, Daiki Akiyama, Tomoya Hoshi, Kazutaka Aonuma. The Association between Serum Lipoprotein (a) and the Coronary Plaque Vulnerability in the Culprit Lesion Determined by Optical Coherence TomographyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  34. Kenji Kuroki, Akihiko Nogami, Miyako Igarashi, Komatsu Yuki, Shinya Kowase, Kenji Kurosaki, Eikou Sai, Satoshi Aita, Yasutoshi Shinoda, Chihiro Ota, Fumi Yamagami, Tomoaki Hasegawa, Keita Masuda, Takeshi Machino, Hiro Yamasaki, Dongzhu Xu, Nobuyuki Murakoshi, Yukio Sekiguchi, Kazutaka Aonuma. FFT Analysis can be Helpful to Detect the True Isthmuses That could not be Identified only by Voltage Limit AdjustmentF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  35. Miyako Igarashi, Akihiko Nogami, Kenji Kurosaki, Yuki Komatsu, Seiji Fukamizu, Itsuro Morishima, Kazuaki Kaitani, Takeshi Machino, Kenji Kuroki, Hiro Yamasaki, Yukio Sekiguchi, Keisuke Kuga, Kazutaka Aonuma. Radiofrequency Catheter Ablation of Ventricular Tachycardia in the Patients with Hypertrophic Cardiomyopathy and Apical Aneurysm: Characteristics, Results, and OutcomeF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  36. Yuichi Hanaki, Yuki Komatsu, Shinya Kowase, Kenji Kurosaki, Akihiko Nogami, Shota Ikeda, Takahiro Watanabe, Tomoyuki Fukuzawa, Shingo Tanaka, Hajime Aoki, Kazuhiko Yumoto. High-Density Pacemap-Guided Ablation of Ventricular Tachycardia in the Setting of Ischemic and Nonischemic CardiomyopathyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  37. Koichi Inoue, Yuji Murakawa, Akihiko Nogami, Morio Shoda, Shigeto Naito, Koichiro Kumagai, Yasushi Miyauchi, Teiichi Yamane, Norishige Morita, Ken Okumura. Current Status of Anti-thrombotic Therapy in Atrial Fibrillation Ablation Patients with Coronary Artery DiseaseF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  38. Akinori Sugano, Yoshihiro Seo, Tomoko Ishizu, Masayoshi Yamamoto, Yoshie Harimura, Isao Nishi, Hidetaka Nishina, Yuko Fumikura, Yuichi Noguchi, Kazutaka Aonuma. Incremental Value of ST-2 to Brain Natriuretic Peptide for Prediction of Prognosis in Patients with Acute Decompensated Heart FailureF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  39. Yoshiaki Yui, Yukio Sekiguchi, Kazuya Tateishi, Masakazu Kaneko, Tomohiko Harunari, Norihiro Kuroki, Daisuke Abe, Takao Yuba, Ko Suzuki, Toru Iwama, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Nobuyuki Murakoshi, Akira Satoh, Keisuke Kuga, Akihiko Nogami, Kazutaka Aonuma. The Characteristics of Recurrent Fatal Arrhythmias in the Patients with Vasospastic AnginaF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  40. Masayoshi Yamamoto, Yoshihiro Seo, Yu Yamada, Taishi Nakagawa, Tomofumi Nakatsukasa, Akinori Sugano, Yoshie Harimura, Tomoko Machino, Tomoko Ishizu, Kazutaka Aonuma. Effect of Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Outcomes in Japanese Patients with Type 2 Diabetes and Heart FailureF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  41. Kojiro Ogawa, Miyako Igarashi, Akinori Sugano, Yuki Kakefuda, Takeshi Machino, Kenji Kuroki, Hideaki Aihara, Yuko Fumikura, Hidetaka Nishina, Yukio Sekiguchi, Yuichi Noguchi, Akihiko Nogami, Kazutaka Aonuma, Impedance Cardiography is a Promising Tool to Optimize Atrioventricular and Interventricular Intervals of Cardiac Resynchronization Therapy DevicesF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  42. Takeshi Machin, Akihiko Nogami, Yukio Sekiguchi, Kenji Kuroki, Hiro Yamasaki, Miyako Igarashi, Dongzhu Xu, Nobuyuki Murakoshi, Shinya Kowase, Kenji Kurosaki, Kazutaka Aonuma. The Effect of Trigger Elimination in Patients with Inherited Ventricular FibrillationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  43. Yasutoshi Shinoda, Miyako Igarashi, Akihiko Nogami, Fumi Yamagami, Chihiro Ota, Satoshi Aita, Eikou Sai, Tomoaki Hasegawa, Keita Masuda, Takeshi Machino, Kenji Kuroki, Yukio Sekiguchi, Kazutaka Aonuma. Clinical Impact of Provocation Method Using Bolus Epinephrine for Radiofrequency Catheter Ablation of Idiopathic Premature Ventricular ContractionsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  44. Yuki Komatsu, Akihiko Nogami, Kenji Kurosaki, Keita Masuda, Itsuro Morishima, Tomoya Ozawa, Yuichi Hanaki, Shinya Kowase, Kazutaka Aonuma. Fascicular Ventricular Tachycardia Originating from Papillary Muscles: Purkinje Network Involvement in the Reentrant CircuitF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  45. Yoshiaki Yui, Akihiko Nogami, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Nobuyuki Murakoshi, Kazuya Tateishi, Masakazu Kaneko, Tomohiko Harunari, Norihiro Kuroki, Daisuke Abe, Takao Yuba, Ko Suzuki, Toru Iwama, Yukio Sekiguchi, Keisuke Kuga, Kazutaka Aonuma. Catheter Ablation of Idiopathic Ventricular Outflow Tract Arrhythmias with Non-RBBB and Non-LBBB Morphologies: Center Type of the Ventricular Outflow TractF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  46. Masayoshi Yamamoto, Yoshihiro Seo, Yu Yamada, Akinori Sugano, Yoshie Harimura, Tomoko Machino, Tomoko Ishizu, Kazutaka Aonuma. Mechanical Resynchronization by Cardiac Resynchronization Therapy Improve Left Ventricular Hemodynamics and Energy EfficiencyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  47. Yuu Yamada, Masayoshi Yamamoto, Daishi Nakagawa, Akinori Sugano, Yoshie Harimura, Tomoko Machino, Tomoko Ishizu, Yoshihiro Seo, Kazutaka Aonuma. Novel Method of Early Diastolic Intraventricular Pressure Gradients Measurements by Vector Flow Mapping; A Clinical Validation by Exercise Stress EchocardiographyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  48. Yoshihiro Seo, Tomoko Ishizu, Masayoshi Yamamoto, Tomoko Machino, Kazutaka Aonuma. Incremental Value of Speckle Tracking Echocardiography in a Scoring System to Predict CRT RespondersF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  49. Masayuki Kawabe, Akira Satoh, Tomoya Hoshi, Ikuo Yoshida, Masae Endoh, Kazutaka Aonuma. Impact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography AngiographF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  50. Miyako Igarashi, Yoshihiro Seo, Tomoko Ishizu, Kenji Kuroki, Takeshi Machino, Keita Masuda, Tomoaki Hasegawa, Satoshi Aita, Yasutoshi Shinoda, Eikou Sai, Chihiro Ota, Fumi Yamagami, Hiro Yamasaki, Yukio Sekiguchi, Akihiko Nogami, Kazutaka Aonuma. Left Atrial Conduction Time by 3D-Echocardiography in Patients with Atrial Fibrillation is a Novel Predictor of Recurrence after Catheter AblationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  51. Naoto Kawamatsu, Yoshihiro Seo, Yoshie Harimura, Tomoko Ishizu, Tomofumi Nakatsukasa, Seika Sai, Kimi Sato, Akinori Sugano, Akiko Atsumi, Masayoshi Yamamoto, Tomoko Machino, Daigo Hiraya, Isao Nishi, Kenichi Obara, Kazutaka Aonuma. Continuous Tolvaptan Treatment Improves Clinical Outcomes in Patients with Well-Controled Right-Sided Heart Congestion at DischargeF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  52. Yasutoshi Shinoda, Kenji Kuroki, Akihiko Nogami, Aya Yamagami, Chihiro Ota, Satoshi Aita, Eikou Sai, Tomoaki Hasegawa, Keita Masuda, Takeshi Machino, Miyako Igarashi, Yukio Sekiguchi, Kazutaka Aonuma. Clinical Features of Balloon Temperature Profiles Which Required Touch-up Catheter during Pulmonary Vein Isolation Using 2nd Generation CryoballoonF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  53. Noriko Iida, Yoshihiro Seo, Hideki Nakajima, Tomoko Machino, Masayoshi Yamamoto, Tomoko Ishizu, Yasushi Kawakami, Kazutaka Aonuma. Usefulness of the 3-Dimensional Echocardiography Derived Sphericity Index of Cross-Section of Inferior Vena Cava to Estimate Central Venous PressureF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  54. Tomoya Hoshi, Akira Satoh, Hiroaki Watabe, Daiki Akiyama, Kazutaka Aonuma. Vulnerable Coronary Plaque Assessed by Coronary Magnetic Resonance Imaging in Patients with Acute Coronary Syndrome and Stable Angina PatientsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  55. Satoki Gen, Akira Satoh, Hiroaki Watabe, Daiki Akiyama, Tomoya Hoshi, Kazutaka Aonuma. Association of Malondialdehyde-modified Low-density Lipoprotein Levels with Thin-cap Fibroatheromas Determined by Optical Coherence Tomography in Non-diabetic PatientsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  56. Hidetaka Suzuki, Shigeyuki Watanabe, Masahiro Toyama, Eiji Ojima, Yuta Oishi, Yumiko Muta, Yasuhisa Kuroda, Sachiko Kimura, Saiichi Uchida, Toshiyuki Ishimitsu, Kazutaka Aonuma. The Clinical Significance of Sharp ST-T Angle in Daily Medical PracticeF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  57. Daishi Nakagawa, Yoshihiro Seo, Yoshie Harimura, Tomoko Ishizu, Masayoshi Yamamoto, Akinori Sugano, Isao Nishi, Kazutaka Aonuma. The Role of Clinical Scenario to Predict Clinical Outcomes in Acute Decompensated Heart FailureF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  58. Jo Kato, Yuta Takayanagi, Rujie Qin, Arisa Nagamine, Kosuke Hayashi, Longmei Wu, Isao Nishi, Akira Koike, Kazutaka Aonuma. Exertional Alternations of the QRS Complex and Cardiopulmonary Indices in Patients with Cardiac Resynchronization TherapyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  59. Tomoko Machino, Yoshihiro Seo, Masayoshi Yamamoto, Tomoko Ishizu, Kenji Kuroki, Takeshi Machino, Yukio Sekiguchi, Akihiko Nogami, Kazutaka Aonuma. Intensive Rhythm Control Based on Catheter Ablation for Atrial Fibrillation Suppresses Adverse Cardiac Events in Patients with HFPEFF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  60. Yoshiaki Yui, Akihiko Nogami, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Nobuyuki Murakoshi, Kazuya Tateishi, Masakazu Kaneko, Tomohiko Harunari, Norihiro Kuroki, Daisuke Abe, Takao Yuba, Ko Suzuki, Toru Iwama, Yukio Sekiguchi, Keisuke Kuga, Kazutaka Aonuma. The Experience of Catheter Ablation and Device Therapy for Cardiomyopathy with Lamin A/C Mutations: Comparison with Sarcoidosis about Clinical FeatureF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  61. Kenji Kuroki, Akihiko Nogami, Tomoaki Hasegawa, Eikou Sai, Satoshi Aita, Yasutoshi Shinoda, Chihiro Ota, Fumi Yamagami, Keita Masuda, Takeshi Machino, Hiro Yamasaki, Dongzhu Xu, Miyako Igarashi, Nobuyuki Murakoshi, Yukio Sekiguchi, Kazutaka Aonuma. The Feasibility of Intracardiac Echo-guided Cryoballoon Ablation of Atrial FibrillationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  62. Eiji Ojima, Shigeyuki Watanabe, Masahiro Toyama, Yasuhisa Kuroda, Yuta Oishi, Yumiko Muta, Hidetaka Suzuki, Kazutaka Aonuma. Impact of Using Zilver PTX Stent on Endovascular Therapy for Femoropopliteal LesionsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  63. Toshihiro Nozato, Akira Satoh, Atsushi Sakakibara, Yoshinori Yoshida, Tetsuo Ohmi, Masakazu Ohno, Ryuichi Katoh, Yoshihide Takahashi, Hiroyuki Hikita, Atsushi Takahashi, Takashi Ashikaga, Yasuhiro Satoh, Mitsuaki Isobe. Endovascular Treatment Improves Cardiovascular Events through Canceling Pressure Gradient in the Patients with Aorto-iliac LesionsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  64. Tomoko Ishizu, Yoshihiro Seo, Yuu Yamada, Daishi Nakagawa, Masayoshi Yamamoto, Tomoko Machino, Kazutaka Aonuma. Right Ventricular Area Strain as the New Indicator for Right Ventricular Systolic FunctionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  65. Mitsuhiro Fukata, Eikou Sai, Kojiro Ogawa, Masayoshi Yamamoto, Kenji Kuroki, Miyako Igarashi, Yukio Sekiguchi, Tomoko Ishizu, Yoshihiro Seo, Koichi Akashi1, Toru Maruyama, Akihiko Nogami, Kazutaka Aonuma, Synchronized Left Ventricular Pacing in Relatively Narrow QRS PatientsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  66. Tomoko Machino, Yoshihiro Seo, Masayoshi Yamamoto, Tomoko Ishizu, Kazutaka Aonuma. Elimination of Atrial Fibrillation by Catheter Ablation Improves Annulus Dilated Mitral RegurgitationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  67. Yuta Oishi, Shigeyuki Watanabe, Masahiro Toyama, Eiji Ojima, Yumiko Muta, Hidetaka Suzuki, Yasuhisa Kuroda, Kazutaka Aonuma. Favorable and Unfavorable Vascular Responses Early after Second-Generation Drug Eluting Stent Implantation: An Optical Coherence Tomographic StudyF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  68. Eiji Ojima, Shigeyuki Watanabe, Masahiro Toyama, Yasuhisa Kuroda, Yuta Oishi, Yumiko Muta, Hidetaka Suzuki, Kazutaka Aonuma. Association with Vasa Vasorum and Lumen Area of the Coronary Artery Observed in Optical Coherence Tomography at One YearF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  69. Toru Adachi, Yasuhiro Yokoyama, Akira Kimata, Hiro Yamasaki, Akihiko Nogami, Kazutaka Aonuma. New Maneuver to Make Very Slow Pathway Apparent by Atrio-ventricular Simultaneous Pacing during Basic StimulationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  70. Akinori Sugano, Yoshihiro Seo, Tomoko Ishizu, Masayoshi Yamamoto, Yoshie Harimura, Isao Nishi, Hidetaka Nishina, Yuko Fumikura, Yuichi Noguchi, Kazutaka Aonuma. Hypoalbuminemia as a Poor Prognosticator in Heart Failure with Preserved Ejection FractionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  71. Masayoshi Yamamoto, Yoshihiro Seo, Tomoko Ishizu, Seika Sai, Kazutaka Aonuma. The Renal Arterial and Venous Doppler Flow Profile in Acute Renal Congestion; Validation by Small Animal ExperimentsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  72. Ahmed Talib, Akihiko Nogami, Yasutoshi Shinoda, Eikou Sai, Mitsuhiro Fukata, Yoshiaki Yui, Keita Masuda, Kenji Kuroki, Miyako Igarashi, Hiro Yamasaki, Yukio Sekiguchi, Kazutaka Aonuma.@Neurohormonal Modulation-guided Ablation: A Novel Step-wise Approach for Induction and Guiding Ablation of Idiopathic Ventricular ArrhythmiasF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  73. Yoshiaki Yui, Akihiko Nogami, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Nobuyuki Murakoshi, Kazuya Tateishi, Masakazu Kaneko, Tomohiko Harunari, Norihiro Kuroki, Daisuke Abe, Takao Yuba, Ko Suzuki, Toru Iwama, Yukio Sekiguchi, Keisuke Kuga, Kazutaka Aonuma. Catheter Ablation of Idiopathic Ventricular Arrhythmias Originated from Ventricular Septum near His-bundle: Electrophysiological Characteristics and Mid-term OutcomeF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  74. Daiki Akiyama, Akira Satoh, Shunsuke Maruta, Shunsuke Sakai, Daigo Hiraya, Masayuki Kawabe, Hiroaki Watabe, Tomoya Hoshi1, Daisuke Abe, Kazutaka Aonuma. Comparison of Safety between Warfarin and NOAC with Dual Antiplatelet Therapy after Percutaneous Coronary InterventionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  75. Taizo Kimura, Akira Satoh, Kazuko Tajiri, Satoshi Sakai, Toshimichi Yoshida, Michiaki Hiroe, Kyoko Imanaka, Kazutaka Aonuma.Tenascin-C Modulates Inflammaotion and Aggravate Ventricular Remodeling after Myocardial Infarction in Mice ModelF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  76. Shunsuke Maruta, Hiroaki Watabe, Daiki Akiyama, Tomoya Hoshi, Akira Satoh, Kazutaka Aonuma.Long-term Cardiovascular Outcomes in Patients with Collagen Disease Who Underwent Percutaneous Coronary InterventionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  77. Satoshi Sakai, Junya Honda, Hidekazu Maruyama, Taizo Kimura, Kazuko Tajiri, Satoshi Homma, Takashi Miyauchi, Kazutaka Aonuma.Involvement of the Peptidyl-Isomerase Pin1 to Development of Hypoxia-Induced Pulmonary HypertensionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  78. Hidekazu Maruyama, Satoshi Sakai, Celine Dewachter, Asmae Belhaj, Benoit Rondelet, Myriam Remmelink, Jean-Luc Vachiery, Kazutaka Aonuma, Robert Naeije, Laurence Dewachter.Distinct Pattern of Lysyl Oxidase Expression in Pulmonary Artery Smooth Muscle Cells from Pulmonary HypertensionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  79. Yumiko Muta, Shigeyuki Watanabe, Masahiro Toyama, Eiji Ojima, Yuta Oishi, Hidetaka Suzuki, Yasuhisa Kuroda, Sachiko Kimura, Seichi Uchida, Toshiyuki Ishimitsu, Kazutaka Aonuma.The Clinical Significance of Fragmented-Onset QRS in Daily Medical PracticeF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  80. Yoko Ito, Masayuki Igawa, Ai Hattori, Tsuyoshi Enomoto, Miyako Igarashi, Akihiko Nogami, Kazutaka Aonuma.What is the Useful Parameter for Effective Clinical Ablation in Atrial Fibrillation with Contact Force Catheter?F‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  81. Yuto Abe, Hiroaki Watabe, Satoki Gen, Daiki Akiyama, Tomoya Hoshi, Akira Satoh, Kazutaka Aonuma.The Association between In-Stent Yellow Plaque at Following up CAG and Future Cardiac Event in 2nd Generation Drug-Eluting StentF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  82. Satoshi Aita, Kenji Kuroki, Fumi Yamagami, Chihiro Ota, Yasutoshi Shinoda, Eikou Sai, Tomoaki Hasegawa, Keita Masuda, Hiro Yamasaki, Miyako Igarashi, Yukio Sekiguchi, Akihiko Nogami, Kazutaka Aonuma.The Predictive Impact of Plasma Natriuretic Peptides on Procedural Outcomes in Radiofrequency Ablation of Atrial FibrillationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  83. Kenji Kurosaki, Yuki Komatsu, Shinya Kowase, Yuichi Hanaki, Masayuki Hattori, Tsubasa Kanaya, Shota Ikeda, Takahiro Watanabe, Tomoyuki Fukuzawa, Shingo Tanaka, Hajime Aoki1, Kazuhiko Yumoto, Akihiko Nogami.Long-term Outcome Following Catheter Ablation of Macroreentrant Atrial Tachycardia after Mitral Valve Surgery via a Superior Transseptal ApproachF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  84. Masayuki Igawa, Ai Hattori, Yoko Ito, Yasuto Uchida, Hideo Nii, Kenji Wagatsuma, Tsuyoshi Enomoto, Susumu Koseki, Kazutaka Aonuma. Gastro-esophageal Injury after Atrial Fibrillation Ablation; The Impact of Esophageal Temperature MonitoringF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  85. Tomohiko Harunari, Yukio Sekiguchi, Yasutoshi Shinoda, Eikou Sai, Tomoaki Hasegawa, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Akihiko Nogami, Kazutaka Aonuma.Utility of a Femoral Snare Approach in Transvenous Lead ExtractionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  86. Yuto Abe, Kenji Kuroki, Fumi Yamagami, Chihiro Ota, Yasutoshi Shinoda, Satoshi Aita, Eikou Sai, Tomoaki Hasegawa, Keita Masuda, Takeshi Machino, Hiro Yamasaki, Miyako Igarashi, Yukio Sekiguchi, Akihiko Nogami, Kazutaka Aonuma.Intracardiac Echocardiography is a Useful Tool to Predict Difficulty to Block Cavotricuspid IsthmusF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  87. Fumi Yamagami, Tomoko Machino, Akihiko Nogami, Kazutaka Aonuma.Success of Pre-procedural Electrical Cardioversion Predicts Favorable Outcome of Catheter Ablation of Persistent Atrial FibrillationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  88. Haruhiko Higuchi, Takashi Fujiwara, Shunsuke Maruta, Yoko Endo, Rikako Yamauchi, Akihiro Suzuki, Yutaka Eki, Yoshihiro Seo, Shigeyuki Watanabe, Kazutaka Aonuma.To Maintain Positive Airway Pressure Ventilation is Valuable in Acute Cardiogenic Pulmonary Edema, Regardless of Severity of Sleep-disordered BreathingF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  89. Haruhiko Higuchi, Takashi Fujiwara, Shunsuke Maruta, Yoko Endo, Rikako Yamauchi, Akihiro Suzuki, Yutaka Eki, Yoshihiro Seo, Shigeyuki Watanabe, Kazutaka Aonuma.Clinical Benefit to Maintain Positive Airway Pressure Ventilation in the Management of Acute Cardiogenic Pulmonary EdemaF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  90. Satoshi Aita, Kenji Kuroki, Miyako Igarashi, Yukio Sekiguchi, Akihiko Nogami, Kazutaka Aonuma.Characteristics of Left Atrial Low Voltage Area in Persistent Atrial FibrillationF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  91. Nobuyuki Murakoshi, Dongzhu Xu, Chihiro Ueoka, Haruka Noguchi, Kazutaka Aonuma.Knockdown of Transcriptional Factor NRF-2 Exacerbates Cardiac Function in Myocardial InfarctionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  92. Toshihiro Nozato, Akira Satoh, Atsushi Sakakibara, Yoshinori Yoshida, Tetsuo Ohmi, Masakazu Ohno, Ryuichi Katoh, Yoshihide Takahashi, Hiroyuki Hikita, Atsushi Takahashi, Takashi Ashikaga, Yasuhiro Satoh, Mitsuaki Isobe.Pulse Pressure Has Predictive Value of Cardiovascular Events in the Patients with Aorto-iliac LesionsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  93. Yasufumi Nagata, Masaaki Takeuchi, Kyoko Otani, Masaki Izumo, Kengo Suzuki, Kimi Sato, Yoshihiro Seo, Tomoko Ishizu, Yoshihiro Akashi, Kazutaka Aonuma, Yutaka Otsuji.3D Strain in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection FractionF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  94. Hiroaki Watabe, Akira Satoh, Yui Takaiwa, Akinori Sugano, Yuki Kakefuda, Hideaki Aihara, Tomoya Hoshi, Yuko Fumikura, Hidetaka Nishina, Yuichi Noguchi, Kazutaka Aonuma.Segmental Extent of Hyperenhancement after Acute Myocardial Infarction Detected by Multidetector Computed Tomography Predicts Regional Functional ImprovementF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  95. Yuta Takayanagi, Osamu Nagayama, Arisa Nagamine, Rujie Qin, Longmei Wu, Jo Kato, Isao Nishi, Yuko Katoh, Takeshi Yamashita, Akira Koike, Kazutaka Aonuma.Clinical Significance of the Overshoot Phenomena of Respiratory Gas Indices during Recovery from Maximal Exercise TestingF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  96. Kosuke Hayashi, Jo Kato, Kenji Kunimitsu, Yuta Takayanagi, Rujie Qin, Arisa Nagamine, Longmei Wu, Isao Nishi, Akira Koike, Kazutaka Aonuma. Relation between End-tidal Oxygen Pressure during Cardiopulmonary Exercise Testing and the Severity of Heart Failure in Patients with Cardiac DiseaseF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  97. Arisa Nagamine, Osamu Nagayama, Yuta Takayanagi, Rujie Qin, Longmei Wu, Jo Kato, Isao Nishi, Yuko Katoh, Takeshi Yamashita, Akira Koike, Kazutaka Aonuma.The Reduction Rates of Ventilatory Equivalents during Incremental Exercise are Related to Cardiopulmonary Function in Cardiac PatientsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  98. Hideki Nakajima, Yoshihiro Seo, Noriko Iida, Masayoshi Yamamoto, Tomoko Machino, Tomoko Ishizu, Yasushi Kawakami, Kazutaka Aonuma.Tricuspid Valve Area as a Risk Factor of Worsening Tricuspid Regurgitation after CRT or ICD Devices ImplantationsF‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(å‘ä)3ŒŽ,2016
  99. ¼Œ³—C仁CÎ’Ã’qŽqC•yŽR”ŽŽjCìã@NCŽR‰È@ÍCFMDJŒ¤‹†ƒOƒ‹[ƒvFŒz“®–¬‹…•”“à’†–Œ•¡‡‘Ì‚Ì’áƒGƒR[‹P“x”ìŒú•a•Ï‚Ísmall Dense LDL‚ÆŠÖ˜A‚·‚éF‘æ1‰ñ“ú–{ŒŒŠÇ•s‘SŠw‰ïŠwpW‰ïi“Œ‹žj2016,4,17
  100. ’¬–ì’qŽqFIntensive Rhythm Control Based on Catheter Ablation for AF Suppresses Adverse Cardiac Events in Patients with HFPEF(ƒvƒ‰ƒNƒeƒBƒJƒ‹ƒZƒbƒVƒ‡ƒ“‚Q)F“ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4,22-4,24
  101. Î’Ã’qŽqF3D Speckle tracking ‚É‚æ‚éWPWÇŒóŒQ‚ÌŽûk“`”dƒ}ƒbƒsƒ“ƒO(ƒvƒ‰ƒNƒeƒBƒJƒ‹ƒZƒbƒVƒ‡ƒ“‚T)F“ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4,22-4,24
  102. £”ö—RLFCRT‚É‚¨‚¯‚éSƒGƒR[G¡Œã‚Ì“W–](ƒvƒ‰ƒNƒeƒBƒJƒ‹ƒZƒbƒVƒ‡ƒ“‚V)F“ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4
  103. ’¬–ì’qŽqFU40 Research Hypothesis and Design AwardFU40H-1 4ŽŸŒ³SƒGƒR[}–@‚É‚æ‚茟o‚µ‚½öÝ“I•Ù—֍d‰»‚Í“®–¬d‰»‚̐V‹K—\‘ªˆöŽq‚Å‚ ‚éF“ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4,22-4,24
  104. ’¬–ì’qŽqFPrognostic significance of novel diastolic dysfunction grade with gE/A<0.8,DcT>150,andE/E>13hin HEREFF“ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4
  105. ŽR“c@—DFVector Flow Mapping‚ð—p‚¢‚½Intraventricular Pressure Gradients‚̉^“®‚É‚æ‚é•Ï‰»‚ÌŒŸ“¢F“ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4
  106. ŽR–{¹—ǁFS‘ŸÄ“¯Šú—Ö@‚̍¶Žº“àŒŒ—¬“®‘Ô‚¨‚æ‚уGƒlƒ‹ƒM[Œø—¦‚Ö—^‚¦‚é‰e‹¿‚ÌŒŸ“¢F“ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4
  107. ’¬–ì’qŽqFElimination of Atrial Fibrillation by Catheter Ablation Improves Atrial Functional Mitral
  108. “ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4
  109. ’¬–ì’qŽqFThe impact of annulus calcification on aortic-mitral coupling assessed by 4D-echocardiographyF“ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4
  110. £”ö—RLFV‚½‚ȃ`ƒƒƒŒƒ“ƒW-LV‚©‚çRV‚Ü‚Åvolume‚Őf‚é-F“ú–{SƒGƒR[}Šw‰ï27‰ñŠwpW‰ïi‘åãj2016,4
  111. ‰Ô–Ø—TˆêC¬¼—YŽ÷C¬˜a£W–íC•èŒ’ŽiC–ìãº•FCÂÀ˜a—²D‘O•ÇS‹Ø[Ç‚É‚æ‚è“`“±’x‰„‚ð‚«‚½‚µ‚½¶‹r‘OŽ}—̈æPurkinje‘gD‚ðƒŠƒGƒ“ƒgƒŠ[‰ñ˜H‚Æ‚·‚éfascicular VT‚Ì1—áF‘æ46‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi‹à‘òj2016,5
  112. ‘“cŒc‘¾C–ìãº•FCŽRã@•¶C‘¾“cçqCŽÂ“cNrC˜ð“c@•qCäï@žÄƒC’·’Jì’q–¾C’¬–ì@‹BC•–ØŒ’ŽuCŒÜ\—’@“sCŽRú±@_CŠÖŒûK•vCÂÀ˜a—²DŒã“û“ª‹Ø‹ß–T‚ÌPurkinje–Ԃɉñ˜H‚̈ꕔ‚ð—L‚µA•p”ƒJƒCƒg‚Ì‘½—l«‚ª„Ž@‚³‚ꂽƒxƒ‰ƒpƒ~ƒ‹Š´Žó«“Á”­«SŽº•p”‚̈ꈟŒ^F‘æ46‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi‹à‘òj2016,5
  113. X“‡ˆí˜Y,X“cNO,‚–ØŒ’“Â,‹g“c˜H‰Á,‰iˆä”Žº,’–Ž”‰ÀO,Ž›“c˜aŽn,ŽÄ“c’¼‹I,“s’zˆêm,’؈ä‰p”V,–ìãº•FF’Ê“d‚É‚æ‚è•p”‚Ì’âŽ~‚𔺂킸–k¼Ž²‚©‚ç‰EŽ²‚Ömorphology‚̕ω»‚ð”F‚ß‚½ƒxƒ‰ƒpƒ~ƒ‹Š´Žó«“Ë”­«¶ŽºSŽº•p”‚Ì‚P—áF‘æ46‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi‹à‘òj2016,5
  114. ’†ì˜a–çCóì“N–çC›Œ´’m¹C“cŠÛ@Ÿ«C¼‘º‘‰ÀCŽR“àNÆCÂÀ˜a—²D‘½Ê‚ȐS“d}ŠŒ©‚ð’悵‚½“úƒŠƒGƒ“ƒgƒŠ[«SŽº“ñd‰ž“š•p”‚Ì1—áF‘æ46‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi‹à‘òj2016,5
  115. –Ø‘º‘׎O,²“¡–¾,“cK˜aŽq,Žðˆär,œA]“¹º,ÂÀ˜a—²,¡’†‹±ŽqFS•s‘S‚̐is‚ðCü‚·‚鉊Ç‚̐§ŒäˆöŽqF“ú–{S•s‘SŠw‰ï‘æ2‰ñ“ú–{S‹ØÇŒ¤‹†‰ïi¼–{j2016,5
  116. ŽR“c—D,£”ö—RO,’†ì‘åŽk,ŽR–{¹—Ç,’¬–ì’qŽq,Î’Ã’qŽq,ÂÀ˜a—²FDŽ_‹…«‘½”­ŒŒŠÇ‰Š«“÷‰èŽîÇ‚É•¹”­‚µ‚½LofflerS“à–Œ‰Š‚̈ê—áF“ú–{S•s‘SŠw‰ï‘æ2‰ñ“ú–{S‹ØÇŒ¤‹†‰ïi¼–{j2016,5
  117. ŽR–{¹—Ç,£”ö—RO,’¬–ì’qŽq,Î’Ã’qŽq,ÂÀ˜a—²FÇðÇƒŠƒXƒNF¶–[/¶SŽ¨•]‰¿‚©‚çÇðƒŠƒXƒN‚ª•]‰¿‚Å‚«‚é‚©FUltrasonic Week2016(‹ž“s)2016,5
  118. ŽR–{¹—Ç,£”ö—RO,’¬–ì’qŽq,Î’Ã’qŽq,ÂÀ˜a—²FVector Flow mapping‚ð—p‚¢‚½¶–[E¶Žº“àƒGƒlƒ‹ƒM[Œø—¦‚ÉŠÖ‚·‚錟“¢FUltrasonic Week2016(‹ž“s)2016,5
  119. Î’Ã’qŽq,£”ö—RO,’¬–ì’qŽq,ŽR–{¹—Ç,j‘º‰À],ÂÀ˜a—²FRight Ventricular Area Strain as the New Indicator for Global Right Ventricular Systolic FunctionFUltrasonic Week2016(‹ž“s)2016,5
  120. Î’Ã’qŽq,£”ö—RO,’¬–ì’qŽq,ŽR–{¹—Ç,‰|–{^”üF3ŽŸŒ³SƒGƒR[–@‚É‚æ‚éWPWÇŒóŒQ‚Ì•›“`“±˜H•”ˆÊf’fFUltrasonic Week2016(‹ž“s)2016,5
  121. Î’Ã’qŽq,£”ö—RO,ŽR–{¹—Ç,’¬–ì’qŽq,à_“c‰À]F‚—îŽÒ‚Ì‹S«¶ŽºƒŠƒ‚ƒfƒŠƒ“ƒO‚ƍ¶Žº—¬o˜H‹·óFUltrasonic Week2016(‹ž“s)2016,5
  122. ÂÀ˜a—²FS‘Ÿ“Ë‘RŽ€‚ɑ΂·‚é”ñ–ò•¨—Ö@gImpacts of trigger eliminations in VF surviveshF‘æ7‰ñŽ¸_Œ¤‹†‰ï(“Œ‹ž)2016,7,22
  123. ÂÀ˜a—²FS–[×“®‚𑨂¦‚È‚¨‚·`RŒŒðŽ¡—ÂƍR•s®–¬Ž¡—ÁF‘æ55‰ñ¶ŠU‹³ˆçu‰‰‰ï(ŽD–y)2016,7,24
  124. ¯@’q–ç,²“¡@–¾,“n•”_–¾,ŽR–{¹—Ç,Î’Ã’qŽq,£”ö—RL,ÂÀ˜a—²,‰|–{‰ÀŽ¡FdÇ‘å“®–¬•Ù‹·óÇ‚Æ•Ù—ÖŠg‘å‚ð”F‚ß‚½‘å“®–¬ˆêë•Ù‚̈ê—áF‘æ7‰ñ“ú–{ŒoƒJƒe[ƒeƒ‹S‘Ÿ•ÙŽ¡—Êw‰ïŠwpW‰ïJTVT2016(‘åã)2016,8
  125. ‘å’Øa–ç,Žðˆä@r,ŒIŽR˜aŽq,–Ø‘º‘׎O,–ìãº•F,–{ŠÔ@Šo,ÂÀ@˜a—².ŠÌ“à‘½”­ƒVƒƒƒ“ƒg‚É”º‚¤‚S”oó‘Ô‚ð’悵‚½ˆâ“`«oŒŒ«–э׌ŒŠÇŠg’£Ç‚É”º‚¤”x“®–¬«”x‚ŒŒˆ³Ç‚̈ê—áF‘æ241‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2016,9
  126. ŽRú±@_,ŠÖŒûK•v,ÂÀ˜a—²F’†“™“xQRS•‚ÌŠg‘å‚ð”F‚߂鍶‹rƒuƒƒbƒNÇ—á‚ɑ΂·‚éadaptive CRTƒAƒ‹ƒSƒŠƒYƒ€‚Ì—L—p«\adaptive CRT trialƒTƒu‰ðÍ\F‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(“Œ‹ž)2016,9
  127. £”ö—RL,ÂÀ˜a—²FS•s‘S‚ð’T‚邽‚ß‚Ì’´‰¹”g‚Ɛf‚邽‚ß‚Ì’´‰¹”gF‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(“Œ‹ž)2016,9
  128. ŽR–{¹—Ç,£”ö—RL,Î’Ã’qŽq,ÂÀ˜a—²FSƒTƒ‹ƒRƒCƒh[ƒVƒX‚ɑ΂·‚éCRT—Ö@‚Ì—LŒø«‚ÌŒŸ“¢FJ-CRT‚ÆSTART study‚©‚ç‚Ì’mŒ©F‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(“Œ‹ž)2016,9
  129. ›Á@¯‰Í,ŽR–{¹—Ç,Î’Ã’qŽq,£”ö—RL,ÂÀ˜a—²FS•s‘S‚É‚¨‚¯‚ét‹@”\‚Æ—\Œãiƒ|ƒXƒ^[jF‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(“Œ‹ž)2016,9
  130. ’†–±’q•¶,ŽR–{¹—Ç,j‘º‰À],Î’Ã’qŽq,£”ö—RL,ÂÀ˜a—²FHFpEFŠ³ŽÒ‚É‚¨‚¢‚Đt‹@”\‚ª—\Œã‚É—^‚¦‚é‰e‹¿‚ÌŒŸ“¢iƒ|ƒXƒ^[jF‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(“Œ‹ž)2016,9
  131. ŽR“c@—D,ŽR–{¹—Ç,’†ì‘åŽk,›–쏺Œ›,ûM“c‰À],’¬–ì’qŽq,Î’Ã’qŽq,£”ö—RL,ÂÀ˜a—²F‰^“®•‰‰×SƒGƒR[}ŒŸ¸‚É‚¨‚¯‚é,Vector Flow Mapping‚ð—p‚¢‚½Intraventricular Pressure Gradients‚Ì‘ª’èF‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(“Œ‹ž)2016,9
  132. ’†ì‘åŽk,£”ö—RL,›–쏺Œ›,ûM“c‰À],ŽR–{¹—Ç,Î’Ã’qŽq,ÂÀ˜a—²FS•s‘S‚̃^ƒCƒv‚É‚æ‚炸AƒNƒŠƒjƒJƒ‹ƒVƒiƒŠƒI‚R‚Í—\Œã•s—Ç‚Å‚ ‚éF‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(“Œ‹ž)2016,9
  133. ì¼’¼l,£”ö—RL,j‘º‰À],Î’Ã’qŽq,›Á@¯‰Í,²“¡Šó”ü,›–쏺Œ›,ŽR–{¹—Ç,•½’J‘åŒá,¼@Œ÷,¬Œ´Œ’ˆê,ÂÀ˜a—²F‘Þ‰@Œã‚àƒgƒ‹ƒoƒvƒ^ƒ““à•ž‚ðŒp‘±‚·‚邱‚Æ‚É‚æ‚è—\Œã‚ª‰ü‘P‚·‚éS•s‘S‚ƍ¡Œã‚̉ۑèF‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(“Œ‹ž)2016,9
  134. ÂÀ˜a—²F–«S•s‘SÅVŽ¡—Ð헪`CRT‚ðS•s‘Sˆã••s®–¬ˆã‚Ì—§ê‚©‚çÄl‚·‚é`•s®–¬ˆã‚Ì—§ê‚©‚çF‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽD–yj2016,10
  135. £”ö—RL,’¬–ì’qŽq,ŽR–{¹—Ç,Î’Ã’qŽq,ÂÀ˜a—²FHFpEF‚ɍ‡•¹‚µ‚½S–[×“®‚ւ̃Aƒvƒ[ƒ`F‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽD–yj2016,10
  136. £”ö—RL,ŽR–{¹—Ç,’¬–ì’qŽq,Î’Ã’qŽq,ÂÀ˜a—²F‰ES•s‘S‚É‚¨‚¯‚é’´‰¹”gŒŸ¸‚̐i•à‚ƐV‚½‚È•a‘Ô”cˆ¬‚Ö‚Ì’§íF‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽD–yj2016,10
  137. Akinori Sugano,Yoshihiro Seo,Tomoko@Ishizu,Masayoshi@Yamamoto,Yoshie@Hamada,Tomoko@Machino|Ohtsuka,Kenichi@Obara,Kimito Ishikawa,Kazutaka AonumaFThe Value of Galectin-3@and ST-2 for Prediction of Prognosis in Patients with Acute Decompensated Heart FailureF‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽD–yj2016,10
  138. Masayoshi@Yamamoto,Yoshihiro Seo,Yu Yamada,Taishi Nakagawa,Tomofumi Nakatsukasa,Akinori Sugano,Yoshie Hamada,Tomoko Machino,Tomoko Ishizu,Kazutaka AonumaFEffects of Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and DiabetesF‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽD–yj2016,10
  139. Akinori Sugano,Yoshihiro Seo,Tomoko Izhizu,Masayoshi Yamamoto,Yoshie Hamada-Harimura,Tomoko Macihno-Ohtsuka,Kenichi Obara,Kimito Ishikawa,Kazutaka AonumaFMineralocorticoid Receptor Autagonist in Heart Failure with Preserved Ejection FractionF‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽD–yj2016,10
  140. éŒËG‰À,‚–ì^—R”ü,–¼Žæ—˜Œb,ŽR–{¹—Ç,Î’Ã’qŽq,£”ö—RL,ÂÀ˜a—²FŽYåñS‹ØÇŠ³ŽÒ‚ɑ΂·‚éƒ`[ƒ€‚ł̗×{Žx‰‡F‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽD–yj2016,10
  141. Isao Nishi,Yoshihiro Seo,Tomoko Ishizu,Seika Sai,Masayoshi Yamamoto,Akinori Sugano,Kenichi Obara,Shoji Suzuki,Yoshie Hamada,Kazutaka AonumaFUtility of Nutritional Assessment Using Controlling Nutritional Status for Predicting Short-term Prognosis in Patients with Heart FailureF‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽD–yj2016,10
  142. ”щª—El,ŽR–{¹—Ç,ˆêŒË‹MŽq,’¬–ì’qŽq,Î’Ã’qŽq,£”ö—RL,ÂÀ˜a—²FˆêŽ_‰»’Y‘f’†“Å‚É‚æ‚éS‹ØáŠQ‚ÌŒŸo‚ɍ¶Žº’·Ž²•ûŒüƒXƒgƒŒƒCƒ“‚ª—L—p‚Å‚ ‚Á‚½ˆê—áF“ú–{’´‰¹”gˆãŠw‰ï‘æ28‰ñŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ï(“Œ‹ž)2016,10
  143. ˆêŒË‹MŽq,ŽR–{¹—Ç,”щª—El,’¬–ì’qŽq,Î’Ã’qŽq,£”ö—RL,ÂÀ˜a—²FRŒ‹Šj–ò‹y‚уXƒeƒƒCƒh‚Ì“Š—^‚ª‘tŒ÷‚µS–Œ”—£p‚É‚ÄŒy‰õ‚µ‚½Œ‹Šj«S–Œ‰Š‚̈ê—áF“ú–{’´‰¹”gˆãŠw‰ï‘æ28‰ñŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ï(“Œ‹ž)2016,10
  144. k@‹±ˆêCˆäâ‚Ü‚¢CX’J’‰¶C’¹‰H´Žu˜YCâŒ³—Y‰îCŽR–{ƒˆÌCˆÀ“‡—Ç‹PŽqC”~’Á@–±C’¬–ì@‹BC•–ØŒ’ŽuCŽRú±@_CŠÖŒûK•vC–ìãº•FCÂÀ˜a—²DCryoballoon ablationŒã‚ɍĔ­‚µ‚½”­ì«S–[×“®Š³ŽÒ‚ÌŒŸ“¢FƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  145. ¬ìF“ñ˜YCŽRú±@_Cm‰ÈG’C–ìŒû—SˆêC’¬–ì@‹BC•–ØŒ’ŽuCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²DL”Í‚È’á“dˆÊ—̈æ“à‚̃Gƒ“ƒgƒŠ‰ñ˜H‚ðthe Number Needed to Entrain(NNE)‚ð—p‚¢‚Ä•]‰¿‚µ“¾‚½1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  146. ˆä“¡—tŽqCˆäì¹KC–ìãº•FCÂÀ˜a—²D¶SŽ¨‚ð‹NŒ¹‚Æ‚·‚éS–[•p”‚ɑ΂µ¶SŽ¨“à‚̍đŠú•”ˆÊ‚Ö‚Ì’Ê“d‚Å•p”‚ðªŽ¡‚µ‚¦‚½1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  147. ’Ëȕۏ²C‹g“cŒ’‘¾˜YCí‰ªG˜aC—с@F“TC‘•{“c®–îC”nê‰ëŽqC”üè¹ŽqC’|ˆÀ–@”VC–ìãº•FCÂÀ˜a—²D–[ŽºÚ‡•”•p”‚ð‹^‚¤•¡”‚̏ŠŒ©‚ð”F‚ß‚½‚ªAŽ©‘R”­¶‚µ‚½ãŽ¿ŠúŠOŽûk‚ɑ΂·‚é•p”‚Ì”½‰ž‚©‚çslow/fast AVNRT‚Ɛf’f‚³‚ꂽ1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  148. äï@žÄƒCŽRú±@_C•ž•”@ˆ¤CŽRã@•¶CŽÂ“cNrCˆÀ’B@‹œC¬¼—YŽ÷C‘“cŒc‘¾C’¬–ì@‹BC•–ØŒ’ŽuCŽRú±@_CŠÖŒûK•vC–ìãº•FCÂÀ˜a—²DCombined Superior Transseptal Apporoach‚É‚æ‚é‘ž–X•ÙŒ`¬pŒã‚ɐ¶‚¶‚½Lower Loop ReentryŒ^‚̐S–[×“®‚ɑ΂·‚éƒAƒuƒŒ[ƒVƒ‡ƒ“FƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  149. ‘¾“cçqCŠÖŒûK•vC•–ØŒ’ŽuCŽRã@•¶CŽÂ“cNrC˜ð“c@•qCäï@žÄƒC’·’Jì’q–¾C’¬–ì@‹BCŽRú±@_C‘º‰zLsC–ìãº•FCÂÀ˜a—²DSŽºS“à–Œ‘¤‚©‚ç‚̃AƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚ésteam pop‚ðŒ_‹@‚ÉŠ¥“®–¬¶Žºá‘‚ð’悵‚½1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  150. ŽÂ“cNrC–ìãº•FCŽRã@•¶Cäï@žÄƒC•ž•”@ˆ¤CˆÀ’B@‹œC¬¼—YŽ÷C‘“cŒc‘¾C’¬–ì@‹BC•–ØŒ’ŽuCŽRú±@_CŠÖŒûK•vCÂÀ˜a—²D’†S‘ŸÃ–¬“à‚Ì“d‹É‚ðŽw•W‚Æ‚µ‚½‰EŽºS“à–Œ‘¤‚©‚ç‚̍‚Žü”g’Ê“d‚Å—}§‚³‚ꂽapi -@cal crux ventricular tachycardia‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  151. ’Ëȕۏ²C‹g“cŒ’‘¾˜YCí‰ªG˜aC—с@F“TC‘•{“c®–îC”nê‰ëŽqC”üè¹ŽqC’|ˆÀ–@”VC–ìãº•FCÂÀ˜a—²D”­ì«S–[×“®‚ª‹­‚­‹^‚í‚ê”xÃ–¬Šu—£p‚¤‚¡—\’肵‚½‚ªA‰E–[‹NŒ¹‚̏㎺ŠúŠOŽûk‚ɑ΂·‚éƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚è•p””­ì‚ð—}§‚Å‚«‚½1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  152. ‘“cŒc‘¾C•–ØŒ’ŽuCŽRã@•¶CŽÂ“cNrCäï@žÄƒC•ž•”@ˆ¤CˆÀ’B@‹œC¬¼—YŽ÷C’¬–ì@‹BCŽRú±@_CŠÖŒûK•vC–ìãº•FCÂÀ˜a—²D’ʏíŒ^S–[‘e“®‚Æ‚ÌŽ¯•Ê‚ª–â‘è‚Æ‚È‚Á‚½biatrial tachycardia‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  153. ’¹‰H´Žu˜YCk@‹±ˆêC‰ª“c’¼Ž÷C‹e’rᩈê˜YCŽÂ“cNrC–ìãº•FCŽRã@•¶Cäï@žÄƒC•ž•”@ˆ¤CˆÀ’B@‹œC¬¼—YŽ÷C‘“cŒc‘¾C’¬–ì@‹BC•–ØŒ’ŽuCŽRú±@_CŠÖŒûK•vCÂÀ˜a—²D’†S‘ŸÃ–¬“à‚Ì“d‹É‚ðŽw•W‚Æ‚µ‚½‰EŽºS“à–Œ‘¤‚©‚ç‚̍‚Žü”g’Ê“d‚Å—}§‚³‚ꂽapi -@cal crux ventricular tachycardia‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  154. ŽÂ“cNrC–ìãº•FCŽRã@•¶Cäï@žÄƒC•ž•”@ˆ¤CˆÀ’B@‹œC¬¼—YŽ÷C‘“cŒc‘¾C’¬–ì@‹BC•–ØŒ’ŽuCŽRú±@_CŠÖŒûK•vCÂÀ˜a—²D’†S‘ŸÃ–¬“à‚Ì“d‹É‚ðŽw•W‚Æ‚µ‚½‰EŽºS“à–Œ‘¤‚©‚ç‚̍‚Žü”g’Ê“d‚Å—}§‚³‚ꂽapi -@cal crux ventricular tachycardia‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  155. ŽÂ“cNrC–ìãº•FCŽRã@•¶Cäï@žÄƒC•ž•”@ˆ¤CˆÀ’B@‹œC¬¼—YŽ÷C‘“cŒc‘¾C’¬–ì@‹BC•–ØŒ’ŽuCŽRú±@_CŠÖŒûK•vCÂÀ˜a—²D’†S‘ŸÃ–¬“à‚Ì“d‹É‚ðŽw•W‚Æ‚µ‚½‰EŽºS“à–Œ‘¤‚©‚ç‚̍‚Žü”g’Ê“d‚Å—}§‚³‚ꂽapi -@cal crux ventricular tachycardia‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ‰ªj2015,10
  156. ’·’Jì’q–¾CŠÖŒûK•vC–ìãº•FCÂÀ˜a—². ƒfƒoƒCƒXŠ´õÇ‚ɑ΂·‚郊[ƒh”²‹ŽŽž‚É”—£‘gD‚É‚æ‚Á‚Ä”xÇðÇ‚ð‡•¹‚µ‚½1Ç—áF‘æ9‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi‘åãj2017,2
  157. ’Ëȕۏ²C‹g“cŒ’‘¾˜YCí‰ªG˜aC—с@F“TC‘•{“c®–îC”nê‰ëŽqC”üè¹ŽqC’|ˆÀ–@”VC–ìãº•FCÂÀ˜a—². Œy“x‚̍¶ŽºŽûk•s‘S‚ð’æ‚·‚éS•s‘SŠ³ŽÒ‚ɐS‘ŸÄ“¯Šú—Ö@‚𓱓ü‚µ‚½‚Æ‚±‚ëAœ×“®’ïR«‚Å‚ ‚Á‚½’·ŠúŽ‘±«S–[×“®‚Ì“´’²—¦‰»‚ð‚¦‚ç‚ꂽ1—áF‘æ9‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi‘åãj2017,2
  158. ˆÉ“¡—tŽqCˆäì¹KC–ìãº•FCÂÀ˜a—². ‹¹•”‘å“®–¬áŽ‚ɑ΂·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}pŒã‚̃y[ƒXƒ[ƒJ[Až‚ݏp‚É’ˆÓ‚ð—v‚µ‚½1—áF‘æ9‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi‘åãj2017,2
  159. ”~’Á@–±CˆÀ“‡—Ç‹PŽqCk@‹±ˆêC•–ØŒ’ŽuCŽRú±@_CŠÖŒûK•vC–ìãº•FCÂÀ˜a—². Narrow QRS‚É‚ÄCRTAž‚ñ‚¾Š³ŽÒ‚ÌSuper Responder‚ð’æ‚·‚éŠm—¦‚ƁASuper Responder‚Ì—\‘ªˆöŽq‚ÌŒŸ“¢F‘æ9‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi‘åãj2017,2
  160. £”ö—RL. JCRT‚ÆSTARTŒ¤‹†‚©‚çCRT responder—\‘ª‚ðl‚¦‚éF‘æ9‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi‘åãj2017,2
  161. ŽRú±@_. Multi-Site pasingF‘æ9‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi‘åãj2017,2
  162. •–ØŒ’Žu. ‘å‹K–͗Տ°ŽŽŒ±Œ‹‰Ê‚ÆŒ»ó‚ɂ‚¢‚āF‘æ9‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi‘åãj2017,2
  163. £”ö—RL. CRT‚ÌAV/VVŽŠ“K‰»iÇ—á’ñŽ¦EƒRƒƒ“ƒe[ƒ^[jF‘æ9‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi‘åãj2017,2

@2015”N“xi2015”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. ’†–±’q•¶CÎ’Ã’qŽqCˆä“¡—tŽqC–{“cŸ«–çC•½’J‘¾ŒáCt¬’q•FCˆÀ’B@‹CŒÜ\—’@“sCŠÖŒûK•vC–ìãº•FC£”ö—RLCÂÀ˜a—²FLQT1‚ÉŽYåñS‹ØÇ‚ð‡•¹‚µAŽYŒãtorsade de pointes‚ɑ΂µ’…ˆßŒ^œ×“®Ší‚ƃƒLƒVƒŒƒ`ƒ“Ž¡—ª’˜Œø‚µ‚½‚P—áF‘æ235‰ñ@“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2015C2
  2. ŽÂ“cNrCŒÜ\—’@“sCäï@žÄƒCƒAƒnƒƒhƒ^ƒŠƒuC¬ìF“ñ˜YC[“cŒõŒhC‘“cŒc‘¾C–ûˆäŒcWC’¬–ì@‹BC•–ØŒ’ŽuCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²FƒAƒhƒŒƒiƒŠƒ“‚—e—Ê•‰‰×‚É‚æ‚èÄŒ»«‚ð‚à‚Á‚Ä—U”­‚³‚ꂽSŽºŽw“±‚ɑ΂µ‚ÄtriggerVPC‚ÆŽü•Ó‚ÌPurkinje network‚É’Ê“d‚ðs‚¢—}§‚µ‚¦‚½‚P—áF‘æ13‰ñ@“Á”­«SŽº×“®Œ¤‹†‰ïiJ-IVFSji“Œ‹žj2015C2
  3. ”~’Á@“wCˆÀ“‡—Ç‹PŽqC•ì‚Ý‚âŽqCk@‹±ˆêC¬ìF“ñ˜YCäï@‰hƒCŽÂ“cNrC[“cŒõŒhC•–ØŒ’ŽuCŒÜ\—’@“sCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²D’ZŠúŠÔ‚ÉFidelis ƒŠ[ƒh’füCƒoƒbƒeƒŠ[‚Ì‹}Œƒ‚Ȓቺ‚Æ2 “x‚ÌFracture ‚É‚æ‚éÄŽèp‚ÉŒ©•‘‚í‚ꂽÇ—á‚©‚ç”ð‚¯‚ç‚ê‚ÊMechanical Fracture‚̑Ήž‚ðl‚¦‚éF‘æ7‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2015,2
  4. ¬ìF“ñ˜YCŒÜ\—’@“sC’Ëȕۏ²C’†–±’q•¶C–{“cŸ«–çCƒ^ƒŠƒuƒAƒnƒƒhCŽÂ“cNrCäï@‰hƒC[“cŒõŒhC‘“cŒc‘¾C–ûˆäŒcWCˆÀ“‡—Ç‹PŽqC’¬–ì@‹BC•–ØŒ’ŽuC”~’Á@“wCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²DS‘ŸÄ“¯Šú—Ö@Œã‚ÌŽŠ“KAV‚¨‚æ‚ÑVV delay Ý’è‚É‚¨‚¯‚éimpedance cardiography‚Ì—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢F‘æ7‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2015,2
  5. [“cŒõŒhCŠÖŒûK•vC’Ëȕۏ²C•–ØŒ’ŽuC¬ìF“ñ˜YCŽR–{¹—ǁCÎ’Ã’qŽqC£”ö—RLC–ìãº•FCÂÀ˜a—²DS•s‘S‚̉ü‘P‚ɐSƒGƒR[î•ñ‚ðŠˆ—p‚µ‚½ƒŠ[ƒh”²‹Ž‚¨‚æ‚эđ}“üp‚ª—LŒø‚Å‚ ‚Á‚½ŽOë•Ù•Â½•s‘SÇ‚̏ǗáF‘æ7‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2015,2
  6. ˆÀ“‡—Ç‹PŽqC”~’Á@“wC•ì‚Ý‚âŽqCéŒËG‰ÀCk@‹±ˆêC•–ØŒ’ŽuCŒÜ\—’@“sCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²DŽ©“®ŽÔ–Æ‹–ˆÈŠO‚̉^“]C‘€ìŒn–Æ‹–Žæ“¾‚ɂ‚¢‚Ä‚Ì’²¸F‘æ7‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2015,2
  7. ˜ð“c@•qCˆäì¹KCŽÂ“cNrC‰|–{‹­ŽuCÂÀ˜a—²D¶Žº’P“ƃy[ƒVƒ“ƒOŽž‚ɐSŽº“à“`“±áŠQ‚É‚æ‚èSŽºƒCƒxƒ“ƒg‚̃_ƒuƒ‹ƒJƒEƒ“ƒg‚ð”F‚ß‚½1—áF‘æ7‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2015,2
  8. Hiroaki Watabe, kira Satoh, omoya Hoshi, Hidetaka Nishina, Yuichi Noguchi, Kazutaka AonumaFImpact of Heterogeneous Enhancement Detected by Multidetector Computed Tomography on Microvascular Obstruction and Left Ventricular Remodeling after Acute Myocardial InfarctionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  9. Akihiko NogamiFCatheter Ablation for Ventricular FibrillationsF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  10. Yukio Sekiguchi, Akihiko Nogami, Kazutaka AonumaFCatheter Ablation for Catecholaminergic Polymorphic Ventricular TachycardiaF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  11. Hiroshi Sohara, Tohru Ohe, Ken Okumura, Shigeto Naitoh, Kenzo Hirao, Morio Shoda, Youichi Kobayashi, Yasuteru Yamauchi, Atsushi Takahashi, Haruo Hirayama0, Yeong-Hwa Chun, Kengo Kusano, Yoshihisa Nakagawa, Kimikazu Banba, Satoki Fujii, Koichiro Kumagai, Hisashi Yoshida, Kazutaka AonumaFA Pivotal Study of Radiofrequency Hot Balloon Catheter (TSB-002C) for the Treatment of Paroxysmal Atrial FibrillationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  12. Yoshiaki Yui, Akihiko Nogami, Yukio Sekiguchi, Yasutoshi Shinoda, Eikou Sai, Ahmed Talib, Kojiro Ogawa, Mitsuhiro Fukata, Keita Masuda, Takeshi Machino, Kenji Kuroki, Hiro Yamasaki, Kentaro Yoshida, Miyako Igarashi, Keisuke Kuga, Kazutaka AonumaFCatheter Ablation of Idiopathic Ventricular Arrhythmias Originated from Ventricular Septum Near His-bundle: Electrophysiological Characteristics and Long-term OutcomeF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  13. Miyako Igarashi, Hiroshi Tada, Hiro Yamasaki, Yoshihiro Seo, Tomoko Ishizu, Kenji Kuroki, Takeshi Machino, Yukio Sekiguchi, Yuichi Noguchi, Akihiko Nogami, Kazutaka AonumaFFragmented-QRS after Receiving Cardiac Resynchronization Therapy was Associated with Ventricular Arrhythmias or Sudden Cardiac DeathF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  14. Satoshi Sakai, Taizo Kimura, Kazuko Tajiri, Hidekazu Maruyama, Junya Honda, Satoshi Honma, Takashi Miyauchi, Kazutaka AonumaFInhibition of RNA Polymerase II Activity by Myocardial FCP1 Overexpression Induces Severe Cardiac DysfunctionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  15. Koichi Inoue, Yuji Murakawa, Akihiko Nogami, Morio Shoda, Shigeto Naito, Koichiro Kumagai, Yasushi Miyauchi, Teiichi Yamane, Norishige Morita, Ken OkumuraFTrends of Atrial Fibrillation Ablation in Japan: More Intensive Ablation Performed with Less Fluoroscopy as a First-line TherapyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  16. Masayuki Kawabe, Akira Satoh, Tomoya Hoshi, Masae Endoh, Takumi Saitoh, Ikuo Yoshida, Kazutaka AonumaFIncremental Value of B-type Natriuretic Peptide for Detection and Risk Reclassification of Obstructive Coronary Artery Disease on Computed Tomography AngiographyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  17. Miyako Igarashi, Yoshihiro Seo, Tomoko Ishizu, Kenji Kuroki, Takeshi Machino, Yoshiaki Yui, Kojiro Ogawa, Yasutoshi Shinoda, Eikou Sai, Mitsuhiro Fukat, Keita Masuda, Ahmed Talib, Yukio Sekiguchi, Akihiko Nogami, Kazutaka AonumaFValidation Study of Left Atrial Conduction Time by 3D-Echocardiography in Patients with Atrial FibrillationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  18. Kimi Sato, Yoshihiro Seo, Tomoko Ishizu, Naoto Kawamatsu, Akinori Sugano, Akiko Atsumi, Masayoshi Yamamoto, Yoshie Harimura, Tomoko Machino, Yutaka Eki, Kazutaka AonumaFGlobal Circumferential Strain Predict Improvement of Left Ventricular Ejection Fraction after Aortic Valve Replacement in Patients with Severe Aortic StenosisF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  19. Daishi Nakagawa, Yoshie Harimura, Yoshihiro Seo, Tomoko Ishizu, Seika Sai, Kimi Sato, Daigo Hiraya, Akinori Sugano, Masayoshi Yamamoto, Ikuo Yoshida, Isao Nishi, Kenichi Obara, Kazutaka Aonuma FPeripheral Coldness Associates with Left Ventricular Functional Reserve in Patients with Heart Failure with Preserved Ejection FractionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  20. Kimi Sato, Yoshihiro Seo, Tomoko Ishizu, Yoko Endo, Rikako Yamauchi, Hidekazu Tsuneoka, Haruhiko Higuchi, Akihiro Suzuki, Yutaka Eki, Kazutaka Aonuma FSeasonal Variation in Heart Failure with Preserved Ejection Fraction: Association with Left Ventricular RemodelingF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  21. Kojiro Ogawa, Miyako Igarashi, Kenji Kuroki, Yasutoshi Shinoda, Ahmed Talib, Eikou Sai, Mitsuhiro Fukata, Keita Masud, Yoshiaki Yu, Takeshi Machino, Yukio Sekiguchi, Takeshi Inaba, Akihiko Nogami, Kazutaka AonumaFMagnetocardiograms is a Novel Non-invasive Method to Estimate the Reconnection between Left Atrium and Pulmonary Vein after Primary PV IsolationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  22. Tomoko Ishizu, Akiko Atsumi, Yoshihiro Seo, Akihiro Nakamura, Yoshiharu Enomoto, Yasushi Kawakami, Kazutaka AonumaFDifferential Right Ventricular Myocardial Response to Afterload Elevation or Beta-Blocker; Assessments Using 3D Speckle Tracking Echocardiography in Sheep HeartsF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  23. Akinori Sugano, Yoshihiro Seo, Naoto Kawamatsu, Kimi Sato, Seika Sai, Masayoshi Yamamoto, Yoshie Harimura, Hidetaka Nishina, Isao Nishi, Tomoko Ishizu, Yuko Fumikura, Yuichi Noguchi, Kazutaka AonumaFRelationship between Pentraxin 3 and Atrial Fibrillation in Patients Hospitalized for Heart Failure: From the ICAS-HF RegistryF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  24. Naoto Kawamatsu, Tomoko Ishizu, Akiko Atsumi, Akihiro Nakamura, Kimi Sato, Akinori Sugano, Masayoshi Yamamoto, Yoshie Harimura, Tomoko Machino, Ryo Kawamura, Yoshihiro Seo, Kazutaka AonumaFRV Function Might Have More Important Role in Subjective Symptoms of Heart Failure Patients Than LV Systolic FunctionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  25. Masao Yoshinaga, Hiromitsu Ogata, Hiroshi Suzuki, Hiroya Ushinohama, Naokata Sumitomo, Hitoshi Horigome, Shigeru Tateno, Kenji Hoshino, Mari Iwamoto, Junko Shiono, Seiichi Satoh, Yu Kucho, Nobuo Tauchi, Masami NagashimaFRisk Assessment of Pediatric Patients with Long QT Syndrome Who were Diagnosed by School-Based Screening Program in JapanF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  26. Daisuke Abe, Akira Satoh, Kazuya Tateishi, Tomohiko Harunari, Masakazu Kaneko, Norihiro Kuroki, Takao Yuba, Ko Suzuki, Tomoya Hoshi, Toru Iwama, Kazutaka AonumaFPrognostic Impact of CHA2DS2-VASc Score in Patients of ST-segment Elevation Myocardial InfarctionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  27. Naoto Kawamatsu, Tomoko Ishizu, Akiko Atsumi, Akihiro Nakamura, Kimi Sato, Akinori Sugano, Masayoshi Yamamoto, Yoshie Harimura, Tomoko Machino, Ryo Kawamura, Yoshihiro Seo, Kazutaka AonumaFExercise Tolerability of Dilated Cardiomyopathy Cases Might be Defined by Their Own Right Ventricular Systolic FunctionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  28. Hiroshi Ohara, Akira Takahara, Ken Kitahara, Nobuyuki Murakoshi, Akira Satoh, Kazutaka Aonuma, Takanori Ikeda, Atsushi SugiyamaFCharacterization of Antiarrhythmic Potential of Renal Denervation in the Chronic Atrioventricular Block Dogs: Comparison with That of AmiodaroneF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  29. Satoshi Aita, Yukio Sekiguchi, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Akihiko Nogami, Kazutaka AonumaPrognostic Factor for Maintenance of Sinus Rhythm after Radiofrequency Catheter Ablation of Atrial Fibrillation in Patients with Left Atrial DilationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  30. Shunsuke Sakai, Akira Satoh, Tomoya Hoshi, Daiki Akiyama, Shunsuke Maruta, Kazutaka AonumaFClinical Impact of a Newly Diagnosed Cancer in Patients with Acute Coronary Syndrome Undergoing Emergent Percutaneous Coronary InterventionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  31. Mitsuhiro Fukata, Yasutoshi Shinoda, Kojiro Ogawa, Eikou Sai, Ahmed Talib, Yoshiaki Yui, Keita Masuda, Kenji Kuroki, Takeshi Machino, Miyako Igarashi, Nobuyuki Murakoshi, Yukio Sekiguchi, Keisuke Kuga, Akihiko Nogami, Kazutaka AonumaFVariations in CRP before and after the Recurrence of Atrial Arrhythmias following Pulmonary Vein IsolationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  32. Taichi Hayashi, Satoshi Yamada, Masahiro Nakabachi, Hiroyuki Iwano, Mamoru Sakakibara, Kazunori Okada, Daisuke Murai, Hisao Nishino, Kenya Kusunose, Kiyotaka Watanabe, Tomoko Ishizu, Kazuaki Wakami, Hirotsugu Yamada, Kaoru Dohi, Yoshihiro Seo, Nobuyuki Ohte, Taisei Mikami, Hiroyuki TsutsuiFRatio of Transmitral E to Global Longitudinal Speckle-Strain Can Accurately Estimate Filling Pressure in Reduced and Preserved Ejection Fraction PatientsF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  33. Masahiro Nakabachi, Satoshi Yamada, Taichi Hayashi, Hiroyuki Iwano, Mamoru Sakakibara, Kazunori Okada, Hisao Nishino, Shinobu Yokoyama, Ayako Ichikawa, Daisuke Murai, Hirotsugu Yamada, Kaoru Dohi, Yoshihiro Seo, Nobuyuki Ohte, Mutsumi Nishida, Hitoshi Shibuya, Chikara Shimizu, Taisei Mikami, HiroyukiFTsutsui Effects of Hypertrophy on the Estimation of Left Ventricular Relaxation and Filling Pressure Using Tissue Doppler ImagingF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  34. 36.Toshihiro Nozato, Akira Satoh, Tetsuo Ohmi, Tasuku Yamamoto, Junichi Doi, Atsushi Sakakibara, Mayumi Masumura, Yoshinori Yoshida, Naoyuki Miwa, Sinsuke Iwai, Masakazu Ohno, Ryuichi Katoh, Yoshihide Takahashi, Hiroyuki Hikita, Atsushi Takahashi, Takashi Ashikaga, Yasuhiro Satoh, Mitsuaki IsobeFSystemic Blood Pressure Reduction and Improvement of Prognosis after Endovascular Treatment for the Peripheral Artery DiseaseF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  35. Yoshihiro Seo, Tomoko Ishizu, Noriko Iida, Masayoshi Yamamoto, Akira Koike, Kazutaka Aonuma FClinical and Prognostic Significance of Intra-Renal Hemodynamic Analysis in Congestive Heart FailureF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  36. Yusuke Kuroda, Shinsuke Yuasa, Yasuhide Watanabe, Tetsuhisa Hattori, Seiko Ohno, Toru Egashira, Tomohisa Seki, Shinichiro Okata, Atsushi Tanaka, Yoshiyasu Aizawa, Tomoyuki Suzuki, Mitsushige Murata, Takeshi Aiba, Naomasa Makita, Tetsushi Furukawa, Wataru Shimizu, Itsuo Kodama, Minoru Horie, Hitoshi Horigome, Kaichiro Kamiya, Keiichi FukudaDisease Modeling of Long-QT Syndrome Type 7 Using Patient-specific iPS CellsF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  37. Masaki Izumo, Masaaki Takeuchi, Yoshihiro Seo, Eiji Yamashita, Kengo Suzuki, Tomoko Ishizu, Kimi Sato, Shigeru Oshima, Kazutaka Aonuma, Yutaka Otsuji, Yoshihiro Akashi FPrognostic Value of Aortic Valve Area Flow Rate Ratio in Low-gradient Aortic Stenosis with Preserved Ejection Fraction: Japanese Multicenter StudyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  38. Yoshiyasu Aizawa, Masahito Sato, Seiko Ohno, Minoru Horie, Seiji Takatsuki, Keiichi Fukuda, Masaomi Chinushi, Tatsuya Usui, Kazutaka Aonuma, Yukio Hosaka, Haissaguerre Michel, Yoshifusa AizawaFCircadian Pattern of Ventricular Fibrillation in Patients with Non-Brugada-type Idiopathic Ventricular Fibrillation and Its Association with J WavesF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  39. Masayoshi Yamamoto, Tomoko Ishizu, Yoshimi Sudo, Naoto Kawamatsu, Kimi Sato, Seika Sai, Akinori Sugano, Akiko Atsumi, Dongzhu Xu, Nobuyuki Murakoshi, Yoshihiro Seo, Kazutaka Aonuma FTeneligliptin Prevent Myocardial Hypertrophy and Fibrosis in Dahl Salt-sensitive RatsF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  40. Keita Masuda, Akihiko Nogami, Yasutoshi Shinoda, Kojiro Ogawa, Eikou Sai, Mitsuhiro Fukata, Ahmed Talib, Yoshiaki Yui, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Yukio Sekiguchi, Kazutaka Aonum, Yuki Komatsu, Shinya Kowase, Kenji Kurosaki, Yutaro Nishi, Koichiro NiwaFShort- and Long-term Outcome after Ablation of Ventricular FibrillationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  41. Ahmed Talib, Akihiko Nogami, Masahiko Takagi, Shinya Kowase, Kenji Kurosaki, Makoto Nakano, Koji Fukuda, Yukio Sekiguchi, Kazutaka AonumaFFeasibility of Unrecognized Windows for Catheter Ablation of Ventricular Fibrillation in High-risk Brugada Syndrome (BrS)F‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  42. Ahmed Talib, Akihiko Nogami, Yasutoshi Shinoda, Eikou Sai, Kojiro Ogawa, Mitsuhiro Fukata, Yoshiaki Yui, Keita Masuda, Kenji Kuroki, Dongzhu Xu, Miyako Igarashi, Yukio Sekiguchi, Kazutaka AonumaFCombined Functional and Anatomical Approach for Channeling Old-myocardial Infarction Ventricular Tachycardia (OMI-VT)F‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  43. Yoshiaki Yui, Yukio Sekiguchi, Yasutoshi Shinoda, Eikou Sai, Ahmed Talib, Kojiro Ogawa, Takeshi Machino, Kenji Kuroki, Hiro Yamasaki, Kentaro Yoshida, Miyako Igarashi, Keisuke Kuga, Akihiko Nogami, Kazutaka AonumFInfluence of Bi-ventricular Pacing Beats Triggered by Fatal Ventricular Arrhythmias in the Patients Implanted Cardiac Resynchronization Therapy with DefibrillatorF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  44. Tomoya Hoshi, Akira Satoh, Yuki Kakefuda, Noriyuki Takeyasu, Yuichi Noguchi, Kazutaka AonumaFIncremental Value of SYNTAX Score for Predicting Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary InterventionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  45. Kojiro Ogawa, Miyako Igarashi, Yasutoshi Shinoda, Ahmed Talib, Eikou Sai, Keita Masuda, Yoshiaki Yui, Mitsuhiro Fukata, Takeshi Machino, Kenji Kuroki, Yukio Sekiguchi, Takeshi Inaba, Akihiko Nogami, Kazutaka AonumaFProlonged Frontward P-wave Duration on Magnetcardiogram is Associated with Atrial Recurrence after Successful Pulmonary Vein IsolationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  46. Kenji Kuroki, Akihiko Nogami, Ahmed Talib, Yoshihisa Naruse, Yoshiaki Yui, Takeshi Machino, Kojiro Ogawa, Eikou Sai, Mitsuhiro Fukata, Yasutoshi Shinoda, Keita Masuda, Toru Adachi, Yuuki Komatsu, Shinya Kowase, Kenji Kurosaki, Dongzhu Xu, Nobuyuki Murakoshi, Miyako Igarashi, Yukio Sekiguchi, Kazutaka AonumaFA Novel Three-Dimensional Substrate Map Using Fast-Fourier Transform of the Local Ventricular Signals in Patients with Postinfarction Ventricular TachycardiaF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  47. Tomofumi Nakatsukasa, Masayoshi Yamamoto, Yoshihiro Seo, Tomoko Ishizu, Yoshie Harimura, Akiko Atsumi, Tomoko Machino, Akinori Sugano, Kimi Satou, Naoto Kawamatsu, Kazutaka AonumaFComparison between Clinical Scenario and Pathophysiology in Patients with Acute Decompensated Heart Failure in JapanF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  48. Yoshihiro Seo, Akiko Atsumi, Tomoko Ishizu, Yoshiharu Enomoto, Naoto Kawamatsu, Akinori Sugano, Masayoshi Yamamoto, Tomoko Machino, Yoshie Harimura, Ryo Kawamura, Kazutaka AonumaFExperimental Validation Study for the Purpose-built 3-Dimensional Speckle Tracking Echocardiography System for Right VentricleF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  49. Tomoko Ishizu, Akiko Atsumi, Yoshihiro Seo, Akihiro Nakamura, Yumiko Tanaka, Yasushi Kawakami, Kazutaka AonumaFRight Ventricular Three-Dimensional Speckle Tracking Echocardiography; Comparison with Cardiac Magnetic Resonance ImagingF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  50. Yoshie Harimura, Yoshihiro Seo, Tomoko Ishizu, Daishi Nakagawa, Tomofumi Nakatsukasa, Seika Sai, Kimi Sato, Akinori Sugano, Daigo Hiraya, Masayoshi Yamamoto, Isao Nishi, Kenichi Obara, Kazutaka AonumaFBrain Natriuretic Peptide Levelin Heart Failure with Preserved Ejection Fraction Associates with Pulmonary Hypertension rather than Left Ventricular Diastolic PropertyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  51. Shunsuke Sakai, Tomoya Hoshi, Shunsuke Maruta, Daigo Hiraya, Daiki Akiyama, Akira Satoh, Kazutaka AonumaFImpact of Aspirin Alone Therapy in Patients with Grade 1 Neointimal Stent Coverage Observed by Coronary Angioscopy after Everolimus-Eluting StentF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  52. Yoshiaki Kato, Lisheng Lin, Miho Takahashi-Igari, Kuniomi Ogata, Akihiko Kandori, Akihiro Nakamura, Yoshihiro Nozaki, Hitoshi HorigomeFHeart Rate Variability Analysis Using Fetal Magnetocardiography Predicts Prognosis of Fetuses with Heart Failure Combined with Congenital Heart DiseaseF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  53. Takeshi Machino, Nobuyuki Murakoshi, Akira Satoh, Dongzhu Xu, Shunsuke Maruta, Tomoya Hoshi, Miyako Igarashi, Kentaro Setoyama, Ryozo Kamimura, Akihiko Nogami, Kazutaka AonumaFLate Recovery from Acute Attenuation of Blood Pressure Response to Electrical Renal Nerve Stimulation after the Renal DenervationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  54. Tomoko Machino, Yoshihiro Seo, Naoto Kawamatsu, Kimi Sato, Akinori Sugano, Akiko Atsumi, Masayoshi Yamamoto, Yoshie Harimura, Tomoko Ishizu, Kazutaka AonumaFDynamic 3-dimensional Echocardiographic Assessment of Mitral Valve Geometry in Patients with Mitral Regurgitation Caused by Lone Atrial FibrillationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  55. Yoshie Harimura, Yoshihiro Seo, Tomoko Ishizu, Daishi Nakagawa, Tomofumi Nakatsukasa, Seika Sai, Kimi Sato, Akinori Sugano, Daigo Hiraya, Masayoshi Yamamoto, Ikuo Yoshida, Isao Nishi, Kenichi Obara, Kazutaka AonumaFLeft Atrial Volume Index Predicts Frequent Hospitalization in Heart Failure with Preserved Ejection FractionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  56. Yasuaki Tsumagari, Akira Satoh, Tomoya Hoshi, Daiki Akiyama, Shunsuke Sakai, Shunsuke Maruta, Keita Masuda, Yasutoshi Shinoda, Toru Adachi, Kazutaka AonumaFClinical Characteristics of Vasospastic Angina Patients with Implantable Cardioverter-Defibrillator for Recurrent Lethal Ventricular ArrhythmiaF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  57. Kaoru Komuro, Kazuyuki Soutome, Noriko Yokoyama, Misaki Shibuya, Kyo Shimazu, Kazuki Kagami, Naonori Hirose, Teisuke Anzai, Kazuya Yonezawa, Tomoko Ishizu, Yoshihiro SeoFAssessments of Renal Congestion Induced Renal Perfusion Impairments in Patients with Congestive Heart Failure by Contrast-enhanced UltrasonographyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  58. Haruhiko Higuchi, Naoki Asahina, Kimi Sato, Yoko Endo, Rikako Yamauchi, Hidekazu Tsuneoka, Akihiro Suzuki, Yutaka Eki, Yoshihiro Seo, Shigeyuki Watanabe, Kazutaka AonumaFlinical Benefit of Non-Invasive Positive Pressure Ventilation and Adaptive Servo-Ventilation Combinational Method in Acute Heart Failure with Pulmonary EdemaF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  59. Masayoshi Yamamoto, Yoshihiro Seo, Naoto Kawamatsu, Kimi Sato, Akinori Sugano, Yoshie Harimura, Tomoko Ishizu, Kazutaka AonumaFElevated Central Venous Pressure by Echocardiography Associates with Increased Neurohumoral Activity and Renal Insufficiency in Acute Decompensated Heart FailureF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  60. Naoto Kawamatsu, Yoshihiro Seo, Yoshie Harimura, Seika Sa, Kimi Sato, Akinori Sugano, Akiko Atsumi, Masayoshi Yamamoto, Tomoko Machino, Isao Nishi, Tomoko Ishizu, Kazutaka AonumaFWorsening and Improving Renal Function among Ibaraki Cardiac Assessment Study Heart Failure RegistryF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  61. Tomohiko Harunari, Yukio Sekiguchi, Kojiro Ogawa, Mitsuhiro Fukata, Ahmed Talib, Kenji Kuroki, Miyako Igarashi, Akihiko Nogami, Kazutaka AonumaFThe Difficulty in Transvenous Lead Extraction of the Leads Cut Shortly at the Previous ProcedureF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  62. Akihiko Nogami FCatheter Ablation for Idiopathic Polymorphic Ventricular Tachycardia and Ventricular FibrillationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  63. Koichi Node, Junichi Oyama, Tomoko Ishizu, Mamoru Nanasato, Kazuhisa Kodama, Yasuko Bandoh, Haruo Kamiya, Kazuo Kitagawa, Shinichiro Ueda, Hirofumi Tomiyama, Masataka Sata, Koji Maemura, Munehide Matsuhisa, Teruo Inoue, Yukihito Higashi, Hirotsugu Yamada, Masaharu Ishihara, Akira Yamashina, Naoki Kashihara, Yasunori Sato, Toyoaki MuroharaFThe Study to Evaluate the Effects of DPP-4 Inhibitor on Atherosclerosis in Patients with Diabetes Mellitus: PROLOGUE StudyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  64. Akira Sato, Makoto Watanabe, Atsushi Hirayama, Nagara Tamaki, Hiroyuki Tsutsui, Toyoaki Murohara, Hisao Ogawa, Takashi Akasaka, Michihiro Yoshimura, Tadateru Takayama, Mamoru Sakakibara, Kenichi Ishigami, Susumu Suzuki, Kazutaka Aonuma, Yoshihiko SaitoFAssociation of Contrast-induced Nephropathy (CIN) with Risk of Adverse Clinical Outcomes in Patients with Cardiac Catheterization: From the CINC-J StudyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  65. Yuji Murakawa, Akihiko Nogami, Morio Shoda, Shigeto Naitoh, Koichi Inoue, Koichiro Kumagai, Yasushi Miyauchi, Teiichi Yamane, Norishige Morita, Ken OkumuraFDabigatran, Xa Inhibitors, and Warfarin as Periprocedural Oral Anticoagulation Therapy of Catheter Ablation for Atrial Fibrillation: J-CARAF StudyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  66. Takeshi Aiba, Hisaki Makimoto, Takeru Makiyama, Hiroshi Watanabe, Kenshi Hayashi, Yukiko Nakano, Hiroshi Morita, Kazutaka Aonuma, Nobuhisa Hagiwara, Keiichi Fukuda, Masao Yoshinaga, Hitoshi Horigome, Naokata Sumitomo, Toshihiro Tanaka, Akihiro Sekine, Shiro Kamakura, Yoshihiro Miyamoto, Kengo Kusano, Naomasa Makita, Minoru Horie, Wataru ShimizuFDiverse Gender Difference of Arrhythmic Risk in Patients with Congenital Long QT Syndrome: From Japanese Congenital LQTS Multicenter RegistryF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  67. Keita Masuda, Akihiko Nogami, Yasutoshi Shinoda, Kojiro Ogawa, Eikou Sai, Mitsuhiro Fukata, Ahmed Talib, Yoshiaki Yui, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Yukio Sekiguchi, Kazutaka Aonuma, Yuki Komatsu, Shinya Kowase, Kenji Kurosaki, Yutaro Nishi, Koichiro NiwaFVT Conversion after VF Storm Ablation in Patients with Ischemic Heart DiseaseF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  68. Kimi Sato, Yoshihiro Seo, Tomoko Ishizu, Haruhiko Higuchi, Hidekazu Tsuneoka, Yutaka Eki, Kazutaka AonumaFLeft Atrial Volume Index Associates with Left Ventricular Reveres Remodeling after Aortic Valve Replacement in Patients with Severe Aortic StenosisF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  69. Taisuke Ishikawa, Shinya Kowase, Kenji Kurosaki, Akihiko Nogami, Akinori Kimura, Takuro Arimura, Naomasa Makita, Yukiomi Tsuji, Daniel HarrellFA Novel Splicing Mutation in a Sarcomeric Gene MYPN Responsible for Familial Sick Sinus Syndrome Identified by Whole Exome SequencingF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  70. Dongzhu Xu, Nobuyuki Murakoshi, Keisuke Kuga, Taizo Kimura, Kazuko Tajiri, Akihiko Nogami, Kazutaka AonumaFXanthine Oxidase Inhibitor Febuxostat Prevents Atrial Fibrillation Susceptibility by Inhibition of Oxidative CaMKII in Dahl Salt-sensitive RatsF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  71. Yoko Ito, Miyako Igarashi, Tomoko Ishizu, Yoshiaki Yui, Koujiro Ogawa, Ahmed Talib, Takeshi Machino, Kenji Kuroki, Yukio Sekiguchi, Akihiko Nogami, Kazutaka AonumaFAtrial Stunning was Frequently Observed Just after Electrical Cardioversion in the Patients with Atrial Fibrillation: Who is More Susceptible?F‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  72. Yasutoshi Shinoda, Akihiko Nogami, Kenji Kuroki, Miyako Igarashi, Yukio Sekiguchi, Kojiro Ogawa, Eikou Sai, Ahmed Talib, Mitsuhiro Fukata, Keita Masuda, Yoshiaki Yui, Takeshi Machino, Kazutaka AonumaFChange of Signal-averaged ECG after Ablation is Useful for Predicting the Recurrence of Ventricular Tachycardia in Arrhythmogenic Right Ventricular CardiomyopathyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  73. Akira Kimata, Yukio Sekiguchi, Kojiro Ogawa, Ahmed Talib, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Akihiko Nogami, Kazutaka AonumaFThe Comparison of the Device Infection between the Patients with Systematic and Local Pocket InfectionF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  74. Kazuko Tajiri, Satoshi Sakai, Taizo Kimura, Tomoko Machino, Nobuyuki Murakoshi, Dongzhu Xu, Akira Satoh, Takashi Miyauchi, Kazutaka AonumaFProtective Role of Endothelin in Myocardial Inflammation: Experimental Studies Using an Endothelin Antagonist SB209670F‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  75. Hidekazu Maruyama, Celine Dewachter, Satoshi Sakai, Asmae Belhaj, Benoit Rondelet, Myriam Remmelink, Jean-Luc Vachiery, Robert Naeije, Laurence Dewachter FSource of Components of Elastic Lamina in Pulmonary ArteriesF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  76. Junya Honda, Taizo Kimura, Kazuko Tajiri, Hidekazu Maruyama, Dongzhu Xu, Nobuyuki Murakoshi, Satoshi Sakai, Takashi Miyauchi, Satoshi Honma, Kazutaka Aonum FThe Glucagon-Like Peptide-1 Receptor Agonist Improves Hypoxia Induced Pulmonary Hypertension in Mice ModelF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  77. Daiki Akiyama, Akira Satoh, Shunsuke Maruta, Shunsuke Sakai, Tomoya Hoshi, Kazutaka AonumaFRestenotic Lesion Characteristics of Drug-Eluting Stent Assessed by Optical Coherence Tomography and Coronary AngioscopyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  78. Eiji Ojima, Shigeyuki Watanabe, Masahiro Toyama, Yasuhisa Kuroda, Akira Sato, Kazutaka AonumaFTolvaptan Does not Worsen Renal Function in the Patient Who was Performed Cardiac CatheterizationF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  79. Satoshi Aita, Yukio Sekiguchi, Kenji Kuroki, Takeshi Machino, Miyako Igarashi, Akihiko Nogami, Kazutaka AonumaFCharacteristics and Efficacy of Radiofrequency Catheter Ablation for Symptomatic Atrial Premature ContractionsF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  80. Tomofumi Nakatsukasa, Yoshihiro Seo, Tomoko Ishizu, Yoshie Harimura, Kazutaka Kazutaka, Masayoshj Yamamoto, Akinori Sugano, Kimi Satou, Naoto Kawamatsu Clinical Significance of Sequential Evaluations of Left Ventricular Ejection Fraction During Hospitalizations for Acute Decompensated Heart FailureF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  81. Akinori Sugano, Yoshihiro Seo, Naoto Kawamatsu, Kimi Sato, Akiko Atsumi, Masayoshi Yamamoto, Yoshie Harimura, Tomoko Machino, Hidetaka Nishina, Tomoko Ishizu, Yuko Fumikura, Yuichi Noguchi, Kazutaka AonumaFSignificance of Global Longitudinal Strain in Assessing the Risk of Ventricular Arrhythmia in Patients with Hypertrophic CardiomyopathyF‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‘åã)4ŒŽ,2015
  82. £”ö—RLCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCÎ’Ã’qŽqC‰|–{‰ÀŽ¡C ÂÀ˜a—²DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð‰EŽº‚Ö‰ž—p‚·‚éF“ú–{’´‰¹”gˆãŠw‰ï@‘æ88‰ñŠwpW‰ïi“Œ‹žj2015, 5
  83. ˆ­”üˆÀ‹IŽqC£”ö—RLCŽR–{¹—ǁCÎ’Ã’qŽqC‰|–{‰ÀŽ¡C ÂÀ˜a—²D‰EŽº“®‘Ô‰ðÍ—p3ŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ÌŠJ”­‚Æ‚»‚̐M—Š«‚ÉŠÖ‚·‚錤‹†F“ú–{’´‰¹”gˆãŠw‰ï@‘æ88‰ñŠwpW‰ïi“Œ‹žj2015, 5
  84. “yŠò_‰îC ”’ŽR—S‹PC ŠÖŒûK•vC‹v‰ê, Œ\—SCÂÀ˜a—²C–{ŠÔ^lDƒvƒƒpƒtƒFƒmƒ“‚ÌTDM‚É‚¨‚¯‚éÌŒŒŽžŠÔ‚ÌŒŸ“¢F‘æ32‰ñ“ú–{TDMŠw‰ïEŠwp‘å‰ïi’·–ìj2015, 5
  85. ˆî—t@—, ŽR“àNÆ, ŠÖì‰ë—T, ŽR‰º@Žü, •½”ö—´•F, Šâˆä—Y‘å, rˆähŽj, ŽRŒûƒŽi, ¯Ži@‘, ì‰Š°“¹, ‹{è—ºˆê, ŽRŒû“O—Y, Œ´@M”Ž, ”~–{•üK, ‹{–{‹M—f, ”ö—с@“O, •½”öŒ©ŽO, ÂÀ˜a—², óì“N–çD–[ŽºŽOd“`“±˜H‚ð—L‚µA•p”’†‚ɐS–[“ñd‰ž“š‚ð”F‚ß‚½’ʏíŒ^–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[«•p”‚Ì1—áF‘æ45‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj2015, 5
  86. äï@žÄƒ, –ìãº•F, ƒ^ƒŠƒuƒAƒnƒƒh, ŽÂ“cNr, ¬ìF“ñ˜Y, ’·’Jì’q–¾, ‘“cŒc‘¾, –ûˆäŒcW, ’¬–ì@‹B, [“cŒõŒh, •–ØŒ’Žu, ŒÜ\—’@“s, ŠÖŒûK•v, ÂÀ˜a—²D‰ESŽº‚¨‚æ‚э¶SŽº‘¤‚Éexit‚ð—L‚·‚éŒã’†ŠuS‹Ø‘w“à‚Ì•p”‰ñ˜H‚ª„’肳‚ꂽ‰EŽºES•ÇS‹Ø[ÇŒãSŽº•p”‚̈ê—áF‘æ45‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj2015, 5
  87. “n•”_–¾CŒº“NŽ÷CHŽR‘åŽ÷C¯ ’q–çC ²“¡–¾C ÂÀ˜a—²D’x”­«CypherƒXƒeƒ“ƒg•ÂÇ‚ɑ΂·‚éPOBA‹y‚ÑDCBŽ¡—ÃŒã‚ÉŒŒŠÇ“à–Œ‚ðŒoŽž“I‚ÉŠÏŽ@‚µ“¾‚½ˆê—áF‘æ7‰ñŠÖ“ŒŒŒŠÇ“àŽ‹‹¾Œ¤‹†‰ïi“Œ‹žj2015C6
  88. ’Ëȕۏ²CHŽR‘åŽ÷C²“¡@–¾C¯@’q–çCŽðˆär‰îCŠÛ“cr‰îCÂÀ˜a—²D‘¢‰eÜƒAƒŒƒ‹ƒM[‚É‚æ‚éƒAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚É”º‚¢ˆŸ‹}«ƒXƒeƒ“ƒgŒŒðÇ‚𔭏ǂµ‚½ˆê—áF‘æ236‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2015, 6
  89. óì“N–ç, ’†ì˜a–ç, ›Œ´’m¹, “cŠÛ@Ÿ«, ¼‘º‘‰À, ŽR“àNÆ, ÂÀ˜a—²D¶–[Œã•ÇŠu—£pŒã‚É‹}«–ƒáƒ«ˆÝŠg’£‚ð‚«‚½‚µ‚½”­ì«S–[×“®‚Ì1—áF‘æ5‰ñŠÖ“ŒƒAƒuƒŒ[ƒVƒ‡ƒ“ƒtƒƒ“ƒeƒBƒAi“Œ‹žj2015, 6
  90. “cK˜aŽq, ¼”ö˜a_, œA]“¹º, •Û•xNG,ÂÀ˜a—², ¡’†‹±ŽqDˆâ“`Žq‘g‚ÝŠ·‚¦BCGƒVƒXƒeƒ€‚ð—p‚¢‚½V‚½‚È–«S‹Ø‰Šƒ}ƒEƒXƒ‚ƒfƒ‹‚ÌŠm—§F‘æ1‰ñ“ú–{S‹ØÇŒ¤‹†‰ïi“Œ‹žj2015, 7
  91. Akira Mizukami, Yuya Matsue, Yoshihisa Naruse, Shinya Kowase, Kenji Kurosaki, Makoto Suzuki, Akihiko Matsumura, Akihiko Nogami, Kazutaka Aonuma, Yuji HashimotoFImplication of Right Ventricular Septal Pacing on Long-term Prognosis and Heart Failure Hospitalization: A Propensity-matched Analysis FThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  92. Ahmed Talib, Akihiko Nogami, Kenji Kuroki, Miyako Igarashi, Yukio Sekiguchi, Kazutaka AonumaFNovel strategy of combined functional and anatomical approach for dechanneling old-myocardial infarction ventricular tachycardia (OMI-VT)FThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  93. Nobuyuki Murakoshi, Dong-Zhu Xu, Toshimi Sairenchi, Miyako Igarashi, Fujiko Irie, Takuji Tomizawa, Hiroyasu I so, Iwao Yamaguchi, Hitoshi Ota, Kazutaka AonumaFPrognostic impact ofsupraventricular arrhythmias: From the Ibaraki Prefectural Health Study (IPHS)FThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  94. Yukio Sekiguchi, Akihiko Nogami, Kazutaka AonumaFTreatment ofventricular arrhythmias in patients with sarcoidosisFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  95. Ai Hattori, Masayuki Igawa, Satoshi Aita, Tsuyoshi Enomoto, Kazutaka AonumaFVentricular Tachycardia in a patient with hyperkalemia and coved STsegment elevation in the inferior leadsFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  96. Dong-Zhu Xu, Nobuyuki Murakoshi, Taizou Kimura, Kazuko Tajiri, Akihiko Nogami,Kazutaka AonumaFXanthine oxidase inhibitor prevents atrial fibrillation susceptibility by inhibition ofoxidative CaMKII in Dahl salt-sensitive ratsFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  97. Yasuaki Tsumagari, Yukio Sekiguchi, Yasutoshi Shinoda, Kojiro Ogawa, Eiko Sai, Yoshiaki,Yui, Keita Masuda, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Akihiko Nogami, Kazutaka AonumaFEsophageal injury related to cryoablation in patients with paroxysmal atrial fibrillationFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  98. Akira Kimata, Kentaro Yoshida, Yoko I to, Masako Misaki, Masako Baba, Daigo Hiraya, Naoya Koda, Kazutaka Aonuma, Noriyuki TakeyasuFIntra-atrial Conduction Block after Multiple Ablation Procedures for Atrial Tachycardias in Patient Undergoing Mitral Valve PlastyFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  99. Yoshiaki Yui, Akihiko Nogami, Eiko Sai, Yasutoshi Shinoda, Ahemd Talib, Kojiro Ogawa,Mitsuhiro Fukada, Keita Masuda, Takeshi Machino, Kenji Kuroki, Miyako Igarashi, Yukio Sekiguchi, Kazutaka AonumaFEvaluation ofthe activation spread in patients with intraventricular conduction disturbance using 3D electro-anatomical map: Conduction block and conduction delay in the left ventricleFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  100. Masahiko Takagi, Yukio Sekiguchi, Yasuhiro Yokoyama, Naohiko Aihara, Masayasu Hiraoka, Kazutaka Aonuma, The Japan Idiopathic Ventricular Fibrillation Study (J-IVFS) InvestigatorsFThe prognostic value ofearly repolarization (ER) and ST-segment morphology following the ER in Brugada syndrome: Multicenter study in JapanFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  101. Kojiro Ogawa, Kenji Kuroki1, Yasutoshi Shinoda1, Eikou Sai1, Mitsuhiro Fukata1, Keita Masuda, Yoshiaki Yui, Takeshi Machino, Miyako Igarashi, Yukio Sekiguchi, Akihiko Nogami, Kazutaka Aonuma, Yuji MizokamiFRethink the purpose and effectiveness of prophylactic proton pump inhibition after pulmonary vein isolationFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  102. Akihiko NogamiFCatheter Ablation for Supraventricular Tachycardia after Fontan Surgery FThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  103. Miyako Igarashi, Akihiko Nogami, Yukio Sekiguchi, Kenji Kuroki, Hiro Yamasaki, Takeshi Machino, Yoshiaki Yui, Kojiro Ogawa, Yasutoshi Shinoda, Eikou Sai, Keita Masuda, Ahmed Talib, Nobuyuki Murakoshi, Keisuke Kuga, Kazutaka AonumaFThe QRS morphology pattern in V5R is a novel and simple parameter for differentiating the origin of idiopathic outflow tract ventricular arrhythmiasFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  104. Kenji Kuroki, Yukio Sekiguchi, Tomohiko Harunari, Mitsuhiro Fukata, Kojiro Ogawa,Yoshiaki Yui, Eikou Sai, Yasutoshi Shinoda, Takeshi Machino, Miyako Igarashi, Keisuke Kuga, Akihiko Nogami, Kazutaka AonumaFThe prevalence and clinical characteristics in the patients who underwent lead extraction using a femoral approachFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  105. Keita Masuda, Miyako Igarashi, Yasutoshi Shinoda, Kojiro Ogawa, Eikou Sai, Mitsutaka Fukata, Ahmed Talib, Yoshiaki Yui, Takeshi Machino, Kenji Kuroki, Yukio Sekiguchi, Akihiko Nogami, Kazutaka AonumaFImpact of CARTO Univu System on Radiation Exposure Time in Radiofrequency Catheter AblationFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  106. Miyako Igarashi, Kenji Kuroki, Takeshi Machino, Yoshiaki Yui, Kojiro Ogawa, Yasutoshi Shinoda, Eikou Sai, Mitsuhiro Fukata, Keita Masuda, Ahmed Talib, Yukio Sekiguchi, keisuke Kuga, Akihiko Nogami, Kazutaka AonumaFLeft Atrial 3D Anatomical Mapping Using Three Different Directional Views ofCARTOSOUND Can Easily Visualize Detailed Anatomy without CT IntegrationFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  107. Yoko Ito, Kentaro Yoshida, Akira Kimata, Naoya Koda, Daigo Hiraya, Masako Misaki, Kazutaka Aonuma, Noriyuki TakeyasuFThe efficacy of transesophageal echocardiography for the prevention of systemic embolization in the patients with atrial fibrillation taking Nonvitamin K antagonist oral anticoagulantsFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  108. Satoshi Aita, Kenji Kuroki, Miyako Igarashi, Yukio Sekiguchi, Akihiko Nogami, Kazutaka AonumaFPre-procedural plasma atrial natriuretic peptide level might be a predictive factor for the maintenance of sinus rhythm after radiofrequency catheter ablation of atrial fibrillationFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  109. Eikou Sai, Miyako Igarashi, Yasutoshi Shinoda, Kojiro Ogawa, Mitsuhiro Fukata, Ahmed Talib, Keita Masuda, Yoshiaki Yui, Takeshi Machino, Kenji Kuroki, Yukio Sekiguchi, Akihiko Nogami, Kazutaka AonumaFLong-term outcome ofthe patients with and without structural heart disease: Impact ofVT/VF induction on appropriate ICD therapy FThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  110. Tomoaki Hasegawa, Yukio Sekiguchi, Kojiro Ogawa, Mitsuhiro Fukata, Toru Adachi, Yasuhiro Yokoyama, Akihiko Nogami, Kazutaka AonumaFThe case of lead fracture of the Linox implantable cardiac defibrillator (ICD) leadFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  111. Yasutoshi Shinoda, Kenji Kuroki, Kojiro Ogawa, Eikou Sai, Mitsuhiro Fukata, Yoshiaki Yui, Takeshi Machino, Miyako Igarashi, Yukio Sekiguchi, Akihiko Nogami, Kazutaka AonumaFCatheter ablation of frequent ventricular premature complexes with left bundle-branch block morphology improve left ventricular function than right bundle-branch block morphologyFThe 30th annual Meeting of The Japanese Heart Rhythm Societyi‹ž“sj2015,7
  112. HŽR‘åŽ÷C²“¡@–¾CŠÛ“cr‰îCŽðˆär‰îC•½’J‘¾ŒáCì•Ó³”VC“n•”_–¾C¯@’q–çCˆÀ”{‘å•ãCÂÀ˜a—². Œo”ç“IŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚̍RŒŒð–ò3Ü•¹—p—Ö@Fƒ[ƒtƒ@ƒŠƒ“‚ƐV‹KR‹ÃŒÅ–ò‚Ì—L—p«‚¨‚æ‚шÀ‘S«”äŠrF‘æ62‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[i•ºŒÉj2015,8
  113. Î’Ã’qŽq,£”ö—RLC–x•ÄmŽuCŽR–{¹—ǁC’¬–ì’qŽqCÂÀ˜a—²DV‚µ‚¢‰EŽº3ŽŸŒ³ƒGƒR[ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚é‰EŽº‹ìo—¦‚ÌŒv‘ª¸“xF‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(‰¡•l)2015,9
  114. ¬“‡‰hŽ¡, ÂÀ˜a—²DTolvaptan does not Worsen Renal Function in the Patient Who was Performed Cardiac Catheterizationifollow up dataj, Especially DM patientF‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(‰¡•l)2015,9
  115. –´“c —T”üŽq,ÂÀ˜a—²DV1‚©‚çV3‚Ìnarrow r wave‚͉½‚ðŽ¦‚·‚©F‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(‰¡•l)2015,9
  116. ›–쏺Œ›,ÂÀ˜a—²DSTã¸Œ^S‹Ø[Ç‹}«Šú‚É‚¨‚¯‚é3ŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚éMicrovascular obstruction‚Ì—\‘ª‚ƍ¶ŽºƒŠƒ‚ƒfƒŠƒ“ƒO‚Æ‚ÌŠÖ˜AF‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(‰¡•l)2015,9,18-20
  117. £”ö—RL,ÂÀ˜a—²Dƒhƒvƒ‰–@‚ð—p‚¢‚½t“àŒŒs“®‘Ô•]‰¿‚̐S•s‘S‚É‚¨‚¯‚é—Տ°“IˆÓ‹`‚ɂ‚¢‚āF‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï(‰¡•l)2015,9
  118. •ž•”@ˆ¤, ¼@Œ÷, Œà@—´”~, ’†àV—zŽq, —é–؏ˎi, ÂÀ˜a—²D¶Žº’Ô–§‰»áŠQ‚ɍ‚‹P“x‹‘卶Žº“àŒŒð‚ð‡•¹‚µ‚½‚à‚̂̍R‹ÃŒÅ—Ö@‚É‚ÄŒŒðÄŽ¸‚µ‚½—áF‘æ237‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2015, 9
  119. ÂÀ˜a—²DS–[×“®‚𑨂¦’¼‚·F‘æ237‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2015,9
  120. ’Ëȕۏ², ‹g“cŒ’‘¾˜Y, í‰ªG˜a, ‘•{“c®–î, •½’J‘¾Œá, ”üè¹Žq, ÂÀ˜a—², •ˆÀ–@”VD‹ts«’x“`“±˜H‚̏oŒû‚ƐS–[•p”‚Ì‹NŒ¹‚ª‹ßÚ‚µ‚Ä‚¢‚½‚½‚߂ɐf’f‚É“ïa‚µ‚½S–[•p”‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  121. –Ø‘S@Œ[, ‰¡ŽR‘לA, ˆÀ’B@‹œ, VÀœAK, ’O‰HŒöˆê˜Y, ÂÀ˜a—²D¶–[’†Šu‚ÌContinuous Electrical Activity ‚ɑ΂·‚éƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚½”­ì«S–[×“®‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  122. ¬˜a£W–í, ‰Ô–Ø—Tˆê, ¬¼—YŽ÷, •èŒ’Ži, –ìãº•FDë‰s‚Ȑæs“dˆÊ‚ª1mm“d‹É‚ł̍‚–§“xƒ}ƒbƒsƒ“ƒO‚Å–¾‚ç‚©‚É‚È‚èƒAƒuƒŒ[ƒVƒ‡ƒ“‚ɐ¬Œ÷‚µ‚½”x“®–¬Š²‰EŽºÚ‡•”‹NŒ¹‚̐SŽº•p”‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  123. ‰Ô–Ø—Tˆê, ¬¼—YŽ÷, ¬˜a£W–í, •èŒ’Ži, –ìãº•FD‡–°Žž–³ŒÄ‹zÇŒóŒQ‚ÌŠÖ—^‚ª‹^‚í‚ꂽ“Á”­«SŽº×“®‚ɑ΂µƒGƒsƒlƒtƒŠƒ““Š—^‚É‚æ‚è—U”­‚³‚ê‚éƒgƒŠƒK[VPCƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚½1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  124. —с@—m‰î, V“c‡ˆê, Šâè@Ži, —›@ŠîèM, “n•ÓŒh‘¾, •½”ö—´•F, ˆî‘ºK—m, —é–؉ëm, ª–؁@Œª, —с@’BÆ, ²“¡@–¾, ‘å˜aP”Ž, ¼‘º@õ, ŸÇìŠì—T, —é–ØŒ’Ži, –ìãº•F, ‡‰®‰ë•F, •½”öŒ©ŽODBipolar ablation‚É‚æ‚莡—µ“¾‚½SŽº’†ŠuŠî•”‹NŒ¹SŽº•p”‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  125. •ž•”@ˆ¤, ˆäì¹K, ˆä“¡—tŽq, “à“c–õl, V‹G˜Y, ‰äÈŒ«Ži, ‰|–{‹­Žu, –ìãº•F, ÂÀ˜a—²DS–[×“®‚ƐS–[•p”‚ð’æ‚·‚é•¡”‚Ìthoracic vein tachycardia‚ɑ΂µƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  126. í‰ªG˜a, ‹g“cŒ’‘¾˜Y, ’Ëȕۏ², ‘•{“c®–î, •½’J‘¾Œá, ”üè¹Žq, ÂÀ˜a—², •ˆÀ–@”VF–«Š®‘S•ÂÇ•a•Ï‚ɑ΂·‚錌sÄŒšŒã‚ÉVF storm‚Æ‚È‚è, •¡”‰ñ‚ÌŒŒsÄŒš‚ƃAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Âɂæ‚Á‚Ä‹~–½‚µ“¾‚½Purkinje-related VF‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  127. –ûˆäŒcW, —é–؁@g, ŠâŠÔ@“O, ŽÂ“cNr, ‘\“c@•q, ¬ìF“ñ˜Y, äï@žÄƒ, ’·’Jì’q–¾, ‘“cŒc‘¾, ’¬–ì@‹B, •–ØŒšŽu, ‹g“cŒ’‘¾˜Y, ŒÜ\—’@“s, ŠÖŒûK•v, –ìãº•F, ÂÀ˜a—²DŠ¥óÃ–¬Œã‘¤Ž}‚Ö‘}“ü‚µ‚½2-Fr ‘½‹É“d‹ÉƒJƒe[ƒeƒ‹‚©‚ç‚̃}ƒbƒsƒ“ƒO‚ŐSŽº•p”‚̐SŠO–Œ‘¤critical isthmus‚𓯒肵‚¦‚½1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  128. ŽÂ“cNr, ŒÜ\—’@“s, ŽRã@•¶, ‘¾“cçq, äï@‰hƒ, ‰ï“c@•q, ’·’Jì’q–¾, ‘“cŒc‘¾, •–ØŒ’Žu, ’¬–ì@‹B, ŠÖŒûK•v, –ìãº•F, ÂÀ˜a—²D‰EŽº—¬o˜HSŠO–Œ‘¤ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚Á‚ăsƒ‹ƒWƒJƒCƒjƒh—U”­«‘O‹¹•”STã¸‚ƐSŽº×“®ƒXƒg[ƒ€‚ª—}§‚³‚ꂽ‰º‘¤•ÇJ”g‚𔺂¤ƒuƒ‹ƒKƒ_ÇŒóŒQ‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  129. •@Š°, “à“¡Ž l, —é–؍ؕäŽq, ‘å’ˉÀ–ž, ŒBàV‘å•ã, ´…@Šw, ŽRŒû—R–¾, ç‰ê’ʐ°, –î–ì—˜–¾, “쌒‘¾˜Y, ²X–ØŒ’l, ’†‘ºh‹K, ›ˆä‹`®, ŒF’J_Ži, ‘哇@–Î, –ìãº•FD‘m–X•Ù—Ö‹NŒ¹‚̐SŽº•p”‚¨‚æ‚э¶‘¤•›“`“±˜H‚ð‰î‚·‚éãŽº«•p”‚É‚æ‚è‰E‹rƒuƒƒbƒN, ‰º•ûŽ²Œ^‚Ì•¡”‚Ì•p”‚ð”F‚ߐf’f‚ª¢“ï‚Å‚ ‚Á‚½1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  130. ŠâˆäT‰î, ‚‹´—ljp, ŽR–{@—C, ‘‘º–ƒ—R”ü, ŽR‰º@Žü, “y‹~ˆê, åŒ´‰·Žu, –ì–{‰pŽk, ‹g“c‘P‹I, ™ŽR’m‘ã, ‹ß]“N¶, ‘å–쐳˜a, –ì—¢ŽõŽj, ²“¡NO, –ìãº•F, •½”öŒ©ŽO, ˆé•”ŒõÍDƒoƒCƒ|[ƒ‰[‚Žü”g’Ê“d‚É‚æ‚荪Ž¡‚µ‚½¶SŽº‘O‘¤•Ç‹NŒ¹”ñŽ‘±«SŽº•p”‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  131. óì“N–ç, ’†ì˜a–ç, ›Œ´’m¹, “cŠÛ@Ÿ«, ¼‘º‘‰À, ŽR“àNÆ, ÂÀ˜a—²D¶–[Œã•ÇŠu—£pŒã‚É‹}«–ƒáƒ«ˆÝŠg’£‚ð‚«‚½‚µ‚½”­ì«S–[×“®‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  132. ‘“cŒc‘¾, ŽÂ“cNr, ¬ìF“ñ˜Y, äï@žÄƒ, [“cŒõŒh, ƒ^ƒŠƒu ƒAƒnƒƒh, –ûˆäŒcW, ’¬–ì@‹B, •–ØŒ’Žu, ŒÜ\—’@“s, ŠÖŒûK•v, –ìãº•F, ÂÀ˜a—²DS–[’†ŠuúŽh‚É‚¨‚¯‚éŒëúŽh‚ɂ‚¢‚āFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  133. ’·’Jì’q–¾, •–ØŒ’Žu, ŽRã@•¶, ŽÂ“cNr, ˜ð“c@•q, äï@‰hƒ, ‘“cŒc‘¾, ’¬–ì@‹B, ŒÜ\—’@“s, ŠÖŒûK•v, –ìãº•F, ÂÀ˜a—²D‘¢‰eÜƒAƒŒƒ‹ƒM[‚Ì‚ ‚éS–[×“®Š³ŽÒ‚ɑ΂µCryoballoon‚¨‚æ‚Ñintracardiac echocardiographyiICEj‚ð—p‚¢‚Ä‘¢‰eÜ•sŽg—p‚ŃAƒuƒŒ[ƒVƒ‡ƒ“‚ð‚È‚µ‚¦‚½Ç—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  134. ‘“cŒc‘¾, –ìãº•F, ŽÂ“cNr, ¬ìF“ñ˜Y, äï@žÄƒ, [“cŒõŒh, ƒ^ƒŠƒu ƒAƒnƒƒh, –ûˆäŒcW, ’¬–ì@‹B, •–ØŒ’Žu, ŒÜ\—’@“s, ŠÖŒûK•v, ÂÀ˜a—²D‘åSÃ–¬‚Ì’†ŠuŽ}‚É‘}“ü‚µ‚½“d‹É‚É‚æ‚èf’f‚µ‚½’†Šu‹Ø‘w“àSŽºŠúŠOŽûk‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  135. ”~’Á@“w, ˆÀ“‡—Ç‹PŽq, ¬›mŽq, k@‹±ˆê, âŒ³—Y‰î, ’¹‰H½Žu˜Y, •–ØŒ’Žu, ŒÜ\—’@“s, ŠÖŒûK•v, –ìãº•F, ÂÀ˜a—²DCryo Balloon AblationiCBAj“±“ü‚©‚ç1 ”N‚ªŒo‰ß‚µŽè‹Z‚̉~n‰»‚ª}‚ꂽŒã‚ÌŒy’ÁÃ‰º‚Å‚ÌRadio FrequencyiRFjPVI ‚ÆCBA‚ÌŠ³ŽÒáu’É”äŠrFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  136. ‘¾“cçq, –ìãº•F, ŒÜ\—’@“s, •–ØŒ’Žu, ’¬–ì@‹B, ˆÀ•”—Il, ŽRã@•¶, ŽÂ“cNr, ‘\“c@•q, äï@žÄƒ, ’·’Jì’q–¾, ‘“cŒc‘¾, ŠÖŒûK•v, ÂÀ˜a—²DŽOë•Ù—ÖŒã•Ç‚É–[ŽºŒ‹ßrightward extension ‚ð—L‚·‚é”ñ’ʏíŒ^–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[•p”‚Ì1—áFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïi•Ÿ“‡j2015,10
  137. ŽR–{¹—Ç, £”ö—RL, ÂÀ˜a—²DSƒTƒ‹ƒRƒCƒh[ƒVƒX‚ɑ΂·‚éS‘ŸÄ“¯Šú—Ö@‚Ì—L—p«‚ÌŒŸ“¢@?J-CRT‚¨‚æ‚ÑSTART study‚©‚ç‚Ì’mŒ©?FEffects of Cardiac Resynchronization Therapy in Patients with Cardiac Sarcoidosis ~Insight from J-CRT Registry and START Study~F‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‘åãj2015,10
  138. £”ö—RL, ŽR–{¹—Ç, ›Á@¯‰Í, ’¬–ì’qŽq, Î’Ã’qŽq, ÂÀ˜a—²D–«S•s‘S‚É‚¨‚¯‚ét“àƒhƒvƒ‰ŒŒ—¬•]‰¿: t‚¤‚ÁŒŒ•]‰¿–@‚Æ‚µ‚Ä‚Ì—L—p«FIntra-Renal Doppler Profile in Chronic Heart Failure: A Link with Central Venous Pressure and Renal FunctionF‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‘åãj2015,10
  139. ’¬–ì’qŽq, £”ö—RL, ŽR–{¹—Ç, j‘º‰ÀŒb, Î’Ã’qŽq, ÂÀ˜a—²DƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚é“´’²—¥ˆÛŽ‚͐S–[×“®‚ð‡•¹‚µ‚½HFPEFÇ—á‚̐SƒCƒxƒ“ƒg‚ð—}§‚·‚éFIntensive Rhythm Control Based on Catheter Ablation for Atrial Fibrillation Suppresses Adverse Cardiac Events in Patients with HFPEFF‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‘åãj2015,10
  140. £”ö—RL, ŽR–{¹—Ç, ’¬–ì’qŽq, Î’Ã’qŽq, ÂÀ˜a—²Dæi“ISƒGƒR[‹Zp‚ðS•s‘Sƒ}ƒl[ƒWƒƒ“ƒg‚ÉŠˆ‚©‚·F‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‘åãj2015,10
  141. ’†ì‘åŽk, £”ö—RL, j‘º‰ÀŒb, ›–쏺Œ›, ŽR–{¹—Ç, Î’Ã’qŽq, ÂÀ˜a—²D––½—⊴‚Ì‚ ‚é‹}«”ñ‘㏞«S•s‘SŠ³ŽÒ‚É‚¨‚¯‚é—Տ°Œo‰ß‚Ì‘½—l«FDiversity of Clinical Courses in Patients with Acute Decompensated Heart Failure and ColdF‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‘åãj2015,10
  142. ŽR–{¹—Ç, Î’Ã’qŽq, ì¼’¼l, ²“¡Šó”ü, ›Á@¯‰Í, ›–쏺Œ›, ‹–@“ŒŸª, ‘º‰zLs, £”ö—RL, ÂÀ˜a—²DDPP-4‘jŠQ–ò‚͐S•s‘S‚É‚Æ‚Á‚Ä—L‰v‚©—LŠQ‚©@`S•s‘Sƒ‚ƒfƒ‹ƒ‰ƒbƒg‚ɑ΂·‚éƒeƒlƒŠƒOƒŠƒvƒ`ƒ“‚ÌŒø‰Ê‚ÌŒŸ“¢`FIs DPP-4 Inhibitor for Heart Failure Beneficial or Harmful? Research on Teneligliptin in Heart Failure Model RatsF‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‘åãj2015,10
  143. ŽR“c@—D, ŽR–{¹—Ç, ’†ì‘åŽk, ²“¡Šó”ü, ›–쏺Œ›, j‘º‰ÀŒb, ’¬–ì’qŽq, Î’Ã’qŽq, £”ö—RL, ÂÀ˜a—²D‹}«”ñ‘㏞«S•s‘S‚É‚¨‚¢‚ĐSƒGƒR[‚Å•]‰¿‚µ‚½’†SÃ–¬ˆ³ã¸‚͐_Œo‘̉tˆöŽqŠˆ«‰»‚Ɛt‹@”\áŠQ‚ÉŠÖ˜A‚·‚éFElevated Central Venous Pressure Estimated by Echocardiography Associates with Increased Neurohumoral Activity and Renal Insufficiency in Acute Decompensated Heart FailureF‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‘åãj2015,10
  144. ’†–±’q•¶, ŽR–{¹—Ç, j‘º‰ÀŒb, Î’Ã’qŽq, £”ö—RL, ÂÀ˜a—²D‹}«”ñ‘㏞«S•s‘S‚É‚¨‚¯‚éŒoŽž“I¶Žº‹ìo—¦•]‰¿‚̗Տ°“IˆÓ‹`FFClinical Significance of Sequential Evaluations of Left Ventricular Ejection Fraction during Hospitalizations for Acute Decompensated Heart FailureF‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‘åãj2015,10
  145. ’†–±’q•¶, Î’Ã’qŽq, ˆä“¡—tŽq, –{“cŸ«–ç, •½’J‘¾Œá, t¬’q•F, ˆÀ’B@‹, ŒÜ\—’@“s, ŠÖŒûK•v, –ìãº•F, £”ö—RL, ÂÀ˜a—²FLQT1‚ÉŽYåñS‹ØÇ‚ð‡•¹‚µAŽYŒãtorsade de pointes‚ɑ΂µ’…ˆßŒ^œ×“®Ší‚ƃƒLƒVƒŒƒ`ƒ“Ž¡—ª’˜Œø‚µ‚½‚P—áF‘æ238‰ñ@“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2015,12
  146. ‘¾“cçq, –ìãº•F, ŒÜ\—’@“s, •–ØŒ’Žu, ˆÀ•”—Il, ŽRã@•¶, ŽÂ“cNr, ˜ð“c@•q, äï@žÄƒ, ’·’Jì’q–¾, ‘“cŒc‘¾, ’¬–ì@‹B, ŠÖŒûK•v, ÂÀ˜a—². ŽOë•Ù—ÖŒã•Ç‚É–[ŽºŒ‹ßrightward extension‚ð—L‚·‚é”ñ’ʏíŒ^–[ŽºŒ‹ßƒGƒ“ƒgƒŠ[•p”‚̈ê—áF‘æ238‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2015,12
  147. –Ø‘º‘׎OC–{“cŸ«–çC“cK˜aŽqC‹–@“ŒŸªC‘º‰zLsCŽðˆä@rCÂÀ˜a—²DThe glucagon-like peptide-1 receptor agonist ameliorates hypoxia induced pulmonary hypertension in mice model.32nd Annual Meeting of the International society for Heart Researcch Japanese Sectioni_ŒËj2015,12
  148. Žðˆä@rC–Ø‘º‘׎OC“cK˜aŽqCŠÛŽRG˜aC–{“cŸ«–çC–{ŠÔ@ŠoC’¬–ì@‹BCÂÀ˜a—²DEstablishment of heart failure model by inhibition of RNA polymerase II activity. 32nd Annual Meeting of the International society for Heart Researcch Japanese Sectioni_ŒËj2015,12
  149. ’Ëȕۏ², •–ØŒ’Žu, ŽRã@•¶, ‘¾“cçq, ŽÂ“cNr, ˜ð“c@•q, äï@žÄƒ, ’·’Jì’q–¾, HŽR‘åŽ÷, ’¬–ì@‹B, ŽRú±@_, ŒÜ\—’@“s, Î’Ã’qŽq, ŠÖŒûK•v, £”ö—RL, –ìãº•F, ÂÀ˜a—². ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚èSŽº•p”‚ªƒRƒ“ƒgƒ[ƒ‹‚³‚ꂽœ×“®’ïR«Malignant bileaflet mitral prolapse syndrome@‚Ì1—áF‘æ62‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[i•ºŒÉj2015,12

@2014”N“xi2014”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. Žðˆär‰îC¯@’q–çC²“¡@–¾CÂÀ˜a—²D‹}«Š¥ÇŒóŒQ‚É‚¨‚¯‚鈫«Žîᇂ̐V‹KœëŠ³—¦‚Æ‚»‚̗Տ°“I“Á’¥.‘æ48‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žj2014, 1
  2. ŽR‰º@ŽüCŽR“àNÆC–ö‰º“Ö•FC²“¡O“TC‰Pˆä‰p—SCì‰Š°“¹C‹{è—ºˆêCŽRŒû“O—YCŒ´@M”ŽC”~–{•üKC‹{–{‹M—fC”ö—с@“OCÂÀ˜a—²C•½”öŒ©ŽOD–«Šú‚É”xÃ–¬¶–[ŠÔ‚̈ê•ûŒü«“`“±ƒuƒƒbƒN‚ð’悵A‚»‚Ì•]‰¿‚ª”ñ”xÃ–¬‹NŒ¹‚̐„‘ª‚É—L—p‚Å‚ ‚Á‚½”­ì«S–[×“®‚Ì1—áD ‘æ26‰ñ—Տ°•s®–¬Œ¤‹†‰ï(“Œ‹ž)@1ŒŽC2014
  3. —с@—mŽjC‘º“cL–΁C‹{“à–õŽjC—с@–¾ãàCŠâè—YŽ÷C—„ìŒ°ŽiC‚‹´Œ’‘¾CA’|r‰îC’؈äˆê•½C´…@ÂCV“c@—²Câ–{rˆê˜YC“¡ˆä³‘åCŒ÷“‚µ‚̂ԁCÂÀ˜a—²C—с@‰pŽçCŠÖ“c@ŠwDØœ•s”\‚ȐS‘ŸŽîᇂɊ֘A‚µ‚½SŽº•p”‚ðŠJ‹¹‰º“€Œ‹‹ÃŒÅ‚É‚æ‚è—}§‚µ‚¦‚½GorlinÇŒóŒQ‚Ì1—áF•a—Šw“IŒ©’n‚à“¥‚Ü‚¦‚Ä.‘æ26‰ñ—Տ°•s®–¬Œ¤‹†‰ï(“Œ‹ž)@1ŒŽC2014
  4. ì¼’¼lCÎ’Ã’qŽqCŒº@“NŽ÷C˜ð“c@•qC–Ø‘S@Œ[CŽðˆär‰îC²“¡Šó”üC›–쏺Œ›C‰Á“¡@õCì•Ó³”VC‹–@“ŒŸªC–Ø‘º‘׎OC£”ö—RLCÂÀ˜a—²CŒ´@—BŽjC‰|–{‰ÀŽ¡F‘å“®–¬•Ù’uŠ·pŒã•Ù•s‘S‚©‚çÄ’uŠ·p‚ð•K—v‚Æ‚µ‚½‚ªA–Ɖu—}§Ü‚É‚æ‚èŒo‰ß—ǍD‚Æ‚È‚Á‚½Ž©ŒÈ–Ɖu«‘å“®–¬‰ŠD‘æ231‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï(“Œ‹ž)@2ŒŽC2014
  5. ì¼’¼lC£”ö—RLC’†“‡‰pŽ÷C²“¡Šó”üC›–쏺Œ›Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqC’¬–ì@‹BCˆä“¡—tŽqC•–ØŒ’ŽuCŽRè@_Cì‘º@—´CŒÜ\—’@“sCŠÖŒûK•vCÎ’Ã’qŽqC–ìãº•FCÂÀ˜a—²Dƒy[ƒXƒ[ƒJ[‚Æ‹Nˆö«ŽOë•Ù‹t—¬Ç‚Ì—L•a—¦‚ƃŠƒXƒNƒtƒ@ƒNƒ^[A‚¨‚æ‚уŠ[ƒh—¯’uˆÊ’u‚ÆŽOë•Ù’ʉߕ”ˆÊ‚ɂ‚¢‚Ä‚ÌŒŸ“¢‘æ6‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïiL“‡j2014,2
  6. ¬ìF“ñ˜YC’†–±’q•¶C–{“cŸ«–çCƒ^ƒŠƒu@ƒAƒnƒƒhCt¬’q•FC•½’J‘¾ŒáCŽOŽ÷—TŽqCˆÀ’B@‹œCŽR–{¹—ǁCˆä“¡—tŽqC•–ØŒ’ŽuCŽRè@_CŒÜ\—’@“sCŠÖŒûK•vC£”ö—RLC–ìãº•FCÂÀ˜a—²DŠ¥ˆÞk‚É‚æ‚é’‹Œ«S‹Ø[Ç‚ð”wŒi‚Æ‚µ‚½’áS‹@”\Š³ŽÒ‚ɁAPMTERNRVASEAV Block‚Ì•¹”­‚É‚æ‚èAÝ’è‚É“ïa‚µ‚½1—á.‘æ6‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïiL“‡j2014,2
  7. ”~’Á@–±CˆÀ“‡—Ç‹PŽqC•ì‚Ý‚âŽqCk@‹±ˆêC“¡àVL‹gC¬ìœëF“ñ˜YC•–ØŒ’ŽuCŒÜ\—’@“sCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²D”_‘º’n‹æ‚ÌŽåH‚ðŽx‚¦‚éƒRƒCƒ“¸•Ä‹@Žg—p’†‚ÉICD‚̃I[ƒo[ƒZƒ“ƒVƒ“ƒO‚ð’悵AVF”FŽ¯‚³‚ꂽÇ—á‚©‚璍ˆÓŠ©‚·‚ׂ«‚©‚ðl‚¦‚é.‘æ6‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïiL“‡j2014,2
  8. ˜ð“c@•qCˆäì¹KC•ž•”@ˆ¤C‰|–{‹­ŽuDƒAƒuƒŒ[ƒVƒ‡ƒ“’ïR«‚ÌŒJ‚è•Ô‚·SŽº•p”‚ɑ΂µ‚āACRT‚𓱓ü‚µS•s‘S‚ƐSŽº•p”‚̃Rƒ“ƒgƒ[ƒ‹‚ª‰Â”\‚Å‚ ‚Á‚½Šg’£Œ^S‹ØÇ‚Ì1—á.‘æ6‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïiL“‡j2014,2
  9. •èŒ’ŽiC¬˜a£W–íCŽÂ“cNrCˆÀ¼@kC¬£‘ãŽm‹vCì‰zƒŽuC–ìãº•FDŠ¥ˆÞk«‹·SÇ‚É”º‚¤SŽº×“®‚ɑ΂·‚éICDAž‚Ý‚©‚甼”NŒã‚ɐS”x’âŽ~‚Å‹~‹}”À‘—‚³‚ꂽ1—á.‘æ6‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïiL“‡j2014,2
  10. ˆÀ“‡—Ç‹PŽqC”~’Á@–±C•ì‚Ý‚âŽqCk@‹±ˆêC“¡àVL‹gC¬ìF“ñ˜YC•–ØŒ’ŽuCŒÜ\—’@“sCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²DICD‚Ì•p‰ñƒVƒ‡ƒbƒNŽ¡—ÂðŒoŒ±‚µ‚½CPVT‚Ì1Ç—á.‘æ6‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïiL“‡j2014,2
  11. Seo Y ,Ishizu T , Aonuma KFThree-Dimensional Echocardiographic Propagation Imaging of Left Ventricular Activation Based on Electro-Mechanical Coupling to Predict Responses for Cardiac Resynchronization Therapy.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  12. Masuda K ,Asano T , Mizuno A, Shirai T , Niinuma H , Nishi Y , Niwa K , Aonuma KFCombination Therapy of Arrhythmia in Adult Congenital Heart Disease Patients.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  13. Kuwahara T, Takahashi A, Okubo K, Takagi K, Nakajima J, Takigawa M, Watari Y, Nakashima E, Yamao K, Yamagami Y, Shigeta T, Kojima K, Sagawa Y, Otani H, Hishikari K, Sugiyama T, Kimura S, Hikita H, Sato A , Aonuma KFAblation Strategy Based on Pulmonary Vein Isolation and Non-pulmonary Vein Trigger Ablation for Non-paroxysmal Atrial Fibrillation.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  14. Igarashi M ,Sekiguchi Y , Kuroki K , Machino T , Ito Y , Adachi T , Yui Y , Aita S , Kimata A , Ogawa K , Miki Y , Ahmed Talib , Kuga K , Nogami A , Aonuma KFThe Difference in the Waveforms during Pacemapping at Subdivided Portions within the Outflow Tract: The Usefulness of Synthesized 18-lead Electrocardiograms.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  15. Sugano A ,Seo Y , Ishizu T , Kawamatsu N , Sato K , Atsumi A , Yamamoto M , Harimura Y , Machino-Otsuka T , Kawamura R , Nishina H , Fumikura Y , Noguchi Y , Aonuma K FOptimal Cut-off Value of Reverse Remodeling for Predicting Long-Term Outcome after Cardiac Resynchronization Therapy in Ischemic Cardiomyopathy.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  16. Maruta S ,Abe D , Misaki M , Yoshida K , Takeyasu N , Satoh A , Aonuma K FClinical Value of Beta-blockers and Reperfusion Time in ST-Segment Elevated Myocardial Infarction; From ICAS Registry.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  17. Yamashita E , Takeuchi M , Seo Y , Izumo M , Ishizu T , Sato K , Suzuki K, Akashi Y, Aonuma K , YOtsuji Y, Oshima SFConcentric Left Ventricular Hypertrophy for Paradoxical Low-flow Low-gradient Severe Aortic Stenosis: Results from Japanese Multicenter Aortic Stenosis Study, Retrospective Registry (JUST-R) .‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  18. Yamashita E ,Takeuchi M , Seo Y , Izumo M , Ishizu T , Sato K , Suzuki K , Akashi Y , Aonuma K , Otsuji Y , Oshima S FPrognostic Impact of Conversion to High Pressure Gradient in Patients with Paradoxical Low-Flow Low Pressure Gradient Severe Aortic Stenosis.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  19. Sato K ,Seo Y , Ishizu T , Takeuchi M , Izumo M , Suzuki K , Yamashita E , Oshima S , Akashi Y , Otsuji Y , Aonuma KFPrognostic Value of Left Ventricular Longitudinal Strain in Patients with Paradoxical Low-flow, Low-gradient Severe Aortic Stenosis and Preserved Ejection Fraction.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  20. Sato K ,Seo Y , Nakajima H , Ishizu T , Takeuchi M , Otsuji Y , Aonuma K FReliability of Aortic Stenosis Severity Classified by Three-Dimensional Echocardiography in Prediction of Cardiovascular Events.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  21. Machino T ,Murakoshi N , Satoh A , Xu D , Hoshi T , Kimura T , Aonuma KFThe Anti-hypertensive Effect of Radiofrequency Renal Denervation with a Reduction of Renal Tissue Norepinephrine Content in the Spontaneously Hypertensive Rats.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  22. Yui Y ,Igarashi M , Adachi T , Ogawa K , Miki Y , Ito Y , Machino T , Kuroki K , Sekiguchi Y , Nogami A , Aonuma KFEffect of Hybrid Therapy of Amiodarone and Bepridil on Sinus Rhythm Maintenance after Catheter Ablation for Long-standing Persistent Atrial Fibrillation.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  23. Miki Y ,Nogami A , Murakoshi N , Nakazawa Y , Nobufumi Otani , Kawamatsu N , Hiraya D , Harunari T , Ogawa K , Yamamoto M , Yui Y , Adachi T , Ito Y , Machino T , Kuroki K , Igarashi M , Yamasaki H , Sekiguchi Y , Aonuma K FCharacteristics of Induced Repetitive Ventricular Responses Degenerating into Ventricular Fibrillation in Brugada Syndrome and Ischemic Heart Disease.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  24. Kawabe M ,Satoh A , Hoshi T , Takeyasu N , Aonuma KFImpact of Gender Differences on Clinical Outcomes in Patients with Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  25. Kimura T ,Satoh A , Kakefuda Y , Ojima E , Adachi T , Watabe H , Aonuma K FImpact of Serum Uric Acid Levels on the Characteristics of Coronary Plaques Using Computed Tomography Angiography.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  26. Abe D ,Takeyasu N , Misaki M , Hoshi T , Satoh A , Aonuma KFPrognostic Impact of Beta-blocker in Patients with ST-segment Elevation Myocardial Infarction and High Value of Plasma Glucose on Admission.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  27. Kuroki K ,Igarashi M , Ishizu T , Satoh A , Ito Y , Machino T , Yui Y , Adachi T , Ogawa K , Miki Y , Ahmed Talib , Xu D , Murakoshi N , Sekiguchi Y , Seo Y , Nogami A , Aonuma K FLong-duration Effects of Arial Fibrillation on Atherosclerosis in Patients with Atrial Fibrillation.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  28. Sugano A ,Seo Y , Ishizu T , Kawamatsu N , Sato K , Atsumi A , Yamamoto M , Harimura Y , Machino-Otsuka T , Kawamura R , Nishina H , Fumikura Y , Noguchi Y , Aonuma KFUsefulness of Myocardial Strain by Speckle-tracking Echocardiography in Assessing the Risk of Ventricular Arrhythmia.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  29. Takeuchi M ,Seo Y , Ishizu T , Sato K , Yamashita E , Izumo M , Suzuki K , Aonuma K , Akashi Y , Oshima S , Otsuji Y FDifferent Impact of Pressure Recovery Among 4 Types of Severe Aortic Stenosis with Preserved Left Ventricular Ejection Fraction.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  30. Igarashi M ,Ishizu T , Seo Y , Kuroki K , Machino T , Ito Y , Adachi T , Yui Y , Ogawa K , Miki Y , Ahmed Talib , Sekiguchi Y , Nogami A , Aonuma KFThe Left Atrial Regional Deformation Analysis in the Patients with Atrial Fibrillation: 2D Speckle Tracking Echocardiography Using CARTOSOUND.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  31. Harunari T ,Satoh A , Hiraya D , Watabe H , Kakefuda Y , Hoshi T , Nishina H , Takeyasu N , Noguchi Y , Aonuma K FPrognostic Value of Serum Potassium Level on Short-term Mortality in Acute Coronary Syndrome Patients with and without Chronic Kidney Disease.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  32. Sekiguchi Y ,Nogami A , Tada H , Igarashi M , Kuroki K , Machino T , Yamasaki H , Aonuma KFCatheter Ablation for Ventricular Tachycardias in Patients with Structural Heart Disease: Characteristics between the Patients with and without Myocardial Scar.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  33. Hoshi T ,Satoh A , Akiyama D , Aonuma KFSignal High Intensity on T1-weighted Magnetic Resonance Imaging of Coronary Plaque Associated with Myocardial Injury after Percutaneous Coronary Intervention.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  34. Machino-Otsuka T ,Seo Y , Ishizu T , Machino T , Kuroki K , Igarashi M , Sekiguchi Y , Nogami A , Aonuma K FInsufficient Left Atrial Reverse Remodeling after Catheter Ablation Associates with Existence of Echocardiographic Thromboembolic Milieu in Patients with Persistent AF.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  35. Ito Y ,Igarashi M , Ishizu T , Nogami A , Aonuma KFFluororeduction in Interventional Electrophysiology for Female Doctors.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  36. Seo Y ,Aonuma K FCardiac Resynchronization Therapy is Sufficiently Performed Even in the Patients Who are Predicted as Non-responders through Echocardiographic Examinations.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  37. Igarashi M ,Sekiguchi Y , Kuroki K , Machino T , Ito Y , Yui Y , Adachi T , Aita S , Kimata A , Ogawa K , Miki Y , Ahmed Talib , Kuga K , Nogami A , Aonuma K FQRS Morphology Pattern in V5R is Novel and Simple Parameter for Differentiating the Origin of Idiopathic Outflow Tract Ventricular Arrhythmias.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  38. Kuroki K ,Sekiguchi Y , Goya M , Fukunaga M , Kaitani K , Onishi N , Mine T , Koyama T , Igawa M , Nitta J , Yamauchi Y , Machino T , Ito Y , Yamasaki H , Xu D , Igarashi M , Murakoshi N , Nogami A , Aonuma KFLong-term Efficacy of Ultralow Voltage Area-targeted Endocardial Linear Ablation for Postinfarction Ventricular Tachycardia.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  39. Xu D ,Murakoshi N , Nogami A , Makita N , Sekiguchi Y , Igarashi M , Isaka Y , Kurosaki K , Kowase S , Naruse Y , Aonuma KFCommon Variants at SCN5A, SCN10A, and HEY2 are Associated with Cardiac Conduction Disturbance in Patients with Brugada Syndrome.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  40. Ishizu T ,Seo Y , Kawamatsu N , Sato K , Sugano A , Atsumi A , Yamamoto M , Machino-Otsuka T , Kawamura R , Aonuma KFMyocardial Strain and Ventricular-Arterial Coupling in a Rat Model of Heart Failure with Preserved Ejection Fraction.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  41. Iida N ,Seo Y , Ishizu T , Yamamoto M , Atsumi A , Machino-Otsuka T , Enomoto M , Kawamura R , Aonuma K FRelation between Renal Function and Renal Vascular Doppler Profiles in Patients with Congestive Heart Failure.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  42. Murakoshi N ,Numanoi N , Noguchi H , Xu D , Hirayama A , Aonuma KFActivation of Transcriptional Factor NRF-2 Plays Protective Roles in Myocardial Infarction.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  43. Sakai S ,Kimura T , Zheng Wang , Tajiri K , Maruyama H , Kuga K , Honma S , Miyauchi T , Aonuma KFInhibition of RNA Polymerase II Function by the C-Terminal Domain Phosphatase FCP1 in the Development of Cardiac Dysfunction.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  44. Kuroki K ,Murakoshi N , Xu D , Igarashi M , Yamasaki H , Ito Y , Sekiguchi Y , Nogami A , Aonuma KFThe Inhibitory Effects of Prednisolone on Atrial Fibrillation Recurrence after Ablation in a Rat Model.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  45. Kakefuda Y ,Satoh A , Hoshi T , Harunari T , Watabe H , Nishina H , Takeyasu N , Noguchi Y , Aonuma KFPrognostic Value of Serum Potassium Level after Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  46. Tajiri K ,Satoh A , Hoshi T , Kimura T , Seo Y , Takeyasu N , Sakai S , Watanabe S , Aonuma K FEvaluation of the Neointima Following Bare-metal, Sirolimus- and Everolimus-eluting Stents Implantation by Optical Coherence Tomography and Histology in Rabbits.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  47. Watabe H ,Satoh A , Takaiwa Y , Sugano A , Kakefuda Y , Aihara H , Fumikura Y , Yuri Hiranuma , Nishina H , Noguchi Y , Aonuma KFDetection of Microvascular Obstruction by Multidetector Computed Tomography Immediately after Percutaneous Coronary Intervention in Acute Myocardial Infarction.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  48. Iida N ,Seo Y , Ishizu T , Yamamoto M , Atsumi A , Machino-Otsuka T , Enomoto M , Kawamura R , Aonuma KFAlternations of Renal Vein Flow Pattern by Hemodynamic Aggravations Relate with Renal Dysfunction in Congestive Heart Failure.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  49. Nakajima H ,Ishizu T , Iida N , Sakamaki F , Kawamatsu N , Sato K , Sugano A , Atsumi A , Yamamoto M , Machino-Otsuka T , Kawamura R , Seo Y , Aonuma K FTransthoracic Echo Findings of Active Infective Endocarditis without Vegetation.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  50. Akiyama D ,Satoh A , Hoshi T , Hiraya D , Aonuma K FFavorable Vascular Repair after Everolimus-Eluting Stent Compared with Sirolimus-Eluting Stent: An Angioscopic Study.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  51. Kimata A ,Sekiguchi Y , Aita S , Ogawa K , Miki Y , Talib Ahmed , Adachi T , Yui Y , Ito Y , Machino T , Kuroki K , Igarashi M , Nogami A , Aonuma K FPredictive Factors of the Cardiac Implantable Electrophysiological Device Infection by Methicillin-Resistant Staphylococcus Aureus.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  52. Sugano A ,Seo Y , Ishizu T , Kawamatsu N , Sato K , Atsumi A , Yamamoto M , Harimura Y , Machino-Otsuka T , Kawamura R , Nishina H , Fumikura Y , Noguchi Y , Aonuma K FComparisons of Clinical Parameters Reliability as a Surrogate for Long-Term Outcome after Cardiac Resynchronization Therapy.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  53. Takagi M ,Aonuma K , Sekiguchi Y , Yokoyama Y , Hiraoka M FNon-invasive Risk Stratification in Brugada Syndrome without History of Cardiac Arrest: Prognostic Value of J-wave and ST-segment Morphology.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  54. Ishizu T ,Seo Y , Kawamatsu N , Sato K , Sugano A , Atsumi A , Akihiro Nakamura , Yamamoto M , Machino-Otsuka T , Kawamura R , Aonuma K FSearching for the New Imaging Biomarker Using Strain and Stress.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  55. Atsumi A ,Ishizu T , Maruo T , Furugen A , Arita T , Kaoru Dohi , Yamada S , Shiga T , Seo Y , Aonuma KFThe Clinical Significance of Right Ventricular Functional Improvement by Cardiac Resynchronization Therapy: Sub-analysis of the START Study.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  56. Izumo M ,Takeuchi M , Seo Y , Yamashita E , Suzuki K , Ishizu T , Sato K , Oshima S , Aonuma K , Otsuji Y , Akashi Y FStress Echocardiography for Assessing True Severity in Patients with Paradoxical Low-Flow Low-Gradient Severe Aortic Stenosis: Japanese Multicenter Aortic Stenosis Study.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  57. Kuwahara T ,Takahashi A , Ohkubo K , Takagi K , Takigawa M , Watari Y , Nakashima E , Yamao K , Nakajima J , Kojima K , Hishikari K , Yamakami Y , Sugiyama T , Sagawa Y , Kimura S , Hikita H , Satoh A , Aonuma KFEsophageal Cooling with Ice Water Reduces the Severity of Esophageal Lesions Complicating Catheter Ablation of Atrial Fibrillation: Randomized Controlled Study.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  58. Machino T ,Tada H , Igarashi M , Sekiguchi Y , Kuroki K , Yamasaki H , Nogami A , Aonuma KFScoring Scheme Using Pharmacologic Cardioversion for Predicting Outcome of the Following Catheter Ablation in Patients with Long-standing Persistent Atrial Fibrillation.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  59. Kuwahara T ,Takahashi A , Ohkubo K , Takagi K , Takigawa M , Watari Y , Nakashima E , Yamao K, Nakajima J , Kojima K , Hishikari K , Yamakami Y , Sugiyama T , Sagawa Y , Kimura S , Hikita H , Satoh A , Aonuma K FRadiofrequency Transseptal Needle Can Puncture the Targeted Site of Foramen Ovale Compared to Standard Needle in Atrial Fibrillation Ablation.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  60. Nogami A ,Shinoda Y , Naruse Y , Junji Kawagoe , Kowase S , Kurosaki K , Machino T , Adachi T , Yui Y , Ogawa K , Miki Y , Ahmed Talib , Ito Y , Kuroki K , Igarashi M , Sekiguchi Y , Kuga K , Aonuma KFNew Three-Dimensional Substrate Map Using Fast-Fourier Transform of the Local Ventricular Signals.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  61. Ahmed Talib ,Nogami A , Kowase S , Kurosaki K , Takahashi A , Matsui Y , Takahashi Y , Asakawa T , Nishiuchi S , Kumagai K , Naitoh S , Sekiguchi Y , Aonuma K FIdiopathic Upper Septal Fascicular Ventricular Tachycardia: A Rare Form of Verapamil-Sensitive Fascicular Tachycardia with QRS Configuration Similar to Sinus Rhythm.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  62. Ahmed Talib ,Nogami A , Oginosawa Y , Shinoda Y , Naruse Y , Kagaoe J , Kowase S , Kurosaki K , Sekiguchi Y , Aonuma K FNon-reentrant Idiopathic Focal Purkinje Ventricular Tachycardia: Characteristics and Efficacy of Catheter Ablation of a Distinct Clinical Entity.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  63. Harimura Y ,Ishizu T , Kawamatsu N , Sato K , Sugano A , Atsumi A , Yamamoto M , Machino-Otsuka T , Kawamura R , Nakajima H , Iida N , Nishi I , Seo Y , Aonuma KFLeft Ventricular LongitudinalStrain and Ventricular-Arterial Coupling in Heart Failure with Preserved Ejection Fraction; Results from ICAS-HF Registry.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  64. Kuwahara T ,Takahashi A , Ohkubo K , Takagi K , Takigawa M , Watari Y , Nakashima E , Yamao K , Nakajima J , Kojima K , Hishikari K , Sagawa Y , Sugiyama T , Yamakami Y , Kimura S , Hikita H , Satoh A , Aonuma KFCharacteristics of the Electrograms of the Conduction Gap to Simultaneously Isolate the Ipsilateral Pulmonary Veins in Patients with Atrial Fibrillation.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  65. Sato A ,Hoshi T , Akiyama D , Hiraya D , Kakefuda Y , Watabe H , Abe D , Takeyasu N , Noguchi Y , Aonuma KFImpact of Mehran Contrast-Induced Nephropathy Risk Score for the Prediction of Clinical Outcomes After Percutaneous Coronary Intervention.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  66. Yui Y ,Sekiguchi Y , Adachi T , Ogawa K , Miki Y , Ito Y , Machino T , Kuroki K , Igarashi M , Nogami A , Aonuma K FCatheter Ablation for Idiopathic Ventricular Arrhythmias Originating from the Ostium of Coronary Sinus.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  67. Higuchi H ,Asahina N , Sato K , Endo Y , Yamauchi R , Tsuneoka H , Suzuki A , Eki Y , Seo Y , Watanabe S , Aonuma KFUltrasound Guidance Backflow Confirmatory Method Enables Extrathoracic Subclavian Venipuncture to be Safe and Reliable Procedure in Implantation of Pacemaker Leads.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  68. Ishizu T ,Seo Y , Ogawa K , Kuroki K , Sekiguchi Y , Igarashi M , Yamashita E , Nogami A , Aonuma KFNoninvasive Activation Imaging Using Three-Dimensional Speckle Tracking Echocardiography in Wolff-Parkinson-White Syndrome.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  69. Nakazawa Y ,Yoshida K , Inaba T , Ogata K , Nogami A , Aonuma KFNon-Invasive Identification of Dominant Frequency on the Magnetocardiogram in Patients with Persistent Atrial Fibrillation.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  70. Igarashi M ,Ageyama Y , Katakai Y , Yui Y , Xu D , Kuroki K , Sekiguchi Y , Murakoshi N , Nogami A , Aonuma KFA Non-human Primate Model of Atrial Fibrillation with Atrial Electrical and Structural Remodeling by Atrial Tachy-pacing.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  71. Izumo M ,Takeuchi M , Seo Y , Yamashita E , Suzuki K , Ishizu T , Sato K , Oshima S , Aonuma K , Otsuji Y , Akashi YFDeterminants and Prognostic Implications for Symptomatic Presentations in Patients with Severe Aortic Stenosis: Japanese Multicenter Aortic Stenosis (JUST) Study.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  72. Yamashita E ,Takeuchi M , Seo Y , Izumo M , Ishizu T , Sato K , Suzuki K , Akashi Y , Aonuma K , Otsuji Y , Oshima S FInfluence of Stature and Obesity on Left Ventricular Chamber Mechanics in Japanese Severe Aortic Stenosis: Retrospective Multicenter Study.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  73. Kawabe M ,Satoh A , Hoshi T , Takeyasu N , Aonuma KFRelationship between Systolic Blood Pressure on Admission and Mortality in Patients with Acute Coronary Syndrome.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  74. Abe D ,Takeyasu N , Misaki M , Hoshi T , Satoh A , Aonuma KFImpact of Trans-radial Approach for the Incidence of Contrast-Induced Acute Kidney Injury after Percutaneous Coronary Intervention; Propensity Score Matched Analysis.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  75. Takeuchi M ,Seo Y , Ishizu T , Sato K , Yamashita E , Izumo M , Suzuki K , Oshima S , Aonuma K , Akashi Y , Otsuji Y FPrognostic Value of Left Atrial Volume for Future Cardiac Death in Severe Aortic Stenosis with Preserved Left Ventricular Ejection Fraction.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  76. Misaki M ,Satoh A , Abe D , Kakefuda Y , Hoshi T , Yoshida K , Takeyasu N , Aonuma KFClinical Impact of Drug-eluting Stent Implantation after In-stent Restenosis of First- versus Second Generation Drug-eluting Stent.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  77. Sato K ,Seo Y , Ishizu T , Kawamatsu N , Sugano A , Atsumi A , Yamamoto M , Harimura Y , Machino-Otsuka T , Kawamura R , Eki Y , Aonuma K FAlternation of Longitudinal Dysfunction after Aortic Valve Replacement in Severe Aortic Stenosis by Two-dimensional Speckle-tracking Echocardiography.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  78. Yamamoto M ,Seo Y , Kawamatsu N , Sato K , Sugano A , Atsumi A , Machino-Otsuka T , Kawamura R , Ishizu T , Aonuma KFIncreased Diastolic Myocardial Stiffness Assessed by Diastolic Wall Strain in Light-Chain Amyloidosis with Cardiac Involvement.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  79. Yamamoto M ,Seo Y , Kawamatsu N , Sato K , Sugano A , Atsumi A , Machino-Otsuka T , Kawamura R , Ishizu T , Aonuma KFVariation of Left Ventricular Activation Pattern in Patients with Left Bundle Branch Block.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  80. Adachi T ,Yoshida K , Sekiguchi Y , Takeyasu N , Nogami A , Aonuma KFSeptal Atrial Tachycardia Post Open-heart Surgery.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  81. Aita S ,Kuroki K , Yamasaki H , Machino T , Ito Y , Igarashi M , Sekiguchi Y , Nogami A , Aonuma K FComparison of Dabigatran and Warfarin for Periprocedural Anticoagulation in Radiofrequency Ablation of Atiral Fibrillation.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  82. Hiraya D ,Hoshi T , Satoh A , Aonuma K FImpact of Discontinuation Thienopyridine Therapy in Patients with Grade 1 Neointimal Stent Coverage Observed by Coronary Angioscopy after Everolimus-Eluting Stent.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  83. Naruse Y ,Nogami A , Shinoda Y , Kowase S , Kurosaki K , Kuroki K , Igarashi M , Sekiguchi Y , Aonuma K FJ Wave is an Independent Predictor for the Occurrence of Life-threatening Ventricular Tachyarrhythmia in Patients with Nonischemic Cardiomyopathy.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  84. Ahmed Talib ,Nogami A , Kaneshiro T , Takagi M , Kurosaki K , Ootani N, Kawamatsu N , Hiraya D , Harunaru T , Ogawa K , Miki Y , Yamamoto M , Ito Y , Kuroki K , Yui Y , Adachi T , Igarashi M , Yamasaki H , Sekiguchi Y , Murakoshi N , Aonuma K FRadiofrequency Catheter Ablation (RFCA) of Ventricular Fibrillation in Brugada Syndrome: Results of Long-term Follow up.‘æ78‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi“Œ‹žj3ŒŽ,2014
  85. Kenji Kuroki, Nobuyuki Murakoshi, Dongzhu Xu, Kazuko Tajiri, Miyako Igarashi, Yoshiaki Yui, Takeshi Machino, Yukio Sekiguchi, Akihiko Nogami, and Kazutaka Aonuma: Inhibitory effects of prednisolone on the recurrence after Atrial Fibrillation Ablation in a Rat Model. ‘æ78‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (“Œ‹ž) 3ŒŽC2014
  86. ²“¡Šó”üC‘¼8–¼DdÇ‘å“®–¬•Ù‹·óÇ‚É‚¨‚¯‚éÇó”­Œ»‚Æ•a‘Ô‚ÌŒŸ“¢F‘æ111‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïi“Œ‹žj2014,4
  87. –ö‰º“Ö•FCŽR“àNÆC²“¡O“TCŽR‰º@ŽüC•½”ö—´•FC¯Ži@‘Cì‰Š°“¹C‰Pˆä‰p—SC‹{è—ºˆêCŒ´@M”ŽCŽRŒû“O’jC”~–{•üKC‹{–{‹M—fC”ö—с@“OCŠÖ“c@ŠwC•½”öŒ©ŽOCÂÀ˜a—²D”xÃ–¬Šu—£pŒãASVC-‰E–[Ú‡•”‚ÌLocalized@reentry@‚ª•p”‚Ì”­¶‚ƈێ‚ÉŠÖ—^‚µ‚½AT‚ƉE–[”xÃ–¬ŠÔ‚ÌGap-related@AT‚É‚æ‚é“ñd•p”‚ð”F‚ß‚½”­ì«S–[×“®‚Ì1—á‘æ44‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj2014,5
  88. ’†ì˜a–çCóì“N–çC´…‘ô–çC¼‘º‘‰ÀCŽR“àNÆCÂÀ˜a—²DƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚萶‚¶‚½ƒPƒ“ƒg‘©phase3•4block‚Ì‹@˜‚ðÚ×‚ÉŒŸ“¢‚µ“¾‚½AVRT‚̈ê—á‘æ44‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj2014,5
  89. ¬ìF“ñ˜YC•–ØŒ’ŽuC–ìãº•FCƒvƒ‰ƒTƒhƒOƒ‹Cƒ^ƒŠƒuƒAƒnƒƒhCŽOŽ÷—TŽqCˆÀ’B@‹œC–ûˆäŒcWCˆä“¡—tŽqC’¬–ì@‹BCŒÜ\—’@“sCŠÖŒûK•vCÂÀ˜a—²DŒ¸Š“`“±A‰ßí“`“±AATPŠ´Žó«‚ð—L‚µ‚½Œã’†ŠuŽÎ‘–•›“`“±˜H‚̐f’f‚ɁA‘I‘ð“IHis‘©•ß‘¨‚ðŠÜ‚Þ–THis‘©ƒy[ƒVƒ“ƒO–@‚ª—L—p‚Å‚ ‚Á‚½ˆê—áF‘æ44‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj2014,5
  90. ›ˆä‹`®C‘ŠàVŒ’‘¾˜YC¬¼^‹±C•“c@’qC[–xk•½C•šŒ©‰xŽqC‚‹´r–¾C–xŒû@‘C–ìãº•FCÂÀ˜a—²D¶‹rƒuƒƒbƒN‚Ì‚½‚ß“ÁˆÙ‚È“`“±—lŽ®‚ð’悵‚½LV fascicular VT‚̈ê—áF‘æ44‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj2014,5
  91. ‹àé‹MŽmC—é–؁@‹ÏC_ŽR”ü”VC’|Î‹±’mCŽá¼‘•äC“cè˜a—mCˆäì@CCÂÀ˜a—²DSŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª’˜Œø‚µA–UŒŸS‚ʼn摜“If’f‚¨‚æ‚Ñ‘gDŠw“I•]‰¿‚Ì”äŠr‚ª‰Â”\‚Å‚ ‚Á‚½Šg’£Œ^S‹ØÇ‚̈êÇ—áF‘æ44‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj2014,5
  92. ŽR‰º•¶’jCŒº@“NŽ÷C”óŒûŠî–¾CŽR“c“TOCç—t‹`˜YC‘啽WŽiC‘º“c@ŽÀFPQ’Zk‚𔺂í‚È‚¢WPWÇŒóŒQ‚Ì1—áF‘æ201‰ñˆïéŒ§“à‰ÈŠw‰ïi…ŒËj2014C6
  93. ÂÀ˜a—².S–[×“®‚ɑ΂·‚éÅV‚̍l‚¦•û@?RŒŒðŽ¡—ÂƍR•s®–¬Ž¡—ÁF•½¬26”N“x“ú–{“à‰ÈŠw‰ï¶ŠU‹³ˆçu‰‰‰ïi‘åãj2014,6
  94. ŽR–{¹—ǁC£”ö—RLCÎ’Ã’qŽqCÂÀ˜a—²C‰|–{‹­Žu.‚“x¶Žº‹@”\•s‘S‚ɖƉu—}§—Ö@‚ªŒø‰Ê“I‚Å‚ ‚Á‚½‘å“®–¬‰ŠÇŒóŒQ‚̈ê—áF‘æ232‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï(“Œ‹ž)@6ŒŽC2014
  95. ÂÀ˜a—²DƒrƒfƒIƒ‰ƒCƒuF‘æ1‰ñ“ú–{SŒŒŠÇ”]‘²’†Šw‰ïŠwpW‰ïi‘å‹{j2014,6
  96. ”~’Á@“wCˆÀ“‡—Ç‹PŽqCk@‹±ˆêC–ìãº•FCÂÀ˜a—²C“¡àVL‹g˜R‚ê“d—¬‚É‚æ‚èICD‚ÌVF”FŽ¯‚ðˆø‚«‹N‚±‚µ‚½ƒRƒCƒ“¸•ÄŠ‚ðƒ`[ƒ€‚É‚Ä–â‘è‰ðŒˆ‚µ‚½‚P—áFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  97. Yoshihisa Naruse , Akihiko Nogami , Yasutoshi Shinoda , Tagayasu Anzai , Shinya Kowase , Junji Kawagoe , Kenji Kurosaki , Kazutaka Aonuma:The Feasibility and Safety of Right Ventricular Septal Pacing Using a Tined LeadFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  98. Yoshihisa Naruse , Hiroshi Tada , Yoshie Harimura , Mayu Ishibashi , Yuki Kakefuda , Miyako Igarashi , Yukio Sekiguchi , Akihiko Nogami , Kazutaka Aonuma:The Clinical Impact of J-Wave Syndrome on the Occurrence of Ventricular Tachyarrhythmias and Sudden Death in the Chronic Phase of an Acute Myocardial InfarctionFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  99. Masahiko Takagi , Yukio Sekiguchi , Yasuhiro Yokoyama , Naohiko Aihara , Masayasu Hiraoka , Kazutaka Aonuma:Long-term Prognosis in Patients with Brugada Syndrome based on Class ‡U Indication for Implantable Cardioverter Defibrillator in the JCS Guideline and the HRS/EHRA/APHRS Expert Consensus Statement:J-IVFS StudyFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7C22-25
  100. Ahmed Talib , Akihiko Nogami , Yasushi Oginosawa , Kenji Kurosaki , Shinya Kowase , Kojiro Ogawa , Youko Itou , Yoshiaki Yui , Toru Adachi , Takeshi Mashino , Yuko Miki , Kenji Kuroki , Miyako Igarashi , Yukio Sekiguchi , Kazutaka Aonuma:Focal Purkinje Ventricular Tachycardia:a Distinct Entity of Non-reentrant Ventricular Tachycardia with a Challenging OutcomeFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  101. Kenji Kuroki , Yukio Sekiguchi , Kazuaki Kaitani , Masayuki Igawa , Takashi Koyama , Kojiro Ogawa , Yoshiaki Yui , Takeshi Machino , Dongzhu Xu , Miyako Igarashi , Nobuyuki Murakoshi , Akihiko Nogami , Kazutaka Aonuma:The Clinical and Electriphysiological Characteristics of Postinfarction Ventricular Tachycardia with Left Bundle-Branch BlockFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  102. Kojiro ogawa , Miyako Igarashi , Kenji Kuroki , Ahmed Talib , Yuko Miki , Toru Adachi , Yoko Nakazawa , Yoshiaki yui , Yoko Ito , Takeshi Machino , Yukio Sekiguchi , Akihiko Nogami , Kazutaka Aonuma:The Frontward P Wave Duration in Magnetocardiography is a Novel Parameter to Estimate Pulmonary Vein Reconnections after Radiofrequency Catheter Ablation of Atrial FibrillationFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7C22-25
  103. Yoshiaki Yui , Yukio Sekiguchi , Toru Adachi , Kojiro Ogawa , Yuko Miki , Yoko Ito , Takeshi Machino , Kenji Kuroki , Miyako Igarashi , Akihiko Nogami , Kazutaka Aonuma:Acute Pericarditis after Catheter Ablation with Cardiac Tamponade or Pericardial EffusionFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  104. Yoko Ito , Akihiko Nogami , Miyako Igarashi , Yoshiaki Yui , Toru Adachi , Kojiro Ogawa , Yuko Miki , Takeshi Machino , Kenji Kuroki , Yukio Sekiguchi , Kazutaka Aonuma:Inflammatory State after Catheter Ablation of Atrial FibrillationFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  105. Keita Masuda , Atsushi Mizuno , Shuzo Nishihara , Hiroyuki Niinuma , Yutaro Nishi , Koichiro Niwa , Kazutaka Aonuma:Usefulness of the Lewis Lead to Differentiate the Origin of Atrial TachycardiaFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  106. Yoko Ito , Akihiko Nogami , Miyako Igarashi , Talib Ahmed , Kojiro Ogawa , Yuko Miki , Toru Adachi , Yoshiaki Yui , Takeshi Machino , Kenji Kuroki , Yukio Sekiguchi , Kazutaka Aonuma:A Novel Porous Tip Open-irrigated Catheter for Cavo-tricuspid Isthmus AblationFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7C22-25
  107. Takeshi Machino , Miyako Igarashi , Akihiko Nogami , Hiroshi Tada , Yukio Sekiguchi , Kenji Kuroki , Toru Adachi , Ahmed Talib , Kazutaka Aonuma:Superior Venous Approach and Three-dimensional Electro-anatomical Mapping System for Catheter Ablation of Atrio-ventricular Nobel Reentrant Tachycardia in a Patient with Hypoplastic Inferior Vena CavaFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  108. Toru Adachi , Akihiko Nogami , Yoko Ito , Ahmed Talib , Kojiro Ogawa , Yuko Miki , Yoshiaki Yui , Takeshi Machino , Kenji Kuroki , Hiro Yamasaki , Miyako Igarashi , Yukio Sekiguchi , Keisuke Kuga , Kazutaka Aonuma , Sunao Tada:A Case with Node-ventricular Fiber and Antidromic Atrioventricular Reciprocating TachycardiaFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  109. Ai Hattori , Masayuki Igawa , Makiko Tachibana , Yoshihisa Naruse , Tsuyoshi Enomoto , Akihiko Nogami , Kazutaka Aonuma:Rapid Ventricular Tachycardia in a Patient Taking Cilostazol:Ventricular Tachyarrhythmias associated with CilostazolFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  110. Taishi kuwahara , Atsushi Takahashi , Kenji Okubo , Katsumasa Takagi , Masateru Takigawa , Yuji Watari , Jun Nakajima , Emiko Nakashima , Kazuya Yamao , Kazutaka Aonuma:Ablation Strategy based on Pulmonary Vein Isolation and Non-pulmonary Vein Trigger Ablation of Non-paroxysmal Atrial FibrillationFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  111. Satoshi Aita , masayuki Igawa , Ai Hattri , Tsuyoshi Enomoto , Kenji Kuroki , Miyako Igarashi , Yukio Sekiguchi , Akihiko Nogami , Kazutaka Aonuma:Radiofrequency Catheter Ablation of Symptomatic Frequent Atrial Premature Contractions:Origin , Efficacy , and PrognosisFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  112. Tomohiko Harunari , Yukio Sekiguchi , Kojiro Ogawa , Yuko Miki , Ahmed Abdulkarim , Yoko Ito , Kenji Kuroki , Miyako Igarashi , Akihiko Nogami , Kazutaka Aonuma:Negative Factors of Succsessful Intravenous Lead ExtractionFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  113. Akira kimata , Yukio Sekiguchi , Satoshi Aita , Ahmed Talib , Kojiro Ogawa , Yoshiaki Yui , Yoko Ito , Takeshi Machino , Kenji Kuroki , Miyako Igarashi , Akihiko Nogami , Kazutaka AonumaFThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  114. k@‹±ˆêCŠÖŒûK•vC‰H’¹´Žu˜YCâ–{—Y‰îCÔ¯”Ž˜aCŽR–{ƒˆÌC”~’Á@“wC•–ØŒ’ŽuCŒÜ\—’@“sC–ìãº•FCÂÀ˜a—²FƒfƒoƒCƒXŠ´õƒŠ[ƒh”²‹ŽŽž‚É‚¨‚¯‚éEV1000ƒNƒŠƒeƒBƒJƒ‹ƒPƒAƒ‚ƒjƒ^[‚ÌŽg—pŒoŒ±FThe 29th annual Meeting of The Japanese Heart Rhythm Societyi“Œ‹žj2014C7
  115. Kenji Kuroki, Hiroshi Tada,* Akihiko Nogami, Takeshi Machino, Yoshiaki Yui, Kojiro Ogawa, Ahmed Talib, Yasutoshi Shinoda, Keita Masuda, Mitsutaka Fukata, Dongzhu Xu, Miyako Igarashi, Nobuyuki Murakoshi, Yukio Sekiguchi, Kazutaka Aonuma: What Kind of Patients and Which Part of the Heart Have Abundant Epicardial Fat?: A Quantitative Computed Tomographic Analysis. ‘æ29‰ñ“ú–{•s®–¬Šw‰ïŠwpW‰ï (“Œ‹ž) 7ŒŽC2014
  116. Kenji Kuroki, Yukio Sekiguchi, Kazuaki Kaitani, Takashi Koyama, Masayuki Igawa, Takeshi Machino, Yoshiaki Yui, Kojiro Ogawa, Dongzhu Xu, Miyako Igarashi, Nobuyuki Murakoshi, Akihiko Nogami, Kazutaka Aonuma:The Clinical and Electrophysiological Characteristics of Postinfarction Ventricular Tachycardia with Left Bundle-Branch Block. ‘æ29‰ñ“ú–{•s®–¬Šw‰ïŠwpW‰ï (“Œ‹ž) 7ŒŽC2014
  117. “n•”_–¾C²“¡@–¾C¯@’q–çC•ˆÀ–@”VCˆÀ”{‘å•ãCHŽR‘åŽ÷CŠ|ŽD—YŠîCm‰ÈG’C–ìŒû—SˆêCÂÀ˜a—²F‹Ù‹}Š¥“®–¬Œ`¬p‚ªŽ{s‚³‚ꂽ–«t‘Ÿ•a‚ð—L‚·‚é‹}«Š¥ÇŒóŒQŠ³ŽÒ‚̐¶–½—\Œã‚Æ‘¢‰eÜtÇ‚Æ‚ÌŠÖŒWF‘æ61‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[i_ŒËj2014C8C2
  118. Kenji Kuroki, Yukio Sekiguchi, Masahiko Goya, Kazuaki Kaitani, Takanao Mine, Takashi Koyama, Masayuki Igawa, Miyako Igarashi, Akihiko Nogami, and Kazutaka Aonuma:Long-term Efficacy of Ultralow Voltage Area-targeted Ablation for Postinfarction Ventricular Tachycardia. ESC Congress 2014 (ƒoƒ‹ƒZƒƒi) 8ŒŽ, 2014
  119. ¬Œ´@_C’†‘º—T“ñC‘‚@VC‰¡ŽR_ŽjC’†£ŒÃiòjŠ°ŽqCˆÀ“ŒŒ«‘¾˜YC‘º‰zLsC²“¡@–¾CÂÀ˜a—²C‚Œ´@ÍC’r“c—²“¿C™ŽR@“āFt“®–¬ƒfƒiƒx[ƒVƒ‡ƒ“‚¨‚æ‚уAƒ~ƒIƒ_ƒƒ“–«“Š—^‚É‚æ‚éS‘Ÿ“d‹C–ò—Šw“Iì—p‚Ì—ÞŽ—«F–«–[ŽºƒuƒƒbƒNŒ¢ƒ‚ƒfƒ‹‚ð—p‚¢‚Ä‚ÌŒŸ“¢F‘æ19‰ñƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ïi“Œ‹žj2014C9
  120. ¬ìF“ñ˜YC•–ØŒ’ŽuC–ìãº•FCŽÂ“cNrCƒ^ƒŠƒuƒAƒnƒƒhCäï@žÄƒC[“cŒõŒhC‘“cŒc‘¾C–ûˆäŒcWC’¬–ì@‹BCŒÜ\—’@“sCŠÖŒûK•vCÂÀ˜a—²FŒJ•Ô‚·VT storm‚ւ̃Aƒ~ƒIƒ_ƒƒ“‚ƃJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ìhybrid therapy`”j‰ó«bó‘B‰Š‚ňê’U“Š—^’†’fŒã‚ɍēxVT storm‚Æ‚È‚Á‚½ˆê—á‚ÌŒoŒ±‚©‚ç`F‘æ19‰ñƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ïi“Œ‹žj2014C9
  121. ²“¡@–¾C¬£‘ãŽm‹vC¯@’q–çCÂÀ˜a—²D3Ü‚̍RŒŒð—Ö@‚ÍŠ¥“®–¬ƒXƒeƒ“ƒg—¯’uŒã‚Ì‘åoŒŒ‡•¹Ç‚Ì“Æ—§‚µ‚½—\‘ªˆöŽq‚Å‚ ‚éF-Percent Time in Therapeutic Range‚©‚ç‚̉ðÍ-F‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiå‘äj2014,9
  122. “¿ŽRälC’†–ì—R‹IŽqC¼‘º½–çC“n粋`˜aCì•›@GC–ØŒ´NŽ÷C•–ØŒ’ŽuC–ìãº•FCÂÀ˜a—²DSŽºŠúŠOŽûk‚ÌŠÖ˜A‚ª‹^‚í‚ê‚éSŽº×“®Ç—á‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—L—p«‚ɂ‚¢‚āF‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiå‘äj2014,9
  123. •–ØŒ’ŽuCŠÖŒûK•vC‡‰®‰ë•FC•Ÿ‰i^lCŠL’J˜aºC‘吼®ºC•ô@—²’¼C¬ŽR@’Cˆäì¹KCV“c‡ˆêCŽR“àNÆC’¬–ì@‹BCŒÜ\—’@“sC‘º‰zLsC–ìãº•FCÂÀ˜a—²DS‹Ø[ÇŒãSŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹S‹ØÄŽÜp‚Ì’·Šú—\Œã‚ÌŒŸ“¢F’´’á“dˆÊ—̈æ‚ð•W“I‚Æ‚µ‚½•s®–¬ŠíŽ¿‚̐ϋɓImodification‚̏d—v«F‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiå‘äj2014,9
  124. ì¼’¼lCÎ’Ã’qŽqCˆ­”üˆÀ‹IŽqC’†‘ººGC²“¡Šó”üC›–쏺Œ›CŽR–{¹—ǁCj‘º‰ÀŒbC’¬–ì’qŽqCì‘º@—´C£”ö—RLCÂÀ˜a—²DŒo‹¹•ÇSƒGƒR[}ŒŸ¸‚©‚瓾‚ç‚ê‚éS‹@”\Žw•W‚͉^“®‘Ï—p”\‚ð—\‘ª‚µ‚¤‚é‚©F‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiå‘äj2014,9
  125. ‹{“à—T”üCJesmin SbrinaCŽðˆä@rC‰ºžŠMˆÐCŠÛŽRG˜aC–{ŠÔ@ŠoC…’J‘¾˜YCÂÀ˜a—²C‹{“à@‘ìD“œ”A•aƒ‰ƒbƒgS‘Ÿ‚É‚¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“AŽó—e‘ÌŽÕ’f–ò‚ÆA/B—¼ŽÕ’f–ò‚ÌŒø‰Ê‚ÌŒŸ“¢FS‹@”\‚ÆVEGFƒVƒOƒiƒŠƒ“ƒO‚ւ̉e‹¿F‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiå‘äj2014,9
  126. Žðˆär‰îC•–ØŒ’ŽuC‰H’¹Œõ°C’†¼Œ[‘¾C¬Œ´Œ’ˆêC‘O“c—TŽjC•½’J‘¾ŒáCˆÀ’B@‹œCHŽR‘åŽ÷C¯@’q–çC²“¡@–¾CÂÀ˜a—²DŠ¥ˆÞk‚É‚æ‚éS”x’âŽ~‚ɑ΂µ‚ďWŠw“I‰Á—Âŋ†–¾‚µ‚¦‚½Žá”N—«‚̈ê—á`S“d}•Ï‰»‚É–R‚µ‚¢Ç—á‚É‚¨‚¯‚éƒAƒZƒXƒƒ“ƒg‚̏d—v«`F‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiå‘äj2014,9
  127. £”ö—RLCì¼’¼lCŽR–{¹—ǁC²“¡Šó”üCˆ­”üˆÀ‹IŽqC’¬–ì’qŽqCì‘º@—´CÎ’Ã’qŽqCÂÀ˜a—²DS•s‘SÇ—á‚É‚¨‚¯‚étŒŒŠÇƒhƒvƒ‰ƒGƒR[ŠŒ©‚ƐSŒŒs“®‘Ô‚¨‚æ‚ѐt‹@”\‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚āF‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiå‘äj2014,9
  128. ŽÂ“cNrCŒÜ\—’@“sC•–ØŒ’ŽuC’¬–ì@‹BC–ûˆäŒcWC¬ìF“ñ˜YCäï@žÄƒC[“cŒõŒhCƒ^ƒŠƒu ƒAƒnƒƒhCŠÖŒû@K•vC–ìã@º•FCÂÀ@˜a—²DSŠO–Œ‘¤‚É‘¶Ý‚·‚éSŽº•p”‰ñ˜H‚̐„’è‚É‘OŽºŠÔÃ–¬‰“ˆÊ•”‚©‚ç‚̃Gƒ“ƒgƒŒƒCƒ“ƒƒ“ƒg‚ª—L—p‚Å‚ ‚Á‚½Šg’£Œ^S‹ØÇ‚Ì1 —áF‘æ26‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiVŠƒj2014,10
  129. ‹àé‹MŽmC—é–؁@‹ÏC–쎛@õCã‰ª³ŽuC_ŽR”ü”VC‘ˆä_sC’|Î‹±’mC•Ÿ“c_“ñC‰ºìG–¾CŠÖŒûK•vC–ìãº•FCÂÀ˜a—²D¶‹rŒãŽ}—̈æPurkinje network ‹NŒ¹‚ÌVF trigger ‚ƐSŠO–Œ‹NŒ¹VT ‚ւ̃AƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚èVT/VF storm ‚©‚ç’E‹p‚µ“¾‚½¶Žºãk–§‰»áŠQ‚Ì1 —áF‘æ26‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiVŠƒj2014,10
  130. ’†ì˜a–çCóì“N–çC›Œ´’m¹C“cŠÛ@Ÿ«C¼‘º‘‰ÀCŽR“àNÆCÂÀ˜a—²D’˜–¾‚É’·‚¢AH ŽžŠÔ‚Ì‚½‚߂ɁC‚¢‚í‚ä‚é–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[«’²—¥‚ðŽ¦‚µC’Ê“dŒã‚É–[ŽºÚ‡•”«•p”‚ªoŒ»‚µ‚½1 —áF‘æ26‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiVŠƒj2014,10
  131. ‘“cŒc‘¾CŒÜ\—’@“sCŽÂ“cNrCäï@‰hƒCƒ^ƒŠƒu ƒAƒnƒƒhC¬ìF“ñ˜YC[“cŒõŒhC–ûˆäŒcWC’¬–ì@‹BC•–ØŒ’ŽuCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²D—lX‚È•s®–¬‚̃AƒuƒŒ[ƒVƒ‡ƒ“‚É‚¨‚¯‚éCartoUnivu ‚ÌŽg—pŒoŒ±F‘æ26‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiVŠƒj2014,10
  132. í‰ªG˜aC‹g“cŒ’‘¾˜YC–Ø‘S@Œ[Cˆä“¡—tŽqC•ˆÀ–@”VCÂÀ˜a—²Dã‘åÃ–¬‚ƉEã”xÃ–¬‚Ì‘o•û‚Ésmall reentrant circuit‚Ì‘¶Ý‚ª‹^‚í‚ꂽS–[•p”‚Ì1 —áF‘æ26‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiVŠƒj2014,10
  133. ”~’Á@“wCŸNˆä@ˆ¤CˆÀ“‡—Ç‹PŽqC“‡‘Ü–¢‰›C•ì‚Ý‚âŽqCk@‹±ˆêCâŒ³—Y‰îC’¹‰H´Žu˜YC•–ØŒ’ŽuCŒÜ\—’@“sCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²DŒy’ÁÃ‰º‚É‚¨‚¯‚éCryoballoon Ablation ‚Ìáu’ɂ̍lŽ@‘æF26‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiVŠƒj2014,10
  134. •ž•”@ˆ¤Cˆäì¹KC˜ð“c@•qC“à“c–õlCV‹G˜YC‰äÈŒ«ŽiC‰|–{‹­ŽuC¬ŠÖ@猁C–ìãº•FCÂÀ@˜a—²DS“à–Œ‘¤’P‹É—U“±‹L˜^‚©‚ç‰EŽº‚Ì‘Šú•a•Ï‚ªŽ¦´‚³‚ꂽ¶Žº‹@”\’ቺ‚𔺂¤‰EŽº—¬o˜H‹NŒ¹SŽº«ŠúŠOŽûk‚Ì1 —á@F‘æ26‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiVŠƒj2014,10
  135. Žðˆär‰îAŠÛ“cr‰îAHŽR‘åŽ÷A¯ ’q–çA²“¡ –¾AÂÀ˜a—²FIgG4 ŠÖ˜AŽ¾Š³‚ɍ‡•¹‚µ‚½’˜–¾‚ÈŠ¥“®–¬•Ç”ìŒú‚ð”F‚ß‚½•sˆÀ’è‹·SÇ‚̈ê—áF45‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠÖ“ŒbM‰z’n•û‰ï2014,10
  136. ’†–±’q•¶C¼@Œ÷CÎ‹´^—RC—é–؏ˎiC²“¡@–¾CÂÀ˜a—²F•¡”‰ñ‚ÌŒŸ¸‚Őf’f‚µ‚¦‚½tŒŒŠÇ«‚ŒŒˆ³‚Ì“ñÇ—áF‘æ22‰ñˆïézŠÂŠíŒ¤‹†‰ïiˆïéj2014,11
  137. ’Ëȕۏ²CŠÛ“cr‰îCŽðˆär‰îCHŽR‘åŽ÷C¯@’q–çC²“¡@–¾CÂÀ˜a—²FŠ¥¹k«‹·SÇ‚Ì”­Ç‚ÉŽq‹{“÷Žî‚ɑ΂·‚éƒzƒ‹ƒ‚ƒ“—Ö@‚ÌŠÖ—^‚ª‹^‚í‚ꂽˆê—áF‘æ22‰ñˆïézŠÂŠíŒ¤‹†‰ïiˆïéj2014C11

@2013”N“xi2013”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. ‰|–{^”üCÎ’Ã’qŽqC£”ö—RLCŽðˆä@rC—é–؍_–¾Cìã@NC“‡–ì@mCÂÀ˜a—²F“œ”A•a‚É‚¨‚¯‚鍶–[stiffness‚ÆŒŒ´ƒŒƒvƒ`ƒ“‚Æ‚ÌŠÖ˜A.‘æ47‰ñ“ú–{¬l•a(¶ŠˆKŠµ•a)Šw‰ï (“Œ‹ž) 1ŒŽC2013
  2. —é–؁@“Ä, ŽR“àNÆ, –ö‰º“Ö•F, ²“¡O“T, ‰Pˆä‰p—S, ì‰Š°“¹, ‹{è—ºˆê, ŽRŒû“O—Y, Œ´@M”Ž, ¬¼—T“ñ, ”~–{•üK, ‹{–{‹M—f, ”ö—с@“O, •½”öŒ©ŽO, ÂÀ˜a—²D‚ˆÊ‰E–[’†Šu‚ł̏Ď܂ɂæ‚荪Ž¡‚µ“¾‚½perimitral atrial flutter‚̈ê—áD‘æ25‰ñ—Տ°•s®–¬Œ¤‹†‰ï(“Œ‹ž)@1ŒŽC2013
  3. ›–쏺Œ›Cì¼’¼lC–Ø‘S@Œ[,Žðˆär‰îC²“¡Šó”üC’·’Jì’q–¾Cì•Ó³”VC£”ö—RLC˜ð“c•qCÂÀ˜a—²C¬—јalC“‡–ìm.ƒAƒ~ƒIƒ_ƒƒ“Œ¸—Ê‚ðŒ_‹@‚É”­Ç‚µ‚½ƒAƒ~ƒIƒ_ƒƒ“—U”­«bó‘B’†“ŏǂ̈ê—á.‘æ227‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï(“Œ‹ž)@2ŒŽC2013
  4. ˜ð“c@•q, ŒÜ\—’“s, ŠÖŒûK•v, ŽRè@_, •–ØŒ’Žu, ’¬–ì@‹B, ˆä“¡—tŽq, –Ø‘S@Œ[, Î’Ã’qŽq, £”ö—RL, ÂÀ˜a—², šê“c@_F¶ã‘åÃ–¬ˆâŽcŒo—R‚ʼnESŽº‚¨‚æ‚э¶SŽºƒŠ[ƒh‚ð‘}“ü‚µS‘ŸÄ“¯Šú—Ö@‚ðs‚Á‚½–«S•s‘S‚̈ê—á.‘æ5‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï(“Œ‹ž)2ŒŽC2013
  5. ˆÀ“‡—Ç‹PŽq, ”~’Á@“w, •ì‚Ý‚âŽq, ŽRè@_, ŒÜ\—’“s, ŠÖŒûK•v, ÂÀ˜a—²FICDƒVƒ‡ƒbƒNƒŠ[ƒh—¯’u’†‚É,“ào‚É‘½—Ê‚ÌŒŒ‰t¬“ü‚ð”F‚ߍė¯’u‚Æ‚È‚Á‚½1Ç—áD‘æ5‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï(“Œ‹ž)2ŒŽC2013
  6. ”~’Á@“w, ˆÀ“‡—Ç‹PŽq, •ì‚Ý‚âŽq, k@‹±ˆê, ŽRè@_, ŒÜ\—’“s, ŠÖŒûK•v, ÂÀ˜a—²FƒfƒoƒCƒXŠO—ˆ‚É‚¨‚¯‚é1ŽžŠÔˆÈã‚̃NƒŒ[ƒ€‚ð‘i‚¦‚ç‚ꂽ3Ç—á‚©‚çŠw‚ԁD‘æ5‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï(“Œ‹ž)2ŒŽC2013
  7. £ì«lCŒË“c@’¼C›Á@Œ³‹gC‚–Ø—S‰îC–©’J@–LCŽR–{‹`lC™@³•¶CÂÀ˜a—²C‰ºìG–¾FIsoproterenol“Š—^‚ªelectrical storm‚̃Rƒ“ƒgƒ[ƒ‹‚É—LŒø‚Å‚ ‚Á‚½J wave syndrome‚̈ê—áD‘æ11‰ñ“Á”­«SŽº×“®Œ¤‹†‰ïiJ-IVFSj(“Œ‹ž)@2ŒŽC2013
  8. Seo Y, Aonuma KFLeft Ventricular Activation Imaging by 3D-Speckle Tracking Echocardiography. ‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  9. Aita T, Igarashi M, Kuroki K, ItoY, Machino T, Yamasaki H, Sekiguchi Y, Kuga K, Aonuma K: Prolongation of the Coupling Interval of Idiopathic Ventricular Arrhythmias is a Strong Predictor for Late Success of Catheter Ablation.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  10. Kimata A, Sekiguchi Y, Aita T, Kuroki K, Machino T, ItoY, Yamasaki H, Igarashi M, Aonuma K:Prognostic Impacts of the Ventricular Fibrillation Inducibility after Catheter Ablation of Recurrent Ventruculat Tachycardia in Patients with Healed Myocardial Infarction.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  11. Tachibana M, Murakoshi N, Xu D, Yamamoto M, Sekiguchi Y, Seo Y, Aonuma K:Clinical Feature and Risk Factors for Left Atrial Appendage Thrombus in Patient with Atrial Fibrillation with Low CHADS2 Score.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  12. Himi T, Koike A, Nagayama O, Sakurada K, Kato J, Yamashita T:A Spiral Phenomenon in the Plot of CO2 Output vs. O2 Uptake in Cardiac Patients with Oscillatory Breathing.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  13. Xu D, Murakoshi N, Igarashi M, ItoY, Seo Y, Tada H, Aonuma K:PPAR-gamma Activator Pioglitazone Prevents Age-related Atrial Fibrillation Susceptibility by Reducing Apoptosis in Rat Model.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  14. Yamasaki H, Murakoshi N, Xu D, ItoY, Igarashi M, Sekiguchi Y, Tada H, Aonuma K:Vulnerability of Atrial Fibrillation is Increased in a Rat Model of Metabolic Syndrome Via Phosphorylation of Calcium- Calmodulin-Dependent Protein Kinase II.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  15. Wang Z, Satoh A, Kimura T, Sakai S, Imanaka K, Hiroe M, Aonuma K:Tenascin-C Plays a Significant Role in Left Ventricular Remodeling in the Remote Myocardium Following Infarction in Mice Model.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  16. Higuchi H, Endo Y, Adachi T, Yamauchi R, Tsuneoka H, Suzuki A, Eki Y, Seo Y, Watanabe S, Aonuma K:Higher Oxidation State of LDL-Cholesterol, Even with Statin Therapy, is Strongly Associated with the Recurrence of Angina Pectoris.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  17. Maruyama H, Dewachter C, Sakai S, Belhaj A, Rondelet B, Remmelink M, Vachiery J, Naeije R, Dewachter L:Endothelin-1 Downregulates BMP Signaling in Pulmonary Artery Smooth Muscle cells.Kawamatsu N, Seo Y, Nakajima H, Sato K, Sugano A, Atsumi A, Yamamoto M, Machino-Ohtsuka M, Machino.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  18. T, ItoY, Kuroki K, Yamasaki H, Kawamura R, Igarashi M, Sekiguchi Y, Ishizu T, Aonuma K:Prevalence and Risk Factors of Tricuspid Regurgitation Caused by Pacemaker Device Leads.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  19. Watabe H, Satoh A, Takaiwa Y, Sai S, Harunari T, Kakefuda Y, Hiranuma Y, Fumikura Y, Nishina H, Noguchi Y, Aonuma K:Effect of Stain Therapy on Long-Term Outcome after Percutaneous Coronary Intervention in Patients with Low Low-Density Lipoprotein Cholesterol.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  20. Hikita H, Shigeta T, Kozima K, Hishikari K, Osaka Y, Kawaguchi N, Yamao K, Nakashima E, Akiyama D, Sugiyama T, Watari Y, Takigawa M, Handa K, Kamiishi T, Ohkubo K, Kimura S, Takagi K, Kuwahara T, Satoh A, Takahashi A, Isobe M:Coronary Flow Velocity and Fluid Shear Stress at Follow-up Angiography Predict Late Catch-up after Sirolimus-Eluting Stent Implantation.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  21. Himi T, Koike A, Nagayama O, Sakurada K, Kato J, Yamashita T:Clinical Significance of Oscillatory Breathing During Exercise in Patients with Cardiac Patients.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  22. Misaki M, Satoh A, Abe D, Takeyasu N, Yui Y, Maruta M, Aonuma K:Clinical Outcome of Bare-metal Stents Implantation in the Patients with ST-segment Elevation Myocardial Infarction in Drug-eluting Stent Era.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  23. Maruta S, Takeyasu N, Abe D, Misaki M, Yui Y, Yoshida K, Hoshi T, Satoh A, Aonuma K:Clinical Value of Everolimus-Eluting Stents over Bare-Metal Stents in ST-segment Elevated Myocardial Infarction; From ICAS Registry.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  24. Nagayama O, Koike A, Sakurada K, Kato J, Himi T, Yamashita T, Aonuma K:Mechanisms Underlying Disappearance of Oscillatory Ventilation During Exercise in Cardiac Patients.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  25. Toyama M, Watanabe S, Kuroda Y, Isono H, Honda J, Nakagawa Y, Okubo S, Satoh A, Seo Y, Aonuma K, Study IHAT:The Interindividual Variation in Blood Pressure and Pulse Rate of the Diabetes. From Ibaraki Hypertension Assessment Trial (I-HAT).‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  26. Seo Y, Aonuma K:Speckle Tracking Echocardiography in Assessing Vulnerable Myocardial Characteristics.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  27. Sekiguchi Y, Takagi M, Aihara N, Yokoyama Y, Aonuma K, Hiraoka M:New Mechanism of Ventricular Arrhythmias in the Patients with Idiopathic Ventricular Fibrillation; from the J-IVFS Database.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  28. Higuchi H, Endo Y, Adachi T, Yamauchi R, Tsuneoka H, Suzuki A, Eki Y, Seo Y, Watanabe S, Aonuma K:Vascular Susceptibility to Anti-inflammatory Effect of Statin Evaluated by FDG-PET/CT is Strongly Associated with Coronary Event in Acute Myocardial Infarction.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  29. Iwazaki M, Yamashita E, Takeuchi M, Ishizu T, Seo Y, Izumo M, Suzuki K, Miyake F, Aonuma K, Otsuji Y, Oshima S:Aortic Valve Replacement for Japanese Paradoxical Low-Flow Severe Aortic Stenosis: Retrospective Multicenter Study.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  30. Yoshitani H, Takeuchi M, Yamashita E, Oshima S, Ishizu T, Seo Y, Aonuma K, Izumo M, Suzuki K, Miyake F, Otsuji Y:Left Chamber Mechanics in Patients with Paradoxical Low Flow Low Gradient Severe Aortic Stenosis: A Multicenter Study.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  31. Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Kuroki K, Machino T, ItoY, Murakoshi N, Kuga K, Aonuma K:Effect of Sinus Rhythm Restoration by Extensive Antiarrhythmic Drugs in Predicting Results of Catheter Ablation of Persistent Atrial Fibrillation.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  32. Yamashita E, Takeuchi M, Izumo M, Ishizu T, Seo Y, Suzuki K, Miyake F, Aonuma K, Otsuji Y, Oshima S:Prognosis of Paradoxical Low-Flow Profile in Japanese Aortic Valve Stenosis: Retrospective Multicenter Study.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  33. Satoh A, Machino T, Kimura T, Hoshi T, Murakoshi N, Seo Y, Watanabe S, Aonuma K:Current Status of Blood Pressure Control and Antihypertensive Therapy in Patients with Resistant Hypertension ?Ibaraki Hypertension Assessment Trial-.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  34. ItoY, Yoshida K, Kandori A, Ogata K, Nakazawa Y, Inaba T, Sekihara K, Aonuma K:A Novel Magnetocardiography Algorithm for Localizing the Origin of Idiopathic Ventricular Outflow Tract Tachycardia.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  35. Kawabe M, Hoshi T, Satoh A, Takeyasu N, Aonuma K:Predictive Value of Serum Uric Acid on Clinical Outcome in Patients with Coronary Artery Disease Undergoing Coronary Revascularization.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  36. Hiraya D, Obara K, Hatori M, Nakanishi K, Maeda H, Hoshi T, Satoh A, Aonuma K:Impact of Body Mass Index on Clinical Outcomes in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  37. Hikita H, Shigeta T, Kojima K, Hishikari K, Osaka Y, Kawaguchi N, Yamao K, Nakashima E, Akiyama D, Sugiyama T, Watari Y, Takigawa M, Kamiishi T, Ohkubo K, Kimura S, Takagi K, Kuwahara T, Satoh A, Takahashi A, Isobe M:Impact of Statin Use before Acute Myocardial Infarction on Coronary Plaque, Inflammatory Response, and Viable Myocardium.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  38. Okaniwa H, Yamashita E, Takeuchi M, Izumo M, Ishizu T, Seo Y, Suzuki K, Miyake F, Aonuma K, Otsuji Y, Oshima S:Influences of Gender Difference and Body Size on the Prevalence of Paradoxical Low Flow Aortic Valve Stenosis in Japanese Population.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  39. Sato K, Seo Y, Iida N, Kawamatsu N, Sugano A, Atsumi A, Yamamoto M, Harimura Y, Machino-Ohtsuka M, Kawamura R, Enomoto M, Ishizu T, Aonuma K:Two-dimensional Speckle Tracking Echocardiography is Useful to Assess the Low-Flow, Low-Gradient Severe Aortic Stenosis Despite Normal Ejection Fraction.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  40. Kuroki K, Tada H, Nemoto D, Igawa M, Yamasaki H, Igarashi M, Sekiguchi Y, Enomoto T, Koseki S, Aonuma K:Who and Which Part of the Heart Has Abundant Epicardial Fat in Japanese Subjects?: A Quantitative Computed Tomographic Analysis.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  41. Nakajima H, Seo Y, Sato K, Sugano A, Atsumi A, Machino-Ohtsuka M, Yamamoto M, Kawamura R, ItoY, Kuroki K, Machino T, Yamasaki H, Igarashi M, Sekiguchi Y, Ishizu T, Aonuma K:A Visualization of the Left Atrial Appendage Morphologyby Newly Developed Three Dimensional Transesophageal Echocardiography.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  42. Nakamura A, Kato Y, Ishizu T, Seo Y, Aonuma K:Pulmonary Regurgitation Impairs Left Ventricular Free Wall Contraction in Repaired Tetralogy of Fallot.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  43. Tajiri K, Shimojoh N, Sakai S, Machino-Ohtsuka M, Kimura T, Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Aonuma K:Pitavastatin Regulates Helper T-cell Differentiation through the Inhibition of Rheb and mTOR Signaling.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  44. Abe D, Takeyasu N, Misaki M, Maruta S, Yui Y, Yoshida K, Hoshi T, Satoh A, Aonuma K:Drug-eluting Versus Bare-metal Stents in Large Coronary Arteries in the Patients with ST-segment Elevation Myocardial Infarction: from ICAS Registry.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  45. Toyama M, Watanabe S, Kuroda Y, Isono H, Honda J, Nakagawa Y, Okubo S, Satoh A, Seo Y, Aonuma K, Study IHAT:Effects of Antihypertensive-Drug Class on Interindividual Variation of Blood Pressure with and without Diabetes. From Ibaraki Hypertension Assessment Trial (I-HAT).77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  46. Sakai S, Wang Z, Kimura T, Tajiri K, Maruyama H, Honma S, Kuga K, Miyauchi T, Aonuma K:Cardio-specific Overexpression of the RNA Polymerase II Phosphatase FCP1 Induces Severe Cardiac Dysfunction in Mice.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  47. Xu D, Sairenchi T, Irie F, Igarashi M, Murakoshi N, Sekiguchi Y, Tomizawa T, Yamaguchi I, Iso H, Aonuma K:Anemia and Reduced Kidney Function as Risk Factors for AF Incidence - The Ibaraki Prefectural Health Study.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  48. Sato K, Seo Y, Ishizu T, Takeuchi M, Izumo M, Suzuki K, Yamashita E, Oshima S, Miyake F, Otsuji Y, Aonuma K:Prognostic Value of Echocardiographic Parameters in Patients with Unoperated Severe Aortic Stenosis in Japan; Multi-center Study.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  49. Kawabe M, Hoshi T, Satoh A, Takeyasu N, Aonuma K:Impact of Blood Urea Nitrogen for Long-term Risk Stratification in Patients with Coronary Artery Disease.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  50. Murakoshi N, Kawano S, Xu D, Sekiguchi Y, Yoshida K, Kaneshiro T, Yamasaki H, Kuroki K, Machino T, ItoY, Naruse Y, Seo Y, Tada H, Aonuma K:Immunohistochemical Analysis of Endocardial Biopsy Samples in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  51. Hoshi T, Satoh A, Kawabe M, Sakai S, Takeyasu N, Aonuma K:Short- and Long-term Prognostic Value of Plasma Glucose and White Blood Cell on Admission in Patients with Acute Myocardial Infarction.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  52. Naruse Y, Satoh A, Hoshi T, Kakefuda Y, Abe D, Nishina H, Takeyasu N, Enomoto T, Aonuma K:Impact of Triple Antithrombotic Therapy on Clinical Outcomes and Major Bleeding Complications after Percutaneous Coronary Intervention; Results from ICAS Registry.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  53. Kimura T, Satoh A, Kakefuda Y, Adachi T, Ojima E , Watabe H, Ishizu T, Seo Y, Aonuma K:Impact of Carotid Plaque Echogenicity for Prediction of Coronary Vulnerable Plaque in Asymptomatic Patients with Diabetes Mellitus.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  54. Kaneshiro T, Kato Y, Sekiguchi Y, Tada H, Nogami A, Goya M, Takagi M, Horigome H, Aonuma K:Prognostic Effects of Catheter Ablation Targeting the Triggering Arrhythmia in Inherited Chatecholaminergic Polymorphic Ventricular Tachycardia and Brugada Syndrome.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  55. Igarashi M, Tada H, Kurosaki K, Yamauchi Y, Kuroki K, Yamasaki H, Machino T, Sekiguchi Y, Naito S, Nogami A, Aonuma K:Detailed ECG Analyses may Enable the Differential Diagnosis of Ventricular Arrhythmias Arising from Subdivided Portions within the Left-sided Outflow Tract.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  56. Sugano A, Seo Y, Kawamatsu N, Sato K, Atsumi A, Yamamoto M, Machino-Ohtsuka M, Harimura Y, Kawamura R, Enomoto M, Ishizu T, Aonuma K:Left Ventricular Longitudinal Strain by Two-dimensional Speckle Tracking Images as Predictive Factor of Arrhythmic Events in Patients with Hypertrophic Cardiomyopathy.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  57. Kakefuda Y, Satoh A, Harunari T, Hiraya D, Watabe H, Ojima E, Hoshi T, Abe D, Nishina H, Takeyasu N, Noguchi Y, Aonuma K:Long Term Prognostic Value of Persistent Renal Damage after Onset of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angioplasty.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  58. Sugano A, Seo Y, Kawamatsu N, Sato K, Atsumi A, Yamamoto M, Machino-Ohtsuka M, Harimura Y, Kawamura R, Enomoto M, Ishizu T, Aonuma K:Left Ventricular Dyssynchrony Relates with Myocardial Fibrosis Burden in Patients with Narrow QRS Duration and Left Ventricular Dysfunction.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  59. Machino-Ohtsuka M, Tajiri K, Kimura T, Yasutomi Y, Hiroe M, Aonuma K, Imanaka -Yoshida K:Tenascin-C Aggravates Myocardial Inflammation in Experimental Autoimmune Myocarditis in Mice.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  60. Atsumi A, Ishizu T, Kameda Y, Yamamoto M, Machino-Ohtsuka M, Nogami Y, Enomoto M, Seo Y, Aonuma K:Application of Three-Dimensional Speckle Tracking Imaging to Right Ventricular Regional Deformation Assessment.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  61. Ishizu T, Kameda Y, Kawamura R, Shimojoh N, Seo Y, Aonuma K:The Relation between Longitudinal Left Ventricular Systolic Deformation and Chamber Function in Hypertensive Heart Disease Rat Model.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  62. Machino T, Sekiguchi Y, Igarashi M, Kuroki K, Naruse Y, Yamasaki H, ItoY, Yoshida K, Aonuma K:Left Atrial Appendage Function Predicted the Outcome of Long-standing Persistent Atrial Fibrillation Treated with the Index and Repeat Catheter Ablations.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  63. Abe D, Takeyasu N, Misaki M, Maruta S, Yui Y, Yoshida K, Hoshi T, Satoh A, Aonuma K:Prognostic Impact of Rennin-Angiotensin System Inhibitors: Propensity Score Analysis from ICAS Registry.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  64. Izumo M, Takeuchi M, Seo Y, Yamashita E, Suzuki K, Ishizu T, Sato K, Oshima S, Aonuma K, Miyake F, Otsuji Y:Projected Aortic Valve Area Reflects True Severity in Patients with Paradoxical Low-Flow Low-Gradient Severe Aortic Stenosis: A Multicenter Study.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  65. Atsumi A, Ishizu T, Yamada S, Shiga T, Arita T, Dohi K, Maruo T, Furugen A, Takenaka K, Seo Y, Aonuma K:The Prognostic Impact of Right Ventricular Dysfunction on Cardiac Resynchronization Therapy: a Study from START Study.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  66. Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Kuroki K, Machino T, ItoY, Kaneshiro T, Kuga K, Aonuma K:Low Voltage Area in the Left Atrium is Strong Predictor for Atrial Fibrillation Recurrences Following Ablation: Who is More Susceptible.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  67. ItoY, Yoshida K, Kaneshiro T, Murakoshi N, Yamasaki H, Kuroki K, Machino T, Naruse Y, Aita T, Kimata A, Igarashi M, Sekiguchi Y, Aonuma K:Inflammatory State before Ablation is Associated with Recurrence of Atrial Fibrillation in Patients with Persistent Atrial Fibrillation after Ablation.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  68. Kuroki K, Sekiguchi Y, Kazuaki Kaitani, Igawa M, Koyama T, Nitta J, Yamauchi Y, ItoY, Machino T, Yamasaki H, Xu D, Igarashi M, Murakoshi N, Aonuma K:Long-term Efficacy of an Extremely Low Voltage Areatargeted Linear Ablation for Postinfarction Ventricular Tachycardia: Results of the Multicenter J-PIVT-study.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  69. Nakanishi K, Fukuda S, Watanabe H, Seo Y, Hyohdoh E, Ishizu T, Shimada K, Aonuma K, Yoshiyama M, Yoshikawa J:Utility of Fully Automated Real-time Three-dimensional Echocardiography for Assessment of Left Ventricular Diastolic Function.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  70. Harimura Y, Seo Y, Ishizu T, Noguchi Y, Aonuma K:Predictors of Persistent or Worsening Ischemic Mitral Regurgitation in the Chronic Phase of Myocardial Infarction.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  71. Nogami Y, Seo Y, Atsumi A, Yamamoto M, Ishizu T, Aonuma K:Wave Intensity as a Noninvasive Modality in Assessing Heart Failure Pathophysiology Based on Ventriculo-Arterial Coupling.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  72. Sai S, Seo Y, Ishikawa K, Takeyasu N, Yamanouchi T, Maeda H, Tokunaga T, Kawano S, Aonuma K:Clinical Impact of Tolvaptan, Vasopressin Receptor Antagonist, in Refractory Volume Overload Heart Failure from Ibaraki Multicenter Experiences.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  73. Kuwahara T, Takahashi A, Ohkubo K, Takagi K, Takigawa M, Watari Y, Nakashima E, Yamao K, Kawaguchi N, Osaka Y, Sugiyama T, Akiyama D, Kimura S, Hikita H, Satoh A, Aonuma K:Clinical Characteristics of Periesophageal Nervous Injury Complicating Left Atrial Ablation of Atrial Fibrillation: Lessons from 11 Cases.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  74. Atsumi A, Ueda K, Irie F, Sairenchi T, Watanabe H, Iso H, Aonuma K:The Assessment of the Effect of Extreme Hot Weather on Cardiovascular Mortality with Risk Stratification: The Ibaraki Prefectural Health Study.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  75. Yamamoto M, Seo Y, Kawamatsu N, Sato K, Sugano A, Atsumi A, Machino-Ohtsuka M, Kawamura R, Inaba T, Sekiguchi Y, Ishizu T, Aonuma K:Usefulness of Electrical Propagation Assessed byMagnetocardiography to Predict Response to Cardiac Resynchronization Therapy.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  76. Abe D, Takeyasu N, Misaki M, Maruta S, Yui Y, Yoshida K, Hoshi T, Satoh A, Aonuma K:Clinical Value of Everolimus-Eluting Stent Over Zotarolimus-Eluting Stents: From Result of Ibaraki Cardiovascular Assessment Study (ICAS) Registry.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  77. Yamamoto M, Seo Y, Sato K, Sugano A, Machino-Ohtsuka M, Kawamura R, Nakajima H, Igarashi M, Sekiguchi Y, Ishizu T, Aonuma K:Left Atrial Appendage Morphology Relates with Left Atrial Appendage Thrombus Formation in Patients with Atrial Fibrillation.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  78. Aita T, Yamasaki H, Kuroki K, Naruse Y, ItoY , Machino T, Igarashi M, Sekiguchi Y, Kuga K, Aonuma K:Prevalence and the Efficacy of the Catheter Ablation of Ventricular Arrhythmias in Patients receiving Cardiac Resynchronization Therapy.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  79. Igarashi M, Sairenchi T, Irie F, Murakoshi N, Xu D, Tada H, Sekiguchi Y, Tomizawa T, Yamaguchi I, Iso H, Aonuma KFVentricular Premature Complexes in Healthy Subjects were Independent Risk Factors for Cardio-Vascular Disease Mortality in the Large-Scale Community-Based Cohort Study.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  80. Tada H, Naruse Y, Sekiguchi Y, Yamasaki H, Igarashi M, Kuroki K, Machino T, Ishizu T, Seo Y, Aonuma K:The Left Atrial Volume is a Strong Echocardiographic Parameter for Predicting Recurrence of Atrial Fibrillation Following Radiofrequency Catheter Ablation.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  81. ÂÀ˜a—²:QT ‰„’·ÇŒóŒQiæ“V«E“ñŽŸ«j‚ÆBrugada ÇŒóŒQ‚̐f—ÂɊւ·‚éƒKƒCƒhƒ‰ƒCƒ“i2012 ”N‰ü’ù”Łj.77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  82. ‹{“à—T”ü, ƒWƒFƒXƒ~ƒ“EƒTƒuƒŠƒi, Žðˆä@r, ‰ºžŠMˆÐ, ‘O“c´Ži, –{ŠÔ@Šo, “n•Óds, ÂÀ˜a—², ‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“A/B —¼Žó—e‘ÌŽÕ’f–ò‚̐S‘Ÿ‚Ɛt‘Ÿ‚ɑ΂·‚éŒø‰ÊF‚ŒŒˆ³”ì‘åSA“œ”A•a«S‹ØÇA‚ŒŒˆ³«ŒŒŠÇáŠQ‚̃‚ƒfƒ‹‚É‚¨‚¢‚Ä.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  83. ’†“‡ ‰pŽ÷, £”ö—RL, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t•, ã–q@—², “ì–؁@—Z, Î’Ã’qŽq, ìã@N, ÂÀ˜a—²:‘å“®–¬•Ù‹·óÇ•ÙŒû–ʐόv‘ª’l‚ÉŠÖ‚·‚éDoppler –@‚Æ3D SƒGƒR[–@‚É‚æ‚é”äŠrŒŸ“¢.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  84. Ô¯”Ž˜a, •Ÿ“c—²“¿, ’¹‰H´Žu˜N, âŒ³—Y‰î, k@‹±ˆê, ìã@N, •½’J‘åŒá, ¯@’q–ç, ²“¡@–¾, ÂÀ˜a—²:ƒVƒƒŠƒ€ƒX—no«ƒXƒeƒ“ƒg‚Ìfracture ‚ªŠÖ—^‚·‚é‚Æ‹^‚í‚ê‚éÄ‹·ó•”ˆÊ‚ðŠeŽíimaging modality ‚É‚æ‚茟“¢‚µ‚½ˆê—á.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  85. ˆî—t@•, ‹g“cŒ’‘¾˜Y, ’†àV—zŽq, ‰Á“¡ˆ¤Í, ŠÖŒûK•v, Î’Ã’qŽq, ²“¡@–¾, £”ö—RL, –x•Ä@mŽu, “n•Ó ds, ÂÀ˜a—²:SŽºŠúŠOŽûkiVPCj‚Ì‚R•ûŒüSŽ¥}ƒpƒ^[ƒ“‚ÌŒŸ“¢.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  86. k@‹±ˆê, ²“¡@–¾, ’¹‰H´Žu˜N, âŒ³—Y‰î, Ô¯”Ž˜a, ìã@N, ˆÀ“‡—Ç‹PŽq, ”~’Á@“w, Žðˆär‰î, ¯@’q–ç, ÂÀ˜a—²:Everolimus-Eluting stent —¯’uŒã‚̃Xƒeƒ“ƒgV¶“à–Œ”í–Œó‘Ԃɂ‚¢‚ÄŒŒŠÇ“àŽ‹‹¾ŠŒ©‚ÆOCT ‚Å‚Ì”äŠrŒŸ“¢.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  87. âŒ³—Y‰î, k@‹±ˆê, ’¹‰H´Žu˜N, Ô¯”Ž˜a, ìã@N, ˆÀ“‡—Ç‹PŽq, ”~’Á@“w, Žðˆär‰î, ¯@’q–ç, ²“¡@–¾, ÂÀ˜a—²F‹}«Š¥ÇŒóŒQ(ACS)‚É‚¨‚¯‚éŒo”ç“IŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Žž‚Ì“®–¬ˆ³S”o—Ê‘ª’èƒVƒXƒeƒ€‚ð—p‚¢‚½ŒŒs“®‘Ԃɂ‚¢‚Ä‚ÌŒŸ“¢.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  88. ’¹‰H´Žu˜Y, k@‹±ˆê, âŒ³—Y‰î, Ô¯”Ž˜a, ŒÃŠ_’B–ç, ìã@N, Žðˆär‰î, ¯@’q–ç, ²“¡@–¾, ÂÀ˜a—²F–«t‘Ÿ•aŠ³ŽÒ‚É‚¨‚¯‚éS‘ŸƒJƒe[ƒeƒ‹ŒŸ¸EŽ¡—ÃŽž‚̃ˆ[ƒh‘¢‰eÜ‚ªt‹@”\‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚Ä.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  89. ”~’Á@“w, ˆÀ“‡—Ç‹PŽq, •ì‚Ý‚âŽq, k@‹±ˆê, ŽRè@_, ‹àé‹MŽm, ŒÜ\—’“s, ŠÖŒûK•v, ÂÀ˜a—²:S‘ŸA‚¦ž‚ÝŒ^ƒfƒoƒCƒX(High power device)A‰“Šuƒ‚ƒjƒ^ƒŠƒ“ƒO‚É‚æ‚é–³ÇŒó«ƒCƒxƒ“ƒg‚ÌRetrospective analysis.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  90. ŸNˆä@ˆ¤, ˆÀ“‡—Ç‹PŽq, ”~’Á@“w, •ì‚Ý‚âŽq, “¡àVL‹g, k@‹±ˆê, ŽRè@_, ŒÜ\—’“s, ŠÖŒûK•v, ÂÀ˜a—²F’·ŽžŠÔ‚ð—v‚·‚é•s®–¬ƒJƒe[ƒeƒ‹Ž¡—Âɔº‚¤Œûo“àŠ£‘‡ŒyŒ¸ô‚ÌŒŸ“¢.‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï(‰¡•l) 3ŒŽC2013
  91. ›–쏺Œ›C£”ö—RLCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCj‘º‰À]Cì‘º@—´C‰|–{^”üCÎ’Ã’qŽqCÂÀ˜a—²F”ì‘åŒ^S‹ØÇŠ³ŽÒ‚É‚¨‚¯‚é•s®–¬ƒCƒxƒ“ƒg‚Æ2ŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚Æ‚ÌŠÖ˜A.‘æ110‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ï(“Œ‹ž) 4ŒŽC2013
  92. •½’J‘¾ŒáC¬Œ´Œ’ˆêC‰H’¹Œõ°C’†¼Œ[‘¾C‘O“c—TŽjC¯@’q–çC²“¡@–¾CÂÀ˜a—²FŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½Š¥“®–¬Ž¾Š³Š³ŽÒ‚ÌBMI‚ƐSŒŒŠÇƒCƒxƒ“ƒg‚ÌŠÖ˜A.‘æ110‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ï(“Œ‹ž) 4ŒŽC2013
  93. ’†“‡‰pŽ÷C£”ö—RLC²“¡Šó”üC›–쏺Œ›Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCì‘º@—´C‰|–{^”üCÎ’Ã’qŽqCÂÀ˜a—²Ff’f‰¿’l‚Ì‚ ‚é‰æ‘œ‚ƗՏ°ˆã‚ª‹‚߂錟¸ƒŒƒ|[ƒg‚Æ‚Í‚È‚É‚©.“ú–{’´‰¹”gˆãŠw‰ï‘æ86‰ñŠwpW‰ï (‘åã) 5ŒŽC2013
  94. –ìã‰ÀŒbC£”ö—RLCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCÎ’Ã’qŽqCÂÀ˜a—²F‚—îŽÒ‚ŒŒˆ³Ç—á‚É‚¨‚¯‚éWave-Intensity ‚̈Ӌ`‚ɂ‚¢‚Ä.“ú–{’´‰¹”gˆãŠw‰ï‘æ86‰ñŠwpW‰ï (‘åã) 5ŒŽC2013
  95. ˆ­”üˆÀ‹IŽqCÎ’Ã’qŽqC£”ö—RLCÂÀ˜a—²CSTART@investigatorsFS‘ŸÄ“¯Šú—Ö@‚ÌŒø‰Ê—\‘ª‚É‚¨‚¯‚é‰EŽº‹@”\•]‰¿‚Ì•t‰Á“I‰¿’lFSTART Œ¤‹†‚©‚ç‚ÌŒŸ“¢.“ú–{’´‰¹”gˆãŠw‰ï‘æ86‰ñŠwpW‰ï (‘åã) 5ŒŽC2013
  96. ŽR–{¹—ǁC£”ö—RLCì¼’¼lC²“¡Šó”üC›–쏺Œ›Cˆ­”üˆÀ‹IŽqC’¬–ì’qŽqC’†“‡‰pŽ÷CÎ’Ã’qŽqCÂÀ˜a—²F¶–[ˆ³‚̏㏸‚͍¶SŽ¨‚ðŠg‘傳‚¹‚é‚©.“ú–{’´‰¹”gˆãŠw‰ï‘æ86‰ñŠwpW‰ï (‘åã) 5ŒŽC2013
  97. ’†‘ººGC–x•ÄmŽuC£”ö—RLCÎ’Ã’qŽqCÂÀ˜a—²Fƒtƒ@ƒ[Žl’¥ÇªŽ¡pŒã‚̍¶ŽºŽ©—R•Ç‚̋ǏŠ•Ç‰^“®‚͒ቺ‚·‚é.“ú–{’´‰¹”gˆãŠw‰ï‘æ86‰ñŠwpW‰ï (‘åã) 5ŒŽC2013
  98. ²“¡Šó”üC£”ö—RLC’|“à³–¾Co‰_¹Ž÷CŽR‰º‰pŽ¡C‘哇@–΁CŽO‘î—Ç•FC”ö’ҁ@–LCÂÀ˜a—²FdÇ‘å“®–¬•Ù‹·óÇ‚̃GƒR[Žw•W‚É‚æ‚é—\Œã•]‰¿‚ÌŒŸ“¢.“ú–{’´‰¹”gˆãŠw‰ï‘æ86‰ñŠwpW‰ï (‘åã) 5ŒŽC2013
  99. ›–쏺Œ›C£”ö—RLCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCj‘º‰À]Cì‘º@—´CÎ’Ã’qŽqCÂÀ˜a—²FQRS •‚Ì‹·‚¢¶ŽºŽûkáŠQŠ³ŽÒ‚É‚¨‚¯‚éS‹ØüˆÛ‰»‚ƍ¶Žº”ñ“¯Šú‚ÌŠÖ˜A.“ú–{’´‰¹”gˆãŠw‰ï‘æ86‰ñŠwpW‰ï (‘åã) 5ŒŽC2013
  100. –Ø‘S@Œ[CŒÜ\—’@“sC•–ØŒ’ŽuCŽRú±@_C˜ð“c@•qC’¬–ì@‹BCˆä“¡—tŽqCŠÖŒûK•vCÂÀ˜a—²D•¡”‚Ì‹ts«’x“`“±˜H‚ð”F‚߁A‰E–[‘¤‚¨‚æ‚э¶–[‘¤‚©‚ç’Ê“d‚ð—v‚µŽ¡—Âɓïa‚µ‚½‹H—LŒ^–[ŽºŒ‹ß‰ñ‹A«•p”‚̈ê—á.‘æ43‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïiˆ¤’mj2013
  101. HŽR ‘åŽ÷C¯@’q–çC‘å’J’¨ŽjCì¼’¼lC•½’J‘åŒáCt¬’q•FC²“¡@–¾CÂÀ˜a—²D’¼Œa8mm‚ð’æ‚·‚é’˜–¼‚ÈPositive vessel remodeling‚𔺂Á‚½ƒVƒƒŠƒ€ƒX—no«ƒXƒeƒ“ƒgAž‚ÝŒã‚Ì’´’x”­«ƒXƒeƒ“ƒgŒŒðÇ‚̈ê—á.‘æ3‰ñŠÖ“ŒŒŒŠÇ“àŽ‹‹¾Œ¤‹†‰ï@6ŒŽC2013
  102. ˆÀ’B@‹œCŒÜ\—’“sCŽRè@_C•–ØŒ’ŽuC’¬–ì@‹BCˆä“¡—tŽqC–ûˆäŒcWCŠÖŒûK•vC–ìãº•FCÂÀ˜a—².’x‰„“dˆÊ‚Ɉê’v‚µ‚½•¡”‚̐SŽºáŽ‚ðCARTOSOUND‚É‚ÄŒŸo‚Å‚«‚½Šî‘bSŽ¾Š³•s–¾‚̐SŽº•p”Ç—áD‘æ3‰ñŠÖ“ŒƒAƒuƒŒ[ƒVƒ‡ƒ“ƒtƒƒ“ƒeƒBƒA(“Œ‹ž)@6ŒŽC2013
  103. Ahmed TCSato NCSugiyama ECSakamoto NCTanabe YCKawamura YCAonuma KCHasebe NFIntra-Noctural Analysis of Rate-Dependent Ventricular Repolarization: Insight into the Pathophysiology of Sudden Cardiac Death in Early Repolarization Syndrome.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  104. Machino-Ohtsuka TCSeo YCMachino TCKuroki KCYamasaki HCIgarashi MCSekiguchi YCAonuma KFElimination of Atrial Fibrillation by Catheter Ablation Suppresses Adverse Cardiac Events in Patients with Heart Failure Preserved Ejection Fraction.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  105. Igarashi MCTada HCKurosaki KCSekiguchi YCYamasaki HCKuroki KCMachino TCNogami ACAonuma KFElectrocardiographic Determinants of the Polymorphic QRS Morphology in Idiopathic Right Ventricular Outflow Tract Tachycardia.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  106. Aonuma K:OMI.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  107. Naruse Y, Nogami A, Yamasaki H, Igarashi M, Sekiguchi Y, Kowase S, Kurosaki K, Kato K, Aonuma KFEarly Repolarization Increases the Occurrence of Life-Threatening Ventricular Tachyarrhythmia in Patients with Non-Ischemic Heart Disease.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  108. Hattori A, Suematsu Y, Igawa M, Tachibana M, Naruse Y, Enomoto T, Morizumi M, Aonuma K, Kato J, Kaneshiro TFMinimum Invasive Epicardial Lead Implantation in an Electrical Storm Patient after Pacing Failure of the Left Ventricle: a Bailout Method.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  109. Ito Y, Igarashi M, Yamasaki H, Kuroki K, Machino T, Adachi T, Sekiguchi Y, Aonuma KFHigh-Sensitivity C-Reactive Protein Level is a Predictor of Recurrence after Catheter Ablation in the Patients with Persistent Atrial Fibrillation.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  110. Kuroki K, Igarashi M, Ishizu T, Sato A, Yamasaki H, Ito Y, Machino T, Hu D, Murakoshi N, Sekiguchi Y, Seo Y, Aonuma KFThe Relationship between the Duration of Arial Fibrillation and Atherosclerosis.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  111. Adachi T, Endo Y, Yamauchi R, Higuchi H, Tsuneoka H, Suzuki A, Eki Y, Takeyasu N, Hoshi T, Sato A, Aonuma KFPrognostic Impact of Atrial Fibrillation in Patients withAcute Coronary Syndrome from Ibaraki Cardiovascular Assessment Study (ICAS) Registry.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  112. Kimata A, Sekiguchi Y, Aita A, Kuroki K, Machino T, Ito Y, Yamasaki H, Igarashi M, Ishizu T, Seo Y, Aonuma KFPredictive Factors of the Intravascular Lead Infection in the Patients with Cardiac Implantable Electrophysiological Device Infection.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  113. Xu D, Murakoshi N, Aonuma KFPreventive Effect of Corticosteroid on Recurrence of Atrial Fibrillation after Radiofrequency Catheter Ablation.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  114. Ito Y, Igarashi M, Yamasaki H, Kuroki K, Machino T, Aita A, Kimata A, Sekiguchi Y, Aonuma KFThe Relationship between Early Recurrence and Late Recurrence of Atrial Tachyarrhythmias after Catheter Ablation of Atrial Fibrillation.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  115. Suzuki A, Yamauchi Y, Yagishita A, Sato H, Miyamoto T, Obayashi T, Hirao K, Aonuma KFPerimitral Atrial Flutter withPseudo Conduction Block at Mitral Isthmus.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  116. Yamasaki H, Kuroki K, Machino T, Ito Y, Kimata A, Aita S, Igarashi M, Sekiguchi Y, Aonuma KFOutcome of Esophageal Luminal Temperature Monitoring Guided Ablation on Development of the Asymptomatic Excessive Transmural Injury after Extensive Pulmonary Vein Isolation.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  117. Igarashi M, Ageyama N, Katakai Y, Murakoshi N, Yui Y, Kuroki K, Xu D, Sekiguchi Y, Tada H, Aonuma KFA Non-Human Primate Model of Atrial Fibrillation withAtrial Electrical and Structural Remodeling Using Atrial Tachypacing.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  118. Aita S, Kimata A, Ito Y, Naruse Y, Machino T, Kuroki K, Yamasaki H, Igarashi M, Sekiguchi Y, Seo Y, Kuga K, Aonuma KFDabigatoran vs Warfarin for Periprocedural Anticoagulation Therapy in Radiofrequency Ablation for Atrial Fibrillation.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  119. Yui Y, Yoshida K, Maruta S, Misaki M, Abe D, Takeyasu N, Aonuma KFImpact of Right Atrial and Ventricular Conduction Disturbance on the Diagnosis of Type B WPW Syndrome in a Patient who Underwent Atrial Septal Defect Repair.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  120. ”~’Á@“wCˆÀ“‡—Ç‹PŽqC•ì‚Ý‚âŽqCk@‹±ˆêC•–ØŒ’ŽuCŽRè@_CŒÜ\—’“sCŠÖŒûK•vCÂÀ˜a—²FAž‚ÝŒ^ƒfƒoƒCƒXŠ³ŽÒ‚É‚¨‚¯‚éS–[«•s®–¬‚ɑ΂·‚éR•p”ƒy[ƒVƒ“ƒO‚ÌŠˆ—p‚Ɛ„§.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  121. Aonuma K: Beyond LDL Cholesterol- Possibility of Omega-3 Fatty Acids in Antiarrhythmic.‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï(“Œ‹ž)7ŒŽC2013
  122. ˆ­”üˆÀ‹IŽqCã“c‰À‘ã,“ü]‚Ó‚¶‚±C¼˜A’n—˜ŒÈ,“n•ÓGCˆé”ŽN,ÂÀ˜a—²F‚ŒŒˆ³ÇŠ³ŽÒ‚É‚¨‚¯‚é‹C‰·‚ƏzŠÂŠíŽ¾Š³Ž€–S‚ÌŠÖŒWFThe Ibaraki Prefectural Health Study(IPHS)‚æ‚è.‘æ46‰ñˆïéŒ§‚ŒŒˆ³Œ¤‹†‰ïŠwpu‰‰‰ï(‚‚­‚Î)@7ŒŽC2013
  123. ˆÀ’B@‹œCŠÖŒûK•vC–Ø‘S@Œ[C˜ð“c@•qC•–ØŒ’ŽuCˆä“¡—tŽqC’¬–ì@‹BCŽRè@_CŒÜ\—’“sC‹v‰êŒ\—SCÂÀ˜a—²F“d‹C“Iœ×“®‚É•s‰ž«‚ŃAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚è’âŽ~‚µ“¾‚½”ñ‹•ŒŒ«SŽº•p”‚̈ê—áD‘æ229‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï(“Œ‹ž)@9ŒŽC2013
  124. ŠÛ“cr‰îC–ûˆäŒcWC”üè¹ŽqC‹g“cŒ’‘¾˜YCˆÀ”{‘å•ãC•ˆÀ–@”VC²“¡@–¾CÂÀ˜a—²C“¿‰iç•äCH“‡M“ñCåŒ´ŒªF‹}«¶S•s‘S‚Å”­Ç‚µ‚½S‘ŸŒ´”­Malignant fibrous histiocytoma(MFH)‚̈ê—áD‘æ229‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï(“Œ‹ž)@9ŒŽC2013
  125. ’¬–ì’qŽqC£”ö—RLCÎ’Ã’qŽqCŒÜ\—’@“sCŠÖŒûK•vCÂÀ˜a—²DElimination of Atrial Fibrillation by Catheter Ablation Suppresses Adverse Cardiac Events in HFPEF.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j2013
  126. £”ö—RLCÂÀ˜a—²DSƒGƒR[‚É‚æ‚郌ƒXƒ|ƒ“ƒ_[—\‘ªFJ-CRT,STARTŒ¤‹†‚©‚ç.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  127. ˆÀ“‡—Ç‹PŽqC”~’Á@–±C•ì‚Ý‚âŽqCŒÜ\—’@“sCŽRú±@_CŠÖŒûK•vC–ìãº•FCÂÀ˜a—²DƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚¨‚¯‚éŠÅŒìŽt‚Ì–ðŠ„.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  128. £”ö—RLCÂÀ˜a—²DƒŠƒo[ƒXEƒŠƒ‚ƒfƒŠƒ“ƒO‚Ö‚Ì’§íFCRT.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  129. ì¼’¼lC£”ö—RLC’†“‡‰pŽ÷C²“¡Šó”üC›–쏺Œ›Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCˆä“¡—tŽqC•–ØŒ’ŽuCŽRè@_Cì‘º@—´CŒÜ\—’@“sCŠÖŒûK•vCÎ’Ã’qŽqCÂÀ˜a—²Dƒy[ƒXƒ[ƒJƒŠ[ƒh‚Æ‹Nˆö«ŽOë•Ù‹t—¬Ç‚Ì—L•a—¦‹y‚уŠƒXƒNƒtƒ@ƒNƒ^[‚ɂ‚¢‚Ä‚ÌŒŸ“¢.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  130. ¬£‘ãŽm‹vC¬˜a£W–íC•èŒ’ŽiCˆÀ”{‘å•ãC‹g“cŒ’‘¾˜YC’|ˆÀ–@”VCÂÀ˜a—²D‰ESŽºë•”ƒy[ƒVƒ“ƒO‚ª¶Žºˆê‰ñ”o—Ê‚É—^‚¦‚鈫‰e‹¿.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  131. ²“¡Šó”üC£”ö—RLCÎ’Ã’qŽqC’|“à³–¾Co‰_¹Ž÷C—é–ØŒ’ŒáCŽR‰º‰pŽ¡C‘哇@–΁CŽO‘î—Ç•FC”ö’ҁ@–LCÂÀ˜a—²D’á—¬—ʒሳŠr·dÇ‘å“®–¬•Ù‹·óÇ‚Ì—\Œã•]‰¿‚É‚¨‚¯‚éLongitudinal strain‚Ì—L—p«.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  132. Î’Ã’qŽqC£”ö—RLCŠÖŒûK•vCÂÀ˜a—²DWPWÇŒóŒQ‚É‚¨‚¯‚éSƒGƒR[‚RŽŸŒ³ƒXƒyƒbƒNƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½•›“`“±˜H‚Ì•]‰¿.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  133. ˆä“¡—tŽqC–ìãº•FCŽRè@_C¬£‘ãŽm‹vC•–ØŒ’ŽuC’¬–ì@‹BCŒÜ\—’@“sCŠÖŒûK•vCÂÀ˜a—²D’·ŠúŽ‘±Œ^S–[×“®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚¨‚¯‚郌ƒjƒ“[ƒAƒ“ƒWƒIƒ“ƒVƒ“[ƒAƒ‹ƒhƒXƒeƒƒ“Œn‘jŠQ–ò‚Ì•¹—pŒø‰Ê‚ɂ‚¢‚Ä.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  134. ÂŽRŒ‹ŠóCÂÀ˜a—²C£”ö—RLCÎ’Ã’qŽqCì‘º@—´C’¬–ì’qŽqCŽR–{¹—ǁCˆ­”üˆÀ‹IŽqC‰|–{^”üC²“¡@½DS•s‘SŠ³ŽÒ‚ɑ΂·‚é—zˆ³Š·‹C—Ö@‚ÌŒø‰Ê.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  135. ›–쏺Œ›C£”ö—RLC²“¡Šó”üCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCj‘º‰ÀŒbCì‘º@—´CÎ’Ã’qŽqC–ìŒû—SˆêCÂÀ˜a—²D”ì‘åŒ^S‹ØÇ‚É‚¨‚¯‚鍶Žº
  136. Šâ‘ë–ƒˆßC£”ö—RLC‰i“c‘ו¶CŒK–؁@PC‘å’J‹±ŽqC–F’J‰prC’|“à³–¾C”ö’ҁ@–LCÂÀ˜a—²DS‘ŸÄ“¯Šú—Ö@‚É‚æ‚鍶Žº‹@”\‰ü‘P‚̋Ǎ݁F‚QŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½ŒŸ“¢.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  137. ‰H’¹Œõ°C’†¼Œ[‘¾CŽðˆär‰îC¬Œ´Œ’ˆêC‘O“c—TŽjCÂÀ˜a—²D‹¹’É‚ðŽå‘i‚É—ˆ‰@‚µ‚½‹ÇŠS‹Ø‰Š‚Ì2Ç—á.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  138. ì¼’¼lCÎ’Ã’qŽqCŒº@“NŽ÷C˜ð“c@•qC–Ø‘S@Œ[CŽðˆär‰îC²“¡Šó”üC›–쏺Œ›C‰Á“¡@õCì•Ó³”VC‹–@“ŒŸªC–Ø‘º‘׎OCŒ´@—BŽjC‰|–{‰ÀŽ¡C£”ö—RLCÂÀ˜a—²Dƒy[ƒXƒ[ƒJƒŠ[ƒh‹Nˆö«ŽRë•Ù‹t—¬Ç‚Ì—L•a—¦‹y‚уŠƒXƒNƒtƒ@ƒNƒ^[‚ɂ‚¢‚Ä‚ÌŒŸ“¢.‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŒF–{j,2013
  139. –ö‰º“Ö•FCŽR“àNÆC²“¡O“TCŽR‰º@ŽüC•½”ö—´•FCì‰Š°“¹C‰Pˆä‰p—SC‹{è—ºˆêCŽRŒû“O—YCŒ´@M”ŽC”~–{•üKC‹{–{‹M—fC”ö—с@“OC•½”öŒ©ŽOCÂÀ˜a—²DTermination without global capture‚ð”F‚ß‚½•”ˆÊ‚Å‚Ì’Ê“d‚É‚æ‚èSŽº•p”‚Ì’âŽ~‚ª“¾‚ç‚ê‚È‚©‚Á‚½w‹Œ«S‹Ø[Ç‚Ì1—á.‘æ30‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiÂXj,2013
  140. –Ø‘S@Œ[C‹g“cŒ’‘¾˜YC‘•{“c®–îC‰Á“¡@õC”nê‰ëŽqC”üè¹ŽqCˆÀ”{‘å•ãCÂÀ˜a—²C•ˆÀ–@”VDŒƒ—ó‚ȏǏ󂪓Á’¥“I‚Å‚ ‚Á‚½–ò•¨Ž¡—Ã’ïR«‚Ìincessant typeS–[•p”‚Ì3—á.‘æ30‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiÂXj,2013
  141. –쎛@õC•“cŠ°lC“n糏r‰îC‹ààVWŽqCÎ“cŒå˜NC‰““¡‹³ŽqCVÈŒ’•vC¬¼é•vC’|Î‹±’mCŠÖŒûK•vCÂÀ˜a—²D‚¢‚©‚È‚é•û–@‚É‚Ä‚à’âŽ~¢“ï‚ÈŽ‘±«SŽº•p”‚ɑ΂µA‹~‹}‚ŐSŠO–ŒƒAƒvƒ[ƒ`‚ɂăAƒuƒŒ[ƒVƒ‡ƒ“‚ɐ¬Œ÷‚µ‚½SƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—á.‘æ30‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiÂXj,2013
  142. ˆÀ’B@‹œCŒÜ\—’@“sCì¼’¼lC˜ð“c@•qC–Ø‘S@Œ[C¬ìF“ñ˜YCTalib AhmedCŽOŽ÷—SŽqC–ûˆäŒcWCˆä“¡—tŽqC’¬–ì@‹BC•–ØŒ’ŽuCŽRè@_CŠÖŒûK•vC–ìãº•FCÂÀ˜a—²DSŽº•p”ŠîŽ¿‚Ì“¯’è‚ÉCARTO sound‚ª—LŒø‚Å‚ ‚Á‚½SƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—á.ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ï2013i‰¡•lj,2013
  143. ‹àé‹MŽmC—é–؁@‹ÏC_ŽR”ü”VC’†—¢˜a•FCÖ“¡CˆêC’|Î‹±’mCÂÀ˜a—²DŒoS–[’†ŠuƒAƒvƒ[ƒ`‚ɂĐSŽº•p”‚̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ɐ¬Œ÷‚µ‚½‹‘å‚ȍ¶ŽºáŽ‚𔺂¤Šg’£Œ^S‹ØÇ‚Ì1—á.ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ï2013i‰¡•lj,2013
  144. ˜ð“c@•qCˆäì¹KC•ž•”@ˆ¤C“à“c–õlCV‹G˜YC‰äÈŒ«ŽiC‰|–{‹­ŽuC–ìãº•FCÂÀ˜a—²D•p”‹NŒ¹‚Ì“¯’肪¢“ï‚Å‚ ‚Á‚½”xÃ–¬Šu—£pŒãS–[•p”‚Ì1—á.ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ï2013i‰¡•lj,2013
  145. –Ø‘S@Œ[CŒÜ\—’@“sC˜ð“c@•qC¬ìF“ñ˜YCŽOŽ÷—SŽqCAhamed@TalibC–ûˆäŒcWCˆÀ’B@‹œCˆä“¡—tŽqC’¬–ì@‹BC•–ØŒ’ŽuCŠÖŒûK•vC–ìãº•FCÂÀ˜a—²D¶Žº—¬o˜H‹NŒ¹‚̐SŽºŠúŠOŽûk‚ɑ΂µ‚Ä‘å“®–¬•Ù‰ºS“à–Œ‘¤‚©‚ç‚Ì’Ê“dŒã‚ÉŠ¥“®–¬‹·ó‚𐶂¶‚½1—á.ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ï2013i‰¡•lj,2013
  146. –ö‰º“Ö•FCŽR“àNÆC²“¡O“TCŽR‰º@ŽüC•½”ö—´•FC‰Pˆä‰p—CCì‰Š°“¹C‹{è—ºˆêCŒ´@M”ŽCŽRŒû“O—YC”~–{•üKC‹{–{‹M—fC”ö—с@“OC•½”öŒ©ŽOCÂÀ˜a—²DRSPV“à‚ÌFar-Field“dˆÊ‚Ì‹@ŠB“IÁŽ¸‚ðØ–¾‚µAATP‚É‚æ‚éSVC‚̍ۓ`“±‚ðŒ°Ý‰»‚µ‚¦‚½”­ì«S–[×“®‚Ì1—á.ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ï2013i‰¡•lj,2013
  147. ›–쏺Œ›CÎ’Ã’qŽqC‹à–{^–çC•½¼—S“ñC£”ö—RLCÂÀ˜a—².A Hybrid Cardiac Resynchronization Therapy in Patient with Failing Systemic Right Ventricle after SenningProcedure for Transposition of the Great Arteries Š®‘S‘匌ŠÇ“]ˆÊÇS–[ƒXƒCƒbƒ`pŒã‚̑̏zŠÂSŽº•s‘S‚ɑ΂µ“à‰ÈŠO‰È‡“¯‚ł̐S‘ŸÄ“¯Šú —Ö@‚ðs‚Á‚½ˆê—á.‘æ17‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï2013i‘å‹{j,2013
  148. ŽR–{¹—ǁC£”ö—RLCˆî—t@•C’†àV—zŽqCÎ’Ã’qŽqCÂÀ˜a—².Electrical Dyssynchrony Assessed by Magnetocardiography Related to Mechanical Dyssynchrony in Patients with Cardiac Resynchronization Therapy SŽ¥}‚É‚æ‚é“d‹C“I“`“±‰ðÍ‚ÍCRTŠ³ŽÒ‚É‚¨‚¯‚é‹@ŠB“I”ñ“¯Šú‚Æ‘ŠŠÖ‚·‚é.‘æ17‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï2013i‘å‹{j,2013
  149. £”ö—RLCÂÀ˜a—²CJ-CRT@Investigators.Features of Cardiac Resynchronization Therapy in Patients with Cardiac Sarcoidosis SƒTƒ‹ƒRƒCƒh[ƒVƒX‚É‚¨‚¯‚éS‘ŸÄ“¯Šú—Ö@‚Ì“Á’¥‚ɂ‚¢‚Ä.‘æ17‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï2013i‘å‹{j,2013
  150. ²“¡Šó”üC£”ö—RLCÎ’Ã’qŽqC‰xŠì@–LCÂÀ˜a—²DRegional Changes of Myocardial Function after Aortic Valve Replacement in Aortic Stenosis with Preserved Ventricular Function by Speckle Tracking Echocardiography.ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚édÇ‘å“®–¬•Ù‹·óÇ‚Ì‘å“®–¬•Ù’uŠ·pŒã‚̐S‹@”\•Ï‰»‚ÌŒŸ“¢.‘æ17‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï2013i‘å‹{j,2013
  151. t¬’q•FCŽðˆä@rCì•Ó³”VC›Á@¯‰ÍC’·’Jì’q–¾C–Ø‘º‘׎OC–{ŠÔ@ŠoCÂÀ˜a—²C•½¼—SŽiC‹à–{^–çC‰|–{‰ÀŽ¡CåŒ´@ŒªFS–[’†ŠuŒ‡‘¹•Â½p‚É‘ˆ«‚µ‚½”x‚ŒŒˆ³Ç‚ɑ΂µ‚ăVƒ‹ƒfƒiƒtƒBƒ‹‚ªŒø‰Ê‚ðŽ¦‚µ‚½ˆê—áD‘æ230‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï(“Œ‹ž)C2013

@2012”N“xi2012”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. Î’Ã’qŽqC£”ö—RLC–{ŠÔ@ŠoC’†“‡‰pŽ÷CÂÀ˜a—²FS–[×“®Ž¡—ÃŒã‚Ì“´’²—¥—á‚É‚¨‚¯‚鍶SŽ¨“à‚à‚â‚à‚âƒGƒR[‚ÌŒŸ“¢D‘æ15‰ñˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ïi‚‚­‚΁j1ŒŽC2012
  2. ˆÀ’B@‹œCŠÖŒûK•vC—RˆäŒcWC’†–ìŒb”üC•–ØŒ’ŽuC‹àé‹MŽmCˆä“¡—tŽqC’¬–ì@‹BCŽRè@_CŒÜ\—’“sC‹g“cŒ’‘¾˜YCšê“c@_C‹v‰êŒ\—S¤ÂÀ˜a—²FpŽ®•sÚ‚ÌŠJSpŒã‚̐S–[•p”‚ɑ΂µ‚ďڍׂÈmapping ‚É‚æ‚è‰ñ˜H‚Ì“¯’è‚ð‚µ“¾‚½1—áD‘æ24‰ñ—Տ°•s®–¬Œ¤‹†‰ïi“Œ‹žj1ŒŽC2012
  3. •½’J‘åŒáC¯@’q–çC²“¡@–¾C‰Í–ì@—¹CŽRŒû@ŠÞCÂÀ˜a—²F”xÃ–¬Šu—£p‚ðŽ{s‚µ‚½S–[×“®Š³ŽÒ‚É‚¨‚¯‚銥“®–¬Ž¾Š³—L•a—¦‚ÉŠÖ‚·‚錟“¢D‘æ46‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žj1ŒŽC2012
  4. –ìã‰ÀŒbC£”ö—RLCÎ’Ã’qŽqC‹T“c—L—¢CXŽR^‹ICì‘º@—´CŽR–{¹—ǁCí‰ªG˜aC‰Í–ì@—¹CŽRŒû@›ÜCÂÀ˜a—²F‰^“®‘Ï—e”\‚ð‹K’è‚·‚éS- ŒŒŠÇ‹@ŠÖ‚Ì‘ã•\“IŽw•WƒEƒF[ƒuEƒCƒ“ƒeƒ“ƒVƒeƒB‚Ì—L—p«D‘æ46‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žj1ŒŽC2012
  5. ‹{“à@‘ìC‘O“c´ŽiC‹{“à—T”üCŽðˆä@rC›Œ´@‡C‰ºžŠMˆÐCƒWƒFƒXƒ~ƒ“EƒTƒuƒŠƒiC–{ŠÔ@ŠoC“n•ÓdsCÂÀ˜a—²FƒGƒ“ƒhƒZƒŠƒ“‚¨‚æ‚Ñ‘O‹ì‘̃rƒbƒOƒGƒ“ƒhƒZƒŠƒ“‚̃qƒg‚É‚¨‚¯‚錌’†”Z“x‚¨‚æ‚ÑŽó—e‘ÌA/B ŽÕ’f–òƒ{ƒZƒ“ƒ^ƒ“‚Ì”½‰ž«D‘æ41‰ñ“ú–{S–¬ŠÇì“®•¨Ž¿Šw‰ïiH“cj2ŒŽC2012
  6. ˆÀ’B@‹œC‹g“cŒ’‘¾˜YC—RˆäŒcWC’†–ìŒb”üC•–ØŒ’ŽuC‹àé‹MŽmCˆä“¡—tŽqC’¬–ì@‹BCŽRè@_CŒÜ\—’“sCŠÖŒûK•vCÎ’Ã’qŽqC£”ö—RLCšê“c@_C‹v‰êŒ\—SCÂÀ˜a—²FSŽº3“_ƒy[ƒVƒ“ƒO‚Ì—LŒø«‚ªŠm”F‚³‚ꂽŠg’£Œ^S‹ØÇ‚É‚æ‚édÇ¶S•s‘S‚Ì1—áD‘æ4‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi–k‹ãBj2ŒŽC2012
  7. ‹Ê–ö‰ëOC–“–ì‘å•ãC–Ȋс@OCA‘~ˆêC”~’Á@“wCˆÀ“‡—Ç‹PŽqC‹g“cŒ’‘¾˜YC’†–ìŒb”üC•–ØŒ’ŽuC‹àé‹MŽmCˆä“¡—tŽqC’¬–ì@‹BCŽRè@_CŒÜ\—’“sCŠÖŒûK•vCšê“c@_CÂÀ˜a—²FFar-field R Wave –hŽ~‹@”\‚É‚æ‚è•s“KØ‚ɐS–[«•s®–¬’âŽ~‚Æ”FŽ¯‚µ‚½1—áD‘æ4‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi–k‹ãBj2ŒŽC2012
  8. •–ØŒ’ŽuCšê“c@_CŠÖŒûK•vCÂÀ˜a—²Cˆäì¹KC‰|–{‹­ŽuC¬ŠÖ@猁F«Šú‰EŽºƒŠ[ƒhúE‚Ì’›Œó‚Æ‚µ‚趋¹–Œ‰Š‚¨‚æ‚уmƒCƒY‚̃I[ƒo[ƒZƒ“ƒVƒ“ƒO‚ªŠÏŽ@‚³‚ꂽ1Ç—áD‘æ4‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi–k‹ãBj2ŒŽC2012
  9. –ûˆäŒcWCŠÖŒûK•vC‹àé‹MŽmC‹g“cŒ’‘¾˜YC’†–ìŒb”üC•–ØŒ’ŽuCŽRè@_Cšê“c@_CÂÀ˜a—²CåŒ´@ŒªFzŠÂŠí“à‰ÈEzŠÂŠíŠO‰È‚Ìhybrid Ž¡—ÂɂčªŽ¡‚µ‚¦‚½CƒŠ[ƒhŠÖ˜AŠ´õÇ‚Ì3—áD‘æ4‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi–k‹ãBj2ŒŽC2012
  10. k@‹±ˆêCìã@NCˆÀ“ˆ—Ç‹PŽqC”~’Á@“wCŠÖŒûK•vC•–ØŒ’ŽuC‹àé‹MŽmCŽRè@_C‹g“cŒ’‘¾˜YCšê“c@_CÂÀ˜a—²F“–‰@‚̃fƒoƒCƒXƒŠ[ƒh”²‹Ž‹Æ–±‚ÌŽæ‚è‘g‚݂ɂ‚¢‚āD‘æ4‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi–k‹ãBj2ŒŽC2012
  11. Žðˆär‰îC“n•ÓdsCŠOŽR¹OC•“c—T‹vCÂÀ˜a—²FŒJ‚è•Ô‚·Ž¸_¸¸’†‚É–³ÇŒó«‚ÌŠ¥¹k‚ª–¾‚ç‚©‚Æ‚È‚èC‚»‚ÌŒã3•ªŽ}“¯Žž•ÂÇ‚Ì‹}«S‹Ø[Ç‚𔭏ǂµ‚½Ç—áD‘æ223‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽC2012
  12. ˆÀ’B@‹œC‹àé‹MŽmC‹g“cŒ’‘¾˜YC–ûˆäŒcWC’†–ìŒb”üC•–ØŒ’ŽuCž­“c–[‹ICˆä“¡—tŽqC’¬–ì@‹BCŽRè@_CŒÜ\—’“sCŠÖŒûK•vCšê“c@_C‹v‰êŒ\—SCÂÀ˜a—²F‰E‹rƒuƒƒbƒNŒ^SŽº•p”‚ɑ΂µ‚ĉEŽº—¬o˜H‚©‚ç‚̏Ď܂Ŏ¡—ɔ\‚Å‚ ‚Á‚½Fallot Žl’¥ÇpŒãSŽº•p”‚̈ê—áD‘æ223‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽC2012
  13. t¬’q•FCm‰ÈG’CŠ|ŽD—YŠîC‹k@Œ«œACj‘º‰À]CŒË“c@’¼C•¶‘ —DŽqC•½À‚ä‚èC–ìŒû—SˆêCÂÀ˜a—²Fƒgƒ‹ƒoƒvƒ^ƒ“‚É‚æ‚Á‚ĉü‘P‚µ‚½dÇ‹•ŒŒ«S•s‘S‚̈ê—áD‘æ223‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽC2012
  14. ÂÀ˜a—²F‹³ˆçƒZƒbƒVƒ‡ƒ“‡VFuS–[×“®‚̐V‚½‚ȍl‚¦•ûv‘æ223‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽC2012
  15. Seo Y, Yamada S, Arita T, Dohi K, Ishizu T, Shiga T , FurugenA , Maruo T, Murata K, Yuda S, Fumikura Y, Yamashita E, Tsuruta H, Daimon M, Ozawa T, Kawai H, Izumi C, Inoue K , Nishigami K, Takenaka K, Aonuma K: Speckle Tracking Imaging for the Assessment of Cardiac Resynchronization TherapyiSTARTjStudy. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïLate Breaking Clinical Triali•Ÿ‰ªj3ŒŽC2012
  16. Seo Y: Application of 3-Dimensional Speckle Tracking Imaging to Evaluate Regional Function. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  17. Satoh A, Hoshi T, Watabe H, Kakefuda Y, Adachi T , Ojima E, Akiyama D, Murakoshi N, Seo Y, Aonuma K: Impact of Spotty Calcification on Computed Tomography for Prediction of Cardiac Troponin Elevation after Percutaneous Coronary Intervention. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  18. Seo Y, Ishizu T, Sugano A, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R , Enomoto M , Aonuma K: New Developed 3-dimensional Dyssynchrony Imaging by Speckle Tracking Echocardiography. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  19. Sekiguchi Y, Tada H, Yoshida K, Igarashi M, Kuroki K, Machino T, Yamasaki H, Nakano E, Kaneshiro T, Aonuma K: Utility of 3-Dimensional Electroanatomic Mapping and Ablation for Ventricular Tachycardias in Patients with Nonischemic Heart Disease: A Substrate Modification Approach. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  20. Ishizu T, Seo Y, Koshizuka R, Kameda Y, Atsumi A, Yamamoto M, Kawamura R, Aonuma K: Underlying Cause and Functional Importance of Left Ventricular Long Axis Dysfucntion in Heart Failure with Preserved Ejection Fraction. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  21. Kuga K, Xu D, Ohtsuka M, Aonuma K: Current Status and Prevention of Cardiovascular Diseases in University Students. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  22. Seo Y: Speckle Tracking Echocardiography Provides Breakthrough or Might be a One-hit Wonder in Assessing Diastolic Function. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  23. Seo Y: 3D Speckle Tracking Imaging in Assessing Cardiac Geometry and Function. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  24. Ishizu T, Seo Y, Aonuma K: Clinical Impact of Carotid Ultrasound in Cardiovascular Medicine. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  25. Hoshi T, Satoh A, Aonuma K, Takeyasu N: Efficacy of Long Term Beta-blocker Treatment on Clinical Outcome after Coronary Angioplasty; Propensity Score Matched Analysis from ICAS Registry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  26. Kuroki K, Tada H, Seo Y, Ishizu T, Igawa M, Igarashi M, Yamasaki H, Machino T, Naruse Y, Sekiguchi Y, Murakoshi N, Aonuma K: Short-coupled Ventricular Premature Contractions with a Following Atrial Contraction cause Hemodynamic Deterioration: A New Concept of VPC-induced Left Ventricular Dysfunction. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  27. Kameda Y, Ishizu T, Enomoto M, Koshiduka R, Atsumi A, Yamamoto M, Kawamura R, Nogami Y, Seo Y, Suzuki H, Kawakami Y, Shimano H, Aonuma K: Diagnostic Utility of Echocardiography Derived Left Ventricular Myocardial Strain in Subclinical Diabetic Cardiomyopathy. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  28. Naruse Y, Takeyasu N, Hayashi M, Misaki M, Abe D, Hoshi T, Satoh A, Aonuma K: Triple Antithrombotic Therapy is Associated with the Increasing Risk of Major Bleeding Complications; Results from the ICAS Registry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  29. Sakai S, Nakagawa Y, Shimojoh N, Kuga K, Honma S, Shimano H, Aonuma K: Involvement of Sterol Regulatory Element Binding Protein-1iSREBP-1jin Angiotensin IIInduced Cardiac Injury via Chronic Inflammatory Responses. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  30. Naruse Y, Tada H, Harimura Y, Hayashi M , Takeyasu N , Satoh A , Sekiguchi Y , Yoshida K , Aonuma K: Close Relationship between Ventricular Fibrillation in the Chronic Phase of Acute Myocardial Infarct ion and Early Repolarization. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  31. Xu D, Murakoshi N, Sairenchi T , Irie F, Igarashi M, Tsuneoka H, Otaka E, Tada H, Sekiguchi Y , Tomizawa T, Yamaguchi I, Iso H, Aonuma K: The Relationships of Proteinuria, Glomerular Filtration Rate with Incidence of Atrial Fibrillation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  32. Hattori A, Kuga K , Yamasaki H , Watanabe S, Sekiguchi Y, Tada H , Aonuma K, Kohro T, Yamazaki T, Nagai R, Shiga T, Hagiwara N: Prognosis of Patients with Myocardial Infarction and Left Ventricular Dysfunction: Nation-wide Comparison with JCAD and Other Major Japanese and Western Studies. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  33. Kuroki K, Yoshida K, Sekiguchi Y, Kaitani K, Igarashi M, Yamasaki H, Machino T, Naruse Y, Kaneshiro T, Nakano E, Tsuneoka H, Ito Y, Adachi T , Yui Y Hattori A, Murakoshi N, Tada H, Kuga K, Aonuma K: Long-term Outcome of Catheter Ablation Guided by High-Density Substrate Map in Patients with Post-Infarction Ventricular Tachycardia. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  34. Naruse Y, Sekiguchi Y, Machino T, Yamasaki H, Igarashi M, Kuroki K, Ito Y, Nakano E, Kaneshiro T, Tada H, Okada H, Yamauchi Y, Aonuma K: The Clinical Outcome of Multimodality Therapy to Ventricular Tachycardia Associated with Cardiac Sarcoidosis. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  35. Machino T, Tada H , Sekiguchi Y , Kuroki K, Yamasaki H, Naruse Y, Igarashi M, Ito Y, Yoshida K, Aonuma K: The Prevalence and Long-term Outcome of Hyperthyroidismr elated Atrial Fibrillation in Candidates for the Radiofrequency Catheter Ablation of Drug-resistant Atrial Fibrillation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  36. Sakai S, Watanabe S, Kuroda Y, Toyama M, Nakagawa Y, Okubo S, Satoh A, Seo Y, Aonuma K, Study IHAT: Actual Condition and its Clinical Implications of the Difference of the Home Blood Pressures Measured Repeatedly on One Occasion. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  37. Tachibana M, Sekiguchi Y, Yamasaki H, Yoshida K, Tada H, Aonuma K: Electrocardiographic Characteristics of Ventricular Tachycardia Originating from the Epicardium in Dilated Cardiomyopathy. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  38. Nakano E, Tada H , Sekiguchi Y , Yoshida K , Igarashi M , Yamasaki H , Machino T , Kuroki K, Kaneshiro T, Ito Y, Adachi T, Yui Y, Aonuma K: Are Radiofrequency Energy Applications within Aortic Sinus Cusp for Curing Ventricular Arrhythmias Really Effective and Safe in the Long Run? ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  39. Murakoshi N, Xu D, Sairenchi T, Igarashi M, Irie F, Tomizawa T, Yamaguchi I, Iso H, Ota H, Aonuma K: The Presence of Supraventricular Premature Complexes is Associated with Increased Risk for Cardiovascular Death and All-cause Death in General Population. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  40. Hoshi T, Satoh A , Kakefuda Y, Hiraya D, Nishina H, Noguchi Y, Aonuma K: Favorable Vascular Healing Response after Everolimus-eluting Stent Implantation Using by Coronary Angioscopy; Comparison with First Generation Drug-eluting Stent. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  41. Kato J, Nagayama O, Sakurada K, Nishi I, Yamashita T, Aonuma K: Calculation Window is Important for the Determination of VE-VCO2 Slope in Cardiac Patients. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  42. Tachibana M, Sekiguchi Y, Ishizu T, Yoshida K, Xu D, Murakoshi N, Tada H, Seo Y, Aonuma K: Clinical Feature and Therapeutic Strategy for Left Atrial Appendage Thrombus Complicated with Atrial Fibrillation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  43. Harimura Y, Seo Y , Ishizu T, Nishina H, Toda S, Fumikura Y, Hiranuma Y, Noguchi Y, Aonuma K: Onset and Persistent Mechanism of Ischemic Mitral Regurgitation in Patients with Acute Myocardial Infarction. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  44. Yamamoto M, Seo Y, Sakamaki F, Atsumi A, Kawamura R, Nakajima H, Iida N, Enomoto M, Ishizu T, Yoshida K, Sekiguchi Y, Tada H, Aonuma K: Prognostic Significance of Remaining Severe Left Ventricular Diastolic Dysfunction after Cardiac Resynchronizaion Therapy. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  45. Abe D, Takeyasu N, Hayashi M, Naruse Y, Misaki M, Hoshi T, Satoh A, Aonuma K: Culprit-only Versus Multivessel Percutaneous Coronary Intervention in Patients with STsegment Elevated Myocardial Infarction: From ICAS Registry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  46. Ito Y, Yoshida K, Murakoshi N, Satoh Y, Inaba T, Igarashi M, Aonuma K: Magnetocardiography Visualizes the Origin of Atrial Premature Contraction Hidden in T Wave. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  47. Adachi T, Yoshida K, Yui Y , Nakano E, Kuroki K, Kaneshiro T, Ito Y, Machino T, Yamasaki H, Igarashi M, Sekiguchi Y, Tada H, Kuga K, Aonuma K: Catheter Ablation of Atrial Tachycardia Involving Intra-Atrial Septum: Its Procedural Characteristics and the Clinical Outcomes. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  48. Yamamoto M, Seo Y, Sakamaki F, Atsumi A, Kawamura R, Nakajima H, Iida N, Yoshida K, Enomoto M, Ishizu T, Sekiguchi Y, Tada H, Aonuma K: Acute Effects of Cardiac Resynchronization Therapy on Hemodynamic Improvement and Left Ventricular Rotational Mechanics. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  49. Higuchi H, Endo Y, Watabe H, Yamauchi R, Satoh Y, Suzuki A, Eki Y, Seo Y, Watanabe S, Aonuma K: Carotid Vascular Inflammation Evaluated by FDG-PET/CT is a Promising Predictor for Severity and Future Cardiovascular Events in Acute Myocardial Infarction. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  50. Misaki M, Takeyasu N, Abe D, Naruse Y, Hayashi M, Satoh A, Aonuma K: Clinical Outcome of Drug-eluting Stents Implantation for the Treatment of In-stent Restenosis: Results From ICAS Registry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  51. Hayashi M, Takeyasu N, Abe D, Misaki M, Naruse Y, Satoh A, Aonuma K: Concurrent Implantation of Sirolimus- and Different Drug-Eluting Stents in the Same Patient with Multiple Coronary Artery Lesions: From ICAS Registry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  52. Adachi T, Satoh A, Hoshi T, Takeyasu N, Kimura T, Aonuma K: Clinical Prognosis and Predictive Factors of Octogenarians Undergoing Percutaneous Coronary Intervention from Ibaraki Cardiovascular Assessment StudyiICASjRegistry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  53. Yamasaki H, Tada H, Sekiguchi Y, Igarashi M, Kuroki K, Machino T, Kaneshiro T, Nakano E, Naruse Y, Yui Y, Ito Y, Yoshida K, Aonuma K: Catheter Ablation of Ventricular Tachyarrhythmias in Patientsrece iving Cardiac Resynchronization Therapy: The Prevalence, Characteristics, and Results of Ablation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  54. Nakano E, Ishizu T, Seo Y, Tada H, Sekiguchi Y, Yoshida K, Aonuma K: The Impacts of Conventional Echocardiographic Parameters for the Prediction of the Recurrence of Chronic Atrial fibrillation after Pulmonary vein isolation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  55. Machino-Ohtsuka T, Seo Y, Ishizu T , Yoshida K, Sekiguchi Y, Tada H, Aonuma K: Long-term Effects of Successful Catheter Ablation on Left Atrium and Appendage in Patients with Long-standing Persistent Atrial Fibrillation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  56. Iida N, Seo Y, Ishizu T, Yamamoto M, Atsumi A, Kawamura R, Enomoto M, Yanaka S, Nakajima H, Sakamaki F, Aonuma K: Preoperative Myocardial Strain Distribution and The Difference of Post-operative Response of Left Ventricular Function between in Aortic Regurgitation and Mitral Regurgitation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  57. Xu D, Sairenchi T, Irie F, Murakoshi N, Igarashi M, Otaka E, Tada H, Sekiguchi Y, Tomizawa T, Yamaguchi I, Iso H, Aonuma K: Association between Left Ventricular Hypertrophy and Cardiovascular event in the Ibaraki Prefectural Health Study. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  58. Nogami Y, Seo Y, Ishizu T, Kameda Y, Kawamura R, Yamamoto M, Tsuneoka H, Sakamaki F, Yanaka S, Nakajima H, Iida N, Aonuma K: Left Ventricular Longitudinal Functional Reserve Determines Exercise Capacity in Healthy Subjects. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  59. Kakefuda Y, Satoh A, Takeyasu N, Harunari T, Tachibana T, Harimura Y, Hoshi T, Nishina H, Noguchi Y, Aonuma K: Long-term Prognosis of Stent Thrombosis Treated With Drugeluting and Bare-metal Stents: From ICAS Registry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  60. Sato Y, Yoshida K, Inaba T, Ogata K, Kandori A, Tada H, Sekiguchi Y, Aonuma K: P-wave Dispersion on the Magnetocardiogram in Patients with Lone Atrial Fibrillation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  61. Yanaka S, Seo Y, Ishizu T, Nakajima H, Iida N, Sakamaki F, Atsumi A, Yamamoto M, Koshino Y, Kawamura R, Enomoto M, Sekiguchi Y, Tada H, Aonuma K: Usefulness of Strain Rate Analysis to Assess Changes of Left Atrial Function by Pulmonary Vein Isolation in Chronic Atrial Fibrillation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  62. Tajiri K, Maruyama H, Satoh A, Shimojoh N, Saitoh T, Endoh M, Aihara H, Kawano S, Watanabe S, Sakai S, Aonuma K: Prediction of Chronic Renal Insufficiency after Coronary Angiography by Early Increase in Oxidative Stress and Decrease in Glomerular Filtration Rate. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  63. Abe D, Takeyasu N, Hayashi M, Naruse Y, Misaki M, Hoshi T, Satoh A, Aonuma K: Clinical Value of Everolimus-eluting Stent Over Paclitaxel- and Zotarolimus-Eluting Stents: From Result of Ibaraki Cardiovascular Assessment Study (ICAS) Registry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  64. Nagayama O, Koike A ,Sakurada K, Kato J, Tsuneoka H, Yamashita T: Clinical Significance of the Change in End-tidal PCO2 (PETCO2) During Exercise in Cardiac Patients. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  65. Watabe H, Eki Y, Endo Y, Satoh Y, Yamauchi R, Higuchi H, Suzuki A, Satoh A, Aonuma K: The Impact of MDA-LDL/HDL-C Ratio on TIMI Flow Grade in Patients with Acute Myocardial Infarction. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  66. Sai S, Satoh A, Hoshi T, Hiraya D, Adachi T, Aonuma K: Impact of Body Mass Index and the Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  67. Igarashi M, Tada H, Yamasaki H, Sekiguchi Y, Ishizu T, Seo Y, Kuroki K, Machino T, Yoshida K, Kuga K, Noguchi Y, Aonuma K: Fragmented QRS is a Novel and Strong Predictor of the Clinical Out comeafter Receiving Cardiac Resynchronization Therapy. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  68. Iida N, Seo Y, Ishizu T, Nakajima H, Sakamaki F, Nogami Y, Atsumi A, Yamamoto M, Koshino Y, Kawamura R, Enomoto M, Aonuma K: Impact of Total Left Ventricular Load on Myocardial Function in Patients with Aortic Stenosis and Preserved Ejection Fraction. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  69. Sakamaki F, Seo Y, Ishizu T, Iida N, Nakajima H, Nogami Y, Atsumi A, Yamamoto M, Koshino Y, Kawamura R, Enomoto M, Aonuma K: Intraventricular Dyssynchrony Caused by Left Ventricular Pacing Improves Out-tract Obstruction in Hypertrophic Obstructive Cardiomyopathy. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  70. Watabe H, Satoh A, Hoshi T, Endo Y, Satoh Y, Yamauchi R, Higuchi H, Suzuki A, Takeyasu N, Eki Y, Aonuma K: Impact of Anemia on Cardiovascular Events in Acute Coronary Syndrome Patients with Chronic Kidney Disease:Results from ICAS Registry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  71. Higuchi H, Endo Y, Watabe H, Yamauchi R, Satoh Y, Suzuki A, Eki Y, Seo Y, Watanabe S, Aonuma K: The Degree of Oxidation of Low-Density Lipoprotein Cholesterol is a Key Element for the Recurrence of Angina Pectoris. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  72. Watanabe S, Shindo Y, Seo Y, Takeyasu N, Ishizu T, Toyama M, Kuroda Y, Sakai S, Satoh A, Aonuma K: The Time Course of Serum High Sensitive-CRP Change and the Occurrence of Cardiovascular Events. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  73. Yui Y, Machino T, Tada H, Yamasaki H, Igarashi M, Yoshida K, Ishizu T, Seo Y, Sekiguchi Y, Aonuma K: Restoration of Impaired Left Ventricular Systolic Function after the Radiofrequency Catheter Ablation of Persistent Atrial Fibrillation Combined with Dilated Cardiomyopathy. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  74. Yui Y, Sekiguchi Y, Tada H, Naruse Y, Kaneshiro T, Kuroki K, Yamasaki H, Yoshida K, Igarashi M, Aonuma K: Poor Outcome of Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation in the Patients with Hypertrophic Cardiomyopathy. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  75. Hikita H, Satoh A, Kuroda S, Osaka Y, Kawaguchi N, Yamao K, Nakashima E, Akiyama D, Sugiyama T, Takigawa M, Watari Y, Kamiishi T, Ohkubo K, Takagi K, Takahashi Y, Kimura S, Kuwahara T, Takahashi A, Isobe M: Coronary Flow Velocity and Fluid Shear Stress Predict Late Restenosis after Sirolimus-Eluting Stent Implantation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  76. Nakagawa Y, Watanabe S, Kuroda Y, Toyama M, Sakai S, Okubo S, Satoh A, Seo Y, Kuniya T, Yoshida Y, Takeshi N, Aonuma K, I-HAT Study: Clinical Implications of the Increased Pulse Pressure in Home Blood Pressure Measurement. From Large Scale, Ibaraki Hypertension Assessment TrialiI-HATj. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  77. Seo Y: Application of 3D speckle tracking imaging to evaluate regional function. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï Asian joint conferencei•Ÿ‰ªj3ŒŽC2012
  78. Aizawa Y, Sato A, Hasegawa K, Chinushi M, FurushimaH, Sato M, Horie M, Imaizumi T, Watanabe I, Aizawa Y, Fukuda K, Kaneko Y, Kurabayashi M, Shinozaki T, Aonuma K, Kuwano H, Haissaguerre M: Dynamicity of J Wave in Idiopathic Ventricular Fibrillation with a Special Reference to Pause-dependent Augmentation of J Wave. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  79. Tachibana T, Nishina H, Harunari T, Kakefuda Y, Harimura Y, Toda S, Fumikura Y, Hiranuma Y, Noguchi Y, Satoh A, Aonuma K: Prognostic Impact of Transient Slow Flow in Patients with ST Elevation Myocardial Infarction who Underwent Percutaneous Coronary Intervention. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  80. Nishina H, Noguchi Y, Tachibana T, Kakefuda Y, Harunari T, Harimura Y, Toda S, Fumikura Y, Hiranuma Y, Hoshi T, Takeyasu N, Satoh A, Aonuma K: Prognostic Impact of Admission Hyperglycemia among Patients without Known Diabetes Hospitalized with Acute Coronary Syndrome. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  81. Nakano E, Ishizu T, Seo Y, Hoshi T, Satoh A, Aonuma K: Therapeutic Impacts of Statin Treatment of Coronary Artery Disease with normal Level of LDL-cholesterol: Results from ICAS Registry. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  82. Kuwahara T, Takahashi A, Takahashi Y, Takagi K, Ohkubo K, Takigawa M, Watari Y, Nakashima E, Yamao K, Kawaguchi N, Osaka Y, Sugiyama T, Akiyama D, Kamiishi T, Kimura S, Hikita H, Satoh A, Aonuma K: Stepping Stone Approach of Radiofrequency Ablation on the Left Atrial Posterior Wall Prevents Serious Esophagus-related Complication in Atrial Fibrillation Ablation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  83. Yamada S, Iwano H, Ohte N, Seo Y, Yamada H, Ishizu T, Kusunose K, Wakami K, Sakakibara M, Yamada S, Onozuka H, Taisei Mikami, Tsutsui H, and for the SMAP Investigators: Echocardiographic Indexes are Limited for the Accurate Estimation of Left Ventricular Relaxation and Filling Pressure: A Multicenter Study in Japan. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  84. Yamada S, Iwano H, Ohte N, Seo Y, Yamada H, Ishizu T, Kusunose K, Wakami K, Sakakibara M, Yamada S, Onozuka H, Mikami T, Tsutsui H, and for the SMAP Investigators: Global Circumferential Strain Rate During Isovolumic Relaxation Period for the Estimation of Left Ventricular Relaxation: A Multicenter Study in Japan. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  85. Nakajima H, Seo Y, Ishizu T, Yanaka S, Iida N, Sakamaki F, Atsumi A, Yamamoto M, Koshino Y, Kawamura R, Enomoto M, Sekiguchi Y, Tada H, Aonuma K: Left Atrial Appendage Morphological and Functional Changes After Pulmonary Vein Isolation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  86. Hiraya D, Satoh A, Hoshi T, Sai S, Aonuma K: Evaluation of Fibrous Cap Thickness by Optical Coherence Tomography for Positive Remodeling and Low-attenuation Plaques on Computed Tomography. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  87. Toyama M, Watanabe S, Kuroda Y, Sakai S, Nakagawa Y, Okubo S, Satoh A, Seo Y, Aonuma K, Study IHAT: The Characteristics of the Hypertension of the Diabetes. From Large Scale Home Blood Pressure Study: Ibaraki Hypertension Assessment TrialiI-HATj. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  88. Higuchi H, Endo Y, Satoh Y, Yamauchi R, Watabe H, Suzuki A, Eki Y, Seo Y, Watanabe S, Aonuma K: Is It a Proper Selection to Use a Drug-Eluting Stent for Acute Myocardial Infarction Patients without Obvious Clinical Background? ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  89. Hikita H, Satoh A, Kuroda S, Osaka Y, Kawaguchi N, Yamao K, Nakashima E, Sugiyama T, Akiyama D, Takigawa M, Watari Y, Kamiishi T, Ohkubo K, Kimura S, Takagi K, Takahashi Y, Kuwahara T, Takahashi A, Isobe M: Impact of Statin Use before the Onset of Acute Myocardial Infarction on Coronary Plaque Morphology of the Culprit Lesion. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  90. Yoshida K, Ogata K, Sato Y, Ito Y, Inaba T, Tada H, Sekiguchi Y, Kandori A, Aonuma K: Ability of the Magnetocardiogram to Detect the Regional Frequency and Regularity of Atrial Fibrillation. ‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  91. âŒ³—Y‰îC²“¡@–¾Ck@‹±ˆêCìã@NC¯@’q–çCÂÀ˜a—²F–«t‘Ÿ•aŠ³ŽÒiCKDj‚É‚¨‚¯‚郈[ƒh‘¢‰eÜ‚̉e‹¿@‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  92. k@‹±ˆêC²“¡@–¾CâŒ³—Y‰îCìã@NC“cK˜aŽqC–Ø‘º‘׎OC¯@’q–çCÂÀ˜a—²FƒEƒTƒMŽÀŒ±ƒ‚ƒfƒ‹‚É‚æ‚éDrug-eluting stent —¯’uŒã‚Ìstent “àV¶“à–Œ”í–Œó‘Ԃɂ‚¢‚ÄŒŒŠÇ“àŽ‹‹¾ŠŒ©‚ÆOCT ‚Å‚Ì”äŠrŒŸ“¢D‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  93. ˆî—t@•C²“¡—zŽqCˆä“¡—tŽqC‰Á“¡ˆ¤ÍC‹g“cŒ’‘¾˜YC²“¡@–¾CÎ’Ã’qŽqC£”ö—RLC–x•ÄmŽuC“n粏dsCÂÀ˜a—²FSŽ¥}‹óŠÔƒxƒNƒgƒ‹‰ðÍ‚É‚Ä‘o‘΃s[ƒNƒxƒNƒgƒ‹ù‰ñ“d—¬‚ð’悵‚½’á“dˆÊ•s’莲S“d}‚̈ê—áD‘æ76‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  94. ‹{“à—T”üCŽðˆä@rC‘O“c´ŽiC›Œ´@‡C‰ºžŠMˆÐCƒWƒFƒXƒ~ƒ“EƒTƒuƒŠƒiC–{ŠÔ@ŠoC“n•ÓdsCÂÀ˜a—²C‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“‚¨‚æ‚Ñ‘O‹ì‘̃rƒbƒOƒGƒ“ƒhƒZƒŠƒ“‚̃qƒg‚É‚¨‚¯‚錌’†”Z“x‚¨‚æ‚ÑŽó—e‘ÌŽÕ’f–òƒ{ƒZƒ“ƒ^ƒ“‚Ì”½‰žD‘æ76‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  95. ”~’Á@“wCˆÀ“‡—Ç‹PŽqC•ì‚Ý‚âŽqCk@‹±ˆêCŽRè@_CŠÖŒûK•vCšê“c@_CÂÀ˜a—²Fƒ`[ƒ€ˆã—Âðl—¶‚µ‚½ƒRƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒtƒXƒLƒ‹‚ÌŠJ”­D‹³ˆçC”F’萧“x‚Ì“W–]i“ú–{•s®–¬Šw‰ïAž‚ÝŒ^ƒfƒoƒCƒX‹³ˆç”F’萧“xˆÏˆõ‰ï‚Ì“®Œü‚©‚çj‘æ76‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽC2012
  96. ‹{“à—T”üC‘O“c´ŽiCŽðˆä@rC›Œ´@‡C‰ºžŠMˆÐCƒWƒFƒXƒ~ƒ“EƒTƒuƒŠƒiC–{ŠÔ@ŠoC“n•ÓdsCÂÀ˜a—²C‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“‚¨‚æ‚Ñ‘O‹ì‘̃rƒbƒOƒGƒ“ƒhƒZƒŠƒ“‚ÌŒŒ’†”Z“x‚ÌŒŸ“¢‚ÆŽó—e‘ÌŽÕ’f–òƒ{ƒZƒ“ƒ^ƒ“‚Ì”½‰žFzŠÂŠíŠ³ŽÒ‚ÆŒ’ílD“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yj3ŒŽC2012
  97. •–ØŒ’ŽuC‹g“cŒ’‘¾˜YCŠÖŒûK•vCŠL’J˜aºCˆäì¹KCŒÜ\—’“sCŽRè@_C’¬–ì@‹BCí‰ªG˜aCˆä“¡—tŽqCˆÀ’B@‹œC–ûˆäŒcWC’†–ìŒb”üC‹àé‹MŽmC‘½“c@_C‹v‰êŒ\—SCÂÀ˜a—²F’‹Œ«S‹Ø[Ç‚É”º‚¤SŽº•p”‚ɑ΂·‚鍂–§“x”÷×ƒ}ƒbƒsƒ“ƒOƒKƒCƒh‰ºƒJƒe[ƒeƒ‹S‹ØÄŽÜp‚ÆIII ŒQR•s®–¬–ò‚É‚æ‚éƒnƒCƒuƒŠƒbƒh—Ö@‚Ì’·Šú—\ŒãD•s®–¬ƒnƒCƒuƒŠƒbƒhŽ¡—ÃŒ¤‹†‰ï ‘æ4‰ñŠwpW‰ïi“Œ‹žj3ŒŽC2012
  98. ˆÀ’B@‹œC²“¡@–¾C¯@’q–çC•ˆÀ–@”VCÂÀ˜a—²F80ÎˆÈã‚—îŽÒ‚ɑ΂·‚éŒo”ç“IŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“iPCIj‚̗Տ°—\Œã‚¨‚æ‚Ñ—\Œã—\‘ªˆöŽq‚ÌŒŸ“¢D‘æ109‰ñ“ú–{“à‰ÈŠw‰ïi‹ž“sj4ŒŽC2012
  99. ’·’Jì’q–¾C‹g“cŒ’‘¾˜YCÂÀ˜a—²F‚—îŽÒ‚ł̐S–[×“®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Â̗LŒø«D‘æ109‰ñ“ú–{“à‰ÈŠw‰ïi‹ž“sj4ŒŽC2012
  100. Ishizu T, Seo Y, Aonuma K: Diastolic functional reserve in patients with preserved left ventricular ejection fraction. ‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012”N
  101. Yamada S, lwano H, Ohte N, Seo Y, Yamada H, Tsutsui H: Accuracy of echo indexes of left ventricular relaxation and filling pressure: A multicenter study in JapaniSMAPj‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012”N
  102. £”ö—RLFWhat we learned from a multicenter trial Japan iSTARTj?@ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“ ‘æ23‰ñ@“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  103. £”ö—RLFKeynote lecture; Visiting new technology speckle tracking echocardiographyClearn achievements of our predecessors and open the black boxD‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  104. Î’Ã’qŽqC£”ö—RLFS‹Ø“àŠO–Œ‘w•Ê‚̍őåŽûk‚Æ‹ìoŒãŽûk•]‰¿‚É‚æ‚鍂“xŠ¥“®–¬‹·ó—̈æ‚̕lj^“®‰ðÍ@ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“ ‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  105. Î’Ã’qŽqFƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚éS‹@”\DƒVƒ“ƒ|ƒWƒEƒ€ ‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  106. ’†“‡‰pŽ÷C£”ö—RLC”Ñ“c“TŽqCŽðŠª•¶ŽqCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCì‘º@—´C‰|–{^”üCÎ’Ã’qŽqCÂÀ˜a—²F”xÃ–¬Šu—£pŒã‚É‚¨‚¯‚é‚à‚â‚à‚âƒGƒR[‚ÌŽc‘¶‚ƍ¶SŽ¨‹@”\‚¨‚æ‚ÑŒ`‘ԕω»‚ÉŠÖ‚·‚錟“¢D‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  107. ’¬–ì’qŽqC£”ö—RLC’J’†—¢”üC’†“‡‰pŽ÷Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCì‘º—´CÎ’Ã’qŽqCÂÀ˜a—²FŽ‘±«S–[×“®Ç—á‚É‚¨‚¯‚éŽûkŠú¶–[ƒXƒgƒŒƒCƒ“‚̈Ӌ`@- ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚ÌŽ¡—ÃŒø‰Ê—\‘ª‚ÉŠÖ‚·‚錟“¢\D‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  108. £”ö—RLCŽR–{¹—ǁCˆ­”üˆÀ‹IŽqCj‘º‰À]Cì‘º@—´C’†“‡‰pŽ÷CŽðŠª•¶ŽqC”Ñ“c“TŽqCÎ’Ã’qŽqCÂÀ˜a—²F¶‹rƒuƒƒbƒN‚Ì“d‹C“I‚¨‚æ‚Ñ‹@ŠB“IŽûk“`”d‚̑ΔäFS“à–Œ“dˆÊƒ}ƒbƒsƒ“ƒOƒVƒXƒeƒ€‚ƐSƒGƒR[‚Ì”äŠrD‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  109. ŽR–{¹—ǁC£”ö—RLCˆ­”üˆÀ‹IŽqCj‘º‰À]Cì‘º—´C’†“‡‰pŽ÷CŽðŠª•¶ŽqC”Ñ“c“TŽqCÎ’Ã’qŽqCÂÀ˜a—²FCRTŒã‚ÌAV ŽžŠÔ’²ß‚ª‘厖‚¾‚Æ’ÉŠ´‚µ‚½Ç—áD‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  110. –ìã‰ÀŒbC£”ö—RLCÎ’Ã’qŽqCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCì‘º—´C‹T“c—L—¢CŽðŠª•¶ŽqC’J’†—¢”üC’†“‡‰pŽ÷C”Ñ“c“TŽqCÂÀ˜a—²F¶Žº’·Ž²Žûk—\”õ”\‚Ɖ^“®‘Ï—e”\‚Æ‚ÌŠÖ˜AD‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  111. ‹T“c—L—¢CÎ’Ã’qŽqC£”ö—RLCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCì‘º—´CŽðŠª•¶ŽqC’J’†—¢”üC’†“‡‰pŽ÷C”Ñ“c“TŽqCÂÀ˜a—²F‚ŒŒˆ³ƒ‚ƒfƒ‹ƒ‰ƒbƒg‚É‚¨‚¯‚éƒXƒgƒŒƒCƒ“ƒŒ[ƒg‚ÌŒoŽž“IŠÏŽ@D‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  112. ”Ñ“c“TŽqC£”ö—RLCÎ’Ã’qŽqC’J’†—¢”üC’†“‡‰pŽ÷CŽðŠª•¶ŽqCÂÀ˜a—²F‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚ɍ‡•¹‚µ‚½‹·ó•Ù‚Ì2Žèp—áD‘æ23‰ñ@“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  113. ŽðŠª•¶ŽqC£”ö—RLC”Ñ“c“TŽqC’†“‡‰pŽ÷Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCì‘º@—´C‰|–{^”üCÎ’Ã’qŽqCÂÀ˜a—²F‰ESŽºƒŠ[ƒhúE‚̐f’f‚É3D SƒGƒR[}‚ª—L—p‚Å‚ ‚Á‚½ˆê—áD‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  114. ’†“‡‰pŽ÷CÎ’Ã’qŽqC£”ö—RLFS‹@”\Œv‘ª‚ð‚¢‚©‚ɐ¸“x—Ç‚­s‚¤‚©@‰ES‹@”\‚ɂ‚¢‚ā@‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïC2012”N4ŒŽC‘åã
  115. £”ö—RLF3D –mƒ‰ƒbƒLƒ“ƒO‚Å”ñ“¯Šú‚ð•]‰¿‚·‚éDƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“ ‘æ23‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‘åãj4ŒŽC2012
  116. Žðˆär‰îC²“¡@–¾C¯@’q–çCŠ|ŽD—YŠîCÂÀ˜a—²FDES —¯’uŒã‚ÌPlaque protrusion ‚ÌŒoŽž“I•Ï‰»‚ðŒŒŠÇ“àŽ‹‹¾‚ÆOCT ‚É‚Ä‚É‚ÄŠÏŽ@‚µ‚¦‚½ˆê—áD‘æ8‰ñˆïéŒ§“슥Ž¾Š³Œ¤‹†‰ïi‚‚­‚΁j4ŒŽC2012
  117. ’†“‡‰pŽ÷C£”ö—RLCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCì‘º@—´C‰|–{^”üCÎ’Ã’qŽqCÂÀ˜a—²F3D SƒGƒR[–@‚ð—p‚¢‚½¶Žº—e—ÊŒv‘ª¸“x‚ÉŠÖ‚·‚錟“¢D‘æ86‰ñ@“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi“Œ‹žj4ŒŽC2012
  118. ŽR“c@‘CŠâ–ìOKC‘åŽèM”VC£”ö—RLCŽR“c”ŽˆûCÎ’Ã’qŽqCŽáŒ©˜a–¾C¬–ì’Ë‹v•vCŽO_‘吢C“›ˆä—T”VFSƒGƒR[–@‚É‚æ‚鍶Žº’oŠÉ”\E[–žˆ³„’萸“x‚̍ČŸØF‘½Ž{Ý‹¤“¯SMAP Œ¤‹†‘æ1 •ñ D‘æ86‰ñ@“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi“Œ‹žj4ŒŽC2012
  119. ŽðŠª•¶ŽqC£”ö—RLCÎ’Ã’qŽqCÂÀ˜a—²F ŽŠ“K AVdelay Ý’è‚É‚¨‚¯‚éSƒGƒR[}ŒŸ¸‚Ì—L—p«D‘æ86‰ñ@“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi“Œ‹žj4ŒŽC2012
  120. –ìã‰ÀŒbC£”ö—RLCÎ’Ã’qŽqC‹T“c—L—¢CŽðŠª•¶ŽqC’J’†—¢”üCŽR–{¹—ǁCì‘º@—´CÂÀ˜a—²F¶Žº’·Ž²•ûŒü‚ւ̃XƒgƒŒƒCƒ“•Ï‰»‚͉^“®‘Ï—e”\‚ð‹K’è‚·‚éD‘æ86‰ñ@“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi“Œ‹žj4ŒŽC2012
  121. Î’Ã’qŽqC£”ö—RLCXŽR^ŠóCˆ­”üˆÀ‹IŽqC’¬–ì’qŽqCŽR–{¹—ǁCì‘º@—´CÂÀ˜a—²F¶Žº•ÇŽûk•ûŒü‚ƍ¶Žº‘S‘Ì‹@”\‚Æ‚ÌŠÖ˜AF3 ŽŸŒ³ƒGƒR[–@‚ð—p‚¢‚½—Տ°“IŒŸ“¢D‘æ86‰ñ@“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi“Œ‹žj4ŒŽC2012
  122. ’¬–ì’qŽqC£”ö—RLCÎ’Ã’qŽqCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCì‘º@—´C˜–쌋ŠóCÂÀ˜a—²FƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚ÌŽ‘±«S–[×“®Š³ŽÒ‚É‚¨‚¯‚鍶–[E¶SŽ¨‚Ì’·ŠúŠÏŽ@D‘æ86‰ñ@“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi“Œ‹žj4ŒŽC2012
  123. ‹T“c—L—¢CÎ’Ã’qŽqC‰|–{^”üC’¬–ì’qŽqC–ìã‰ÀŒbCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCì‘º@—´C£”ö—RLCÂÀ˜a—²F“œ”A•a”÷¬ŒŒŠÇáŠQ‚ƐöÝ«S‹ØáŠQ‚Æ‚ÌŠÖ˜A; ŽOŽŸŒ³Speckle Tracking –@‚ð—p‚¢‚½ŒŸ“¢D‘æ86‰ñ@“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi“Œ‹žj4ŒŽC2012
  124. ŽR–{¹—ǁC£”ö—RLC’†“‡‰pŽ÷Cˆ­”üˆÀ‹IŽqC’¬–ì’qŽqCì‘º@—´CÎ’Ã’qŽqCÂÀ˜a—²F¶SŽ¨Œ`‘Ԃƍ¶SŽ¨ŒŒð‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä; ŽOŽŸŒ³SƒGƒR[}–@‚É‚æ‚錟“¢D‘æ86‰ñ@“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi“Œ‹žj4ŒŽC2012
  125. ¯’q–çC²“¡–¾C›Á@¯‰ÍCÂÀ˜a—²F’Z’°ÇŒóŒQ‚ɍ‡•¹‚µ‚½•sˆÀ’è‹·SÇ‚̈ê—á@‘æ40‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj5ŒŽC2012
  126. “c”ö@iCŽR“àNÆC‰ª“cŠ°”VC‘O“c^ŒáCŒ®ŽR’¨”VC¬¼—T“ñCŒ´@M”ŽCŽRŒû“O—YC“à“¡‹MŠîC‹{è—ºˆêC”~–{•üKC‹{–{‹M—fC”ö—с@“OC•½”öŒ©ŽOCÂÀ˜a—²F”xÃ–¬Šu—£’†‚É”xÃ–¬¶–[ŠÔ‚Ì‹U«ˆê•ûŒü«“`“±‚̏ŠŒ©‚ð”F‚ß‚½Ž‘±«S–[×“®‚Ì1—á. ‘æ42‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj5ŒŽC2012
  127. ŽRè@_CŠÖŒûK•vCšê“c@_C’¬–ì@‹BC•–ØŒ’ŽuCˆä“¡—tŽqCŒÜ\—’“sC‹g“cŒ’‘¾˜YCÂÀ˜a—²FgŽžŒvh‚¨‚æ‚сg”½ŽžŒvh•ûŒü‚ɐù‰ñ‚·‚é2Ží‚ÌLocalized reentry ‚ª”F‚ß‚ç‚ꂽ‘m–X•Ù—Ö‹¬•”ÄŽÜpŒã‚Ì1—áD‘æ42‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj5ŒŽC2012
  128. óì“N–çC’†ì˜a–çC–]“c“NŽiC‘º¼‘‰ÀCŽR“àNÆCŽRè@_CÂÀ˜a—²F‘æ2“x–[ŽºƒuƒƒbƒNŠŒ©‚ð’悵‚½SŽº“ñd‰ž“š‚̈ê—áD‘æ42‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj5ŒŽC2012
  129. “yŠò_‰îC–{ŠÔ^lCÂÀ˜a—²C‹v‰êŒ\—SCK“cK’¼FSCN5A ƒvƒƒ‚[ƒ^[ƒnƒvƒƒ^ƒCƒv‚ªƒtƒŒƒJƒCƒjƒh‚Ì—LŒøŒŒ’†”Z“x‚É‚¨‚æ‚Ú‚·‰e‹¿D‘æ29‰ñ“ú–{TDM Šw‰ïi_ŒËj6ŒŽC2012
  130. ²“¡Šó”üCÎ’Ã’qŽqCŠÛ“cr‰îC‹àé‹MŽmCŽR–{¹—ǁC£”ö—RLCÂÀ˜a—²F”DP’†‚É”x–EoŒŒ‚𗈂µ‚½‘m–X•Ù‹·óÇ—áD‘æ36‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj6ŒŽC2012
  131. ŽR–{¹—ǁCŽðŠª•¶ŽqC£”ö—RLCÎ’Ã’qŽqCÂÀ˜a—²F•ÂÇ«”ì‘åŒ^S‹ØÇ‚̃y[ƒXƒ[ƒJŽ¡—Âɂ¨‚¯‚鍶Žº“àŒŒ—¬‚ƕlj^“®‚Æ‚ÌŠÖ˜AD‘æ36‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj6ŒŽC2012
  132. •½’J‘åŒáC¯@’q–çC›Á@¯‰ÍCˆÀ’B@‹œC–ûˆäŒcWC’†–ìŒb”üC•–ØŒ’ŽuC‹àé‹MŽmC²“¡–¾CÂÀ˜a—²FˆêŽž“IS–[ƒy[ƒVƒ“ƒO‚É‚æ‚è’˜–¾‚ɏzŠÂ“®‘Ô‚ð‰ü‘P‚µ‚¦‚½‹}«‰º•Ç‰EŽºS‹Ø[Ç‚̈ê—áD‘æ224‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï 6ŒŽC2012
  133. ’¬–ì’qŽqC£”ö—RLC’¬–ì‹BC•–ØŒ’ŽuCŽRè_C‹g“cŒ’‘¾˜YCŒÜ\—’“sCŠÖŒûK•vCšê“c@_CÂÀ˜a—²FŽ‘±«S–[×“®‚ɑ΂·‚鍂Žü”gƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚̃Šƒo[ƒXƒŠƒ‚ƒfƒŠƒ“ƒOF¶–[ƒXƒgƒŒƒCƒ“/ ƒXƒgƒŒƒCƒ“ƒŒ[ƒg‚¨‚æ‚э¶SŽ¨•Ç‰^“®‘¬“x‚É‚æ‚é•]‰¿DƒVƒ“ƒ|ƒWƒEƒ€ ‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwpW‰ïi‰¡•lj7ŒŽC2012
  134. šê“c@_F—¬o˜H‹NŒ¹‚̐SŽº«•s®–¬D‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  135. ‰¡ŽR‘לACŠÖŒûK•vCÂÀ˜a—²C‚–؉ë•FC‘ŠŒ´’¼•FC•½‰ª¹˜aFJ-IVFS “o˜^Brugada ÇŒóŒQÇ—á‚É‚¨‚¯‚é“d‹C“IƒXƒg[ƒ€‚Ì”­¶ó‹µD‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•ljC2012
  136. ÂÀ˜a—²Fu•s®–¬‚Ì”ñ–ò•¨Ž¡—ÃKƒCƒhƒ‰ƒCƒ“v@SŽº«•s®–¬‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“D‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  137. ˆÀ’B@‹œC•–ØŒ’ŽuCšê“c@_CŽRè@_CŒÜ\—’“sC‹g“cŒ’‘¾˜YCŠÖŒûK•vC‹v‰êŒ\—SCÂÀ˜a—²F–[ŽºÚ‡•”«•p”‚ÆŠÓ•Ê‚µ‚¦‚½’ʏíŒ^–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[«•p”‚Ì1—áD‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi ‰¡•ljC2012
  138. ’†ì˜a–çCóì“N–çC¼‘º‘‰ÀCŽR“àNÆCÂÀ˜a—²F’˜–¾‚ÈŒŒˆ³’ቺ‚𗈂µ‚½’ʏíŒ^–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[«•p”‚Ì2 —áD‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  139. ŒÜ\—’“sCšê“c@_CŠÖŒûK•vCŽRè@_C•–ØŒ’ŽuC’¬–ì@‹BCˆä“¡—tŽqC‹àé‹MŽmC’†–ìŒb”üC‹g“cŒ’‘¾˜YC‹v‰êŒ\—SCÂÀ˜a—²F‰EŽº‹NŒ¹“Á”­«SŽºŠúŠOŽûk‚ɑ΂·‚鍂Žü”gƒJƒe[ƒeƒ‹S‹ØÄŽÜŒã‚ɐSŽº•p”‚ª•p”­‚µ‚½1—áD‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  140. ŒÜ\—’“sCšê“c@_CŠÖŒûK•vCŽRè@_C•–ØŒ’ŽuC’¬–ì@‹BCˆä“¡—tŽqC‹àé‹MŽmC’†–ìŒb”üC‹g“cŒ’‘¾˜YC‹v‰êŒ\—SCÂÀ˜a—²FS–[×“®Ç—á‚É”F‚߂鍶Žº“à’á“dˆÊ—̈æF—Տ°“I“Á’¥‚ƏĎ܏pŒã‚̍Ĕ­‚ÆŠÖ˜A«D‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  141. ”~’Á@“wCˆÀ“‡—Ç‹PŽqC•ì‚Ý‚âŽqCk@‹±ˆêCŽRè@_C‹g“cŒ’‘¾˜YCŠÖŒûK•vCšê“c@_CÂÀ˜a—²F‰“Šuƒ‚ƒjƒ^ƒŠƒ“ƒO‚É‚æ‚Á‚Ä‘Šú”­Œ©‚ÆŽ¡—Éî“ü‚ª‰Â”\‚Æ‚È‚Á‚½–³ÇŒó«ƒCƒxƒ“ƒg‚ÌŽÀ‘Ԃɂ‚¢‚āD‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  142. •–ØŒ’ŽuCŠÖŒûK•vC‹g“cŒ’‘¾˜YCŒÜ\—’“sCŽRè@_C¬£‘ãŽm‹vC’¬–ì@‹BC–ûˆäŒcWCˆÀ’B@‹œC’·’Jì’q–¾Cˆä“¡—tŽqCí‰ªG˜aCšê“c@_C‹v‰êŒ\—SCÂÀ˜a—²FŠ®‘SŒŒsÄŒšpŒãˆŸ‹}«Šú‚Éelectrical storm ‚ð’悵CƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª’˜Œø‚µ‚½2Ç—áD‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  143. ‹àé‹MŽmC¬£‘ãŽm‹vC’†–ìŒb”üC•–ØŒ’ŽuCˆä“¡—tŽqC’¬–ì@‹BCŽRè@_Cí‰ªG˜aCŒÜ\—’“sC‹g“cŒ’‘¾˜YCŠÖŒûK•vCšê“c@_CÂÀ˜a—²C‰Á“¡ˆ¤ÍC–x•Ä@mC‡‰®‰ë•FC–ìãº•FFƒŠƒAƒmƒWƒ“Žó—e‘̈â“`ŽqˆÙí‚𔺂¤ƒJƒeƒRƒ‰ƒ~ƒ“—U”­«‘½Œ`«SŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—L—p«D‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  144. ‹Ê–ö‰ëOC–“–ì‘å•ãC–Ȋс@OCA‘~ˆêC”~’Á@“wCˆÀ“‡—Ç‹PŽqC‹g“cŒ’‘¾˜YC’†–ìŒb”üC•–ØŒ’ŽuC‹àé‹MŽmCˆä“¡—tŽqC’¬–ì@‹BCŽRè@_CŒÜ\—’“sCŠÖŒûK•vCšê“c@_CÂÀ˜a—²FSŽº•p”‚ɑ΂·‚鎡—Âð•s“KØ‚É—}§‚µ‚½3—áD‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï@CDR ƒZƒbƒVƒ‡ƒ“i‰¡•lj7ŒŽC2012
  145. ¬£‘ãŽm‹vCšê“c@_Cí‰ªG˜aC’¬–ì@‹BC•–ØŒ’ŽuCŽRè@_CŒÜ\—’“sCˆä“¡—tŽqC‹g“cŒ’‘¾˜YCŠÖŒûK•vCÂÀ˜a—²C²“¡@½C–öŒ´–œ—¢ŽqF‡–°Žž–³ŒÄ‹zÇŒóŒQ‚̍‡•¹‚ªS–[×“®ƒAƒuƒŒ[ƒVƒ‡ƒ“‚̐¬Ñ‚É—^‚¦‚é‰e‹¿‚ÆŽ‘±“I—zˆ³Š·‹CŽ¡—Â̗L—p«D‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  146. Tada H: Predictors of the Recurrence of Atrial Fibrillation after Radiofrequency Catheter Ablation. ‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  147. ¼“à@‰pCûŠ–쌒ˆêC²X–ØŒ’lC’Ë“c’¼ŽjC‘–ì@ŒìC•Ÿ‰Æ‰xŽqCŽOŽ÷—SŽqCâ–{@—LC’†‘ºŒ[“ñ˜YC’†‘ºh‹KCŒF’J_ŽiC“à“¡Ž lC‘哇@–΁Cšê“c@_FMason-Likar —U“±S“d}‚ª—¬o˜H‹NŒ¹SŽº«ŠúŠOŽûk‚̋Ǎݐf’f‚É—^‚¦‚é‰e‹¿D‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj7ŒŽC2012
  148. ¯’q–çF‹}«Š¥ÇŒóŒQ‚É‚¨‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒx[ƒVƒ‡ƒ“’†‚É“Š—^‚µ‚½ƒ‰ƒ“‰–ƒ[ƒ‹‚ÌŽg—pŒoŒ±D‘æ5‰ñˆïéŽüpŠúzŠÂŠÇ—ƒZƒ~ƒi[i‚‚­‚΁j7ŒŽC2012
  149. Abe D, Takeyasu N, Hoshi T, Sato A, Harunari T, Ojima E, Hiraya D, Watabe H, Kakefuda, Aonuma K: Impact of transradial approach for the incidence of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiVŠƒj 7ŒŽC2012
  150. Harunari T, Sato A, Hoshi T, Kakefuda Y, Abe D, Takeyasu N, Ojima E, Hiraya D, Watabe H, Nishina H, Noguchi Y, Aonuma K: Impact of ACEI or ARB pretreatment on contrastinduced nephropathy in acute coronary syndrome patients undergoing coronary angioplasty; From ICAS registry. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiVŠƒj 7ŒŽC2012
  151. Naruse Y, Takeyasu N, Hayashi M, Misaki M, Abe D, Hoshi T, Sato A, Aonuma K: A case of myocatdial infarction due to left main trunk spontaneous coronary artery dissection successfully treated with stent deployment. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiVŠƒj 7ŒŽC2012
  152. Ojima E, Sato A, Hoshi T, Abe D, Takeyasu N, Harunari T, Hiraya D, Watabe H, Kakefuda Y, Endo M, Aonuma K: Impact of Mehran Risk Score for the Prediction of Contrastinduced Nephropathy in the Patients who Undergoing Percutaneous Coronary Intervention. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi VŠƒj 7ŒŽC2012
  153. Hikita H, Sato A, Kozima K, Kuroda S, Osaka Y, Akiyama D, Kamiishi T, Kawaguchi N, Nakashima E, Sugiyama T, Kimura S, Takahashi A, Isobe M: Impact of Lesion Morphology of instrastent restenosis on minor nyocardial infarction associated with percutaneous coronary intervention. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi VŠƒj 7ŒŽC2012
  154. Hikita H, Sato A, Kozima K, Kuroda S, Osaka Y, Akiyama D, Kamiishi T, Kawaguchi N, Nakashima E, Sugiyama T, Kimura S, Kuwahara T, Takahashi A, Isobe M: Coronary Flow Velocity Measured with TIMI Frame Count Predicts Myocardial Viability and Functional Recovery in TIMI-3 Reperfused Acute Myocardial Infarction. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi VŠƒj 7ŒŽC2012
  155. Hiraya D, Hoshi T, Sai S, Adachi T, Nakano E, Kuroki K, Kaneshiro T, Sato A, Aonuma K: The prevalence of coronary artery disease in patients with atrial fibrillation who underwent intial pulomary vein isolation. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi VŠƒj 7ŒŽC2012
  156. Kakefuda Y, Sato A, Hoshi T, Abe D, Takeyasu N, Harunari T, Ojima E, Hiraya D, Watabe H, Nishina H, Noguchi Y, Aonuma K: Minimizing contrast dose on the basis of eGRF might be valuable in contrast-induced nephropathy after PCI. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiVŠƒj 7ŒŽC2012
  157. Hoshi T, Sato A, Abe D, Takeyasu N, Kakefuda Y, Harunari T, Ojima E, Hiraya D, Watabe H, Aonuma K: Preventive effect of statin pretreatment on contrast-induced nephropathy in patients undergoing coronary angiography; propensity score analysis from ICAS registry. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi VŠƒj 7ŒŽC2012
  158. Nozato T, Sato A, Hirasawa K, Yoshida Y, Sekigawa M, Hayashi T, Ito J, Kato R, Ogawa T, Sakurai K, Yokoyama Y, Ashikaga T, Satoh Y, Isobe M: Effect of renal function of percutaneous transluminal renal angioplasty. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi VŠƒj 7ŒŽC2012
  159. Nozato T, Sato A, Hirasawa K, Yoshida Y, Sekigawa M, Hayashi T, Ito J, Kato R, Ogawa T, Sakurai K, Yokoyama Y, Ashikaga T, Satoh Y, Isobe M: Endovascular treatment for the peripheral artery disease reduces blood pressure and pronosis. ‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiVŠƒj7ŒŽC2012
  160. k@‹±ˆêC²“¡@–¾CâŒ³—Y‰îCÔ¯”Ž˜aCìã@NCˆÀ“‡—Ç‹PŽqC”~’Á@“wC¯@’q–çCÂÀ˜a—²F‹}«S‹Ø[Ç‚ɑ΂µŒo”ç“IŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Žž‚É“®–¬ˆ³S”o—Ê‘ª’èƒVƒXƒeƒ€‚ð—p‚¢‚ÄŒŒs“®‘Ôƒ‚ƒjƒ^ƒŠƒ“ƒO‚µ‚½Ç—áD‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiVŠƒj7ŒŽC2012
  161. âŒ³—Y‰îCk@‹±ˆêCÔ¯”Ž˜aCìã@NCˆÀ“‡—Ç‹PŽqC”~’Á@“wC¯@’q–çC²“¡@–¾CÂÀ˜a—²FFD-OCTuILUMIENv‚É‚¨‚¯‚éACIST ƒCƒ“ƒWƒFƒNƒgƒVƒXƒeƒ€‚ð—˜—p‚µ‚½‰æ‘œ•]‰¿‚ɂ‚¢‚āD‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiVŠƒj7ŒŽC2012
  162. •–ØŒ’ŽuC‹g“cŒ’‘¾˜YCŠÖŒûK•vCŠL’J˜aºCŽR“àNÆCŽRè@_C’¬–ì@‹BC¬£‘ãŽm‹vCˆä“¡—tŽqC‹àé‹MŽmCŒÜ\—’@“sCšê“c@_C‹v‰êŒ\—SCÂÀ˜a—²Fu•s®–¬f—Âɂ¨‚¯‚éV‹Zpv’‹Œ«S‹Ø[Ç‚É”º‚¤SŽº•p”‚ɑ΂·‚鍂–§“x”÷×ƒ}ƒbƒsƒ“ƒOƒKƒCƒh‰ºƒJƒe[ƒeƒ‹S‹ØÄŽÜp‚Ì‘½Ž{Ý‚É‚¨‚¯‚é’·Šú—\Œã‚ÌŒŸ“¢D‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òj9ŒŽC2012
  163. ŽRè@_Cšê“c@_CŠÖŒûK•vC•–ØŒ’ŽuC’¬–ì@‹BC‹àé‹MŽmCŒÜ\—’“sCÂÀ˜a—²FuS•s‘S‚Ì”ñ–ò•¨—Ö@vS‘ŸÄ“¯Šú—Ö@‚Ì—\Œã—\‘ªˆöŽq‚ÌŒŸ“¢- –ò•¨‚Æ”ñ–ò•¨Ž¡—Âɂæ‚éƒnƒCƒuƒŠƒbƒhŽ¡—Â̌ø‰Ê-DƒVƒ“ƒ|ƒWƒEƒ€ ‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òjC2012
  164. ¼“à@‰pCûŠ–쌒ˆêCšê“c@_C’Ë“c’¼ŽjC²X–ØŒ’lC‘–ì@ŒìC’†’J—m‰îC’†‘ºŒ[“ñ˜YC’†‘ºh‹KCŒF’J_ŽiC“à“¡Ž lC‘哇@–΁FMason-Likar —U“±S“d}‚ð—p‚¢‚½—¬o˜H‹NŒ¹SŽº«ŠúŠOŽûk‚̋Ǎݐf’fD‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òjC2012
  165. ¯@’q–çC²“¡@–¾CŠ|ŽD—YŠîCm‰ÈG’C–ìŒû—SˆêCÂÀ˜a—²FŒŒŠÇ“àŽ‹‹¾‚ð—p‚¢‚½–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚Ì“à–ŒŽ¡–ü”½‰ž‚ÌŒŸ“¢; ƒGƒxƒƒŠƒ€ƒX—no«ƒXƒeƒ“ƒg‚Æ‘æˆê¢‘ã–òÜ—no«ƒXƒeƒ“ƒg‚Ì”äŠrD‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òjC2012
  166. ¬£‘ãŽm‹vCšê“c@_C‰|–{‹­ŽuC—с@^—RC–ìŒû—SˆêC•ˆÀ–@”VC²“¡@–¾CÂÀ˜a—²F‘ŠúÄ•ª‹É‚ƐS‹Ø[Ç‹}«Šú‚ɏoŒ»‚·‚éSŽº×“®‚Æ‚ÌŠÖ˜AD‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òjC2012
  167. ŽO‹´•ŽiC´…º•FCŠÖŒûK•vC¼ˆäL—mCŒÃ“ˆ”ŽŽiC^’†“N”VC‰¡Ž®®ŽiCãŽR@„CV“c@—²C‰œ‘º@ŒªF‰ä‚ª‘‚É‚¨‚¯‚éAž‚ÝŒ^œ×“®ŠíŠ³ŽÒ‚̍쓮ó‹µ‚Æ—\Œã‚ÌŒŸ“¢D-JCDTR Œo‰ßŠÏŽ@ƒf[ƒ^ƒx[ƒX‚æ‚è-D‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òjC2012
  168. £”ö—RLCˆî—t@•CÎ’Ã’qŽqCÂÀ˜a—²FŽOŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚éactivation imaging –@‚Íelectro-mechanical coupling ‚𔽉f‚µ‚½“¯Šú•s‘S•]‰¿‚ð‰Â”\‚É‚·‚éD‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi‹à‘òj9ŒŽC2012
  169. ŒÜ\—’“sCšê“c@_CŽRè@_CŠÖŒûK•vCÎ’Ã’qŽqC£”ö—RLC‹àé‹MŽmC•–ØŒ’ŽuC’¬–ì@‹BCˆä“¡—tŽqC’·’Jì’q–¾C‹v‰êŒ\—SC–ìŒû—SˆêCÂÀ˜a—²FFragmented QRS ‚͐S‘Ÿ“¯Šú—Ö@Œã‚̐V‚½‚È—\Œã—\‘ªˆöŽq‚Å‚ ‚éD‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òjC9ŒŽ 2012
  170. k@‹±ˆêCâŒ³—Y‰îCÔ¯”Ž˜aCìã@NCˆÀ“‡—Ç‹PŽqC”~’Á@“wC‘åŽR‚ˆêC“¡àVL‹gC¯@’q–çC‹g“cŒ’‘¾˜YCÎ’Ã’qŽqCŠÖŒûK•vC²“¡@–¾C£”ö—RLCšê“c@_CÂÀ˜a—²FƒJƒeƒ‰ƒ{‚Å‚ÌŠeŽíS‘ŸŽ¡—ÃŽè‹ZŽž‚É‚¨‚¯‚éƒ`[ƒ€ˆã—Âɑ΂·‚é—Տ°HŠw‹ZŽm‚̐ϋɓIŽæ‘g‚݁D‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òj9ŒŽC2012
  171. ‰H’¹Œõ°C’†¼Œ[‘¾C•½’J‘¾ŒáC¬Œ´Œ’ˆêC‘O“c—TŽjCÂÀ˜a—²FMRI ‚ªf’f‚É—L—p‚Å‚ ‚Á‚½DŽ_‹…«S‹Ø‰Š‚Ì1—áD‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òj9ŒŽC2012
  172. ’†–ìŒb”üCŒ´“c’q—YCÎ’Ã’qŽqC£”ö—RLCÂÀ˜a—²CŽO‘î—Ç•FF–«S–[×“®Š³ŽÒ‚É‚¨‚¯‚é”xÃ–¬Šu—£pŒãÄ”­‚Ì—\‘ªˆöŽqFŒoH“¹SƒGƒR[‚ð—p‚¢‚Ä‚ÌŒŸ“¢D‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òj9ŒŽC2012
  173. ûŠ–쌒ˆêC“à“¡Ž lC’†‘ºh‹KC²X–ØŒ’lC’Ë“c’¼ŽjC‘–ì@ŒìC¼“à@‰pC’†’J—m‰îC’†‘ºŒ[“ñ˜YCŽR‰º‰pŽ¡CŒF’J_ŽiCšê“c@_C‘哇–΁Fƒ_ƒrƒKƒgƒ‰ƒ“i220mg/ “új‚É‚æ‚éS–[×“®ƒAƒuƒŒ[ƒVƒ‡ƒ“ŽüpŠú‚É‚¨‚¯‚éR‹ÃŒÅ—Ö@‚Ì—L—p«D‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïi‹à‘òj9ŒŽC2012
  174. ‹{“à@‘ìF‘̍‚ŒŒˆ³‚Æ”x‚ŒŒˆ³‚É‚¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“FV‹K‚ÌŽó—e‘ÌŽÕ’f–ò‚Ì”x‚ŒŒˆ³Ç‚ɉÁ‚¦‚Ă̑̍‚ŒŒˆ³‚ɑ΂·‚éV‚µ‚¢Ž¡—Öò‚Æ‚µ‚Ä‚Ì“K‰žŠg‘å‚̉”\«D‘æ35‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ïi–¼ŒÃ‰®j9ŒŽC2012.
  175. ‹{“à—T”üCŽðˆä@rC‘O“c´ŽiC›Œ´@‡C‰ºžŠMˆÐCƒTƒuƒŠƒiEƒWƒFƒXƒ~ƒ“C–{ŠÔ@ŠoC“n•ÓdsCÂÀ˜a—²C‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“‚Æ‘O‹ì‘̃rƒbƒOƒGƒ“ƒhƒZƒŠƒ“‚̃qƒg‚É‚¨‚¯‚錌’†”Z“x‚¨‚æ‚ÑŽó—e‘ÌŽÕ’f–òƒ{ƒZƒ“ƒ^ƒ““Š—^‚Ì”½‰žD‘æ1‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽC2012
  176. Žðˆä@rC–{ŠÔ@ŠoCŠÛŽRG˜aC–Ø‘º‘׎OC‹{“à@‘ìCÂÀ˜a—²F”x‚ŒŒˆ³Š³ŽÒ‚É‚¨‚¯‚錌’†ƒ}ƒCƒNƒRNA ‚Ì‘ª’è‚̈Ӌ`D‘æ1‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽC2012
  177. ˆ­”üˆÀ‹IŽqC–{ŠÔ@ŠoCHŽR‘åŽ÷C–Ø‘º‘׎OCŽðˆä@rC£”ö—RLC‹{“à@‘ìCÂÀ˜a—²FƒGƒ|ƒvƒƒXƒeƒm[ƒ‹‚̍ݑ‘±“_“H—Ö@‚©‚ç—£’E‚µC5”NŠÔ‚ðŒo‰ß‚µ‚½”x“®–¬«”x‚ŒŒˆ³‚̏ǗáD‘æ1‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽC2012
  178. Žðˆär‰îC“n•ÓdsCŠOŽR¹OC•“c—T‹vCÂÀ˜a—²FƒAƒ“ƒuƒŠƒZƒ“ƒ^ƒ“‚ª’˜Œø‚µ‚½–å–¬ˆ³˜´iÇ‚É”º‚¤”x‚ŒŒˆ³Ç‚̈ê—áD‘æ225‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽC2012
  179. –ûˆäŒcWCŠÖŒûK•vCŒÜ\—’“sC•–ØŒ’ŽuC’†–ìŒb”üCˆÀ’B@‹œC‹àé‹MŽmC’·’Jì’q–¾C›Á@¯‰ÍCÎ’Ã’qŽqC‰Í–ì@—¹C£”ö—RLCÂÀ˜a—²FŽüŽYŠúƒ`[ƒ€ˆã—ÂƁCIABPCS-G ƒJƒe[ƒeƒ‹‰º‚̏W’†ŠÇ—‚ª‘tŒ÷‚µ‚½Šg’£Œ^S‹ØÇ‡•¹”DPoŽY‚Ì1—áD‘æ225‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽC2012
  180. ¯@’q–çC•½’J‘åŒáC²“¡@–¾CÂÀ˜a—²FStent fracture ‚ªŠÖ—^‚·‚éƒVƒƒŠƒ€ƒX—no«ƒXƒeƒ“ƒgÄ‹·ó•”ˆÊ‚Éneoatherosclerosis ‚ð”F‚ß‚½ˆê—áD‘æ26‰ñ“ú–{S‘ŸŒŒŠÇ“àŽ‹‹¾Šw‰ïiˆ¤•Qj10ŒŽC2012
  181. Naruse Y, Tada H, Harimura Y, Hayashi M, Noguchi Y, Sato A, Yoshida K, Sekiguchi Y, Aonuma K: Early repolarization is an independent predictor of occurrences of ventricular fibrillation in the very early phase of acute myocardial infarction. ‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi ç—tj 10ŒŽC2012
  182. ŠÖŒûK•vFŠg’£Œ^S‹ØÇ‚É”º‚¤SŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Ð헪D‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  183. ŠÖŒûK•vFŽw’è”­Œ¾F‰uŠw“IŠÏ“_‚©‚猩‚éJ ”g‚̗Տ°‘œ\J-IVFS “Á”­«SŽº×“®—á‚©‚ç\D‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  184. ŠÖŒûK•vFƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚éSŽº«•s®–¬‚ÌŽ¡—ÁDƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“ ‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  185. •–ØŒ’ŽuCŠÖŒûK•vCŠL’J˜aºCˆäì¹KCŒÜ\—’“sCŽRè@_C’¬–ì@‹BCˆä“¡—tŽqC’·’Jì’q–¾C‘\“c@•qC–Ø‘S@Œ[C‹àé‹MŽmCšê“c@_C‹v‰êŒ\—SCÂÀ˜a—²F’‹Œ«S‹Ø[Ç‚É”º‚¤¶‹rƒuƒƒbƒNŒ^SŽº•p”‚̗Տ°“I, “d‹C¶—“I“Á’¥D‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  186. ŠÖŒûK•vC‘ŠŒ´’¼•FC‚–؉ë•FC‰¡ŽR‘לACÂÀ˜a—²C•½‰ª¹˜aF–{–M‚Å‚Ì“Á”­«SŽº×“®Ç—á‚É‚¨‚¯‚éJ ”g‚̗Տ°“I“Á’¥\J-IVFS ƒf[ƒ^‚©‚ç\D‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  187. ¬£‘ãŽm‹vCšê“c@_Cj‘º ‰À]C—с@^—RC–ìŒû—SˆêC²“¡@–¾C‹g“cŒ’‘¾˜YCŠÖŒûK•vCÂÀ˜a—²FJ ”gÇŒóŒQ‚ƐS‹Ø[Ç‰ñ•œŠú‚©‚疝«Šú‚ɏoŒ»‚·‚éSŽº«•s®–¬E“Ë‘RŽ€‚Æ‚ÌŠÖ˜AD‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  188. —§‰Ô–qŽqCŠÖŒûK•vCŽRè@_C¬£‘ãŽm‹vC•–ØŒ’ŽuCŒÜ\—’“sCšê“c@_CÂÀ˜a—²F“–‰@‚É‚¨‚¯‚鏜×“®ƒŠ[ƒhwRiatax‚É‚¨‚¯‚鑹‚ÌŒŸ“¢D‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  189. ŽRè@_Cšê“c@_CŠÖŒûK•vC•–ØŒ’ŽuC’¬–ì@‹BCˆä“¡—tŽqC’·’Jì’q–¾C‹àé‹MŽmCŒÜ\—’“sCŒÜ\—’“sCÂÀ˜a—²FS–[×“®Š³ŽÒ‚É‚¨‚¯‚éDŠ´“xCRP ã¸‚ÉŠñ—^‚·‚é”wŒiˆöŽq‚ÌŒŸ“¢D‘æ29‰ñ“ú–{S“dŠw‰ïiç—tj10ŒŽC2012
  190. ‹àé‹MŽmC’†–ìŒb”üC•–ØŒ’ŽuCˆä“¡—tŽqC’¬–ì@‹BCŽRè@_CŒÜ\—’“sC‹g“cŒ’‘¾˜YCŠÖŒûK•vCšê“c@_CÂÀ˜a—²FS–[×“®‚̒ʏíŒ^S–[‘e“®‚ւ̍‡•¹‚Æ—U”­‹@“]‚Ö‚ÌŠÖ—^D‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  191. ì•Ó³”VCŽRè@_C˜ð“c@•qC–Ø‘S@Œ[C’·’Jì’q–¾C’¬–ì@‹BC•–ØŒ’ŽuCˆä“¡—tŽqC‹àé‹MŽmCŒÜ\—’“sCŠÖŒûK•vCšê“c@_CÂÀ˜a—²FS–[×“®‚ð—L‚·‚éS‘ŸÄ“¯Šú—Ö@Š³ŽÒ‚ɑ΂·‚é–[ŽºŒ‹ßƒAƒuƒŒ[ƒVƒ‡ƒ“‚Í‚·‚ׂĂ̊³ŽÒ‚É—LŒø‚©H@‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  192. ‘\“c@•qC•–ØŒ’ŽuC–Ø‘S@Œ[C’·’Jì’q–¾C’¬–ì@‹BCˆä“¡—tŽqCŽRè@_C‹àé‹MŽmCŒÜ\—’@“sCŠÖŒûK•vCšê“c@_C‹v‰êŒ\—SCÂÀ˜a—²FCRT-D Až‚ÝŒã‚É•p”­‚µ‚½SŽº«ŠúŠOŽûk‚ւ̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ªS•s‘SŽ¡—ÂɗLŒø‚Å‚ ‚Á‚½1—áD‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  193. ˆä“¡—tŽqCšê“c@_C•–ØŒ’ŽuC–ûˆäŒcWCŽRè@_CŒÜ\—’“sC‹àé‹MŽmC’¬–ì@‹BC’·’Jì’q–¾CŠÖŒûK•vCÂÀ˜a—²F‰EŽº—¬o˜H‚ƍ¶Žº—¬o˜H‚̐SŽº«ŠúŠOŽûk‚ɑ΂µ¶Š¥ë‚©‚ç‚Ì’Ê“d‚É‚æ‚è‚Æ‚à‚ɍªŽ¡‚µ“¾‚½Ç—áD‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  194. ˆÀ’B@‹œCŽR“à—ŽqC‰““¡—mŽqC²“¡—zŽqC”óŒû r•FCí‰ªG˜aC—é–؏͍OC‰xŠì@–LCÂÀ˜a—²FIkr ƒ`ƒƒƒlƒ‹ˆâ“`Žq‚ُ̈킪‹^‚í‚ꂽCtype 1—l‚ÌT ”gŒ`‚ð’æ‚·‚éQT‰„’·ÇŒóŒQ‚̈ê—áD‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiç—tj10ŒŽC2012
  195. £”ö—RLF‚»‚ë‚»‚ë–{‹C‚Å3D ƒGƒR[D3ŽŸŒ³’´‰¹”g`Še—̈æ‚ł̗Տ°‰ž—p‚ÌŽÀî‚ÆŠú‘Ò‚³‚ê‚éV‹Zp`D“ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ24‰ñŠwpW‰ïi‘å‹{j10ŒŽC2012
  196. ‘å’ËŽÑ“y”üC£”ö—RLCªè—¢”üC¬—эhŽqC’†“‡‰pŽ÷C”Ñ“c“TŽqCŽðŠª•¶ŽqCã–q@—²CÎ’Ã’qŽqCÂÀ˜a—²FpŒã‰¼«SŽºáŽ‚𐶂¶‚½Œ€ÇŒ^Š´õ«S“à–Œ‰Š‚̈ê—áD“ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ24‰ñŠwpW‰ïi‘å‹{j10ŒŽC2012
  197. í‰ªG˜aC¬’r@˜NC’·ŽR@ˆãCŸN“cOŽ¡C²“¡@–¾FRate Control Medications for Atrial Fibrillation Influence Cardiopulmonary Function during ExerciseD‘æ49‰ñ“ú–{—Տ°¶—Šw‰ï‘‰ïi’·èj10ŒŽC2012
  198. •–ØŒ’ŽuCŠÖŒûK•vCŠL’J˜aºCˆäì¹KC¬ŽR@’CV“c‡ˆêCŽR“àNÆC’¬–ì@‹BCˆä“¡—tŽqCŽRè@_C‹–@“ŒŸªCŒÜ\—’“sC‘º‰zLsCÂÀ˜a—²F’‹Œ«S‹Ø[Ç‚É”º‚¤SŽº•p”‚ɑ΂·‚鍂–§“x”÷×ƒ}ƒbƒsƒ“ƒOƒKƒCƒh‰ºá­“àüóÄŽÜp‚Ì’·Šú—\ŒãD‘æ10‰ñƒI[ƒ^ƒ€zŠÂŠíƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi“Œ‹žj10ŒŽC2012
  199. ›Á@¯‰ÍCŽðˆä@rC’·’Jì’q–¾C–Ø‘º‘׎OCÂÀ˜a—²C•½¼—SŽiC‹tˆä‰À‰iC‹à–{^–çC‰|–{‰ÀŽ¡CåŒ´@ŒªF‚—î‚ŏ‰”­‚̐S•s‘S‚ð‚«‚½‚µ‚½ASDCPS ‚̏ǗáD‘æ20‰ñˆïézŠÂŠíŒ¤‹†‰ïi‚‚­‚΁j11ŒŽC2012
  200. ‘“cŒc‘¾C¼Œ´’‘nCVÀœAKC¼—T‘¾˜YC’O‰HŒöˆê˜YCŠÖŒûK•vCÂÀ˜a—²FPre-potential ‚ðŽw•W‚Æ‚µ‚½‘å“®–¬Š¥ëƒAƒuƒŒ[ƒVƒ‡ƒ“‚ōªŽ¡‚µ‚¦‚½“TŒ^“I¶‹rƒuƒƒbƒNŒ^SŽº•p”‚Ì1—áD‘æ24‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiŽRŒûj11ŒŽC2012
  201. ²“¡O“TCŽR“àNÆC–ö‰º“Ö•FC—é–؁@“āCì‰O“¹C‰Pˆä‰p—SC‹{è—ºˆêCŽRŒû“O—YC¬¼—T“ñCŒ´@M”ŽC”~–{•üKC‹{–{‹M—fC”ö—с@“OC•½”öŒ©ŽOCÂÀ˜a—²F—‘‰~â|‰S–[×“®‚Əã‘åÃ–¬×“®‚Ì“ñd×“®‚ð’悵‚½1—áFS–[×“®’†‚Éthoracic vein isolation ‚ðs‚¤Û‚Ì’ˆÓ“_D‘æ24‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiŽRŒûj11ŒŽC2012
  202. —é–؁@“āCŽR“àNÆC–ö‰º“Ö•FC²“¡O“TCì‰Š°“¹C‰Pˆä‰p—SC‹{è—ºˆêCŽRŒû“O—YC¬¼—T“ñCŒ´@M”ŽC”~–{•üKC‹{–{‹M—fC”ö—с@“OC•½”öŒ©ŽOCÂÀ˜a—²F¶Š¥ë“à‚É‚Ä“ñŽí—Þ‚Ìprepotential ‚ð”F‚ß‚½—¬o˜HŒ^SŽº«ŠúŠOŽûk‚Ì1—áD‘æ24‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiŽRŒûj11ŒŽC2012
  203. –ûˆäŒcWC‹g“cŒ’‘¾˜YCŠÛ“cr‰îC”üè¹ŽqCˆÀ”{‘å•ãC•ˆÀ–@”VC“¿‰iç•äCH“‡M“ñC’†–ìŒb”üC‹àé‹MŽmCÂÀ˜a—²FS‹Ø[ÇŒã‚̍¶‹rƒvƒŠƒLƒ“ƒG‘gD—R—ˆE‘½Œ¹«SŽº•s®–¬‚ɑ΂µ‚ăJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ª‘tŒø‚µ‚½ˆê—áD‘æ24‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiŽRŒûj11ŒŽC2012
  204. ’†–ìŒb”üC’‡“‡–ƒ—¢‰ÂC‹{èG˜aCŒ´“c’q—YCŽO‘î—Ç•FCšê“c@_CÂÀ˜a—²F‘å“®–¬Š¥ëŒ¹SŽº«•s®–¬‚̃AƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ÁFŠ¥ë“àÄŽÜ‚Í’·Šú“I‚ɈÀ‘S‚©”Û‚©? ‘æ24‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiŽRŒûj11ŒŽC2012
  205. ¬£‘ãŽm‹vC•ž•”@ˆ¤C‰Á“¡@õC—§‰Ô–qŽqCˆäì¹KC‰|–{‹­ŽuCÂÀ˜a—²F’x‰„“dˆÊ‚ƃvƒ‹ƒLƒ“ƒG“dˆÊ‚ðŽw•W‚Æ‚µ‚½ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Åtriggered VPC ‚̍ªŽ¡‚ª‚¦‚ç‚ꂽS‹Ø[ÇŒãVF storm ‚Ì1—áD‘æ24‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiŽRŒûj11ŒŽC2012
  206. ”~’Á@“wCˆÀ“‡—Ç‹PŽqC•ì‚Ý‚âŽqCk@‹±ˆêC“‡“c¹DC“c’†@½CŽRè@_C•–ØŒ’ŽuCŒÜ\—’“sCŠÖŒûK•vCÂÀ˜a—²FƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚¨‚¯‚éƒfƒNƒXƒƒfƒgƒ~ƒWƒ“‚ð—p‚¢‚½’ÁÃ‚ÌŒŸ“¢D‘æ24‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiŽRŒûj11ŒŽC2012
  207. —§‰Ô–qŽqC¬£‘ãŽm‹vCˆäì¹KC‰|–{‹­ŽuCŠÖŒûK•vCÂÀ˜a—²C–ìãº•FCŒc“c‹B•FF ‰EŽºŽ©—R•Ç‚Ì––½Purkinge ‘@ˆÛ‹NŒ¹trigger ‚ɑ΂µ‚ăAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½“Á”­«SŽº×“®‚Ì1—áD‘æ24‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiŽRŒûj11ŒŽC2012
  208. “cK˜aŽqC‰ºžŠMˆÐC’¬–ì’qŽqCŽðˆä@rC¡’†|‹g“c‹±ŽqCœA]“¹ºC•Û•xNGCÂÀ˜a—²FƒXƒ^ƒ`ƒ“‚ÍCD4—z«T ×–E‚ÌTh1/Th17×–E‚Ö‚Ì•ª‰»‚ð—}§‚µS‘Ÿ‚̉ŠÇ‚𐧌䂷‚éD‘æ16‰ñ“ú–{SŒŒŠÇ“à•ª”å‘ãŽÓŠw‰ïŠwp‘‰ïi“Œ‹žj11ŒŽC2012
  209. Î’Ã’qŽqFSƒGƒR[‚É‚æ‚鑁Šúf’fD‘æ16‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiå‘äj12ŒŽC2012
  210. ›–쏺Œ›CÎ’Ã’qŽqCŽðˆä@rC–ûˆä ŒcWCˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCì‘º—´C£”ö—RLCÂÀ˜a—²F”x‚ŒŒˆ³Ž¡—Öò‚É‚æ‚è•a‘Ԃ̈«‰»‚ð’悵‚½2Ç—áD‘æ16‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiå‘äj12ŒŽC2012
  211. ì•Ó³”VCŽðˆä@rCŒà@—´”~Cì¼’¼lC˜ð“c@•qC²“¡Šó”üCŽðˆär‰îC›–쏺Œ›C’·’Jì’q–¾C–Ø‘º‘׎OC‘º‰zLsC‰Í–ì@—¹CÂÀ˜a—²FDŽ_‹…«S‹Ø‰Š‚ð‡•¹‚µ‚½Churg-Strauss syndrome ‚̈ê—áD‘æ226‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj12ŒŽC2012
  212. “n•”_–¾C›Á@¯‰ÍCt¬’q•FCŠ|ŽD—YŠîC•¶‘ —DŽqC•½À‚ä‚èCm‰ÈG’C–ìŒû—SˆêCÂÀ˜a—²F“œ”A•a«ƒPƒgƒAƒVƒh[ƒVƒX‚ªŒ_‹@‚ƂȂ葽Ž}Š¥“®–¬¹k‚É”º‚¤S‹Ø[Ç‚ð‡•¹‚µ‚½Œ€ÇŒ^“œ”A•a‚Ì1—áD‘æ226‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj12ŒŽC2012
  213. ì¼’¼lC£”ö—RLC’†“‡‰pŽ÷CÎ’Ã’qŽqCÂÀ˜a—²Fƒy[ƒXƒ[ƒJƒŠ[ƒhÇ—á‚É‚¨‚¯‚éŽOë•Ù‹t—¬”­Ç‚ÉŠÖ‚·‚錟“¢D‘æ37‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj12ŒŽC2012

@@@¡ ‚»‚Ì‘¼

  1. ‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇE‚ŒŒˆ³ES•s‘SDˆ¤•Q”x‚ŒŒˆ³ÇŒ¤‹†‰ï2012i¼ŽRj1ŒŽC2012
  2. Žðˆä@rF”x‚ŒŒˆ³Ž¡—Âɂ¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“Žó—e‘̝hR–ò‚̈ʒu‚¯D‚¢‚΂炫PAH u‰‰‰ïi‚‚­‚΁j@2ŒŽC2012
  3. –ûˆäŒcWCŠÖŒûK•vCŽRè@_C‹àé‹MŽmC‹g“cŒ’‘¾˜YCšê“c@_CÂÀ˜a—²FS–[×“®‚ðŽä‹N‚·‚é‰EŽº—¬o˜H‹NŒ¹SŽº«ŠúŠOŽûk‚ɑ΂·‚éÄŽÜp‚ª’˜Œø‚µ‚½Brugada ÇŒóŒQ‚Ì1—áD‘æ2‰ñŠÖ“ŒƒAƒuƒŒ[ƒVƒ‡ƒ“ƒtƒƒ“ƒeƒBƒAi“Œ‹žj2ŒŽC2012
  4. ‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇES•s‘SD‘æ8‰ñCTD/PH Seminari“Œ‹žj3ŒŽC2012
  5. Sakai S, Warabi E, Katayanagi S, Yanagawa T, Ishii T: Deficiency of sequestosome 1 accelerates neointimal hyperplasia and carotid artery remodeling. Molecular Mechanisms of Stress Response in Diseasei‚‚­‚΁j4ŒŽC2012
  6. ‹{“à@‘ìFk“Á•Êu‰‰l ƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‹y‚Ñ”x‚ŒŒˆ³ÇE‚ŒŒˆ³ES•s‘SD‘æ4‰ñ¼Vh”x‚ŒŒˆ³ÇƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi“Œ‹žj4ŒŽC2012
  7. ÂÀ˜a—²FS–[×“®Š³ŽÒ‚É‚¨‚¯‚éRŒŒð—Ö@‚ðŠÜ‚ß‚Ä–ò•¨Ž¡—Â̈ʒu‚¯DPharmacy Seminar in Tsukubai‚‚­‚΁j4ŒŽC2012
  8. ›–쏺Œ›CÎ’Ã’qŽqC”Ñ“c“TŽqC’†“‡‰pŽ÷Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCì‘º—´C‰|–{^”üC£”ö—RLCÂÀ˜a—²F”x‚ŒŒˆ³‚¨‚æ‚Ñ”x…Žî‚ÌŽ¡—Âɓïa‚µ‚½ˆê—áD‘æ51‰ñ“Œ‹žSƒGƒR[}Œ¤‹†‰ïi“Œ‹žj5ŒŽC2012
  9. Î’Ã’qŽqF•‰‰×SƒGƒR[}‚ðf—Âɐ¶‚©‚·D‘æ48‰ñ’}”gzŠÂŠí§˜b‰ïi‚‚­‚΁j5ŒŽC2012
  10. Î’Ã’qŽqF’·Ž²‚Ö‘z‚¢D‘æ3‰ñŽD–yƒRƒŒƒMƒEƒ€SƒGƒR[iŽD–yj5ŒŽC2012
  11. ‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇE‚ŒŒˆ³ES•s‘SDìŒ§”x‚ŒŒˆ³Çu‰‰‰ïi‚¼j5ŒŽC2012
  12. Žðˆä@rF”x“®–¬«”x‚ŒŒˆ³Ç‚ÌŽ¡—Âɂ¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“hR–ò‚̈ʒu‚¯DH“c”x‚ŒŒˆ³ÇƒtƒH[ƒ‰ƒ€iH“cj5ŒŽC2012
  13. ˜–쌋ŠóFÇ—á•ñDASV ƒGƒLƒXƒp[ƒgƒ~[ƒeƒBƒ“ƒOi‚‚­‚΁j5ŒŽC2012
  14. ÂÀ˜a—²FS•s‘S‡•¹S–[×“®Ž¡—Â̐V‚µ‚¢“WŠJD–kŠC“¹‘åŠwˆãŠw•”zŠÂŠí“à‰È“¯–å‰ïŒ¤C‰ïiŽD–yj6ŒŽC2012
  15. ÂÀ˜a—²F S–[×“® Up-To-DateD‘æ17‰ñé‹ÊzŠÂŠíƒtƒH[ƒ‰ƒ€ié‹Êj6ŒŽC2012
  16. ¯’q–çC²“¡–¾C›Á@¯‰ÍCÂÀ˜a—²FOCT ‚¨‚æ‚ÑŒŒŠÇ“àŽ‹‹¾‚É‚ÄŠÏŽ@‚µ‚¦‚½“Á”­«Š¥“®–¬‰ð—£‚̈ê—áD‘æˆê‰ñŠÖ“ŒŒŒŠÇ“àŽ‹‹¾Œ¤‹†‰ïi“Œ‹žj6ŒŽC2012
  17. ÂÀ˜a—²FƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ƐV‚µ‚¢R‹ÃŒÅ—Ö@DThe 29th Live Demonstration in KOKURAi•Ÿ‰ªj6ŒŽC2012
  18. ÂÀ˜a—²F”ñ–ò•¨—Ö@DˆïéS–[×“®ƒTƒ~ƒbƒgi…ŒËj6ŒŽC2012
  19. ‘º‰zLsF‰uŠwDˆïéS–[×“®ƒTƒ~ƒbƒgi…ŒËj6ŒŽC2012
  20. ÂÀ˜a—²FS–[×“®‚̍ŐV‚ÌŽ¡—ÁD‘Š–ÍŒ´Žs“à‰Èˆã‰ïŠwpu‰‰‰ïi‘Š–ÍŒ´j7ŒŽC2012
  21. “cK˜aŽqFŠg’£Œ^S‹ØÇ‚ɑ΂·‚éSuppressor of cytokine signaling 1iSOCS1jDNA ‚É‚æ‚éV‹Kˆâ“`Žq–Ɖu—Ö@‚̉”\«Dˆã–òŠî”ÕŒ¤‹†ŠƒZƒ~ƒi[i‚‚­‚΁j7ŒŽC2012
  22. •–ØŒ’ŽuCŠÖŒûK•vCŒÜ\—’“sCŽRè@_C’¬–ì@‹BC’·’Jì’q–¾Cˆä“¡—tŽqC‹àé‹MŽmC‘½“c@_C‹v‰êŒ\—SCÂÀ˜a—²Câ–{—TºCH“¡—m•½CåŒ´@ŒªFŠ¥“®–¬ƒoƒCƒpƒXpŒã‚É”­Ç‚µ‚½Vf storm ‚ɑ΂µCƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚½ˆêÇ—áD‘æ17‰ñ_“ސì—Տ°•s®–¬ƒtƒH[ƒ‰ƒ€i‰¡•lj7ŒŽC2012
  23. ÂÀ˜a—²FSŽº•s®–¬‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“D‘æ27‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï ¢•s®–¬‚Ì”ñ–ò•¨Ž¡—ÃKƒCƒhƒ‰ƒCƒ“£2011”N‰ü’ù”ʼnðàƒZƒbƒVƒ‡ƒ“i‰¡•lj7ŒŽ,2012
  24. Î’Ã’qŽqF¶Žº‹ìo•ª‰æEF ‚ð‚à‚¤ˆê“xl‚¦‚éDƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[ ‘æ14‰ñŽOdŒ§’´‰¹”gŒ¤‹†‰ïiŽOdj7ŒŽC2012
  25. ÂÀ˜a—²FS–[×“®@Å‹ß‚̍l‚¦•ûD‘æ3‰ñ‰ï’Ã’n‹æ•s®–¬u‰‰‰ïi•Ÿ“‡j8ŒŽC2012
  26. ‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇE‚ŒŒˆ³ES•s‘S`ƒGƒ“ƒhƒZƒŠƒ“A Žó—e‘́CB1Žó—e‘Ì,B2Žó—e‘Ì‚ÌŽÕ’f‚ɂ‚¢‚ā`D‚‚­‚Δx‚ŒŒˆ³Çu‰‰‰ïi‚‚­‚ÎŽsj9ŒŽC2012
  27. Î’Ã’qŽqFƒCƒ“ƒNƒŒƒ`ƒ“»Ü‚ÌŒ»ó‚ÆŠú‘ҁD‘æ13‰ñˆïé¶ŠˆKŠµ•aƒtƒH[ƒ‰ƒ€i‚‚­‚΁j9ŒŽC2012
  28. ÂÀ˜a—²FS–[×“®‚̍ŋ߂̍l‚¦•ûD•XŒ©“®–¬d‰»ƒŠƒXƒNƒtƒ@ƒNƒ^[Œ¤‹†‰ïi•xŽRj9ŒŽC2012
  29. ÂÀ˜a—²FS–[×“®‚ɑ΂·‚éÅV‚̍l‚¦•ûD‘æ4‰ñ“Œ–k—Տ°•s®–¬Œ¤‹†‰ï@iÂXj9ŒŽC2012
  30. Î’Ã’qŽqFAS ‚ÆMR ‚Ì•a‘Ô‚ð’m‚éD‘æ3‰ñˆïéƒGƒR[ƒnƒ“ƒYƒIƒ“ƒgƒŒ[ƒjƒ“ƒOƒZƒ~ƒi[i‚‚­‚΁j 10ŒŽC2012
  31. Î’Ã’qŽqF‰ES•s‘S‚ÌŽÀÛD‘æ9‰ñ“ú–{SƒGƒR[}Šw‰ïHŠúuK‰ïi“Œ‹žj10ŒŽC2012
  32. ‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇE‚ŒŒˆ³ES•s‘SD2012•l¼ƒGƒ“ƒhƒZƒŠƒ“‚Æ•a‘Ô‚ðl‚¦‚é‰ïi•l¼j10ŒŽC2012
  33. ÂÀ˜a—²F‰ŠÇ‚ƐS–[×“®D‘æ29‰ñ“ú–{S“dŠw‰ïŠwpW‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[7i–‹’£j10ŒŽC2012
  34. ÂÀ˜a—²FS–[×“®- ÅV‚̍l‚¦•û-D‘æ14‰ñ”ûŽRzŠÂŠíƒJƒ“ƒtƒ@ƒŒƒ“ƒXi“¿“‡j@10ŒŽC2012
  35. Î’Ã’qŽqFˆË—Š•ÊSƒGƒR[ŒŸ¸‚̐i‚ß•û‡@S“d}ˆÙíD“ú–{’´‰¹”gˆãŠw‰ï‘æ11‰ñŠÖ“ŒbM‰z’n•û‰ïuK‰ïi‘å‹{j10ŒŽC2012
  36. ‹{“à@‘ìFƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇE‚ŒŒˆ³ES•s‘S- ƒGƒ“ƒhƒZƒŠƒ“A Žó—e‘́CB1Žó—e‘Ì,B2Žó—e‘Ì‚ÌŽÕ’f‚ɂ‚¢‚Ä-D‘æ1‰ñ ”xzŠÂƒtƒƒ“ƒeƒBƒA TOKYO `–ڂŐf‚é”xzŠÂ`i“Œ‹žj10ŒŽC2012
  37. ŒÜ\—’“sC‘º‰zLsC‹–@“ŒŸªCšê“c@_CŠÖŒûK•vCŽRú±@_C•–ØŒ’ŽuC’¬–ì@‹BCˆä“¡—tŽqCÎ’Ã’qŽqC£”ö—RLC‹v‰êŒ\—SCÂÀ˜a—²F‚ŒŒˆ³ƒ‰ƒbƒg‚É‚¨‚¯‚éƒAƒ~ƒIƒ_ƒƒ“‚̐S–[×“®—}§‚̃ƒJƒjƒYƒ€‚ɂ‚¢‚Ä- ƒxƒvƒŠƒWƒ‹‚Æ‚Ì”äŠrŒŸ“¢-D‘æ17‰ñƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ïi“Œ‹žj10ŒŽC2012
  38. ŒÜ\—’“sFS–[×“®‚̐¬‚è—§‚¿‚ÉŠÖ—^‚·‚éˆöŽq‚ɂ‚¢‚āF—Տ°Œ¤‹†‚¨‚æ‚Ñ—ì’·—Þ‚ð—p‚¢‚½S–[×“®ƒ‚ƒfƒ‹\’zŽÀŒ±‚æ‚èD ‘æ8‰ñ—ì’·—Þˆã‰ÈŠwƒtƒH[ƒ‰ƒ€i‚‚­‚΁j11ŒŽC2012
  39. ì•Ó³”VCŽðˆä@rCŒà@—´”~Cì¼’¼lC˜ð“c@•qC²“¡ŠóŽÀCŽðˆär‰îC›–쏺Œ›C’·’Jì’q–¾C–Ø‘º‘׎OC‘º‰zLsC‰Í–ì@—¹C–ìŒû‰ë”VCÂÀ˜a—²FƒXƒeƒƒCƒhŽ¡—ª’˜Œø‚µ‚½DŽ_‹…«S‹Ø‰Š‡•¹Churg-Strauss ÇŒóŒQ‚̈ê—áD‘æ34‰ñS‹Ø¶ŒŸŒ¤‹†‰ïi¼–{j11ŒŽC2012
  40. ’¬–ì’qŽqC“cK˜aŽqCœA]“¹ºCÂÀ˜a—²C¡’†‹±ŽqFŽ©ŒÈ–Ɖu«S‹Ø‰Š‚É‚¨‚¯‚éƒeƒlƒCƒVƒ“C ‚Ì‹@”\‰ðÍD‘æ2‰ñƒeƒlƒCƒVƒ“ƒtƒH[ƒ‰ƒ€i“Œ‹žj11ŒŽC2012
  41. Î’Ã’qŽqFèò“®–¬ƒGƒR[‚Ì“®–¬d‰»ƒXƒNƒŠ[ƒjƒ“ƒO‚Æ‚µ‚Ä‚Ì–ðŠ„D’·èƒGƒR[Œ¤‹†‰ïi’·èj12ŒŽC2012
  42. Î’Ã’qŽqF—«zŠÂŠíˆã‚ÌŽdŽ–‚ƈ玙Žx‰‡FŒoŒ±‚ÆŠó–]D‘æ226‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïF‘æ2‰ñ’j—‹¤“¯ŽQ‰æˆÏˆõ‰ïƒZƒ~ƒi[i“Œ‹žj12ŒŽC2012
  43. ’¬–ì@‹BF—«zŠÂŠíˆã‚ÌŽdŽ–‚ƈ玙Žx‰‡FŽdŽ–EŒ¤‹†EˆçŽ™‚ÌŒoŒ±D‘æ226‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïF‘æ2‰ñ’j—‹¤“¯ŽQ‰æˆÏˆõ‰ïƒZƒ~ƒi[12ŒŽC2012
  44. ÂÀ˜a—²F’vŽ€«•s®–¬‚ɑ΂·‚éƒg[ƒ^ƒ‹Ž¡—ÁD‘æ76‰ñ‹{èŽsŒSˆãŽt‰ï•a‰@S‘Ÿ•aŒ¤‹†‰ïi‹{èj12ŒŽC2012
  45. ÂÀ˜a—²FS–[×“®‚𑽊p“I‚ɂƂ炦‚é\–ò•¨Ž¡—Â̐V‚½‚È–ðŠ„\D‰¡{‰êŽsˆãŽt‰ïŠwpu‰‰‰ïi‰¡{‰êj12ŒŽC2012
  46. Žðˆä@rF‹•ŒŒ«SŽ¾Š³Œ¤‹†‚ÌŒ»óD‘æ1‰ñSŒŒŠÇ•aiCVDjŒ¤‹†‰ïC2012
  47. ì•Ó³”VCŽðˆä@rCÂÀ˜a—²FDŽ_‹…«S‹Ø‰Š‚ð‚«‚½‚µ‚½Churg-Strauss ÇŒóŒQ‚̈ê—áD‘æ8‰ñ“Œ‹žS‘Ÿ•a—ƒtƒH[ƒ‰ƒ€i“Œ‹žj2012
  48. Žðˆä@rFS‹Ø‰Š‚̐i“W‚É‚¨‚¯‚éŽ_‰»ƒXƒgƒŒƒX‚ÌŠÖ—^D‚‚­‚ÎŽ_‰»ƒXƒgƒŒƒXŒ¤‹†‰ïEŠwÛƒoƒCƒIƒ[ƒNƒVƒ‡ƒbƒvi‚‚­‚΁jC2012
  49. Î’Ã’qŽqCŠÛŽRG˜aCŽðˆä@rC–{ŠÔ@ŠoCÂÀ˜a—²F¬‡«Œ‹‡‘gD•a‚ð‡•¹‚µ‚½S–[’†ŠuŒ‡‘¹Ç‚Ì”x‚ŒŒˆ³Ç‚Ƀ{ƒZƒ“ƒ^ƒ“‚ª—LŒø‚Å‚ ‚Á‚½ˆê—áD”x‚ŒŒˆ³ÇƒZƒ~ƒi[in ‚‚­‚΁i‚‚­‚΁jC2012
  50. Î’Ã’qŽqFSƒGƒR[}‚ÅŒ©‚鍶Žº‚Ì•”•ª‚Æ‘S‘́D‘æ5‰ñH÷‰ïiH“cjC2012

@2011”N“xi2011”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. ÂÀ˜a—²F SŽº•s®–¬‚̃AƒuƒŒ[ƒVƒ‡ƒ“D ‘æ23‰ñ—Տ°•s®–¬Œ¤‹†‰ï (“Œ‹ž) 1ŒŽC2011
  2. ’†–ìŒb”üCšê“c@_C‹g“cŒ’‘¾˜YCŠÖŒûK•vCŽRè@_CŒÜ\—’@“sC•–ØŒ’ŽuC’¬–ì@‹BC¬£‘ãŽm‹vCˆä“¡—tŽqCž­“c–[‹IC‹àé‹MŽmCŒË“c@’¼CÂÀ˜a—²C–ìãº•FF ƒJƒe[ƒeƒ‹ÄŽÜp‚É‚æ‚荪Ž¡‚µ‚½“«¶ŽºŒã“û“ª‹Ø‹NŒ¹SŽº«ŠúŠOŽûk‚Ì1—áFp’†EpŒãSƒGƒR[ŒŸ¸‚Ì—L—p«D ‘æ23‰ñ—Տ°•s®–¬Œ¤‹†‰ï (“Œ‹ž) 1ŒŽC2011
  3. ›–쏺Œ›C£”ö—RLCŽR–{¹—ǁCì‘º@—´C’†“‡‰pŽ÷CâŠª•¶ŽqC”Ñ“c“TŽqCÎ’Ã’qŽqC‰Í–ì@—¹CÂÀ˜a—²F ‹r‹CS‚Ì‚R—áD ‘æ45‰ñ“ú–{¬l•a(¶ŠˆKŠµ•a)Šw‰ï (“Œ‹ž) 1ŒŽC2011
  4. “¡Œ´˜aÆ,‘åè–F“T,¬—јal,–î“¡@”É,‚‹´ºŒõ,—é–؍_–¾,“‡–ì@mCÎ’Ã’qŽqC“n•ÓdsC‘]ª”ŽmF ‘å“®–¬‰ŠÇŒóŒQ‚ð‡•¹‚µ‚½‰Æ‘°«‚ƒRƒŒƒXƒeƒ[ƒ‹ŒŒÇi‚e‚gj‚Ì‚P—áD ‘æ14‰ñˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï (‚‚­‚Î) 1ŒŽC2011
  5. ‘º‰zLsCí‰ªG˜aCŽRŠÝˆê‹§C‰¡ŽR‘לAC‹–@“ŒŸªCŒÜ\—’@“sCŽRè@_Cˆä“¡—tŽqC–k‘º–¾•FC‰ª“c••vC‘啽“N–çC’Jì@•CŠÖŒûK•vCšê“c@_C‚–؉ë•FCˆé@”ŽNCÂÀ˜a—²F ˆê”ʏZ–¯ŒŸf‚É‚¨‚¯‚éƒuƒ‹ƒKƒ_Œ^S“d}‚Ì’·Šú—\Œã’²¸-Circulatory Risk in Communities Study(CIRCS)-. ‘æ9‰ñ“Á”­«SŽº×“®Œ¤‹†‰ï(J-IVFS) (“Œ‹ž) 2ŒŽC2011
  6. ŒÜ\–씎ŠîCŠOŽR¹OCˆÀ’B@‹œC‹ãŒË“c—T‹vC“n•ÓdsC’|“àhŽqCŠÛ“cr‰îC‘¾“c—Ç—YC¬—Ñ—TKC“¿“cˆÀtC•½–ì@“āF ƒAƒ‹ƒKƒgƒƒoƒ“‚Ì“Š—^‰º‚É‚àŠÖ‚í‚炸PCI’†‚ÉŠ¥“®–¬“àŒŒð‚𐶂¶‚½ƒwƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒ¸­(HIT)‚̈ê—áD ‘æ219‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (‰¡•l) 2ŒŽC2011
  7. t¬’q•FCŒË“c@’¼C‚”¨MŽqC‹k@Œ«œACj‘º‰À]C¯@’q–çCm‰ÈG’C•¶åU—DŽqC•½À‚ä‚èC–ìŒû—SˆêCÂÀ˜a—²F Až‚ÝŒã14”NŒo‰ß‚µŒoÃ–¬“I‚ɃŠ[ƒh”²‹Ž‚ɐ¬Œ÷‚µ‚½ƒy[ƒXƒ[ƒJ[Š´õÇ‚̈ê—áD ‘æ219‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (‰¡•l) 2ŒŽC2011
  8. ‰Á“¡@õCÎ’Ã’qŽqCÂÀ˜a—²F ¬lŠú‚ɐf’f‚³‚ꂽ¶Žå”x“®–¬Œ‡‘¹Ç‡•¹‚µ‚½‘m–X•Ù•Â½•s‘SÇ‚ÌŽ¡—Ð헪D ‘æ219‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (‰¡•l) 2ŒŽC2011
  9. j‘º‰À]CŒË“c@’¼C–ìŒû—SˆêCšê“c@_Cˆä“¡—tŽqC‹àé‹MŽmC•–ØŒ’ŽuC’¬–ì@‹BC’†–ìŒb”üC¬£‘ãŽm‹vCŽRè@_CŒÜ\—’@“sC‹g“cŒ’‘¾˜YCŠÖŒûK•vCÂÀ˜a—²F ‰EŽºSë•”ƒy[ƒVƒ“ƒO‚ª—LŒø‚Å‚ ‚Á‚½‰EŽº“ñoÇ‚Ì‚P—áD ‘æ3‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (“Œ‹ž) 2ŒŽC2011
  10. ŒË“c@’¼Ct¬’q•FC‚”¨MŽqCj‘º‰À]C‹k@Œ«œAC¯@’q–çCm‰ÈG’C•¶‘ —DŽqC•½À‚ä‚èC–ìŒû—SˆêCÂÀ˜a—²F Až‚ÝŒã14”NŒo‰ß‚µŒoÃ–¬“I‚ɃŠ[ƒh”²‹Ž‚ɐ¬Œ÷‚µ‚½ƒy[ƒXƒ[ƒJ[Š´õÇ‚Ì‚P—áD ‘æ3‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (“Œ‹ž) 2ŒŽC2011
  11. ‰Í–ì@—¹CˆÀ“c@vC‰ºžŠMˆÐC¼–ìO•¶C”‹’JŒ\ˆêC‚‹´L“ñC¯@‘ñ’jC…’J‘¾˜YC£”ö—RLCÂÀ˜a—²F Electrical Storm‚ɑ΂·‚é’´’ZŽžŠÔì—pŒ^ƒÀŽÕ’f–ò‰–Ž_ƒ‰ƒ“ƒWƒIƒ[ƒ‹‚ÌŒø‰ÊD ‘æ38‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (‰¡•l) 2ŒŽC2011
  12. ŠÖ@‹`Œ³C‰ºžŠMˆÐCŸN–{G–¾C”‹’JŒ\ˆêCˆÀ“c@vC¼–ìO•¶C‰Í–ì@—¹C…’J‘¾˜Y: ƒ‰ƒ“ƒWƒIƒ[ƒ‹‚Í”sŒŒÇƒ‚ƒfƒ‹ƒ‰ƒbƒg”x‚̃Gƒ“ƒhƒZƒŠƒ“Œn˜´i‚ð—}§‚µ‚È‚©‚Á‚½D ‘æ38‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (‰¡•l) 2ŒŽC2011
  13. ‰ºžŠMˆÐC’¬–ì@‹BC‹–@“ŒŸªCŸN–{G–¾CŠÖ@‹`Œ³C”‹’JŒ\ˆêCˆÀ“c@vC‰Í–ì@—¹CÂÀ˜a—²C…’J‘¾˜Y: “Á”­«SŽº•p”‚ɑ΂·‚éG-CSFiè÷—±‹…ƒRƒƒj[ŽhŒƒˆöŽqj—\–h“Š—^‚É‚æ‚é—}§Œø‰Ê‚ÌŒŸ“¢D ‘æ38‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (‰¡•l) 2ŒŽC2011
  14. ”‹’JŒ\ˆêC‚‹´@GC’–ŒÒLˆêC“c’†@½C¼–ìO•¶C‰ºžŠMˆÐCˆÀ“c@vC‰Í–ì@—¹C…’J‘¾˜Y: Colforsin (…—n«forskolin—U“±‘Ì) ‚Ì‹­Sì—p‚ɃAƒVƒh[ƒVƒX‚ª‹y‚Ú‚·‰e‹¿D ‘æ38‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (‰¡•l) 2ŒŽC2011
  15. Œ•Ž—Y“ñC‰K–ì–؁@Œ’C‹{–{‹BŽ¡C²“¡‚Ý‚¦C–q–ìWŽqCŽl–{—³ˆêCŸN–{G–¾C‰ºžŠMˆÐC…’J‘¾˜Y: ‚¹‚ñ–Ï•]‰¿ƒc[ƒ‹ICDSC (Intensive Care Delirium Screening Checklist) ‚̐lHŒÄ‹zŠ³ŽÒ‚ɑ΂·‚é‘Ó–«•]‰¿D ‘æ38‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (‰¡•l) 2ŒŽC2011
  16. Š|ŽD—YŠîC²“¡@–¾C¬“‡‰hŽ¡CHŽR‘åŽ÷C“n•”_–¾CÂÀ˜a—²F —¼‘¤‘’°œ“®–¬‚̍‚“xÎŠD‰»•a•Ï‚ɑ΂·‚éKissing Stent‚̍ۂÉExpress Stent‚ª’E—Ž‚µ‚©‚©‚Á‚½Ç—áD ‘æ6‰ñ ˆïéPPIŒ¤‹†‰ïi‚‚­‚΁j3ŒŽC2011
  17. ’J’†—¢”üC£”ö—RLC‹T“c—L—¢C˜’Ë—Ú”üC›–쏺Œ›Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCì‘º@—´C–ìã‰ÀŒbC’†“‡‰pŽ÷C”Ñ“c“TŽqCŽðŠª•¶ŽqCÎ’Ã’qŽqCÂÀ˜a—²F –«S–[×“®‚É‚¨‚¯‚é”xÃ–¬Šu—£p‚̍¶–[Œ`‘Ô‚¨‚æ‚э¶–[‹@”\‚ւ̉e‹¿D ‘æ22‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïiŽ­Ž™“‡j4ŒŽC2011
  18. ˆ­”üˆÀ‹IŽqCÎ’Ã’qŽqCŽR–{¹—ǁCj‘º‰À]C’¬–ì’qŽqCì‘º@—´C‰|–{^”üCŠÖŒûK•vCšê“c@_C£”ö—RLCÂÀ˜a—²F ‚RŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚é‰EŽº‹ÇŠ•Ç‰^“®•]‰¿D ‘æ22‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïiŽ­Ž™“‡j4ŒŽC2011
  19. ŽR–{¹—ǁCÎ’Ã’qŽqC˜’Ë—Ú”üC’J’†—¢”üC›–쏺Œ›Cˆ­”üˆÀ‹IŽqCj‘º‰À]Cì‘º@—´C’†“‡‰pŽ÷C”Ñ“c“TŽqCŽðŠª•¶ŽqC£”ö—RLCÂÀ˜a—²F ‰^“®—U”­«‘m–X•Ù‹t—¬‚ÉŠÖ—^‚·‚鍶ŽºŒ`‘ԕω»‚¨‚æ‚э¶Žºwall stress‚ÌŒŸ“¢`ƒGƒ‹ƒSƒ[ƒ^•‰‰×SƒGƒR[–@‚ð—p‚¢‚ā`D ‘æ22‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïiŽ­Ž™“‡j4ŒŽC2011
  20. ˜’Ë—Ú”üC£”ö—RLC‹T“c—L—¢C’J’†—¢”üC›–쏺Œ›Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁC’¬–ì’qŽqCj‘º‰À]Cì‘º@—´C’†“‡‰pŽ÷C”Ñ“c“TŽq,ŽðŠª•¶ŽqCÎ’Ã’qŽqCÂÀ˜a—²F ¶Žº‹ìo—¦³í—á‚É‚¨‚¯‚éTMAD‹K’èˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢D ‘æ22‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïiŽ­Ž™“‡j4ŒŽC2011
  21. ’†“‡‰pŽ÷C£”ö—RLCÎ’Ã’qŽqCŽR–{¹—ǁCˆ­”üˆÀ‹IŽqCì‘º@—´Cìã@NCÂÀ˜a—²CÎ’Ã’qŽqF 3DSƒGƒR[–@‚ð—p‚¢‚½¶Žº—e—ÊŒv‘ª‚É‚¨‚¯‚鐸“x‚ÌŒŸ“¢D ‘æ22‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïƒƒVƒ“ƒ|ƒWƒEƒ€„iŽ­Ž™“‡j4ŒŽC2011
  22. Î’Ã’qŽqF 3Dƒgƒ‰ƒbƒLƒ“ƒO‚̐S‹Ø‹•ŒŒf’f‚É‚¨‚¯‚é“W–]D ‘æ22‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„iŽ­Ž™“‡j4ŒŽC2011
  23. ‹àé‹MŽmCšê“c@_C¬£‘ãŽm‹vC’†–ìŒb”üC’¬–ì@‹BC•–ØŒ’ŽuCˆä“¡—tŽqCŽRè@_CŒÜ\—’@“sCž­“c–[‹ICŠÖŒûK•vC‹v‰êŒ\—SCÂÀ˜a—²F S–[×“®‚̃gƒŠƒK[‚Æ‚È‚éSŽº«ŠúŠOŽûk‚ɑ΂·‚éƒJƒe[ƒeƒ‹ÄŽÜp‚ª’˜Œø‚µ‚½ƒJƒeƒRƒ‰ƒ~ƒ“Š´Žó«SŽº•p”‚̈êÇ—áD ‘æ41‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ï (‘åã) 5ŒŽC2011
  24. ‹k@Œ«œACt¬’q•FC‚”¨MŽqCj‘º‰À]C¯@’q–çCŒË“c’¼C•¶åU—DŽqCm‰ÈG’C•½À‚ä‚èC–ìŒû—SˆêF ‘å—Ê‚ÌŒŒð‚ð—L‚µ‚½AMI‚ɑ΂µ‚Ä8ƒtƒŒƒ“ƒ`‚ÌŒŒð‹zˆøƒJƒe[ƒeƒ‹‚ª—LŒø‚Å‚ ‚Á‚½2—áD ‘æ38‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj5ŒŽC2011
  25. Š|ŽD—YŠîC²“¡@–¾C¯@’q–çC¬“‡‰hŽ¡C“n•”_–¾CHŽR‘åŽ÷CÂÀ˜a—²F DES—¯’uŒã‚Ìprotrusion‚ðIVUSEOCTEŒŒŠÇ“àŽ‹‹¾‚ÅŠÏŽ@‚µ“¾‚½ˆê—áD ‘æ38‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj5ŒŽC2011
  26. ‹àé‹MŽmCšê“c@_C¬£‘ãŽm‹vC’†–ìŒb”üC’¬–ì ‹BC•–ØŒ’ŽuCˆä“¡—tŽqCŽRè@_CŒÜ\—’@“sCž­“c–[‹ICŠÖŒûK•vC‹v‰êŒ\—SCÂÀ˜a—²F SŽº×“®‚̃gƒŠƒK-‚Æ‚È‚éSŽº«ŠúŠOŽûk‚ɑ΂·‚éƒJƒe-ƒeƒ‹ÄŽÜp‚ª’˜Œø‚µ‚½ƒJƒeƒRƒ‰ƒ~ƒ“Š´Žó«SŽº•p”‚̈êÇ—áD ‘æ41‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi‘åãj5ŒŽC2011
  27. Î’Ã’qŽqC£”ö—RLF q“Á•Ê‰‰‘èŠé‰æ@ŒŒ—¬•]‰¿–@‚𐮗‚µ‚Ä—‰ð‚·‚érƒRƒ“ƒgƒ‰ƒXƒg‚É‚æ‚鍶Žº“àŒŒ—¬“®‘Ԃ̉ðÍD “ú–{’´‰¹”gˆãŠw‰ï‘æ84‰ñŠwpW‰ïi“Œ‹žj5ŒŽC2011
  28. Î’Ã’qŽqC£”ö—RLC‹T“c—L—¢Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCì‘º@—´CÂÀ˜a—²F 3ŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚éöÝ«“œ”A•a«S‹ØÇ‚̐f’f“IˆÓ‹`‚ÉŠÖ‚·‚錟“¢D “ú–{’´‰¹”gˆãŠw‰ï‘æ84‰ñŠwpW‰ïi“Œ‹žj5ŒŽC2011
  29. ˜’Ë—Ú”üCÎ’Ã’qŽqC£”ö—RLC‹T“c—L—¢Cˆ­”üˆÀ‹IŽqCŽR–{¹—ǁCì‘º@—´CÂÀ˜a—²F DahlH‰–Š´Žó«ƒ‰ƒbƒg‚É‚¨‚¢‚Ä’´Ž²•ûŒüƒXƒgƒŒƒCƒ“’ቺ‚͐S“à–Œ‘¤S‹ØüˆÛ‰»‚ÆŠÖ˜A‚·‚éD “ú–{’´‰¹”gˆãŠw‰ï‘æ84‰ñŠwpW‰ïi“Œ‹žj5ŒŽC2011
  30. k@‹±ˆê, ‹àé‹MŽm, Ô¯”Ž˜a, ²“¡Œc, ìã@N, Î’Ã’qŽq, ²“¡@–¾, ‹g“cŒ’‘¾˜Y, ŠÖŒûK•v, šê“c@_, ÂÀ˜a—²F –«S•s‘S‹}«‘ˆ«Šú‚ɏoŒ»‚µ‚½“«Ž‘±«SŽº•p”‚ɑ΂µAˆêŽž“I‰ESŽ¨ƒy[ƒVƒ“ƒO‚ª—LŒø‚Å‚ ‚Á‚½1Ç—áD@ ‘æ21‰ñ“ú–{—Տ°HŠw‰ïi‘啪j5ŒŽC2011
  31. ²“¡@Œc, ‹g“cŒ’‘¾˜Y, Ô¯”Ž˜a, k@‹±ˆê, –x•ÄmŽu, ìã@N, ÂÀ˜a—²F ‚o—͐S‘Ÿ“d‹CŽhŒƒ‘•’uBC-1100‚Ì—LŒø«D ‘æ21‰ñ“ú–{—Տ°HŠw‰ïi‘啪j5ŒŽC2011
  32. £”ö—RLF q“Á•Ê‰‰‘èŠé‰æ@•Ç‰^“®•]‰¿–@‚𐮗‚µ‚Ä—‰ð‚·‚érŽOŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒOSƒGƒR[}–@‚É‚æ‚é•Ç‹@”\•]‰¿D “ú–{’´‰¹”gˆãŠw‰ï‘æ84‰ñŠwpW‰ïi“Œ‹žj5ŒŽC2011
  33. ˜–쌋ŠóC²“¡@–¾CÂÀ˜a—²C£”ö—RLCÎ’Ã’qŽqC–öŒ´–œ—¢ŽqC²“¡@½CHector R. Villarraga, Marek Orban, Virend K. Somers, Fransisco Lopez-JimenezF OSA‚É‚¨‚¯‚é–³ŒÄ‹z’†‚Ì‹¹o“àˆ³’ቺ‚ªS‹@”\‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚āD ‘æ12‰ñzŠÂŠíSASŒ¤‹†‰ïi“Œ‹žj5ŒŽC2011
  34. £”ö—RLF q‹³ˆçu‰‰rSƒGƒR[ŒŸ¸–@‚̋ɈӁ\Šg’£‹@”\‚ðl‚¦‚é\D ‘æ36‰ñ@“ú–{’´‰¹”gŒŸ¸Šw‰ïi‚‚­‚΁j6ŒŽC2011
  35. ’¬–ì@‹BCšê“c@_CŠÖŒûK•vC¬£‘ãŽm‹vCŽRè@_CŒÜ\—’@“sC‹g“cŒ’‘¾˜YC‹v‰êŒ\—SCÂÀ˜a—²F His-PurkinjeŒn‚ðù‰ñ‚·‚é‰E‹rƒuƒƒbƒNŒ^SŽº•p”‚Ì2—áD ‘æ‚P‰ñŠÖ“ŒƒAƒuƒŒ-ƒVƒ‡ƒ“ƒtƒƒ“ƒeƒBƒAi“Œ‹žj6ŒŽC2011
  36. ¯@’q–çCt¬’q•FCm‰ÈG’C‹k@Œ«œACj‘º‰À]C‚”¨MŽqCŒË“c@’¼C•¶‘ —DŽqC•½À‚ä‚èC–ìŒû—SˆêC“à“c@‰·C‹e’r˜a“¿C¡…—¬’q_C¼èŠ°“ñCŽ²‰®’qºC‹g“cˆè—YC‰““¡—DŽ}CÂÀ˜a—²F S•s‘S‚É‚Ä”­Ç‚µ‚½”~“Ő«‘å“®–¬‰Š‚Ì1—áD ‘æ220‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 6ŒŽC2011
  37. Š|ŽD—YŠîC²“¡@–¾C•ž•”@ˆ¤C‰Á“¡@õCˆ­”üˆÀ‹IŽqC’†–ìŒb”üC¬£‘ãŽm‹vC‹àé‹MŽmCÎ’Ã’qŽqC‘º‰z LsCšê“c@_C£”ö—RLCÂÀ˜a—²F ‹}«S‹Ø[Ç—l‚̐S“d}•Ï‰»‚ƐSŒ´«ƒVƒ‡ƒbƒN‚ðŒJ‚è•Ô‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•aS‹ØZ‚Ì1—áD ‘æ220‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 6ŒŽC2011
  38. ’·’Jì’q–¾CŽR“àF‹`C›–쏺Œ›C¬‘îN”VC–{ŠÔ@ŠoCÂÀ˜a—²F ƒGƒ{ƒvƒƒXƒeƒ[ƒ‹‚ª‘tŒ÷A‚»‚ÌŒãƒAƒ“ƒuƒŠƒZƒ“ƒ^ƒ“‚ɐ؂è‘Ö‚¦‰Â”\‚Å‚ ‚Á‚½Œ´”­«”x“®–¬«‚ŒŒˆ³Ç‚Ì1—áD ‘æ220‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 6ŒŽC2011
  39. k@‹±ˆêC‹àé‹MŽmCÔ¯”Ž˜aC²“¡@ŒcCìã@NCˆÀ“‡—Ç‹PŽqC”~’Á@–±CŠ|ŽD—YŠîC¬“‡‰hŽ¡Cˆ­”üˆÀ‹IŽqC‹g“cŒ’‘¾˜YC²“¡@–¾CÂÀ˜a—²F Ž‘±«SŽº•p”Ç‚ɑ΂µA‹Ù‹}‰ESŽ¨ƒy[ƒVƒ“ƒO‚ªŒŒs“®‘ÔˆÛŽ‚É—LŒø‚Å‚ ‚Á‚½‚P—áD ‘æ220‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 6ŒŽC2011
  40. –Ø‘º‘׎O, ‹g‘ºkˆê, Â–؍_Ž÷, ¡’†‹±Žq, ‹g“c—˜’Ê, ÂÀ˜a—², œA]“¹º, ¡ò@•×, ¼è‰v“¿F ƒeƒlƒCƒVƒ“C‚Í‘å“®–¬‰ð—£‚ð—\–h‚·‚镪Žq“IƒVƒ‡ƒbƒNƒAƒuƒ\[ƒo[‚Å‚ ‚éD ‘æ43‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ïE‘æ58‰ñƒ}ƒgƒŠƒbƒNƒXŒ¤‹†‰ï‘å‰ï‡“¯ŠwpW‰ï (“Œ‹ž) 6ŒŽC2011
  41. ˆÀ”{‘å•ã, ¬£‘ãŽm‹v, —Ñ ^—R, ”üè¹Žq, •ˆÀ–@”V: “–‰@‚ÌPCPS Žg—pŒoŒ±D ‘æ9 ‰ñ…ŒË“ú—§zŠÂƒtƒŠ[ƒJƒ“ƒtƒ@ƒŒƒ“ƒXi…ŒËj6ŒŽ, 2011
  42. “cK˜aŽqCŠÛŽRG˜aC²“¡–¾C‰ºžŠMˆÐCÄ“¡IC‰““¡—DŽ}C‘ŠŒ´‰p–¾C‰Í–ì—¹C“n•ÓdsCŽðˆä@rCÂÀ˜a—²F Š¥“®–¬‘¢‰eŒã–«Šú‚É‚¨‚¯‚ét‹@”\‚Ì—\‘ªˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢D ‘æ42‰ñˆïéŒ§‚ŒŒˆ³Œ¤‹†‰ïi‚‚­‚΁j 6ŒŽC2011
  43. ¬£‘ãŽm‹vC—с@^—RC”üè¹ŽqCˆÀ”{‘å•ãC•ˆÀ–@”VF S‹Ø[ÇˆŸ‹}«Šú‚ɏoŒ»‚µ‚½SŽº•p”ESŽº×“®‚ɑ΂µWŠw“IŽ¡—ª‘tŒ÷‚µ‚½‚P—áD ‘æ25‰ñˆïéŒ§PCIŒ¤‹†‰ïi‚‚­‚΁j 6ŒŽC2011
  44. ‹g“cŒ’‘¾˜YCÂÀ˜a—²Cˆî—t@•C”öŒ`–MbC_’¹–¾•F: SŽ¥}‚ð—p‚¢‚½S–[×“®”gŒ`‚ÌŽü”g”‰ðÍ\S“àƒ}ƒbƒsƒ“ƒOŠŒ©‚Ƃ̑Δä\D ‘æ31‰ñ“ú–{ƒzƒ‹ƒ^[Eƒmƒ“ƒCƒ“ƒxƒCƒVƒuS“dŠwŒ¤‹†‰ïi“Œ‹žj7ŒŽC2011
  45. ‹àé‹MŽm, ”‹’JŒ\ˆê, ¼–ìO•¶, ‰ºžŠMˆÐ, ˆÀ“c@v, ‰Í–ì@—¹C…’J‘¾˜YF ƒJƒtƒFƒCƒ“’†“Å‚É‚æ‚éQT‰„’·‚ð”F‚߁AŒŒ’†”Z“x‚ÌŒoŽž“I•Ï‰»‚ðŠÏŽ@‚µ“¾‚½1—áD ‘æ33‰ñ“ú–{’†“ÅŠw‰ï‘‰ïEŠwpW‰ïi‘åŠ_j7ŒŽC2011
  46. ‰Í–ì@—¹C‹´–{”ü’qŽqCˆÀ“c@vC‰ºžŠMˆÐC¼–ìO•¶C”‹’JŒ\ˆêC…’J‘¾˜YC‚‹´L“ñC‚‹´@GF Žq‹{ŒzŠà‚ɑ΂·‚铯Žž‰»Šw•úŽËü—Ö@’†‚ɐS’âŽ~‚𗈂µ‚½Ç—áD ‘æ20‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 7ŒŽC2011
  47. ‰œ“c‘ñ–çC’†“‡³lC—é–؉сC_—ё׍sC–{ŠÔ^lCK“cK’¼C‚‹´’åŽqC‰Í–ì@—¹C…’J‘¾˜YF ICU‚É‚¨‚¯‚é–òÜŽt‚ÌŠˆ“® (‘æ1•ñ) –òÜî•ñ’ñ‹Ÿ‚̉ðÍD ‘æ20‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 7ŒŽC2011
  48. ‹´‘º^—TŽqC…’J‘¾˜YC‚‹´’åŽqC¬ù—YŽiC’†“‡—TŽqC‘å“à“N•vC‚‹´L“ñC‰Í–ì@—¹C”‹’JŒ\ˆê: “}ˆõICU‚É‚¨‚¯‚éƒJƒeƒRƒ‰ƒ~ƒ“EƒvƒŒƒtƒBƒ‹ƒhƒVƒŠƒ“ƒWƒgƒ‰ƒuƒ‹‚ւ̑ΉžD ‘æ20‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 7ŒŽC2011
  49. Sato A, Hoshi T, Kakefuda Y, Nishina H, Takeyasu N, Noguchi Y, Aonuma KF Prognostic value of Myocardial Contrast Delayed Enhancement with 64-slice Multidetector Computed Tomography After Acute Myocardial Infarction. ‘æ20‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi‘åãj7ŒŽC2011
  50. Naruse Y, Yamasaki H, Tachibana M, Atsumi A, Kakefuda Y, Sekiguchi Y, Satoh A, Tada H, Aonuma KF Coronary Venous Lead Implantation after an Evaluation by Virtual Histology Intravascular Ultrasound and Percutaneous Venous Angioplasty with a Coronary Stent: A Case Report. ‘æ20‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi‘åãj7ŒŽC2011
  51. Kakefuda Y, Sato A, Hattori A, Kato J, Atusmi A, Ojima E, Naruse Y, Murakoshi N, Seo Y, Aonuma KF Incomplete neointimal coverage and red thrombi with massive yellow plaques of stent edge after paclitaxel-eluting stent implantation: coronary angioscopic findings. ‘æ20‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi‘åãj7ŒŽC2011
  52. Nozato T, Sato A, Kamiishi T, Kawaguchi N, Nagai N, Kuroda S, Fujinami T, Nakashima E, Sugiyama T, Ookubo K, Fujino T, Takahashi Y, Kuwahara T, Hikita H, Takahashi A, Isobe MF Endovascular treatment for the lower limb peripheral artery disease reduces blood pressure. ‘æ20‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi‘åãj7ŒŽC2011
  53. Hirose S, Hata A, Nozato T, Sato A, Isobe MF Effectiveness of low concentration contrast for the diagnosis of in-stent restenosis using 64-slice computed tomography. ‘æ20‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi‘åãj7ŒŽC2011
  54. Hikita H, Sato A, Kamiishi T, Kawaguchi N, Nagai N, Kuroda S, Fujinami T, Nakashima E, Sugiyama T, Ookubo K, Fujino T, Takahashi Y, Kuwahara T, Nozato T, Takahashi A, Isobe MF Impact of fluid shear stress on predictors of restenosis after drug-eluting stent, compared with after bare metal stent. ‘æ20‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi‘åãj7ŒŽC2011
  55. Î’Ã’qŽqC£”ö—RLC˜’Ë—Ú”üC‹T“c—L—¢CÂÀ˜a—²: ¶Žº‹ìo—¦•ÛŽŒ^S•s‘Sƒ‚ƒfƒ‹ƒ‰ƒbƒg‚É‚¨‚¯‚éS‹ØƒXƒgƒŒƒCƒ“‚ƕljž—Í‚É‚æ‚éS‹@”\•]‰¿D ‘æ9‰ñæiSŒŒŠÇƒGƒR[Œ¤‹†‰ï (‘åã) 8ŒŽC2011
  56. Š|ŽD—YŠîC²“¡@–¾C“n•”_–¾CˆÀ’B‹œC¬“‡‰hŽ¡C¯’q–çCÂÀ˜a—²F Paclitaxel-eluting stent (PES) ‚ÆSirolimus-eluting stent (SES) ‚̃Xƒeƒ“ƒg—¼’[•”‚É‚¨‚¯‚錌ð‚¨‚æ‚щ©Fƒvƒ‰[ƒNŒ`¬‚Ì”äŠrD ‘æ58‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[ (_ŒË) 8ŒŽC2011
  57. Tada H, Igarashi M, Sekiguchi Y, Yamasaki H, Kuroki K, Naruse Y, Machino T, Nakano E, Kunugita F, Itoh Y, Tsuneoka H, Kaneshiro T, Yoshida k, Murakoshi N, Kuga K, Aonuma KF Hybrid Therapy with Extensive Antiarrhythmic Drugs and the Following Catheter Ablation as a Novel Approach for Long-lasting Persistent Atrial Fibrillation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  58. Kuwahara T, Takahashi A, Takahashi Y, Kusa S, Ohkubo K, Fujino T, Kuroda S, Nagai S, Kawaguchi N, Fujinami T, Nakashima E, Kamiishi T, Nozato , Hikita H, Sato A, Aonuma KF Noninducibility of Atrial Fibrillation and Ectopy by High-dose Isoproterenol Is Useful End Point of Persistent Atrial Fibrillation Ablation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  59. Seo Y, Ishizu T, Iida N, Sugano A, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Aonuma KF qSymposium Current Advances in EchocardiographyrCompensated Mechanism of Wall Thickening in Patients with Aortic Regurgitation and Preserved Ejection Fraction. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  60. Tada HF Effect of the Left Ventricular Lead Location on the Response to Cardiac Resynchronization Therapy in Patients with Advanced Heart Failure. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  61. Takagi M, Sekiguchi Y, Yokoyama Y, Aihara N, Aonuma K, Hiraoka MF The Incidence and the Significance for Risk Assessment of Early Repolarization (J wave) in Brugada Syndrome. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  62. Aonuma KF The Patient Selection of CRT in End-stage Heart Failure: Is CRT Really Effective in Patients with Very End-stage of Heart Failure? ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  63. Nogami Y, Ishizu T, Kawamura R, Seo Y, Ajisaka R, Aonuma KF Diastolic Suction in Heart Failure: Perspective from Left Ventricular Geometry, Untwist, and Flow Mechanics. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  64. Sato Y, Yoshida K, Ogata K, Inaba T, Tada H, Sekiguchi Y, Igarashi M, Yamasaki H, Machino T, Kuroki K, Itoh Y, Ishizu T, Seo Y, Kandori A, Aonuma KF An Increase in the Atrial Magnetic Strength Predicts Recurrence of Atrial Fibrillation after Radiofrequency Catheter Ablation: A Novel Predictor. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  65. Tajiri K, Imanaka-Yoshida K, Hiroe M, Aonuma K, Yasutomi YF Gene Delivery of Suppressor of Cytokine Signaling 1 Showed Therapeutic Effects to Autoimmune Myocarditis in Mice. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  66. Tada HF Effect of the Left Ventricular Lead Location on the Response to Cardiac Resynchronization Therapy in Patients with Advanced Heart Failure. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  67. Atsumi A, Ishizu T, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Seo Y, Aonuma KF Application of the Three-dimensional Speckle Tracking Imaging to Right Ventricular Regional Deformation Assessment in Normal Subjects. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  68. Tsuneoka H, Yokoyama Y, Yamagishi K, Takagi M, Itoh Y, Naruse Y, Xu D, Yamasaki H, Igarashi M, Murakoshi N, Sekiguchi Y, Tada H, Okada N, Ohira T, Iso H, Aonuma KF The Prevalence and Over 20-year Long-term Prognosis of the Brugada-type Electrocardiogram: From the Circulatory Risk in Community Study (CIRCS). ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  69. Kaneshiro T, Naruse Y, Nakano E, Kunugita F, Machino T, Itoh Y, Yamasaki H, Igarashi M, Tsuneoka H, Yshida K, Sekiguchi Y, Tada H, Aonuma KF Cumulative Effects of Irbesartan and Eplerenone to Maintain Sinus Rhythm after Pulmonary Vein Isolation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  70. Kuwahara T, Takahashi A, Takahashi Y, Kusa S, Ohkubo K, Fujino T, Kuroda S, Nagai N, Kawaguchi N, Fujinami T, Nakashima E, Kamiishi T, Nozato T, Hikita H, Sato A, Aonuma KF Can a New Device of Esophageal Temperature Monitoring, "ESOTEST", Prevent Esophageal Injury During Atrial Fibrillation Ablation? ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  71. Koshizuka R, Ishizu T, Kameda Y, Kimura T, Xu D, Murakoshi N, Sakai S, Seo Y, Aonuma KF Two-dimensional Speckle Tracking Imaging Detects Early Myocardial Contraction Abnormality in Dahl Salt-sensitive Rat. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  72. Abe D, Takeyasu N, Hayashi M, Baba M, Suzuki S, Sato A, Aonuma KF Clinical Value of Sirolimus-Eluting Stent Over Paclitaxel- and Zotarolimus-Eluting Stents: From Result of Ibaraki Cardiovascular Assessment Study (ICAS) Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  73. Abe D, Takeyasu N, Hayashi M, Baba M, Suzuki S, Sato A, Aonuma KF Clinical Value of Sirolimus-Eluting Stent Over Paclitaxel- and Zotarolimus-Eluting Stents in Patients with Diabetes Mellitus (DM): From Result of ICAS Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  74. Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Kuroki K, Machino T, Naruse Y, Itoh Y, Nakano E, Kunugita F, Kaneshiro T, Yoshida K, Kuga K, Aonuma KF The Low Voltage Area, not the Size, in the Left Atrium Predicts Recurrences following Catheter Ablation of Persistent Atrial Fibrillation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  75. Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Kuroki K, Machino T, Naruse Y, Itoh Y, Nakano E, Kunugita F, Kaneshiro T, Yoshida K, Kuga K, Aonuma KF What Kind of Atrial Fibrillation Patients Develop Atrial Remodeling with a Voltage Reduction? ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  76. Abe D, Takeyasu N, Hayashi M, Baba M, Suzuki S, Sato A, Aonuma KF Clinical Value of Sirolimus-, Paclitaxel- and Zotarolimus-Eluting Stents in Patients with Diabetes Mellitus (DM): From Result of Multi-center Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  77. Tsuneoka H, KoikeA, Nagayama O, Sakurada K, Sawada H, Aonuma K, Aizawa TF Correlation between the Presence of Atrial Fibrillation and Future Cardiac Events. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  78. Hikita H, Kuroda S, Sato A, Nagai N, Kawaguchi N, Nakashima E, Fujinami T, Kusa S, Kamiishi T, Ohkubo K, Fujino T, Takahashi Y, Nozato T, Kuwahara T, Takahashi A, Isobe MF Lipoprotein(a) is an Important Factor to Determine Coronary Artery Plaque Morphology in Patients with Acute Myocardial Infarction. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  79. Naruse Y, Tada H, Sato M, Yanagihara M, Hirata Y, Tsuneoka H, Sekiguchi Y, Machino T, Yamasaki H, Igarashi M, Itoh Y, Nakano E, Kaneshiro T, Kunugita F, Kuroki K, Yoshida K, Kuga K, Aonuma KF Concomitant Sleep-disordered Breathing Increases the Recurrences of Atrial Fibrillation Following Radiofrequency Catheter Ablation of Atrial Fibrillation: Efficacy of CPAP Therapy. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  80. Murakoshi N, Xu D, Sairenchi T, Irie F, Igarashi M, Tomizawa H, Iso H, Yamaguchi I, Aonuma KF Is High LDL-cholesterol Harmful for Japanese Health? - Analysis of Ibaraki Prefectural Health Study -. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  81. Sakai S, Nakagawa Y, Shimojoh N, Yoshida K, Kimura T, Maruyama H, Honma S, Shimano H, Aonuma KF Slowly Progressed Inflammatory Responses May Contribute to the Angiotensin II-Induced Cardiac Dysfunction. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  82. Hoshi T, Nishina H, Noguchi Y, Tachibana T, Harimura Y, Toda S, Fumikura Y, Hiranuma Y, Takeyasu N, Sato A, Aonuma KF Prognostic Impact of Optimal Medical Treatment in Patients who Underwent Coronary Revascularization; Analysis from ICAS Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  83. Hattori A, Naruse Y, Tada H, Sekiguchi Y, Yoshida K, Kunugita F, Kaneshiro T, Nakano E, Machino T, Yamasaki H, Igarashi M, Kuroki K, Itoh Y, Kuga K, Aonuma KF Left Atrial Volume is a Strong Echocardiographic Parameter to Predict Recurrence of Atrial Fibrillation after Radiofrequency Catheter Ablation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  84. Machino T, Shimojoh N, Xu D, Sakuramoto H, Koshitsuka R, Kameda Y, Kawano S, Sekiguchi Y, Tada H, Aonuma KF G-CSF Reduces Inducibility of Ventricular Tachycardia via Up-regulation of Phosphorylated Connexin-43 in Left Ventricular Hypertrophy Model Rats. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  85. Naruse Y, Tada H, Noguchi Y, Nishina H, Hoshi T, Toda S, Sato A, Sekiguchi Y, Yoshida K, Kuga K, Aonuma KF Early Repolarization is an Independent Predictor of Occurrences of Ventricular Fibrillation in the Very Early Phase of Acute Myocardial Infarctions. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  86. Sekiguchi Y, Tada H, Kuroki K, Machino T, Naruse Y, Yamasaki H, Yoshida K, Igarashi M, Kuga K, Aonuma KF A Novel Ablation Strategy for Ventricular Tachycardias in Non-Ischemic Heart Disease: A Combined Approach of Endocardial and/or Epicardial Accesses. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  87. Tsuneoka H, Koike A, Nagayama O, Sakurada K, Sawada H, Aonuma K, Aizawa TF Prognostic value of Cardiopulmonary Exercise Testing in Patients with Atrial Fibrillation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  88. Toyama M, Watanabe S, Kuroda Y, Sato A, Seo Y, Okubo S, I-HAT Study InvestigatorsF Diabetes and Obesity are Significant Risk of Morning Hypertension. From Large Scale Home BP Study: Ibaraki Hypertension Assessment Trial (I-HAT). ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  89. Iida N, Seo Y, Yanaka S, Nakajima H, Sakamaki F, Atsumi A, Yamamoto M, Kawamura R, Enomoto M, Ishizu T, Aonuma KF Relationship between Preoperative Myocardial Strain Distribution and Postoperative Response of Left Ventricular Function in Patients with Mitral Regurgitation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  90. Sato A, Takeyasu N, Kakefuda Y, Ojima E, Adachi T, Watabe H, Akiyama D, Murakoshi N, Seo Y, Aonuma KF Cardiovascular Outcomes in Patients Using Clopidogrel with Proton Pump Inhibitors Following Coronary Stenting -A Propensity Score Analysis- :From ICAS Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  91. Kakefuda Y, Sato A, Takeyasu N, Ojima E, Naruse Y, Hoshi T, Nishina H, Murakoshi N, Seo Y, Noguchi Y, Aonuma KF Comparison of Stent Thrombosis Treated with Sirolimus-, Paclitaxel- or Zotarolimus-Eluting Stents: From Result of Ibaraki Cardiovascular Assessment Study (ICAS) Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  92. Toyama M, Watanabe S, Kuroda Y, Sato A, Seo Y, Okubo S, I-HAT Study InvestigatorsF Effect of Antihypertensive Agents in Treating Morning Hypertension. From Large Scale Home Blood Pressure Study: Ibaraki Hypertension Assessment Trial (I-HAT). ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  93. Sato A, Watanabe S, Murakoshi N, Ishizu T, Seo Y, Sakai S, Aonuma KF Clinical Importance of Home Blood Pressure Assessment and Combination Antihypertensive Therapy for Achieving Target Blood Pressure Control:Ibaraki Hypertension Assessment Trial. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  94. Ojima E, Sato A, Adachi T, Watabe H, Kakefuda Y, Murakoshi N, Seo Y, Aonuma KF Impact of Microalbuminuria on the Characteristics of Coronary Plaques in Diabetic Patients. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  95. Watanabe S, Shindo Y, Seo Y, Takeyasu N, Ishizu T, Toyama M, Kuroda Y, Adachi T, Sato A, Aonuma KF Prognostic Impact of Strict LDL-cholesterol and CRP Reduction of the Patients with Coronary Artery Disease: The CODON Study. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  96. Nozato T, Sato A, Kamiishi T, Nagai N, Kuroda S, Kawaguchi N, Fujinami T, Nakashima E, Kusa S, Ohkubo K, Fujino T, Takahashi Y, Kuwahara T, Hikita H, Takahashi A, Imanaka-Yoshida K, Yoshida T, Aonuma K, Isobe I, Hiroe MF Impact of Serum Tenascin-C on the Aortic Healing Process during the Chronic Stage in Acute Type B Aortic Dissection. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  97. Kawamura R, Seo Y, Sugano A, Atsumi A, Yamamoto M, Harimura Y, Ishizu T, Aonuma KF Left Ventricular Mechanical Dyssynchrony and Surface Electrocardiographic Characteristics of Patients Underwent Cardiac Resynchronization Therapy. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  98. Naruse Y, Tada H, Sato M, Yanagihara M, Hirata Y, Tsuneoka H, Sekiguchi Y, Yoshida K, Igarashi M, Kuroki K, Machino T, Yamasaki H, Nakano E, Kaneshiro T, Kunugita F, Itoh Y, Kuga K, Aonuma KF Radiofrequency Catheter Ablation for Persistent Atrial Fibrillation Improves Sleep-disordered Breathing. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  99. Naruse Y, Sato A, Kasahara K, Makino K, Sano M, Takeuchi Y, Nagasaka S, Wakabayashi Y, Aonuma KF The Clinical Impact of Delayed Gadolinium Hyperenhancement in Takotsubo Cardiomyopathy: Serial Analysis of Cardiac Magnetic Resonance Images. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  100. Ueda K, Sato A, Takeyasu N, Nozato T, Aonuma KF The Short-term Effects of Weather on the Onset of Acute Coronary Syndrome: Elderly are More Sensitive to Ambient Temperature. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  101. Yamasaki H, Kuga K, Watanabe S, Sekiguchi Y, Tada H, Aonuma K, Kohro T, Yamazaki T, Nagai RF Prophylactic ICD Therapy is Useful in Patients With Left Ventricular Dysfunction after Old Myocardial Infarction in Japan: Subanalysis of JCAD-Study. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  102. Kimura T, Sato A, Kakefuda Y, Ojima E, Adachi T, Watabe H, Atsumi A, Ishizu T, Seo Y, Aonuma KF Impact of Carotid Intima-Media Thickness for Prediction of Coronary Artery Disease in Asymptomatic Patients With Diabetes Mellitus. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  103. Kawamura R, Ishizu T, Nogami Y, Sugano A, Yamamoto M, Atsumi A, Harimura Y, Seo Y, Aonuma KF The Risk Prediction of Left Ventricular Thrombus Formation by Quantifying Vortex Flow with Vector Flow Mapping. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  104. Higuchi H, Hattori A, Endo Y, Yamauchi R, Sato Y, Yukawa A, Suzuki A, Eki Y, Seo Y, Watanabe S, Aonuma KF Relationship between Severity of Illness and Carotid Intima-Media Thickness in Acute Coronary Syndrome from the Aspect of Vascular Inflammation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  105. Baba M, Seo Y, Ishizu T, Hayashi M, Abe D, Suzuki S, Takeyasu N, Aonuma K, Sato MF The Relation between Severities of Arterial Inflammation and Calcification in Carotid Arteries Evaluated by 18F-FDG PET/CT. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  106. Sekiguchi Y, Tada H, Kuroki K, Machino T, Naruse Y, Yamasaki H, Yoshida k, Igarashi M, Kuga K, Aonuma KF Left Atrial Posterior Wall triggering Atrial Fibrillation (AF) as a Distinct Subgroup of AF: Prevalence, Characteristics, and Results of Ablation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  107. Adachi T, Sato A, Kakefuda Y, Ojima E, Atsumi A, Watabe H, Aonuma KF Association of Diabetic Retinopathy and the Characteristics of Coronary Plaques on Computed Tomography Angiography. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  108. Higuchi H, Hattori A, Endo Y, Yamauchi R, Sato Y, Yukawa A, Suzuki A, Eki Y, Seo Y, Watanabe S, Aonuma KF FDG-uptake with PET/CT at Common Carotid Artery is a Promising Inflammatory Predictor of Severity of Acute Coronary Syndrome. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  109. Kawamura M, Nagaoka I, Dohchi K, Itoh H, Kimura H, Miyamoto A, Mizusawa Y, Makiyama T, Ohno T, Sumitomo N, Oyama K, Murakoshi N, Honda T, Horie MF Genetic Background of Catecholaminergic Polymorphic Ventricular Tachycardia in Japan. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  110. Igarashi M, Murakoshi N, Xu D, Itoh Y, Tada H, Sekiguchi Y, Ishizu T, Seo Y, Kuga K, Aonuma KF Amiodarone and Bepridil are Equally Effective for Treating Atrial Fibrillation in Hypertensive Rats through Different Mechanisms. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  111. Murakoshi N, Xu D, Igarashi M, Ito Y, Tada H, Seo Y, Aonuma KF The Inhibitory Effects of Pioglitazone on Atrial Fibrillation in Diabetes Mellitus Rats. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  112. Adachi T, Toyama M, Kuroda Y, Watanabe S, Takeyasu N, Sato A, Aonuma KF Clinical Characteristics and Outcomes of Octogenarians Undergoing Percutaneous Coronary Intervention from Ibaraki Cardiovascular Assessment Study (ICAS) Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  113. Kakefuda Y, Sato A, Takeyasu N, Ojima E, Naruse Y, Hoshi T, Nishina H, Murakoshi N, Seo Y, Noguchi Y, Aonuma KF Long-Term Prognosis of Stent Thrombosis Treated With Drug-Eluting and Bare-Metal Stents: From ICAS Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  114. Yamasaki H, Tada H, Sekiguchi Y, Igarashi M, Machino T, Naruse Y, Kuroki K, Itoh Y, Yoshida k, Ishizu T, Seo Y, Kuga K, Aonuma KF Intensification of Pharmacotherapy Shortly after Receiving Cardiac Resynchronization Therapy (CRT) is a New, Independent Predictor for the Long-term Prognosis of CRT. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  115. Kunugita F, Sekiguchi Y, Tada H, Yoshida k, Igarashi M, Yamasaki H, Machino T, Naruse Y, Kaneshiro T, Itoh Y, Nakano E, Aonuma KF The Characteristics of Ventricular Tachycardia in Patients with Cardiac Sarcoidosis. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  116. Kurosaki K, Nogami A, Kowase S, Shirai Y, Sasaki H, Fukuzawa T, Nishiyama H, Tanaka S, Funada S, Anzai T, Inoue A, Aoki H, Yumoto K, Tamaki T, Katoh K, Tada H, Aonuma K, Fukamizu S, Sakurada H, Morishima I, Kaitani KF Mapping and Catheter Ablation of Ventricular Tachycardia in Hypertrophic Cardiomyopathy with Apical Aneurysm. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  117. Maruyama H, Sato M, Sakai S, Kawano S, Shimojo N, Aonuma KF Platelet Activation during Sleep in Obstructive Sleep Apnea. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  118. Toyama M, Watanabe S, Kuroda Y, Sato A, Seo Y, Okubo S, I-HAT Study InvestigatorsF Morning Hypertension is Frequent in Chronic Kidney Disease Patients. From Large Scale Home BP Study: Ibaraki Hypertension Assessment Trial (I-HAT). ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  119. Abe D, Takeyasu N, Hayashi M, Baba M, Suzuki S, Tada H, Aonuma KF The Right Ventricular Septal Pacing Provides Better Diastolic Performances During the Long-term Follow-up in Patients Receiving Pacemaker Implantation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  120. Igarashi M, Tada H, Yamasaki H, Sekiguchi Y, Yoshida k, Kuroki K, Machino T, Naruse Y, Itoh Y, Nakano E, Kunugita F, Kaneshiro T, Kuga K, Aonuma KF Post-implant QRS Narrowing: A Simple and Strong Predictor of the Long-term Outcome after Receiving Cardiac Resynchronization Therapy. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  121. Akiyama D, Sato A, , Takeyasu N, Sugano A, Misaki M, Seo Y, Watanabe S, Aonuma KF Impact of Body Mass Index on Long-term Clinical Outcomes in Patients with Coronary Artery Disease; Result from ICAS Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  122. Yamasaki H, Tada H, Sekiguchi Y, Igarashi M, Kuroki K, Machino T, Naruse Y, Murakoshi N, Ishizu T, Seo Y, Kuga K, Aonuma KF Preexcitation-induced Ventricular Dyssynchrony as a New Entity of Cardiomyopathy: Its Prevalence and Characteristics. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  123. Enomoto M, Ishizu T, Seo Y, Sakai S, Suzuki H, Kawakami Y, Shimano H, Aonuma KF Left ventricular Subendocardial Contractile Dysfunction with Normotensive Diabetic Patients Correlated with Oxidative Stress. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  124. Enomoto M, Ishizu T, Seo Y, Sakai S, Suzuki H, Kawakami Y, Shimano H, Aonuma KF The Relationship with the Fatty Liver and Longitudinal Systolic Dysfunction in Normotensive Diabetic Patients with Preserved Ejection Fraction. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  125. Watabe H, Sato A, Takeyasu N, Nishi I, Igawa M, Enomoto T, Murakoshi N, Seo Y, Aonuma KF Impact of Chronic Kidney Disease on cardiovascular event with Acute Coronary Syndrome:Results From Ibaraki Coronary Artery Disease Study (ICAS) Registry. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  126. Igarashi M, Tada H, Kurosaki K, Akiyama D, Sekiguchi Y, Yamasaki H, Arimoto T, Kuroki K, Machino T, Nogami A, Aonuma KF Shorter Coupling Intervals of the Initial Several Beats of a Tachycardia Cause a Polymorphic QRS Morphology in Idiopathic Ventricular Tachycardia. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  127. Hayashi M, Baba M, Seo Y, Abe D, Suzuki S, Ishizu T, Takeyasu N, Aonuma K, Sato MF Generation and Sex Differences in Localization and Prevalence of Vulnerable Atherosclerotic Plaques among Large Arteries; Imaging Study with 18F-FDG PET. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  128. Yamasaki H, Tada H, Sekiguchi Y, Igarashi M, Machino T, Naruse Y, Kuroki K, Itoh Y, Yoshida k, Murakoshi N, Igawa M, Kuga K, Aonuma KF Atrio-Ventricular Conduction Ratios during Persistent Atrial Flutter are the Predictor of Emerging Sinus Node Dysfunction after Restoring Sinus Rhythm. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  129. Igarashi M, Sairenchi T, Irie F, Murakoshi N, Xu D, Tada H, Sekiguchi Y, Tomizawa T, Yamaguchi I, Iso H, Aonuma KF Atrial Fibrillation is an Independent Risk Factor for Ischemic Heart Disease Mortality as Well as Risk of Cerebral Infarction Mortality. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  130. Hikita H, Sato A, Kuroda S, Nagai N, Kawaguchi N, Fujinami T, Nakashima E, Kusa S, Kamiishi T, Ohkubo K, Tada H, Takahashi Y, Nozato T, Kuwahara T, Takahashi A, Isobe MF Optimal Cut-off Value of Coronary Flow Velocity to Predict Functional Recovery in TIMI-3 Reperfused Acute Myocardial Infarction. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  131. Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Kuroki K, Machino T, Naruse Y, Itoh Y, Nakano E, Kunugita F, Kaneshiro T, Yoshida K, Murakoshi N, Kuga K, Aonuma KF Tachyarrhythmia Characteristics and Results of Catheter Ablation in Patients Following a Surgical Atriotomy: Importance of Cavo-Tricuspid Isthmus Ablation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  132. Kaneshiro T, Yoshida k, Nakano E, Naruse Y, Kunugita F, Machino T, Itoh Y, Yamasaki H, Igarashi M, Tsuneoka H, Sekiguchi Y, Tada H, Aonuma KF Relationship between the Characteristics of Local Electrograms and Difficulty in Creating Complete Cavotricuspid Isthmus Block. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  133. Yamamoto M, Seo Y, Sugano A, Kawamura R, Nakajima H, Sakamaki F, Iida N, Enomoto M, Ishizu T, Maeda H, Aonuma KF Complex Remodeling of Left Atrial Appendage and Thrombus Formation in Patients with Atrial Fibrillation. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï (‰¡•l) 8ŒŽC2011
  134. “cK˜aŽqC¡’†-‹g“c‹±ŽqCœA]“¹ºC’‡@“NŽ¡CÂÀ˜a—²C•Û•xNGF SOCS1‚ð—p‚¢‚½ˆâ“`Žq–Ɖu—Ö@‚É‚æ‚鎩ŒÈ–Ɖu«S‹Ø‰Š‚̐§ŒäŒø‰Ê‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ 2 ‰ñ Molecular Cardiovascular Conference II (–kŠC“¹) 9ŒŽC2011
  135. –{“cŸ«–çC‹àé‹MŽmC‹g“cŒ’‘¾˜YCŠÖŒûK•vCšê“c@_CÂÀ˜a—²C¬–ì’¼OC‰œ“c@ƒ: ƒ}ƒ‰ƒ\ƒ“’†SŽº×“®‚ªŽä‹N‚³‚ꂽŽá”NŽÒS”x‘h¶—á@\S–[•p”A•p–¬ˆË‘¶«J”g‘‹­‚ÆQT‰„’·‚ÌŠÖ—^\D ‘æ221‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 9ŒŽC2011
  136. Igawa M, Kuroki K, Enomoto T, Nishi I, Ojima E, Katoh J, Koseki S, Aonuma K: Ventricular parasystole in a patient with complete atrioventricular block. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  137. Chidimi K, Kaneshiro T, Kawakami Y, Kuroki K, Ishidu K, Ishidu T, Sekiguchi Y, Tada H, Aonuma K: The effect of temporal right Atrial appendage pacing against cardioversion-refractory ventricular. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  138. Kuroki K, Tada H, Igawa M, Sekiguchi Y, Aonuma K: Delayed perforation of a right ventricular ICD lead following subacute pleuritis. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  139. Naruse Y, Tada H, Harimura H, Hayashi M, Takeyasu T, Sato A, Sekiguchi Y, Yoshida K, Aonuma K: Concomitant early repolarization increases occurrences of ventricular fibrillation in patients with acute myocardial infarctions. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  140. Endo E, Saito H, Sato K, Satake H, Fukui S, Takahashi T, Nakamura A, Nozaki E, Tamaki K, Yagi T, Tada H, Aonuma K: A case of sustained ventricular tachycardia originated from left ventricular posterior papillary muscle, which was misinterpreted as posterior fascicular ventricular tachycardia in ECG morphology. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  141. Tachibana M, Sekiguchi Y, Yoshida K, Tada T, Aonuma K: Electrocardiographic characteristics of the epicardial ventricular tachycardia in dilated cardiomyopathy. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  142. Tachibana M, Sekiguchi Y, Toda S, Yoshida K, Tada H, Seo Y, Aonuma K: Anticoagulation strategies for atrial fibrillation patients with left atrial appendage thrombus. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  143. Ito Y, Naruse N, Yoshida K, Kaneshiro T, Murakoshi N, Igarashi M, Nakano E, Yamsaki H, Kunugita F, Sekiguchi Y, Tada H, Aonuma K: Eplerenone in patients with persistent atrial fibrillation after catheter ablation. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  144. Kaneshiro T, Sekiguchi Y, Yoshida K, Tada H, Aonuma K: P wave morphology in inferior leads may predict the higher recurrence after the catheter ablation of atrial tachycardia originating from para-hisian area. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  145. Nakano E, Harada T, Soejima K, Sasaki T, Mizuno K, Miyake F, Aonuma K: Reduction of left atrial volume as a predictor for the recurrence of atrial fibrillation after pulmonary vein isolation. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  146. Yamasaki H, Tada H, Sekiguchi Y, Igarashi M, Kuroki K, Machino T, Naruse Y, Ito Y, Nakano E, Kaneshiro T, Yoshida K, Aonuma K: Underlying inflammation in current smokers or obese subjects may be responsible for concomitant, drug-resistant atrial fibrillation. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  147. Kunugita F, Naruse Y, Nakano E, Kuroki K, Kaneshiro T, Yamasaki H, Igarashi M, Yoshida K, Sekiguchi Y, Tada H, Aonuma K: Clinical and electrophysiological characteristics of ventricular tachycardia of epicardialorigin associated with cardiac sarcoidosis. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  148. Adachi T, Sato A, Kawano S, Baba B, Yoshida K, Sekiguchi Y, Murakoshi N, Ishizu T, Seo Y, Tada H, Aonuma K: Novel use of an ultra-short-acting intravenous beta blocker, landiolol for supraventricular tachyarrhythmias in patients with severe congestive heart failure. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  149. Adachi T, Yoshida K, Sekiguchi Y, Tada H, Aonuma K: Catheter ablation for atrial tachycardia which re-entrant circuit involves inter-atrial septum. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  150. Seo Y, Yoshida K, Sekiguchi Y, Ishizu T, Tada H, Aonuma K: Changes of left atrial function after pulmonary vein isolation in chronic atrial fibrillation. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  151. Sekiguchi Y: Endocardial and epicardial ablation of ventricular tachycardia associated with organic heart disease. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  152. Nakano E, Harada T, Soejima K, Sasaki T, Mizuno K, Miyake F, Aonuma K: Catheter ablation of reentrant left ventricular tachycardia associated with fabry disease: a case report. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  153. Tsuneoka H, Yamagishi K, Xu D, Murakoshi N, Sekiguchi Y, Tada H, Okada T, Kitamura A, Ohira T, Aonuma K, Iso: The prevalence and over 20 years long term prognosis of the brugada-type electrocardiogram: from the circulatory risk in communities study (CIRCS) The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  154. Yui Y, Machino T, Tada T, Kuroki K, Nakano E, Yamasaki H, Igarashi M, Yoshida K, Ishizu T, Sekiguchi Y, Aonuma A: Restoration of impaired cardiac function in patients with dilated cardiomyopathy after the radiofrequency catheter ablation of long-standing persistent atrial fibrillation with adequate ventricular rate control. The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  155. Yui Y, Machino T, Tada T, Kuroki K, Kaneshiro T, Nakano E, Yamasaki H, Igarashi M, Yoshida K, Sekiguchi Y, Aonuma A: Transient advanced atrioventricular block and left bundle branch block during the catheter ablation of idiopathic ventricular arrhythmias originating from the ventricular outflow tracts The 4rd Asia-Pacific Heart Rhythm Society Scientific SessionE‘æ26‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïE‘æ28‰ñ“ú–{S“dŠw‰ïŠwpW‰ï (•Ÿ‰ª) 9ŒŽC2011
  156. £”ö—RLCŽR–{¹—ǁCÎ’Ã’qŽqCÂÀ˜a—²F qƒrƒWƒ…ƒAƒ‹ƒ[ƒNƒVƒ‡ƒbƒv 3ŽŸŒ³SƒGƒR[}–@‚̐i•àr¶SŽ¨“àŒŒðŒ`¬‚ÉŠÖ˜A‚µ‚½¶SŽ¨\‘¢‚ÌŒŸ“¢D ‘æ59‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi_ŒËj9ŒŽC2011
  157. Î’Ã’qŽqC£”ö—RLC˜’Ë—Ú”üC–Ø‘º‘׎OC‘º‰zLsCŽðˆä@rCÂÀ˜a—²F DahlH‰–•‰‰×ƒ‰ƒbƒg‚É‚¨‚¯‚鍶Žº2D ƒXƒgƒŒƒCƒ“‚ƕljž—Í‚¨‚æ‚Ñ•a—Šw“I•Ï‰»‚Æ‚ÌŠÖ˜AD ‘æ59‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi_ŒËj9ŒŽC2011
  158. £”ö—RLCÎ’Ã’qŽqCŽR–{¹—ǁCÂÀ˜a—²F 3DSƒGƒR[}–@‚É‚æ‚鍶SŽ¨Œ`‘Ô‰ðÍ‚ƍ¶SŽ¨“àŒŒð‚ÌŠÖ˜A‚ɂ‚¢‚āD ‘æ59‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi_ŒËj9ŒŽC2011
  159. £”ö—RLCÂÀ˜a—²F qƒrƒWƒ…ƒAƒ‹ƒ[ƒNƒVƒ‡ƒbƒv CRTƒŒƒXƒ|ƒ“ƒ_[Eƒmƒ“ƒŒƒXƒ|ƒ“ƒ_[‚Ì—\‘ª‚Ƒ΍ôrCRT‚ÉŠÖ‚·‚éƒCƒ[ƒWƒ“ƒO–@‚ɂ‚¢‚āFoverview. ‘æ59‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi_ŒËj9ŒŽC2011
  160. £”ö—RLF q‹³ˆçu‰‰rV‚µ‚¢SƒGƒR[ŒŸ¸‚ÌŽg‚¢•ûFƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@D ‘æ59‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi_ŒËj9ŒŽC2011
  161. ˜’Ë—Ú”üCÎ’Ã’qŽqC‹T“c—L—¢Cì‘º@—´C–Ø‘º‘׎OC‹–@“ŒŸªC‘º‰zLsCŽðˆä@rC–{ŠÔ@ŠoC£”ö—RLCÂÀ˜a—²F 2D ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚éŠg’£•s‘Sƒ‰ƒbƒgƒ‚ƒfƒ‹‚ÌŒpŽž“IŠÏŽ@D ‘æ59‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi_ŒËj9ŒŽC2011
  162. ’†–ìŒb”üCÎ’Ã’qŽqCšê“c@_CŒÜ\—’@“sC‹àé‹MŽmCž­“c–[‹ICˆä“¡—tŽqCˆ­”üˆÀ‹IŽqC£”ö—RLCÂÀ˜a—²F ”xÃ–¬Šu—£pŒã‚É‚¨‚¯‚éS–[×“®Ä”­‚Ì—\‘ªˆöŽq‚ÌŒŸ“¢D ‘æ59‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï (_ŒË) 9ŒŽC2011
  163. ì‘º@—´C£”ö—RLC’¬–ì’qŽqCˆ­”üˆÀ‹IŽqC’†“‡‰pŽ÷CÎ’Ã’qŽqCÂÀ˜a—²F Comparison Between Three Dimensional Echocardiographic Quantification Technologies and Validation with Cardiac MRI. ‘æ59‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi_ŒËj9ŒŽC2011
  164. ‚–ØŒOŽq, ‰ºžŠMˆÐ, ˆÀ“c@v, ”‹’JŒ\ˆêC¼–ìO•¶C‰Í–ì@—¹C…’J‘¾˜YF ’}”g‘åŠw•‘®•a‰@‚̍ЊQŽžER‘̐§D ‘æ35‰ñˆïéŒ§‹~‹}ˆãŠw‰ïi‚‚­‚΁j9ŒŽC2011
  165. àV“cKŽqCˆÀ“c@vC”’ì—mŽqC‰¡“c‚·‚¢ŽqC–ì’|“TŽqC…’J‘¾˜YC‰Í–ì@—¹C‚‹´L“ñC‹à–{^–çCŒÜ\—’“O–çF “Œ“ú–{‘åkÐˆŸ‹}«Šú‚̗׌§Žx‰‡•ñD ‘æ35‰ñˆïéŒ§‹~‹}ˆãŠw‰ïi‚‚­‚΁j9ŒŽC2011
  166. ‰Í–ì@—¹CˆÀ“c@vC‚‹´L“ñC‹à–{^–çC…’J‘¾˜YCŒÜ\—’“O–çF ’}”g‘åŠw•‘®•a‰@‚É‚æ‚ékÐŽž‚Ì–kˆïéŽs‚ɑ΂·‚éˆã—ÃŽx‰‡D ‘æ35‰ñˆïéŒ§‹~‹}ˆãŠw‰ïi‚‚­‚΁j9ŒŽC2011
  167. ‰Í–ì@—¹F qƒVƒ“ƒ|ƒWƒEƒ€r‹}«Šú‚ÌŒŒs“®‘Ԃɑ΂·‚éV‚½‚ÈŽ¡—Ð헪D ‘æ35‰ñˆïéŒ§‹~‹}ˆãŠw‰ïi‚‚­‚΁j9ŒŽC2011
  168. ÂÀ˜a—²F S•s‘S‚̐S“d}‚ð“ǂށD ‘æ15‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽ­Ž™“‡j10ŒŽC2011
  169. Seo YCIshizu TCSakai SCKawano SCAonuma KF Initial experience of tolvaptan in patients with refractory heart failure. ‘æ15‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽ­Ž™“‡j10ŒŽC2011
  170. £”ö—RLF S•s‘S‚É‚¨‚¯‚éCRT‚Ì–ðŠ„D ‘æ15‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiŽ­Ž™“‡j10ŒŽC2011
  171. £”ö—RLCÂÀ˜a—²F ARB‚©‚烍ƒTƒ‹ƒ^ƒ“^ƒqƒhƒƒNƒƒƒ`ƒAƒWƒh”z‡Ü‚ւ̐؂è‘Ö‚¦‚É‚æ‚éSŒŒŠÇ/t‹@”\‚Ì•ÛŒìŒø‰ÊD ‘æ34‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ïi‰F“s‹{j10ŒŽC2011
  172. ˆÀ“c@vC…’J‘¾˜YC‰Í–ì@—¹C‰ºžŠMˆÐC¼–ìO•¶C”‹’JŒ\ˆêC’Óc‹±Ž¡C‚“c’q–çC‚‹´L“ñF ˆïéŒ§‚É‚¨‚¯‚é“–‰@‚̍ЊQ‹}«ŠúDMATŠˆ“®‚ÆŒŸØD ‘æ39‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (“Œ‹ž) 10ŒŽC2011
  173. ˆÀ“c@vC…’J‘¾˜YC‰Í–ì@—¹C‰ºžŠMˆÐC¼–ìO•¶C”‹’JŒ\ˆêC’Óc‹±Ž¡C‚“c’q–çC‚‹´L“ñF “Œ“ú–{‘åkÐ‚ÅŽÀ‘H‚µ‚½V‹Ù‹}ÐŠQˆã—Ñ̐§E”íÐ’nˆïéŒ§‚É‚¨‚¯‚錋‰Ê‚ÆŒŸØD ‘æ39‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (“Œ‹ž) 10ŒŽC2011
  174. ‰Í–ì@—¹C›Á@¯‰ÍCˆÀ“c@vC‰ºžŠMˆÐC¼–ìO•¶C”‹’JŒ\ˆêC…’J‘¾˜YF ”DP––Šú‚É”­Ç‚µ‚½ŒƒÇŒ^‚`Œ^—nŒŒ«˜A½‹…‹ÛŠ´õÇ‚Ì‹~–½—áD ‘æ39‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (“Œ‹ž) 10ŒŽC2011
  175. ¯@’q–çC•½’J‘åŒáC²“¡@–¾CÂÀ˜a—²F ‚n‚b‚s‚¨‚æ‚ÑŒŒŠÇ“àŽ‹‹¾‚É‚ÄŠÏŽ@‚µ‚¦‚½“Á”­«Š¥“®–¬‰ð—£‚̈ê—áD ‘æ39‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 10ŒŽC2011
  176. ˜–쌋ŠóCÂÀ˜a—²C£”ö—RLCÎ’Ã’qŽqC–öŒ´–œ—¢ŽqC²“¡@½CHector R. Villarraga, Marek Orban, Virend K. Somers, Fransisco Lopez-Jimenez: OSA‚É‚¨‚¯‚é–³ŒÄ‹z’†‚Ì‹¹o“àˆ³’ቺ‚ªS‹@”\‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚āD ‘æ36‰ñ“ú–{‡–°Šw‰ï (‹ž“s) 10ŒŽC2011
  177. ¬£‘ãŽm‹vCŠÖŒûK•vC’¬–ì@‹BCŽRè@_CŒÜ\—’“sC•–ØŒ’ŽuCˆä“¡—tŽqC’†–ìŒb”üC‹àé‹MŽuC‹g“cŒ’‘¾˜YCšê“c@_CÂÀ˜a—²F SƒTƒ‹ƒRƒCƒh[ƒVƒXŠ³ŽÒ‚ɍ‡•¹‚µ‚½SŽº•p”‚ɑ΂·‚éWŠw“IŽ¡—ÂƂ»‚ÌŽ¡—ЬÑDqYoung Investigator Award Competitionr ‘æ31‰ñ“ú–{ƒTƒ‹ƒRƒCƒh[ƒVƒX“÷‰èŽî«Ž¾Š³Šw‰ï‘‰ïi–¼ŒÃ‰®j10ŒŽC2011
  178. •ˆÀ–@”VCˆÀ”{‘å•ãC”üè¹ŽqC¬£‘ãŽm‹vC—Ñ ^—RC“¿‰iç•äCH“‡M“ñF ‘s”NŠú‹•ŒŒ«S‹ØÇ‚̈ê—áD X-pert Forumi‚‚­‚΁j10 ŒŽ, 2011
  179. ¬£‘ãŽm‹vC—Ñ ^—RC”üè¹ŽqCˆÀ”{‘å•ãC•ˆÀ–@”VF S‘ŸŽîᇂÌ1 —áD ‘æ8‰ñS‘Ÿ‰æ‘œf’fŒ¤‹†‰ïi“y‰Yj11 ŒŽ, 2011
  180. ˆÀ”{‘å•ãA¬£‘ãŽm‹vC—Ñ ^—RC”üè¹ŽqC•ˆÀ–@”VF LMT ‚ÉŒŒð‚ð”F‚ß‚½1 —áD ‘æ7‰ñˆïéŒ§“슥Ž¾Š³Œ¤‹†‰ï (‚‚­‚Î) 11ŒŽC2011
  181. ¯@’q–çC•½’J‘åŒáC›Á@¯‰ÍCˆÀ’B@‹œC–ûˆäŒcWC’†–ìŒb”üC•–ØŒ’ŽuC‹àé‹MŽmC²“¡@–¾CÂÀ˜a—²F ‚n‚b‚s‚¨‚æ‚ÑŒŒŠÇ“àŽ‹‹¾‚É‚ÄŠÏŽ@‚µ‚¦‚½“Á”­«Š¥“®–¬‰ð—£‚̈ê—áD ‘æ7‰ñˆïéŒ§“슥Ž¾Š³Œ¤‹†‰ï (‚‚­‚Î) 11ŒŽC2011
  182. •½’J‘åŒáC¯@’q–çC›Á@¯‰ÍCˆÀ’B@‹œC–ûˆäŒcWC’†–ìŒb”üC•–ØŒ’ŽuC‹àé‹MŽmC²“¡@–¾CÂÀ˜a—²F ˆêŽž“IS–[ƒy[ƒVƒ“ƒO‚É‚æ‚è’˜–¼‚ɏzŠÂ“®‘Ô‚ð‰ü‘P‚µ‚¦‚½‹}«‰º•Ç‰EŽºS‹Ø[Ç‚̈ê—áD ‘æ19‰ñˆïézŠÂŠíŒ¤‹†‰ï (‚‚­‚Î) 11ŒŽC2011
  183. Žðˆär‰îC“n•ÓdsCŠOŽR¹OC•“c—T‹vC¬—Ñ—TKC“¿“cˆÀtF Œ€Ç1Œ^“œ”A•a‚ɁAœŠi‹Ø—Z‰ð‚Æ’˜–¼‚ȍ¶S‹@”\•s‘S‚ð’悵‚½ˆê—áD ‘æ19‰ñˆïézŠÂŠíŒ¤‹†‰ï (‚‚­‚Î) 11ŒŽC2011
  184. ‘¾“ìO˜aC–x@F•¶CÎˆä‰f”üC‹àŽq@„C‘å’ː·’jCŽR–{­]C•½“cŽO‘ãŽqCŽ›–åŒb”üŽqC‹v‰êŒ\—SF Šw¶Œ’f‚É‚¨‚¯‚邤‚ƒXƒNƒŠ-ƒjƒ“ƒO“±“ü‚Ì—\”õ“IŒŸ“¢D ‘æ49‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—ƒZƒ“ƒ^-ŠÇ—Œ¤‹†W‰ïi‰ºŠÖj11ŒŽC2011
  185. “cK˜aŽq, ²“¡@–¾, ÂÀ˜a—²F Šg’£Œ^S‹ØÇ‚ɑ΂·‚é–Ɖu§Œäí—ªFSOCS1ˆâ“`Žq‚ð—p‚¢‚½Ž÷ó×–E—}§Œø‰Ê‚ð‰î‚·‚éˆâ“`Žq–Ɖu—Ö@‚ÌŽŽ‚݁D ‘æ‚U‰ñ‚ŒŒˆ³‚ÆŠ¥“®–¬Ž¾Š³Œ¤‹†‰ïi“Œ‹žj 11ŒŽC2011
  186. ¬£‘ãŽm‹vC—с@^—RC”üè¹ŽqCˆÀ”{‘å•ãC•ˆÀ–@”VF S‘ŸŽîᇂ̂P—áD ‘æ‚W‰ñS‘Ÿ‰æ‘œf’fŒ¤‹†‰ïi“y‰Yj 11ŒŽC2011
  187. ŠÛ“cr‰îC‹àé‹MŽm, Î’Ã’qŽq, ¬£‘ãŽm‹v, ’†–ìŒb”üCŠ|ŽD—YŠîCˆ­”üˆÀ‹IŽqC‰Á“¡@õCˆÀ’B@‹œC£”ö—RLCÂÀ˜a—²F ”x–EoŒŒ‚𗈂µ‚½dÇ‘m–X•Ù‹·ó‡•¹Ç”D•w‚ɑ΂µAŒo”ï“I‘m–X•Ù—ôŠJp‚É‚æ‚è•êŽ™‹¤‚ɗǍD‚ÈŒo‰ß‚𓾂½1—áD ‘æ222‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (“Œ‹ž) 12ŒŽC2011
  188. ž­“c–[‹ICšê“c@_CŠÖŒûK•vC•–ØŒ’ŽuCŽRè@_C–ûˆäŒcWC’†–ìŒb”üC‹àé‹MŽmC’¬–ì@‹BCˆä“¡—tŽqCŒÜ\—’@“sC‹g“cŒ’‘¾˜YCÂÀ˜a—²F SŽº×“®‚ðŽä‹N‚·‚é”x“®–¬‹NŒ¹SŽº«ŠúŠOŽûk‚ɑ΂·‚éÄŽÜp‚ª’˜Œø‚µ‚½“Á”­«SŽº×“®‚Ì‚P—áD ‘æ24‰ñS‘Ÿ«‹}Ž€Œ¤‹†‰ï (“Œ‹ž) 12ŒŽC2011
  189. “yŠò _‰îC–{ŠÔ^lC‹v‰êŒ\—SCÂÀ˜a—²CK“cK’¼F ‰Á—î‚É”º‚¤ƒtƒŒƒJƒCƒjƒh‚Ì‘ãŽÓƒNƒŠƒAƒ‰ƒ“ƒX’ቺ‚É‚¨‚æ‚Ú‚·CYP2D6‚̉e‹¿D ‘æ32‰ñ“ú–{—Տ°–ò—Šw‰ï”N‰ï (•l¼) 12ŒŽC2011

@@@¡ ‚»‚Ì‘¼

  1. £”ö—RLF CRT‚Ì“K‰ž”»’èD ‘æ13‰ñEcho Winter Seminar at Karuizawa (Œyˆä‘ò) 1ŒŽC2011
  2. ‰Í–ì@—¹,…’J‘¾˜YF W’†Ž¡—ÃŽº‚É‚¨‚¯‚éŠÅŒì‚Ì‹Æ–±Šg‘å‚Æ‚»‚Ì—vŒ‚ɂ‚¢‚āD ‘æ26‰ñ‘S‘‘Œö—§‘åŠw•a‰@W’†Ž¡—Õ”‹¦‹c‰ïi’}”g‘åŠwj 1ŒŽC2011
  3. £”ö—RLF Speckle tracking‚É‚æ‚éS‹@”\”»’èD ‘æ13‰ñEcho Winter Seminar at Karuizawa (Œyˆä‘ò) 1ŒŽC2011
  4. ²“¡@–¾F ––½“®–¬Ž¾Š³‚̐f’f‚ÆŽ¡—Ã-zŠÂŠí“à‰È‚Ì—§ê‚©‚çD ‚‚­‚ÎPADƒZƒ~ƒi[i‚‚­‚Î) 1ŒŽC2011
  5. ²“¡@–¾F Š¥“®–¬•sˆÀ’èƒvƒ‰[ƒN‚̉摜f’fD ‘æ1‰ñ“¹ŸóŽRzŠÂŠíƒZƒ~ƒi[i“Œ‹ž) 1ŒŽC2011
  6. ‘º‰zLsF ŒoŒûR‹ÃŒÅ–òƒvƒ‰ƒUƒLƒT‚Ö‚ÌŠú‘ҁD Tsukuba AF Summiti‚‚­‚΁j2ŒŽC2011
  7. ²“¡@–¾F Š¥“®–¬^––½“®–¬Ž¾Š³‚̐f’f‚ÆŽ¡—ÁD ‘æ39‰ñŒ§“쐼’n‹æ“§ÍŒ¤‹†‰ïi‚‚­‚΁j 3ŒŽC2011
  8. ‰Í–ì@—¹F S“d}‹êŽèŽ•ž‚Ö‚Ì“¹|‰‹‰•Ò@‚»‚Ì‚PD 2011”N“xƒiƒCƒ`ƒ“ƒQ[ƒ‹ŒŽŠÔ ƒi[ƒX2011ˆïéE“Œ“ú–{‘åkÐ”íÐ’nŽx‰‡Šé‰æi’}”g‘åŠwj 4ŒŽC2011
  9. ‘º‰zLsF ŒoŒûR‹ÃŒÅ–òƒvƒ‰ƒUƒLƒT‚Ö‚ÌŠú‘ҁD Ibaraki Stroke Summiti‚‚­‚΁j5ŒŽC2011
  10. ¯@’q–çF Ž¡—Âɓïa‚µ‚½•ªŠò•a•Ï‚̈ê—áD ‘æ4‰ñ’†“ú–{Case Review Coursei‘å‹{j5ŒŽC2011
  11. ¬£‘ãŽm‹vC—с@^—RC”üè¹ŽqCˆÀ”{‘å•ãC•ˆÀ–@”VF ‹}«Œã•ÇS‹Ø[Ç‚Ì‚Q—áD ˆïéŒ§—§’†‰›•a‰@•af˜AŒgiŠ}ŠÔj 6ŒŽC2011
  12. ‘º‰zLsF ‰uŠw“I”wŒi‚©‚çl‚¦‚éSŒŒŠÇ•aD ˆïéŒ§•ÛŒ¯ˆã‹¦‰ïŠwpu‰‰‰ïi‚‚­‚΁j6ŒŽC2011
  13. £”ö—RLF S•s‘S‚ƐSƒGƒR[D IBARAKI ECHO HANDS ON TRINNING SEMINARi‚‚­‚΁j7ŒŽC2011
  14. £”ö—RLF •s®–¬‚ƐSƒGƒR[D –¼ŒÃ‰®SƒGƒR[Œ¤‹†‰ïi–¼ŒÃ‰®j7ŒŽC2011
  15. Machino T, Tada H, Igarashi M, Sekiguchi Y, Yamasaki H, Kuroki K, Naruse Y, Nakano E, Kunugita F, Ito Y, Tsuneoka H, Kaneshiro T, Yoshida K, Murakoshi N, Kuga K, Aonuma KF Hybrid Therapy with Extensive Antiarrhythmic Drugs and the Following Catheter Ablation as a Novel Approach for Long-lasting Persistent Atrial Fibrillation. ƒnƒCƒuƒŠƒbƒhŒ¤‹†‰ï2011i“Œ‹žj7ŒŽC2011
  16. £”ö—RLF ‹ÇŠS‹@”\‚Æ‘S‘Ì‹@”\D •ŸŽRŽsˆãŽt‰ïzŠÂŠíŒ¤‹†‰ïiL“‡j9ŒŽC2011
  17. Žðˆä@rF ƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–òD ‘æ‚R‰ñˆïéŒ§“ì—Տ°”x‚ŒŒˆ³ÇŒ¤‹†‰ïi‚‚­‚΁j9ŒŽC2011
  18. £”ö—RLF CRT‚ŐS•s‘S‚É’§‚ށ@Dyssynchrony•]‰¿–@‚ƐM—Š«D “ú–{’´‰¹”gˆãŠw‰ï’´‰¹”gf’fuK‰ïi‰ªŽRj10ŒŽC2011
  19. £”ö—RLF CRT‚ɂ‚¢‚āD “ú–{SƒGƒR[}Šw‰ï“Œ–kŽx‰‡uK‰ïiå‘äj10ŒŽC2011
  20. ²“¡@–¾F ‹}«Š¥ÇŒóŒQ‚̉uŠw‚Æ•a‘ԁD ‘æ7‰ñ’nˆæˆã—Âðl‚¦‚é‰ïTSUKUBAi‚‚­‚΁j10ŒŽC2011
  21. Žðˆä@rF ”x“®–¬«”x‚ŒŒˆ³Ç‚ÌŽ¡—Âɂ¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“hR–ò‚ÌŒ»ÝD ŽRŒ`’n‹æ”x‚ŒŒˆ³ÇƒZƒ~ƒi[iŽRŒ`j10ŒŽC2011
  22. ²“¡@–¾F S‹Ø[ÇŒãSŽºƒŠƒ‚ƒfƒŠƒ“ƒOAS•s‘S‚É‚¨‚¯‚éƒeƒlƒCƒVƒ“C ‚Ì–ðŠ„‚Æ—Õ°‰ž—pD ‘æˆê‰ñƒeƒlƒCƒVƒ“ƒtƒH[ƒ‰ƒ€i’Áj11ŒŽC2011
  23. ‰Í–ì@—¹F Šg’£Œ^S‹ØÇ‚ƏãŽè‚ɂ‚«‚ ‚¤‚½‚ß‚Ì’mŽ¯D “ï•aŠ³ŽÒ’nˆæŽx‰‡‘΍ô„iŽ–‹Æ “Á”­«Šg’£Œ^S‹ØÇu‰‰‰ïiŒÃ‰Íj12ŒŽC2011

@2010”N“xi2010”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. “n•”_–¾, ²“¡@–¾, HŽR‘åŽ÷, ˆ­”üˆÀ‹IŽq, Î’Ã’qŽq, £”ö—RL, ‰Í–ì@—¹, ÂÀ˜a—²: ƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚É‚¨‚¯‚銥“®–¬ƒvƒ‰[ƒN‚Ì“Á’¥\Š¥“®–¬CT‚É‚æ‚錟“¢\D ‘æ44‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žj1ŒŽ, 2010
  2. Î’Ã’qŽq, £”ö—RL, “cŒû‰Ä”ü, ˆ­”üˆÀ‹IŽq, ŽR–{¹—Ç, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, ‰|–{^”ü, “n•Óds, ÂÀ˜a—²: èò“®–¬’´‰¹”g–@‚̐SŒŒŠÇŒnƒCƒxƒ“ƒg”­Ç—\‘ªˆöŽq‚Æ‚µ‚Ă̈Ӌ`D ‘æ44‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žj1ŒŽ, 2010
  3. ¬àV^l, ŠÖŒûK•v, šê“c@_, ’¬–ì@‹B, ¬£‘ãŽm‹v, j‘º‰À], HŽR‘åŽ÷, “n•”_–¾, ˆä“¡—tŽq, ÂÀ˜a—²: ‚—îŽÒ‚̐S–[×“®—á‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—L—p«‚ƈÀ‘S«D ‘æ44‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žj1ŒŽ, 2010
  4. ‘º‰zLs, ‹–@“ŒŸª, •x‘òIŽ¡, “n•Ó@G, ŒÜ\—’@“s, ˆä“¡—tŽq, ŠÖŒûK•v, šê“c@_, ŽRŒû@›Ü, ÂÀ˜a—²: S–[×“®‚̊댯ˆöŽqD ‘æ44‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žj1ŒŽ, 2010
  5. ’†ì‹`Žk, “n•Óds, VˆäŒb”ü, i“¡–퐶, ²“¡—zŽq, •ˆÀ–@”V, “cK˜aŽq, éˍ◲ˆê, ‰Í–ì@—¹, ‘ŠŒ´‰p–¾, ²“¡@–¾, ÂÀ˜a—²: ‚Ž‰ŒŒÇŠ³ŽÒ‚É‚¨‚¯‚é‰^“®‘Ï—e”\‚ÆŠˆ“®‹Ø‹y‚Ñ”]ŒŒ‰tŸó—¬‚ÌŠÖ˜AD ‘æ44‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žj1ŒŽ, 2010
  6. Î’Ã’qŽq, ‰Í–ì@—¹, “n•Óds, ’‡‘º—DŽq, ¬‘q@„, £”ö—RL, ‹gì—T”V, ÂÀ˜a—²: Ø”—‘ŽYŽž‚É‹}«‰ES•s‘S‚ð’悵‚½AlagilleÇŒóŒQ‚̈ê—áD ‘æ12‰ñ“ú–{¬læ“V«SŽ¾Š³Œ¤‹†‰ïi‘åãj1ŒŽ, 2010
  7. ²“¡‰Ã—m, ¬¼@—², ‹k@‰p–¾, ¬‘ò^l, ž­“c–[‹I, ’†‘ºŒ³s, ŠÖŒûK•v, ÂÀ˜a—²: ”­ì«S–[×“®‚ɑ΂·‚é”xÃ–¬Šu—£pŒã, ‰Eã”xÃ–¬-¶–[ŠÔ‚ð‹»•±ù‰ñ‚·‚éS–[•p”‚ª¶‚¶‚½1—áD ‘æ22‰ñ—Տ°•s®–¬Œ¤‹†‰ïi“Œ‹žj1ŒŽ, 2010
  8. ’†ì˜a–ç, óì“N–ç, ¼‘º‘‰À, ÷—с@‘Ï, ŽR“àNÆ, ÂÀ˜a—²: ’ʏí–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[«•p”‚Æ‚ÌŠÓ•Ê‚É“ïa‚µslow pathway—̈悩‚ç‚Ì’Ê“d‚ª—LŒø‚Å‚ ‚Á‚½–[ŽºÚ‡•”«•p”‚Ì1—áD ‘æ22‰ñ—Տ°•s®–¬Œ¤‹†‰ïi“Œ‹žj1ŒŽ, 2010
  9. ŽRè@_, šê“c@_, ŠÖŒûK•v, ŒÜ\—’@“s, •–ØŒ’Žu, ’¬–ì@‹B, ¬àV^l, ¬£‘ãŽm‹v, ˆä“¡—tŽq, ÂÀ˜a—²: ‰ESŽºë•”ƒy[ƒVƒ“ƒO‚©‚çupgrade‚µ‚½Ç—á‚É‚¨‚¯‚éS‘ŸÄ“¯Šú—Ö@‚Ì’·ŠúŒø‰Ê‚Æ—\ŒãFV‹KAž‚ݏǗá‚Æ‚Ì”äŠrŒŸ“¢D ‘æ22‰ñ—Տ°•s®–¬Œ¤‹†‰ïi“Œ‹žj1ŒŽ, 2010
  10. Î’Ã’qŽq, £”ö—RL, ‘º‰zLs, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: ‹•ŒŒ«SŽ¾Š³Ç—á‚É‚¨‚¯‚éèò“®–¬positive remodeling‚Æ’á‹P“xƒGƒR[ƒvƒ‰[ƒN‚Ì—\Œã—\‘ªˆöŽq‚Æ‚µ‚Ă̈Ӌ`D ‘æ13‰ñˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ïi‚‚­‚΁j2ŒŽ, 2010
  11. j‘º‰À], Î’Ã’qŽq, ’·’Jì’q–¾, ˆ­”üˆÀ‹IŽq, “n•”_–¾, HŽR‘åŽ÷, ’¬–ì@‹B, ¬£‘ãŽm‹v, £”ö—RL, ‰Í–ì@—¹, ÂÀ˜a—²: ‰EŽºˆ³Šr·‰ü‘P‚ɉEŽºSë•”ƒy[ƒWƒ“ƒO‚¨‚æ‚уVƒxƒ“ƒ]ƒŠƒ“‚ª’˜Œø‚µ‚½‰EŽº—¬o˜HŒ^•ÂÇ«”ì‘åŒ^S‹ØÇ‚̈ê—áD ‘æ215‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽ, 2010
  12. ŽRè@_, šê“c@_, ŠÖŒûK•v, ŒÜ\—’@“s, •–ØŒ’Žu, ’¬–ì@‹B, ¬àV^l, ¬?‘ãŽm‹v, ˆä“¡—tŽq, ÂÀ˜a—²: ŒãŠú‚—îŽÒi†75Îj‚ɑ΂·‚éS‘ŸÄ“¯Šú—Ö@‚Ì’·ŠúŒø‰Ê‚¨‚æ‚Ñ—\Œã‚ÌŒŸ“¢D ‘æ2‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2ŒŽ, 2010
  13. ’¬–ì@‹B, ŠÖŒûK•v, šê“c@_, ‡‰®‰ë•F , X@Œ’ì , ¬£‘ãŽm‹v, ¬àV^l, •–ØŒ’Žu, ŽRè@_, ŒÜ\—’@“s, ˆÉ“¡—tŽq, ‹g“cŒ’‘¾˜Y, ‹v‰êŒ\—S, ÂÀ˜a—²: Excimer Laser‚É‚æ‚é—¼‘¤ƒfƒoƒCƒX”²‹ŽŒã‚ÉŠ´õ‚ªŒy‰õ‚µ, ½œ‰ºÃ–¬ƒoƒ‹[ƒ“Šg’£p‚É‚æ‚é”ñŠ´õ‘¤‚©‚ç‚̃Š[ƒh—¯’u‚ª‰Â”\‚Å‚ ‚Á‚½Ç—áD ‘æ2‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2ŒŽ, 2010
  14. Žðˆä@r: ƒXƒgƒŒƒX’`”’Œ‡‘¹‚É‚æ‚éV‹Kƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚ÌŠJ”­‚Æ‚»‚Ì•a‘Ô‰ðÍD ‰«’†‹L”O¬l•aŒ¤‹†ŠŒ¤‹†•¬‹à•ñ‰ïi“Œ‹žj3ŒŽ, 2010
  15. Tada H, Koyama T, Sekiguchi Y, Yamasaki H, Arimoto T, Igarashi M, Kuroki K, Machino T, Aonuma K: Prevention of Atrial Fibrillation Recurrence with Corticosteroids after Radiofrequency Catheter Ablation: A Randomized Controlled Trial. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  16. Seo Y, Ito H, Nakatani S, Shiga T, Takami M, Aonuma K: Current Task and Perspective of Echocardiography to Predict Responders of CRT From Japan Cardiac Resynchronization Therapy Registry Trial (J-CRT). ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  17. Aoki H, Kimura T, Yoshimura K, Imanaka-Yoshida K, Aonuma K, Hiroe M, Shigematsu H, Matsuzaki M, Imaizumi T: Molecular Network of Abdominal Aortic Aneurysm. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  18. Tsuneoka H, Koike A, Nagayama O, Senba H, Sawaba H, Aonuma K, Aizawa T: Relationship between Left Atrial Diameter and Cardiopulmonary Function during Exercise in Patients with Atrial Fibrillation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  19. Sekiguchi Y, Tada H, Aonuma K: Significant Increase of the Occurrence of Ventricular Arrhythmic Events after Intrathoracic Impedance Change with a Cardiac Resynchronization Therapy Defibrillator. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  20. Xu D, Sairenchi T, Irie F, Murakoshi N, Igarashi M, Tada H, Sekiguchi T, Tomizawa T, Yamaguchi I, Iso H, Aonuma K: The Presence of Supraventricular Premature Contractions is the Strongest Predictor for Atrial Fibrillation Incidence in the Ibaraki Prefectural Health Study. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  21. Murakoshi N, Xu D, Tomizawa T, Watanabe H, Igarashi M, Ito Y, Sekiguchi Y, Tada H, Yamaguchi I, Aonuma K: Chronic Kidney Disease is a Strong Independent Risk Factor for Atrial Fibrillation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  22. Kobori A, An Y, Kuwahara T, Honda S, Nishino T, Funakoshi S, Kimura N, Kim K, Kitai T, Ehara N, Kinoshita M, Kaji S, Yamamuro A, Tani T, Furukawa Y, Takahashi A, Aonuma K: Esophagus Temperature during Left Atrium Ablation Using Irrigation Tip and 8mm Tip Catheter. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  23. Yamasaki H, Tada H, Sekiguchi Y, Igarashi M, Machino T, Ozawa M, Naruse Y, Kuroki K, Ito Y, Murakoshi N, Kuga K, Aonuma K: What Kind of Patients are Susceptible to Esophageal Thermal Injury during Radiofrequency Ablation of Atrial Fibrillation?: Its Prevalence and Characteristics. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  24. Naruse Y, Sekiguchi Y, Machino T, Kuroki K, Ito Y, Yamasaki H, Ozawa M, Igarashi M, Tada H, Kuga K, Aonuma K: Clinical and Electrophysiological Characteristics of Ventricular Tachycardia Associated with Cardiac Sarcoidosis. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  25. Sekiguchi Y, Tada H, Yamasaki H, Machino T, Kuroki K, Ozawa M, Naruse Y, Igarashi M, Aonuma K: Efficacy and Safety of a Combined Endocardial and Epicardial Ablation of Ventricular Tachycardia Associated with Dilated Cardiomyopathy. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  26. Higuchi H, Endo Y, Sato Y, Yamauchi R, Yukawa A, Suzuki A, Eki Y, Aonuma K: High FDG Accumulation with PET/CT at Common Carotid Artery in Acute Coronary Syndrome: Possible Finding for Systemic Active Atherosclerosis. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  27. Naruse Y, Sekiguchi Y, Tada H, Machino T, Ozawa M, Igarashi M, Ito Y, Yamasaki H, Kuroki K, Kuga K, Aonuma K: The Effects of Extensive Pulmonary Vein Isolation Using an Open Irrigation Catheter for the Treatment of Atrial Fibrillation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  28. Seo Y, Ishizu T, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Enomoto Y, Aonuma K: Usefulness of Area Tracking Imaging in Assessing Regional Left Ventricular Deformation; a Comparison Study with One-dimensional Strain Analysis. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  29. Nogami Y, Ishizu T, Kawamura R, Seo Y, Aonuma K, Ajisaka R: Abnormal Early Diastolic Intraventricular Flow Momentum Assessed by Echo-dynamography in Patients with Left Ventricular Diastolic Dysfunction. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  30. Ishizu T, Seo Y, Nakajima H, Sakamaki F, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Aonuma K: Three Dimensional Left Ventricular Movement Affect the Strain Measurement Using Two-Dimensional Speckle Tracking Imaging. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  31. Baba M, Seo Y, Ishizu T, Hayashi M, Yoshida K, Abe D, Suzuki S, Takeyasu N, Aonuma K, Sato M: The Relationship between Vascular F-FDG-PET-accumulation and Cardiovascular Events. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  32. Aihara H, Sato A, Takeyasu N, Yoshida I, Saito T, Endo M, Aonuma K: Effect of Individual Proton Pump Inhibitor on Cardiovascular Events in Patients Treated with Clopidogrel Following Coronary Stenting; Result from ICAS-Registry. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  33. Ueda K, Sato A, Takeyasu N, Aonuma K: Factors Modifying the Association between Particulate Air Pollution and Acute Coronary Syndrome: Results from ICAS Registry. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  34. Aihara H, Sato A, Endo M, Yoshida I, Saito T, Seo Y, Aonuma K: Impact of Coronary Calcium Score as an Index of Peripheral Artery Diseases with the Continuously Imaging Method. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  35. Ishizu T, Seo Y, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Watanabe S, Aonuma K: Prognostic Impact of Carotid Artery Positive Remodeling and Plaque Echolucency in Patients with Coronary Artery Disease. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  36. Yamamoto M, Seo Y, Machino T, Kawamura R, Nakajima H, Ishizu T, Watanabe S, Aonuma K: Elevated Left Atrial Pressure Dilates Left Atrium and Left Atrial Appendage? ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  37. Igarashi M, Tada H, Yamauchi Y, Sekiguchi Y, Yamasaki H, Machino T, Kuroki K, Naruse Y, Ozawa M, Ito Y, Kuga K, Naito S, Oshima S, Aonuma K: ECG Characteristics of Ventricular Arrhythmias Arising from the Right Coronary Cusp or Junction of the Left and Right Coronary Cusps. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  38. Hayashi M, Takeyasu N, Baba M, Yoshida K, Abe D, Suzuki S, Sato A, Aonuma K: Clinical Impact of 6-months Dual Anti-platelet Therapy on Prognosis of Sirolimus-Eluting Stent in Patients with ACS: ICAS. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  39. Kuwahara T, Takahashi A, Takahashi Y, Koura K, Hirose S, Nakashima E, Fujinami T, Fujii A, Kusa S, Yagishita A, Kamiishi T, Ohkubo K, Fujino A, Nozato T, Takei A, Hikita H, Sato A, Aonuma K: The Use of High Dose Isoproterenol Brings Better Clinical Outcome of Paroxysmal Atrial Fibrillation Ablation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  40. Sato A, Maruyama H, Akiyama D, Watabe H, Shimojo N, Murakoshi N, Seo Y, Sakai S, Aonuma K: Impact of Plasma Pentraxin 3 Levels on Cardiac Troponin Elevation after Percutaneous Coronary Intervention. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  41. Watabe H, Sato A, Hasegawa T, Atsumi A, Akiyama D, Harimura Y, Naruse Y, Machino T, Murakoshi N, Seo Y, Aonuma K: Impact of Coronary Plaque Composition on Cardiac Troponin Elevation after Percutaneous Coronary Intervention: A Computed Tomography Analysis. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  42. Igarashi M, Sairenchi T, Irie F, Murakoshi N, Xu D, Tada H, Sekiguchi Y, Tomizawa T, Yamaguchi I, Iso H, Aonuma K: Obesity and Drinking Habit are Independent Risk Factors for Developing Atrial Fibrillation in Japanese General Population; Ibaraki Prefectural Health Study. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  43. Harimura Y, Seo Y, Ishizu T, Sakamaki F, Atsumi A, Yamamoto M, Machino T, Kawamura R, Yamazaki A, Sekiguchi Y, Tada H, Aonuma K: Responsible Factors of Cardiac Resynchronization Therapy Effect on Functional Mitral Regurgitation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  44. Seo Y, Ishizu T, Sakamaki F, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Aonuma K: Diverse Mechanical Propagation Pattern Assessed by 3-Dimentional Speckle Tracking Imaging in Patients with Left Bundle Branch Block. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  45. Higuchi H, Endo Y, Sato Y, Yamauchi R, Yukawa A, Suzuki A, Eki Y, Aonuma K: Feasibility of Continuous Intravenous Administration of Landiolol for Acute Myocardial Infarction |First Clinical Experience and Its Safe Directions for Use-. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  46. Yoshida K, Watanabe S, Nakagawa Y, Liang J, Seo Y, Takeyasu N, Sato A, Ishizu T, Sato Y, Sakai S, Murakoshi N, Aonuma K: Abnormal Vascular Endothelial Function after Pacritaxel-eluting Stent Implantation. A Comparison among Bare-metal, Sirolimus- and Pacritaxel-eluting Stents. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  47. Sakai S, Shimojo N, Yoshida K, Hayashi S, Ishigaki N, Shimano H, Aonuma K: Possible Involvement of SREBP-1 in Development of Angiotensin II-Induced Cardiac Dysfunction. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  48. Hoshi T, Nishina H, Noguchi Y, Tachibana T, Kakefuda Y, Toda S, Hiranuma Y, Fumikura Y, Takeyasu N, Sato A, Aonuma K: Impact of Optimal Medical Treatment for Long Term Prognosis in Patients with Coronary Artery Disease Who Underwent Revascularization; Analysis from ICAS-registry. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  49. Miyauchi T, Maeda S, Miyauchi Y, Sugawara J, Shimojo N, Jesmin S, Sakai S, Watanabe S, Aonuma K: High-dose Bosentan on Systemic Arterial Compliance (Distensibility) before and after Exercise Training: Possible Implication of Endothelin Antagonist for Metabolic Syndrome. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  50. Atsumi A, Ishizu T, Seo Y, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Iida N, Sakamaki F, Yamasaki H, Sekiguchi Y, Tada H, Aonuma K: The Usefulness of Assessment of Twist Motion in Patients Referred for Cardiac Resynchronization Therapy. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  51. Ishizu T, Seo Y, Higuchi H, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Sato A, Aonuma K: Impaired Subendocardial Contraction and Postsystlic Shortening are Signs of Myocardial Ischemia with Flow Limiting Coronary Stenosis. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  52. Machino T, Tada H, Sekiguchi Y, Naruse Y, Ozawa M, Yamasaki H, Igarashi M, Kuroki K, Ito Y, Kuga K, Aonuma K: Prevalence and Characteristics of gHyper-respondersh to Radiofrequency Catheter Ablation for Persistent Atrial Fibrillation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  53. Yamasaki H, Tada H, Sekiguchi Y, Igarashi M, Machino T, Kuroki K, Ozawa M, Naruse Y, Ishizu T, Seo Y, Kuga K, Aonuma K: Hyper-responders in Patients with Non-ischemic Cardiomyopathy Receiving Cardiac Resynchronization Therapy. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  54. Nogami Y, Ishizu T, Kawamura R, Seo Y, Aonuma K, Ajisaka R: Early Diastolic Intraventricular Flow Propagation Delay Relates with Reduced Untwisting Rate and Dilatation of Left Ventricle. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  55. Watanabe S, Aonuma K, Investigators I-HAT Study: Blood Pressure Control Status in Diabetes or Obesity. From Large Scale Japanese Home Blood Pressure Study: Ibaraki Hypertension Assessment Trial (I-HAT). ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  56. Watanabe S, Aonuma K, Investigators I-HAT Study: Unlike Systolic Blood Pressure, Home Diastolic Blood Pressure is not so Lower than Clinic Blood Pressure (Ibaraki Hypertension Assessment Trial: I-HAT). ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  57. Kimura T, Yoshimura K, Aoki H, Ikeda Y, Imanaka-Yoshida K, Hamano K, Hiroe M, Imaizumi T, Aonuma K, Matsuzaki M: Tenascin-C Protects Aortic Tissue from Multiple Insults against the Development of Aortic Aneurysm. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  58. Kawamura R, Ishizu T, Nogami Y, Atsumi A, Yamamoto M, Machino T, Harimura Y, Enomoto M, Sakamaki F, Nakajima H, Iida N, Enomoto Y, Seo Y, Aonuma K: Ability of Vector Flow Mapping for Assessing Left Ventricular Blood Movement and Verification by Analyzing Cases Including Mitral Valve Repairment. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  59. Adachi T, Oyake Y, Tanaka K, Yamanouchi T, Takeyasu N, Sato A, Watanabe S, Aonuma K: Clinical Characteristics in Oldest Old Patients with PCI from ICAS Registry. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  60. Machino T, Tada H, Arimoto T, Asakawa T, Sekiguchi Y, Naruse Y, Ozawa M, Yamasaki H, Igarashi M, Kuroki K, Ito Y, Kuga K, Aonuma K: Unusual Macro-reentrant Atrial Flutter Utilizing a Conduction Gap in the Crista Terminalis: Its Prevalence and Characteristics. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  61. Tsuneoka H, Koike A, Nagayama O, Yamashita T, Sawada H, Aonuma K, Aizawa T: Influence of Rate Control Medications on Cardiopulmonary Function during Exercise in Atrial Fibrillation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  62. Enomoto M, Ishizu T, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R, Seo Y, Aonuma K: Left Ventricular Subendocardial Dysfunction in Normotensive Diabetic Patients; Assessment by Two-dimensional Speckle Tracking Imaging. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  63. Kuroki K, Tada H, Machino T, Naruse Y, Yamasaki H, Ozawa M, Igarashi M, Ito Y, Sekiguchi Y, Kuga K, Aonuma K, Igawa M, Nakajima T, Ito S, Naito S, Oshima S: What is the Most Reliable Electrocardiographic Predictor of a Failed Radiofrequency Catheter Ablation in Patients with Idiopathic Outflow Tract Tachyarrhythmias? ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  64. Iida N, Seo Y, Ishizu T, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Kawakami Y, Aonuma K: elationship between Endomyocardial Radial Strain and Wall Stress in Patients with Aortic Regurgitation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  65. Arimoto T, Tada H, Sekiguchi Y, Sato A, Igarashi M, Yamasaki H, Machino T, Kuroki K, Kuga K, Aonuma K: High Washout Rate of Iodine-123-Metaiodobenzylguanidine Imaging Predicts Late Recurrence of Atrial Fibrillation Following Radiofrequency Catheter Ablation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  66. Harimura Y, Sekiguchi Y, Tada H, Hasegawa T, Watabe H, Atsumi A, Akiyama D, Machino T, Naruse Y, Ito Y, Ozawa M, Seo Y, Kawano S, Aonuma K: The Efficacy and the Safety of Irrigation-Tip Catheter for Ablation of Atrial Fibrillation: A Comparative Study with Conventional-Tip Catheter. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  67. Sato A, Takeyasu N, Akiyama D, Watabe H, Atsumi A, Harimura Y, Murakoshi N, Seo Y, Aonuma K: Long-Term Prognosis of Stent Thrombosis in Patients with Acute Coronary Syndrome Treated with Drug-Eluting and Bare-Metal Stents: From ICAS Registry. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  68. Shimojo N, Hagiya K, Seki Y, Kawano S, Tsuneoka H, Yasuda S, Aonuma K, Mizutani T: Landiolol, Very Short Acting Beta-blocker, Ameliorates Acute Systemic Circulatory Failure through Suppressing Cardiac Endothelin System in Septic Shock Rats. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  69. Nogami Y, Ishizu T, Kawamura R, Atsumi A, Harimura Y, Machino T, Yamamoto M, Enomoto M, Seo Y, Aonuma K, Ajisaka R: Dobutamine Stress-induced Increases in Left Ventricular Untwisting Rate Correlates with Improvement of Apical Flow Filling; Echo-dynamographic Study. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  70. Sakamaki F, Seo Y, Iida N, Nakajima H, Inaba T, Atsumi A, Yamamoto M, Harimura Y, Machino T, Kawamura R, Enomoto M, Ishizu T, Aonuma T: Analysis of Left Ventricular Dyssynchrony with 3D Speckle Tracking. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  71. Machino T, Tada H, Sekiguchi Y, Naruse Y, Ozawa M, Yamasaki H, Igarashi M, Kuroki K, Ito Y, Kuga K, Aonuma K: The Impact of Anatomical Variations of Kochfs Triangle on the Optimal Target Site for Catheter Ablation of the Cavotricuspid Isthmus. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  72. Nishi I, Sugiyama A, Kuroki K, Igawa M, Enomoto T, Iida K, Koseki S, Aonuma K: Exercise Training Can Ameliorate Reduced Repolarization Reserve. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  73. Tsuneoka H, Koike A, Nagayama O, Senba H, Sawada H, Aonuma K, Aizawa T: Influence of Systolic and Diastolic Function on Cardiopulmonary Indices during Exercise. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  74. Akiyama D, Sato A, Hasegawa T, Watabe H, Harimura Y, Machino T, Seo Y, Takeyasu N, Watanabe S, Aonuma K: Usefulness of Culprit Plaque Assessment by Virtual Histology-intravascular Ultrasound on Cardiac Troponin Elevation after Percutaneous Coronary Intervention. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  75. Hasegawa T, Sekiguchi Y, Tanoue K, Nuruki N, Atsumi A, Watabe H, Akiyama D, Machino T, Naruse Y, Harimura Y, Kuroki K, Yamasaki H, Ito Y, Igarashi M, Ozawa M, Kuga K, Yamaguchi I, Tada H, Aonuma K: Predictor of Successful Catheter Ablation for Ventricular Tachycardia Associated with Arrhythmogenic Right Ventricular Cardiomyopathy. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  76. Baba M, Seo Y, Ishizu T, Hayashi M, Yoshida K, Abe D, Suzuki S, Takeyasu N, Sato M, Aonuma K: Evaluation of vascular 18F-FDG-PET-accumulation is correlation with cardiovascular events. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  77. ‹{“à—T”ü, “n•Óds, ‰ºžŠMˆÐ, Žðˆä@r, ÂÀ˜a—², ‹”ö_Ž÷, ‘O“c´Ži, ‹{“à@‘ì: ~ˆ³‚¨‚æ‚ѐS””‚É‹y‚Ú‚·ARBŠÔ‚ÌŒø‰Ê‚̈Ⴂ‚ɂ‚¢‚āF‹«ŠEˆæƒRƒ“ƒgƒ[ƒ‹‚ŒŒˆ³Š³ŽÒ‚É‚¨‚¯‚錟“¢D ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  78. ‹{“à—T”ü, ‘O“c´Ži, ›Œ´@‡, ‰ºžŠMˆÐ, Žðˆä@r, Subrina Jesmin, –{ŠÔ@Šo, “n•Óds, ÂÀ˜a—², ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“ŽÕ’f–òƒ{ƒZƒ“ƒ^ƒ“‚̒ʏí—p—ʂƍ‚—p—ʂ̃qƒg‚Ö‚Ì“Š—^‚É‚æ‚錌ŠÇ”½‰žF”x‚ŒŒˆ³Š³ŽÒ‚ÆŒ’í’†‚—îŽÒ‚Å‚ÌŒŸ“¢D ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  79. Nozato T, Sato A, Hiroe M, Hirose H, Koura K, Fujinami T, Yagishita A, Kusa S, Takahashi Y, Kuwahara T, Hikita H, Takahashi A, Isobe M: Serum Tenascin-C Levels Might be a Novel Biomarker for Predicting Short-term Prognosis of Type B Acute Aortic Dissection. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  80. Nozato T, Hirose H, Kamiishi T, Sato A, Koura K, Fujinami T, Yagishita A, Kusa S, Takahashi Y, Kuwahara T, Hikita H, Takahashi A, Isobe M: Long-term Outcome of Nitinol Stent Implantation for Superficial Femoral Artery Lesions. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  81. Nozato T, Hirose H, Kamiishi T, Sato A, Koura K, Fujinami T, Yagishita A, Kusa S, Takahashi Y, Kuwahara T, Hikita H, Takahashi A, Isobe M: Statin is Effective for the Management of the Patients with Peripheral Artery Disease after Endovascular Treatment. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  82. Hirose H, Nozato T, Kamiishi T, Sato A, Koura K, Kamiishi T, Ohkubo K, Fujinami T, Yagishita A, Kusa S, Takahashi Y, Kuwahara T, Hikita H, Takahashi A, Isobe M: Clinical Outcome of Critical Limb Ischemia with Below Knee Lesion Needed Endovascular Therapy. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  83. Hikita H, Sato A, Koura K, Hirose S, Nakashima E, Fujinami T, Fujii A, Fujino T, Kusa S, Yagishita A, Kamiishi T, Ohkubo K, Takahashi Y, Nozato T, Kuwahara T, Isobe M, Takahashi A: Differential Characteristics of Inflammatory Response to Stent Implantation Between De Novo and In-stent Restenosis Lesion in Patients with Stable Angina. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  84. Kuwahara T, Takahashi A, Takahashi Y, Takei A, Koura K, Hirose S, Fujii A, Fujino T, Nakashima E, Fujinami T, Kamiishi T, Ohkubo K, Hikita H, Yagishita A, Kawashima T, Nozato T, Hikita H, Sato A, Aonuma K: The Use of High Dose Isoproterenol Brings Better Clinical Outcome of Atrial Fibrillation Ablation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  85. Hikita H, Sato A, Koura K, Hirose S, Nakashima E, Fujinami T, Fujii A, Fujino T, Kusa S, Yagishita A, Kamiishi T, Ohkubo K, Takahashi Y, Nozato T, Kuwahara T, Isobe M, Takahashi A: Determination of Optimal Cut-off Values of Coronary Flow Velocity and Shear Stress to Predict restenosis after Sirolimus-eluting Stent Implantation. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‹ž“sj3ŒŽ, 2010
  86. ŠÖ@‹`Œ³, ‰ºžŠMˆÐ, ”‹’JŒ\ˆê, ‚‹´L“ñ, ˆÀ“c@v, ‰Í–ì@—¹, …’J‘¾˜Y: Iandiolol‚ÍHIF-1 a‚ð‰î‚µ‚Ä”sŒŒÇƒ‚ƒfƒ‹ƒtƒ‰ƒbƒg‚̘´i‚µ‚½S‘Ÿ‚Ìendothelin-1‚ð—}§‚µ‚½D ‘æ37‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ïiL“‡j3ŒŽ, 2010
  87. ‰Í–ì@—¹, ˆÀ“c@v, ‰ºžŠMˆÐ, ”‹’JŒ\ˆê, ŠÖ@‹`Œ³, ‚‹´L“ñ, …’J‘¾˜Y: ŽüpŠúS–[×“®‚ɑ΂·‚é’ZŽžŠÔì—pŒ^ƒÀŽÕ’f–ò‚ÌŽ¡—ÃŒø‰ÊD ‘æ37‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ïiL“‡j3ŒŽ, 2010
  88. ‰Í–ì@—¹: W’†Ž¡—Õª–ì‚É‚¨‚¯‚éƒÀŽÕ’f–ò‚Ì—L—p«‚ðzŠÂŠí“à‰Èˆã‚ÌŽ‹“_‚©‚çl‚¦‚éD ‘æ37‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ïiL“‡j3ŒŽ, 2010
  89. ‰Í–ì@—¹, …’J‘¾˜Y, ŽR‰º‘nˆê˜Y: ƒnƒ“ƒYƒIƒ“1 ICU-Bedside Procedures Course. ‘æ37‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ïiL“‡j3ŒŽ, 2010
  90. ‹{“à—T”ü, ‘O“c´Ži, ‰ºžŠMˆÐ, Žðˆä@r, –{ŠÔ@Šo, “n•Óds, ÂÀ˜a—², ‹{“à@‘ì: ”x‚ŒŒˆ³Š³ŽÒ‚ÆŒ’í’†‚—îŽÒ‚É‚¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“ŽÕ’f–òƒ{ƒZƒ“ƒ^ƒ“‚̒ʏí—p—ʂƍ‚—p—Ê‚Ì“Š—^‚É‚æ‚錌ŠÇ”½‰žD ‘æ130‰ñ“ú–{–òŠw‰ï”N‰ïi‰ªŽRj3ŒŽ, 2010
  91. ‹{“à—T”ü, ‘O“c´Ži, ›Œ´@‡, ‰ºžŠMˆÐ, Subrina J, Žðˆä@r, “n•Óds, ÂÀ˜a—², ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“ŽÕ’f–òƒ{ƒZƒ“ƒ^ƒ“‚̍‚—p—Ê“Š—^‚ªƒqƒg“®–¬ƒRƒ“ƒvƒ‰ƒCƒAƒ“ƒXiL“W«j‚É‹y‚Ú‚·Œø‰ÊF’·ŠúƒgƒŒ[ƒjƒ“ƒO‘OŒã‚Å‚ÌŒŸ“¢D ‘æ83‰ñ“ú–{–ò—Šw‰ï”N‰ïi‘åãj3ŒŽ, 2010
  92. ŽR–{¹—Ç, £”ö—RL, ’†“‡‰pŽ÷, ŽðŠª•¶Žq, ’¬–ì’qŽq, ì‘º@—´, Î’Ã’qŽq, ÂÀ˜a—²: CRTŽŠ“KÝ’è‚É‚¨‚¯‚éS–[ŠÔ“`“±’x‰„‚ÌŒŸ“¢D ‘æ21‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïiŽD–yj5ŒŽ, 2010
  93. ’J’†—¢”ü, £”ö—RL, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ŽðŠª•¶Žq, ŽR–{¹—Ç, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, Î’Ã’qŽq, ÂÀ˜a—²: ‘å“®–¬•Ù•Â½•s‘SÇ‚É‚¨‚¯‚錌Ÿ÷BNP’l‚Ì‹K’èˆöŽq‚ÉŠÖ‚·‚錟“¢D ‘æ21‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïiŽD–yj5ŒŽ, 2010
  94. ”Ñ“c“TŽq, £”ö—RL, ŽR–{¹—Ç, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, ’†“‡‰pŽ÷, ŽðŠª•¶Žq, Î’Ã’qŽq, ÂÀ˜a—²: ‘å“®–¬•Ù•Â½•s‘SÇ‚É‚¨‚¯‚éradial strain‚ƍ¶Žº•Ç‰ž—Í‚ÌŠÖŒWD ‘æ83‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‹ž“sj5ŒŽ, 2010
  95. £”ö—RL, ’†“‡‰pŽ÷, ŽR–{¹—Ç, ˆ­”üˆÀ‹IŽq, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, Î’Ã’qŽq, ÂÀ˜a—²: ¶SŽ¨“àŒŒðŒ`¬‚ÉŠÖ˜A‚µ‚½¶SŽ¨\‘¢‚ÌŒŸ“¢D ‘æ83‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‹ž“sj5ŒŽ, 2010
  96. £”ö—RL, ŽðŠª•¶Žq, ŽR–{¹—Ç, ˆ­”üˆÀ‹IŽq, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, Î’Ã’qŽq, ÂÀ˜a—²: S‘ŸÄ“¯Šú—Ö@‚Æ”ñ“¯ŠúŽw•WGJ-CRT‚©‚çÄl‚·‚éD ‘æ83‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‹ž“sj5ŒŽ, 2010
  97. ŽðŠª•¶Žq, £”ö—RL, ˆ­”üˆÀ‹IŽq, ŽR–{¹—Ç, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, ‰|–{^”ü, Î’Ã’qŽq, ÂÀ˜a—²: 3-dinensional speckle tracking imaging‚ð—p‚¢‚½¶Žº“àdyssynchrony‚Ì•]‰¿D ‘æ83‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‹ž“sj5ŒŽ, 2010
  98. ’†“‡‰pŽ÷, £”ö—RL, ˆ­”üˆÀ‹IŽq, ŽR–{¹O, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, ‰|–{^”ü, Î’Ã’qŽq, ÂÀ˜a—²: 3DSƒGƒR[‚ð—p‚¢‚½’PS”–@‚É‚¨‚¯‚鍶Žº—e—Ê‚ÌŒv‘ª¸“x‚ÉŠÖ‚·‚錟“¢D ‘æ83‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‹ž“sj5ŒŽ, 2010
  99. –ìã‰ÀŒb, Î’Ã’qŽq, ì‘º@—´, £”ö—RL, ÂÀ˜a—², éˍ◲ˆê: Šg’£•s‘SS‚É‚¨‚¯‚éŠg’£Šú¶Žº“àŒŒ—¬‰^“®—Ê‚ÌŽžŠÔ•Ï‰»‚ÌŒŸ“¢D ‘æ83‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‹ž“sj5ŒŽ, 2010
  100. ¬£‘ãŽm‹v, ’¬–ì@‹B, ˆä“¡—tŽq, ŽRè@_, ¬àV^l, í‰ªG˜a, ŒÜ\—’@“s, ŠÛŽRG˜a, ŠÖŒûK•v, ²“¡@–¾, šê“c@_, ÂÀ˜a—², •½“c—T”ü, –öŒ´–œ—¢Žq, ²“¡@½: S–[×“®Š³ŽÒ‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‡–°ŒÄ‹záŠQ‚É‹y‚Ú‚·‹}«ŠúŒø‰Ê‚ÌŒŸ“¢D ‘æ11‰ñzŠÂŠíSASŒ¤‹†‰ïi“Œ‹žj5ŒŽ, 2010
  101. ¬£‘ãŽm‹v, ’¬–ì@‹B, ŠÖŒûK•v, ˆä“¡—tŽq, ŽRè@_, ¬àV^l, ŒÜ\—’@“s, šê“c@_, ÂÀ˜a—²: •p”‰ñ˜H“¯’è‚ÉCARTO‚ª—L—p‚Å‚ ‚Á‚½‹rŽˆŠÔƒŠƒGƒ“ƒgƒŠ[«SŽº•p”‚̈ê—áD ‘æ40‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj5ŒŽ, 2010
  102. ’†–ìŒb”ü, šê“c@_, ŠÖŒûK•v, ’¬–ì@‹B, ŽRè@_, ŒÜ\—’@“s, •–ØŒ’Žu, ¬£‘ãŽm‹v, ˆä“¡—tŽq, ‹àé‹MŽm, ÂÀ˜a—², Œ´“c’q—Y, •›“‡‹žŽq, —é–Ø•¶’j: Micro-reentry‹@˜‚𐄒肵‚½”xÃ–¬Šu—£pŒã¶–[”xÃ–¬Ú‡•”•p”‚Ì1—áD ‘æ40‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj5ŒŽ, 2010
  103. k@‹±ˆê, ²“¡@–¾, Ô¯”Ž˜a, ²“¡@Œc, ìã@N, ˆÀ“‡—Ç‹PŽq, ”~’Á@–±, ÂÀ˜a—²: “–‰@‚ÌOCTƒtƒ‰ƒbƒVƒ…–@‚̉摜•]‰¿‚ɂ‚¢‚āD ‘æ37‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj5ŒŽ, 2010
  104. “n•”_–¾, ²“¡@–¾, —с@^—R, HŽR‘åŽ÷, —§‰Ô–qŽq, ˆ­”üˆÀ‹IŽq, ŽR–{¹—Ç, j‘º‰À], í‰ªG˜a, ÂÀ˜a—²: LAD‹ßˆÊ•”‚©‚çLMT‚É‚©‚¯‚Ä’E—Ž‚µL‚Ñ‚«‚Á‚½EndeavorƒXƒeƒ“ƒg‚ðbail out‚Æ‚µ‚½‚P—áD ‘æ5‰ñˆïéŒ§“슥Ž¾Š³Œ¤‹†‰ïi‚‚­‚΁j5ŒŽ, 2010
  105. “yŠò_‰î, –{ŠÔ^l, ÂÀ˜a—², ‹v‰êŒ\—S, ‹´–{’¼–¾, K“cK’¼: ƒtƒŒƒJƒCƒjƒh‚ƃAƒ~ƒIƒ_ƒƒ“‚Ì–ò•¨‘ŠŒÝì—p‚É‚¨‚æ‚Ú‚·ŠÌEt‹@”\‚̉e‹¿D ‘æ27‰ñ“ú–{TDMŠw‰ïiŽD–yj6ŒŽ, 2010
  106. šê“c@_, —L–{‹M”Í, ŠÖŒûK•v, ŒÜ\—’@“s, ŽR?@_, ’¬–ì@‹B, •–ØŒ’Žu, ‹v‰êŒ\—S, ÂÀ˜a—²: Electrical storm‚ɑ΂·‚錵–§‚È“dˆÊŽwŠÂ‚ð—p‚¢‚½ƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—LŒø«D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  107. “n•Óds: ƒXƒe[ƒgƒƒ“ƒg‰ü’ùŒã‚ÌICDŠ³ŽÒ‚ÌŽ©“®ŽÔ‰^“]‚ÉŠÖ‚·‚éf’f‘ì¬‚ÌŽÀÛD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  108. ŒÜ\—’@“s, šê“c@_, ŠÖŒûK•v, £”ö—RL, Î’Ã’qŽq, ŽR?@_, ’¬–ì@‹B, •–ØŒ’Žu, ¬£‘ãŽm‹v, ¬àV^l, í‰ªG˜a, ˆä“¡—tŽq, ‰““¡GW, ‹v‰êŒ\—S, ÂÀ˜a—²: ¶‹rƒuƒƒbƒN‚̏oŒ»‚¨‚æ‚ѐi“W‚Æ‚Æ‚à‚ɐS•s‘S‚̏oŒ»E‘mˆ«‚𗈂µ, S‘ŸÄ“¯Šú—Ö@‚ª’˜Œø‚µ‚½1—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  109. —é–؉ëm, ŽR“àNÆ, ‰ª“cŠ°”V, ‘O“c^Œá, “c”ö@i, ìè‚Ü‚èŽq, ‚’Ö­Žq, Œ´@M”Ž, “n•”^Œá, •ž•”‰p“ñ˜Y, ‹{–{‹M—f, ”ö—с@“O, ‹gè@², ÂÀ˜a—²: •p”­‚·‚é‰EŠ¥ë‹NŒ¹‚̐SŽº«ŠúŠOŽûk‚Å”­Ç‚µƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½SƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  110. ‰““¡GW, ¬£‘ãŽm‹v, ˆä“¡—tŽq, ’¬–ì@‹B, ŽR?@_, í‰ªG˜a, ¬àV^l, ŒÜ\—’@“s, ŠÖŒûK•v, šê“c@_, ÂÀ˜a—²: S“à–Œ, SŠO–ŒƒAƒvƒ[ƒ`‚É‚ÄŠ®‘SÄŽÜ‚ª¢“ï‚Å‚ ‚Á‚½¶Š¥“®–¬ŽåŠ²•”‹ß–T—R—ˆ‚̐SŽº•p”‚Ì1—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  111. ‚’Ö­Žq, ŽR“àNÆ, ‰ª“cŠ°”V, ‘O“c^Œá, “c”ö@i, ìè‚Ü‚èŽq, —é–؉ëm, Œ´@M”Ž, “n•”^Œá, •ž•”‰p“ñ˜Y, ‹{–{‹M—f, ”ö—с@“O, ˆé•”ŒõÍ, ÂÀ˜a—²: ƒAƒuƒŒ[ƒVƒ‡ƒ“‚̃Gƒ“ƒhƒ|ƒCƒ“ƒgŒˆ’è‚ɍ¢˜f‚µ‚½Œð‘㐫‹rƒuƒƒbƒN‚𔺂¤nonreentrant AV nodal tachycardia‚Ì1—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  112. ‘º‰zLs, ‹–@“ŒŸª, ŒÜ\—’@“s, ŠÖŒûK•v, šê“c@_, ÂÀ˜a—², •½ŽR@‹Å: ƒsƒIƒOƒŠƒ^ƒ]ƒ“‚ÍŽ_‰»ƒXƒgƒŒƒX‚ðŒyŒ¸‚µ, ‚—ƒbƒg‚É‚¨‚¯‚éS–[×“®‚ð—}§‚·‚éD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  113. ‹´–{F”V, ‹´ˆä°Žq, ŽR?@_, ŠÖŒûK•v, šê“c@_, ÂÀ˜a—², ‹´–{@—T, »ì˜a•F: ƒy[ƒXƒ[ƒJ[, ‚¨‚æ‚ѐAž‚ÝŒ^œ×“®Ší‚ɑ΂·‚é—zŽqüŽ¡—Ẩe‹¿•]‰¿ŽÀŒ±D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  114. ¬£‘ãŽm‹v, šê“c@_, ŠÖŒûK•v, ’¬–ì@‹B, ¬àV^l, ŽR?@_, ŒÜ\—’@“s, ‰““¡GW, ˆä“¡—tŽq, ÂÀ˜a—²: –«t‘Ÿ•a‚̍‡•¹‚ªS–[×“®‚ɑ΂·‚éƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚̐S–[×“®Ä”­‚É‹y‚Ú‚·‰e‹¿D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  115. óì“N–ç, ’†ì˜a–ç, ¼‘º‘‰À, ÷—с@‘Ï, ŽR“àNÆ, ÂÀ˜a—²: Crista Terminalis‚ª’ʏíŒ^S–[‘d“®‚Ìdominant pathway‚Å‚ ‚邱‚Æ‚ªŽ¦´‚³‚ꂽ2Ç—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  116. ‚’Ö­Žq, ‰ª“cŠ°”V, ŽR“àNÆ, ‘O“c^Œá, “c”ö@i, —é–؉ëm, Œ´@M”Ž, ìè‚Ü‚èŽq, “n•”^Œá, •ž•”‰p“ñ˜Y, ‹{–{‹M—f, ”ö—с@“O, ˆé•”ŒõÍ, ÂÀ˜a—²: Differential pacing‚Å‚ÍŠÓ•Ê‚Å‚«‚È‚¢‚Ù‚Ç‚Ì’˜–¼‚È“`“±’x‰„‚ð‹¬•”‚É”F‚ß‚½‹tù‰ñŒ^’ʏíŒ^S–[‘d“®‚Ì1—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  117. ìè‚Ü‚èŽq, ŽR“àÆN, ‰ª“cŠ°”V, ‘O“c^Œá, “c”ö@i, —é–؉ëm, ‚’Ö­Žq, Œ´@M”Ž, “n•”^Œá, •ž•”‰p“ñ˜Y, ‹{–{‹M—f, ”ö—с@“O, ‹gè@², ÂÀ˜a—²: ‘m–X•Ù—Ö‘O•Ç‚ƉEã”xÃ–¬ŠÔ‚̐üóÄŽÜ‚ɂčªŽ¡‚µ“¾‚½‘m–X•Ù—Ö‚ðù‰ñ‚·‚é”ñ’ʏíŒ^S–[‘d“®‚Ì2—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  118. í‰ªG˜a, šê“c@_, ˆä“¡—tŽq, ¬£‘ãŽm‹v, ’¬–ì@‹B, ŽR?@_, ¬àV^l, ŠÖŒûK•v, ÂÀ˜a—²: CRTƒfƒoƒCƒXŠ´õ‚Ì—\Œã‚ÆŠÇ—D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  119. ŽR?@_, šê“c@_, ŠÖŒûK•v, ŒÜ\—’@“s, •–ØŒ’Žu, ’¬–ì@‹B, ¬àV^l, ¬£‘ãŽm‹v, ˆä“¡—tŽq, ‹v‰êŒ\—S, ÂÀ˜a—²: “ñŽŸ«S‹ØÇ‚ɍ‡•¹‚µ‚½SŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚ÌŽ¡—ЬÑ|“Á”­«S‹ØÇ‚ɑ΂·‚鎡—ÂƂ̔äŠrŒŸ“¢|D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  120. ˆä“¡—tŽq, ‘º‰zLs, šê“c@_, ŠÖŒûK•v, ¬£‘ãŽm‹v, ŒÜ\—’@“s, ŽR?@_, ¬àV^l, ‰““¡GW, í‰ªG˜a, ’¬–ì@‹B, ÂÀ˜a—², ‹g“cŒ’‘¾˜Y: ’x‰„“dˆÊ‚̐f’f‚ɐSŽ¥}‚ª—L—p‚Å‚ ‚Á‚½•s®–¬Œ¹«‰EŽºS‹ØÇ‚̏ǗáD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  121. í‰ªG˜a, ŠÖŒûK•v, ¬£‘ãŽm‹v, ˆä“¡—tŽq, ŽR?@_, ‰““¡GW, ¬àV^l, ŒÜ\—’@“s, šê“c@_, £”ö—RL, ÂÀ˜a—²: ”­”M‚ªŒ´ˆö‚ÌQT‰„’·‚Ì‚æ‚éSŽº×“®‚ÅICD‚ª•p‰ñì“®‚µ‚½1—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  122. ¬àV^l, ŠÖŒûK•v, ¬£‘ãŽm‹v, ’¬–ì@‹B, ŽR?@_, ˆä“¡—tŽq, ‰““¡GW, ŒÜ\—’@“s, šê“c@_, ÂÀ˜a—²: ‚—îŽÒ‚̐S–[×“®Ç—á‚ɑ΂·‚éƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—L—p«‚ƈÀ‘S«D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  123. ‹´ˆä°Žq, ‹´–{F”V, ŽR?@_, ŠÖŒûK•v, šê“c@_, ÂÀ˜a—²: ƒy[ƒXƒ[ƒJ[“™‚̃fƒoƒCƒXAž‚ݏǗá‚ɑ΂·‚é—zŽqüŽ¡—Â̍ۂ̃NƒŠƒeƒBƒJƒ‹ƒpƒX‚̍쐬D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  124. ’¬–ì@‹B, ŠÖŒûK•v, šê“c@_, ¬£‘ãŽm‹v, ¬àV^l, ŽR?@_, ŒÜ\—’@“s, •–ØŒ’Žu, ‹v‰êŒ\—S, ÂÀ˜a—², ‡‰®‰ë•F, X@Œ’ì: Exima Laser‚É‚æ‚銴õƒfƒoƒCƒX‚Ì”²‹ŽŒã, ”ñŠ´õ‘¤‚©‚ç‚̃Š[ƒh‘}“ü‚ɍ½œ‰ºÃ–¬ƒoƒ‹[ƒ“Šg’£p‚ª•K—v‚Å‚ ‚Á‚½Ç—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  125. ”~’Á@“w, ˆÀ“‡—Ç‹PŽq, •ì‚Ý‚âŽq, “¡àVL‹g, ²“¡@Œc, k@‹±ˆê, ŽR?@_, ŠÖŒûK•v, šê“c@_, ÂÀ˜a—²: S‹ØƒŠ[ƒh—¯’uŽž‚É‚¨‚¯‚éunipolar“dˆÊ‚Ì—L—p«D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  126. “c”ö@i, ŽR“àNÆ, ‰ª“cŠ°”V, ‘O“c^Œá, ìè‚Ü‚èŽq, ‚’Ö­Žq, —é–؉ëm, Œ´@M”Ž, “n•”^Œá, •ž•”‰p“ñ˜Y, ‹{–{‹M—f, ”ö—с@“O, ˆé•”ŒõÍ, ÂÀ˜a—²: ”xÃ–¬Šu—£pŒã‚ɐ¶‚¶‚½4Ží—ނ̃}ƒNƒƒŠƒGƒ“ƒgƒŠ[«•p”‚ɑ΂µ‚ăJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½”­ì«S–[×“®‚Ì1—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  127. ‘O“c^Œá, ŽR“àNÆ, ‰ª“cŠ°”V, “c”ö@i, ìè‚Ü‚èŽq, —é–؉ëm, Œ´@M”Ž, ‚’Ö­Žq, “n•”^Œá, •ž•”‰p“ñ˜Y, ‹{–{‹M—f, ”ö—с@“O, ÂÀ˜a—², ˆé•”ŒõÍ: ‹ÇŠ“`“±ƒuƒƒbƒN‚𔺂¤¶˜r“ªÃ–¬’¼‰º‹NŒ¹‚̏ã‘åÃ–¬•p”‚ªŒ´ˆö‚Å‚ ‚Á‚½”­ì«S–[×“®‚Ì1—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  128. •–ØŒ’Žu, ‹v‰êŒ\—S, —§‰Ô–qŽq, “n•”_–¾, ˆä“¡—tŽq, ¬£‘ãŽm‹v, ’¬–ì@‹B, ŽR?@_, í‰ªG˜a, ¬àV^l, ŒÜ\—’@“s, ŠÖŒûK•v, šê“c@_, ÂÀ˜a—²: •s®–¬Œ¹«‰EŽºS‹ØÇ‚É”º‚¤d“xŽOë•Ù‹t—¬Çp‘O‚É’†SÃ–¬‚ɏœ×“®ƒŠ[ƒhˆÚAp‚ðŽ{s‚µ‚½1Ç—áD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  129. ²“¡@Œc, k@‹±ˆê, “¡àVL‹g, ”~’Á@“w, ÂÀ˜a—²: ƒGƒLƒVƒ}ƒŒ[ƒUS“àƒŠ[ƒh”²‹ŽƒVƒXƒeƒ€‚É‚¨‚¯‚éƒGƒLƒVƒ}ƒŒ[ƒUƒV[ƒXÆŽË‰º‚ł̃y[ƒXƒ[ƒJ[ƒŠ[ƒh‚ւ̉e‹¿D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  130. ”óŒûƒ‹ƒ~, šê“c@_, ‘º“c@½, •‘º’¼Ž÷, ²“¡ç’ß, —с@’BÆ, ŽOŽ÷—TŽq, â–{@—L: C³¶Žº[–žŽžŠÔiLVFTcj‚ð—p‚¢‚½ŽŠ“KAV delayiAVDj‚ÌŒŸ“¢D ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  131. ”óŒûƒ‹ƒ~, šê“c@_, ‘º“c@½, •‘º’¼Ž÷, ²“¡ç’ß, —с@’BÆ, ŽOŽ÷—TŽq, â–{@—L: PQŽžŠÔ, ‚¨‚æ‚яC³¶ŽºŠg’£Šú[–žŽžŠÔiLVFTcj‚͐S‘ŸÄ“¯Šú—Ö@iCRTj‚Ì“K‰žŒˆ’è‚É—L—p‚Å‚ ‚éD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi–¼ŒÃ‰®j6ŒŽ, 2010
  132. ¼@@Œ÷, “n•”_–¾, •–ØŒ’Žu, ˆäì¹K, ‰|–{‹­Žu, ”Ñ“c@—v, ¬ŠÖ@çŒ, £”ö—RL, ÂÀ˜a—²: Šg’£Œ^S‹ØÇ‚É‚æ‚éS•s‘S‚É‚¨‚¢‚Ä“à‰È–ò•¨—Ö@‚Ɖ^“®—Ö@‚𕹗p‚µ, Çó‰ü‘P‚µ‚½1Ç—áD ‘æ216‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2010
  133. ˆÀ’B@‹œ, ¬‘îN”V, ’·’Jì’q–¾, ŽR“àF‹`, ÂÀ˜a—²: Š¥¹k«‹·SÇ‚©‚çSŽº×“®‚𗈂½‚µ, ‘h¶‚ɐ¬Œ÷‚µ‚½1Ç—áD ‘æ216‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2010
  134. ¬“‡ŒcŽq, •¶åU—DŽq, t¬’q•F, ‹k@Œ«œA, Š|ŽD—YŠî, ¯@’q–ç, ŒË“c@’¼, m‰ÈG’, •½À‚ä‚è, –ìŒû—Sˆê, ÂÀ˜a—²: 10‘ã‚ŐSŽº×“®‚𔭏ǂµ‚½‹Ø‹­’¼«ƒWƒXƒgƒƒtƒB[‚Ì1—áD ‘æ216‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2010
  135. ”üè¹Žq, —é–ØŒ’Ži, ¬£‘ãŽm‹v, ÂÀ˜a—²: ‹ß”N‚̎Љï–â‘è‚ðÛ’¥‚·‚é‹r‹CS‚Ì2Ç—áD ‘æ216‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2010
  136. ¼“c—m—S, “n•Óds, HŽR‘åŽ÷, •“c—T‹v, ŠOŽR¹O, •½’J‘¾Œá, –؉ºŒ«•ã, ‘ŠàV“NŽj, ˜Ô“c’¼”ü, ã–{’¼–ç, ¬—Ñ—TK, “¿“cˆÀt, •½–ì@“Ä, ²“¡@–¾, ÂÀ˜a—²: ‘lèò•”‚æ‚è‘}“ü‚µ‚½‰ESƒJƒe‚̐Ö¬ƒV[ƒX‚ª‘¼‚̐Ö¬‚É–À“ü‚µ‚Ä‚¢‚邱‚Æ‚ª‚»‚Ì‘–s‚©‚ç‚ÍŠ´’mŽ¡•s”\‚¾‚Á‚½1—áD ‘æ216‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2010
  137. ¬“‡ŒcŽq, •¶åU—DŽq, t¬’q•F, Š|ŽD—YŠî, ‹k@Œ«œA, ¯@’q–ç, ŒË“c@’¼, m‰ÈG’, •½À‚ä‚è, –ìŒû—Sˆê, ÂÀ˜a—²: æ“V«‹Ø‹­’¼«ƒWƒXƒgƒƒtƒB[‚ÅŽá”NŠú‚ɉ^“®—U”­«SŽº«•s®–¬‚𔭏ǂµ‚½1—áD ‘æ216‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2010
  138. ‰H’¹Œõ°, ’†¼Œ[‘¾, ÎìŒöl, ‘O“c—TŽj, ¬¼‘׉î, ‘åâŠî’j, ¬Î‘ò³, ÂÀ˜a—²: ‹‘åƒoƒ‹ƒTƒ‹ƒo“´“®–¬áŽ‚É‚Ä”­Œ©‚³‚ꂽ‘½”­“®–¬áŽ‚Ì1—áD ‘æ216‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2010
  139. ¼“c—m—S, “n•Óds, HŽR‘åŽ÷, •“c—T‹v, ŠOŽR¹O, •½’J‘¾Œá, –؉ºŒ«•ã, ‘ŠàV“NŽj, ˜Ô“c’¼”ü, ã–{’¼–ç, ¬—Ñ—TK, “¿“cˆÀt, •½–ì@“Ä, ²“¡@–¾, ÂÀ˜a—²: ‘lŒa•”‚æ‚è‘}“ü‚µ‚½‰ESƒJƒe‚̐Ö¬ƒV[ƒX‚ª‘¼‚̐Ö¬‚É–À“ü‚µ‚Ä‚¢‚邱‚Æ‚ª‚»‚Ì‚»‚¤‚±‚¤‚©‚ç‚ÍŠ´’m•s”\‚Å‚ ‚Á‚½1—áD ‘æ216‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2010
  140. ¬Œ´Œ’ˆê, ì‘º@—´, ŠOŽR¹O, ÂÀ˜a—²: ‰ES–[“à‚Å•‚“®‚µ‚Ä‚¢‚錌ð‚ðSƒGƒR[‚ÅŽw“E‚Å‚«‚½”x“®–¬ŒŒðÇðÇ‚Ì1—áD ‘æ216‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2010
  141. ‹v‰êŒ\—S, ‘å’ː·’j, ÂÀ˜a—², —«@‰ï’†, “n•Ó®•F, ‘å’Ë–M–¾: Nifedipine coat-core‚Æ amlodipine ‚Ì“ú“à~ˆ³Œø‰Ê‚ɂ‚¢‚ÄABPM‚ð—p‚¢‚½’è—Ê“I‚È”äŠrŒ¤‹†D ‘æ12‰ñŽžŠÔzŠÂŒŒˆ³Œ¤‹†‰ïi“Œ‹žj7ŒŽ, 2010
  142. ˆ­”üˆÀ‹IŽq, –{ŠÔ@Šo, HŽR‘åŽ÷, –Ø‘º‘׎O, X–{—²Žj, ‰F–ìŠó¢Žq, ŠÛŽRG˜a, —é–؁@‹, —с@‘¾’q, Z“cF”V, ²“¡@–¾, £”ö—RL, ‰Í–ì@—¹, ÂÀ˜a—²: ƒGƒ|ƒvƒƒXƒeƒm[ƒ‹iƒtƒ[ƒ‰ƒ“j‚̍ݑ‘±“_“H—Ö@‚©‚ç—£’E‚µ‚½Ç—áD ‘æ11‰ñ”x‚ŒŒˆ³ÇŽ¡—ÃŒ¤‹†‰ïi“Œ‹žj6ŒŽ, 2010
  143. ‰Í–ì@—¹: “à‰Èˆã‚ÌŽ‹“_‚©‚çpŒãzŠÂŠÇ—‚ðl‚¦‚éD ‘æ19‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï“Œ–k’n•û‰ïiå‘äj7ŒŽ, 2010
  144. “cK˜aŽq, Žðˆä@r, ŠÛŽRG˜a, ²“¡@–¾, ‰ºžŠMˆÐ, Ä“¡@I, ‰““¡—DŽ}, ‘ŠŒ´‰p–¾, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: ‘¢‰eÜ‚É‚æ‚éŽ_‰»ƒXƒgƒŒƒX‚Æ‘¢‰eŒã–«Šú‚̐t‹@”\‚ÌŠÖŒW‚ɂ‚¢‚Ä‚ÌŒŸ“¢D t‚ƐSŒŒŠÇáŠQŒ¤‹†‰ïi“Œ‹žj7ŒŽ, 2010
  145. ƒWƒFƒXƒ~ƒ“ƒTƒuƒŠƒi, œA]“¹º, Šâ“ˆ‹`—Y, ‰ºžŠMˆÐ, ÂÀ˜a—²: “œ”A•a«S‹ØÇ‚ÌŠ¥”÷¬zŠÂáŠQ‚ƐS‹@”\áŠQ‚ɑ΂·‚épitavastatin‚ÌŒø‰Ê: in vivoŽÀŒ±‚É‚æ‚é•a‘Ô‰ðÍ‚Ɛ§Œä–@‚ÌŠJ”­D ‘æ56‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[i_ŒËj8ŒŽ, 2010
  146. ¯@’q–ç, m‰ÈG’, –ìŒû—Sˆê, •ˆÀ–@”V, ²“¡@–¾, ÂÀ˜a—²: ŒŒsÄŒšŒã‚ÌŠ¥“®–¬Ž¾Š³Š³ŽÒ‚É‚¨‚¯‚鎊“K“à‰ÈŽ¡—Â̌»ó‚Æ’·Šú—\Œã; ICASiIbaraki Cardiovascular Assessment Studyjregistry ‚ð—p‚¢‚Ä‚ÌŒŸ“¢D ‘æ56‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[i_ŒËj8ŒŽ, 2010
  147. ‰Í–ì@—¹, ˆÀ“c@v, ‰ºžŠMˆÐ, ¼–ìO•¶, ”‹’JŒ\ˆê, …’J‘¾˜Y, £”ö—RL, ÂÀ˜a—²: “«SŽº«•s®–¬‚ɑ΂·‚鉖Ž_ƒ‰ƒ“ƒWƒIƒ[ƒ‹‚ÌŒø‰ÊŒŸ“¢D ‘æ4‰ñˆïéŒ§ŽüpŠúzŠÂŠÇ—ƒZƒ~ƒi[i‚‚­‚΁j8ŒŽ, 2010
  148. ‹{@@Œ°, ‰Í–ì@—¹, ‰ºžŠMˆÐ, ”‹’JŒ\ˆê, ¼–ìO•¶, ˆÀ“c@v, ‚‹´L“ñ, …’J‘¾˜Y, Î’Ã’qŽq: ––½«”x“®–¬‹·óÇ‚É‚æ‚é”x‚ŒŒˆ³‚ª”DP‚É‚æ‚è‹}«‘ˆ«‚µ‚½Ç—áD ‘æ19‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj8ŒŽ, 2010
  149. Hoshi T, Nishina H, Tachibana T, Harimura Y, Tsukiori N, Toda S, Hiranuma Y, Fumikura Y, Noguchi Y, Sato A, Aonuma K: Favorable mid-term Outcome of Crossover to Paclitaxel-Eluting Stent Restenosis. ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  150. Š|ŽD—YŠî, ²“¡@–¾, ¬“‡‰hŽ¡, ¬£‘ãŽm‹v, ¯@’q–ç, m‰ÈG’, •ˆÀ–@”V, –ìŒû—Sˆê, ÂÀ˜a—²: DES‚¨‚æ‚ÑBMS‚ð—p‚¢‚ÄŽ¡—µ‚½‹}«Š¥ÇŒóŒQ‚É‚¨‚¯‚éƒXƒeƒ“ƒgŒŒðÇ‚Ì’·Šú—\Œã‚̉ðÍD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  151. ¬“‡‰hŽ¡, ²“¡@–¾, Š|ŽD—YŠî, •ˆÀ–@”V, ‘O“c—TŽj, –ìŒû—Sˆê, ÂÀ˜a—²: 64—ñŠ¥“®–¬CT‚ð—p‚¢‚Ä•]‰¿‚³‚ꂽ–«t‘Ÿ•a‚ªŠ¥“®–¬d‰»‚É—^‚¦‚é‰e‹¿D ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  152. “n•”_–¾, ²“¡@–¾, —с@^—R, HŽR‘åŽ÷, —§‰Ô–qŽq, ˆ­”üˆÀ‹IŽq, ŽR–{¹—Ç, j‘º‰À], í‰ªG˜a, ‘º‰zLs, £”ö—RL, ÂÀ˜a—²: LAD‹ßˆÊ•”‚©‚çLMT‚É‚©‚¯‚Ä’E—Ž‚µL‚Ñ‚«‚Á‚½EndeavorƒXƒeƒ“ƒg‚ðbail out‚µ‚½1—áD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  153. œA£r•ã, –ì—¢ŽõŽj, ²“¡@–¾, ŒÃ‰YŒ«“ñ, ìŒû’¼•F, ’†“‡‰i”üŽq, “¡”g—³–ç, ‹v²–ÎŽ÷, ãÎ“N¶, ‘吼Œ’‘¾˜Y, ‚‹´—ljp, ŒKŒ´‘åŽu, •D“c_”V, ‚‹´@~, ˆé•”ŒõÍ: EVT‚ðs‚Á‚½BK•a•Ï‚É‚æ‚éCLIŠ³ŽÒ‚Ì’·Šú—\ŒãD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  154. –ì—¢ŽõŽj, ²“¡@–¾, œA£r•ã, ŒÃ‰YŒ«“ñ, ìŒû’¼•F, ’†“‡‰i”üŽq, “¡”g—³–ç, ‹v²–ÎŽ÷, ãÎ“N¶, ‘吼Œ’‘¾˜Y, ‚‹´—ljp, ŒKŒ´‘åŽu, •D“c_”V, ‚‹´@~, ˆé•”ŒõÍ: –òÜ’ïR«‚ŒŒˆ³‚Ì“§ÍŠ³ŽÒ‚ÉPTRAS‚ðŽ{s‚µ, ŒŒˆ³ƒRƒ“ƒgƒ[ƒ‹‚ª‰ü‘P‚µ‚½‚P—áD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  155. –ì—¢ŽõŽj, ²“¡@–¾, œA£r•ã, ŒÃ‰YŒ«“ñ, ‰iˆä@’¼, •“cr‰î, ìŒû’¼•F, ’†“‡‰i”üŽq, “¡”g—³–ç, ‹v²–ÎŽ÷, ãÎ“N¶, ‘吼Œ’‘¾˜Y, ‚‹´—ljp, ŒKŒ´‘åŽu, •D“c_”V, ‚‹´@~, ˆé•”ŒõÍ: Corsair‚ª—LŒø‚Å‚ ‚Á‚½‚“xÎŠD‰»•a•Ï‚Ì1—áD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  156. –ì—¢ŽõŽj, ²“¡@–¾, œA£r•ã, ŒÃ‰YŒ«“ñ, ‰iˆä@’¼, •“cr‰î, ìŒû’¼•F, ’†“‡‰i”üŽq, “¡”g—³–ç, ‹v²–ÎŽ÷, ãÎ“N¶, ‘吼Œ’‘¾˜Y, ‚‹´—ljp, ŒKŒ´‘åŽu, •D“c_”V, ‚‹´@~,ˆé•”ŒõÍ: ‰ºŽˆ•ÂÇ«“®–¬d‰»Ç‚ɑ΂·‚錌ŠÇ“àŽ¡—Âðs‚Á‚½“§ÍŠ³ŽÒ‚ÌŒŒˆ³ŠÇ—‚͍אS‚Ì’ˆÓ‚ª•K—v‚Å‚ ‚éD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  157. •D“c_”V, ²“¡@–¾, •“cr‰î, ìŒû’¼•F, ’†“‡‰i”üŽq, ŒÃ‰YŒ«“ñ, œA£r•ã, ‹v²–ÎŽ÷, ãÎ“N¶, ‘吼Œ’‘¾˜Y, ˆé•”ŒõÍ, ‚‹´@~: TIMIƒtƒŒƒCƒ€ƒJƒEƒ“ƒg‚ÆQCA‚ð‘g‚ݍ‡‚킹‚ÄŽZo‚µ‚½Š¥“®–¬ŒŒ—¬‘¬“x‚͍Ċҗ¬Œã‚Ì‹}«S‹Ø[ÇÇ—á‚Ì‹@”\‰ñ•œ‚ð—\‘ª‚·‚éD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  158. ¯@’q–ç, m‰ÈG’, ‹k@Œ«œA, j‘º‰À], ŒŽ‰ªLŽq, ‘½“c@’¼, •¶‘ —DŽq, •½À‚ä‚è, –ìŒû—Sˆê, ²“¡@–¾, ÂÀ˜a—²: ƒVƒƒŠƒ€ƒX—no«ƒXƒeƒ“‚ƍċ·ó‚ɑ΂·‚éƒpƒNƒŠƒ^ƒNƒZƒ‹—no«ƒXƒeƒ“ƒg—¯’u‚ÌŒø‰ÊD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  159. k@‹±ˆê, Ô¯”Ž˜a, ²“¡@Œc, ìã@N, ²“¡@–¾, ÂÀ˜a—²: OCTŽ{sŽž‚ɉ•ώ®‘¢‰eÜ’“üƒVƒXƒeƒ€‚ð—˜—p‚µ‚½ƒtƒ‰ƒbƒVƒ…–@‚ł̉摜f’f•]‰¿‚ɂ‚¢‚āD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  160. ²“¡@–¾: Š¥“®–¬Ž¾Š³‚Ì”ñNP“If’f‚É’u‚¯‚銥“®–¬CT‚Æ•‰‰×S‹ØƒVƒ“ƒ`‚Ì—L—p«iSymposiumjD ‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiå‘äj8ŒŽ, 2010
  161. £”ö—RL, Î’Ã’qŽq, ÂÀ˜a—²: ¶Žº‹ÇŠ‹@”\•]‰¿‚Ì—L—p«D ‘æ58‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2010
  162. Î’Ã’qŽq, £”ö—RL, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: –«Š¥“®–¬Ž¾Š³Ç—á‚Ì—\Œã„’è‚É‚¨‚¯‚éCRP‚Æèò“®–¬ƒvƒ‰[ƒN‰æ‘œ•]‰¿‚Ì—L—p«D ‘æ58‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2010
  163. âŠª•¶Žq, £”ö—RL, ”Ñ“c“TŽq, ’†“‡GŽ÷, ˆ­”üˆÀ‹IŽq, ŽR–{¹—Ç, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, ‰|–{^”ü, Î’Ã’qŽq, ÂÀ˜a—²: CRTƒŒƒXƒ|ƒ“ƒ_[—\‘ª‚É‚¨‚¯‚é‘gDƒhƒvƒ‰‚¨‚æ‚ÑMƒ‚[ƒh–@‚ð—p‚¢‚½Žw•W‚Ì—L—p«D ‘æ58‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2010
  164. ˆ­”üˆÀ‹IŽq, Î’Ã’qŽq, ŽR–{¹—Ç, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, ‰|–{^”ü, ŠÖŒûK•v, šê“c@_, £”ö—RL, ÂÀ˜a—²: •s®–¬Œ´«‰EŽºS‹ØÇ‚É‚¨‚¯‚é3DƒGƒR[–@‚ƐV“à–Œ–Ê“dˆÊ•ª•z‚Æ‚Ì”äŠrD ‘æ58‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2010
  165. £”ö—RL, Î’Ã’qŽq, ”nê‰ëŽq, ²“¡@–¾, ÂÀ˜a—²: ‰–Ž_ƒTƒ‹ƒ|ƒOƒŒƒ‰[ƒg‚É‚æ‚錌ŠÇ“à”ç‹@”\‰ü‘P‚¨‚æ‚Ñ“®–¬d‰»‘ޏkŒø‰Ê‚ÉŠÖ‚·‚錟“¢D ‘æ58‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2010
  166. ”nê‰ëŽq, £”ö—RL, —с@^—R, ˆÀ•”‘å•ã, —é–؏ˎi, •ˆÀ–@”V, Î’Ã’qŽq, ²“¡ŽnL, ÂÀ˜a—²: 18F-FDG PET/CT‚ð—p‚¢‚½–³ÇŒó«Š³ŽÒ‚Ìèò“®–¬d‰»•a•Ï‚Ì•]‰¿D ‘æ58‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2010
  167. ”Ñ“c“TŽq, £”ö—RL, âŠª•¶Žq, ’†“‡GŽ÷, ˆ­”üˆÀ‹IŽq, ŽR–{¹—Ç, j‘º‰À], ’¬–ì’qŽq, ì‘º@—´, ‰|–{^”ü, Î’Ã’qŽq, ÂÀ˜a—²: ‘ž–X•Ù•Â½•s‘SÇ‚Æ‘å“®–¬•Ù•Â½•s‘SÇ‚É‚¨‚¯‚鍶Žº•ÇƒXƒgƒŒƒCƒ“•ª•z‚ƕljž—Í‚ÌŠÖŒWD ‘æ58‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2010
  168. “n•”_–¾, ˆäì¹K, •–ØŒ’Žu, ¼@@Œ÷, ‰|–{‹­Žu, ÂÀ˜a—²: ƒGƒsƒlƒtƒŠƒ““Y•tƒK[ƒ[‚Ì•@o“à‘}“üŒã‚ɐSŽº×“®‚𗈂µ‚½ICDAž‚ÝŠ³ŽÒ‚Ì1—áD ‘æ217‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2010
  169. ˆ­”üˆÀ‹IŽq, £”ö—RL, Î’Ã’qŽq, ‰Í–ì@—¹, ÂÀ˜a—²: S•s‘S”­Ç‚ðŒ_‹@‚ÉŠŒF×–EŽî‚Æ”»’f‚³‚ê, ŠŒF×–EŽîpŒã‚à’áS‹@”\‚ª‘J‰„‚µ‚½ƒJƒeƒRƒ‰ƒ~ƒ“S‹ØÇ‚Ì1—áD ‘æ217‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2010
  170. £”ö—RL: ¶Žº‹ÇŠ‹@”\•]‰¿‚Ì—L—p«@SƒGƒR[f’f‚̍őOü“¢@ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“D ‘æ58‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2010
  171. Žðˆä@r, ’†ì@‰Ã, ‰ºžŠMˆÐ, ÎŠ_’¼”ü, ÂÀ˜a—², “‡–ì@m: S‹ØáŠQ‚ɑ΂·‚鎉Ž¿“]ŽÊ’²ßˆöŽqSREBP-1‚Ì–ðŠ„‚Ì‰ð–¾D ‘æ1‰ñ Molecular Cardiovascular Conference IIi–kŠC“¹j9ŒŽ, 2010
  172. £”ö—RL: Results from J-CRT. ‘æ14‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi“Œ‹žj10ŒŽ, 2010
  173. £”ö—RL: S•s‘S‚̃fƒoƒCƒX‚É‚æ‚鎡—Á@J-CRT‚ɂ‚¢‚ā@ƒVƒ“ƒ|ƒWƒEƒ€D ‘æ14‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi“Œ‹žj10ŒŽ, 2010
  174. ŒÜ\—’@“s, šê“c@_, ŠÖŒûK•v, ‹g“cŒ’‘¾˜Y, ŽRè@_, ’¬–ì@‹B, •–ØŒ’Žu, ¬£‘ãŽm‹v, ˆä“¡—tŽq, ‹v‰êŒ\—S, ÂÀ˜a—²: ’áS‹@”\‚Ì–«S–[×“®Ç—á‚É‚¨‚¯‚é–ò•¨—Ö@E’¼—¬’Ê“d‚É‚æ‚é“´’²—¥‰»‚̐S‹@”\‰ü‘P‚ƃAƒuƒŒ[ƒVƒ‡ƒ“Œã‚Ì—\Œã‚ÉŠÖ‚·‚éŒø‰ÊD ‘æ27‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi‘啪j10ŒŽ, 2010
  175. ŽRè@_, šê“c@_, ŠÖŒûK•v, ‹g“cŒ’‘¾˜Y, ŒÜ\—’@“s, •–ØŒ’Žu, ’¬–ì@‹B, ¬£‘ãŽm‹v, ’†–ìŒb”ü, ˆä“¡—tŽq, ‹v‰êŒ\—S, ÂÀ˜a—²: SŽº3“_ƒy[ƒVƒ“ƒO‚É‚æ‚éS‘ŸÄ“¯Šú—Ö@‚Ì‹}«ŠúŒø‰Ê—\‘ªˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢D ‘æ27‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi‘啪j10ŒŽ, 2010
  176. ”~’Á@“w, ˆÀ“‡—Ç‹PŽq, •ì‚Ý‚âŽq, “¡àVL‹g, k@‹±ˆê, ²“¡@Œc, ŽRè@_, ŠÖŒûK•v, šê“c@_, ÂÀ˜a—²: “–‰@ƒJƒe[ƒeƒ‹Žº, “d‹C¶—Šw“IŒŸ¸, Ž¡—Ðê–åƒi[ƒX‚É‚æ‚éƒfƒBƒoƒCƒXŽ¡—ÊǗŠÅŒìŽtÝ—§‚Ö‚ÌŽæ‚è‘g‚݁D ‘æ27‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi‘啪j10ŒŽ, 2010
  177. ¬£‘ãŽm‹v, ŠÖŒûK•v, šê“c@_, ’¬–ì@‹B, ŽRè@_, ŒÜ\—’@“s, •–ØŒ’Žu, ˆä“¡—tŽq, ’†–ìŒb”ü, ‹àé‹MŽm, ÂÀ˜a—²: SƒTƒ‹ƒRƒCƒh[ƒVƒXŠ³ŽÒ‚ɍ‡•¹‚µ‚½SŽº•p”‚Ì“d‹C¶—Šw“I“Á’¥D ‘æ27‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi‘啪j10ŒŽ, 2010
  178. ²“¡@Œc, Ô¯”Ž˜a, k@‹±ˆê, ˆÀ“‡—Ç‹PŽq, ”~’Á@“w, ìã@N, ÂÀ˜a—²: ƒtƒNƒ_“dŽqŽÐ»S‘Ÿ“d‹CŽhŒƒ‘•’uBC-1100‚Ì—L—p«‚ɂ‚¢‚āD ‘æ27‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi‘啪j10ŒŽ, 2010
  179. ‘O“c^Œá, ŽR“àNÆ, ‰ª“cŠ°”V, “c”ö@i, ìè‚Ü‚èŽq, —é–؉ëm, Œ®ŽR’¨”V, Œ´@M”Ž, “n•”^Œá, •ž•”‰p“ñ˜Y, ‹{–{‹M—f, ”ö—с@“O, ÂÀ˜a—², ˆé•”ŒõÍ: ‰E–[|ã‘åÃ–¬Ú‡•”‚©‚ç5cmˆÈãã•û‚É‹NŒ¹‚ð‚à‚¿, ã‘åÃ–¬‹ÇŠ“`“±ƒuƒƒbƒN‚𔺂Á‚½ã‘åÃ–¬•p”4Ç—á‚ÌŒŸ“¢D ‘æ27‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi‘啪j10ŒŽ, 2010
  180. ’†–ìŒb”ü, šê“c@_, ŠÖŒûK•v, ’¬–ì@‹B, ŽRè@_, ŒÜ\—’@“s, •–ØŒ’Žu, ¬£‘ãŽm‹v, ˆä“¡—tŽq, ‹àé‹MŽm, ÂÀ˜a—², Œ´“c’q—Y, •›“‡‹žŽq, —é–Ø•¶’j: Micro-reentry‹@˜‚𐄒肵‚½”xÃ–¬Šu—£pŒã¶–[”xÃ–¬Ú‡•”•p”‚Ì1—áD ‘æ27‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi‘啪j10ŒŽ, 2010
  181. £”ö—RL: S‘ŸÄ“¯Šú—Ö@@‘Ì•\S“d}‚ƍ¶Žº‹@ŠB“I”ñ“¯Šú‚ɂ‚¢‚ā@ƒVƒ“ƒ|ƒWƒEƒ€D ‘æ27‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi‘啪j10ŒŽ, 2010
  182. ˆÀ“c@v, …’J‘¾˜Y, ‰Í–ì@—¹, ‰ºžŠMˆÐ, ¼–ìO•¶, ”‹’JŒ\ˆê: ‘å•a‰@‚É‚¨‚¯‚é“ñ‘Š«Žè“®Ž®œ×“®ŠíXVŽž‚Ì“K³”z’uŒŸ“¢D ‘æ38‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žj10ŒŽ, 2010
  183. ìè‚Ü‚èŽq, ŽR“àNÆ, ‰ª“cŠ°”V, ‘O“c^Œá, “c”ö@i, Œ®ŽR’¨”V, —é–؉ëm, Œ´@M”Ž, “n•”^Œá, •ž•”‰p“ñ˜Y, ‹{–{‹M—f, ”ö—с@“O, –I’J@m, •½”öŒ©ŽO, ˆé•”ŒõÍ, ÂÀ˜a—²: ATP—U”­«‚̉ESŽ¨‹NŒ¹”­ì«S–[×“®‚Ì1—áD ‘æ22‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi“Œ‹žj10ŒŽ, 2010
  184. ŠŒ´Œ˜‘¾, ’†–ì—R‹IŽq, “¡Œ´@•‘, Œ³“ceÍ, “¿ŽRäm, ¼ŠyŒ°“T, –Š“c—SŽq, ¬“c@“o, –ØŒ´NŽ÷, ŠÖŒûK•v, ÂÀ˜a—²: Coronary sinus“à‚Ìmyocardial sleeve‚ª•p”‚Ì”­º‚Ɛ¬Œ÷’Ê“d•”ˆÊ‚̑啝‚ȃVƒtƒg‚ÉŠÖ—^‚µ‚Ä‚¢‚½‚ƍl‚¦‚ç‚ꂽS–[•p”‚Ì1—áD ‘æ22‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi“Œ‹žj10ŒŽ, 2010
  185. •–ØŒ’Žu,ˆäì¹K, šê“c@_, ŠÖŒûK•v, ž­“c–[‹I, ŽRè@_, ŒÜ\—’@“s, ¬£‘ãŽm‹v, ’¬–ì@‹B, ˆä“¡—tŽq, í‰ªG˜a, ‹g“cŒ’‘¾˜Y, ‹v‰êŒ\—S, ÂÀ˜a—²: Vein of MarshalliVOMj“à, ‚¨‚æ‚э¶–[S“à–Œ‘¤‚©‚ç‚Ì’Ê“d‚ōªŽ¡‚µ‚½VOM‹NŒ¹Ž‘±«S–[•p”‚Ì1—áD ‘æ22‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi“Œ‹žj10ŒŽ, 2010
  186. óì“N–ç, ’†ì˜a–ç, Ž“c“NŽi, ¼‘º‘‰À, ÷—с@‘Ï, ŽR“àNÆ, ÂÀ˜a—²: Crista terminalis‚ª’ʏíŒ^S–[‘e“®‚Ìdominant path-way‚Å‚ ‚邱‚Æ‚ªŽ¦´‚³‚ꂽ1—áD ‘æ22‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi“Œ‹žj10ŒŽ, 2010
  187. “¿ŽRäm, ’†–ì—R‹IŽq, ¬“c@“o, –Š“c—SŽq, ¼žÙŒ°“T, ŠŒ´Œ˜‘¾, Œ³“ceÍ, “¡Œ´@•‘, –ØŒ´NŽ÷, ŠÖŒûK•v, ÂÀ˜a—²: ‘Ì•\–ʐS“d}‚©‚ç‰EŽº—¬o˜H‹NŒ¹‚ªl‚¦‚ç‚ꂽ“Á”­«VT‚ɑ΂µ‚Ä‘å“®–¬Š¥ë‚©‚ç‚̏Ď܂ōªŽ¡‚µ“¾‚½1—áD ‘æ22‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi“Œ‹žj10ŒŽ, 2010
  188. ™]@ª, ‹v‰êŒ\—S, ²X–ØŒb—, ŽR“cŒ\‰î: zŠÂŠíŠO—ˆ‚É‚¨‚¯‚鎩—¥ŒP—û–@‚Ì“±“ü‚ÌŽŽ‚݁|‘æˆê•ñ|D ‘æ33‰ñ“ú–{Ž©—¥ŒP—ûŠw‰ïiŒä“aêj10ŒŽ, 2010
  189. £”ö—RL: ¶ŽºE¶–[‚Ì—eÏŒv‘ª@Mƒ‚[ƒh, ’f‘w–@VSƒVƒ“ƒvƒ\ƒ“–@E3D–@iƒfƒBƒx[ƒgƒQ[ƒ€jD “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ22‰ñŠwpW‰ïi“Œ‹žj10ŒŽ, 2010
  190. Î’Ã’qŽq: ¶Žº•Ç‰^“®•]‰¿, ‚ ‚È‚½‚͍¡‚Å‚à“÷Šá‚Å‚·‚©Hiƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[jD “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ22‰ñŠwpW‰ïi“Œ‹žj10ŒŽ, 2010
  191. ›–쏺Œ›, ŽR–{¹—Ç, Î’Ã’qŽq, £”ö—RL, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ŽðŠª•¶Žq, ÂÀ˜a—²: ‹r‹CS‚Ì3—áD “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ22‰ñŠwpW‰ïi“Œ‹žj10ŒŽ, 2010
  192. ŽR–{¹—Ç, Î’Ã’qŽq, ˜’Ë—Ú”ü, ›–쏺Œ›, ’†“‡‰pŽ÷, ŽðŠª•¶Žq, ”Ñ“c“TŽq, £”ö—RL, ÂÀ˜a—²: ¶Žº“à‚ɐS‹Ø‰ð—£‚ðŽv‚킹‚éƒtƒ‰ƒbƒv—l\‘¢•¨‚ð”F‚ß‚½1—áD “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ22‰ñŠwpW‰ïi“Œ‹žj10ŒŽ, 2010
  193. šê“c@_: S–[×“®‚ÌŽ¡—ÂƊǗ|–ò•¨Ž¡—ÁD ‘æ47‰ñ“ú–{—Տ°¶—Šw‰ï‘‰ïiŒQ”nj11ŒŽ, 2010
  194. –ìã‡Žq, –ìã‰ÀŒb, ¬ŒËäh, éˍ◲ˆê: Œ’í•ÂŒo—«‚É‚¨‚¯‚é—LŽ_‘f‰^“®Žž‚¨‚æ‚щñ•œŠú‚ÌŒŒˆ³‚Æ“®–¬–¬”g“`”d‘¬“x‚Æ‚ÌŠÖŒWD 21‰ñ“ú–{—Տ°ƒXƒ|[ƒcˆãŠw‰ïŠwpW‰ïi‚‚­‚΁j11ŒŽ, 2010
  195. Š|ŽD—YŠî, ²“¡@–¾, ÂÀ˜a—²: B cell lymphoblastic leukemia‚Ì1—áD ‘æ5‰ñ “Œ‹žS‘Ÿ•a—ƒtƒH[ƒ‰ƒ€i“Œ‹žj11ŒŽ, 2010
  196. ŽRè@_, šê“c@_, ŠÖŒûK•v, ‹g“cŒ’‘¾˜Y, ŒÜ\—’@“s, Î’Ã’qŽq, £”ö—RL, ÂÀ˜a—²: SŽº3“_ƒy[ƒVƒ“ƒO–@‚Ì‹}«Œø‰Ê ‚È‚ç‚тɃŒƒXƒ|ƒ“ƒ_[‚Ì“Á’¥D ‘æ8‰ñƒI[ƒ^ƒ€zŠÂŠíƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi“Œ‹žj11ŒŽ, 2010
  197. ¯@’q–ç, t¬’q•F, m‰ÈG’, ‹k@Œ«œA, j‘º‰À], ‚”¨MŽq, ŒË“c@’¼, •¶åU—DŽq, •½À‚ä‚è, –ìŒû—Sˆê, “à“c@‰·, ‹e’n˜a“¿, ¡…—¬’q_, ¼èŠ°“ñ, Ž²‰®’qº, ‹g“cˆè—Y, ‰““¡—DŽ}, ÂÀ˜a—²: S•s‘S‚É‚Ä”­Ç‚µ‚½”~“Ő«‘å“®–¬‰Š‚̈ê—áD ‘æ18‰ñˆïézŠÂŠíŒ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2010
  198. Š|ŽD—YŠî, ²“¡@–¾, ¬“‡‰hŽ¡, ˆ­”üˆÀ‹IŽq, ‘º‰zLs, £”ö—RL, ÂÀ˜a—²: Paclitaxel-eluting stent—¯’u1”NŒã‚̐V¶“à–ŒŒ`¬‚ɂ‚¢‚ÄŒŒŠÇ“àŽ‹‹¾‚ð—p‚¢‚ÄŠÏŽ@‚µ“¾‚½1—áD ‘æ6‰ñˆïéŒ§“슥Ž¾Š³Œ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2010
  199. ì‘º@—´, Î’Ã’qŽq, £”ö—RL: Vector Flow Mapping–@‚É‚æ‚鍶Žº“à‚̉Q—¬‚ÆŒŒðŒ`¬‚ÉŠÖ‚·‚錟“¢D ‘æ33‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj12ŒŽ, 2010
  200. ŽR–{¹—Ç, Î’Ã’qŽq, £”ö—RL, ÂÀ˜a—², ’†“‡‰pŽ÷, âŠª•¶Žq, ”Ñ“c“TŽq, ŽRŒû“Nl: VŒ^ƒCƒ“ƒtƒ‹ƒGƒ“ƒUŠ´õŒã‚ɐS‹Ø‰~‚Æ‘½”­‹Ø‰Š‚𔭏ǂµ‚½1—áD ‘æ218‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj12ŒŽ, 2010
  201. ŽR?@_, šê“c@_, ŠÖŒûK•v, ÂÀ˜a—²: Ž¸_‚ðŒ_‹@‚É”­Œ©‚³‚ꂽ•s®–¬Œ¹«‰EŽºS‹ØÇ—ÞŽ—•a‘Ô‚ð’悵‚½‘Sg«‹­”çÇ‚Ì1—áD ‘æ23‰ñS‘Ÿ«‹}Ž€Œ¤‹†‰ïi“Œ‹žj12ŒŽ, 2010
  202. ‚Šâ@—R, ŒË“c@’¼, ‚”¨MŽq, t¬’q•F, ‹k@Œ«œA, j‘º‰À], ¯@’q–ç, •¶åU—DŽq, m‰ÈG’, •½À‚ä‚è, –ìŒû—Sˆê, ÂÀ˜a—²: ‰‰ñ•p””­ì‚ŃVƒ‡ƒbƒNó‘Ô‚Å”À‘—‚³‚ꂽWPWÇŒóŒQ‚̈ê—áD ‘æ577‰ñ“ú–{“à‰ÈŠw‰ïŠÖ“Œ’n•û‰ïi“Œ‹žj12ŒŽ, 2010
  203. –Ø‘º‘׎O, ²“¡@–¾, ÂÀ˜a—²: ‘å“®–¬áŽ•ªŽq•a‘Ô‚É‚¨‚¯‚é×–EŠOƒ}ƒgƒŠƒbƒNƒXƒeƒlƒCƒVƒ“C‚Ì–ðŠ„‚Ì‰ð–¾D ‘æ5‰ñ ‚ŒŒˆ³‚ÆŠ¥“®–¬Ž¾Š³Œ¤‹†‰ïi“Œ‹žj12ŒŽ, 2010

@@@¡ ‚»‚Ì‘¼

  1. ÂÀ˜a—²: S–[×“®Ž¡—Âƃ[ƒtƒ@ƒŠƒ“‚Ì“úíŠÇ—D ‘æ2‰ñˆïéŒ§•s®–¬Total management Semineri‚‚­‚΁j1ŒŽ, 2010
  2. £”ö—RL: èò“®–¬ƒGƒR[‚É‚æ‚é“®–¬d‰»Ç”»’èD Œ‹éˆãŽt‰ïŠwpu‰‰‰ïiŒ‹éj1ŒŽ, 2010
  3. £”ö—RL: CRT‚É‚¨‚¯‚éSƒGƒR[–@‚ɂ‚¢‚āD ƒZƒ“ƒgƒWƒ…[ƒhƒƒfƒBƒJƒ‹ŽÐCRTuK‰ïi“Œ‹žj1ŒŽ, 2010
  4. £”ö—RL: ƒŒƒjƒ“ƒAƒ“ƒMƒIƒeƒ“ƒVƒ“Œn‘jŠQ–ò‚É‚æ‚鍂ŒŒˆ³Ž¡—ÂÆARB‡Ü‚ÌŽg—pŒoŒ±‚ɂ‚¢‚āD ˆïéŒ§–òÜŽt‰ïŒÃ‰ÍŽx•”Œ¤C‰ïiŒÃ‰Íj1ŒŽ, 2010
  5. £”ö—RL: I-HATŠT—v‚ɂ‚¢‚āD ‘æ130‰ñ‚‚­‚ΗՏ°Œ¤‹†‰ïi‚‚­‚΁j2ŒŽ, 2010
  6. ‹v‰êŒ\—S: S–[×“® Case PresentationD ‘æ5‰ñˆïéS‘ŸƒtƒH[ƒ‰ƒ€i…ŒËj2ŒŽ, 2010
  7. £”ö—RL: Šg’£•s‘SS‚ɂ‚¢‚āD “ú»…ŒË•a‰@u‰‰‰ïi‚Ђ½‚¿‚È‚©j3ŒŽ, 2010
  8. Î’Ã’qŽq: Š¥“®–¬Ž¾Š³Ç—á‚É‚¨‚¯‚éèò“®–¬ƒGƒR[–@‚̈Ӌ`D ’}”gŒŒŠÇƒGƒR[f’fƒZƒ~ƒi[èò“®–¬•Òi‚‚­‚΁j3ŒŽ, 2010
  9. £”ö—RL: èò“®–¬ƒGƒR[‚É‚æ‚é“®–¬d‰»Ç”»’èD ŽOŽŸˆãŽt‰ïŠwpu‰‰‰ïiL“‡j4ŒŽ, 2010
  10. £”ö—RL: S•s‘SŠÇ—‚É‚¨‚¯‚éSƒGƒR[–@‚Ì—L—p«D ’}”gƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[•a‰@ŒöŠJƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‚‚­‚΁j5ŒŽ, 2010
  11. ‰Í–ì@—¹: ACS‚ɂ‚¢‚Ä‚ÌŠî‘b“I’mŽ¯D Nurse2010ˆïéEƒi[ƒX‚Ì‚½‚߂̉©‹àTŠÔi‚‚­‚΁j5ŒŽ, 2010
  12. ‰Í–ì@—¹: W’†Ž¡—×̈æ‚É‚¨‚¯‚é•s®–¬‚ÌŽ¡—Á|zŠÂŠí“à‰Èˆã‚ÌŽ‹“_‚©‚ç|D “¿“‡‘åŠw Á‰»ŠíEˆÚAŠO‰ÈŠwpu‰‰‰ïi“¿“‡j5ŒŽ, 2010
  13. £”ö—RL: Dyssynchrony‚ƍē¯Šú—Ö@‚ð‚ß‚®‚éV‚½‚È“WŠJ@‘“à‘½Ž{ÝŒ¤‹†‚ÌŒ»óD ‘æ21‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïiŽD–yj5ŒŽ, 2010
  14. Î’Ã’qŽq: ƒŠƒAƒ‹ƒ^ƒCƒ€3DSƒGƒR[‚Ì“ž’B“_@S‹@”\Œv‘ª‚É‚¨‚¯‚éˆÓ‹`D ‘æ21‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïiŽD–yj5ŒŽ, 2010
  15. £”ö—RL: ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚Æ’´‰¹”g@J-CRT‚©‚çÄl‚·‚é@ƒ[ƒNƒVƒ‡ƒbƒvD ‘æ83‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‹ž“sj5ŒŽ, 2010
  16. £”ö—RL: ŽOŽŸŒ³’´‰¹”gf’f‚̍őOü@¶SŽ¨ŒŒðŒ`¬‚ÉŠÖ˜A‚µ‚½¶SŽ¨\‘¢‚ÌŒŸ“¢@ƒVƒ“ƒ|ƒWƒEƒ€D ‘æ83‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‹ž“sj5ŒŽ, 2010
  17. ÂÀ˜a—²: S–[×“®‚Ì”ñ–ò•¨—Ö@|‚»‚Ì—LŒø«‚ÆŒÀŠE|D ‘æ26‰ñŽRŒ`•s®–¬Œ¤‹†‰ïiŽRŒ`j6ŒŽ, 2010
  18. ÂÀ˜a—²: S–[×“®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ÌŒø‰Ê‚Æ‚»‚ÌŒÀŠED ‘æ4‰ñ•s®–¬Ž¡—Íu‰‰‰ïiŒQ”nj6ŒŽ, 2010
  19. £”ö—RL: S•s‘S‚Ì•a‘Ô‚ÆŽ¡—Ã, CRT‚Ì–ðŠ„D Až‚ÝŒ^œ×“®ŠíiICDj/ƒy[ƒVƒ“ƒO‚É‚æ‚éS•s‘SŽ¡—ÁiCRT)‡“¯Œ¤CƒZƒ~ƒi[i–¼ŒÃ‰®j6ŒŽ, 2010
  20. £”ö—RL: S•s‘S‚ÆCRTD ‘æ25‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï@CRT/ICDƒZƒ~ƒi[i–¼ŒÃ‰®j6ŒŽ, 2010
  21. ˆ­”üˆÀ‹IŽq, £”ö—RL, Î’Ã’qŽq, ‰Í–ì@—¹, ÂÀ˜a—²: “TŒ^“I‚È”­ì«‚ŒŒˆ³‚ð’悳‚È‚©‚Á‚½, ƒJƒeƒRƒ‰ƒ~ƒ“S‹ØÇ‚𔺂¤ŠŒF×–EŽî‚̈ê—áD ‘æ40‰ñˆïéŒ§‚ŒŒˆ³Œ¤‹†‰ïŠwpu‰‰‰ïi‚‚­‚΁j6ŒŽ, 2010
  22. £”ö—RL: CRT‚É‚¨‚¯‚éSƒGƒR[–@‚̈Ӌ`‚ɂ‚¢‚āD ‘æ25‰ñŽ ‰êS•s‘SŒ¤‹†‰ïiŽ ‰êj6ŒŽ, 2010
  23. £”ö—RL: CRT‚𓱓ü‚·‚éSƒGƒR[Žw•WD “ú–{’´‰¹”gˆãŠw‰ïuK‰ïiL“‡j6ŒŽ, 2010
  24. ‰Í–ì@—¹: W’†Ž¡—×̈æ‚É‚¨‚¯‚éƒÀ-ŽÕ’f–ò‚Ì–ðŠ„|zŠÂŠí“à‰Èˆã‚ÌŽ‹“_‚©‚ç|D ŽüpŠú•s®–¬ƒZƒ~ƒi[iŽD–yj6ŒŽ, 2010
  25. ‰Í–ì@—¹: –òÜ“Š—^‚É•K—v‚ȍ\‘¢@1.–òÜ“Š—^‚É•K—v‚ȏzŠÂŠíŒn‚̍\‘¢‚Æ‹@”\D Á–hEˆõ“Á•Ê‹³ˆçu‘æ3Šú–òÜ“Š—^uK‰ïvi…ŒËj6ŒŽ, 2010
  26. ”Ñ“c“TŽq, £”ö—RL, ’J’†—¢”ü, Î’Ã’qŽq: ‘å“®–¬•Ù–ŒÇ‚É‚¨‚¯‚éSƒGƒR[ŠŒ©‚ÆBNP’l‚ÌŠÖ˜AD ‘æ32‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj6ŒŽ, 2010
  27. ì‘º@—´, Î’Ã’qŽq, £”ö—RL: ‘m–X•Ù’uŠ·•ÙpŒã‚̍¶Žº“àŒŒ—¬“®‘Ԃ̉ðÍD ‘æ32‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj6ŒŽ, 2010
  28. ˆ­”üˆÀ‹IŽq, £”ö—RL, Î’Ã’qŽq, ‰Í–ì@—¹, ÂÀ˜a—²: “TŒ^“I‚È”­ì«‚ŒŒˆ³‚ð’悳‚È‚©‚Á‚½, ƒJƒeƒRƒ‰ƒ~ƒ“S‹ØÇ‚𔺂¤ŠŒF×–EŽî‚̈ê—áD ‘æ40‰ñˆïéŒ§‚ŒŒˆ³Œ¤‹†‰ïŠwpu‰‰‰ïi‚‚­‚΁j6ŒŽ, 2010
  29. ÂÀ˜a—²: S–[×“®Ž¡—Íŋ߂̍l‚¦•ûD ‘æ61‰ñ_“ސìzŠÂŠíu‰‰‰ïi‰¡•lj7ŒŽ, 2010
  30. ÂÀ˜a—²: zŠÂŠíŽ¾Š³‚É‚¨‚¯‚郁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€D ‘æ10‰ñ“ú–{ˆãŠw‰ïŒöŠJƒtƒH[ƒ‰ƒ€i“Œ‹žj7ŒŽ, 2010
  31. ÂÀ˜a—²: S–[×“®Å‹ß‚̍l‚¦•ûD IUHW Hospital Grand Lecture vol.3i“Ȗ؁j7ŒŽ, 2010
  32. ÂÀ˜a—²: S–[×“®Ž¡—Íŋ߂̍l‚¦•ûD ‘æ15‰ñ_“ސì—Տ°•s®–¬ƒtƒH[ƒ‰ƒ€i‰¡•lj7ŒŽ, 2010
  33. ÂÀ˜a—²: ‚ŒŒˆ³Ž¡—ÃJSH2009‚𓥂܂¦‚½Ž¡—Ð헪D ^•ÇˆãŽt‰ïŠwpu‰‰‰ïi’}¼j7ŒŽ, 2010
  34. ÂÀ˜a—²: S–[×“®‚̍R‹ÃŒÅ—Ö@D ‘æ1‰ñ‚‚­‚ΐS‘ŸƒtƒH[ƒ‰ƒ€i‚‚­‚΁j7ŒŽ, 2010
  35. ‘º‰zLs: S–[×“®‚̉uŠw‚¨‚æ‚Ñ”­Ç‚ÉŽŠ‚é”wŒiˆöŽqD ‘æ1‰ñ‚‚­‚ΐS‘ŸƒtƒH[ƒ‰ƒ€i‚‚­‚΁j7ŒŽ, 2010
  36. ŠÖŒûK•v: S–[×“®‚Ì–ò•¨—Ö@-ƒAƒbƒvƒXƒgƒŠ[ƒ€Ž¡—Âƃ_ƒEƒ“ƒXƒgƒŠ[ƒ€Ž¡—ÁD ‘æ1‰ñ‚‚­‚ΐS‘ŸƒtƒH[ƒ‰ƒ€i‚‚­‚΁j7ŒŽ, 2010
  37. šê“c@_: S–[×“®‚Ì”ñ–ò•¨—Ö@-ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚鎡—Â̍l‚¦•ûD ‘æ1‰ñ‚‚­‚ΐS‘ŸƒtƒH[ƒ‰ƒ€i‚‚­‚΁j7ŒŽ, 2010
  38. ‰Í–ì@—¹: S•s‘S‚̍ŐVŽ¡—ÁD ‘æ6‰ñˆïéS‘ŸƒtƒH[ƒ‰ƒ€i…ŒËj7ŒŽ, 2010
  39. Î’Ã’qŽq: uS•s‘S‚̗Տ°•]‰¿vS•s‘S‚ðŽ¯‚éEŽ¡‚·D ‘æ6‰ñˆïéS‘ŸƒtƒH[ƒ‰ƒ€i…ŒËj7ŒŽ, 2010
  40. £”ö—RL: SƒGƒR[}–@‚Ì•s®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚Ö‚ÌŠÖ‚í‚èD ‘æ107‰ñUCG’k˜b‰ïi‘åãj7ŒŽ, 2010
  41. £”ö—RL: SƒGƒR[‚ŐS‘Ÿ”ñ“¯Šú‚ðf’f‚·‚éD ‘æ5‰ñ‚¢‚í‚ĐS•s‘S‚Æ•s®–¬ƒtƒH[ƒ‰ƒ€i·‰ªj7ŒŽ, 2010
  42. Î’Ã’qŽq: S‘Ÿ•a‚Æ”]‘²’†|”]‘²’†‚É‚È‚ç‚È‚¢‚½‚ß‚É, ”]‘²’†‚É‚È‚Á‚Ä‚µ‚Ü‚Á‚½‚ç|D ‘æ4‰ñ”]‘²’†Žs–¯ŒöŠJuÀi‚‚­‚΁j7ŒŽ, 2010
  43. ‰Í–ì@—¹: “à‰Èˆã‚ÌŽ‹“_‚©‚çŽüpŠúzŠÂŠÇ—‚ðl‚¦‚éD ‘æ5‰ñ•xŽRŒ§ŽüpŠúŠÇ—ƒtƒH[ƒ‰ƒ€i•xŽRj8ŒŽ, 2010
  44. £”ö—RL: CRT: SƒGƒR[‚ªS“d}‚ɏŸ‚é‚©D Tama regression forumi“Œ‹žj8ŒŽ, 2010
  45. ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇES•s‘SD –¼ŒÃ‰®”x‚ŒŒˆ³ÇŒŸ“¢‰ïi–¼ŒÃ‰®j9ŒŽ, 2010
  46. ÂÀ˜a—²: Š¥“®–¬EŒz“®–¬E”]“à“®–¬‚̃Aƒeƒ[ƒ€ŒŒðÇD ˆïéƒAƒeƒ[ƒ€ŒŒðÇ§˜b‰ïi‚‚­‚΁j9ŒŽ, 2010
  47. ‰Í–ì@—¹: ’áS‹@”\Ç—á‚Ì•s®–¬Ž¡—Âɑ΂·‚éƒÀŽÕ’f–òD ¬–ì–ò•iH‹ÆŽÐ“àu‰‰‰ïi“Œ‹žj9ŒŽ, 2010
  48. ÂÀ˜a—²: ‚ŒŒˆ³‚ƐS‘Ÿ•aD ã“cŽsˆãŽt‰ïŠwpu‰‰‰ïi’·–ìj10ŒŽ, 2010
  49. ÂÀ˜a—²: dÇS•s‘SŽ¡—Âɂ¨‚¯‚éÅ‹ß‚̐i•àD SˆÚAƒTƒ|[ƒgŽåÃ‘æ29‰ñŒöŠJŒöŠJu‰‰‰ïi‚‚­‚΁j10ŒŽ, 2010
  50. ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“‚ƃGƒ“ƒhƒZƒŠƒ“hR–òD ‘æ2‰ñé‹Ê¬l”x‚ŒŒˆ³ÇƒtƒH[ƒ‰ƒ€ié‹Êj10ŒŽ, 2010
  51. ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“‚¨‚æ‚ѝhR–ò‚Æ”x‚ŒŒˆ³ÇD ‘æ2‰ñ’·–쌧”x‚ŒŒˆ³ÇƒtƒH[ƒ‰ƒ€i¼–{j10ŒŽ, 2010
  52. ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇES•s‘SD Scientific Symposium in AKASAKAi“Œ‹žj10ŒŽ, 2010
  53. ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇES•s‘SD —Տ°–òŠwŒ¤‹†‰ïi“Œ‹žj10ŒŽ, 2010
  54. ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇES•s‘SD “¿“‡‘åŠwŠwpu‰‰‰ïi“¿“‡j10ŒŽ, 2010
  55. £”ö—RL: •s®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚É‚¨‚¯‚éSƒGƒR[}–@‚ÌŠÖ‚í‚èD ‘æ30‰ñŽO‰Y”¼“‡zŠÂŠí’k˜b‰ïi‰¡{‰êj10ŒŽ, 2010
  56. ‰Í–ì@—¹: ‹}«ŠúŽ¡—Âɂ¨‚¯‚éƒÀŽÕ’f–ò‚Ì–ðŠ„D å‘äŽüpŠúŠÇ—ƒZƒ~ƒi[iå‘äj10ŒŽ, 2010
  57. Î’Ã’qŽq: “œ”A•a‚ƐS•s‘S/“œ”A•a‚ÆŽ©—¥_ŒoáŠQ-ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“D ‘æ11‰ñˆïé¶ŠˆKŠµ•aƒtƒH[ƒ‰ƒ€i‚‚­‚΁j10ŒŽ, 2010
  58. Î’Ã’qŽq: “à‰ÈˆãŽt‚Ɛæ“V«SŽ¾Š³‚Æ3DƒGƒR[D “ú–{SƒGƒR[}Šw‰ï‘æ8‰ñHŠúuK‰ïi“Œ‹žj10ŒŽ, 2010
  59. Î’Ã’qŽq: “œ”A•a«S‹ØÇ‚̐SƒGƒR[D ‘æ37‰ñ•ŒÉìSƒGƒR[ƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi•ºŒÉj10ŒŽ, 2010
  60. ‹v‰êŒ\—S: Œ’NŠÇ—‚ÆŒ’Nf’fD •½¬22”N“x‘ސE€”õƒZƒ~ƒi[i‚‚­‚΁j11ŒŽ, 2010
  61. ‹v‰êŒ\—S: ‘ސEŒã‚ÌŒ’NŠÇ—‚ÆŒ’Nf’fD •½¬22”N“x‘ސE€”õƒZƒ~ƒi[i‚‚­‚΁j11ŒŽ, 2010
  62. ‰Í–ì@—¹: “Á”­«Šg’£Œ^S‹ØÇ‚ƏãŽè‚ɂ‚«‚ ‚¤‚½‚ß‚Ì’mŽ¯D “ï•aŠ³ŽÒ’nˆæŽx‰‡‘΍ô„iŽ–‹Æ “Á”­«Šg’£Œ^S‹ØÇu‰‰‰ïi—´ƒ–èj11ŒŽ, 2010
  63. ‰Í–ì@—¹: –«S•s‘S‚É‚¨‚¯‚é~ˆ³Ž¡—Â̎ÀÛ@‚ŒŒˆ³‚ðl‚¦‚éD ‘æ7‰ñˆïéS‘ŸƒtƒH[ƒ‰ƒ€i…ŒËj11ŒŽ, 2010
  64. Žðˆä@r: ‚»‚Ì‘¼‚̍‡•¹Ç‚ð—L‚·‚鍂ŒŒˆ³‚É‚¨‚¯‚é~ˆ³Ž¡—Â̎ÀÛD ‘æ7‰ñˆïéS‘ŸƒtƒH[ƒ‰ƒ€i…ŒËj11ŒŽ, 2010
  65. Î’Ã’qŽq: ‹•ŒŒ«SŽ¾Š³‚ÌŒ©•û: ‚ ‚È‚½‚͍¡‚Å‚à“÷Šá‚Å‚·‚©D “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[i“Œ‹žj11ŒŽ, 2010
  66. “n•Óds: Visualization of Normal and Abnormal Atrial or Ventricular Excitation Process using Magnetocardiography. The 3rd Asian Symposium on Magnetocardiographyi‚‚­‚΁j12ŒŽ, 2010
  67. ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“‚ƝhR–ò‚¨‚æ‚Ñ”x‚ŒŒˆ³ÇES•s‘SD ‹v—¯•Ä‘åŠw@S‘ŸEŒŒŠÇƒZƒ~ƒi[i‹v—¯•Äj12ŒŽ, 2010
  68. ‹v‰êŒ\—S: QT‰„’·ÇŒóŒQ, Torsades de pointes, BrugadaÇŒóŒQD ’}”g‘åŠwˆãŠw¶EŒ¤Cˆã‚Ì‚½‚߂̐S“d}“ljeƒZƒ~ƒi[i‚‚­‚΁j12ŒŽ, 2010
  69. ‰Í–ì@—¹: W’†Ž¡—×̈æ‚Ì•s®–¬‚ɑ΂·‚éƒÀŽÕ’f–ò‚Ì–ðŠ„D _ŒËŽüpŠúŠÇ—ƒZƒ~ƒi[i_ŒËj12ŒŽ, 2010
  70. Î’Ã’qŽq: •Ù–ŒÇ‚ð‹É‚ß‚é`‹t—¬«Ž¾Š³‚É‚¨‚¯‚é•]‰¿–@‚ÆŒŒs“®‘Ԃ̍l‚¦•û`D ˆïéŒ§—Տ°ŒŸ¸Šw‰ï@‘æ3‰ñ¶—‹@”\ŒŸ¸•”–匤C‰ïi‚‚­‚΁j12ŒŽ, 2010

@2009”N“xi2009”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. ’¬–ì’qŽq, £”ö—RL, Î’Ã’qŽq, –{ŠÔ@Šo, “n•Óds, ÂÀ˜a—²: táŠQ, CRP‚’l, DŽ_‹…‘‰Á‚Éèò“®–¬•sˆÀ’èƒvƒ‰[ƒN‚𔺂¤Š³ŽÒ‚͍‚—¦‚É‘å“®–¬•sˆÀ’èƒvƒ‰[ƒN‚ð—L‚·‚éD ‘æ12‰ñˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ïi‚‚­‚΁j1ŒŽ, 2009
  2. “cK˜aŽq, ÂÀ˜a—²: Drug-eluting stent—¯’uŒã‚ÌŒŒŠÇ‘gD”½‰ž‚Ì“ÁŽê«ƒEƒTƒM“®–¬•a—‘gD‚ÆOCT‚É‚æ‚錟“¢D ‘æ19‰ñ“ú–{SŒŒŠÇ‰æ‘œ“®‘ÔŠw‰ïi˜a‰ÌŽRj1ŒŽ, 2009
  3. £”ö—RL: ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚é‘å“®–¬•Ù‹t—¬Ç‚̐öÝ“IS‹ØáŠQ‚ÌŒŸoD ‘æ4‰ñS‹Ø‰ïi“Œ‹žj2ŒŽ, 2009
  4. Ishii T, Warabi E, Yanagawa T, Harada H, Okada K, Sakai S: Obesity formation and enhanced carotid artery remodeling in Sequestosome 1/A170/p62 deficient mice. JST-International Symposium, Molecular Mechanism of Environmental, Response to Food and Oxygen IIIiå‘äj2ŒŽ, 2009
  5. £”ö—RL: CRT“K‰žÇ—á‘I•Ê‚É‚¨‚¯‚éSƒGƒR[}–@‚Ì—L—p«‚Ɖۑè@ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“@CRT-D UpdatedD ‘æ1‰ñA‚¦ž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2ŒŽ, 2009
  6. ŽRè@_, šê“c@_, ²“¡@–¾, —L–{‹M”Í, ŠÖŒûK•v, ’¬–ì@‹B, •–ØŒ’Žu, ŒÜ\—’“s, ‹v‰êŒ\—S, ÂÀ˜a—²: Š¥Ã–¬‹·ó•”‚ւ̃Xƒeƒ“ƒg‘}“üŒã‚ɍ¶ŽºƒŠ[ƒh‚̍ė¯’u‚ɐ¬Œ÷‚µ‚½–òÜ’ïR«S•s‘S‚Ì‚P—á: IVUS‚É‚æ‚é‘gD«óf’f‚Ì—L—p«D ‘æ1‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2ŒŽ, 2009
  7. ‰Í–ì@—¹, ˆÀ“c@v, ”‹’JŒ\ˆê, ŠÖ@‹`Œ³, ‰ºžŠMˆÐ, ’r“cW•F, …’J‘¾˜Y, ”nê‰ëŽq, £”ö—RL, ÂÀ˜a—²: ‰–Ž_ƒ‰ƒ“ƒWƒIƒ[ƒ‹‚É‚æ‚é’áS‹@”\Ç—á‚̐S”§ŒäD ‘æ36‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ïi‘åãj2ŒŽ, 2009
  8. ‹{“à@‘ì: ƒGƒ“ƒhƒZƒŠƒ“‚Æ”x‚ŒŒˆ³Ç‹y‚ÑŽ¡—Ö@‚ɂ‚¢‚āD ‘æ3‰ñ_“ސìäPŒ´•a«”x‚ŒŒˆ³ÇƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‰¡•lj2ŒŽ, 2009
  9. ì“‡•ü”V, •D“c_”V, ŒÃ‰YŒ«“ñ, œA£r•ã, “¡ˆä@º, –ö‰º“Ö•F, ‹v²–ÎŽ÷, “¡–ì‹I”V, ‚‹´—ljp, –ì—¢ŽõŽj, •‹–¾“ú”ü, ŒKŒ´‘åŽu, ‚‹´@~, ²“¡@–¾, ˆé•”ŒõÍ: 14“úŠÔ‚ÌPCPSŽg—p‚ð—v‚µ‚½‚ª, ŒãˆâÇ–³‚­‹~–½‚µ“¾‚½Œ€ÇŒ^S‹Ø‰Š‚Ì‚P—áD ‘æ211‰ñ “ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽ, 2009
  10. HŽR‘åŽ÷, “n•Óds, ²“¡@–¾, ŽR–{¹—Ç, ”nê‰ëŽq, ’¬–ì@‹B, ’¬–ì’qŽq, ²“¡—zŽq, •–ØŒ’Žu, ŽRè@_, —L–{‹M”Í, £”ö—RL, ‘º‰zLs, ÂÀ˜a—²: Laser‚𕹗p‚µ‚½PPI‚ª‘tŒ÷‚¹‚¸‰ºŽˆØ’f‚ð—v‚µ‚½“œ”A•a«––½ŒŒŠÇáŠQ‚̈ê—áD ‘æ2‰ñˆïéPPIŒ¤‹†‰ïi‚‚­‚΁j2ŒŽ, 2009
  11. ‹{“à@‘ì, ‰ºžŠMˆÐ, Žðˆä@r: zŠÂŠíŽ¾Š³‚É‚¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“‚̃VƒOƒiƒ‹ŽÕ’f‚É‚æ‚鎡—Ö@D ‘æ82‰ñ“ú–{–ò—Šw‰ï”N‰ïi‰¡•lj3ŒŽ, 2009
  12. Žðˆä@r, ˜n@‰hŽ¡, ˆî—t”ŽŽq, Œ´“ct”ü, –öì@“O, —é–؉hŽq, —F”ö@F, Îˆä“N˜Y: V‹K”ì–žƒ‚ƒfƒ‹A170ƒmƒbƒNƒAƒEƒgƒ}ƒEƒX‚͈ÀÃŽžŠÔ‚ÌŒŒˆ³ã¸‚ðŽ¦‚·D ‘æ82‰ñ“ú–{–ò—Šw‰ï”N‰ïi‰¡•lj3ŒŽ, 2009
  13. Sakamaki F, Seo Y, Ishizu T, Machino T, Iida N, Nakajima H, Inaba T, Kawamura R, Kanemoto M, Sekiguchi Y, Fumikura Y, Kawano S, Noguchi Y, Watanabe S, Aonuma K: Utility of Modified Septal-to-Posterior Wall Motion Delay with Anatomical M-Mode Echocardiography as a Predictor of Responders of Cardiac@Resynchronization Therapy. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  14. Maruyama H, Sakai S, Sumida T, Goto D, Ito S, Matsumoto I, Hayashi T, Kawano S, Ishizu T, Watanabe S, Aonuma K: Altered Characteristics of Endothelial Cells in Patients with Pulmonary Arterial Hypertension Estimated by Endothelial Cell-Derived Microparticles. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  15. Shimojo N, Maruyama H, Yoshizawa M, Niwayama J, Miyahara T, Misono M, Miyaki A, Tajiri K, Miyauchi T, Maeda S, Aonuma K: Lactotripeptide Ameliorates Vascular Endothelial Cell Function via Inhibition of Angiotensin II and Recruitment of Endothelial Progenitor Cells in Elderly Women. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  16. Shimizu A, Nitta T, Imai K, Kurita T, Kimura T, Kobayashi Y, Niwano, Watanabe S, Soejima K, Abe N: A comparison of IGD Implantation in the United States Versus JapanICD Therapy for Idiopathic Ventricular Fibrillation in Japan -The ICD-WEB Registry administered by the Japanese Heart Rhythm Society. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  17. Yamaguchi N, Zaedi S, Shimojo N, Sultana SN, Iwashima Y, Koyama A, Hiroe M, Sakuma I, Hattori Y, Jesmin S: Estrogen Receptor-ƒ¿ Plays Dominant Role in the Preservation of VEGF Signaling in Coronary Microcirculation in Heart of Female Mice. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  18. Jesmin S, Zaedi S, Shimojo N, Sultana NS, Iwashima Y, Hiroe M, Yamaguchi N, Miyauchi T: Superiority of Dual Endothelin Receptor Antagonist to Selective Receptor Antagonist in Ameliorating Altered VEGF Signaling in Early Diabetic Hearts. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  19. Jesmin S, Sultana NS, Shimojo N, Zaedi S, Iwashima Y, Miyauchi T, Hiroe M, Yamaguchi N: Endothelin Antagonist Normalizes the Downregulated VEGF, NO and BCL-2 Expression in Penile Tissues in Early Type 1 Diabetic Rat Model. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  20. Tajiri K, Maruyama H, Sakai S, Shimojo N, Aihara H, Endoh M, Saitoh T, Kawano S, Watanabe S, Aonuma K: Contrast Medium-Induced Renal Damage is Tightly Associated with Endothelial Injury in Patients. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  21. Sakai S, Shimojo N, Ogata T, Aonuma K: Regulation of RNA Polymerase II (Pol-II)-Driven Gene Expression and Cardiomyocyte Size by C-Terminal Domain Phosphatase of Pol II. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  22. Adachi T, Seo Y, Ishizu T, Yamamoto M, Machino T, Kawamura R, Sakai S, Kawano S, Watanabe S, Aonuma K: Commercially Available Serum N-terminal proBNP Level Accurately Differentiates Presence of Cardiac Morphological and Hemodynamic Abnormalities Compared with Brain Natriuretic Peptide. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  23. Kawashima T, Hikita H, Koura K, Hirose S, Kawashima T, Fujii A, Fujino T, Kusa S, Yagishita A, Takahashi Y, Takei A, Nozato T, Takahashi A, Sato A, Isobe M: Differential Clinical and Angiographical Characteristics of Early and Late Restenosis after Sirolimus-eluting Stent Implantation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  24. Hikita H, Sato A, Koura K, Hirose S, Kawashima T, Fujii A, Fujino T, Kusa S, Yagishita A, Takahashi Y, Takei A, Nozato T, Kuwahara T, Isobe M, Hiroe M, Takahashi A: Elevated C-Reactive Protein after Coronary Stent Implantation Predicts Plaque Morphology. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  25. Nakagawa Y, Liang J, Watanabe S, Liang J, Tajiri K, Seo Y, Satoh Y, Takeyasu N, Aihara H, Sato A, Ishizu T, Sakai S, Murakoshi N, Kawano S, Aonuma K, Shiomi M: Can Intravascular Optical Cohenrence Tomographic Findings of Macrophage Accumulation in Atherosclerosis Lesions. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  26. Kawashima T, Hikita H, Koura K, Hirose S, Fujii A, Fujino T, Kusa S, Yagishita A, Takahashi Y, Takei A, Nozato T, Kuwahara T, Takahashi A, Sato A, Isobe M: Risk Assessment of Developing Renal Dysfunction on Patients Undergoing Repetitive Percutaneous Coronary Intervebtion. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  27. Hikita H, Sato A, Koura K, Hirose S, Kawashima T, Fujii A, Fujino T, Kusa S, Yagishita A, Takahashi Y, Takei A, Nozato T, Kuwahara T, Isobe M, Takahashi A: Remnant-like Particle-cholesterol is an Important Factor to Determinane Plaque Morphology of the Culprit Lesions in Acute Myocardial Infarction. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  28. Hoshi T, Nishina H, Noguchi Y, Watabe H, Kakefuda Y, Tachibana T, Toda S, Fumikura Y, Hiranuma Y, Takeyasu N, Sato A, Watanabe S, Aonuma K: An Excellent Chronic Angographic Outcome of Modified-T Stenting to Left Anterior Descending/ Diagonal Artery Bifurcated Lesions. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  29. Kuwahara T, Takahashi A, Takahashi Y, Takei A, Koura K, Hirose S, Fujii A, Fujino T, Kawashima T, Hikita H, Yagishita A, Kawashima T, Nozato T, Hikita H, Sato A, Aonuma K: Clinical Significance of Early Recurrence of Atrial Fibrillation After Left Atrial Ablation in Patients with Permanent Type of Atrial Fibrillation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  30. Liang J, Watanabe S, Nakagawa Y, Tajiri K, Seo Y, Sato Y, Takeyasu N, Aihara H, Sato A, Ishizu T, Sakai S, Murakoshi N, Kawano S, Aonuma K, Shiomi M: Can Intravascular Optical Cohenrence Tomography Detect Plaque Erosion?: Some New Finding in Rabbit Models. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  31. Suzuki A, Yamauchi Y, Okada H, Kusa S, Suzuki M, Kozu T, Hara N, Kawasaki M, Sugiyama T, Watanabe S, Takamura C, Hattori E, Miyamoto T, Obayashi T, Aonuma K, Sekiguchi Y, Isobe M: Paroxysmal Atrial Fibrillation Orginating from Atrial Septum: Signficance of Biatrial Mapping and Ablation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  32. Tada H, Tanaka Y, Takemura N, Naitoh S, Ooshima S, Taniguchi K, Aonuma K: Three-Dimensional Cardiac Image Integration Facilitates Isolation of Wide Area of the Antrum in Patients with Atrial Fibrillation: A Prospective, Randomized Study. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  33. Watanabe Y, Watanabe S, Aonuma K, Yamazaki T, Hayashi D, Kohno T, Okada Y, Nagai R, Investigators JCAD study: The Impact of Diabetes on the Prognosis of Japanese Patients with Coronary Artery Disease. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  34. Nakajima H, Ishizu T, Seo Y, Iida N, Sakamaki F, Inaba T, Yamamoto M, Machino T, Kawamura R, Aonuma K: The Role of Longitudinal Displacement on Difference of Strain Value Derived from Two- Dimensional and Three-Dimensional Speckle Tracking Imaging. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  35. Takei A, Takahashi A, Koura K, Hirose S, Kawashima T, Fujii A, Kusa S, Yagishita A, Fujino T, Nozato T, Takahashi Y, Kuwahara T, Hikita H, Aonuma K: Clinical Course of Left Atrial Appendage Flow Velocity in Patients with Chronic Atrial Fibrillation after Catheter Ablation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  36. Seo Y, Ishizu T, Enomoto Y, Yamamoto M, Ohtsuka T, Kawamura R, Watanabe S, Aonuma K: Validation of a Newly Developed 3-dimensional Speckle Tracking Technique to Quatify Regional Myocardial Function. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  37. Ishizu T, Seo Y, Enomoto Y, Sugimori H, Watanabe S, Aonuma K: Experimental Validation of Trasmural Strain Gradient with a Newly Developed 2-dimensional Speckle Tracking System. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  38. Ishizu T, Seo Y, Baba M, Yamamoto M, Ohtuska T, Kawamura R, Watanabe S, Aonuma K: Utility of End-diastolic Strain Rate in the Estimation of Left Ventricular Passive Compliance. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  39. Sakai S, Warabi E, Inaba H, Harada H, Yanagawa T, Suzuki E, Tomoo T, Aonuma K, Ishii T: Elevated Blood Pressure in Resting Daytime-Phase in A170-Knockout Mice, a Newly Established Obese Model. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  40. Ishizu T, Seo Y, Watanabe S, Yamamoto M, Machino T, Kawamura R, Sato A, Aonuma K: Beneficial Effect of Statin Treatment on Carotid Atherosclerosis in Patients with Stable Coronary Artery Disease Stratified by Rental Function. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  41. Machino T, Sekiguchi Y, Kuroki K, Yamasaki H, Igarashi M, Murakoshi N, Tada H, Kuga K, Aonuma K: Efficacy of Endocardial and Epicardial substrate mapping in patients with Non-ischemic Ventricular Tachycardia. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  42. Tanoue K, Nuruki N, Yamashita E, Kawano T, Hayakawa H, Amiya S, Tohfuku K, Sata N, Hamada N, Tsubouchi H, Sekiguchi Y, Aonuma K: The Impact of High Resolution Substrate Mapping Guided Catheter Ablation for Ventricular Tachycardia in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  43. Tada H, Tanaka Y, Naito S, Kumagai K, Oshima S, Taniguchi K, Sekiguchi Y, Aonuma K: The Morphological Features and Role of the Left Lateral Atrial Ridge in Catheter Ablation of Atrial Fibrillation: 3-dimensional Computed Tomographic Analysis. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  44. Nakagawa Y, Watanabe S, Liang J, Tajiri K, Seo Y, Sato Y, Takeyasu N, Aihara H, Sato A, Ishizu T, Sakai S, Murakoshi N, Kawano S, Aonuma K, Shiomi M: Optical Coherence Tomographic Findings of Macrophage Accumulation in Atherosclerotic Lesions. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  45. Tomizawa T, Yamaguchi I, Aonuma K: Prevalence of Atrial Fibrillation in General Population is Increasing beyond Aging. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  46. Seo Y, Ishizu T, Yamamoto M, Machino T, Kawamura R, Sakamaki F, Yamasaki H, Igarashi M, Sekiguchi Y, Kawano S, Tada H, Watanabe S, Aonuma K: Relationship between Intraventricular Dyscoordination of Myocardial Work and left Ventricular Function, and Responsiveness to Cardiac Resynchronization Therapy. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  47. Atsumi A, Ishizu T, Watanabe S, Aihara H, Nishina H, Sato A, Aonuma K: Underestimation of Post-Stress Left Ventricular Ejection Fraction on Vasodilator-Stress Gated-SPECT: A Comparative Study with Echocardiography. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  48. Aihara H, Watanabe S, Nishina H, Seo Y, Takeyasu N, Aonuma K, Takeda T: Evaluation of Left Ventricular Dyssynchrony by Gated Blood-pool Radionuclide Ventriculography with a Novel Analysis Program (CardioPOOL). ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  49. Tada H, Yamasaki H, Sekiguchi Y, Arimoto T, Kuroki K, Machino T, Murakoshi N, Ishizu T, Seo Y, Aonuma K: The Advantage of Triangle Ventricular Pacing over Convention Biventricular Pacing Becomes More Prominent during the Tachycardia Setting. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  50. Sato A, Nozato T, Hirota H, Seo Y, Ishizu T, Watanabe S, Hiroe M, Aonuma K: Utility of Cardiac Biomarker in Predicting Long-term Clinical Outcome after Acute infarction: Combination of Serum Tenascin-C and Plasma BNP Levels. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  51. Koyama T, Sekiguchi Y, Tada H, Arimoto T, Yamasaki H, Kuroki K, Machino T, Tajiri K, Xu D, Kanemoto M, Sugiyasu A, Kuga K, Ito H, Aonuma K: Characteristics and Significance of Immediate Recurrence of Atrial Fibrillation after Catheter Ablation: A Close Relation to the Inflammatory Process. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  52. Kuwahara T, Takahashi A, Takahashi Y, Fujii A, Kusa S, Fujino T, Takei A, Hirose S, Kura K, Kawashima T, Yagishita A, Nozato T, Hikita H, Sato A, Aonuma K: Efficacy of Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  53. Akiyama D, Sato A, Nozato T, Hikita H, Seo Y, Ishizu T, Watanabe S, Hiroe M, Aonuma K: Early Risk Stratification after Anterior Acute Myocardial Infarction Using the Combination of Serum Tenascin-C and Plasma BNP Levels. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  54. Hikita H, Sato A, Koura K, Hirose S, Kawashima T, Fujii A, Fujino T, Kusa S, Yagishita A, Takahashi Y, Takei A, Nozato T, Kuwahara T, Isobe M, Hiroe M, Takahashi A: Coronary Flow Velocity Mesured with TIMI Frame Count and Quantitative Angiogram Functional Recovery in TIMI 3 Reperfused Acute Myocardial Infarction. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  55. Kimura T, Yoshimura K, Aoki H, Ikeda Y, Imanaka-yoshida K, Hiroe M, Aonuma K, Matsuzaki M: Tenascin-C is Tissue Protective during the Development of Abdominal Aortic Aneurysm in Mice. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  56. Arimoto T, Tada H, Sekiguchi Y, Igarashi M, Yamasaki H, Machino T, Kuroki K, Kuga K, Aonuma K: High Washout Rate of Iodine-123-Metaiodobenzylguanidine Imaging Predicts Early Recurrance of Atrial Fibrillation Following Radiofrequency Catheter Ablation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  57. Adachi T, Sato A, Kawano S, Baba M, Yamamoto M, Machino T, Kuroki K, Arimoto T, Ishizu T, Sekiguchi Y, Seo Y, Tada H, Kuga K, Watanabe S, Aonuma K: Novel Use of an Ultra-Short-Acting Intravenous Beta Blocker (Landiolol) for Supraventricular Tachyarrhythmias in Patients with Severe Congestive Heart Failure. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  58. Yamasaki H, Sekiguchi Y, Arimoto T, Machino T, Kuroki K, Igarashi M, Tada H, Kuga K, Watanabe S, Aonuma K: Clinical Patients Characteristics with Esophagus Wall Injury after Pulmonary Vein Isolation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  59. Kobori A, Kuwahara T, Funakoshi S, Kimura N, Kim K, Ahn Y, Yamane T, Kitai T, Katayama M, Ehara N, Tamita K, Kinoshita M, Kaji S, Yamamuro A, Tani T, Furukawa Y, Takahashi A, Aonuma K: Predictive Index for Effective Ablation Lesion in Catheter Ablation of Atrial Fibrillation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  60. Kuwahara T, Takahashi A, Takahashi Y, Fujii A, Kusa S, Fujino T, Takei A, Hirose S, Kura K, Kawashima T, Yagishita A, Nozato T, Hikita H, Sato A, Aonuma K: Clinical Characteristics of the Patients with Ischemic Strokes Complicating Left Atrial Ablation for Atrial Fibrillation: Lessons from Five Cases. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  61. Kawamura R, Seo Y, Ishizu T, Sakai S, Watanabe S, Aonuma K: Validation of Left Ventricular Volumetric Data by 3 Dimensional Speckle Tracking Imaging with Cardiac Magnetic Resonance Imaging. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  62. Nishina H, Hoshi T, Noguchi Y, Watabe H, Kakefuda Y, Tachibana T, Toda S, Fumikura Y, Hiranuma Y, Takeyasu N, Sato A, Watanabe S, Aonuma K: Impact of Diabetic Status at Presentation on Long-Term Outcome in Patients Underwent Percutanuous Coronary Intervention for Acute Coronary Syndrome. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  63. Hoshi T, Nishina H, Noguchi Y, Watabe H, Kakefuda Y, Tachibana T, Toda S, Fumikura Y, Hiranuma Y, Takeyasu N, Sato A, Watanabe S, Aonuma K: Long Term Angiographic and Clinical Outcomes of SirolimusEluting Stent in Patients with Acute Coronary Syndrome; 4-year follow-up from ICAS Registry. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  64. Watabe H, Seo Y, Sato A, Murakoshi N, Ishizu T, Takeyasu N, Watanabe S, Aonuma K: Chronic Kidney Disease as a Determinant of Cardiovascular Events and Chronic Left Ventricular Dysfunction in Patients with Acute Coronary Syndrome. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  65. Tajiri K, Watanabe S, Nakagawa Y, Liang J, Seo Y, Takeyasu N, Sato A, Ishizu T, Sato Y, Sakai S, Murakoshi N, Aonuma K: The Histological Findings of Vascular Response to Drug Eluting Stents. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  66. Kato Y, Horigome H, Takahashi M, Yamazaki H, Arimoto T,Kuroki K, Koyama T, Sekiguchi Y, Tada H, Aonuma K: Radiofrequency Catheter Ablation of Atrial Tachycardias Late after Intracardiac-repair of Tetralogy of Fallot. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  67. Seo Y, Ishizu T, Yamamoto M, Kawamura R, Machino T,Uno K, Tsuruta W, Suzuki K, Watanabe S, Aonuma K: Visualization of Neovascularization in Carotid Plaques by B-flow Imaging. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  68. Machino T, Seo Y, Yamamoto M, Kawamura R, Ishizu T, Aonuma K: Combined Assessment of Carotid Vulunerable Plaque, Renal Insuffciency, Hypereosinophilia and Higher CRP Predicts Risky Aortic Plaque of Cholesterol Crystals Embolism. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  69. Hoshi T, Nishina H, Noguchi Y, Kakefuda Y, Tachibana T, Toda S, Fumikura Y, Hiranuma Y, Sato A, Watanabe S, Aonuma K: An Excellent Chronic Angiographic Outcome of Modified-T Stenting to Left Anterior Descending/ Diagonal Artery Bifurcaated Lesions. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  70. Hirose S, Nozato T, Sato A, Koura K, Kawashima T, Fujii A, Fujino T, Kusa S, Yagishita A, Takahashi Y, Takei A, Kuwahara T, Hikita H, Takahashi A, Isobe M: An Effect of the Statin for the Patients with Chronic Limb Ischemia who Recived Endovascular Treatments on Long Term Outcome. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  71. Kuwahara T, Takahashi A, Takahashi Y, Fujii A, Kusa S, Fujino T, Takei A, Hirose S, Koura K, Kawashima T, Yagishita A, Nozato T, Hikita H, Sato A, Aonuma K: Clinical Signficance of Early Recurrence of Atrial Fibrillation after Left Atrial Ablation in Patints with Permanent Type with Permanent Type of Atrial Fibllation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  72. Arai E, Watanabe S, Sato Y, Nakagawa Y, Miyashita T, Liang J, Tajiri K, Inaba T, Seo Y, Ishizu T, Aihara H, Nishina H, Kamdori A, Aonuma K: Visualization of Normal and Abnormal Atrial Excitation Process Using Magnetocardiography. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  73. Sato Y, Watanabe S, Arai E, Nakagawa Y, Miyashita T, Liang J, Tajiri K, Inaba T, Seo Y, Ishizu T, Aihara H, Nishina H, Takeyasu N, Sato A, Kawano S, Kamdori A, Aonuma K: Detection of Injury Current of Ischemic Myocardium by Magnetocardiography: A Treadmill-Stress Magneteocardiographic Study. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  74. Koura K, Hikita H, Koura K, Hirose S, Kawashima T, Fujii A, Fujino T, Kusa S, Yagishita A, Takahashi Y, Takei A, Nozato T, Kuwahara T, Takahashi A, Sato A, Isobe M: Relationship Between Lipoprotein (a) and the Plaque Morphology of the Non-infarcted Vessels in Patients with Acute Myocardial Infarction. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  75. Nozato T, Sato A, Hirose S, Koura K, Kawashima T, Fujii A, Fujino T, Kusa S, Yagishita A, Takahashi Y, Takei A, Kuwahara T, Hikita H, Takahashi A, Isobe M: Clinical Outcome of the Pecutaneous Peripheral Intervention for the Superficial Femoral Artery Lesion. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  76. Yamamoto M, Seo Y, Ishizu T, Nakajima H, Machino T, Kawamura R, Watanabe S, Aonuma K: Three-Dimensional Transesophageal Echocardiographic Diagnosis of Left Atrial Appendage Thrombus, and Characteristics of left Atrial Appendage Characteristics Related Thrombus Formation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  77. Sakamaki F, Seo Y, Ishizu T, Iida N, Nakajima H, Yamamoto M, Machino T, Kawamura R, Yamasaki H, Sekiguchi Y, Kawano S, Tada H, Watanabe S, Aonuma K: Utility of Septal Flash Motion as a Predictor of Responders to Cardiac Resynchronization Therapy. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  78. Arimoto T, Tada H, Sekiguchi Y, Igarashi M, Yamasaki H, Machino T, Kuroki K, Kuga K, Aonuma K: Renin-angiotensin System Blocker Avoids Sinus Node Dysfunction and Recurrent Atrial Fibrillation after Catheter Ablation of Chronic Atrial Fibllation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  79. Takahashi A, Kuwahara T, Takahashi Y, Takei A, Fujino T, Kusa S, Fujii A, Hirose S, Koura K, Yagishita A, Nozato T, Hikita H, Iesaka Y, Aonuma K, Isobe M: Long-term Follow-up of Catheter Ablation for Chronic Atrial Fibrillation: Differences in Clinical Characteristrics between Patients with and without Successful Outcome. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  80. Murakoshi N, Xu D, Igarashi M, Sekiguchi Y, Tada H, Aonuma K: Downregulation of Oxidative Metabolism Related Gene Expressions is Associated with Atrial Fibllation Vulnerability with Age. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  81. Akiyama D, Sato A, Ishizu T, Seo Y, Takeyasu N, Watanabe S, Aonuma K: Impact of Body Mass Index on Long-term Clinical Outcomes in Patients with Acute Coronary Syndrome; Result from ICAS Registry. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  82. Nakajima H, Seo Y, Ishizu T, Iida N, Sakamaki F, Inaba T, Yamamoto M, Machino T, Kawamura R, Sekiguchi Y, Tada H, Aonuma K: Morphological Analiysis of Left Atrial Appendage by Three-Dimensional Transesophageal Echcardiography. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  83. Igarashi M, Tada H, Sekiguchi Y, Arimoto T, Yamazaki H, Kuroki K, Machino T, Kuga K, Watanabe S, Aonuma K: Maintenance of Sinus Rhythm with Class III Antiarrhythmic Drugs Predict Successful Ablation in Patients with Chronic Atrial Fibrillation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  84. Sato Y, Watanabe S, Arai E, Nakagawa Y, Miyashita T, Liang J, Tajiri K, Inaba T, Seo Y, Aihara H, Nishina H, Kamadori A, Aonuma K: Detection of eInjury Currentf of Ischemic Myocardium by Magnetotocadiiography: A Treadmill-Stress Magneteocardiographic Study. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  85. Shimojo N, Maruyama H, Yoshizawa M, Niwayama J, Miyahara T, Miyaki A, Misono M, Tajiri K, Miyauchi T, Maeda S, Aonuma K: Lactotripeptide Ameliorates Vascular Endothelial Cell Function via Inhibition of Angiotensin II and Recruitment of Endothelial Progenitor Cells in Elderly Women. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  86. Sato A, Seo Y, Ishizu T, Akiyama D, Nozato T, Hikita H, Watanabe S, Aonuma K: Coronary Artery Spatial Distribution of Vulnerable Plaques by 64-slice Computed Tomography Angiography in Patients with Acute Myocardial Infarction. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  87. Xu D, Murakoshi N, Igarashi M, Sekiguchi Y, Tada H, Aonuma K: The Effects of Pioglitazone on Atrial Fibrillation in Rat Model. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  88. Sakai S, Shimojo N, Ogata T, Aonuma K: Regulation of RNA Polymerase II (Poll II)- Driven Gene Expression and Cardiomyocyte Size by C-Terminal Domain Phosphatase of Pol II. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  89. Takahashi A, Kuwahara T, Takahashi Y, Takei A, Fujino T, Kusa S, Fujii A, Hirose S, Koura K, Yagishita A, Hikita H, Iesaka Y, Aonuma K, Isobe M: New Strategy of Catheter Ablation for Chronic Atrial Fibllation: Selection of Optimal Strategy according to the Response of Electorical Cardioversion. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  90. Kuroki K, Tada H, Machino T, Yamasaki H, Kanemoto M, Arimoto T, Endo M, Sekiguchi Y, Kuga K, Aonuma K: The Efficacy of Noncoronary Cusp Mapping in Catheter Ablation of Focal Atrial Tachycardia Originating from near the His Bundle. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  91. Adachi T, Sato A, Kawano S, Baba M, Yamamoto M, Machino T,Kuroki K, Arimoto T, Ishizu T, Sekiguchi Y, Seo Y, Tada H, Kuga K, Watanabe S, Aonuma K: Novel Use of an Ultra-Short-Acing Intravenous Beta Blocker (Landiolol) for Supraventricular Tachyarrhythmias in Patients with Severe Congestive Heart Failure. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  92. Hirose S, Nozato T, Sato A, Koura K, Kawashima T, Fujii A, Fujino T, Kusa S, Yagishita A, Takahashi Y, Takei A, Kuwahara T, Hikita H, Takahashi A, Isobe M: Comparision of Assessment of In-stent Restenosis with 64-slice Computed Tomography Using Low Concentration Contrast Media. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  93. Higuchi H, Ishizu T, Seo Y, Suzuki A, Akio Yukawa, Yamauchi R, Watanabe Y, Eki Y, Watanabe S, Aonuma K: Assesment of Subendocardial Myocardial Function with Coronary Stenosis without Visibly Wall Motion Abnormality by Speckle Tracking Imaging. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  94. Iida N, Seo Y, Ishizu T, Yamamoto M, Machino T, Kawamura R, Nakajima H, Sakamaki F, Inaba T, Watanabe S, Aonuma K: Relationship between Endomyocardial Dysfunction and Postoperative LV Function in Patients with Severe Aortic Regurgitation. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  95. Sekiguchi Y, Tada H, Arimoto T, Yamasaki H, Kuroki K, Machino T, Kuga K, Yamaguchi I, Aonuma K: Efficacy and Feasibility of Catheter Ablation for the Marked Low-voltage Areas in Patients with Post- Infarction Ventricular Tachycardia. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  96. Sekiguchi Y, Tada H, Yamasaki H, Arimoto T, Kuroki T, Machino T, Kuga K, Yamaguchi I, Aonuma K: Efficacy and Safety of Radiofrequency Catheter Ablation in Patients with Life-thereatening Ventricular Tachycardias. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  97. Tada H, Igarashi M, Sekiguchi Y, Yamazaki H, Arimoto T, Kuroki K, Machino T, Kuga K, Aonuma K: Efficacy and Safety of a Hybrid Therapy with Amiodarone and Catheter Ablation for Chronic Atrial Fibllation: Comparison with Bepridil. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  98. Sato A, Seo Y, Ishizu T, Nishina H, Nozato T, Hikita H, Watanabe S, Aonuma K: Predictive Value of Myocardial Contrast Delayed Enhancement with Multidetector Computed Tomography after Acute Myocardial Infarction. ‘æ73‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi‘åãj3ŒŽ, 2009
  99. ŠÛŽRG˜a, ²“¡@½, Žðˆä@r, ‰Í–ì@—¹, ‰ºžŠMˆÐ, “cK˜aŽq, ˆÀ“c@‹ž, “n•Óds, ÂÀ˜a—²: ‡–°Žž–³ŒÄ‹zÇŒóŒQ‚É‚¨‚¢‚Ä–éŠÔ‚ÌŒŒŠÇ“à”ç×–E‚ÌŠˆ«‰»‚ªŒŒ¬”ÂŒŒð‚ÉŠÖ˜A‚·‚éD ‘æ106‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïi“Œ‹žj4ŒŽ, 2009
  100. £”ö—RL, Î’Ã’qŽq, ŽR–{¹—Ç, ’¬–ì’qŽq, ì‘º@—´, ‰F–ìŠó¢Žq, ÂÀ˜a—²: ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“@èò“®–¬ŠŸŽî‚É‚¨‚¯‚éSƒGƒR[‹P“x•]‰¿‹y‚ÑŠŸŽî“à”÷¬ŒŒ—¬‘œ•`o‚É‚æ‚é‘gD«ó•]‰¿D ‘æ20‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‚¼j4ŒŽ, 2009
  101. Î’Ã’qŽq, £”ö—RL, ŽR–{¹—Ç, ”nê‰ëŽq, ’¬–ì’qŽq, ì‘º@—´, ÂÀ˜a—²: ƒVƒ“ƒ|ƒWƒEƒ€@2DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½¶ŽºƒRƒ“ƒvƒ‰ƒCƒAƒ“ƒX‚Ì•]‰¿D ‘æ20‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‚¼j4ŒŽ, 2009
  102. ’¬–ì’qŽq, £”ö—RL, ‹T’J—¢”ü, ’†“‡‰pŽ÷, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t@•, ŽR–{¹—Ç, ì‘º@—´, Î’Ã’qŽq, ÂÀ˜a—²: ƒRƒ“ƒgƒ‰ƒXƒg[ƒoƒ‹ƒTƒ‹ƒo–@‚ð—p‚¢‚½ŒoH“¹SƒGƒR[‚Å—‘‰~E‰»ˆË‘¶‚ÌŒŸo‚ª¢“ï‚ȏǗá‚Ì“Á’¥D ‘æ20‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‚¼j4ŒŽ, 2009
  103. ŽR–{¹—Ç, £”ö—RL, ’†“‡‰pŽ÷, ’¬–ì’qŽq, ì‘º@—´, Î’Ã’qŽq, “n•Óds, ÂÀ˜a—²: ‚ǂ̂悤‚ȍ¶SŽ¨‚ÉŒŒð‚ª‚Å‚«‚â‚·‚¢‚©`3ŽŸŒ³ŒoH“¹ƒGƒR[‚ð—p‚¢‚½‰ðÍD ‘æ20‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‚¼j4ŒŽ, 2009
  104. ¬—эhŽq, ’†“‡‰pŽ÷, ‹T’J—¢”ü, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t@•, ã–q@—², “ì–؁@—Z, Î’Ã’qŽq, £”ö—RL, ìã@N, ÂÀ˜a—²: Automated function imaging‚ð—p‚¢‚½¶ŽºŽûk”\•]‰¿‚É‚·‚錟“¢D ‘æ20‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‚¼j4ŒŽ, 2009
  105. ì‘º@—´, £”ö—RL, Î’Ã’qŽq, ’¬–ì’qŽq, ŽR–{¹—Ç, ÂÀ˜a—²: Validation of left ventricular wall mass measured by 3 dimensional echocardiography. ‘æ20‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‚¼j4ŒŽ, 2009
  106. ‹T’J—¢”ü, ŽðŠª•¶Žq, ¬—эhŽq, ’†“‡‰pŽ÷, ”Ñ“c“TŽq, ˆî—t@•, ã–q@—², “ì–؁@—Z, Î’Ã’qŽq, £”ö—RL, ìã@N, ÂÀ˜a—²: Automated function imaging‚ð—p‚¢‚½¶Žº‹ÇŠ•Ç‰^“®•]‰¿‚Ì—L—p«‚ÉŠÖ‚·‚錟“¢D ‘æ20‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‚¼j4ŒŽ, 2009
  107. “cŒû‰Ä”ü, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ŽðŠª•¶Žq, ‹T’J—¢”ü, ¬—эhŽq, ˆî—t@•, ã–q@—², “ì–؁@—Z, Î’Ã’qŽq, £”ö—RL, ìã@N, ÂÀ˜a—²: B-flow imaging‚ð—p‚¢‚½èò“®–¬‹·ó—¦‚ÌŒŸ“¢D ‘æ20‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi‚¼j4ŒŽ, 2009
  108. “n•”_–¾, ²“¡@–¾, ŽRè@_, šê“c@_, ŠÖŒûK•v, ’¬–ì@‹B, •–ØŒ’Žu, HŽR‘åŽ÷, “n•Óds, ÂÀ˜a—²: ‰‰ñCRT-D–„‚ߍž‚ÝŒã‚ÌŠ¥Ã–¬‚ɍ‚“xüˆÛ«‹·ó‚ð”F‚ß, ƒŠ[ƒhÄ—¯’uŽž‚ÉŠ¥“®–¬ƒXƒeƒ“ƒg‘}“ü‚ð•K—v‚Æ‚µ‚½1—áD ‘æ4‰ñˆïéŒ§“슥Ž¾Š³Œ¤‹†‰ïi‚‚­‚΁j5ŒŽ, 2009
  109. “n•”_–¾, ²“¡@–¾, HŽR‘åŽ÷, “n•Óds, ²“¡“¡•v, åŒ´@÷, ÂÀ˜a—²: ŠŸŽî”j’]‚ªŒ´ˆö‚ƍl‚¦‚ç‚ꂽ‹}«¶’°œ“®–¬ŒŒð•ÂÇÇ‚ɑ΂µ‚ÄŒŒð‹zˆø‹y‚уoƒ‹[ƒ“Œ`¬p‚ðŽ{s‚µ‚½1—áD ‘æ3‰ñˆïéPPIŒ¤‹†‰ïi‚‚­‚΁j5ŒŽ, 2009
  110. HŽR‘åŽ÷, –{ŠÔ@Šo, ŒÃì‘å—S, ’ÅŠL^¬, –x•ÄmŽu, ’¬–ì@‹B, •–ØŒ’Žu, ²“¡—zŽq, “n•”_–¾, ²“¡@–¾, £”ö—RL, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: dÇ”x‚ŒŒˆ³Ç‚Ì”­Œ©‚ðŒ_‹@‚ɐüˆÛ«‹ØˆÙŒ`«Ç‚ª‹^‚í‚ꂽÇ—áD ‘æ10‰ñ”x‚ŒŒˆ³ÇŽ¡—ÃŒ¤‹†‰ïi“Œ‹žj5ŒŽ, 2009
  111. ŽRè@_, ŠÖŒûK•v, šê“c@_, —L–{‹M”Í, •–ØŒ’Žu, ’¬–ì@‹B, ŒÜ\—’“s, ‹v‰êŒ\—S, ÂÀ˜a—², åŒ´@Œª, V“c@—², ‰ªè@C, •›“‡—ms, œA]“¹º: Electrical storm‚ð”F‚ß‚½Šg’£Œ^S‹ØÇ‚ɑ΂·‚éS“à–ŒESŠO–Œsubstrate mappingƒKƒCƒh‰º‚̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ƃNƒ‰ƒCƒIƒAƒuƒŒ[ƒVƒ‡ƒ“‚̈Ӌ`D ‘æ39‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi•xŽRj5ŒŽ, 2009
  112. “n•”_–¾, ²“¡@–¾, ’·’Jì’q–¾, ˆ­”üˆÀ‹IŽq, HŽR‘åŽ÷, j‘º‰À], ¬£‘ãŽu‹v, ’¬–ì@‹B, Î’Ã’qŽq, £”ö—RL, ÂÀ˜a—²: ‚ŒŒˆ³‚ðŒ_‹@‚É‹}«S•s‘S‚ð’悵‚½’‹Œ«S‹Ø[Ç‚Ì1—áD ‘æ38‰ñˆïéŒ§‚ŒŒˆ³Œ¤‹†‰ïŠwpu‰‰‰ïi‚‚­‚΁j6ŒŽ, 2009
  113. ŒÃì‘å—S, ‰Í–ì@—¹, HŽR‘åŽ÷, ŽRè@_, £”ö—RL, ÂÀ˜a—²: ’˜‚µ‚¢“ûŽ_ƒAƒVƒh[ƒVƒX‚𗈂µ‚½Žá”NŽÒ‚̈ê—áD ‘æ187‰ñˆïéŒ§“à‰ÈŠw‰ïi…ŒËj6ŒŽ, 2009
  114. ‰ºžŠMˆÐ, ŠÛŽRG˜a, ’ëŽR@~, ŽRŒû@ŠÞ: “§ÍŽ¡—Âɂ¨‚¯‚éSŒŒŠÇŽ¾Š³ƒXƒNƒŠ[ƒjƒ“ƒO–@‚ƐV‚½‚ÈŽ¡—Ö@‚̉”\«‚ɂ‚¢‚āD ‘æ54‰ñ“ú–{“§ÍˆãŠwpW‰ïE‘‰ïi‰¡•lj6ŒŽ, 2009
  115. ”Ñ“c“TŽq, £”ö—RL, “cŒû‰Ä”ü, Î’Ã’qŽq, ÂÀ˜a—²: B-flow imaging–@‚É‚æ‚éèò“®–¬‹·ó—¦‚ÌŒŸ“¢D ‘æ30‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj6ŒŽ, 2009
  116. ²“¡@–¾, ˆ­”üˆÀ‹IŽq, “n•”_–¾, HŽR‘åŽ÷, ‘ŠŒ´‰p–¾, m‰ÈG’, “n•Óds, ÂÀ˜a—²: Š¥“®–¬Ž¾Š³‚̐f’f‚É‚¨‚¯‚é64—ñMDCT‚Æ•‰‰×S‹ØŒŒ—¬ƒCƒ[ƒWƒ“ƒO‚Ì—L—p«D ‘æ19‰ñ“ú–{S‘ŸŠjˆãŠw‰ï‘‰ïŠwp‘å‰ïi“Œ‹žj6ŒŽ, 2009
  117. Sato A, Akiyama D, Watabe H, Seo Y, Ishizu T, Murakoshi N, Watanabe S, Aonuma K: Coronary Artery Spatial Distribution, Morphology, and Composition of Vulnerable Plaques by Computed Tomography Angiography in Patients with Acute Myocardial Infarction. ‘æ18‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiŽD–yj6ŒŽ, 2009
  118. Akiyama D, Sato A, Watabe H, Sato Y, Machino T, Kuroki K, Seo Y, Watanabe S, Aonuma K: Heparin-induced Thtombocytopenia Causing Rapid Glowing Massive Thrombus in LMT During Coronary Intervention. ‘æ18‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïiŽD–yj6ŒŽ, 2009
  119. ŽRè@_, ŠÖŒûK•v, šê“c@_, —L–{‹M”Í, ’¬–ì@‹B, •–ØŒ’Žu, ŒÜ\—’“s, ‹v‰êŒ\—S, ÂÀ˜a—²: Š¥Ã–¬ŒeŽº“à‚Å‚Ì’Ê“d‚É‚æ‚è—£’f‚µ‚¦‚½”x“®–¬‹·óÇpŒãEEbsteinŠïŒ`‚ð—L‚·‚é’ʏíŒ^S–[‘e“®‚̈ê—áD _“ސ쌧•s®–¬ƒtƒH[ƒ‰ƒ€i‰¡•lj6ŒŽ, 2009
  120. ‰Í–ì@—¹, ˆÀ“c@v, ‰ºžŠMˆÐ, ŠÖ@‹`Œ³, ”‹’JŒ\ˆê, ’r“cW•F, ‚‹´L“ñ, …’J‘¾˜Y, •–ØŒ’Žu, £”ö—RL, ÂÀ˜a—²: –«S•s‘S‚ɍ‡•¹‚·‚é“«SŽº«•s®–¬‚ÌŽ¡—Ð헪D ‘æ18‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi¼–{j7ŒŽ, 2009
  121. £”ö—RL, Î’Ã’qŽq, ŽR–{¹—Ç, ’¬–ì’qŽq, ì‘º@—´, ÂÀ˜a—²: ‘m–X•Ù‹t—¬Ç‚É‚¨‚¯‚éinner/outer strain‰ðÍD ‘æ5‰ñS‹Ø‰ïi“Œ‹žj7ŒŽ, 2009
  122. ŠÛŽRG˜a, ŒÜ\—’“s, ”nê‰ëŽq, Žðˆä@r, ‰Í–ì@—¹, “n•Óds, šê“c@_, ÂÀ˜a—²: S–[×“®‚ƈÀ’è‹·SÇ‚ÅŒŒŠÇ“à”ç‹@”\’ቺ‚Ì‹@˜‚͈قȂéD ‘æ24‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ï^‘æ26‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi‹ž“sj7ŒŽ, 2009
  123. VˆäŒb”ü, “n•Óds, ²“¡—zŽq, ’†ì‹`Žk, —À@ŒiŠâ, “cK˜aŽq, ˆî—t@•, £”ö—RL, Î’Ã’qŽq, ‘ŠŒ´‰p–¾, m‰ÈG’, •ˆÀ–@”V, ²“¡@–¾, ‰Í–ì@—¹, ‹v‰êŒ\—S, ÂÀ˜a—², ‹{‰º@‹, _’¹–¾•F: SŽ¥}‚ð—p‚¢‚½³í‚¨‚æ‚шُíSŽº’E•ª‹É‰ß’ö‚ÌŽ‹Šo‰»D ‘æ24‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‹ž“sj7ŒŽ, 2009
  124. —L–{‹M”Í, šê“c@_, ŠÖŒûK•v, “n•”_–¾, •–ØŒ’Žu, ’¬–ì@‹B, ŽRè@_, ŒÜ\—’“s, ‹v‰êŒ\—S, ÂÀ˜a—²: ˆê’è‚Ì•p”ŽüŠú‚Ő…•½•ûŒü‚Ɛ‚’¼•ûŒü‚ɐù‰ñ‚·‚é‰E–[“àƒ}ƒNƒƒŠƒGƒ“ƒgƒŠ[«S–[•p”‚Ì1—áD ‘æ24‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‹ž“sj7ŒŽ, 2009
  125. ŒÜ\—’“s, šê“c@_, ŠÖŒûK•v, —L–{‹M”Í, ŽRè@_, •–ØŒ’Žu, ’¬–ì@‹B, ‹v‰êŒ\—S, ÂÀ˜a—²: æ“V«SŽ¾Š³‚ɍ‡•¹‚µ‚½Š¥Ã–¬“´ŒeŽº“à‚ւ̏Ď܂ɂæ‚èƒuƒƒbƒNƒ‰ƒCƒ“‚ªŠ®¬‚³‚ꂽ“«‚̒ʏíŒ^S–[‘e“®‚Ì1—áD ‘æ24‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‹ž“sj7ŒŽ, 2009
  126. ’¬–ì@‹B, šê“c@_, “n•”_–¾, •–ØŒ’Žu, ŽRè@_, ŒÜ\—’“s, —L–{‹M”Í, ŠÖŒûK•v, ‘º‰zLs, £”ö—RL, ‹v‰êŒ\—S, ÂÀ˜a—²: ’ʏíŒ^–[ŽºÚ‡•”‰ñ‹A«•p”‚ÉŠ¥Ã–¬“´“üŒû•”‹NŒ¹‚̐S–[•p”‚ð‡ •¹‚µ, “ñŽí—Þ‚Ì•p”‚ɑ΂·‚éƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Âɐ¬Œ÷‚µ‚½Ç—áD ‘æ24‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‹ž“sj7ŒŽ, 2009
  127. “n•”_–¾, šê“c@_, •–ØŒ’Žu, ’¬–ì@‹B, ŽRè@_, —L–{‹M”Í, ŠÖŒûK•v, ‹v‰êŒ\—S, ÂÀ˜a—²: ”xÃ–¬Šu—£pŒã‚ɃŠƒGƒ“ƒgƒŠ[«”xÃ–¬•p”‚ð”F‚ß‚½3—áD ‘æ24‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‹ž“sj7ŒŽ, 2009
  128. ŒÜ\—’“s, šê“c@_, ŠÖŒûK•v, —L–{‹M”Í, ŽRè@_, •–ØŒ’Žu, ’¬–ì@‹B, ‹v‰êŒ\—S, ÂÀ˜a—²: –«S–[×“®‚ɑ΂·‚é?ŒQR•s®–¬–ò‚¨‚æ‚Ñ?ŒQR•s®–¬–ò•¹—p—Ö@‚ÌŒø‰Ê‚ƈÀ‘S«‚ÉŠÖ‚·‚錟“¢|ƒyƒvƒŠƒWƒ‹‚ƃAƒ~ƒIƒ_ƒƒ“‚Ì”äŠr|D ‘æ24‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‹ž“sj7ŒŽ, 2009
  129. ŽRè@_, šê“c@_, ŠÖŒûK•v, —L–{‹M”Í, ’¬–ì@‹B, •–ØŒ’Žu, ŒÜ\—’“s, ‹v‰êŒ\—S, ÂÀ˜a—²: ‹•ŒŒE”ñ‹•ŒŒ«SŽ¾Š³‚ɍ‡•¹‚µ‚½SŽº•p”‚ɑ΂·‚é“´’²—¥‰º‚–§“xƒ}ƒbƒsƒ“ƒO‚ÉŠî‚­ƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—L—p«EˆÀ‘S«‚Ì”äŠrEŒŸ“¢D ‘æ24‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‹ž“sj7ŒŽ, 2009
  130. ‘º‰zLs: –«t‘Ÿ•a‚ƐS–[×“®D 9th Symposium of the Meet the Professor in Cardiovascular Diseasei“Œ‹žj7ŒŽ, 2009
  131. ‘O“c´Ži, ‰ºžŠMˆÐ, ‹{“à—T”ü, ‹{“à@‘ì: KŠµ“I‚ȉ^“®‚É‚æ‚é“®–¬ƒXƒeƒBƒtƒlƒX‚̉ü‘P‚ƃGƒ“ƒhƒZƒŠƒ“F‰^“®—Ö@‘OŒã‚ł̃Gƒ“ƒhƒZƒŠƒ“Žó—eŽÕ’f–ò‚ɑ΂·‚锽‰žD ‘æ9‰ñCardiovascular Medicine 21 ƒtƒH[ƒ‰ƒ€i“Œ‹žj8ŒŽ, 2009
  132. ¯@’q–ç, m‰ÈG’, –ìŒû—Sˆê, •ˆÀ–@”V, ²“¡@–¾, ÂÀ˜a—²: ‹}«Š¥ÇŒóŒQ‚É‚¨‚¯‚éSirolimus-Eluting Stent‚ÆBare-Metal Stent‚Ì’·Šú¬Ñ‚Ì”äŠrGICAS iIbaraki Cardiac Assessment StudyjRegistryŒ¤‹†‚©‚çD ‘æ54‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[i_ŒËj8ŒŽ, 2009
  133. £”ö—RL, ŽR–{¹—Ç, ’¬–ì’qŽq, ì‘º@—´, ’†“‡‰pŽ÷, Î’Ã’qŽq, ÂÀ˜a—²: “¯Šú•s‘SS‚É‚¨‚¯‚é•Ç‰^“®‚ƐS‹ØŒŒ‰t—Ê‚Æ‚ÌŠÖ˜AD ‘æ7‰ñæiSŒŒŠÇƒGƒR[Œ¤‹†‰ïi‘åãj8ŒŽ, 2009
  134. ’†“‡‰pŽ÷, £”ö—RL, ’¬–ì’qŽq, ŽR–{¹—Ç, ì‘º@—´, Î’Ã’qŽq, ÂÀ˜a—²: 3ŽŸŒ³ŒoH“¹SƒGƒR[}‚ð—p‚¢‚½¶SŽ¨“àŒŒð‚ƍ¶SŽ¨Œ`‘Ô‚¨‚æ‚Ñ‹@”\“I“Á’¥‚Ì•]‰¿D ‘æ7‰ñæiSŒŒŠÇƒGƒR[Œ¤‹†‰ïi‘åãj8ŒŽ, 2009
  135. ¬?‘ãŽm‹v, ÂÀ˜a—², •“cŒ’‰î, Š}Œ´˜a”V, –q–ì‹I˜a, ²–ì@½, ’|“à‘בã, ’·âŽm˜Y, Žá—с@N: ”²ŠÇŒãA“ª•‚Žî‚ɑ΂·‚锲ŠÇ‘OƒXƒeƒƒCƒh“Š—^‚Ì—\–hŒø‰ÊD ‘æ57‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŽD–yj9ŒŽ, 2009
  136. £”ö—RL, Î’Ã’qŽq, ‰|–{‰ÀŽ¡, ÂÀ˜a—²: ƒVƒ“ƒ|ƒWƒEƒ€@Å‹ß‚̐SƒGƒR[‚̐i•à@3Dƒgƒ‰ƒbƒLƒ“ƒO‚Ì—L—p«‚ÆŒÀŠED ‘æ57‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŽD–yj9ŒŽ, 2009
  137. ’¬–ì’qŽq, £”ö—RL, Î’Ã’qŽq, ÂÀ˜a—²: S–[×“®’âŽ~Œã‚Ìatrial stunning‚ƃoƒ‹ƒTƒ‹ƒo•‰‰×‰º¶Žº—¬“üŒŒ—¬‘¬”gŒ`‚ÌŠÖŒWD ‘æ57‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŽD–yj9ŒŽ, 2009
  138. ŽðŠª•¶Žq, £”ö—RL, Î’Ã’qŽq, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t@•, ŽR–{¹—Ç, ’¬–ì’qŽq, ì‘º@—´, ‰Í–ì@—¹, ÂÀ˜a—²: one-beat 3D wall motion tracking‚É‚æ‚éƒXƒgƒŒƒCƒ“‘ª’è‚̐M—Š«‚ÉŠÖ‚·‚錟“¢D ‘æ57‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŽD–yj9ŒŽ, 2009
  139. ŽR–{¹—Ç, £”ö—RL, ’¬–ì’qŽq, ì‘º@—´, ’†“‡‰pŽ÷, ŽðŠª•¶Žq, Î’Ã’qŽq, ÂÀ˜a—²: 3ŽŸŒ³ŒoH“¹SƒGƒR[}–@‚É‚æ‚鍶SŽ¨Œ`‘Ô‚ÉŠÖ‚·‚錟“¢D ‘æ57‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŽD–yj9ŒŽ, 2009
  140. ì‘º@—´, £”ö—RL, Î’Ã’qŽq, ’¬–ì’qŽq, ŽR–{¹—Ç, Žðˆä@r, “n•Óds, ÂÀ˜a—²: ŽOŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒOƒCƒ[ƒW‚É‚æ‚éS‹@”\‰ðÍ‚ƐS‘ŸMRI‚É‚æ‚錟ØD ‘æ57‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŽD–yj9ŒŽ, 2009
  141. ŽðŠª•¶Žq, £”ö—RL, Î’Ã’qŽq, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t@•, ŽR–{¹—Ç, ’¬–ì’qŽq, ì‘º@—´, ‰Í–ì@—¹, ÂÀ˜a—²: One-beat 3D wall motion tracking‚É‚æ‚éŽûkŠúƒXƒgƒŒƒCƒ“‚Ì•]‰¿D ‘æ57‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiŽD–yj9ŒŽ, 2009
  142. Žðˆä@r, ˜n@‰hŽ¡, ˆî—t”ŽŽq, Œ´“ct”ü, –öì@“O, ÂÀ˜a—², Îˆä“N˜Y: sequestosome1 (SQSTM1) ˆâ“`ŽqŒ‡‘¹‚É‚æ‚é”ì–žƒ‚ƒfƒ‹‚ÌŠJ”­‚ÆŒŒˆ³“®‘Ԃ̉ðÍD ‘æ13‰ñ Molecular Cardiovascular Conferencei—]ŽsŒSj9ŒŽ, 2009
  143. ŒÃì‘å—S, ²“¡—zŽq, “n•”_–¾, HŽR‘åŽ÷, ’¬–ì@‹B, •–ØŒ’Žu, ŽRè@_, —L–{‹M”Í, ‘º‰zLs, Î’Ã’qŽq, ŠÖŒûK•v, ²“¡@–¾, £”ö—RL, šê“c@_, “n•Óds, ÂÀ˜a—²: Žûk«S–Œ‰Š‚Æ‚ÌŠÓ•Ê‚É“ïa‚µ‚½, ‚“x¶ŽºŽûkáŠQ‚É‚æ‚é—¼S•s‘S‚Ì1—á. ‘æ213‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2009
  144. ‹{è@“O, ˆé•”ŒõÍ, –ì—¢ŽõŽj, œA£r•ã, ŒÃ‰YŒ«“ñ, ’†“‡‰i”üŽq, “¡ˆä@º, ‹v²–ÎŽ÷, –ö‰º“Ö•F, ‘å‹v•ÛŒ’Žj, ãÎ“N¶, “¡–ì‹I”V, •‹–¾“ú”ü, ‚‹´—ljp, ŒKŒ´‘åŽu, •D“c_”V, ‚‹´@~, ²“¡@–¾: Š´õ«S“à–Œ‰Š‚É”º‚¤ã’°ŠÔ–Œ“®–¬áŽ‚ª–«Šú‚ÉŽ©‘RÁŽ¸‚µ‚½1—áD ‘æ213‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2009
  145. ‰Í–ì@—¹, ˆÀ“c@v, ‰ºžŠMˆÐ, ”‹’JŒ\ˆê, ŠÖ@‹`Œ³, …’J‘¾˜Y, HŽR‘åŽ÷, ŽRè@_, £”ö—RL, ÂÀ˜a—²: ‘½‘ŸŠí•s‘S‚Å”­Ç‚µ‚½‰Â‹t«”x‚ŒŒˆ³ÇE‰ES•s‘S‚̏ǗáD ‘æ37‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïi·‰ªj10ŒŽ, 2009
  146. í‰ªG˜a, ‰Í–ì@—¹, ˆÀ“c@v, ²“¡“¡•v, ŠÖ@‹`Œ³, ‰ºžŠMˆÐ, ”‹’JŒ\ˆê, ¬“‡ŒcŽq, …’J‘¾˜Y: •Û‘¶“IŽ¡—ÂŊǗ‚µ“¾‚½ŠO«‹¹•”‘å“®–¬‘¹‚𔺂¤‚—îŽÒ‘½”­ŠO‚̈ê—áD ‘æ37‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïi·‰ªj10ŒŽ, 2009
  147. ˆÀ“c@v, …’J‘¾˜Y, ‰Í–ì@—¹, ‰ºžŠMˆÐ, ”‹’JŒ\ˆê, í‰ªG˜a, ¬“‡ŒcŽq, ‚‹´L“ñ, âª³F: ˆã—ÐE‚ɑ΂·‚éAHA G2005‹~‹}‘h¶‹³ˆç‘̐§‚Ì‹­‰»Žx‰‡’}”g‘åŠwŽÐ‰ïvŒ£ƒvƒƒWƒFƒNƒgD ‘æ37‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïi·‰ªj10ŒŽ, 2009
  148. ¬?‘ãŽm‹v, ”üè¹Žq, —é–ØŒ’Ži, šê“c@_, ŠÖŒûK•v, ’¬–ì@‹B, ˆä“¡—tŽq, ŽRè@_, ¬àV^l, ŒÜ\—’“s, ÂÀ˜a—²: Irrigation catheter‚É‚Äcavo-tricuspid isthmus block line‚̍쐬‚ɐ¬Œ÷‚µ‚½1—áD ‘æ21‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiì‰zj10ŒŽ, 2009
  149. ’¬–ì@‹B, ŠÖŒûK•v, ¬£‘ãŽm‹v, •–ØŒ’Žu, ŽRè@ _, ŒÜ\—’“s, ‹v‰êŒ\—S, šê“c@_, ÂÀ˜a—²: CARTO‚Ìsubstarate mapping‚ƋǏŠ‚Ìpace mapping‚𕹗p‚µS“à–Œ‘¤‚¨‚æ‚ѐSŠO–Œ‘¤‚©‚ç‚̃AƒuƒŒ[ƒVƒ‡ƒ“‚ª—LŒø‚Å‚ ‚Á‚½SŽº•p”‚Ì1—áD ‘æ21‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiì‰zj10ŒŽ, 2009
  150. £”ö—RL: ƒVƒ“ƒ|ƒWƒEƒ€@‚ǂ̂悤‚ɐS‹@”\•]‰¿‚·‚é‚©@3DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚éSŽº“à”ñ“¯Šú‚Ì•]‰¿D ‘æ13‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi•Ÿ‰ªj10ŒŽ, 2009
  151. Žðˆä@r, ˜n@‰hŽ¡, ˆî—t”ŽŽq, Œ´“ct”ü, –öì@“O, —é–؉hŽq, —F”ö@F, ÂÀ˜a—², Îˆä“N˜Y: V‹K”ì–žƒ‚ƒfƒ‹SQSTM1/A170/p62ˆâ“`ŽqŒ‡‘¹ƒ}ƒEƒX‚Ínon-dipperŒ^ŒŒˆ³ã¸‚ðŽ¦‚·D ‘æ32‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ïi‘å’Áj10ŒŽ, 2009
  152. ¼‰º¹”V•, ŒÃ“c’qÍ, ‰ºžŠMˆÐ, Žðˆä@r, “¿‰iç•ä, ²X–؏º’¨, ‰|–{‰ÀŽ¡, ‹à–{^–ç, ²“¡“¡•v, •½¼—SŽi, åŒ´@Œª: ƒŒ[ƒU[ƒhƒbƒvƒ‰[—¬—ÊŒv‚ð—p‚¢‚½ƒ}ƒEƒX‚ÌNOˆË‘¶«ŒŒŠÇ“à”ç‹@”\•]‰¿–@D ‘æ50‰ñ“ú–{–¬ŠÇŠw‰ïi“Œ‹žj10ŒŽ, 2009
  153. ‚—œ“TŽq, –{ŠÔ@Šo, Œ´@’‰“Ä, ŽR‰ºŒcŽO, ‹àŽq“¹•v: •a‰@Eˆõ‚ªŽó‚¯‚é–\—́E–\Œ¾‚ÌŽÀ‘ԁD ‘æ4‰ñˆïéŒ§ˆã—ÃŽ–ŒÌ–hŽ~Œ¤‹†‰ïi‚‚­‚΁j10ŒŽ, 2009
  154. j‘º‰À], Î’Ã’qŽq, ˆ­”üˆÀ‹IŽq, ŽR–{¹—Ç, ’¬–ì’qŽq, ì‘º@—´, ‰|–{^”ü, £”ö—RL, ÂÀ˜a—²: æ“V«ƒ~ƒIƒpƒ`[‚ð‡•¹‚µ‚½, ”ì‘åŒ^S‹ØÇ‚̈ê—áD ‘æ46‰ñ“Œ‹žSƒGƒR[}Œ¤‹†‰ïi“Œ‹žj11ŒŽ, 2009
  155. ‰Í–ì@—¹: ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“@‹}«Šú‚©‚çÝ‘î‚ց`Œ»ó‚Æ‚»‚̉ۑèD ‘æ10‰ñˆã—Ã}ƒlƒWƒƒ“ƒgŠw‰ïˆïéŒ§’n•û‰ïŠwpW‰ïi‚‚­‚΁j11ŒŽ, 2009
  156. j‘º‰À], Î’Ã’qŽq, ŽR–{¹—Ç, £”ö—RL, ÂÀ˜a—²: ‰EŽº—¬o˜H‹·ó‚ð‡•¹‚µ‚½•ÂÇ«”ì‘åŒ^S‹ØÇ‚̈ê—áD ‘æ21‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïi“Œ‹žj11ŒŽ, 2009
  157. ’J’†—¢Œ©, £”ö—RL, Î’Ã’qŽq, ÂÀ˜a—²: ‹}«S•s‘S‚Å”­Ç‚µ, ‹ÇŠ•Ç‰^“®ˆÙí, S‹@”\•s‘S‚ª‘J‰„‚µ‚½ŠŒF×–EŽî‚̈ê—áD ‘æ21‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïi“Œ‹žj11ŒŽ, 2009
  158. ‚—œ“TŽq, –{ŠÔ@Šo, Œ´@’‰“Ä, ŽR‰ºŒcŽO, ‹àŽq“¹•v: ‰@“à‚É‚¨‚¯‚éEˆõ‚Ö‚Ì–\—́E–\Œ¾‚ÌŽÀ‘Ô’²¸D ˆã—Â̎¿EˆÀ‘SŠw‰ï‘æ‚S‰ñŠwpW‰ïi“Œ‹žj11ŒŽ, 2009
  159. ¬?‘ãŽm‹v, šê“c@_, ŠÖŒûK•v, ’¬–ì@‹B, ˆä“¡—tŽq, ŽRè@_, ¬àV^l, ŒÜ\—’“s, ÂÀ˜a—², Šâ²@“Ä: Šg’£Œ^S‹ØÇ‚É”º‚¤VT storm‚ɑ΂µSŠO–Œ‘¤ƒAƒvƒ[ƒ`‚É‚æ‚éƒJƒe[ƒeƒ‹ÄŽÜp‚ª—LŒø‚Å‚ ‚Á‚½1—áD ‘æ22‰ñS‘Ÿ«‹}Ž€Œ¤‹†‰ïi“Œ‹žj12ŒŽ, 2009
  160. Žðˆä@r, ‰ºžŠMˆÐ, ÎŠ_’¼”ü, ÂÀ˜a—², “‡–ì@m: Ž‰Ž¿“]ŽÊ’²ßˆöŽqSREBP-1‚̐S‹@”\áŠQ‚¨‚æ‚ѐS‹ØüˆÛ‰»‚É‚¨‚¯‚é–ðŠ„‰ð–¾D ‘æ4‰ñ‚ŒŒˆ³‚ÆŠ¥“®–¬Ž¾Š³Œ¤‹†‰ïi“Œ‹žj12ŒŽ, 2009
  161. “n•”_–¾, ‰Í–ì@—¹, ²“¡—zŽq, ’·’Jì’q–¾, ˆ­”üˆÀ‹IŽq, HŽR‘åŽ÷, j‘º‰À], ¬£‘ãŽm‹v, ’¬–ì@‹B, Î’Ã’qŽq, ²“¡@–¾, £”ö—RL, ÂÀ˜a—²: AED‚ªì“®‚µ‚È‚©‚Á‚½ƒJƒeƒRƒ‰ƒ~ƒ“S‹ØÇ‡•¹SŽº•p”‚Ì1—áD ‘æ214‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj12ŒŽ, 2009
  162. “yŠò_‰î, –{ŠÔ^l, ‹v‰êŒ\—S, ÂÀ˜a—², K“cK’¼: ƒtƒŒƒJƒCƒjƒh‚Ì‘Ì“à“®‘Ô‚É‚¨‚æ‚Ú‚·‰Á—î‚ÆCYP2D6ˆâ“`Žq‘½Œ^‚̉e‹¿D ‘æ30‰ñ“ú–{—Տ°–ò—Šw‰ï”N‰ïi‰¡•lj12ŒŽ, 2009

@@@¡ ‚»‚Ì‘¼

  1. –{ŠÔ@Šo: f—Ísˆ×‚ÉŠÖ˜A‚µ‚½Ž€–S‚Ì’²¸•ªÍƒ‚ƒfƒ‹Ž–‹Æ‚ÌŠT—vD ˆã—ÈÀ‘S’²¸ˆÏˆõ‰ïi‰¼Ìj‚ÉŠÖ‚·‚éƒVƒ“ƒ|ƒWƒEƒ€i‚‚­‚΁j1ŒŽ, 2009
  2. ‰Í–ì@—¹: W’†Ž¡—×̈æ‚É‚¨‚¯‚éƒÀŽÕ’f–ò‚Ì–ðŠ„-“à‰Èˆã‚Ì—§ê‚©‚ç-D ‘æ3‰ñÎìŒ§ŽüpŠúŠÇ—ƒtƒH[ƒ‰ƒ€i‹à‘òj1ŒŽ, 2009
  3. ÂÀ˜a—²: S–[×“®‚ɑ΂·‚é–ò•¨E”ñ–ò•¨‚̃nƒCƒuƒŠƒbƒh—Ö@D ‘æ4‰ñ“ŒŠCƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ïi–¼ŒÃ‰®j2ŒŽ, 2009
  4. ÂÀ˜a—²: ‚±‚±‚܂Ői‚ñ‚¾ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì•p–¬«•s®–¬‚Ì”ñ–ò•¨Ž¡—ÁD ‚‚­‚ÎJOY‰ïi‚‚­‚΁j2ŒŽ, 2009
  5. ÂÀ˜a—²: ARB‚Æ•s®–¬Ž¡—ÁD ’†‹–€E–k‹–€ˆãŽt‰ïŠwpu‰‰‰ïib•{j2ŒŽ, 2009
  6. ÂÀ˜a—²: ˆó¼’n‹æˆãŽt‰ïŠwpu‰‰‰ïD ˆó¼’n‹æˆãŽt‰ïŠwpu‰‰‰ïiç—tj2ŒŽ, 2009
  7. £”ö—RL: ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚̗Տ°ŒoŒ±D ‘æ32‰ñ•ŒÉìSƒGƒR[ƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi_ŒËj2ŒŽ, 2009
  8. £”ö—RL: Šg’£‹@”\E/Ef‚ðŽa‚éI ‘æ11‰ñƒGƒR[ƒEƒBƒ“ƒ^[ƒZƒ~ƒi[iŒyˆä‘òj2ŒŽ, 2009
  9. £”ö—RL: ‘SgŒŒŠÇ•a‚ð‚ǂ̂悤‚ÉŽ¡—·‚é‚©H ‘æ3‰ñˆïé”]‘²’†ƒZƒ~ƒi[i‚‚­‚΁j2ŒŽ, 2009
  10. £”ö—RL: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[@—Տ°‚ɖ𗧂ƒgƒ‰ƒbƒLƒ“ƒO–@D “ú–{SƒGƒR[}Šw‰ï‘æ13‰ñ“~‹GuK‰ïi‘åãj2ŒŽ, 2009
  11. ‰Í–ì@—¹: ”ñS‘ŸŽèp‚É‚¨‚¯‚鍇•¹SŽ¾Š³‚ÌŽ¡—Ð헪zŠÂŠí“à‰Èˆã‚ÌŽ‹“_‚©‚çD aŒûW’†Ž¡—ÃŒ¤‹†‰ïiìèj3ŒŽ, 2009
  12. Žðˆä@r: ‚ŒŒˆ³ƒKƒCƒhƒ‰ƒCƒ“2009E‰ü’ù‚̃|ƒCƒ“ƒgD ^•ÇˆãŽt‰ïŠwpu‰‰‰ïi^•Çj4ŒŽ, 2009
  13. £”ö—RL: 2D‚¨‚æ‚Ñ3D Speckle Tracking ‚ÌŒŸØ‚ƗՏ°D ‘æ20‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[i‚¼j4ŒŽ, 2009
  14. ‰Í–ì@—¹: W’†Ž¡—×̈æ‚É‚¨‚¯‚éƒÀŽÕ’f–ò‚Ì–ðŠ„“à‰Èˆã‚Ì—§ê‚©‚çD zŠÂŠíES‘ŸŠO‰ÈƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi“Œ‹žj5ŒŽ, 2009
  15. £”ö—RL: èò“®–¬ƒGƒR[‚É‚æ‚é“®–¬d‰»‚Ì•]‰¿D ‹Ë¶ˆãŽt‰ïu‰‰‰ïi‹Ë¶j5ŒŽ, 2009
  16. ÂÀ˜a—²: ŠíŽ¿“ISŽ¾Š³‚ɍ‡•¹‚µ‚½’vŽ€«SŽº«•s®–¬‚ÌŽ¡—Ð헪D •Ÿ“‡zŠÂŠí‹³ˆçƒZƒ~ƒi[i•Ÿ“‡j6ŒŽ, 2009
  17. ÂÀ˜a—²: S–[×“®‚ÌŽ¡—Ã: Å‹ß‚̘b‘èD Ž­“‡’n‹æzŠÂŠíƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXiŽ­“‡j6ŒŽ, 2009
  18. ’¬–ì@‹B, ŠÖŒûK•v, •–ØŒ’Žu, ŽRè@_, ¬£‘ãŽm‹v, ˆÉ“¡—tŽq, ¬àV³l, ŒÜ\—’“s, ‘º‰zLs, ‹v‰êŒ\—S, šê“c@_, ÂÀ˜a—²: Rhythm control vs. Rate control: “´’²—¥‰»‚É‚æ‚èS‹@”\‚ª³í‰»‚µ‚½S–[×“®‡•¹Šg’£Œ^S‹ØÇ‚̈ê—áD •s®–¬Ž¡—Íu‰‰‰ïiVŠƒj6ŒŽ, 2009
  19. ’¬–ì@‹B, ŠÖŒûK•v, šê“c@_, ’·’Jì’q–¾, ˆ­”üˆÀ‹IŽq, “n•”_–¾, HŽR‘åŽ÷, j‘º‰À], ¬£‘ãŽm‹v, ŒÜ\—’“s, ‘º‰zLs, ‹v‰êŒ\—S, ÂÀ˜a—²: •p”‰ñ˜H“¯’è‚ÉCARTO‚ª—L—p‚Å‚ ‚Á‚½‹rŽ}ŠÔƒŠƒGƒ“ƒgƒŠ[«SŽº•p”‚̈ê—áD ŠÖ“ŒƒAƒuƒŒ[ƒVƒ‡ƒ“ƒZƒ~ƒi[2009i‚‚­‚΁j6ŒŽ, 2009
  20. ‰Í–ì@—¹: W’†Ž¡—×̈æ‚É‚¨‚¯‚éƒÀŽÕ’f–ò‚Ì–ðŠ„“à‰Èˆã‚Ì—§ê‚©‚çD ŽüpŠú‚Ì•s®–¬ƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi•Ÿˆäj6ŒŽ, 2009
  21. £”ö—RL: S•s‘SŽ¡—Âɂ¨‚¯‚éCRTD CRT/ICDƒZƒ~ƒi[i‹ž“sj6ŒŽ, 2009
  22. £”ö—RL: CRT“K‰žŒˆ’è‚ÌŽÀÛ@’}”g‘åŠw•‘®•a‰@‚ł́D ‘æ8‰ñƒGƒR[ƒ‰ƒCƒu‘åãi_ŒËj6ŒŽ, 2009
  23. £”ö—RL: J-CRTŠTàD ‘æ26‰ñ¬‘qƒ‰ƒCƒuƒfƒ‚ƒ“ƒXƒgƒŒ[ƒVƒ‡ƒ“i¬‘qj6ŒŽ, 2009
  24. £”ö—RL: AV delay, VV delay Ý’èD ‘æ26‰ñ¬‘qƒ‰ƒCƒuƒfƒ‚ƒ“ƒXƒgƒŒ[ƒVƒ‡ƒ“i¬‘qj6ŒŽ, 2009
  25. ÂÀ˜a—²: ãŽº«•s®–¬‚ɑ΂·‚é•ïŠ‡“I‚ȃnƒCƒuƒŠƒbƒh—Ö@D ‘æ20‰ñŽ­Ž™“‡•s®–¬Œ¤‹†‰ïiŽ­Ž™“‡j7ŒŽ, 2009
  26. –{ŠÔ@Šo: ˆã—Ísˆ×ŠÖ˜AŽ€‚Ì’²¸•ªÍƒ‚ƒfƒ‹Ž–‹Æ‚ÌŒ»ó‚ÆŽ–ŒÌ’²¸‚Ì‚ ‚è•ûD “Œ‹žˆã‰ÈŽ•‰È‘åŠwˆã—ÈÀ‘Su‰‰‰ïi“Œ‹žj7ŒŽ, 2009
  27. –{ŠÔ@Šo: ”x‚ŒŒˆ³Ž¡—Â̐i•àD ‘æ3‰ñˆïé”x‚ŒŒˆ³Ç§˜b‰ïi‚‚­‚΁j7ŒŽ, 2009
  28. –{ŠÔ@Šo: ˆã—Ísˆ×ŠÖ˜AŽ€‚Ì’²¸•ªÍƒ‚ƒfƒ‹Ž–‹Æ‚ÌŒ»ó‚ƈã—ÈÀ‘SD ’}”gŠw‰€•a‰@ˆã—ÈÀ‘Su‰‰‰ïi‚‚­‚΁j7ŒŽ, 2009
  29. ‰Í–ì@—¹: W’†Ž¡—×̈æ‚É‚¨‚¯‚éƒÀŽÕ’f–ò‚Ì–ðŠ„“à‰Èˆã‚Ì—§ê‚©‚çD ƒÀƒuƒƒbƒJ[Œ¤‹†‰ïi‰º–ìj7ŒŽ, 2009
  30. ‰Í–ì@—¹: S•s‘S‚Ì”­¶‚̃ƒJƒjƒYƒ€‚©‚çf’fEÅVŽ¡—à S•s‘S‚Ì–ò•¨—Ö@D ˆïéS‘ŸƒtƒH[ƒ‰ƒ€i…ŒËj7ŒŽ, 2009
  31. £”ö—RL: Ï‹É“IŽ‰Ž¿’ቺ—Ö@D ’}”g‹L”O•a‰@˜AŒgŒã‰‡‰ïi‚‚­‚΁j7ŒŽ, 2009
  32. ‰Í–ì@—¹, ˆÀ“c@v, ‰ºžŠMˆÐ, ”‹’JŒ\ˆê, ‚‹´Ls, …’J‘¾˜Y: W’†Ž¡—×̈æ‚É‚¨‚¯‚éS–[×“®‚ÌŽ¡—Ã’´’ZŠúì—pŒ^ƒÀŽÕ’f–ò‚É‚æ‚鎡—Ð헪D ‘æ3‰ñˆïéŒ§ŽüpŠúŠÇ—ƒZƒ~ƒi[iˆïéj8ŒŽ, 2009
  33. £”ö—RL: CRT“K‰žŒˆ’èD “ú–{ƒƒhƒgƒƒjƒbƒNŽÐ“àuK‰ïi“Œ‹žj8ŒŽ, 2009
  34. ÂÀ˜a—²: S–[×“®‚̐V‚µ‚¢l‚¦•û‚ƍŐVŽ¡—Â̈ʒu•t‚¯D ‘æ3‰ñ“ì‹I˜a‰ÌŽRzŠÂŠíƒJƒ“ƒtƒ@ƒŒƒ“ƒXi˜a‰ÌŽRj9ŒŽ, 2009
  35. ÂÀ˜a—²: Management of Atrial Fibrillation: Medical or Ablation. ‘æ12‰ñJCC-ACCƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€iŽD–yj9ŒŽ, 2009
  36. ÂÀ˜a—²: S–[×“®Ž¡—Âƃ[ƒtƒ@ƒŠƒ“‚Ì“úíŠÇ—D ‘æ1‰ñˆïéŒ§•s®Total Management SeminariŒÃ‰Íj9ŒŽ, 2009
  37. –{ŠÔ@Šo: “úí—Տ°‚É‚¨‚¯‚é”x‚ŒŒˆ³Ç‚̐f‚©‚½E‚‚«‚ ‚¢•ûD ŽæŽè–k‘Š”n”x‚ŒŒˆ³ÇƒtƒH[ƒ‰ƒ€iŽæŽèj9ŒŽ, 2009
  38. –{ŠÔ@Šo: ƒ‚ƒfƒ‹Ž–‹Æ‚̈ïéŒ§‚É‚¨‚¯‚錻ó‚ƉۑèD f—Ísˆ×‚ÉŠÖ˜A‚µ‚½Ž€–S‚Ì’²¸•ªÍƒ‚ƒfƒ‹Ž–‹Æu‰‰‰ïiå‘äj9ŒŽ, 2009
  39. Žðˆä@r: JSH2009‚̉ü’è“_‚ƐV‹KƒŒƒjƒ“EƒAƒ“ƒMƒIƒeƒ“ƒVƒ“Œn‘jŠQ–ò‚̘b‘èD ˆïéŒ§—§’†‰›•a‰@E•af˜AŒgƒNƒŠƒjƒJƒ‹ƒŒƒNƒ`ƒƒ[iŠ}ŠÔj9ŒŽ, 2009
  40. £”ö—RL: “®–¬d‰»”»’è‚É‚¨‚¯‚éŒz“®–¬ƒGƒR[‚Ì—L—p«D ¯Œ´ˆãŽt‰ïu‰‰‰ïiL“‡j9ŒŽ, 2009
  41. £”ö—RL: ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚̗Տ°‰ž—pD ‘æ22‰ñÔéSƒGƒR[Œ¤‹†‰ïi‘O‹´j9ŒŽ, 2009
  42. £”ö—RL: ŒŒˆ³’²ß‚̃zƒƒIƒXƒ^[ƒVƒX‚ÆŠe~ˆ³–ò‚̍ì—pD ‘æ4‰ñˆïéS‘ŸƒtƒH[ƒ‰ƒ€i…ŒËj9ŒŽ, 2009
  43. ÂÀ˜a—²: S–[×“®Ž¡—Ã: Å‹ß‚̘b‘èD ‘æ5‰ñ‹{éŒ§Œ§–kzŠÂŠíŒ¤‹†‰ïi‹{éj10ŒŽ, 2009
  44. ’¬–ì@‹B, ŠÖŒûK•v, óì“N–ç, ¬£‘ãŽm‹v, ¬àV³l, ŽRè@_, ŒÜ\—’“s, •–ØŒ’Žu, ˆÉ“¡—tŽq, í‰ªG˜a, ‹v‰êŒ\—S, šê“c@_, ÂÀ˜a—²: Scar—̈æ“à‚ł̍‚o—̓y[ƒVƒ“ƒO‚ð—p‚¢‚Ä, S“à–Œ‘¤‚¨‚æ‚ѐSŠO–Œ‘¤‚©‚ç‚̃AƒuƒŒ[ƒVƒ‡ƒ“‚ɐ¬Œ÷‚µ‚½Non-ischemic VT‚̈ê—áD ƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘å‰ïiì‰zj10ŒŽ, 2009
  45. ‰Í–ì@—¹: Šg’£Œ^S‹ØÇ‚ƏãŽè‚ɂ‚«‚ ‚¤‚½‚ß‚Ì’mŽ¯D •½¬21”N“x‚‚­‚Εی’ŠEí‘•ÛŒ’Š“ï•au‰‰‰ïiÎ‰ºj10ŒŽ, 2009
  46. £”ö—RL: S•s‘SŽ¡—Âɂ¨‚¯‚éCRTD CRT/ICDƒZƒ~ƒi[i•Ÿ‰ªj10ŒŽ, 2009
  47. £”ö—RL: “®–¬d‰»‚ÌŒ´ˆö‚Æ‚»‚ÌŒŸ¸–@D ‚‚­‚ÎŽsŽs–¯ŒöŠJuÀi‚‚­‚΁j10ŒŽ, 2009
  48. £”ö—RL: “®–¬d‰»”»’è‚É‚¨‚¯‚éŒz“®–¬ƒGƒR[‚Ì—L—p«D ”ö“¹ˆãŽt‰ïu‰‰‰ïiL“‡j10ŒŽ, 2009
  49. £”ö—RL: •Ç‰^“®•]‰¿‚ŐSƒGƒR[‚ª–ð‚É—§‚Á‚½2Ç—á‚Æ‚»‚̃|ƒCƒ“ƒgD ‘æ7‰ñ“ú–{SƒGƒR[}Šw‰ïHŠúuK‰ïi“Œ‹žj10ŒŽ, 2009
  50. ÂÀ˜a—²: S–[×“®-Å‹ß‚̘b‘è-D ƒCƒ‹ƒxƒ^ƒ“”­”„1Žü”N‹L”Ou‰‰‰ïiŽR—œj11ŒŽ, 2009
  51. ÂÀ˜a—²: S–[×“®‚̍ŋ߂̍l‚¦•ûD ‘æ7‰ñƒI[ƒ^ƒ€zŠÂŠíƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi“Œ‹žj11ŒŽ, 2009
  52. ‰Í–ì@—¹: ŽüpŠú‚̏zŠÂŠíŽ¾Š³ŠÇ—‚É‚¨‚¢‚Đҍ–ò‚ð‚¤‚Ü‚­Žg‚¢‚±‚È‚·‚ɂ́D ‘æ2‰ñMBŽüpŠúzŠÂŠÇ—Œ¤‹†‰ïi¼–{j11ŒŽ, 2009
  53. £”ö—RL: ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚̗Տ°‰ž—pD ‘æ8‰ñí—¤…ŒË‰æ‘œf’fŒ¤‹†‰ïiŠ}ŠÔj11ŒŽ, 2009
  54. Î’Ã’qŽq: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[@’m‚Á‚Ä‚¢‚Ä‘¹‚Í‚È‚¢SƒGƒR[‚̘bG‹¹’ÉŠ³ŽÒ‚³‚ñ‚̐SƒGƒR[‚ð‚Æ‚éÛ‚ÌtipsD ‘æ21‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ïi“Œ‹žj11ŒŽ, 2009
  55. Žðˆä@r: ƒGƒ“ƒhƒZƒŠƒ“‚Æ”x‚ŒŒˆ³Ç‚Æ‚ÌŠÖŒWD “È–ØŒ§“ì•””x‚ŒŒˆ³ÇƒtƒH[ƒ‰ƒ€i¬ŽRj11ŒŽ, 2009
  56. ÂÀ˜a—²: •s®–¬‚Ì”ñ–ò•¨Ž¡—ÁD ‘æ9‰ñ“ú–{“à‰ÈŠw‰ïŠÖ“ŒŽx•”ŽåÃ“à‰ÈƒZƒ~ƒi[i“Œ‹žj12ŒŽ, 2009
  57. ÂÀ˜a—²: ARB‚ƐS•ÛŒìì—p@|“Á‚ɐS–[×“®‚ɑ΂·‚é‰e‹¿|D “Œ“üŠÔˆãŽt‰ïŠwpu‰‰‰ïiì‰zj12ŒŽ, 2009
  58. £”ö—RL: SƒGƒR[–@‚É‚æ‚éCRT‚Ì“K‰žŒˆ’è‚ɂ‚¢‚āD ‰¡•lŽs—§‚݂ȂƐԏ\Žš•a‰@, ‰¡•l“실Ï•a‰@‡“¯•×‹­‰ïi‰¡•lj12ŒŽ, 2009

@2008”N“xi2008”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. ‰Í–ì@—¹, ”óŒûr•F, ŠÖŒûK•v, ’¬–ì@‹B, “cK˜aŽq, HŽR‘åŽ÷, ¬ŽR@’, ‘º‰zLs, “n•Óds, ÂÀ˜a—²: “ûŠàŽ¡—Ì㉓ŠuŠú‚É”­Ç‚µ‚½ãs‘å“®–¬áŽ‚̈ê—á. ‘æ42‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïŠwpW‰ïi“Œ‹žj1ŒŽ, 2008
  2. ’¬–ì’qŽq, £”ö—RL, Î’Ã’qŽq, –{ŠÔ@Šo, “n•Óds, ÂÀ˜a—²: táŠQ, CRP‚’l, DŽ_‹…‘‰Á‚Éèò“®–¬•sˆÀ’èƒvƒ‰[ƒN‚𔺂¤Š³ŽÒ‚͍‚—¦‚É‘å“®–¬•sˆÀ’èƒvƒ‰[ƒN‚ð—L‚·‚é. ‘æ12‰ñˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ïi‚‚­‚΁j1ŒŽ, 2008
  3. £”ö—RL: ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚é‘å“®–¬•Ù‹t—¬Ç‚̐öÝ“IS‹ØáŠQ‚ÌŒŸo. ‘æ4‰ñS‹Ø‰ïi“Œ‹žj2ŒŽ, 2008
  4. £”ö—RL: CRT“K‰žÇ—á‘I•Ê‚É‚¨‚¯‚éSƒGƒR[}–@‚Ì—L—p«‚Ɖۑè.@ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“@CRT-D Updated. ‘æ1‰ñA‚¦ž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ïi“Œ‹žj2ŒŽ, 2008
  5. “ìê—zˆê, “n•Óds, •ˆÀ–@”V, £”ö—RL, ”óŒûr•F, ’¬–ì’qŽq, ’¬–ì@‹B, ‘º‰zLs, ¬ŽR@’, ”nê‰ëŽq, ‰Í–ì@—¹, ŽR–{¹—Ç, ÂÀ˜a—², ¯–ìä“ñ, –쑺•¶ˆê, ˆé‘º@³: BatistaŽèp‚ðs‚Á‚½Žá”NŠg’£Œ^S‹ØÇ‚̈ê—á. ‘æ207‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽ, 2008
  6. Î’Ã’qŽq, £”ö—RL, “n•Óds, ÂÀ˜a—²: –«t‘Ÿ•a‚ð—L‚·‚鍂—î‹•ŒŒ«SŽ¾Š³—á‚É‚¨‚¯‚éƒXƒ^ƒ`ƒ“‚ÌŒø‰Ê.Œz“®–¬’´‰¹”g–@‚ð—p‚¢‚½ŒŸ“¢. ‘æ47‰ñ“ú–{˜V”NˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj3ŒŽ, 2008
  7. œA“c’qÆ, “n•Óds, ¬ŽR@’, •ˆÀ–@”V, £”ö—RL, ‰|–{‰ÀŽ¡, ’r“cW•F, “¿‰iç•ä, åŒ´@Œª, ÂÀ˜a—²: ‘å“®–¬•Ù’uŠ·‚¨‚æ‚ÑŠ¥“®–¬ƒoƒCƒpƒXŽèp‚ðŽ{s‚µ‚½’´‚—îŽÒ‚̈ê—á. ‘æ47‰ñ“ú–{˜V”NˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj3ŒŽ, 2008
  8. Shimizu A, Nitta T, Imai K, Kurita T, Kobayashi Y, Niwano S, Watanabe S, Soejima K, Abe N: Symposium : ICD Therapy for Idiopathic Ventricular Fibrillation in Japan -The ICD-WEB Registry administered by the Japanese Heart Rhythm Society. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  9. Takagi M, Yokoyama Y, Aonuma K, Aihara N, Hiraoka M: Symposium : Clinical and Electrophysiological Differentiation of Symptomatic and Asymptomatic Patients with Brugada Syndrome -The Japan Idiopathic Ventricular Fibrillation Study (J-IVFS) -. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  10. Takahashi A, Kuwahara T, Kobori A, Takahashi Y, Miyazaki S, Tamura M, Ohhigashi H, Nozato T, Hikita H, Sato A, Iesaka Y, Aonuma K, Isobe M: Symposium : Long Term Follow up of Catheter Ablation Therapy for Chronic Atrial Fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  11. Akiyama D, Sekiguchi Y, Yamauchi Y, Nitta J, Ootomo K, Naitou S, Asagawa T, Koyama T, Yamasaki H, Kuga K, Yamaguchi I, Aonuma K: Clinical and electrophysiological features of the idiopathic polymorphic ventricular tachyarrhythmia triggered by right ventricular outflow origin repetitive ventricular responses. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  12. Yamasaki H, Seo Y, Machino T, Machino T, Kuroki K, Murakoshi N, Sekiguchi Y, Ishizu T, Kawano S, Kuga K, Watanabe S, Aonuma K: Predictive factors of the responders for the cardiac resynchronization therapy with triple-site pacing. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  13. Kuwahara T, Takahashi A, Miyazaki S, Kobori A, Takahashi Y, Takei A, Miyazaki T, Kawashima T, Tamura M, Ohhigashi H, Nozato T, Hikita H, Sato A, Aonuma K: Clinical Characteristics of Air Embolism Complicating Left Atrial Ablation for Atrial Fibrillation :@Lessons from Eight Cases. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  14. Koyama T, Sekiguchi Y, Tajiri K, Higuchi H, Akiyama D, Arimoto T, Yamasaki H, Machino T, Kuroki K, Kuga K, Yamaguchi I, Aonuma K: Predictors of Immediate Recurrence and Early Recurrence after Extensive Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  15. Kuwahara T, Takahashi A, Miyazaki S, Kobori A, Takahashi Y, Takei A, Miyazaki T, Kawashima T, Tamura M, Ohhigashi H, Nozato T, Hikita H, Sato A, Aonuma K: Mechanisms of Recurrent Atrial Fibrillation Resistant to Repeated Ablation Therapy. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  16. Sakamaki F, Seo Y, Ishizu T, Machino T, Iida N, Nakajima H, Inaba T, Kawamura R, kanemoto M, Sekiguchi Y, Fumikura Y, Kawano S, Noguchi Y, Watanabe S, Aonuma K: Utility of Modified Septal-to-Posterior Wall Motion Delay with Anatomical M-Mode Echocardiography as a Predictor of Responders of Cardiac Resynchronization Therapy. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  17. Machino T, Naito S, Sekiguchi Y, Kuroki K, Yamasaki H, Yoshida K, Kanemoto M, Murakoshi N, Kuga K, Tanaka Y, Tada H, Aonuma K: Hybrid therapy of pulmonary vein isolation and percutaneous transluminal mitral commisurotomy in patients with atrial fibrillation and mitral valve stenosis. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  18. Sakai S, Katayanagi S, Warabi E, Sugimoto R, Yanagawa T, Yoshida H, Noguchi N, Aonuma K, Ishii T: A170 Deficiency Causes Enhanced Vascular Remodeling and Vascular Smooth Muscle Cell Proliferation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  19. Kobori A, Takahashi A, Miyazaki S, Takahashi Y, Takei A, Kuwahara T, Miyazaki T, Kawashima T, Tamura M, Ohhigashi H, Nazato T, Hikita H, Sato A, Aonuma K: Adenosine Triphosphate Expose Dormant Conduction between the Thoracic Veins and the Atrium Responsible for Recurrent Atrial Fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  20. Kobori A, Takahashi A, Miyazaki S, Takahashi Y, Takei A, Kuwahara T, Miyazaki T, Kawashima T, Tamura M, Ohhigashi H, Nozato T, Hikita H, Sato A, Aonuma K: Gender-Related Differences in Patients with Drug-Resistant Atrial Fibrillation:Insights from Catheter Ablation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  21. Ishizu T, Seo Y, Shiotsuka J, Nakajima H, Machino T, Kawamura R, Nishina H, Takeyasu N, Noguchi Y, Watanabe S, Aonuma K: Impaired Subendocardial and Compensated Subepicardial Wall Thickening at Rest in Patients with Severe Coronary Stenosis but Visually Normal Wall Motion. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  22. Shimojo N, Sakai S, Maeda S, Miyauchi T, Aonuma K: Inhibitory Effect of Fluvastatin on Cardiac hypertrophy is Partly Attributed to Interference of JNK and Pin-1 Activation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  23. Murakoshi N, Yoshida K, Kamimura R, Setoyama K, Tanoue K, Imanaka K, Yoshida T, Hiroe M, Sekiguchi Y, Yamaguchi I, Aonuma K: AAV-mediated HCN4 Gene Transfer to Cardiac Conduction System is a Therapeutic Potential as a Biological Pacemaker. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  24. Uno K, Tonomura A, Yamakawa M, Ishizu T, Seo Y, Honma S, Shiina T, Aonuma K: Aging of Venous Thrombosis - Comparison between histological and tissue elasticity imaging. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  25. Yamamoto M, Seo Y, Ishizu T, Machino T, Sakamaki F, Nakajima H, Iida N, Kawamura R, Watanabe S, Aonuma K: Importance of Assessing Septal Tissue Velocity during Pre-ejection Period in Identifying Dyssynchrony in Patients with Left Bundle Branch Block. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  26. Arimoto T, Yokoyama Y, Sekiguchi Y, Koyama T, Yamasaki H, Machino T, Kuroki K, Kuga K, Aonuma K: Benefit of radiofrequency catheter ablation for ventricular tachycardia in patients with implantable cardioverter defibrillator. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  27. Seo Y, Ishizu T, Machino T, Nakajima H, Sakamaki F, Iida N, Sekiguchi Y, Kawano S, Watanabe S, Aonuma K: Relationship between Systolic Septal Wall Contraction and Responsiveness to Cardiac Resynchronization Therapy in Patients with Left Bundle Branch Block. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  28. Iida N, Ishizu T, Seo Y, Kanemoto M, Fumikura Y, Hiranuma Y, Kawano S, Noguchi Y, Watanabe S, Aonuma K: Effect of Left Ventricular Dyssynchrony and Resynchronization Therapy on Twist in Patients with Dilated Cardiomyopathy. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  29. Yamasaki H, Seo Y, Machino T, Kuroki K, Machino T, Murakoshi N, Sekiguchi Y, Ishizu T, Kawano S, Kuga K, Watanabe S, Aonuma K: The prognosis of the advanced heart failure patients receiving cardiac resynchronization therapy our initial experience for past 3 years. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  30. Ishizu T, Seo Y, Machino T, Kawamura R, Takeyasu N, Watanabe S, Aonuma K: Improvement of Carotid Arterial Intima-Media Complex Irregularity as a Sensitive Marker of Atherosclerosis Regression in Aggressive Cholesterol Lowering Therapy. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  31. Machino T, Seo Y, Ishizu T, Uno K, Watanabe S, Aonuma K: Patients with Cholesterol Crystal Embolism Have Carotid Vulnerable Plaque Resembling Aortic Plaque. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  32. Tada H, Oral H, Chugh A, Yoshida K, Good E, Pelosi F, Bogun F, Jongnarangsin K, Morady F: Distribution of Continuous Electrical Activity in Paroxysmal and Chronic Atrial Fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  33. Okada H, Yamauchi Y, Suzuki A, Kusa S, Kanoh H, Kawasaki M, Sugiyama T, Ohyama A, Takamizawa C, Miyamoto T, Obayashi T, Sekiguchi Y, Aonuma K, Isobe M: Efficacy of Additional Atrial Linear Ablation for Non-pulmonary Vein Origin Atrial Fibrillation Occurring after Pulmonary Vein Isolation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  34. Sekiguchi Y, Koyama T, Arimoto T, Yamasaki H, Machino T, Kuroki K, Kuga K, Yamauchi Y, Yamaguchi I, Aonuma K: Radiofrequency catheter ablation for chronic atrial fibrillation lasting for an extremely long period. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  35. Sekiguchi Y, Koyama T, Arimoto T, Yamasaki H, Machino T, Kuroki K, Kuga K, Yamauchi Y, Yamaguchi I, Aonuma K: Role of pre-existent left atrial low voltage area in patients with chronic atrial fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  36. Kobori A, Takahashi A, Miyazaki S, Takahashi Y, Takei A, Kuwahara T, Miyazaki T, Kawashima T, Tamura M, Ohhigashi H, Nozato T, Hikita H, Sato A, Aonuma K: Difficulty of Catheter Ablation for the Management of Atrial Fibrillation in patients with Chronic Hemodialysis. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  37. Takahashi A, Kuwahara T, Kobori A, Takahashi Y, Miyazaki S, Takei A, Tamura M, Ohhigashi H, Nozato T, Hikita H, Sato A, Iesaka Y, Aonuma K, Isobe M, Koike A: Catheter Ablation Improves Exercise Tolerance in Patients with Chronic Atrial Fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  38. Kuwahara T, Takahashi A, Miyazaki S, Kobori A, Takahashi Y, Takei A, Miyazaki T, Kawashima T, Tamura M, Ohhigashi H, Nozato T, Hikita H, Sato A, Aonuma K: Effect of Catheter Ablation on the Management of Atrial Fibrillation in Patients With Impaired Left Ventricular Systolic Function. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  39. Machino T, Ishizu T, Seo Y, Machino T, Kuroki K, Machino T, Yamasaki H, Arimoto T, Koyama T, Yoshida K, Sekiguchi Y, Kuga K, Aonuma K: Effects of Pulmonary Vein Isolation to Cardiac Function of Elderly Patients with Atrial Fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  40. Ishizu T, Seo Y, Takeyasu N, Nakajima H, Machino T, Kawamura R, Aihara H, Nishina H, Watanabe S, Aonuma K: Evaluation of Jeopardized Myocardium by Transmural Myocardial Strain Gradient and Adenosine Stress Echocardiography. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  41. Kuroki K, Sekiguchi Y, Koyama T, Yamasaki H, Machino T, Kuga K, Yamaguchi I, Aonuma K: Efficacy of Radiofrequency Catheter Ablation for Frequent Ventricular Premature Beats in Patients with Structural Heart Disease. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  42. Iida N, Seo Y, Ishizu T, Machino T, Kawamura R, Sakamaki F, Nakajima H, Inaba T, Watanabe S, Aonuma K: Relationship between Transmural Strain Rate Distribution and Severity of Aortic Regurgitation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  43. Nakajima H, Ishizu T, Seo Y, Kameya S, Iida N, Sakamaki F, Inaba T, Machino T, Kawamura R, Kawano S, Watanabe S, Aonuma K: Transmural and Segmental Heterogeneity of Strain Distribution in Normal Adult Heart Using Novel Speckle Tracking Imaging. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  44. Shimojo N, Jesmin S, Zaedi S, Maeda S, Miyauchi T, Aonuma K: Estrogen Pre-treatment Prevents ET-1-induced Cardiomyocyte Hypertrophy through Modulation of VEGF. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  45. Yamauchi Y, Suzuki A, Kusa S, Kanoh H, Kawasaki M, Sugiyama T, Ohyama A, Takamura C, Okada H, Miyamoto T, Obayashi T, Sekiguchi Y, Aonuma K, Isobe M: Linear Atrial Substrate Modification in Chronic Atrial Fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  46. Arimoto T, Sekiguchi Y, Koyama T, Higuchi H, Yamasaki H, Machino T, Kuroki K, Kuga K, Yamaguchi I, Aonuma K: Prognostic impact of extra pulmonary vein firing after extensive pulmonary vein electrical isolations. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  47. Uno K, Tonomura A, Yamakawa M, Ishizu T, Seo Y, Honma S, Shiina T, Aonuma K: Aging of Venous Thrombus with Ultrasonographic Tissue Elasticity Imaging. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  48. Nakagawa Y, Watanabe S, Takeyasu N, Arai E, Ajisaka R, Morimoto T, Nishina H, Satoh Y, Tajiri K, Aihara H, Ishiyama M, Liang J, Aonuma K: Effect of Alpha-glucosidase Inhibitor Miglitol on Anaerobic Threshold and Metabolism During Exercise. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  49. Shimojo N, Jesmin S, Zaedi S, Maeda S, Miyauchi T, Aonuma K: Cardioprotective Effect of Eicosapentaenoic Acid, an Important Fish Oil, through Suppression of Endothelin-1-induced Cardiomyocyte Hypertrophy via PPAR-alpha. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  50. Shimojo N, Jesmin S, Zaedi S, Yamaguchi N, Maeda S, Miyauchi T, Aonuma K: Involvement of HIF-1alpha and beta in Contributory Role of VEGF in Endothelin-1-induced Cardiomyocyte Hypertrophy. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  51. Misumi K, Iiduka D, Itakura Y, Arai Y, Oouchi K Kadota K, Hirose M, Tone K, Taniguchi Y, Shimizu S, Hirose M, Tone K, Yoshiwara H, Shimizu S, Inaba Y, Ebihara T, Yamamoto M, Yoshida T, Nitta M, Shibayama H, Kanoh H, Kuramochi T, Sato A: Long term clinical outcome (>1 years) of Rotablator plus Cypher in treating calicified ostial RCA lesion compared to BMS strategy. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  52. Takahashi Y, Miyazaki S, Kuwahara T, Kobori A, Takahashi Y, Takei A, Miyazaki T, Kawashima T, Tamura M, Ohigashi H, Nozato T, Hikita H, Sato A, Isobe M, Takahashi A: Recurrent atrial tachycardias after catheter ablationof chronic atrial fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  53. Kawashima T, Hikita H, Miyazaki T, Tamura M, Ohigashi H, Miyazaki S, Kobori A, Takahashi Y, Takei A, Nozato T, Kuwahara T, Sato A, Takahashi A, Isobe M: Relationship between temporary discontinuation of dual-antiplatelet therapy after Sirolimus-eluting stent implantation and stent thrombosis. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  54. Miyazaki S, Takahashi A, Kobori A, Takahashi Y, Takei A, Kuwahara T, Tamura M, Ohigashi H, Nozato T, Hikita H, Sato A, Isobe M: New strategy of left atrial fibrillation:Bepridil can lead to appropriate ablation strategy. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  55. Ohigashi H, Sato A, Kawashima T, Miyazaki T, Nozato T, Hikita H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Kuwahara T, Takahashi A, Hiroe M, Isobe M: Correlation between myocardial contrast enhancement of multidetector computed tomography and dual 123I-BMIPP/201-thallium SPECT for myocardial viability after acute myocardial infarction. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  56. Kubo T, Misumi K, Iiduka D, Itakura Y, Arai Y, Oouchi K Kadota K, Hirose M, Tone K, Taniguchi Y, Shimizu S, Hirose M, Tone K, Yoshiwara H, Shimizu S, Inaba Y, Ebihara T, Yamamoto M, Yoshida T, Nitta M, Shibayama H, Kanoh H, Kuramochi T, Sato A, Murata M, Kubo I: Clinical impact of simultaneous kissing stent (SKS) using DES to treat bifurcating lesion of LMT/LAD/LCX in non-opeable patient with/without Rotablator. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  57. Hikita H, Sato A, Kawashima T, Miyazaki T, Nozato T, Ohigashi H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Hiroe M, Isobe M, Takahashi A: Lipoprotein (a) is a important factor to determine plaque morphology of the culprit lesion in patients with acute myocardial infarction. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  58. Miyazaki S, Takahashi A, Kobori A, Takahashi Y, Takei A, Kuwahara T, Tamura M, Ohigashi H, Nozato T, Hikita H, Sato A, Isobe M: Left atrial fibrillation can be safely performed in patients with atrial fibrillation and prior cerebral infarction. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  59. Miyazaki S, Takahashi A, Kobori A, Takahashi Y, Takei A, Kuwahara T, Tamura M, Ohigashi H, Nozato T, Hikita H, Sato A, Isobe M: The long-term effect of extensive pulmonary vein isolation for paroxymal atrial fibrillation. How long should we follow the patients? ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  60. Hikita H, Sato A, Kawashima T, Miyazaki T, Nozato T, Ohigashi H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Hiroe M, Isobe M, Takahashi A: Coronary flow velocity and fluid shear stress predict restenosis after drug-eluting stent implantation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  61. Tamura M, Sato A, Miyazaki T, Kawashima T, Nozato T, Ohigashi H, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Takahashi A, Hiroe M, Isobe M: Association of chronic kidney disease, diabetes mellitus and coronary atherosclerosis by Computed Tomography Angiography. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  62. Ohigashi H, Sato A, Kawashima T, Miyazaki T, Nozato T, Hikita H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Kuwahara T, Takahashi A, Hiroe M, Isobe M: Prognostic value of myocardial contrast enhancement with 64-slice multidetector computed tomography after acute myocardial infarction. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  63. Miyazaki T, Takahashi A, Miyazaki S, Kobori A, Takahashi Y, Takei A, Kuwahara T, Kawashima T, Tamura M, Ohigashi H, Nozato T, Hikita H, Sato A, Isobe M: Clinical characteristics of cardiac tamponade complicating catheter ablation therapy for atrial fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  64. Nozato T, Sato A, Miyazaki T, Kawashima T, Hikita H, Ohigashi H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Takahashi A, Kanof H, Misumi K, Isobe M: Evaluation of stent implantation in the superficial femoral artery chronic total occulsion. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  65. Iiduka D, Misumi K, Kubo T, Itakura Y, Arai Y, Oouchi K Kadota K, Hirose M, Tone K, Taniguchi Y, Shimizu S, Hirose M, Tone K, Yoshiwara H, Shimizu S, Inaba Y, Ebihara T, Yamamoto M, Yoshida T, Nitta M, Shibayama H, Kanoh H, Kuramochi T, Sato A, Kubo I: Overall clinical outcome of SMART peripheral stent in treating PAD lesions of iliac and SFA lesions compared to Wall-RP stent. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  66. Sato A, Hiroe M, Kawashima T, Miyazaki T, Nozato T, Hikita H, Ohigashi H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Takahashi A, Isobe M: Relationship between quantitative measurements of coronary stenosis severity by computed tomography angiography and the physiologic significance myocardial perfusion. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  67. Sato A, Hiroe M, Kawashima T, Miyazaki T, Nozato T, Hikita H, Ohigashi H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Takahashi A, Isobe M: Assessment of myocardial viability, left ventricular remodeling and prognosis after acute myocardial infarction with 64-slice multidetector computed tomography. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  68. Sato A, Hiroe M, Kawashima T, Miyazaki T, Nozato T, Hikita H, Ohigashi H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Takahashi A, Kanoh H, Misumi H, Isobe M: Visual and Quantitative Assessment of Angiographic Myocardial Blush Grade in Acute Myocardial Infarction With Multidetector Computed Tomography. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  69. Sato A, Hiroe M, Kawashima T, Miyazaki T, Nozato T, Hikita H, Ohigashi H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Takahashi A, Kanoh H, Misumi H, Isobe M: Clinical profiles of rapid progression of coronary artery lesions from mild to severe stenosis within one year. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  70. Sato A, Hiroe M, Kawashima T, Miyazaki T, Nozato T, Hikita H, Ohigashi H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Takahashi A, Kanoh H, Misumi H, Isobe M: Rapid progression of coronary artery lesions from mild to severe stenosis with intravascular ultrasound virtual histology. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  71. Sato A, Hiroe M, Kawashima T, Miyazaki T, Nozato T, Hikita H, Ohigashi H, Tamura M, Miyazaki S, Takahashi Y, Kobori A, Takei A, Kuwahara T, Takahashi A, Isobe M: Incremental value of combined 64-slice computed tomography angiography and stress myocardial perfusion imaging for detection of coronary artery disease. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  72. Tsurugaya H, Kawaguchi R, Tada H, Adachi H, Toyama T, Naitoh S, Hoshizaki H, Ooshima S, Taniguchi K: The comparison of outcomes between diabetic and non-diabetic patients after drug-eluting stent implantation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  73. Yokokawa M, Tada H, Satoh C, Irie T, Hori Y, Iwamoto J, Tanaka Y, Mani H, Goto K, Naitoh S, Ooshima S, Taniguchi K: Conduction properties of left atrial roof in patients with atrial fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  74. Goto K, Satoh C, Irie T, Hori Y, Tanaka Y, Iwamoto J, Mani H, Yokokawa M, Tada H, Naitoh S, Ooshima S, Taniguchi K: Long-term results of extensive encircling pulmonary vein isolation adding continuous fractionated atrial electrogram ablation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  75. Tsurugaya H, Adachi H, Yanagisawa S, Kawaguchi R, Tada H, Toyama T, Naitoh S, Hoshizaki H, Ooshima S, Taniguchi K: Safety of exercise intervention after drug-eluting stent implantation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  76. Yokokawa M, Tada H, Koyama K, Goto K, Naitoh S, Ooshima S, Taniguchi K: The characteristics and distribution of the scar tissue detected by magnetic resonance imaging may predict impending ventricular tachycardia. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  77. Kaseno K, Tada H, Fujioka N, Tsugawa H, Kajinami K: Considerable morphological differences in ventricular arrhythmias between standard and Mason-Likar modified 12-lead ECGs. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  78. Tanaka Y, Tada H, Irie T, Hori Y, Goto K, Iwamoto J, Mani H, Yokokawa M, Hiramatsu S, Naitoh S, Ooshima S, Taniguchi K: Comparison of the response to cardiac resynchronization therapy (CRT) in patients with sinus rhythm versus chronic atrial fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  79. Naitoh S, Tada H, Ooshima S, Taniguchi K: Recent strategies for total management of atrial fibrillation:the new additional tailored approaches of catheter ablation for the patients with paroxysmal and persistent atrial fibrillation. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  80. Kawamura R, Ishizu T, Seo Y, Iida N, Kanemoto M, Fumikura Y, Hiranuma Y, Kawano S, Watanabe S, Aonuma K: Effect of Left Ventricular Dyssynchrony and Resynchronization Therapy on Twist in Patients with Dilated Cardiomyopathy. ‘æ72‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi•Ÿ‰ªj3ŒŽ, 2008
  81. Î’Ã’qŽq, £”ö—RL, “n•Óds, ÂÀ˜a—²: –«t‘Ÿ•a‚ð—L‚·‚鍂—î‹•ŒŒ«SŽ¾Š³Ç—á‚É‚¨‚¯‚éƒXƒ^ƒ`ƒ“‚ÌŒø‰Ê@Œz“®–¬’´‰¹”g–@‚ð—p‚¢‚½ŒŸ“¢. ‘æ47‰ñ“ú–{˜V”NˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj3ŒŽ, 2008
  82. Î’Ã’qŽq, £”ö—RL, ’†“‡‰pŽ÷, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ’¬–ì’qŽq, •ˆÀ–@”V, m‰ÈG’, ÂÀ˜a—²: ƒVƒ“ƒ|ƒWƒEƒ€: ATP•‰‰×‚É‚¨‚¯‚éS‹ØƒXƒgƒŒƒCƒ“Œù”z‰ðÍ‚É‚æ‚éS‹ØŒŒ—¬ˆÙí‚Ì•]‰¿. ‘æ19‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi_ŒËj4ŒŽ, 2008
  83. ”Ñ“c“TŽq, £”ö—RL, Î’Ã’qŽq, ’¬–ì’qŽq, ì‘º@—´, ŽðŠª•¶Žq, ’†“‡‰pŽ÷, ˆî—t@•, “n•Óds, ÂÀ˜a—²: ‘å“®–¬•Ù•Â½•s‘SÇ‚É‚¨‚¯‚鍶ŽºS“à–Œ‘¤EŠO–Œ‘¤ƒXƒgƒŒƒCƒ“‰ðÍ;‚»‚̏dÇ“x‚¨‚æ‚ÑŽèpŒãS‹@”\‚Æ‚ÌŠÖŒW‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ19‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi_ŒËj4ŒŽ, 2008
  84. ŽR“c^ŠìŽq, £”ö—RL, Î’Ã’qŽq, ¬À´Ž¡, ‰““¡—DŽ}, ÂÀ˜a—²: Speckle-tracking imaging–@‚ð—p‚¢‚½¶–[ŽûkŽž¶ŽºƒXƒgƒŒƒCƒ“ƒŒ[ƒg‚ƍ¶ŽºŠg’£––Šúˆ³‚Æ‚ÌŠÖ˜A. ‘æ19‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi_ŒËj4ŒŽ, 2008
  85. ‹T’J—¢”ü, £”ö—RL, Î’Ã’qŽq, ’†“‡‰pŽ÷, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t@•, ’¬–ì’qŽq, ì‘º@—´, ÂÀ˜a—²: ¶‹rƒuƒƒbƒNÇ—á‚É‚¨‚¯‚é’†Šu•Ç‰^“®‚ƐS‹@”\‚Æ‚ÌŠÖ˜A. ‘æ19‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi_ŒËj4ŒŽ, 2008
  86. ŽðŠª•¶Žq, £”ö—RL, Î’Ã’qŽq, ‹T’J—¢”ü, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t@•, ’¬–ì’qŽq, ‹à–{@“s, –ìŒû—Sˆê, ÂÀ˜a—²: S‘ŸÄ“¯Šú—Ö@ƒŒƒXƒ|ƒ“ƒ_[—\‘ª‚É‚¨‚¯‚é”CˆÓ•ûŒüMƒ‚[ƒh–@‚Ì—L—p«. ‘æ19‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi_ŒËj4ŒŽ, 2008
  87. £”ö—RL, Î’Ã’qŽq, ì‘º@—´, ‰|–{‰ÀŽ¡, ’†“‡‰pŽ÷, ÂÀ˜a—²: ŽOŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½S‹ØƒXƒgƒŒƒCƒ“•]‰¿. ‘æ19‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ïi_ŒËj4ŒŽ, 2008
  88. —L–{‹M”Í, ‰¡ŽR‘לA, ŠÖŒûK•v, ¬ŽR@’, ‹v‰êŒ\—S, ÂÀ˜a—²: SŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—LŒø«Až‚ÝŒ^œ×“®ŠíiICDj‚ð‘}“ü‚µ‚½Ç—á‚Å‚ÌŒŸ“¢. ‘æ105‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïi“Œ‹žj4ŒŽ, 2008
  89. ‹v‰êŒ\—S, ˜–쌋Šó, ŽRè@_, ”óŒûr•F, ’¬–ì@‹B, ŠÖŒûK•v, ™]@ª, ÂÀ˜a—²: R•s®–¬–ò‚¨‚æ‚Ñ”xÃ–¬Šu—£p‚É’ïR«‚Ì”­ì«S–[×“®‚ɑ΂µ‚ÄŽ©—¥ŒP—û–@‚ª’˜Œø‚µ‚½1—á. ‘æ105‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïi“Œ‹žj4ŒŽ, 2008
  90. šê“c@_, “c’†‘׏Í, ‰¡ì”üŽ÷, Œã“¡vŽm, ’†“‡@•×, ‰F’Öؗ‰À, “à“¡Ž l, ¯è@—m, ‘哇@–Î, ’JŒû‹»ˆê: S–[×“®‚ð—L‚·‚éS•s‘SÇ—á‚ɑ΂·‚éS‘ŸÄ“¯Šú—Ö@@“´’²—¥—á‚Æ‚Ì”äŠrŒŸ“¢. ‘æ105‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïi“Œ‹žj4ŒŽ, 2008
  91. ?–쌒ˆê, Š”gN“ñ, šê“c@_, “à“¡Ž l, ‹´–{@“O, •½¼–ÎŽ÷, ‰¡ì”üŽ÷, Œã“¡vŽm, ‘哇@–Î, ’JŒû‹»ˆê: Great Cardiac Vein‚ł̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚荪Ž¡‚µ‚¦‚½¶Žº—¬o˜H‹NŒ¹SŽº•p”‚Ì1—á. ‘æ115‰ñ“ú–{zŠÂŠíŠw‰ï–k—¤’n•û‰ïi‹à‘òj4ŒŽ, 2008
  92. ²“¡@–¾, “n•Óds, £”ö—RL, ‘º‰zLs, ”nê‰ëŽq, ’¬–ì’qŽq, •–ØŒ’Žu, ŽR–{¹—Ç, ˆÀ’B@‹œ, ÂÀ˜a—²: Cypher in Cypher stent‚Ìin-stent restenosis‚ɑ΂µ‚ÄTAXUS stent‚ª—LŒø‚Å‚ ‚Á‚½1—á. ‘æ2‰ñˆïéŒ§“슥Ž¾Š³Œ¤‹†‰ïi‚‚­‚΁j4ŒŽ, 2008
  93. –{ŠÔ@Šo: ”x‚ŒŒˆ³‚ɑ΂·‚é–ò•¨Ž¡—Â̐i•à |ƒ{ƒZƒ“ƒ^ƒ“‚ª”x‚ŒŒˆ³Ç‚É‹y‚Ú‚·Œø‰Ê. ‘æ1‰ñˆïé”x‚ŒŒˆ³Ç§˜b‰ïi‚‚­‚΁j4ŒŽ, 2008
  94. —L–{‹M”Í, ŠÖŒûK•v, ¬ŽR@’, ŽRè@_, ’¬–ì@‹B, •–ØŒ’Žu, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—², •›“‡‹žŽq: SŠO–Œ‘¤‚©‚ç‚̐¶—H‰–…irrigation‰ºƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚Á‚čªŽ¡‚ª‚¦‚ç‚ꂽSŽº•p”‚̈ê—áD ‘æ38‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj5ŒŽ, 2008
  95. ²“¡@–¾, “n•Óds, £”ö—RL, ‘º‰zLs, ”nê‰ëŽq, ’¬–ì’qŽq, •–ØŒ’Žu, ŽR–{¹—Ç, ˆÀ’B@‹œ, ÂÀ˜a—²: —¼‘¤ŠO’°œ|‘å‘Ú“®–¬Š®‘S•ÂÇ«•a•Ï‚ɑ΂µ‚ÄBidirectional approach‚É‚ÄŽ¡—µ‚½ˆê—á. ‘æ1‰ñˆïéPPIŒ¤‹†‰ïi‚‚­‚΁j5ŒŽ, 2008
  96. ’¬–ì’qŽq, £”ö—RL, ”óŒûr•F, Î’Ã’qŽq, ‰Í–ì@—¹, ÂÀ˜a—²: ‘å“®–¬•Ù‚ɛƓڂ·‚鍶Žº“üo˜H‚̃lƒbƒgó\‘¢•¨‚ð”F‚ß‚½1—á. ‘æ43‰ñ“Œ‹žSƒGƒR[}Œ¤‹†‰ïi“Œ‹žj5ŒŽ, 2008
  97. £”ö—RL, Î’Ã’qŽq, “n•Óds, —é–ØŒ’‰î, ÂÀ˜a—²: ŒŒŠÇƒGƒR[‘¼‚̐f’f–@‚Ƃ̃Rƒ‰ƒ{ƒŒ[ƒVƒ‡ƒ“ B-flow imaging‚É‚æ‚éèò“®–¬ƒvƒ‰[ƒN“àŒŒŠÇ‚Ì•`o. “ú–{’´‰¹”gˆãŠw‰ï‘æ81‰ñŠwpW‰ïi_ŒËj5ŒŽ, 2008
  98. Î’Ã’qŽq, £”ö—RL, ”nê‰ëŽq, ’†“‡‰pŽ÷, “n•Óds, ÂÀ˜a—²: 2DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½‚“xŠ¥“®–¬‹·ó—̈æ‚É‚¨‚¯‚éˆÀÃŽžS‹Ø“àƒXƒgƒŒƒCƒ“Œù”z‚̉ðÍ. “ú–{’´‰¹”gˆãŠw‰ï‘æ81‰ñŠwpW‰ïi_ŒËj5ŒŽ, 2008
  99. ’†“‡‰pŽ÷, Î’Ã’qŽq, ‹T’J—¢”ü, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t@•, ì‘º@—´, £”ö—RL, “n•Óds, ÂÀ˜a—²: “ñŽŸŒ³‚¨‚æ‚ÑŽOŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½¶Žº‰~Žü•ûŒüƒXƒgƒŒƒCƒ“•ª•z‚Ì”äŠr. “ú–{’´‰¹”gˆãŠw‰ï‘æ81‰ñŠwpW‰ïi_ŒËj5ŒŽ, 2008
  100. ‰F–ìŠó¢Žq, ŠO‘º–¾Žq, ‘åâ‘ìŽi, ŽO’|@‹B, {“c¹O, ŽRì@½, ’Å–¼@‹B, ˆäâ—R”ü, ÂÀ˜a—²: Ã–¬ŒŒð‚ÌŒoŽž“I•Ï‰»@Elastography‚ƃ‰ƒbƒgƒ‚ƒfƒ‹‚ð—p‚¢‚½‘gD•W–{‚Æ‚Ì”äŠr. “ú–{’´‰¹”gˆãŠw‰ï‘æ81‰ñŠwpW‰ïi_ŒËj5ŒŽ, 2008
  101. ’¬–ì’qŽq, £”ö—RL, Î’Ã’qŽq, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: èò“®–¬ƒGƒR[‚ÅŒoH“¹ƒGƒR[‚Æ—ÞŽ—‚ÌŠŸód‰»«•sˆÀ’èƒvƒ‰[ƒN‚ð”F‚ß‚½ƒRƒŒƒXƒeƒ[ƒ‹ÇðÇ‚Ì2—á. “ú–{’´‰¹”gˆãŠw‰ï‘æ81‰ñŠwpW‰ïi_ŒËj5ŒŽ, 2008
  102. ‹T’J—¢”ü, £”ö—RL, ’†“‡‰pŽ÷, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t@•, ’¬–ì’qŽq, Î’Ã’qŽq, ÂÀ˜a—²: ƒpƒ‰ƒVƒ…[ƒg‘m–X•Ù‚ɌǗ§«‘m–X•Ù—ôŒ„‚̍‡•¹‚ª‹^‚í‚ꂽ1Ç—á. “ú–{’´‰¹”gˆãŠw‰ï‘æ81‰ñŠwpW‰ïi_ŒËj5ŒŽ, 2008
  103. –ì—¢ŽõŽj, ²“¡@–¾, •D“c_”V, “c‘º”üŒbŽq, ‘å“ŒŠ°˜a, ì“‡•ü”V, ‹{è@“O, ‹{èW‰î, ‚‹´—ljp, •‹–¾“ú”ü, ŒKŒ´‘åŽu, ‚‹´@~: —¼‘¤’°œ|‘å‘Ú“®–¬CTO‚ðBidirectional Approach‚É‚ÄŽ¡—µ‚½1—á. ‘æ32‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠÖ“ŒbM‰z’n•û‰ïi’·–ìj5ŒŽ, 2008
  104. ´…º•F, V“c@—², ŒI“c—²Žu, ’ë–ìTˆê, ˆÀ•”Ž¡•F, •›“‡‹žŽq, ¡ˆäŽ•F, ¬—Ñ‹`“T, “n•Óds, –Ø‘º@„: ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“wS•s‘S‚ƐSŽº•p”x@‰ä‚ª‘‚̐S•s‘SŠ³ŽÒ‚É‚¨‚¯‚éICD/CRT-DAž‚Ý‚ÌŽÀ‘Ô‚Æ“K‰ž‚Ì•Ï‘J. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  105. ŽRè@_, ŠÖŒûK•v, ’¬–ì@‹B, •–ØŒ’Žu, ¬ŽR@’, —L–{‹M”Í, £”ö—RL, ‹v‰êŒ\—S, “n•Óds, ÂÀ˜a—²: S•s‘S‚ƐSŽº•p”@—¼SŽºƒy[ƒVƒ“ƒOAž‚Ý––ŠúS•s‘S—á‚É‚¨‚¯‚éSŽº«•s®–¬‚̍‡•¹•p“x‚Æ—\Œã. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  106. £”ö—RL, ŠÖŒûK•v, ŽRè@_, ‹g“cŒ’‘¾˜Y, ‘º‰zLs, Î’Ã’qŽq, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: CRT‚ÌŒ»ó‚Æ–¢—ˆ CRT“K‰žŒˆ’è‚É‚¨‚¯‚éSƒGƒR[ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚̉ž—p. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  107. •–ØŒ’Žu, ŠÖŒûK•v, ’¬–ì@‹B, ŽRè@_, ¬ŽR@’, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: S–[×“®Š³ŽÒ‚ɑ΂µS‘ŸÄ“¯Šú—Ö@‚Æ–[ŽºŒ‹ßƒAƒuƒŒ[ƒVƒ‡ƒ“‚𕹗p‚µ‚½7Ç—á‚ɑ΂·‚錟“¢. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  108. ’¬–ì@‹B, ŠÖŒûK•v, •–ØŒ’Žu, ŽRè@_, ¬ŽR@’, —L–{‹M”Í, ‹à–{@“s, £”ö—RL, ‹v‰êŒ\—S, “n•Óds, ÂÀ˜a—²: Œo”ç“I‘m–X•ÙŒð˜AØŠJpŒã‚Ì“´’²—¥ˆÛŽ‚ÉŠÖ‚·‚é’·Šú¬Ñ. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  109. ‰¡ŽR‘לA, äݖì’qŽq, ˆî—t@—, ˆÉ“¡‡Žq, ´‰ª’•F, ‘剺@“N, ¬ì@‹œ, ŸNˆä@Š], ²“¡NO, ‚‹´@~, •½”öŒ©ŽO, ÂÀ˜a—²: Electrical storm‚ðŒoŒ±‚µ‚½•s®–¬Œ¹«‰EŽºS‹ØÇ‚ɑ΂µ‚ĉEŽº—¬o˜HŠu—£‚ðŽ{s‚µ‚½1—á. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  110. —é–؉ëm, ŽR“àNÆ, —é–؁@“Ä, ‹v²–ÎŽ÷, ‰Ã”[Š°l, ‰ª“cŠ°”V, ™ŽR’m‘ã, ‚‘ºç’q, ìè‚Ü‚èŽq, ‹{–{‹M—f, ”ö—с@“O, ˆé•”ŒõÍ, ÂÀ˜a—², óì“N–ç: “´’²—¥’†‚ÉŠ¥Ã–¬“´“à‚É‚Ädelayed potential‚ð”F‚ß‚½’‹Œ«S‹Ø[ÇŒã‚Ìmitral isthmus dependent ventricular tachycardia‚Ì1—á. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  111. —é–؁@“Ä, ŽR“àNÆ, ‰ª“cŠ°”V, ‹v²–ÎŽ÷, ‰Ã”[Š°l, ìè‚Ü‚èŽq, ™ŽR’m‘ã, ‚‘ºç’q, ‹{–{‹M—f, ”ö—с@“O, ÂÀ˜a—², ˆé•”ŒõÍ: ‰E–[’†Šu‚É‹NŒ¹‚ð—L‚·‚é”­ì«S–[×“®|—¼S–[ƒ}ƒbƒv‚¨‚æ‚уAƒuƒŒ[ƒVƒ‡ƒ“‚Ì•K—v«‚ɂ‚¢‚Ä. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  112. —L–{‹M”Í, ŠÖŒûK•v, ¬ŽR@’, ŽRè@_, ’¬–ì@‹B, •–ØŒ’Žu, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: High-resolution map‚ð—p‚¢‚½ƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—LŒø«|Až‚ÝŒ^™×“®ŠíiICDj‚ð‘}“ü‚µ‚½Ç—á‚Å‚ÌŒŸ“¢. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  113. “cã˜aK, ŽR‰ºŒb—¢, •½•õ¹‹v, –Ô‰®@r, “Œ•ŸŸ“¿, ²‘½’¼K, •Ÿ‰ª‰ÃO, “h–Ø“¿l, ’Ø“à”Žm, ŠÖŒûK•v, ÂÀ˜a—²: Ã•s®–¬«‰EŽºS‹ØÇ‚ɍ‡•¹‚µ‚½SŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“CARTO system‚É‚æ‚éLP mapping‚Ì—L—p«. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  114. –x@‘וF, “à“¡Ž l, ²“¡ç’ß, “ü]’‰M, Œã“¡vŽm, “c’†‘׏Í, Šâ–{÷‘¾˜Y, –œˆäOŠî, ‰¡ì”üŽ÷, šê“c@_, ‘哇@–Î, ’JŒû‹»ˆê, ã“cŠó•F, ‘D‹´L’õ, ¬Žºˆê¬: ”xÃ–¬Šu—£p‚É‚æ‚鍇•¹Ç—\–h‚ɍۂµ‚Ä‚Ì“KØ‚ȏp‘O“à•ž–ò‚ÌŒŸ“¢. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  115. ‰¡ì”üŽ÷, šê“c@_, ¬ŽRŒbŽq, “à“¡Ž l, Œã“¡v“ñ, –œˆäOŠî, “c’†‘׏Í, Šâ–{÷‘¾˜Y, –x@‘וF, “ü]’‰M, ²“¡ç’ß, ‘哇@–Î, ’JŒû‹»ˆê: Contrast-enhanced MRI‚ð—p‚¢‚½SŽº•p”‚Ì‹NŒ¹•”ˆÊ‚Ì“¯’è. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi‰¡•lj6ŒŽ, 2008
  116. ”nê‰ëŽq, “n•Óds, ”óŒûr•F, ’¬–ì’qŽq, ŽR–{¹—Ç, ‰Í–ì@—¹, ‘º‰zLs, £”ö—RL, •ˆÀ–@”V, ¬ŽR@’, —L–{‹M”Í, ÂÀ˜a—²: ‰–Ž_ƒ‰ƒ“ƒWƒIƒ[ƒ‹‚É‚æ‚荶Žº—¬o˜Hˆ³Šr·‚ª‘ˆ«‚µ‚½•ÂÇ«”ì‘åŒ^S‹ØÇ‚Ì1Ç—á. ‘æ208‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2008
  117. “c‘º”üŒbŽq, ì“‡•ü”V, ‹{è@“O, ‘å“ŒŠ°˜a, ‹{èW‰î, ‚‹´—ljp, –ì—¢ŽõŽj, •‹–¾“ú”ü, ŒKŒ´‘åŽu, •D“c_”V, ²“¡@–¾, ‚‹´@~, ˆé•”ŒõÍ: ‹}‘¬‚É‘Sg“]ˆÚ‚µ‚½¶–[Œ´”­ intimal sarcoma‚Ì1—áD ‘æ208‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2008
  118. ’¬–ì’qŽq, £”ö—RL, “n•Óds, ÂÀ˜a—²: Œ´”­«ƒAƒ‹ƒhƒXƒeƒƒ“Ç‚̈ê—á. ‘æ38‰ñˆïéŒ§‚ŒŒˆ³Œ¤‹†‰ïŠwpu‰‰‰ïi‚‚­‚΁j6ŒŽ, 2008
  119. Î’Ã’qŽq, “n•Óds, m‰ÈG’, £”ö—RL, ÂÀ˜a—²: ATP•‰‰×gated SPECT‚É‚¨‚¯‚镉‰×Œã¶Žº‹ìo—¦’ቺ‚Í•‰‰×ŒãS‹Østunning‚𔽉f‚µ‚Ä‚¢‚é‚©.SƒGƒR[–@‚ð—p‚¢‚½ŒŸ“¢. ‘æ18‰ñ“ú–{S‘ŸŠjˆãŠw‰ï‘‰ïEŠwpW‰ïi’Áj6ŒŽ, 2008
  120. ²“¡@–¾, “n•Óds, £”ö—RL, ŠÖŒûK•v, ”nê‰ëŽq, ’¬–ì’qŽq, ÂÀ˜a—², œA]“¹º: ‚½‚±‚‚ڌ^S‹ØÇ‚É‚¨‚¯‚éDual 123I-BMIPP and Thallium-201S‹ØSPECT‚ÌŒoŽž“I•Ï‰»D ‘æ18‰ñ“ú–{S‘ŸŠjˆãŠw‰ï‘‰ïEŠwpW‰ïi’Áj6ŒŽ, 2008
  121. ‹T’J”ü—¢, ŽðŠª•¶Žq, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t@•, ’¬–ì’qŽq, Î’Ã’qŽq, £”ö—RL, ÂÀ˜a—²: CRTƒŒƒXƒ|ƒ“ƒ_[—\‘ª‚É‚¨‚¯‚é”CˆÓ•ûŒüMƒ‚[ƒh–@‚Ì—L—p«. ‘æ33‰ñ“ú–{’´‰¹”gŒŸ¸Šw‰ïi‘O‹´j6ŒŽ, 2008
  122. ’†“‡‰pŽ÷, £”ö—RL, ¬—эhŽq, ‹T’J—¢”ü, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ã–q@—², ˆî—t@•, Î’Ã’qŽq, ÂÀ˜a—²: 2DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO‚É‚æ‚éS‹Ø“àƒXƒgƒŒƒCƒ“•ª•z‚ÌŒŸ“¢. ‘æ33‰ñ“ú–{’´‰¹”gŒŸ¸Šw‰ïi‘O‹´j6ŒŽ, 2008
  123. “cŒû‰Ä”ü, Î’Ã’qŽq, ‹T’J—¢”ü, ’†“‡‰pŽ÷, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ã–q@—², ˆî—t@•, £”ö—RL, ÂÀ˜a—²: èò“®–¬“à–Œ’†–ŒŒú, ƒvƒ‰[ƒN‹P“x‚ÆŒŒ´“®–¬d‰»‘£iˆöŽq‚Æ‚ÌŠÖ˜A. ‘æ33‰ñ“ú–{’´‰¹”gŒŸ¸Šw‰ïi‘O‹´j6ŒŽ, 2008
  124. ’†“‡‰pŽ÷, £”ö—RL, ¬—эhŽq, ‹T’J—¢Œ©, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ã–q@—², ˆî—t@•, Î’Ã’qŽq, ÂÀ˜a—²: 3DSƒGƒR[}–@‚É‚æ‚éƒy[ƒXƒ[ƒJƒŠ[ƒh‹Nˆö«TR‚̐f’f. ‘æ33‰ñ“ú–{’´‰¹”gŒŸ¸Šw‰ïi‘O‹´j6ŒŽ, 2008
  125. ²“¡@–¾, “n•Óds, £”ö—RL, ‘º‰zLs, ”nê‰ëŽq, ’¬–ì’qŽq, •–ØŒ’Žu, ŽR–{¹—Ç, ˆÀ’B@‹œ, ÂÀ˜a—²: Visual and quantitative assessment of angiographic myocardial blush grade in acute myocardial infarction with multidetector computed tomography. ‘æ22‰ñˆïéŒ§PCIŒ¤‹†‰ïi‚‚­‚΁j6ŒŽ, 2008
  126. ‰Á“¡ˆ¤Í, –x•ÄmŽu, ‚‹´ŽÀ•ä, ‰––ì~Žq, ‘ºã@‘ì, ŠÖŒûK•v, ÂÀ˜a—²: ¬Ž™“Á”­«SŽº•p”‚ɑ΂·‚鍂Žü”gƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Ð헪. ‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïiŒSŽRj7ŒŽ, 2008
  127. “cK˜aŽq, “n•Óds, HŽR‘åŽ÷, ’¬–ì@‹B, ”óŒûr•F, ¬ŽR@’, ŠÖŒûK•v, £”ö—RL, ‰Í–ì@—¹, ‹v‰êŒ\—S, ÂÀ˜a—²: ”­ì«S–[×“®‚ð‡•¹‚µ‚½‘m–X•Ù‹·óÇ‚ɑ΂µPTMC‚ÆPVI‚ðŽ{s‚µ‚½ˆê—á. ‘æ20‰ñCASSi‚‚­‚΁j7ŒŽ, 2008
  128. •D“c_”V, ²“¡@–¾, –ì—¢ŽõŽj, ‘å“ŒŠ°˜a, ì“‡•ü”V, ‚‹´@~: Elevated Serum C-reactive Protein Level after Coronary Stent Implantation in Patients with Stable Angina. ‘æ17‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwp‘‰ïi–¼ŒÃ‰®j7ŒŽ, 2008
  129. ²“¡@–¾, –ì—¢ŽõŽj, •D“c_”V, “c‘º”üŒbŽq, ‘å“ŒŠ°˜a, ‚‹´@~: Visual and Quantitative Assessment of Angiographic Myocardial Blush Grade in Acute Myocardial Infarction With Multidetector Computed Tomography. ‘æ17‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwp‘‰ïi–¼ŒÃ‰®j7ŒŽ, 2008
  130. Hoshi T, Nishina H, Kanemoto M, Shiotsuka J, Tachibana T, Kakefuda Y, Machino T, Fumikura Y, Noguchi Y, Watanabe S, Aonuma K: A feasible revascularization strategy of repeated sirolimus-eluting stent implantation in patients with in-stent restenosis following stent fracture. ‘æ17‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwp‘‰ïi–¼ŒÃ‰®j7ŒŽ, 2008
  131. šê“c@_: ‹³ˆçu‰‰:“«S•s‘SÇ—á‚ɑ΂·‚éS‘ŸÄ“¯Šú—Ö@. ‘æ116‰ñ“ú–{zŠÂŠíŠw‰ï–k—¤’n•û‰ïi‹à‘òj7ŒŽ, 2008
  132. ŠÛŽRG˜a, Žðˆä@r, ‰Í–ì@—¹, ‰ºžŠMˆÐ, “cK˜aŽq, ˆÀ“c@‹ž, “n•Óds, ÂÀ˜a—², ²“¡@½: •ÂÇ«‡–°Žž–³ŒÄ‹zÇŒóŒQŠ³ŽÒ‚ł͐‡–°’†‚ÉŒŒ¬”‚ªÁ”‚ê‚é. ‡–°ŒÄ‹záŠQŒ¤‹†‰ïi“Œ‹žj7ŒŽ, 2008
  133. Homma S, Uno K, Ishizu T, Seo Y, Watanabe S, Aonuma K: (symposium) IMT and flow dynamic parameters in carotid artery ultrasound. 40th annual meeting of Japan atherosclerosis society (Tsukuba) , 7ŒŽ, 2008
  134. ŠÛŽRG˜a, Žðˆä@r, ‰Í–ì@—¹, ²“¡@–¾, ‰ºžŠMˆÐ, “cK˜aŽq, ˆÀ“c@‹ž, “n•Óds, ²“¡@½, ÂÀ˜a—², œA]“¹º: •ÂÇ«‡–°Žž–³ŒÄ‹zÇŒóŒQ‚Å‚ÌP-selectin—z«“à”ç×–Eƒ}ƒCƒNƒƒp[ƒeƒBƒNƒ‹‚ÆŒŒ¬”Šˆ«‰»‚Æ‚Ì‘ŠŠÖ. ‘æ52‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[i_ŒËj8ŒŽ, 2008
  135. ²“¡@–¾, £”ö—RL, ŠÛŽRG˜a, Žðˆä@r, ‰Í–ì@—¹, ‰ºžŠMˆÐ, “cK˜aŽq, “n•Óds, ÂÀ˜a—², œA]“¹º: ‹}‘¬‚ÉŒy“x‚©‚獂“x‹·ó•a•Ï‚ɐis‚·‚銥“®–¬•a•Ï‚Ì—\‘ªˆöŽq. ‘æ52‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[i_ŒËj8ŒŽ, 2008
  136. Shimojo N, Jesmin S, Miyauchi T: Estrogen pre-treatment prevents ET-1-induced cardiomyocyte hypertrophy via non-genomic mechanism:potential linkage with VEGF system. Cardiovascular medicine 21 / ‘æ8‰ñƒtƒH[ƒ‰ƒ€i“Œ‹žj8ŒŽ, 2008
  137. –ìã‰ÀŒb, éˍ◲ˆê, £”ö—RL, Î’Ã’qŽq, –ìã‡Žq, “n•Óds, ÂÀ˜a—², ŽRŒû@›Ü: ‚—îŽÒ‚̍¶ŽºS‹@”\‚ɑ΂·‚鉷—•‰‰×‚̉e‹¿. ‘æ58‰ñzŠÂŠí•‰‰×Œ¤‹†‰ïi“Œ‹žj8ŒŽ, 2008
  138. Î’Ã’qŽq, £”ö—RL, ŽR–{¹—Ç, ’¬–ì’qŽq, ”nê‰ëŽq, •–ØŒ’Žu, ŽR“c^‹IŽq, ÂÀ˜a—²: S–[ŽûkŠú¶ŽºƒXƒgƒŒƒCƒ“ƒŒ[ƒg’l‚É‚æ‚鍶ŽºŠg’£––Šúˆ³‚̐„’è. ‘æ56‰ñ‘æ6‰ñæiSŒŒŠÇƒGƒR[Œ¤‹†‰ïi‘åãj8ŒŽ, 2008
  139. ’†“‡‰pŽ÷, Î’Ã’qŽq, £”ö—RL, ¬—эhŽq, ‹T’J—¢”ü, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t@•, “n•Óds, ÂÀ˜a—²: “ñŽŸŒ³‚¨‚æ‚ÑŽOŽŸŒ³ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½¶Žº‰~Žü•ûŒüƒXƒgƒŒƒCƒ“•ª•z‚Ì”äŠr. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  140. •–ØŒ’Žu, ŠÖŒûK•v, ’¬–ì@‹B, ŽRè@_, —L–{‹M”Í, ‹à–{@“s, ‰““¡—DŽ}, šê“c@_, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: “Á”­«SŽºŠúŠOŽûk‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Œã, ’˜‚µ‚¢Œ‹\“®‘Ԃ̉ü‘P‚ð”F‚ß‚½2Ç—á. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  141. £”ö—RL, Î’Ã’qŽq, ì‘º@—´, “n•Óds, ÂÀ˜a—²: ŽOŽŸŒ³S‹Øƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½‹ÇŠS‹ØƒXƒgƒŒƒCƒ“‰ðÍ. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  142. Î’Ã’qŽq, £”ö—RL, ”nê‰ëŽq, ŽR“c^ŠìŽq, ‰““¡—DŽ}, ÂÀ˜a—²: Šg’£––Šú¶Žº˜c‚ÝŒv‘ª‚É‚æ‚鍶ŽºŠg’£––Šúˆ³‚̐„’è. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  143. ’¬–ì’qŽq, £”ö—RL, Î’Ã’qŽq, ÂÀ˜a—²: ¶SŽ¨‰^“®‘¬“x‚͍¶–[Žûk”]‚𔽉f‚·‚é‚©?@”­ì«S–[×“®Š³ŽÒ‚É‚¨‚¯‚鍶SŽ¨‰^“®‘¬“x‚ƍ¶–[ˆ³‚ÌŠÖŒW. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  144. ŽRè@_, £”ö—RL, ’¬–ì@‹B, •–ØŒ’Žu, ŠÖŒûK•v, —L–{‹M”Í, ‹v‰êŒ\—S, “n•Óds, ÂÀ˜a—²: —¼SŽºƒy[ƒVƒ“ƒOAž‚Ý––ŠúS•s‘S—á‚É‚¨‚¯‚é—\Œã. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  145. ”nê‰ëŽq, ²“¡@–¾, ˆÀ’B@‹œ, ŽR–{¹—Ç, ’¬–ì’qŽq, •–ØŒ’Žu, ŽRè@_, ‘º‰zLs, £”ö—RL, “n•Óds, ÂÀ˜a—²: ‹}‘¬‚ɍ‚“x‹·ó•a•Ï‚ɐis‚·‚銥“®–¬•a•Ï‚Ì—\‘ªˆöŽq. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  146. ’†“‡‰pŽ÷, £”ö—RL, Î’Ã’qŽq, ¬—эhŽq, ‹T’J—¢”ü, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t@•, “n•Óds, ÂÀ˜a—²: 2DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚鍶ŽºƒXƒgƒŒƒCƒ“•ª•z‚Ì‹@Ží‚É‚æ‚鍷ˆÙ‚ÉŠÖ‚·‚錟“¢. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  147. ´…º•F, V“c@—², ŒI“c—²Žu, ˆÀ•”Ž¡•F, ¡ˆäŽ•F, ¬—Ñ‹`“T, –Ø‘º@„, •›“‡‹žŽq, ’ë–ìTˆê, “n•Óds: ƒVƒ“ƒ|ƒWƒEƒ€4u•s®–¬‚Ì”ñ–ò•¨—Ö@‚̐i•à £“ú–{‚É‚¨‚¯‚éICD /CRT-D ‚Ì“K‰ž‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“‚̐i•àD ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  148. ‰¡ì”üŽ÷, šê“c@_, ¬ŽRŒbŽq, Œã“¡v“ñ, “à“¡Ž l, ‘哇@–Î, ’JŒû‹»ˆê: S‘ŸÄ“¯Šú—Ö@–³Œø—á‚Ì—\‘ª‚É‚¨‚¯‚éMRI‚Ì—L—p«. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  149. “c’†‘׏Í, šê“c@_, ‰¡ì”üŽ÷, Œã“¡v“ñ, “à“¡Ž l, ‘哇@–Î, ’JŒû‹»ˆê, ÂÀ˜a—²: “d‹C“IŠg‘å”xÃ–¬Šu—£p‚É‚¨‚¯‚éÄŽÜ’†‚̍¶–[“àáu’É•”ˆÊ‚ÌŒŸ“¢: Bispectral Index Monitoring‚Ì—L—p«. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  150. ŽR‰º‰pŽ¡, ŒËo_”V, ‰ª’ë—T‹M, ”óŒûƒ‹ƒ~, ŠÛŽR—TŽq, ŠÖ@GŠi, ‰ÍŒû@—õ, ‘ºã@~, šê“c@_, ˆÀ’B@m, ŠOŽR‘ì“ñ, ¯è@—m, ‘哇@–Î: Š¥“®–¬Ž¾Š³ŒŸo‚É‚¨‚¯‚éSƒGƒR[¶ŽºŠg’£”\Žw•W‚ÌŠ´“xE“ÁˆÙ“x:¶Žº”ì‘å‚ðl—¶‚µ‚½ŒŸ“¢. ‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žj9ŒŽ, 2008
  151. ²“¡—zŽq, ¬‘îN”V, “c’†Šì”ü•v, í‰ªG˜a, ŽR“àF‹`, ÂÀ˜a—²: —°Ž_ƒNƒƒsƒhƒOƒŒƒ‹“Š—^‚É‚æ‚èD’†‹…Œ¸­Ç‚𗈂µ‚½1—á. ‘æ209‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2008
  152. ˆÀ’B@‹œ, —L–{‹M”Í, ŠÖŒûK•v, ŽR–{¹—Ç, •–ØŒ’Žu, ”nê‰ëŽq, ’¬–ì’qŽq, ŽRè@_, ‹v‰êŒ\—S, ÂÀ˜a—²: –«S–[×“®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒuƒŒ[ƒVƒ‡ƒ“Œã‚É“´•s‘SÇŒóŒQ‚ªŒ°Ý‰»‚µ‚½1—á. ‘æ209‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2008
  153. ŒÃ‰YŒ«“ñ, œA£r•ã, ì“‡•ü”V, “¡ˆä@º, –ö‰º“Ö•F, ‹{èW‰î, ‚‹´—ljp, –ì—¢ŽõŽj, •‹–¾“ú”ü, ŒKŒ´‘åŽu, •D“c_”V, ‚‹´@~, ¼‘qˆê˜Y, ŠÛŽRr”V, ²“¡@–¾, ˆé•”ŒõÍ: ¶–[“à‚Ƀ{[ƒ‹ó‚Ì‹‘匌ðŒ`¬‚ðƒ[ƒtƒ@ƒŠƒ“’†Ž~Œã’ZŠúŠÔ‚É”F‚ß‚½‘m–[•Ù‹·óÇ‚Ì1—á. ‘æ209‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2008
  154. šê“c@_: ƒVƒ“ƒ|ƒWƒEƒ€:uS–[×“®‚É‚¨‚¯‚é“®•¨ŠÔi¬“®•¨, ‘å“®•¨, ƒqƒgj‚Ì—ÞŽ—“_‚Æ‘Šˆá“_vƒqƒg‚É‚¨‚¯‚éS–[×“®‚ÌŽ¡—Ái”ñ–ò•¨j. ‘æ35‰ñ”äŠrS“d}Œ¤‹†‰ïi“Œ‹žj9ŒŽ, 2008
  155. “n•Óds, ’†ì‹`Žk, —À@ŒiŠâ, “cK˜aŽq, £”ö—RL, ²“¡@–¾, ÂÀ˜a—², ‰–Œ©‰ëŽu: OCT image discussion : “®–¬d‰»«•a•Ï‚É‚¨‚¯‚é‚Ñ‚ç‚ñ‚ƃ}ƒNƒƒtƒ@[ƒW‚ÌOCTŠŒ©. ‘æ2‰ñŒŒŠÇ“àOCTŒ¤‹†‰ïi˜a‰ÌŽRj10ŒŽ, 2008
  156. •º“ªNŽŸ˜Y, ˆäì¹K, ‹g“cˆè—Y, ¼@@Œ÷, ‰|–{‹­Žu, ¬ŠÖ@çŒ, ÂÀ˜a—², ‹v‰êŒ\—S, šê“c@_, ŠÖŒûK•v, —L–{‹M”Í, ŽRè@_, “n粏GŽ÷: ŠOŒãŽûk«S–Œ‰ŠpŒã30”N‚ðŒo‰ß‚µ‚Ä”­Ç‚µ‚½‘½Œ`«S–[‘e“®‚Ì1—á. ‘æ20‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiå‘äj10ŒŽ, 2008
  157. ŽRè@_, ŠÖŒûK•v, ’¬–ì@‹B, •–ØŒ’Žu, —L–{‹M”Í, ŒÜ\—’“s, šê“c@_, ‹v‰êŒ\—S, ÂÀ˜a—², ŒË“c@’¼: ƒŠƒEƒ}ƒ`«‘m–[•Ù–ŒÇ‚ɍ‡•¹‚µ‚½Së•”SŽºáŽ‚ð‹NŒ¹‚Æ‚·‚éSŽº•p”‚ɑ΂µsubstrate mapping‚ð—˜—p‚µ‚½ƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚½1—á. ‘æ20‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiå‘äj10ŒŽ, 2008
  158. ¬ŽR@’, ”і쌒“ñ, ^•Ç@L, Š`è@Šw, ‚‹´—zˆê˜Y, –ì–x@Œ‰, “n糔Ž”V, ¬ârŒõ, ’·’JìmŽu, ˆÉ“¡@G, ˆ¢•”–F‹v, Ž›“c@Œ’, ÂÀ˜a—²: CARTO system‚ð—p‚¢‚ĐSŽº•p”‚̊ɏ™“`“±˜H‚𓯒肵“¾‚½‘m–[•Ù‹·•”SŽº•p”‚Ì1—á. ‘æ20‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiå‘äj10ŒŽ, 2008
  159. Machino T, Sakai S, Baba M, Watanabe S, Aonuma K: Cardiac Amyloidosis Presenting as Intractable Heart Failure and Arrhythmia:Report of Two Cases. ‘æ12‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi“Œ‹žj10ŒŽ, 2008
  160. Sato A, Seo Y, Kawano S, Aonuma K, Hiroe M: Symposium: A Novel Biomarker, Tenascin C, for Predicting Left Ventricular Remodeling in Acute Myocardial Infarction. ‘æ12‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi“Œ‹žj10ŒŽ, 2008
  161. ÂÀ˜a—²: Symposium: Benefit of Nonpharmacologic Catheter Ablation Treatment of Life Threatening Ventricular Tachyarrhythmia in Patients with End-stage Heart Failure. ‘æ12‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi“Œ‹žj10ŒŽ, 2008
  162. £”ö—RL: Relationship between Septal Wall Contraction and Responsiveness to Cardiac Resynchronization Therapy in Patients with Left Bundle Branch Block. ‘æ12‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi“Œ‹žj10ŒŽ, 2008
  163. Yamasaki H, Seo Y, Machino T, Kuroki K, Arimoto T, Yoshida K, Sekiguchi Y, Ishizu T, Tada H, Kuga K, Aonuma K: Clinical Characteristics of the Responders for the Cardiac Re-synchronization Therapy with Triple-site Pacing. ‘æ12‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi“Œ‹žj10ŒŽ, 2008
  164. Î’Ã’qŽq, £”ö—RL, ˆ­”üˆÀ‹IŽq, ²“¡@–¾, “n•Óds, ÂÀ˜a—²: S‹Ø‹•ŒŒ‚̐f’f‚É‚Í‚Ç‚ÌŽw•W‚ªƒxƒXƒg‚©?ŽûkŠúŽw•W‚ÆŠg’£ŠúŽw•W@ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO‚Å‹•ŒŒ‚ðf’f‚·‚é. “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ20‰ñŠwpW‰ïi“Œ‹žj10ŒŽ, 2008
  165. ¬—эhŽq, £”ö—RL, ‹T’J—¢”ü, ’†“‡‰pŽ÷, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t@•, Î’Ã’qŽq, ‰|–{ŒjŽ¡, ÂÀ˜a—²: ‹‘卶SŽ¨áŽ‚̈ê—á. “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ20‰ñŠwpW‰ïi“Œ‹žj10ŒŽ, 2008
  166. ŽR–{¹—Ç, £”ö—RL, Î’Ã’qŽq, ŽðŠª•¶Žq, ’¬–ì’qŽq, ì‘º@—´, ÂÀ˜a—²: ‰EŽºƒy[ƒVƒ“ƒO‚É‚æ‚éSŽº“àˆ³Šr·‚ÌŒ¸­‚É’·Ž²•ûŒü‚Ì“¯Šú•s‘S‚ªŠñ—^‚µ‚½•ÂÇ«”ì‘åŒ^S‹ØÇ‚̈ê—á. “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ20‰ñŠwpW‰ïi“Œ‹žj10ŒŽ, 2008
  167. ŠÛŽRG˜a, Žðˆä@r, ‰Í–ì@—¹, ²“¡@–¾, ‰ºžŠMˆÐ, “cK˜aŽq, ˆÀ“c@‹ž, “n•Óds, ÂÀ˜a—², ²“¡@½: •ÂÇ«‡–°Žž–³ŒÄ‹zÇŒóŒQŠ³ŽÒ‚ł͐‡–°’†‚ÉŒŒ¬”‚ªÁ”‚ê‚é. ‘æ9‰ñSASŒ¤‹†‰ïi“Œ‹žj10ŒŽ, 2008
  168. HŽR‘åŽ÷, –{ŠÔ@Šo, —é–؁@‹, “n•Óds, ÂÀ˜a—²: ƒGƒ|ƒvƒƒXƒeƒm[ƒ‹—£’EŒã2”N‚ðŒo‰ß‚µ‚½”x‚ŒŒˆ³Ç‚Ì1—á. ‘æ2‰ñˆïé”x‚ŒŒˆ³Ç§˜b‰ïi…ŒËj10ŒŽ, 2008
  169. ŽRè@_, ŠÖŒûK•v, ’¬–ì@‹B, •–ØŒ’Žu, —L–{‹M”Í, ŒÜ\—’“s, šê“c@_, ‹v‰êŒ\—S, ÂÀ˜a—²: ‘m–[•Ù—Ö’†Šu‘¤‚É‚¨‚¢‚ă}ƒCƒNƒƒŠƒGƒ“ƒgƒŠ[‚ð‹@˜‚Æ‚·‚éS–[•p”‚ɑ΂µƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚½1—á. ‘æ25‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiVŠƒj11ŒŽ, 2008
  170. ŠÖŒûK•v, šê“c@_, •–ØŒ’Žu, ’¬–ì@‹B, ŽRè@_, —L–{‹M”Í, ‹v‰êŒ\—S, ÂÀ˜a—²: S‘ŸÄ“¯Šú—Ö@pŒã‚̃fƒoƒCƒX‚ÉŠÖ‚·‚é–â‘è“_‚¨‚æ‚у}ƒl[ƒWƒƒ“ƒg. ‘æ25‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiVŠƒj11ŒŽ, 2008
  171. ŽR–{¹—Ç, ÂÀ˜a—², ŠÖŒûK•v, £”ö—RL, šê“c@_, ‹v‰êŒ\—S, “n•Óds: ƒy[ƒXƒ[ƒJ[Ý’è•ÏX‚ªS‹@”\‰ü‘P‚ÉŠñ—^‚µ‚½–[Žº“`“±áŠQ‚Ì2Ç—á. ‘æ25‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiVŠƒj11ŒŽ, 2008
  172. •–ØŒ’Žu, šê“c@_, ’¬–ì@‹B, ŽRè@_, ŒÜ\—’“s, —L–{‹M”Í, ŠÖŒûK•v, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚荪Ž¡¢“ï‚ȐSŽºŠúŠOŽûk‚̐S“d}Šw“I“Á’¥‚ÉŠÖ‚·‚錟“¢. ‘æ25‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiVŠƒj11ŒŽ, 2008
  173. ‰¡ì”üŽ÷, šê“c@_, ¬ŽRŒbŽq, –x@‘וF, Šâ–{÷‘¾˜Y, “c’†‘׏Í, Œã“¡vŽm, “à“¡Ž l, ‘哇@–Î, ’JŒû‹»ˆê: S–[‘e“®ƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚ÌŽOë•Ù—ց|‰º‘åÃ–¬ŠÔ‹¬•”‚̕ω»@MRI‚É‚æ‚錟“¢. ‘æ25‰ñ“ú–{S“dŠw‰ïŠwpW‰ïiVŠƒj11ŒŽ, 2008
  174. šê“c@_, ŠÖŒûK•v, ÂÀ˜a—²: ƒ[ƒNƒVƒ‡ƒbƒv3.•s®–¬Ž¡—Â̍őOü:ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Â̐V“WŠJ.ŠúŠOŽûk‚ðŠÜ‚ß‚½ŽíX‚Ì•s®–¬‚Ö‚Ì“K‰ž. ‘æ57‰ñ“ú–{”_‘ºˆãŠw‰ïŠwpW‰ïi‚‚­‚΁j , 11ŒŽ, 2008
  175. ÂÀ˜a—²: S‘ŸÄ“¯Šú—Ö@iCRTj‚Ì“K‰ž‚ÆŒø‰Ê. ‘æ13‰ñ“ú–{¬Ž™S“dŠwŒ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2008
  176. ‚‹´ŽÀ•ä, ‰Á“¡ˆ¤Í, Î—x@I, •Ÿ“‡hŽq, –x•ÄmŽu, “¿‰iç•ä, ‹à–{^–ç, •½¼—CŽi, £”ö—RL, ÂÀ˜a—², ‰––ì~Žq, ‹àŽq³‰p, ‰ê“¡@‹Ï: S‘ŸÄ“¯Šú—Ö@‚ðŽ{s‚µ‚½3¬Ž™—á‚̗Տ°‘œ. ‘æ13‰ñ“ú–{¬Ž™S“dŠwŒ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2008
  177. ‰Á“¡ˆ¤Í, ‚‹´ŽÀ•ä, •Ÿ“‡hŽq, ÎìLs, Î—x@I, –x•ÄmŽu, ÂÀ˜a—², Z—F’¼•û: ‘½äBÇ‚É”º‚¤Twin AV node‚É‚æ‚é–[Žº‰ñ‹A«•p”‚ɑ΂µƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½1—á. ‘æ13‰ñ“ú–{¬Ž™S“dŠwŒ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2008
  178. ˜n@‰hŽ¡, Žðˆä@r, ˆî—t”ŽŽq, —é–؉hŽq, —F”ö@F, •x‰ª’qŽq, ‰|–{—R‹IŽq, Œ´“ct”ü, –öì@“O, Îˆä“N˜Y: V‚µ‚¢‚ŒŒˆ³Çƒ‚ƒfƒ‹“®•¨‚Ì”­Œ©@A170/p62Œ‡‘¹ƒ}ƒEƒX. ‘æ3‰ñ—Տ°ƒXƒgƒŒƒX‰ž“šŠw‰ïiH“cj11ŒŽ, 2008
  179. ’†ì‹`Žk, “n•Óds, —À@ŒiŠâ, “cK˜aŽq, £”ö—RL, ²“¡—zŽq, •ˆÀ–@”V, ‘ŠŒ´‰p–¾, ²“¡@–¾, Î’Ã’qŽq, Žðˆä@r, ‘º‰zLs, ‰Í–ì@—¹, ÂÀ˜a—², ‰–Œ©‰ëŽu: ŒŒŠÇ“àOCTŠŒ©‚Æ‘gDŠŒ©‚̑Δä. ‘æ16‰ñˆïézŠÂŠíŒ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2008
  180. ™]@ª, ‹v‰êŒ\—S, •–ØŒ’Žu, ŠÖŒûK•v, ’¬–ì@‹B, ŽRè@_, —L–{‹M”Í, ‹à–{@“s, šê“c@_, ÂÀ˜a—²: ãŽº«•s®–¬Ç—á‚ɑ΂·‚鎩—¥ŒP—û–@‚ÌŒø‰Ê:—\”õ“IŒŸ“¢D ‘æ65‰ñ“ú–{zŠÂŠíSgˆãŠw‰ïi‰¡•lj11ŒŽ, 2008
  181. ‹v‰êŒ\—S, ÂÀ˜a—², ™]@ª: ƒXƒgƒŒƒX‚ƐS‘Ÿ“Ë‘RŽ€iSCDjD ‘æ65‰ñ“ú–{zŠÂŠíSgˆãŠw‰ïi‰¡•lj11ŒŽ, 2008
  182. ‹v‰êŒ\—S: ‘‡“¢˜_:Š³ŽÒ‚³‚ñ‚©‚çŠw‚ԏzŠÂŠíSgˆãŠwD ‘æ65‰ñ“ú–{zŠÂŠíSgˆãŠw‰ïi‰¡•lj11ŒŽ, 2008
  183. ‹v‰êŒ\—S, ˜–쌋Šó, ŽRè@_, HŽR‘åŽ÷, ”óŒûr•F, ’¬–ì@‹B, ¬ŽR@’, ŠÖŒûK•v, ™]@ª, ÂÀ˜a—²: uŠ³ŽÒ‚³‚ñ‚©‚çŠw‚ÔƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXvR•s®–¬–ò‚¨‚æ‚Ñ”xÃ–¬Šu—£p‚É’ïR«‚Ì”­ì«S–[×“®‚ɑ΂µ‚ÄŽ©—¥ŒP—û–@‚ª‘tŒ÷‚µ‚½1—áD ‘æ65‰ñ“ú–{zŠÂŠíSgˆãŠw‰ïi‰¡•lj11ŒŽ, 2008
  184. ŽR–{¹—Ç, Î’Ã’qŽq, ’¬–ì’qŽq, ì‘º@—´, £”ö—RL, ÂÀ˜a—²: ˆŸ‹}«‚ÌŒo‰ß‚É‚æ‚葝ˆ«‚µ‚½‘å“®–¬•Ù‹t—¬ÇD ‘æ44‰ñ“Œ‹žSƒGƒR[}Œ¤‹†‰ïi“Œ‹žj11ŒŽ, 2008
  185. ‘º‰zLs: iƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€j™–¬«•s®–¬‚ɑ΂·‚éƒAƒfƒm”ºƒEƒCƒ‹ƒXiAAVjƒxƒNƒ^[‚ð—p‚¢‚½ˆâ“`ŽqŽ¡—Ã. ‘æ30‰ñS‹Ø¶ŒŸŒ¤‹†‰ïiŽOdj11ŒŽ, 2008
  186. “yŠò_‰î, –{ŠÔ^l, ‹v‰êŒ\—S, ÂÀ˜a—², K“cK’¼: ƒtƒŒƒJƒCƒjƒh‚Ì‘ãŽÓ‚É‚ÍCYP2D6ˆÈŠO‚ÉCYP1A2‚ªŠÖ—^‚·‚éD ‘æ29‰ñ“ú–{—Տ°–ò—Šw‰ï”N‰ïi“Œ‹žj12ŒŽ, 2008
  187. “n•Óds: ƒZƒ~ƒi[ uOCT Case Presentation • DiscussionvD ‘æ22‰ñ“ú–{Š¥Ž¾Š³Šw‰ïŠwpW‰ïi“Œ‹žj12ŒŽ, 2008
  188. ˆî—t”ŽŽq, ˜n@‰hŽ¡, —é–؉hŽq, ‰|–{—R‹IŽq, –öì@“O, Žðˆä@r, Îˆä“N˜Y: SQSTM1/A170Œ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚錌ˆ³“®‘Ԃ̉ðÍ. ‘æ81‰ñ“ú–{¶‰»Šw‰ï‘‰ïi_ŒËj12ŒŽ, 2008
  189. ’¬–ì@‹B, ŠÖŒûK•v, •–ØŒ’Žu, ŽRè@_, ‹g“cŒ’‘¾˜Y, ŒÜ\—’“s, —L–{‹M”Í, ‘º‰zLs, šê“c@_, ‹v‰êŒ\—S, ÂÀ˜a—²: Rhythm control vs. Rate control:“´’²—¥‰»‚É‚æ‚èS‹@”\‚ª³í‰»‚µ‚½S–[×“®‡•¹Šg’£Œ^S‹ØÇ‚Ì1—á. ‘æ210‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj12ŒŽ, 2008
  190. £”ö—RL, Î’Ã’qŽq, •–ØŒ’Žu, ŠÖŒûK•v, šê“c@_, ÂÀ˜a—²: SŽºŠúŠOŽûk‚É‚æ‚éBNPã¸‚Ì‹@˜‚ɂ‚¢‚Ä:ƒhƒvƒ‰SƒGƒR[}–@‚É‚æ‚錟“¢. ‘æ29‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj12ŒŽ, 2008

@@@¡ ‚»‚Ì‘¼

  1. Sakai S, Ohtsuka S, Hyodo K, Ando M: Clinical Intravenous Coronary Angiography at KEK. ISACˆãŠwƒCƒ[ƒWƒ“ƒO•ª‰È‰ïi‚‚­‚΁j2ŒŽ, 2008
  2. “n•Óds: ŽÀ—Տ°‚É‚¨‚¯‚é“®–¬d‰»«Ž¾Š³‚Ì—\–h. Meet the Specialist 2008i“Œ‹žj2ŒŽ, 2008
  3. “n•Óds: SŒŒŠÇƒCƒxƒ“ƒgƒ[ƒ‚ð–ÚŽw‚µ‚½ƒŠƒXƒNƒ}ƒlƒWƒƒ“ƒg@SŒŒŠÇŽ¾Š³ƒCƒxƒ“ƒg—\–h‚É‚¨‚¯‚郊ƒXƒNŠÇ— “úíf—Âłł«‚é–ò•¨Ž¡—Ð헪D Primary Care Symposiumi…ŒËj2ŒŽ, 2008
  4. ‹v‰êŒ\—S: AED‚ɂ‚¢‚Ä. •½¬19”N“x’}”g‘åŠwŒ’NŠÇ—u‰‰‰ïi‚‚­‚΁j2ŒŽ, 2008
  5. £”ö—RL: ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚̗Տ°ŒoŒ±. ‘æ32‰ñ•ŒÉìSƒGƒR[ƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi_ŒËj2ŒŽ, 2008
  6. £”ö—RL: ƒVƒ“ƒ|ƒWƒEƒ€:Šg’£‹@”\E/E‚ðŽa‚éI ‘æ11‰ñƒGƒR[ƒEƒBƒ“ƒ^[ƒZƒ~ƒi[iŒyˆä‘òj2ŒŽ, 2008
  7. £”ö—RL: ‘SgŒŒŠÇ•a‚ð‚ǂ̂悤‚ÉŽ¡—·‚é‚©H ‘æ3‰ñˆïé”]‘²’†ƒZƒ~ƒi[i‚‚­‚΁j2ŒŽ, 2008
  8. £”ö—RL: —Տ°‚ɖ𗧂ƒgƒ‰ƒbƒLƒ“ƒO–@. “ú–{SƒGƒR[}Šw‰ï‘æ13‰ñ“~‹GuK‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[i‘åãj2ŒŽ, 2008
  9. “n•Óds: zŠÂŠí“à‰Èˆã‚©‚ç‚Ý‚½“®–¬d‰»«Ž¾Š³‚Ì–ò•¨Ž¡—Ã. ‚‚­‚ΖòÜŽt‰ïŒ¤C‰ïi‚‚­‚΁j4ŒŽ, 2008
  10. “n•Óds: SŒŒŠÇƒCƒxƒ“ƒg—\–h‚Ì‚½‚ß‚ÌŽ‰Ž¿ŠÇ—í—ª. ˆïéŒ§—§’†‰›•a‰@ zŠÂŠí“à‰È •af˜AŒgƒNƒŠƒjƒJƒ‹ƒŒƒNƒ`ƒƒ[iŠ}ŠÔj5ŒŽ, 2008
  11. “n•Óds: ƒƒ^ƒ{Žž‘ã‚ðÄl‚·‚é@ƒvƒ‰[ƒN‘ޏk‚ð–ÚŽw‚µ‚Ä„Ÿ ŒŒŠÇŽá•Ô‚è‚Ö‚Ì’§í „Ÿ. ‘æ3‰ñŒ§“쐶ŠˆKŠµ•a§˜b‰ïi‚‚­‚΁j5ŒŽ, 2008
  12. Žðˆä@r: ¸ˆ³–òE~ˆ³–ò‚ÌŽg‚¢•û. ƒŒƒWƒfƒ“ƒgƒŒƒNƒ`ƒƒ[i‚‚­‚΁j5ŒŽ, 2008
  13. ‹v‰êŒ\—S: •s®–¬‚ÌŠî‘b‚ƍR•s®–¬–ò. •½¬20”NˆïéŒ§–òÜŽtŠwpu‰‰‰ïi’}¼j5ŒŽ, 2008
  14. £”ö—RL: S•s‘S‚Ì•a‘Ô‚ÆŽ¡—Ã. CRT‚Ì–ðŠ„2008 ICD/CRTƒZƒ~ƒi[i‰¡•lj5ŒŽ, 2008
  15. £”ö—RL: 3“_ƒy[ƒVƒ“ƒOCRT‚Ì—L—p«‚ɂ‚¢‚Ä. •s®–¬Ž¡—Ì㉇‰ïi…ŒËj6ŒŽ, 2008
  16. £”ö—RL: ‹³ˆçu‰‰@SƒGƒR[}–@‚É‚æ‚éCRT“K‰ž‚ÌŒˆ’è. ‘æ33‰ñ“ú–{’´‰¹”gŒŸ¸Šw‰ïi‘O‹´j6ŒŽ, 2008
  17. £”ö—RL, ŠÖŒûK•v, ŽRè@_, ‹g“cŒ’‘¾˜Y, ‘º‰zLs, Î’Ã’qŽq, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: CRT“K‰žŒˆ’è‚É‚¨‚¯‚éSƒGƒR[ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚̉ž—p CRT‚ÌŒ»ó‚Æ–¢—ˆ. ‘æ23‰ñ“ú–{•s®–¬Šw‰ïƒ[ƒNƒVƒ‡ƒbƒvi‰¡•lj6ŒŽ, 2008
  18. “n•Óds: SŒŒŠÇƒCƒxƒ“ƒg—\–h‚É‚¨‚¯‚郊ƒXƒNŠÇ—í—ª@„Ÿ‚ƒŠƒXƒNŠ³ŽÒ‚Ì“¯’è‚ÆŽ‰Ž¿ŠÇ—‚ɂ‚¢‚Ä„Ÿ. “ú—§’n‹æŠwpu‰‰‰ïi“ú—§j6ŒŽ, 2008
  19. “n•Óds: •s®–¬‚ÆŽ¸_, ‚¨‚æ‚ÑŽ©“®ŽÔ‚̉^“]‚ɂ‚¢‚Ä. ‘S‘ŒxŽ@ŠwZ‰^“]“K«‘Š’kê‰Èi¬•½j6ŒŽ, 2008
  20. “n•Óds: ‹•ŒŒ«SŽ¾Š³‚Ì”­Ç ¥i“W‚Ì—\–hí—ª. “y‰Y—Տ°Œ¤‹†‰ïi“y‰Yj6ŒŽ, 2008
  21. “n•Óds: ƒ¿-ƒOƒ‹ƒRƒVƒ_[ƒ[‘jŠQ–òiƒ~ƒOƒŠƒg[ƒ‹j‚̉^“®‘Ï—e”\‚ɑ΂·‚éŒø‰Ê. Œ§“ì’n‹æˆãŽt‰ïŠwpu‰‰‰ïi‚‚­‚΁j6ŒŽ, 2008
  22. “n•Óds: zŠÂŠí“à‰Èˆã‚©‚猩‚½Ï‹É“IŽ‰Ž¿’ቺ—Ö@‚̈Ӌ`. ‚‚­‚ΖòÜŽt‚̏W‚¢i‚‚­‚΁j7ŒŽ, 2008
  23. ‹v‰êŒ\—S: •s®–¬‚ÌŠî‘b‚Æ–ò•¨‚¨‚æ‚Ñ”ñ–ò•¨Ž¡—Ã. ’}”gˆã–ò˜AŒgŠwpu‰‰‰ïi‚‚­‚΁j8ŒŽ, 2008
  24. “n•Óds: ŽÀ—Տ°‚É‚¨‚¯‚é“®–¬d‰»«Ž¾Š³‚Ì”­ÇEi“W—\–h. Atorvastatin Special Meeting 2008i“Œ‹žj9ŒŽ, 2008
  25. “n•Óds: “®–¬d‰»«Ž¾Š³‚Ì”­Ç—\–h‚ƃvƒ‰[ƒN‚̑ޏk‚ð–ÚŽw‚·V‚½‚ÈŽ¡—Ð헪. ‘æ10‰ñ‚ŒŒˆ³‚Æ“œ”A•a‚ðŒê‚é‰ïi…ŒËj9ŒŽ, 2008
  26. “n•Óds: SŒŒŠÇƒCƒxƒ“ƒg—\–h‚É‚¨‚¯‚郊ƒXƒNŠÇ—í—ª@„Ÿ‚ƒŠƒXƒNŠ³ŽÒ‚Ì“¯’è‚ÆŽ‰Ž¿ŠÇ—‚ɂ‚¢‚Ä„Ÿ. “®–¬d‰»«Ž¾Š³ƒVƒ“ƒ|ƒWƒEƒ€in ŒQ”ni‘O‹´j10ŒŽ, 2008
  27. “n•Óds: S“d}‚Ì“Ç‚Ý•û. —´ƒ–èÏ¶‰ï•a‰@uK‰ïi—´ƒ–èj10ŒŽ, 2008
  28. “n•Óds: SŒŒŠÇŽ¾Š³ƒCƒxƒ“ƒg—\–h‚É‚¨‚¯‚郊ƒXƒNŠÇ—. “®–¬d‰»«Ž¾Š³Ž¡—ÃWorkshopiŽç’Jj10ŒŽ, 2008
  29. “n•Óds: “®–¬d‰»‚̃Rƒ“ƒgƒ[ƒ‹‚Ƒޏk‚ÉŒü‚¯‚½V‚½‚ÈŽ¡—Ð헪. VŽž‘ã‚̐SŒŒŠÇƒCƒxƒ“ƒg”­Ç—}§‚ðl‚¦‚éi…ŒËj10ŒŽ, 2008
  30. £”ö—RL: ICD/CRT‡“¯Œ¤CƒZƒ~ƒi[@CRTŠî‘b:1.S•s‘S‚Ì•a‘Ô‚ÆŽ¡—Ã, CRT‚Ì–ðŠ„. ‘æ12‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï ICD/CRT‡“¯Œ¤CƒZƒ~ƒi[i“Œ‹žj10ŒŽ, 2008
  31. šê“c@_: CRTŠî‘b:2.CRTAž‚Ý‚ÌŽÀÛ. ‘æ12‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï ICD/CRT‡“¯Œ¤CƒZƒ~ƒi[i“Œ‹žj10ŒŽ, 2008
  32. ‹v‰êŒ\—S: •s®–¬‚Ì”­¶‚Ì“d‹C¶—Šw“I”wŒi. ’}”g‘åŠwˆãŠw¶EŒ¤Cˆã‚Ì‚½‚߂̐S“d}“ljeƒZƒ~ƒi[i‚‚­‚΁j10ŒŽ, 2008
  33. ‹v‰êŒ\—S: QT‰„’·ÇŒóŒQ, Torsades de pointes, BrugadaÇŒóŒQ. ’}”g‘åŠwˆãŠw¶EŒ¤Cˆã‚Ì‚½‚߂̐S“d}“ljeƒZƒ~ƒi[i‚‚­‚΁j10ŒŽ, 2008
  34. “n•Óds: SŒŒŠÇƒCƒxƒ“ƒg—\–h‚É‚¨‚¯‚郊ƒXƒNŠÇ—í—ª@„Ÿ‚ƒŠƒXƒNŠ³ŽÒ‚Ì“¯’è‚ÆŽ‰Ž¿ŠÇ—‚ɂ‚¢‚Ä„Ÿ. “®–¬d‰»«Ž¾Š³Workshop in “y‰Yi“y‰Yj11ŒŽ, 2008
  35. “n•Óds: ’}”g‘åŠw‚ð’m‚낤@ˆãŠwŒQˆãŠw—Þ. ˆïéŒ§—§’|‰€‚Z ’}”g‘åŠwÐ‰îŽö‹Æi‚‚­‚΁j11ŒŽ, 2008
  36. “n•Óds: SŒŒŠÇŽ¾Š³ƒCƒxƒ“ƒg—\–h‚É‚¨‚¯‚郊ƒXƒNŠÇ—í—ª. ‰F“s‹{“®–¬d‰»«Ž¾Š³u‰‰‰ïi‰F“s‹{j11ŒŽ, 2008
  37. “n•Óds: SŽ¥}. À’k‰ïuzŠÂŠíf’f–@„ŸÅ‹ß‚̘b‘è„Ÿvi‚‚­‚΁j11ŒŽ, 2008
  38. Î’Ã’qŽq: ƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚̗Տ°‰ž—p. “ú–{’´‰¹”gŒŸ¸Šw‰ï ‘æ95‰ñˆã—p’´‰¹”guK‰ïi“Œ‹žj11ŒŽ, 2008
  39. ‹v‰êŒ\—S: QT‰„’·ÇŒóŒQ, Torsades de pointes, BrugadaÇŒóŒQD ’}”g‘åŠwˆãŠw¶EŒ¤Cˆã‚Ì‚½‚߂̐S“d}“ljeƒZƒ~ƒi[i‚‚­‚΁j12ŒŽ, 2008
  40. ‹v‰êŒ\—S: •s®–¬‚Ì”­¶‚Ì“d‹C¶—Šw“I”wŒiD ’}”g‘åŠwˆãŠw¶EŒ¤Cˆã‚Ì‚½‚߂̐S“d}“ljeƒZƒ~ƒi[i‚‚­‚΁j12ŒŽ, 2008
  41. ‹v‰êŒ\—S: S’âŽ~‚ɑ΂·‚éICDŽ¡—ÁD ‘æ1‰ñˆïéS‘ŸƒtƒH[ƒ‰ƒ€i…ŒËj12ŒŽ, 2008
  42. ‹v‰êŒ\—S: Œ’NŠÇ—‚ÆŒ’Nf’fD •½¬20”N“x‘ސE€”õƒZƒ~ƒi[i‚‚­‚΁j12ŒŽ, 2008
  43. £”ö—RL: ŽÀ—Տ°‚É‚¨‚¯‚éÏ‹É“IŽ‰Ž¿’ቺ—Ö@‚ÌŒoŒ±`’}”g‘åŠwzŠÂŠí“à‰È3”NŠÔ‚̃f[ƒ^‚ð‚à‚Æ‚É. ŽOðŽsˆãŽt‰ïŠwpu‰‰‰ïiVŠƒŒ§ŽOðŽsj12ŒŽ, 2008

@2007”N“xi2007”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. ’¬–ì@‹B, ‹v‰êŒ\—S, “n•Óds, ÂÀ˜a—², ŽRŒû@›Ü, “yŠò_‰î, –{ŠÔ^l, Žæ‹v”ü, ’Ë–{»Žq, K“cK’¼: Round Table Discussion: Effect on Hemodynamics and Dyssynchrony by Triangle Ventricular Pacing in Patients with Advanced Heart Failure. ‘æ41‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïŠwpW‰ïi“Œ‹žj1ŒŽ, 2007
  2. ˜–쌋Šó, •ˆÀ–@”V, “n•Óds, •ÐŠñ‘׎q, ’Jì@•, ²“¡@½, ÂÀ˜a—², ŽRŒû@›Ü: Featured Research: Propagation Delay of Active Myocardial Movement Determined By Speckle Tracking Identifies Responders of Cardiac Resynchronization. ‘æ41‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïŠwpW‰ïi“Œ‹žj1ŒŽ, 2007
  3. ’¬–ì@‹B, ŠÖŒûK•v, ‹g“cŒ’‘¾˜Y, •–ØŒ’Žu, ŽRè@_, “cã˜aK, £”ö—RL, ‰Í–ì@—¹, ‹v‰êŒ\—S, “n•Óds, ŽRŒû@›Ü, ÂÀ˜a—²: Coagulofibrinolytic and inflammatory activation associated with spontaneous echo contrast and mitral valve stenosis. ˆïéŒ§“à‰ÈŒ¤‹†‰ïi…ŒËj1ŒŽ, 2007
  4. •–ØŒ’Žu, ŠÖŒûK•v, ²“¡—zŽq, ’¬–ì@‹B, ŽRè _, “cã˜aK, ‹g“cŒ’‘¾˜Y, ‘º‰zLs, “ñ“¡•”äŽi, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: Usefulness of high-density electroanatomical mapping for catheter ablation of nonischemic ventricular tachycardia. ‘æ203‰ñ“ú–{ zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽ, 2007
  5. ÂÀ˜a—²: Contributory Role of VEGF Overexpression in Endothelin-1-induced Cardiomyocyte Hypertrophy. ‘æ143‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[iå‘äj2ŒŽ, 2007
  6. ì‘º@—´, “n•Óds, •–ØŒ’Žu, ’¬–ì@‹B, £”ö—RL, •ˆÀ–@”V, ŽRŒû@›Ü, ÂÀ˜a—²: Dyssynchrony Deteriorate Left Ventricular Twist in Patients with Dilated Cardiomyopathy. The 3rd Meet the Expert in Ibarakii‚‚­‚΁j2ŒŽ, 2007
  7. ÂÀ˜a—²: Limitation of cardiac resynchronization therapy in improvement of severe functional mitral regurgitation due to tethering effect. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  8. ÂÀ˜a—²: Polymorphism in endothelin-related genes affects exercise-induced improvements of arterial stiffness in the Japanese older subjects. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  9. Seo Y, Yoshida K, Yamazaki H, Tanoue K, Ishizu T, Murakoshi N, Sekiguchi Y, Kawano S, Otsuka S, Watanabe S, Yamaguchi I, Aonuma K: MAPK activation change to a single bout of exercise in untrained and trained hearts of rat. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  10. Seo Y, Ishizu T, Yoshida K, Tanoue K, Murakoshi N, Sekiguchi Y, Kawano S, Otsuka S, Watanabe S, Yamaguchi I, Aonuma K: Feasibility and Utility of M-mode Septal to Posterior Wall Motion Delay As a Screening Method of Left Ventricular Dyssynchrony. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  11. Uno K, Homma S, Tanoue K, Yoshida K, Suzuki A, Seo Y, Kawano S, Kuga K, Yamaguchi I, Aonuma K: Utility of real time 3-dimensional echocardiography in evaluation of severe tricuspid regurgitation due to pacemaker or implantable cardioverter-defibrillator leads. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  12. Endo M, Yoshida K, Tanoue K, Suzuki A, Kuga K, Aonuma K, Yamaguchi I: Late Phase Stent Thrombosis in Japan. Relationship Between Antiplatelet Agent and Stent Type. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  13. Shimojo N, Jesmin S, Maeda S, Iemitsu M, Zaedi S, Ootsuki T, Yamaguchi N, Aonuma K, Yamaguchi I, Miyauchi T: Preliminary feasibility and early clinical outcome of the ablation of culprit veins that drives paroxysmal atrial fibrillation. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  14. Ishizu T, Seo Y, Iida N, Sakamaki F, Kawano S, Aonuma K, Yamaguchi I: Detection of the eInjury Currentf of Ischemic Myocardium by High-Tc-SQUIDMagnetocardiography. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  15. Hoshi T, Seo Y, Ishizu T, Tanoue K, Yoshida K, Kawano S, Watanabe S, Aonuma K: Shortening and prolonged filtered P wave duration after pulmonary vein isolation in patients with atrial fibrilltion. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  16. Iemitsu M, Maeda S, Otsuki T, Sugawara J, Tanabe T, Jesmin S, Kuno S, Ajisaka R, Miyauchi T, Matsuda M: Elimination of delayed potential by catheter ablation based on high resolution substrate mapping of reentrant ventricular tachyarrhythmia. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  17. Iemitsu M, Maeda S, Jesmin S, Otsuki T, Kasuya Y, Aonuma K, Yamaguchi I, Miyauchi T: Effects of Statin Treatments on Carotid Plaque Stabilization Associate with Reductions of Oxidized Low-Density Lipoprotein. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  18. Sakamaki F, Seo Y, Ishizu T, Uno K, Kawano S, Watanabe S, Aonuma K, Yamaguchi I: Left Atrial Volumes Assessed by Echocardiography Compared to Magnetic Resonance Imaging. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  19. Nakajima H, Seo Y, Ishizu T, Yoshida K, Tanoue K, Yamazaki H, Kawano S, Watanabe S, Aonuma K, Yamaguchi I: Radionuclide ventriculographic evaluation of the effect of cardiac resynchronization therapy on acute and chronic phase. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  20. Ohtsuka T, Obara K, Toyama M, Aonuma K, Watanabe S, Takeyasu N, Kawano S, Maeda H, Yamazaki A, Noguchi Y, Endo M, Tomizawa T, Tanaka K, Tanaka K, Yamanouchi T, Enomoto T, Ushiyama K: Estrogen Receptor Alpha and Beta Are Equally Involved in Cerebral Vascular Endothelial Growth Factor/KDR/Nitric Oxide Pathway in Female Mice. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  21. Ishikawa K, Ushiyama K, Enomoto T, Endoh M, Tanaka K, Tanaka K, Tomizawa T, Toyama M, Noguchi Y, Maeda H, Yamazaki A, Yamanouchi T, Kawano S, Watanabe S, Aonuma K: Distinction on the electrocardiogram of outlow tract ventricular arrhythmia between left and right ventricular origin. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  22. Kuroki K, Machino T, Yamasaki H, Tanoue K, Yoshida K, Kanemoto M, Murakoshi N, Sekiguchi Y, Suzuki A, Endoh M, Kuga K, Nitobe J, Kubota I, Yamaguchi I, Aonuma K: Chronic hemodynamic effects after radiofrequency catheter ablation of frequent monomorphic ventricular premature beats. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  23. Sato Y, Watanabe S, Kimura T, Nishina H, Aihara H, Takeyasu N, On K, Yamada S, Suzuki A, Ogata K, Kandori A, Miyashita T, Tsukada K, Yamaguchi I, Aonuma K: Clinical application of tissue elasticity imaging for deep vein thrombosis - preliminary findings. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  24. Tanoue K, Machino T, Kuroki K, Yamasaki H, Yoshida K, Kanemoto M, Murakoshi N, Sekiguchi Y, Suzuki A, Endoh M, Kuga K, Yamaguchi I, Aonuma K: Endothelin antagonism greatly reverses upregulated renin-angiotensin system in the hypertrophied heart of SHR-SP. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  25. Yoshida K, Tanoue K, Kuroki K, Yamasaki H, Machino T, Kanemoto M, Murakoshi N, Sekiguchi Y, Suzuki A, Endoh M, Kuga K, Yamaguchi I, Aonuma K: Utility of Tagged Magnetic Resonance Imaging Combined with Deformable Grid Obtained by Block-Matching Algorithm. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  26. Kawamura R, Seo Y, Ishizu T, Takeyasu N, Watanabe S, Aonuma K: Pattern of recurrence periods of atrial fibrillation after extensive pulmonary vein isolation. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  27. Uno K, Seo Y, Ishizu T, Otsuka S, Watanabe S, Aonuma K: Atherogenic Effects of Metabolic Syndrome in Patients with Coronary Heart Disease at Adequete Low-Density Lipoprotein Cholesterol Levels. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  28. Aihara H, Takeyasu N, Watanabe S, Nishina H, Kimura T, Morimoto T, Seo Y, Kuga K, Takeda T, Aonuma K, Yamaguchi I: The Augmentation of Left Atrial Function Maintains Left Ventricular Diastolic Filling in Patients with Concentric Left Ventricular Hypertrophy. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  29. Jesmin J, Maeda S, Zaedi S, Shimojo N, Iemitsu M, Ootsuki T, Yamaguchi N, Miyauchi T: VEGF signaling is disrupted in the heart of mice lacking estrogen receptor. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  30. Sekiguchi Y, Yamauchi Y, Tanoue K, Yoshida K, Kuga K, Yamaguchi I, Aonuma K: Estrogen Pre-treatment Prevents the ET-1-induced Cardiomyocyte Hypertrophy in vitro: Potential Linkage with VEGF. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  31. Kuroki K, Machino T, Yamasaki H, Tanoue K, Yoshida K, Kanemoto M, Murakoshi N, Sekiguchi Y, Suzuki A, Endoh M, Kuga K, Yamaguchi I, Aonuma K, Yamauchi Y: Chronic treatment with Endothelin receptor antagonist normalizes the altered cerebral capillary density in the frontal cortex of SHR-SP rats. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  32. Uno K, Homma S, Tonomura A, Yamakawa M, Shiina T, Yamaguchi I, Aonuma K: AAV-mediated Gene Transfer of HCN4 into Cardiac Conduction System Significantly Increases Heart Rate in the Canine Model of AV Block. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  33. Kimura T, Watanabe S, Takeyasu N, On K, Nishina H, Aihara H, Yamada S, Suzuki D, Ogata K, Kandori A, Miyashita T, Tsukada K, Yamaguchi I, Aonuma K: Endothelin Selective A Receptor Antagonist Recovers Downregulated VEGF, NO andBCL-2 Expression in Penile Tissues in Type 1 Diabetic Rat. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  34. Iemitsu M, Maeda S, Jesmin J, Shimojo N, Zaedi S, Ootsuki T, Togashi H, Yamaguchi N, Aonuma K, Yamaguchi I, Miyauchi T: Sirolimus-Eluting Stent for AMI in Ibaraki -ICAS (Ibatraki Coronary Artery Study)-. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  35. Seo Y, Ohtsuka S, Oyake Y, Yoshida I, Uno K, Minami M, Kudou H, Aonuma K, Yamaguchi I: Role of Endothelin in the impairment cardiac function, cardiac VEGF signaling and coronary collateral development in early diabetic rats. ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  36. Sekiguchi Y, Yamauchi Y, Tanoue K, Yoshida K, Kuga K, Yamaguchi I, Aonuma K: u—Տ°S‘Ÿ“d‹C¶—ŒŸ¸‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“vƒKƒCƒhƒ‰ƒCƒ“ì¬‚Ì–â‘è“_, ™–¬«•s®–¬D ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  37. Seo Y, Ishizu T, Kawamura R, Takeyasu N, Watanabe S, Aonuma K: ‚Ž‰ŒŒÇ‚𔺂¤‹³Eˆõ‚É‚¨‚¯‚éèò•”’´‰¹”gŒŸ¸‚̐¶ŠˆKŠµ‰ü‘P‚Ì“®‹@‚¯‚ɑ΂·‚é—L—p«‚ɂ‚¢‚Ä‚Ì•ñD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  38. Oyake Y, Ohtsuka S, Yoshida I, Seo Y, Uno K, Tanaka Y, Shindo M, Hirano Y, Minami M, Yamaguchi I, Aonuma K: “–‰@‚É‚¨‚¯‚éƒGƒLƒVƒ}ƒŒ[ƒU[Š¥“®–¬Œ`¬p‚̏‰Šú¬ÑD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  39. Iemitsu M, Zaedi S, Maeda S, Jesmin J, Shimojo N, Ootsuki T, Yamaguchi N, Hattori Y, Aonuma K, Yamaguchi I, Miyauchi T: ”x“®–¬‹NŒ¹“Á”­«SŽº«•s®–¬‚É‚¨‚¯‚é”­¶‹NŒ¹•”ˆÊ‚Ì“d‹C¶—Šw“I“Á’¥D ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  40. Shimojo N, Jesmin S, Maeda S, Iemitsu M, Zaedi S, Ootsuki T, Yamaguchi N, Aonuma K, Yamaguchi I, Miyauchi T: Š¥“®–¬Ž¾Š³Ç—á‚É‚¨‚¯‚é“®–¬d‰»Žä‹NˆöŽq‚Æ”ñNP“IŒŸ¸–@‚Æ‚ÌŠÖ˜AD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  41. Ootsuki T, Maeda S, Zaedi S, Shimojo N, Iemitsu M, Togashi@H, Jesmin J, Yamaguchi N, Aonuma K, Yamaguchi I, Miyauchi T: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[i“ŒŽÅƒƒfƒBƒJƒ‹ƒVƒXƒeƒ€jƒXƒyƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚è’m‚肤‚é‹ÇŠS‹Ø‚̘c‚ð—Տ°‚ɉž—p‚·‚éD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  42. Murakoshi N, Yoshida K, Tanoue K, Kuga K, Kamimura R, Setoyama K, Sekiguchi Y, Yamaguchi I, Aonuma K: ¶Žº“¯Šú•s‘S‚͍¶Žº”P‚ê‰^“®‚Ì“Æ—§‹K’èˆöŽq‚Å‚ ‚éD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  43. Jesmin J, Maeda S, Iemitsu M, Shimojo N, Zaedi S, Yamaguchi N, Ootsuki T, Aonuma K, Yamaguchi I, Miyauchi T: SƒGƒR[‚É‚æ‚鍶–[—e—Ê‚Ì‘ª’è|Magnetic Resonance Imaging‚Æ‚Ì”äŠrD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  44. Takeyasu N, Maeda H, Yamazaki A, Noguchi Y, Endoh M, Tomizawa T, Tanaka K, Tanaka K, Yamanouchi T, Toyama M, Enomoto T, Ushiyama K, Misaki M, Aihara H, Hatori M, Oyake Y, Suzuki A, Murakoshi N, Kawano S, Watanabe S, Aonuma K: ƒXƒyƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚é”\“®“I¶ŽºŽûk’x‰„‚Ì“¯’è‚͐SŽºÄ“¯Šú—Ö@ƒŒƒXƒ|ƒ“ƒ_[—\‘ª‚É—L—p‚Å‚ ‚éD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  45. Shimojo N, Maeda S, Zaedi S, Jesmin J, Iemitsu M, Ootsuki T, Hattori Y, Ichiro Sakuma, Yamaguchi N, Aonuma K, Yamaguchi I, Miyauchi T: Šg’£Œ^S‹ØÇ‚É‚¨‚¯‚éMƒ‚[ƒh–@‚ð—p‚¢‚½¶Žº“àdyssynchronyŒŸo‚ÆQRSŽžŠÔ‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä‚ÌŒŸ“¢D ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  46. Shimojo N, Maeda S, Iemitsu M, Zaedi S, Jesmin J, Ootsuki T, Yamaguchi N, Aonuma K, Yamaguchi I, Miyauchi T: ”CˆÓ•ûŒüMƒ‚[ƒh–@‚É‚æ‚鍶ŽºdyssynchronyŒŸo‚ÉŠÖ‚·‚錟“¢D ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  47. Maruyama H, Watanabe S, Kimura T, Liang J, Onodera M, Aonuma K, Yamaguchi I: 3DSƒGƒR[}–@‚É‚æ‚éƒy[ƒXƒ[ƒJƒŠ[ƒh‹Nˆö«ŽOë•Ù•Â½áŠQ‚̐f’fD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  48. ‹v‰êŒ\—S: ‰E–[’†Šu‚ɑ΂·‚éüóÄŽÜ‚ª—LŒø‚Å‚ ‚Á‚½MazeŽèpŒãŽ‘±«S–[×“®‚̈êÇ—áD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  49. ŽR–{­], ‹v‰êŒ\—S, Î’Ã’qŽq, ‹g“cOŽq, ŒÜ“‡—mŽq, •½“cŽO‘ãŽq, X@ŒcŽq, ¼ˆä—TŽj, ‘å’ː·’j: ¶Žº“¯Šú•s‘S‚ƍ¶Žº”P‚ê‰^“®‚ÌŠÖ˜AD ‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïŠwpW‰ïi_ŒËj3ŒŽ, 2007
  50. •ˆÀ–@”V, “n•Óds, £”ö—RL, ‘º‰zLs, ²“¡—zŽq, ŽRè@_, •–ØŒ’Žu, ‰Í–ì@—¹, ÂÀ˜a—², ŽRŒû@›Ü: –«S•s‘S‚ɍ‡•¹‚µ‚½‡–°ŽžŒÄ‹záŠQ‚ɑ΂·‚éS‘ŸÄ“¯Šú—Ö@‚ÌŒø‰ÊD ‘æ104‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïi‘åãj4ŒŽ, 2007
  51. ŠÖŒûK•v, ‹g“cŒ’‘¾˜Y, £”ö—RL, “cã˜aK, ‘º‰zLs, ŽRè@_, ‹v‰êŒ\—S, ‰Í–ì@—¹, ÂÀ˜a—², ŽRŒû@›Ü: ƒAƒ~ƒIƒ_ƒƒ““à•ž’†‚Ìincessant VT‚ÌŒŸ“¢D ‘æ104‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïi‘åãj4ŒŽ, 2007
  52. £”ö—RL, “n•Óds, Î’Ã’qŽq, •ˆÀ–@”V, ÂÀ˜a—²: ¶Žº‹NŒ¹“Ë”­«SŽº•p”‚É‚¨‚¯‚鎊“K’Ê“d•”ˆÊ‚̉ð–UŠw“I“Á’¥D ‘æ104‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïi‘åãj4ŒŽ, 2007
  53. £”ö—RL: DCMEHCM‚ɍ‡•¹‚µ‚½”­ì«S–[×“®‚ɑ΂·‚éPVI‚ÌŒø‰ÊD ‘æ18‰ñ“ú–{SƒGƒR[}Šw‰ïiŒyˆä‘òj4ŒŽ, 2007
  54. Î’Ã’qŽq, £”ö—RL, ‰F–ìŠó¢Žq, ‹T’J—¢”ü, ŽðŠª•¶Žq, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t •, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: ƒqƒX‘©‹ß–T‹NŒ¹SŽº«•s®–¬‚É‚¨‚¯‚éS“d}‚Ì“Á’¥‚ƃAƒuƒŒ[ƒVƒ‡ƒ“ƒJƒe[ƒeƒ‹‚̃Aƒvƒ[ƒ`–@D ‘æ18‰ñ“ú–{SƒGƒR[}Šw‰ïiŒyˆä‘òj4ŒŽ, 2007
  55. ‰F–ìŠó¢ŽqC£”ö—RLCÎ’Ã’qŽqC¬‘îN”VCŽðˆä@rC‘å’Ë’è“¿C“c’†—D”üŽqC“ì@@ŠwC“n•ÓdsCÂÀ˜a—²: “Ë”­«SŽº«ŠúŠOŽûk‚É‚æ‚è’˜–¼‚ÈBNP‚̏㏸‚ð”F‚ß‚½2—á|ƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚Ì‹}«Šú•Ï‰»|D ‘æ18‰ñ“ú–{SƒGƒR[}Šw‰ïiŒyˆä‘òj4ŒŽ, 2007
  56. £”ö—RL, Î’Ã’qŽq, ‰F–ìŠó¢Žq, ‹T’J—¢”ü, ŽðŠª•¶Žq, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t@•, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: –{–M‚É‚¨‚¯‚éICD“o˜^§“x‚ÌŒ»ó‚ƍ¡Œã‚ÌŠˆ—pE–â‘è“_|JCRTƒvƒƒgƒR[ƒ‹‚ɂ‚¢‚ā|D ‘æ18‰ñ“ú–{SƒGƒR[}Šw‰ïiŒyˆä‘òj4ŒŽ, 2007
  57. ŽðŠª•¶Žq, £”ö—RL, ‰F–ìŠó¢Žq, Î’Ã’qŽq, ‹T’J—¢”ü, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t •, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: ƒVƒ“ƒ|ƒWƒEƒ€?FƒVƒ“ƒ|ƒWƒEƒ€CRT-P‚ÆCRT-DAž‚Ý‚ÌŒ»ó‚ƍ¡Œã‚̉ۑè@3“_ƒy[ƒVƒ“ƒOCRT‚Ì—˜“_‚Æ“K‰žÇ—á‚ɂ‚¢‚āD ‘æ18‰ñ“ú–{SƒGƒR[}Šw‰ïiŒyˆä‘òj4ŒŽ, 2007
  58. ŽðŠª•¶Žq, £”ö—RL, ‰F–ìŠó¢Žq, Î’Ã’qŽq, ‹T’J—¢”ü, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t@•, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: ˆê•”‚Ì”­ì«S–[×“®‚Å‚Í, thoracic veinŽ©‘Ì‚ªS–[×“®‚Ìtrigger‚Æ‚È‚é‚݂̂Ȃ炸substrate‚É‚à‚Ȃ肤‚éD ‘æ18‰ñ“ú–{SƒGƒR[}Šw‰ïiŒyˆä‘òj4ŒŽ, 2007
  59. ’†“‡‰pŽ÷, £”ö—RL, ”Ñ“c“TŽq, ŽðŠª•¶Žq, ˆî—t@•, ì‘º@—´, ‰F–ìŠó¢Žq, Î’Ã’qŽq, ÂÀ˜a—²: S–[×“®‚ªœ×“®¢“ï‚Å‚ ‚Á‚½Œ´ˆö‚ª, œ×“®’ïR«‚Ì”xÃ–¬•p”‚Å‚ ‚Á‚½‚±‚Æ‚ðØ–¾‚Å‚«‚½”­ì«S–[×“®‚Ì1—áD ‘æ18‰ñ“ú–{SƒGƒR[}Šw‰ïiŒyˆä‘òj4ŒŽ, 2007
  60. ŠÖŒûK•v, “cã˜aK, ‹g“cŒ’‘¾˜Y, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: ¬Ž™Šú‰”­, ”xÃ–¬‚ð‹NŒ¹‚Æ‚·‚éãŽº•s®–¬‚ɑ΂·‚éƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Á|ŒÂX‚̏Ǘá‚ɍ‡‚킹‚½Tailored Approach|D ‘æ37‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi‰F•”j5ŒŽ, 2007
  61. ”Ñ“c“TŽq, Î’Ã’qŽq, £”ö—RL, ‰F–ìŠó¢Žq, ‹T’J—¢”ü, ŽðŠª•¶Žq, ’†“‡‰pŽ÷, ˆî—t@• , ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: —¬o˜HŠúŒÀSŽº«•s®–¬‚Ì‹NŒ¹„‘ªŽž‚É‚¨‚¯‚é‘Ε\–ʐS“d}V3—U“±R”g‚‚̏d—v«D ‘æ80‰ñ“ú–{’´‰¹”gˆãŠw‰ïiŽ­Ž™“‡j5ŒŽ, 2007
  62. £”ö—RL, Î’Ã’qŽq, ‰F–ìŠó¢Žq, ‹T’J—¢”ü, ŽðŠª•¶Žq, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t@•, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: SŽº«•s®–¬‚É‚¨‚¯‚鐇–°ŒÄ‹záŠQ‚Ì•p“x‚Æ“Á’¥D ‘æ80‰ñ“ú–{’´‰¹”gˆãŠw‰ïiŽ­Ž™“‡j5ŒŽ, 2007
  63. ‹à–{@“s, m‰ÈG’, ‰–’ˏ“ñ, ¯@’q–ç, ÎìŒöl, •¶‘ —DŽq, •½À‚ä‚è, –ìŒû—Sˆê, “n•Óds, ŽRŒû@›Ü, ÂÀ˜a—²: Œo‰ßŠÏŽ@’†‚ɐSë•””ì‘åŒ^‚©‚ç’†•”•ÂÇŒ^‚ֈڍs‚µ, ”ñŽ‘±«SŽº•p”‚ð‡•¹‚µ‚½”ì‘åŒ^S‹ØÇ‚̐S“d}ŠŒ©D ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  64. ‰¡ŽR‘לA, •½”öŒ©ŽO, –I’J@m, ì’[”ü•äŽq, ”óŒû@W, ²X–Ø‹B, ˆé•”ŒõÍ, ÂÀ˜a—²: Velocity difference between early diastolic Doppler transmitral flow and color M-mode propagation as a reliable surrogate measure to estimate the pulmonary wedge pressure. ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  65. ‹g“cŒ’‘¾˜Y, ŠÖŒûK•v, “cã˜aK, ŽRè@_, •–ØŒ’Žu, ’¬–ì@‹B, ‹à–{@“s, —é–؏͍O, ‰““¡—DŽ}, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: Dyssynchrony decreases left ventricular twist in patients with dilated cardiomyopathy. ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  66. ’¬–ì@‹B, ŠÖŒûK•v, ‹g“cŒ’‘¾˜Y, •–ØŒ’Žu, ŽRè@_, “cã˜aK, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: S‹Ø[Ç ‰ñ•œŠú‚É‚¨‚¯‚é2Ží‚̐SŽºŠúŠOŽûk‚ƐSŽº•p”ŠîŽ¿‚Ì‘o•û‚ð•W“I‚Æ‚µ‚½ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ÁD ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  67. “cã˜aK, •–ØŒ’Žu, ’¬–ì@‹B, ŽRè@_, ‹g“cŒ’‘¾˜Y, ‹à–{@“s, ‰““¡—DŽ}, ŠÖŒûK•v, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: S‹Ø[Ç‰ñ•œŠú‚É‚¨‚¯‚é2Ží—ނ̐SŽºŠúŠOŽûk‚ðƒgƒŠƒK[‚É‚µ‚½VTƒXƒg[ƒ€‚ɑ΂µ, ƒgƒŠƒK[‚¨‚æ‚Ñ•s®–¬ŠîŽ¿‘o•û‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½1—áD ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  68. ŽRè@_, ’¬–ì@‹B, •–ØŒ’Žu, “cã˜aK, ‹g“cŒ’‘¾˜Y, ŠÖŒûK•v, ‹v‰êŒ\—S, ÂÀ˜a—²: –«t‘Ÿ•a‚Í“®–¬d‰»‚Ì“Æ—§‹K’èˆöŽq‚©|Š¥“®–¬Ž¾Š³Ç—á‚É‚¨‚¯‚éèò“®–¬ƒGƒR[‚ð—p‚¢‚½ŒŸ“¢|D ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  69. ÂÀ˜a—²: —‘‘ƒŠà‚É‚¨‚¯‚éÃ–¬ŒŒðÇðÇ‹K’èˆöŽq‚Æ‚µ‚Ä‚Ì‘gDˆöŽq‚Ì”­Œ»D ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  70. £”ö—RL, ‹g“cŒ’‘¾˜Y, ‘º‰zLs, ŠÖŒûK•v, Î’Ã’qŽq, “n•Óds, ŽRŒû@›Ü, ÂÀ˜a—²: ¶žôœ‚æ‚è‚Ì TRI ’†‚É”]Š²•”[Ç‚ð‡•¹‚µ‚½ˆê—áD ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  71. ŽR“àNÆ, —é–؁@“Ä, ‹v²–ÎŽ÷, ‰Ã”[Š°l, ‘åŽR–¾Žq, ‹´–{ŒhŽj, ™ŽR’m‘ã, ‚‘ºç’q, ‹{–{‹M—f, ”ö—с@“O, ’O‰H–¾”Ž, ŠÖŒûK•v, ÂÀ˜a—², –I’J@m, •½”öŒ©ŽO, ˆé•”ŒõÍ: ‰EŠ¥“®–¬‹ßˆÊ•”‚̃Xƒeƒ“ƒg—¯’u‚ɂĉ~Ž}•ÂÇ‚ð‚«‚½‚µ, SŽº×“®‚ð‡•¹‚µ‚½Ç—áD ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  72. ‹v²–ÎŽ÷, ŽR“àNÆ, —é–؁@“Ä, ‰Ã”[Š°l, ‚‘ºç’q, ‘åŽR–¾Žq, ™ŽR’m‘ã, ‹´–{ŒhŽj, ‹{–{‹M—f, ”ö—с@“O, ’O‰H–¾”Ž, ŠÖŒûK•v, ÂÀ˜a—², ”óŒûWŽi, –I’J@m, •½”öŒ©ŽO, ˆé•”ŒõÍ: Sƒv[ƒ‹ƒVƒ“ƒ`ƒOƒ‰ƒtƒB‚É‚æ‚éS‘ŸÄ“¯Šú—Ö@‚Ì“¯Šú«•]‰¿‚ÌŒŸ“¢D ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  73. •–ØŒ’Žu, ‹g“cŒ’‘¾˜Y, ’¬–ì@‹B, ŽRè@_, “cã˜aK, ŠÖŒûK•v, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—², ‰Á“¡ˆ¤Í, –x•ÄmŽu, ¼ˆä@—z: Š¥“®–¬MDCT“±“ü‚Å•‰‰×S‹ØSPECT‚Ì“K‰ž‚ɕω»‚Í‚ ‚Á‚½‚©H|“±“ü‘OŒã3‚©ŒŽŠÔ‚ÌŒŸ“¢D ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  74. ŠÖŒûK•v, “cã˜aK, ‹g“cŒ’‘¾˜Y, ‘º‰zLs, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—², ŽR“àNÆ: SŽº«•s®–¬‚Ɛ‡–°ŒÄ‹záŠQ‚ÌŠÖ˜A‚Æ“Á’¥D ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  75. ˜–쌋Šó, ²“¡@½, •ˆÀ–@”V, “n•Óds, •ÐŠñ‘fŽq, ’Jì •, ŽRè _, “cã˜aK, ‹g“cŒ’‘¾˜Y, ŠÖŒûK•v, ‹v‰êŒ\—S, ÂÀ˜a—², ŽRŒû@›Ü: SŽ¥}‚É‚æ‚銥‹·ó—á‚́uŠQ“d—¬vŒŸoD ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  76. ‰““¡—DŽ}, ÂÀ˜a—², ŠÖŒûK•v, ‹v‰êŒ\—S: SŽº«•s®–¬‚Ɛ‡–°ŒÄ‹záŠQ‚ÌŠÖ˜A‚Æ“Á’¥D ‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïiL“‡j6ŒŽ, 2007
  77. ²“¡—zŽq, ÂÀ˜a—², ŠÖŒûK•v, ‹v‰êŒ\—S, ‹g“cŒ’‘¾˜Y, “cã˜aK, ‘º‰zLs, ŽRè@_, ŽRŒû@›Ü, âV“¡@I, ‰““¡—DŽ}, ‘ŠŒ´‰p–¾, •–ØŒ’Žu: Young Investigator Award (2)@Medium-Chain Triglyceride (MCT) Ameliorates the Decreased Capacity of Myocardial Energy Metabolism and Cardiac Dysfunction in SHR. ‘æ204‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2007
  78. ²“¡—zŽq, ‹g“cŒ’‘¾˜Y, ŠÖŒûK•v, ŽRè@_, ’¬–ì@‹B, •–ØŒ’Žu, ¬ŽR@’, ‹v‰êŒ\—S, ÂÀ˜a—²: ˆÝŠàŽèp‚ɍۂµ‚ÄGEAƒoƒCƒpƒX‚ðØ’f‚·‚邽‚߉EŠ¥“®–¬–«Š®‘S•ÂÇ‚ÉPCI‚ðs‚Á‚½ˆê—áD ‘æ15‰ñŠÖ“ŒƒAƒuƒŒ[ƒVƒ‡ƒ“EƒZƒ~ƒi[i‚‚­‚΁j6ŒŽ, 2007
  79. Î’Ã’qŽq, £”ö—RO, XŽR’¼Žq, ì‘º@—´, ‰F–ìŠó¢Žq, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: Blue toe syndrome ‚̐f’f‚¨‚æ‚Ñ‚»‚Ì”­Ç‰ñ”ðô‚ɂ‚¢‚ÄŽ¦´‚ð—^‚¦‚½Ç—áD ˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï‘æ10‰ñŒ¤‹†”­•\‰ïi‚‚­‚΁j6ŒŽ, 2007
  80. ‰F–ìŠó¢Žq, –{ŠÔ@Šo, ²“¡–L”ü, ŸNˆä@Šw, “ì@—Œb, ‰«@–¾“T, Šp“c@”£, ‹gì—T”V, ÂÀ˜a—²: ƒ¿-ƒOƒ‹ƒRƒVƒ_[ƒ[‘jŠQ–òƒ~ƒOƒŠƒg[ƒ‹‚̐SŽ¾Š³Š³ŽÒ‚̉^“®‘Ï—e”\”—ʂɑ΂·‚éŒø‰ÊD ˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï‘æ10‰ñŒ¤‹†”­•\‰ïi‚‚­‚΁j6ŒŽ, 2007
  81. ”óŒûr•F, •ˆÀ–@”V, ’¬–ì@‹B, “cK˜aŽq, HŽR‘åŽ÷, ¬ŽR@’, –Ø‘º‘׎O, ‘º‰zLs, £”ö—RL, “n•Óds, ÂÀ˜a—²: 2DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚½‚“xŠ¥“®–¬‹·ó•a•Ï‚É‚¨‚¯‚éˆÀÃŽžS“à–Œ‘¤•Ç‰^“®ˆÙí‚ÌŒŸ“¢D ‘æ21‰ñˆïéŒ§PCIŒ¤‹†‰ïi“y‰Yj6ŒŽ, 2007
  82. ¯@’q–ç, ’¬–ì’qŽq, m‰ÈG’, ‹à–{@“s, ‰–’ˏ“ñ, ‹k@Œ«œA, Š|ŽD—YŠì, •½À‚ä‚è, •¶‘ —DŽq, –ìŒû—Sˆê, “n•Óds, ÂÀ˜a—²: ¶Žºk¬Œ`¬pŒã‚ÌVT‚É‚æ‚éS•s‘S‚Ì‘ˆ«‚ɑ΂µ‚Äablation‚ª—LŒø‚Å‚ ‚Á‚½Ç—áD ‘æ21‰ñˆïéŒ§PCIŒ¤‹†‰ïi“y‰Yj6ŒŽ, 2007
  83. ‘ŠŒ´‰p–¾, “n•Óds, m‰ÈG’, –Ø‘º‘׎O, “cã˜aK, ‹g“cŒ’‘¾˜Y, •ˆÀ–@”V, ÂÀ˜a—², ŽRŒû@›Ü, •“c@“O: ¶Žº“¯Šú•s‘S‚𔺂¤Šg’£Œ^S‹ØÇ‚É‚¨‚¯‚鍶Žº”P‚¶‚ê‰^“®‚̉ðÍD ‘æ17‰ñ“ú–{S‘ŸŠjˆãŠw‰ï‘‰ïEŠwp‘å‰ïi“Œ‹žj6ŒŽ, 2007
  84. m‰ÈG’, –ìŒû—Sˆê, ‹à–{@“s, ¯@’q–ç, ‰–’ˏ“ñ, •¶‘ —DŽq, ÎìŒöl, •½À‚ä‚è, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: SŽº‡ŽŸƒy[ƒVƒ“ƒO‚ð—p‚¢‚½SŽºÄ“¯Šú—Ö@ŽŠ“KÝ’è‚É‚¨‚¯‚éSƒGƒR[}–@‚Ì—L—p«D ‘æ17‰ñ“ú–{S‘ŸŠjˆãŠw‰ï‘‰ïEŠwp‘å‰ïi“Œ‹žj6ŒŽ, 2007
  85. ÎìŒöl, ‰|–{‹­Žu, ‰““¡—DŽ}, “c’†Šì”ü•v, ŠOŽR¹O, –ìŒû—Sˆê, ‘O“c—TŽj, ‹ŽR˜aŒ›, “c’†ç”Ž, •x‘òIŽ¡, ŽRè@–¾, ŽR“àF‹`, •ˆÀ–@”V, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: ”x“®–¬«”x‚ŒŒˆ³Ç‚É‚¨‚¯‚éƒ{ƒZƒ“ƒ^ƒ“‚É‚æ‚é’ZŠúŒø‰Ê‚ÌŒŸØD ‘æ16‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïiŒSŽRj6ŒŽ, 2007
  86. ˜–쌋Šó, ²“¡@½, •ÐŠñ‘׎q, ˆÀ“c@‹ž, •ˆÀ–@”V, ŠÖŒûK•v, ‹v‰êŒ\—S, “n•Óds, ÂÀ˜a—²: ƒGƒ‰ƒXƒgƒOƒ‰ƒtƒB‚ð—p‚¢‚½Ã–¬ŒŒð‚̍œK‚È•]‰¿•û–@D ‘æ27‰ñ“ú–{ƒzƒ‹ƒ^[Eƒmƒ“ƒCƒ“ƒxƒCƒVƒuS“dŠwŒ¤‹†‰ïi•Ê•{j7ŒŽ, 2007
  87. ²“¡—zŽq, “n•Óds, –Ø‘º‘׎O, ’†ì‹`Žk, m‰ÈG’, ‘ŠŒ´‰p–¾, •ˆÀ–@”V, ‰·@@Œi, ŽR“c‚³‚‚«, —é–Ø‘å‰î, •û–Mb, _’¹–¾•F, ‹{‰º@‹, ’Ë“cŒ[“ñ, ŽRŒû@›Ü, ÂÀ˜a—²: Šg’£‘Šú‘œ–X•Ù—¬“üŒŒ—¬‘¬“x‚ƃJƒ‰[Mƒ‚[ƒh¶Žº—¬“üŒŒ—¬“`”d‘¬“x‚É‚æ‚é”x“®–¬ž¶“ûˆ³‚̐„’èD ‘æ27‰ñ“ú–{ƒzƒ‹ƒ^[Eƒmƒ“ƒCƒ“ƒxƒCƒVƒuS“dŠwŒ¤‹†‰ïi•Ê•{j7ŒŽ, 2007
  88. ˜–쌋Šó, ²“¡@½, •ÐŠñ‘׎q, ˆÀ“c@‹ž, •ˆÀ–@”V, ŠÖŒûK•v, ‹v‰êŒ\—S, “n•Óds, ÂÀ˜a—²: SƒGƒR[‚É‚æ‚鍶–[—e—Ê‘ª’è•û–@‚ÌŒŸ“¢|MRI‚Æ‚Ì”äŠrD ‘æ27‰ñ“ú–{ƒzƒ‹ƒ^[Eƒmƒ“ƒCƒ“ƒx[ƒVƒuS“d}Œ¤‹†‰ïi•Ê•{j7ŒŽ, 2007
  89. ’¬–ì@‹B, ‹v‰êŒ\—S, ŠÖŒûK•v, ˜–쌋Šó, ‹g“cŒ’‘¾˜Y, –Ø‘º‘׎O, ‹à–{@“s, •–ØŒ’Žu, ²“¡—zŽq, ŽRè@_, ‘º‰zLs, “cK˜aŽq, ¬ŽR@’, ”󃍐r•F, HŽR‘åŽ÷, ŽRŒû@›Ü, ÂÀ˜a—²: –«t‘Ÿ•a‚Í“®–¬d‰»‚Ì“Æ—§‹K’èˆöŽq‚©, Š¥“®–¬Ž¾Š³Ç—á‚É‚¨‚¯‚éèò“®–¬ƒGƒR[‚ð—p‚¢‚½ŒŸ“¢D ‘æ27‰ñ“ú–{ƒzƒ‹ƒ^[Eƒmƒ“ƒCƒ“ƒx[ƒVƒuS“d}Œ¤‹†‰ïi•Ê•{j7ŒŽ, 2007
  90. Shimojo N, Sakai S, Aonuma K: ƒGƒ‰ƒXƒgƒOƒ‰ƒtƒB‚ð—p‚¢‚½Ã–¬ŒŒð‚̍œK‚È•]‰¿•û–@D ‘æ30‰ñS‹Ø‘ãŽÓŒ¤‹†‰ïi‹ž“sj7ŒŽ, 2007
  91. •ˆÀ–@”V, “n•Óds, ’¬–ì@‹B, ”óŒûr•F, “cK˜aŽq, ¬ŽR@’, HŽR‘åŽ÷, ‘º‰zLs, £”ö—RL, ÂÀ˜a—²: ƒRƒ“ƒgƒƒo[ƒVw’áS‹@”\Ç—á‚É‚¨‚¯‚éICD‚Ì“K‰žFMADIT II Criteria‚ð“ú–{l‚É‚à‰^—p‚·‚ׂ«‚©x‰^—p‚·‚ׂ«‚Å‚ ‚éD ‘æ27‰ñ‚‚­‚΃Cƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ƒVƒlƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‚‚­‚΁j7ŒŽ, 2007
  92. “n•Óds, •ˆÀ–@”V, ’¬–ì@‹B, ”óŒûr•F, “cK˜aŽq, ¬ŽR@’, HŽR‘åŽ÷, ‘º‰zLs, £”ö—RL, ÂÀ˜a—²: Symposium: Development of Tissue- and Time-Specific Gene Knockout in Mice. ‘æ27‰ñ‚‚­‚΃Cƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ƒVƒlƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‚‚­‚΁j7ŒŽ, 2007
  93. ’†ì‹`Žk, “n•Óds, •ˆÀ–@”V, VˆäŒb”ü, éˍ◲ˆê, X–{—²Žj, m‰ÈG’, ‘ŠŒ´‰p–¾, ÎŽR”üŽ÷, —À@ŒiŠâ, ÂÀ˜a—²: Reverse Remodeling of the Left Ventricle by PV Isolation in a Patient treated as Dilated Cardiomyaopathy with Atrial Fibrillation. ‘æ57‰ñzŠÂŠí•‰‰×Œ¤‹†‰ïi“Œ‹žj8ŒŽ, 2007
  94. Î’Ã’qŽq, –ìŒû—Sˆê, ‰–’ˏ“ñ, ’†“‡‰pŽ÷, ’¬–ì’qŽq, £”ö—RL, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: Granulocytepenia observed during bosentan adminstration therapy in a patient with pulmonary arterial hypertension. æiSŒŒŠÇƒGƒR[Œ¤‹†‰ïi‘åãj8ŒŽ 2007
  95. ’¬–ì@‹BCŠÖŒûK•vCHŽR‘åŽ÷C“cK˜aŽqC”óŒûr•FC¬ŽR@’C•–ØŒ’ŽuCŽRè@_C‹g“cŒ’‘¾˜YC‹à–{ “sC‰““¡—DŽ}C‘º‰zLsC‹v‰êŒ\—SCŽRŒû@›ÜCÂÀ˜a—²: ‰^“®ƒgƒŒ[ƒjƒ“ƒO‚É‚æ‚é’†S“®–¬L“W«‚Ì‘‘å‚ɃGƒ“ƒhƒZƒŠƒ“‚ªŠÖ—^‚·‚éD ‘æ12‰ñ_“ސì—Տ°•s®–¬ƒtƒH[ƒ‰ƒ€i‰¡•lj8ŒŽ, 2007
  96. Î’Ã’qŽq, £”ö—RL, ”Ñ“c“TŽq, ‰F–ìŠó¢Žq, ‹à–{@“s, –ìŒû—Sˆê, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: —¼Žºƒy[ƒXƒ[ƒJ[‚ÆICD•¹—p Ç—á‚É‚¨‚¯‚éICD•s“KØì“®‚ɑ΂µ, CRT-D‚̐A‚¦ž‚Ý‚ðs‚Á‚½1—áD ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  97. £”ö—RL, Î’Ã’qŽq, ì‘º@—´, ‰F–ìŠó¢Žq, ‹g“cŒ’‘¾˜Y, ŠÖŒûK•v, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: “ûŠàpŒã‚Ì•úŽËüŽ¡—Âɂæ‚萶‚¶‚½‹¹•”“®–¬áŽ‚̈ê—áD ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  98. HŽR‘åŽ÷, –{ŠÔ@Šo, ‘º‰zLs, ¬ŽR@’, ”óŒûr•F, ’¬–ì@‹B, “cK˜aŽq, ’؈ä—ml, ‰F–ìŠó¢Žq, £”ö—RL, ‰Í–ì@—¹, ÂÀ˜a—²: Sex difference in pharmacologics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachycardia. ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  99. ‰F–ìŠó¢Žq, ŠO‘º–¾Žq, ‘åã‘ìŽi, ŽO’|@‹B, {“c¹O, ŽRì@½, ’Å–¼@‹B, £”ö—RL, –{ŠÔ@Šo, “n•Óds, ÂÀ˜a—²: High incidence of silent venous thrombo- embolism before treatment in ovarian cancer and prevention of clinical manifestation after surgery. ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  100. ì‘º@—´, £”ö—RL, Î’Ã’qŽq, ‰F–ìŠó¢Žq, “n•Óds, ÂÀ˜a—²: “Á•ÊŠé‰æFR•s®–¬–ò‚̍‘Û‹¤“¯—Տ°ŽŽŒ±Calibrator arm‚Æ‚µ‚ĉ–Ž_ƒAƒ~ƒ_ƒƒ“‚ðŽg—p‚·‚é‚ɍۂµ‚Ă̈À‘S«‚ɑ΂·‚鍑“à‚Å‚Ì“Á•Ê‚È”z—¶D ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  101. ‰F–ìŠó¢Žq, £”ö—RL, Î’Ã’qŽq, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ŽðŠª•¶Žq, ˆî—t •, ¬‘îN”V, Žðˆä@r, ‘å’Ë’è“¿, “c’†—D”üŽq, “ì@@Šw, “n•Óds, ÂÀ˜a—²: 3“_ƒy[ƒVƒ“ƒOitriple-site pacingj‚É‚¨‚¯‚é‰EŽº—¬o˜H‚̃Š[ƒh—¯’u•”ˆÊ‚̏d—v«|12—U“±S“d}‚©‚ç‚ÌŒŸ“¢|D ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  102. Î’Ã’qŽq, £”ö—RL, XŽR’¼Žq, ‰F–ìŠó¢Žq, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: —¼Žºƒy[ƒXƒ[ƒJ[‚ÆICD•¹—pÇ—á‚É‚¨‚¯‚éICD•s“KØì“®‚ɑ΂µ, CRT-D‚̐A‚¦ž‚Ý‚ðs‚Á‚½1—áD ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  103. “cK˜aŽq, ŠÖŒûK•v, ‘º‰zLs, ¬ŽR@’, ”óŒûr•F, ’¬–ì@‹B, HŽR‘åŽ÷, £”ö—RL, ‰Í–ì@—¹, ‘å’Ë’è“¿, ÂÀ˜a—²: ‹•ŒŒ«S•s‘S‚ɑ΂µ‚ĐSŽº3“_ƒy[ƒVƒ“ƒO‚ª—LŒø‚Å‚ ‚Á‚½1—áD ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  104. ‰F–ìŠó¢Žq, ŠO‘º–¾Žq, ‘åã‘ìŽi, ŽO’| ‹B, {“c¹O, ŽRì ½, ’Å–¼ ‹B, £”ö—RL, –{ŠÔ@Šo, “n•Óds, ÂÀ˜a—²: ¶Žºk¬Œ`¬pŒã‚ÌVT‚É‚æ‚éS•s‘S‚Ì‘ˆ«‚ɑ΂µ‚Äablation‚ª—LŒø‚Å‚ ‚Á‚½Ç—áD ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  105. “n•Óds, •ˆÀ–@”V, –ìŒû—Sˆê, ‘O“c—TŽj, •x‘òIŽ¡, —é–؏͍O, “c’†Šì”ü•v, ŽR“àF‹`, ŠOŽR¹O, ‰|–{‹­Žu, ŽRè@–¾, ‰““¡—DŽ}, ÂÀ˜a—²: ŠíŽ¿“ISŽ¾Š³‚ɍ‡•¹‚µ‚½VTƒAƒuƒŒ[ƒVƒ‡ƒ“‚̃|ƒCƒ“ƒgD ‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  106. Sakai S: MahaimüˆÛ‚̃Jƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“|CARTOƒVƒXƒeƒ€‚É‚æ‚éMahaimüˆÛ‘–s‚̏ڍׂȃ}ƒbƒsƒ“ƒO‚̏d—v«|D ‘æ11‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  107. Seo Y: Proarrhy thmias after ablation. ‘æ11‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  108. Machino T, Sekiguchi Y, Yoshida K, Akiyama D, Higuchi H, Koyama T, Yamasaki H, Kuroki K, Kanemoto M, Suzuki A, Seo Y, Endo M, Watanabe S, Yamaguchi I, Aonuma K: R•s®–¬–ò‚¨‚æ‚Ñ”xÃ–¬Šu—£p‚É’ïR«‚Ì”­ì«S–[×“®‚ɑ΂µ‚ÄŽ©—¥ŒP—û–@‚ª’˜Œø‚µ‚½1—áD ‘æ11‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  109. Akiyama D, Homma S, Murakoshi N, Koyama T, Higuchi H, Machino T, Tajiri K, Seo Y, Kawano S, Ohtsuka S, Aonuma K: —‘‘ƒŠà‘gD‚É‚¨‚¯‚é‘gDˆöŽq‚Ì”­Œ»‚ƐÖ¬ŒŒðÇðÇ‚Æ‚ÌŠÖ˜AD ‘æ11‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïiç—tj9ŒŽ, 2007
  110. ‘O“c´Ži, ›Œ´@‡, ‹gàV–rŽq, ‘å’΁@‹B, ¬•ôG•F, —эvˆê˜Y, ‰ÆŒõ‘fs, ‰¡ˆäFŽu, éˍ◲ˆê, ‹{“à@‘ì: Elastography‚É‚æ‚éÃ–¬ŒŒð‚Ì•]‰¿|“®•¨ƒ‚ƒfƒ‹‚ð—p‚¢‚½‘gD•W–{‚Æ‚Ì”äŠrD ‘æ62‰ñ“ú–{‘̗͈ãŠw‰ï‘å‰ïiH“cj9ŒŽ, 2007
  111. HŽR‘åŽ÷, ŠÖŒûK•v, ‘º‰zLs, ¬ŽR@’, ”óŒûr•F, ’¬–ì@‹B, “cK˜aŽq, £”ö—RL, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: ãs‘å“®–¬áŽ‚Ì•ÇŠO«ˆ³”—‚É‚æ‚è, ‰EŠ¥“®–¬“üŒû•”‚ɍ‚“x‹·ó‚ð‚«‚½‚µ‚½‹·SÇ‚̈ê—áD ‘æ205‰ñ“ú–{zŠÂŠíŠw‰ï ŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2007
  112. ”óŒûr•F, ŠÖŒûK•v, ’¬–ì@‹B, ¬ŽR@’, ‘º‰zLs, –Ø‘º‘׎O, “cK˜aŽq, HŽR‘åŽ÷, “n•Óds, ÂÀ˜a—²: Vein-covered CypherƒXƒeƒ“ƒg‚ð—p‚¢‚½Š¥“®–¬áŽ‚ɑ΂·‚éPCI‚̈ê—áD ‘æ205‰ñ“ú–{zŠÂŠíŠw‰ï ŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2007
  113. ÂÀ˜a—²: Contributory Role of VEGF Overexpression in Endothelin-1-induced Cardiomyocyte Hypertrophy: Involvement of Hypoxia Inducible Factor. ‘æ24‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j10ŒŽ, 2007
  114. ŽRè@_, •–ØŒ’Žu, ’¬–ì@‹B, ‹g“cŒ’‘¾˜Y, ŠÖŒûK•v, £”ö—RL, ‹v‰êŒ\—S, ÂÀ˜a—²: Effect of Left Ventricular Dyssynchrony and Resynchronization Therapy on Twist in Patients with Dilated Cardiomyopathy. ‘æ24‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j10ŒŽ, 2007
  115. HŽR‘åŽ÷, ŠÖŒûK•v, ‘º‰zLs, ¬ŽR ’, ”óŒûr•F, ’¬–ì@‹B, “cK˜aŽq, £”ö—RL, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: Clinical Utility of 3-Dimensional Echocardiography in Evaluation of Severe Tricuspid Regurgitation Caused by Pacemaker or Implantable Cardioverter-Defibrillator Leads. ‘æ24‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j10ŒŽ, 2007
  116. ‰¡ŽR‘לA, ‘å“ŒŠ°˜a, ²“¡@–¾, ‚‹´ ~, ²“¡NO, •½”öŒ©ŽO, ÂÀ˜a—²: Exercise training prevents aging-induced cardiomyocyte loss via apoptotic signaling activation in the heart. ‘æ24‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j10ŒŽ, 2007
  117. ’¬–ì@‹B, ŠÖŒûK•v, HŽR‘åŽ÷, “cK˜aŽq, ”óŒûr•F, ¬ŽR@’, •–ØŒ’Žu, ŽRè@_, ‹à–{@“s, ‹g“cŒ’‘¾˜Y, ‹v‰êŒ\—S, ŽRŒû@›Ü, ÂÀ˜a—²: ƒpƒ‰ƒVƒ…[ƒg‘m–X•Ù‚ɌǗ§«‘m–X•Ù—󌄂̍‡•¹‚ª‹^‚í‚ꂽÇ—áD ‘æ24‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j10ŒŽ, 2007
  118. ÂÀ˜a—²: Œz“®–¬ƒGƒR[‚ÅŒoH“¹ƒGƒR[‚Æ—ÞŽ—‚ÌŠŸód‰»«•sˆÀ’èƒvƒ‰[ƒN‚ð”F‚ß‚½ƒRƒŒƒXƒeƒ[ƒ‹ÇðÇ‚Ì2—áD “ú–{•s®–¬Šw‰ï@ƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“Œ¤CƒZƒ~ƒi[iÂXj10ŒŽ, 2007
  119. ’¬–ì@‹B, ŠÖŒûK•v, ‘º‰zLs, ‰““¡—DŽ}, ¬ŽR ’, •–ØŒ’Žu, ŽRè _, ‹g“cŒ’‘¾˜Y, ‹à–{@“s, ‹v‰êŒ\—S, ÂÀ˜a—², —é–؁@“Ä, ŽR“àNÆ, ŒË“c@’¼, –ìãº•F: •Ç‰^“®³í‚ÉŒ©‚¦‚½Š¥“®–¬Ž¾Š³Ç—á‚É‚¨‚¢‚Ä“à–Œ‘¤ƒXƒgƒŒƒCƒ“‚ª’ቺ‚µ‚Ä‚¢‚½Ç—áD ‘æ19‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïiÂXj10ŒŽ, 2007
  120. ‹v‰êŒ\—S, ™]@ª, ¼ˆä‚ß‚®‚Ý, ¬‹Ê³”Ž, ŽRè@_, HŽR‘åŽ÷, ”óŒûr•F, ’¬–ì@‹B, ¬ŽR@’, ŠÖŒûK•v, ÂÀ˜a—²: ”­ì«S–[×“®‚ð‡•¹‚µ‚½‘m–X•Ù‹·óÇ‚ɑ΂µPTMC‚ÆPVI‚ðŽ{s‚µ‚½1Ç—áD ‘æ64‰ñ“ú–{zŠÂŠíSgˆãŠw‰ïi“Œ‹žj10ŒŽ, 2007
  121. ‰F–ìŠó¢Žq, –{ŠÔ@Šo, ²“¡–L”ü, ŸNˆä Šw, “ì@—Œb, ¼–{ŒõŽi, ‰«@–¾“T, Šp“c@”£, ‹gì—T”V, ÂÀ˜a—²: ˆê‰ß«Žûk«S–Œ‰Š‚ð‡•¹‚µ‚½×‹Û«SŠO–Œ‰Š‚Ì1—áD ‘æ48‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi¼–{j10ŒŽ, 2007
  122. ‰F–ìŠó¢Žq, ŠOŽR–¾Žq, ‘åâ‘ìŽi, ŽO’|@‹B, {“c¹O, ŽRì@½, ˆäâ—R”ü, [’J‹MŽq, •Ÿ’†NŽq, ‹eì_Žq, £”ö—RL, –{ŠÔ@Šo, “n•Óds, ÂÀ˜a—²: National Guideline And Risk Stratification For The Primary ICD Implanation For the Patients with Brugada Syndrome and long QT syndrome. ‘æ48‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi¼–{j10ŒŽ, 2007
  123. ¯@’q–ç, m‰ÈG’, ‹à–{@“s, ‰–’ˏ“ñ, ’¬–ì’qŽq, ‹k@Œ«œA, Š|ŽD—YŠî, –ìŒû—Sˆê, “n•Óds, ÂÀ˜a—²: Why is VTAblation Failing in This Patient? -Idiopathic VT-. ‘æ31‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj10ŒŽ, 2007
  124. •ˆÀ–@”V, “n•Óds, £”ö—RL, ÂÀ˜a—², ‰|–{‰ÀŽ¡, åŒ´@Œª: “«’vŽ€«SŽº«•s®–¬‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ÁD ‘æ1‰ñˆïéŒ§“슥Ž¾Š³Œ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2007
  125. “yŠò_‰î, –{ŠÔ^l, ‹v‰êŒ\—S, ÂÀ˜a—², K“cK’¼: Œz“®–¬ƒGƒR[‚ÌŽÀ‘H‚ƃGƒrƒfƒ“ƒXD ‘æ28‰ñ“ú–{—Տ°–ò—Šw‰ï”N‰ïi‰F“s‹{j11ŒŽ, 2007
  126. ‹T’J—¢”ü, £”ö—RL, ’¬–ì’qŽq, Î’Ã’qŽq, ÂÀ˜a—²: Šî‘bSŽ¾Š³‡•¹’vŽ€«SŽº«•s®–¬‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ÁD “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z‘æ19‰ñŠwpW‰ïi“Œ‹žj11ŒŽ, 2007
  127. ’¬–ì’qŽq, £”ö—RL, Î’Ã’qŽq, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: “´’²—¦‚–§“xŠîŽ¿ƒ}ƒbƒsƒ“ƒO‚É‚æ‚é’vŽ€«SŽº«•s®–¬‚̃AƒuƒŒ[ƒVƒ‡ƒ“D “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z‘æ19‰ñŠwpW‰ïi“Œ‹žj11ŒŽ, 2007
  128. ’†“‡‰pŽ÷, Î’Ã’qŽq, £”ö—RL, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: ‹}«S•s‘SŽ¡—Â̂±‚|‹}«Šú‚©‚疝«Šú‚܂Ł|D ‘æ42‰ñ“Œ‹žSƒGƒR[}Œ¤‹†‰ïi“Œ‹žj11ŒŽ, 2007
  129. £”ö—RL, ŠÖŒûK•v, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: S–[×“®Ž¡—à Up to DateD S•s‘SŽ¡—Ð헪EÇ—ጟ“¢‰ïi“Œ‹žj11ŒŽ, 2007
  130. £”ö—RL, Î’Ã’qŽq, ’¬–ì’qŽq, ì‘º@—´, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—²: S–[×“®‚̍ŐV‚ÌŽ¡—ÁD ‘æ27‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj11ŒŽ, 2007
  131. “cK˜aŽq, “n•Óds, ŠÖŒûK•v, HŽR‘åŽ÷, ’¬–ì@‹B, ”óŒûr•F, ¬ŽR@’, £”ö—RL, ‰Í–ì@—¹, ‹v‰êŒ\—S, ÂÀ˜a—²: Šî‘bSŽ¾Š³‚ð—L‚·‚é’vŽ€«SŽº«•s®–¬‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ÁD ‘æ206‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj12ŒŽ, 2007
  132. Š|ŽD—YŠî, ‹k@Œ«œA, ’¬–ì’qŽq, ¯@’q–ç, ‰–’ˏ“ñ, ‹à–{@“s, m‰ÈG’, •¶‘ —DŽq, •½À‚ä‚è, –ìŒû—Sˆê, “n•Óds, ÂÀ˜a—²: HCN4ˆâ“`Žq‚É‚æ‚鏙–¬«•s®–¬‚ɑ΂·‚éˆâ“`ŽqŽ¡—Â̊J”­D ‘æ206‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj12ŒŽ, 2007

@@@¡ ‚»‚Ì‘¼

  1. ÂÀ˜a—²: ŠíŽ¿“ISŽ¾Š³‚ð—L‚·‚é’vŽ€«•s®–¬‚ɑ΂·‚éhigh resolution substrate mapping‚É‚æ‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“D ‘æ21‰ñÔézŠÂŠíƒtƒH[ƒ‰ƒ€i‘O‹´j1ŒŽ, 2007
  2. £”ö—RL: S–[×“®‚̍ŋ߂̘b‘èD —Տ°ŒŒŠÇáŠQƒtƒH[ƒ‰ƒ€i”j1ŒŽ, 2007
  3. Žðˆä@r: S–[×“®‚̍ŐVŽ¡—Á@–ò•¨ƒnƒCƒuƒŠƒbƒhŽ¡—©‚çƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Â܂ŁD ’}¼zŠÂŠíuK‰ïi’}¼j1ŒŽ, 2007
  4. “n•Óds: Œz“®–¬ƒGƒR[‚ÌŽÀ‘H‚ƃGƒrƒfƒ“ƒXD ‰Ž“‡ŒSˆãŽt‰ïMedical Up To Datei‹«’¬j1ŒŽ, 2007
  5. •ˆÀ–@”V, ‰Í–ì@—¹, “n•Óds: CRT‚ÌŠT”O‚Æ—LŒø«, “K‰žŠî€D ^•ÇˆãŽt‰ïŽY‹ÆˆãuK‰ïi’}¼j2ŒŽ, 2007
  6. “n•Óds: ŽÐ‰ï“I–â‘è2@‰^“]–Æ‹–D ˆïéƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€Œ¤‹†‰ïi‚‚­‚΁j2ŒŽ, 2007
  7. ÂÀ˜a—²: zŠÂŠí“à‰Èˆã‚©‚ç‚Ý‚½Ï‹É“IŽ‰Ž¿’ቺ—Ö@‚̈Ӌ`D ‘æ88‰ñ’}¼zŠÂŠíuK‰ïi’}¼Žsj2ŒŽ, 2007
  8. ÂÀ˜a—²: •s®–¬D “úˆã¶ŠU‹³ˆç‹¦—͍uÀƒZƒ~ƒi[u”]ESŒŒŠÇŽ¾Š³uÀvi‚‚­‚΁j2ŒŽ, 2007
  9. £”ö—RL: •s®–¬‚ÆŽ¸_, ‚¨‚æ‚ÑŽ©“®ŽÔ‚̉^“]‚ɂ‚¢‚āD —Տ°ŒŒŠÇáŠQƒtƒH[ƒ‰ƒ€i’}¼j2ŒŽ, 2007
  10. ÂÀ˜a—²: CA LIVE@ƒRƒƒ“ƒe[ƒ^[D ‘æ21‰ñ•s®–¬ŠO‰ÈŒ¤‹†‰ïi“Œ‹žj2ŒŽ, 2007
  11. ÂÀ˜a—²: Šî‘bVŽ¾Š³‚ð—L‚·‚é—á‚Å‚ÌVT/VFD –k—¤—Տ°•s®–¬ƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‹à‘òj2ŒŽ, 2007
  12. ‰Í–ì@—¹: S–[×“®Ž¡—Â̌»ó‚Ə«—ˆD “úˆã¶ŠU‹³ˆç‹¦—͍uÀƒZƒ~ƒi[u”]ESŒŒŠÇŽ¾Š³uÀvi‚‚­‚΁j2ŒŽ, 2007
  13. ÂÀ˜a—²: S–[×“®Up to Date–ò•¨ƒRƒ“ƒrƒl[ƒVƒ‡ƒ“‚©‚çƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚܂ŁD ‘æ7‰ñ•s®–¬–ò•¨—Ö@ƒZƒ~ƒi[i•Ÿ‰ªj3ŒŽ, 2007
  14. ÂÀ˜a—²: S–[×“®Ž¡—Á@Up to DateD ‘æ3‰ñ’†MzŠÂŠí•×‹­‰ïi¼–{j3ŒŽ, 2007
  15. ÂÀ˜a—²: dÇS•s‘S‚ɑ΂·‚éSŽºÄ“¯Šú—Ö@F“K‰ž‚ÆŒ»ó‚ɂ‚¢‚āD Meet The Specialisti“Œ‹žj3ŒŽ, 2007
  16. ÂÀ˜a—²: Œz“®–¬ƒGƒR[‚ð—p‚¢‚½“®–¬d‰»ŠÇ—D ‹ß‹ESŒŒŠÇƒWƒ‡ƒCƒ“ƒgƒ‰ƒCƒu2007@ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[i‹ž“sj3ŒŽ, 2007
  17. ‘º‰zLs, ‹g“cŒ’‘¾˜Y, “cã˜aK, ŠÖŒûK•v, ã‘º—ºŽO, ¡’†‹±Žq, œA]“¹º, ŽRŒû@›Ü, ÂÀ˜a—²: ƒy[ƒVƒ“ƒO‚É‚æ‚éSŽºÄ“¯Šú—Ö@?3“_ƒy[ƒVƒ“ƒO‚É‚æ‚éV‚½‚ȍē¯Šú—Ö@‚ɂ‚¢‚āD ‘æ11‰ñSŒŒŠÇŒ¤‹†•¬”­•\‰ïi“Œ‹žj3ŒŽ, 2007
  18. “n•Óds: ˆãŠwƒCƒ[ƒWƒ“ƒO‚ւ̉ž—pD ˆïéŒ§‘‡Œ’f‹¦‰ïS“d}Œ¤C‰ïi…ŒËj3ŒŽ, 2007
  19. “n•Óds: ¸ˆ³–òE~ˆ³–ò‚ÌŽg‚¢•ûD ‘æ1‰ñŒ’NƒXƒ|[ƒcƒNƒŠƒjƒbƒN‚̏W‚¢i‚‚­‚΁j3ŒŽ, 2007
  20. ÂÀ˜a—²: •p–¬•s®–¬Ž¡—Â̍őOüD •s®–¬Šwpu‰‰‰ïi–¼ŒÃ‰®j4ŒŽ, 2007
  21. ÂÀ˜a—²: S•s‘SŽ¡—Âɂ¨‚¯‚éRƒAƒ‹ƒhƒXƒeƒƒ“–ò‚̈ʒu•t‚¯D ˆã—ØAŒgŒð—¬‰ï“Á•ÊŠwpu‰‰i–¾–F‰ïVŠ‹ü•a‰@ji“Œ‹žj4ŒŽ, 2007
  22. ÂÀ˜a—²: ‹³ˆçu‰‰uáŠQŠw¶‚ɑ΂·‚éAŠwŽx‰‡vD ŽRŒ`ƒAƒuƒŒ[ƒVƒ‡ƒ“ƒZƒ~ƒi[iŽRŒ`j4ŒŽ, 2007
  23. ÂÀ˜a—²: zŠÂŠíƒi[ƒX‚ª’m‚Á‚Ä‚¨‚­‚ׂ«S“d}‚ðŠw‚ԁFƒvƒƒtƒFƒbƒVƒ‡ƒiƒ‹‚È’mŽ¯‚àŠÜ‚߂āD Šwpu‰‰‰ïi‰ªŽRj5ŒŽ, 2007
  24. ÂÀ˜a—²: S–[×“®‚̍ŐVŽ¡—ÁD “ú–{“à‰ÈŠw‰ï‘æ36‰ñ’†‘Žx•”¶ŠU‹³ˆçu‰‰‰ïi‰ªŽRj5ŒŽ, 2007
  25. £”ö—RL: V‚½‚È•s®–¬Ž¡—ÃKƒCƒhƒ‰ƒCƒ“‚ɂ‚¢‚āD —Տ°ŒŒŠÇáŠQƒtƒH[ƒ‰ƒ€i…ŒËj5ŒŽ, 2007
  26. £”ö—RL: “Á”­«SŽº×“®F”­¶‹@˜‚©‚玡—Â܂ŁD ICD/CRT‡“¯Œ¤CƒZƒ~ƒi[iL“‡j5ŒŽ, 2007
  27. “n•Óds: ˆã—Âɂ¨‚¯‚鎖ŒÌ–hŽ~‚ÌŽæ‚è‘g‚݁@Ž©“®ŽÔ‹Zp‰ï@2007”N‰Ä‹G‘å‰ï|GIAƒ_ƒCƒAƒƒO|D ICD/CRT‡“¯Œ¤CƒZƒ~ƒi[iL“‡j5ŒŽ, 2007
  28. “n•Óds: ŽÐ‰ï“I–â‘è@A˜Jó‹µ‚Ɖ^“]–Æ‹–D ‚«‚ʈãŽt‰ïŠwpu‰‰‰ïií‘Žsj5ŒŽ, 2007
  29. “n•Óds: ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚ƐS‹Ø[Ç‚Ì—\–hD —Տ°ŠÅŒì‹³ˆçƒZƒ“ƒ^[ƒNƒŠƒeƒBƒJƒ‹ƒAƒZƒXƒƒ“ƒguKi‚‚­‚΁j6ŒŽ, 2007
  30. “n•Óds: ‹•ŒŒ«SŽ¾Š³f—ÂƐϋɓIŽ‰Ž¿’ቺ—Ö@‚̈Ӌ`D ‘S‘ŒxŽ@ŠwZ‰^“]“K«‘Š’kê‰Èi¬•½Žsj6ŒŽ, 2007
  31. ÂÀ˜a—²: S–[×“®‚̍ŐVŽ¡—ÁD 24th Live Demonstration in KOKURAi¬‘qj6ŒŽ, 2007
  32. ÂÀ˜a—²: S‘Ÿ“Ë‘RŽ€—\–h‚ɑ΂·‚éƒAƒ~ƒIƒ_ƒƒ“‚ÆICD‚Ì–ðŠ„D ‘æ8‰ñ‹ãBdÇ•s®–¬Œ¤‹†‰ïi•Ÿ‰ªj6ŒŽ, 2007
  33. ÂÀ˜a—²: CRT“K‰žŒˆ’è‚É‚¨‚¯‚éSƒGƒR[•]‰¿D •s®–¬Ž¡—Ì㉇‰ïi‘O‹´j6ŒŽ, 2007
  34. ÂÀ˜a—²: 1–‡‚̐SƒGƒR[}‚©‚ç: —¼SŽºƒy[ƒVƒ“ƒOD ‘æ14‰ñŽRŒûŒ§—Տ°•s®–¬ŒŸ“¢‰ïiŽRŒûj6ŒŽ, 2007
  35. ÂÀ˜a—²: ’‹Œ«S‹Ø[Ç‚ɍ‡•¹‚·‚鈫«SŽº«•s®–¬‚̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“D “Œ‹žˆã‰ÈŽ•‰È‘åŠw‘æ“ñ“àˆã‰È“¯‘‹‰ïŠwpu‰‰‰ïi“Œ‹žj6ŒŽ, 2007
  36. £”ö—RL: High resolusion substrate mapping‚É‚æ‚é’vŽ€«SŽº«•s®–¬‚̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“D ‚ŒŒˆ³‚Æ‘ŸŠí•ÛŒìŒ¤‹†‰ïi‚‚­‚΁j6ŒŽ, 2007
  37. £”ö—RL: ‚ƒRƒŒƒXƒeƒ[ƒ‹‚Æ•a‹CDƒhƒƒhƒŒŒ‰t, •|‚¢•a‹C‚ª‚©‚­‚ê‚Ä‚¢‚éI Œz“®–¬ƒGƒR[ƒZƒ~ƒi[i‚‚­‚΁j7ŒŽ, 2007
  38. ÂÀ˜a—²: ‹•ŒŒ«SŽ¾Š³‚Ì”­ÇEi“W‚Ì—\–hí—ªD ‘æ35‰ñ_“ސ쌧S‘Ÿ•aŒ¤‹†‰ï@“Á•Êu‰‰i‰¡•lj7ŒŽ, 2007
  39. Žðˆä@r: SŒŒŠÇŽ¾Š³”­Ç—\–h‚Ì‚½‚ß‚ÌŽ‰Ž¿ŠÇ—‚̏d—v«D ERLŒ¤‹†‰ïuƒRƒ“ƒpƒNƒgERL‚ª‘ñ‚­¢ŠEvi‚‚­‚΁j7ŒŽ, 2007
  40. Žðˆä@r: ‹•ŒŒ«SŽ¾Š³‚Ì”­ÇEi“W‚Ì—\–hí—ª‚Æ‚µ‚Ä‚ÌŽ‰Ž¿ŠÇ—D ƒŒƒWƒfƒ“ƒgƒŒƒNƒ`ƒƒ[i‚‚­‚΁j7ŒŽ, 2007
  41. ŠÖŒûK•v: ‹•ŒŒ«SŽ¾Š³”­ÇƒƒJƒjƒYƒ€‚©‚猩‚½Ï‹É“IŽ‰Ž¿’ቺ—Ö@‚̏d—v«D ‘æ267‰ñ^•ÇˆãŽt‰ï’}¼Žx•”Œ¤C‰ïiˆïéj7ŒŽ, 2007
  42. ‰Í–ì@—¹: S–[×“®‚̍ŋ߂̘b‘èD ALDOSTERONE MEET THE SPECIALISTi‚‚­‚΁j7ŒŽ, 2007
  43. ‹v‰êŒ\—S: S–[×“®@|Å‹ß‚̘b‘è|D ‘æ45‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ¤‹†W‰ïŠÖ“ŒbM‰z’n•û•”‰ïŒ¤‹†W‰ïi‚‚­‚΁j7ŒŽ, 2007
  44. ÂÀ˜a—²: 20cmˆÈã‚̐ó‘å‘å‘Ú“®–¬Š®‘S•ÂÇ‚ðƒGƒR[ƒKƒCƒh‰º‚ŃCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚ðs‚Á‚½ˆêÇ—áD ‘æ1‰ñzŠÂŠíŠÅŒìƒZƒ~ƒi[i“Œ‹žj8ŒŽ, 2007
  45. ÂÀ˜a—²: ŠJSpŒã‚É’x”­«Sƒ^ƒ“ƒ|ƒi[ƒf‚ð‚«‚½‚µ‚½ˆê—áD ‘æ29‰ñŽR—œŒ§•s®–¬•×‹­‰ïiŽR—œj8ŒŽ, 2007
  46. ÂÀ˜a—²: ’}”g‘åŠw•‘®•a‰@‚É‚¨‚¯‚éˆã—ÈÀ‘S‚ÌŽæ‚è‘g‚݁D ‘æ4‰ñ–¾“¿zŠÂŠíƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXiH“cj8ŒŽ, 2007
  47. ÂÀ˜a—²: SŽ¥}–@‚É‚æ‚éSŽ¾Š³‚̐f’fD ‘æ22‰ñŒ¢ŽR•s®–¬ƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi“Œ‹žj8ŒŽ, 2007
  48. –{ŠÔ@Šo: ˆã—Âɂ¨‚¯‚鎖ŒÌ–hŽ~‚ÌŽæ‚è‘g‚݁@Ž©“®ŽÔ‹Zp‰ï@2007”N‰Ä‹G‘å‰ï|GIAƒ_ƒCƒAƒƒO|D Ž–ŒÌ–¢‘R–hŽ~‚ÉŒü‚¯‚½Še•ª–ì‚ÌŒoŒ±‚Æ’mŒbi“Œ‹žj8ŒŽ, 2007
  49. “n•Óds: ‹•ŒŒ«SŽ¾Š³f—Âɂ¨‚¯‚鎉Ž¿ŠÇ—‚¨‚æ‚щ^“®—Ö@‚̈Ӌ`. –k‹ãB ‹}«Š¥ÇŒóŒQŒ¤‹†‰ïi–k‹ãBj8ŒŽ, 2007
  50. “n•Óds: ŽÐ‰ï“I–â‘è@A˜Jó‹µ‚Ɖ^“]–Æ‹–D ICD/CRT‡“¯Œ¤CƒZƒ~ƒi[i‰YˆÀj9ŒŽ, 2007
  51. “n•Óds: ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚ƐS‹Ø[Ç‚Ì—\–hD •½¬19”N“x‰h—{Šwpu‰‰‰ïi…ŒËj9ŒŽ, 2007
  52. “n•Óds: ‹•ŒŒ«SŽ¾Š³f—ÂƐϋɓIŽ‰Ž¿’ቺ—Ö@‚̈Ӌ`D VŠƒŽsˆãŽt‰ï‘æ22”Ç’è—á”ljï‹c zŠÂŠíŽ¾Š³“Á•Ê•×‹­‰ïiVŠƒj9ŒŽ, 2007
  53. ÂÀ˜a—²: S–[×“®‚̍ŐVŽ¡—ÁD ‘½‰êˆãŽt‰ïŠwpu‰‰‰ï^‘æ145‰ñW’k‰ïiˆïéj9ŒŽ, 2007
  54. ‹v‰êŒ\—S: S‘Ÿ“Ë‘RŽ€—\–h‚ɑ΂·‚éƒAƒ~ƒIƒ_ƒƒ“‚ÆICD‚Ì–ðŠ„D ˆïéƒAƒ~ƒIƒ_ƒƒ“u‰‰‰ïi‚‚­‚΁j9ŒŽ, 2007
  55. £”ö—RL: CRT“K‰žŒˆ’è‚É‚¨‚¯‚éSƒGƒR[•]‰¿D ‘æ4‰ñS•s‘S‚ƃy[ƒVƒ“ƒOŒ¤‹†‰ïi_ŒËj9ŒŽ, 2007
  56. £”ö—RL: 1–‡‚̐SƒGƒR[}‚©‚ç: —¼SŽºƒy[ƒVƒ“ƒOD “ú–{SƒGƒR[}Šw‰ï‘æ5‰ñHŠúuK‰ïi“Œ‹žj10ŒŽ, 2007
  57. ÂÀ˜a—²: ’‹Œ«S‹Ø[Ç‚ɍ‡•¹‚·‚鈫«SŽº«•s®–¬‚̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“D ‘æ32‰ñ“ŒŠC•s®–¬Œ¤‹†‰ïi–¼ŒÃ‰®j10ŒŽ, 2007
  58. ŠÖŒûK•v: High resolusion substrate mapping‚É‚æ‚é’vŽ€«SŽº«•s®–¬‚̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“D ‘æ5‰ñ”ªƒ–ŠxzŠÂŠíƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi“Œ‹žj10ŒŽ, 2007
  59. “n•Óds: ‚ƒRƒŒƒXƒeƒ[ƒ‹‚Æ•a‹CDƒhƒƒhƒŒŒ‰t, •|‚¢•a‹C‚ª‚©‚­‚ê‚Ä‚¢‚éI ‰Í“à’¬Œ’NuÀiˆî•~ŒS‰Í“à’¬j10ŒŽ, 2007
  60. “n•Óds: ‹•ŒŒ«SŽ¾Š³‚Ì”­ÇEi“W‚Ì—\–hí—ªD —Տ°Œ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2007
  61. “n•Óds: SŒŒŠÇŽ¾Š³”­Ç—\–h‚Ì‚½‚ß‚ÌŽ‰Ž¿ŠÇ—‚̏d—v«D “®–¬d‰»«Ž¾Š³Ž¡—ÃWorkshopiŒÃ‰Íj11ŒŽ, 2007
  62. “n•Óds: ‹•ŒŒ«SŽ¾Š³‚Ì”­ÇEi“W‚Ì—\–hí—ª‚Æ‚µ‚Ä‚ÌŽ‰Ž¿ŠÇ—D Meet the Specialisti‚‚­‚΁j11ŒŽ, 2007
  63. “n•Óds: ‹•ŒŒ«SŽ¾Š³”­ÇƒƒJƒjƒYƒ€‚©‚猩‚½Ï‹É“IŽ‰Ž¿’ቺ—Ö@‚̏d—v«D ŒÃ‰ÍE‰Ž“‡ˆã—ÃŒ—¶ŠˆKŠµ•aƒtƒH[ƒ‰ƒ€iŒÃ‰ÍŽsj11ŒŽ, 2007
  64. ÂÀ˜a—²: S–[×“®‚̍ŋ߂̘b‘èD ¬‘q•s®–¬ƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX2007i¬‘qj11ŒŽ, 2007
  65. ÂÀ˜a—²: S–[×“®@|Å‹ß‚̘b‘è|D ŠâŽè•s®–¬Ž¡—ͧ˜b‰ïi·‰ªj11ŒŽ, 2007
  66. ”nê‰ëŽq, ÂÀ˜a—²: 20cmˆÈã‚̐ó‘å‘å‘Ú“®–¬Š®‘S•ÂÇ‚ðƒGƒR[ƒKƒCƒh‰º‚ŃCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚ðs‚Á‚½ˆêÇ—áD ‘æ15‰ñˆïézŠÂŠíŒ¤‹†‰ïiˆïéj11ŒŽ, 2007
  67. “cK˜aŽq, ÂÀ˜a—²: ŠJSpŒã‚É’x”­«Sƒ^ƒ“ƒ|ƒi[ƒf‚ð‚«‚½‚µ‚½ˆê—áD ‘æ15‰ñˆïézŠÂŠíŒ¤‹†‰ïiˆïéj11ŒŽ, 2007
  68. –{ŠÔ@Šo: ’}”g‘åŠw•‘®•a‰@‚É‚¨‚¯‚éˆã—ÈÀ‘S‚ÌŽæ‚è‘g‚݁D ’èŠúq‹ó‹¦‰ïi“Œ‹žj11ŒŽ, 2007
  69. “n•Óds: SŽ¥}–@‚É‚æ‚éSŽ¾Š³‚̐f’fD ‘æ1‰ñ‰^“®zŠÂŠí•aŠwŒ¤‹†‰ïi“Œ‹žj12ŒŽ, 2007

@2006”N“xi2006”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. ‰Í–ì@—¹, £”ö—RL, ÎŒõ•qs, ¯@’q–ç, ”ü@¹Žq, “n•Óds, ŽRŒû@›Ü: ¶ŽºŠg’£áŠQ‚̐S“d}ŠŒ©D ‘æ40‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïŠwpW‰ïi“Œ‹žj1ŒŽ, 2006 “ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ï‰ïŽ32, 50, 2006
  2. ì‘º@—´, –{ŠÔ@Šo, ‰F–ìŠó¢Žq, ‘ŠŒ´‰p–¾, –Ø‘º‘׎O, ¯@’q–ç, “cã˜aK, ‹g“cŒ’‘¾˜Y, ‰Í–ì@—¹, “n•Óds, ŽRŒû@›Ü: Œ´”­«”x‚ŒŒˆ³Ç‚ɑ΂µƒGƒ“ƒhƒZƒŠƒ“Žó—e‘̝hR–ò‚𓱓ü‚µ‚½ˆê—áD ‘æ40‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïŠwpW‰ïi“Œ‹žj1ŒŽ, 2006 “ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ï‰ïŽ32, 50, 2006
  3. “n•Óds, –Ø‘º‘׎O, •ˆÀ–@”V, ‰·@@Œi, ‘ŠŒ´‰p–¾, —é–Ø‘å‰î, •û–Mb, _’¹–¾•F, ‹{‰º@‹, ’Ë“cŒ[“ñ, ŽRŒû@›Ü: Š¥‹·ó‚É”º‚¤ŠQ“d—¬‚̐SŽ¥}‚É‚æ‚é‰æ‘œ‰»D ‘æ16‰ñ“ú–{SŒŒŠÇ‰æ‘œ“®‘ÔŠw‰ïi‘åãj1ŒŽ, 2006 ‘æ16‰ñ“ú–{SŒŒŠÇ‰æ‘œ“®‘ÔŠw‰ï´˜^W, 135, 2006
  4. ‘º‰zLs, ÂÀ˜a—², ‹g“cŒ’‘¾˜Y, ŽRŒû@›Ü: HCN4ˆâ“`Žq‚É‚æ‚鏙–¬«•s®–¬‚ɑ΂·‚éˆâ“`ŽqŽ¡—Â̊J”­D ‘æ11‰ñSŒŒŠÇŒ¤‹†•¬”­•\‰ïi“Œ‹žj2ŒŽ, 2006
  5. ŽR–{¹—Ç, ÂÀ˜a—², “cã˜aK, ‹g“cŒ’‘¾˜Y, ‹v‰êŒ\—S, “n•Óds, ŽRŒû@›Ü, ‘º“c@ŽÀ: Šg’£Œ^S‹ØÇ‚ɍ‡•¹‚µ‚½¶‹r‘OŽ}—R—ˆ‚ÌŒƒ”­Šˆ“®‚ð‹@˜‚Æ‚·‚éSŽº•p”‚̈ê—áD ‘æ199‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽ, 2006 Circ J 70 (Suppl III), 1144, 2006
  6. ‹à–{@“s, ‰–’ˏ“ñ, –Ø‘º‘׎O, X–{—²Žj, ÎìŒöl, –ìŒû—Sˆê, “n•Óds, ŽRŒû@›Ü: Œëš‹«”x‰Š‚ðŒ_‹@‚ÉŒ°Ý‰»‚µ‚½ƒAƒ~ƒIƒ_ƒƒ“ŠÔŽ¿«”x‰Š‚̈ê—áD ‘æ199‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽ, 2006 Circ J 70 (Suppl III), 1144, 2006
  7. m‰ÈG’, •ˆÀ–@”V, “n•Óds, ŽRŒû@›Ü: ƒVƒ“ƒ|ƒWƒEƒ€FuS‹ØSPECT‚ð—Տ°‚ɐ¶‚©‚·‚ɂ́v‘å‹K–̓f[ƒ^ƒx[ƒX‚̗Տ°‰ž—pD ‘æ31‰ñƒjƒ…[ƒ^ƒEƒ“ƒJƒ“ƒtƒ@ƒŒƒ“ƒXi_ŒËj2ŒŽ, 2006 ‘æ31‰ñƒjƒ…[ƒ^ƒEƒ“ƒJƒ“ƒtƒ@ƒŒƒ“ƒX´˜^W, 5, 2006
  8. Î’Ë—³‘¾˜Y, ÂÀ˜a—², ‹g“cŒ’‘¾˜Y, “cã˜aK, ŽRè@_, •–ØŒ’Žu, ‹v‰êŒ\—S, ŽRŒû@›Ü, ”nê@—Ç: ‰^“®—U”­«SŽº•p”‚ð”F‚ß‚½’†”N—«‚ÌBrugadaÇŒóŒQ‚Ì1—áD ‘æ4‰ñ“Á”­«SŽº×“®Œ¤‹†‰ïi“Œ‹žj2ŒŽ, 2006
  9. Jesmin S, Miyauchi T, Zaedi S, Iemitsu M, Togashi H, Maeda S, Goto K, Yamaguchi I: Dual endothelin receptor antagonist reverses the upregulated VEGF-KDR axis in frontalcortex of SHR-SP without modulating the cerebral blood flow. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 381-382, 2006
  10. Otsuki T, Miyauchi T, Maeda S, Iemitsu M, Saito Y, Tanimura Y, Ajisaka R, Goto K, Yamaguchi I: Effects of athletic strength-and endurance-exercise training on aortic stiffness and plasma endothelin-1 concentration in young humans. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 499, 2006
  11. Shimojo N, Miyauchi T, Jesmin S, Zaedi S, Maeda S, Goto K, Yamaguchi I: Endothelin-1 induces the expressions of VEGF and its receptors (Flt-1 and Flk-1) in neonatal cardiomyocytes in vitro dose-dependently. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 192-193, 2006
  12. Iemitsu M, Maeda S, Jesmin S, Miyauchi T, Yamaguchi I: Exercise training improves aging-induced impairment of angiogenesis through upregulation of VEGF and Flk-1 in the heart. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 270, 2006
  13. Jesmin S, Miyauchi T, Iemitsu M, Zaedi S, Yamaguchi N, Shimojo N, Maeda S, Goto K, Yamaguchi I: Endothelin receptor antagonist ameliorates the cardiac dysfunction, decreased cardiac VEGF signaling and inadequate coronary collateral development in early diabetic rats. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 394, 2006
  14. Iemitsu M, Miyauchi T, Maeda S, Goto K, Yamaguchi I: Changes of myocardial endothelin-1 level during the formation of exercise training-induced cardiac adaptation. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 587, 2006
  15. Iemitsu M, Maeda S, Miyauchi T, Yamaguchi I: Exercise training improves aging-induced decrease of energy metabolic molecular system through peroxisome proliferator-activated receptorƒÁcoactivator-1ƒ¿(PGC-1ƒ¿) in the heart. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70(Suppl I), 270-271, 2006
  16. Otsuki T, Maeda S, Iemitsu M, Saito Y, Tanimura Y, Ajisaka R, Miyauchi T, Yamaguchi I: Arterial stiffness and competitive sports career in adolescent endurance- and strength-trained athletes. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70(Suppl I), 478, 2006
  17. Jesmin S, Miyauchi T, Zaedi S, Iemitsu M, Maeda S, Sakuma I, Hattori Y, Yamaguchi I: Estrogen receptor Alpha is more actively involved in the cardiac VEGF/KDR/NO/ pathway compared to estrogen receptor Beta in female mice. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®jŒŽ, 2006 Circ J 70 (Suppl I), 483-484, 2006
  18. Shimojo N, Miyauchi T, Jesmin S, Zaedi S, Soma M, Maeda S, Goto K, Yamaguchi I: Eicosapentaenoic acid, a major component of fish oil, prevents the progression of endothelin-1-induced cardiomyocyte hypertrophy through suppressing phosphorylated JNK. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 223, 2006
  19. Seo Y, Watanabe S, Ishizu T, Moriyama N, Takeyasu N, Maeda H, Ishimitsu T, Yamaguchi I: Echolucent Carotid Plaque is a Useful Surrogate Marker for Identifying High Risk Patients for Coronary Arterial Vulnerability. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 149, 2006
  20. Seo Y, Aonuma K, Yoshida K, Kawano S, Watanabe S, Yamaguchi I: Usefulness of Radial Strain Determined by 2-D Tracking Method to Identify the Responder for Cardiac Resynchronization Therapy. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 445, 2006
  21. Seo Y, Watanabe S, Takeyasu N, Ishizu T, Moriyama N, Yamaguchi I: Serum Levels of Malondialdehyde-Modified LDL Associate with Systemic Atherosclerotic Instability in Patients with Coronary Artery Diseases. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 172, 2006
  22. Ishizu T, Seo Y, Obara K, Moriyama N, Yamanouchi T, Noguchi Y, Watanabe S, Yamaguchi I: Stratification of impaired relaxation filling pattern by leg lifting in patients with normal left ventricular ejection fraction. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 502, 2006
  23. Liang J, Liu E, Kitajima S, Koike T, Yu Y, Jin Y, Kitayama C, Shikama H, Morimoto M, Yamaguchi I, Watanabe S, Fan J: Young Investigatorfs Award for International Students Finalists Lectures. Increased macrophage elastase (MMP-12) enhances the progression of atherosclerosis in transgenic rabbits. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 52, 2006
  24. Watanabe S, Takeyasu N, On K, Kimura T, Aihara H, Yamada S, Suzuki D, Ogata K, Kandori A, Miyashita T, Tsukada K, Yamaguchi I: Diagnosis of coronary stenosis by mutiple-current-vector diagram of magnetocardiography: A novel technique to evaluate the inhomogeneity of myocardial repolarization. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 170, 2006
  25. Hoshi T, Seo Y, Yoshida K, Aonuma K, Watanabe S, Yamaguchi I: Severe mitral regurgitation is the strongest predictor for clinical prognosis of advanced heart failure patients receiving cardiac resynchronization therapy. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 260, 2006
  26. Takeyasu N, Watanabe S, Seo Y, Yoshida I, Yoshida K, Aihara H, Hoshi T, Kimura T, Yamaguchi I: Standardized method of remounting Cypher stent \IT (In-Tube remounting) Method\. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 384, 2006
  27. Koshino Y, Uchida K, Kawano S, Takeyasu N, Morimoto T, Noguchi Y, Sato Y, Takano R, Meno K, Kurachi Y, Watanabe S, Yamaguchi I: Proteome analysis of plasma from coronary artery in patients with acute coronary syndrome. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 514, 2006
  28. Morimoto T, Watanabe S, Takeyasu N, Eda K, Ishiyama M, Sakamoto K, Aihara H, Kimura T, Saito T, Arai E, Toyama M, Nishina H, Ajisaka R, Yamaguchi I: Effects of tetrahydrobiopterin on exercise tolerance, vascular function,and exercise hyperemia in patients with coronary artery disesase. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 535, 2006
  29. Aihara H, Takeyasu N, Watanabe S, Kimura T, Morimoto T, Nishina H, Kuga K, Aonuma K, Takeda T, Yamaguchi I: Radionuclide ventriculographic evaluation of the effect by cardiac resynchronization therapy. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 555-556, 2006
  30. Kimura T, Watanabe S, On K, Yamada S, Takeyasu N, Aihara H, Ogata K, Miyashita T, Suzuki D, Kandori A, Tsukada K, Kuga K, Yamaguchi I: Current-arrow map of magnetcardiography is highly sensitive to coronary stenosis, and can visualize theeinjury currentfof ischemic myocardium. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 423, 2006
  31. Suzuki A, Yukawa A, Watanabe Y, Tanaka K, Takei Y, Ejiri N, Kawamura R, Watanabe S, Yamaguchi I: High improving subjective symptoms after successful primary coronary intervention for acute myocardial infarction may be new clinical predictor. ‘æ70‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j3ŒŽ, 2006 Circ J 70 (Suppl I), 634, 2006
  32. “n•Óds, •ˆÀ–@”V, ‘ŠŒ´‰p–¾, –Ø‘º‘׎O, ’Ë“cŒ[“ñ, •û–Mb, ŽRŒû@›Ü: SŽ¥}‚É‚æ‚é‹•ŒŒ«SŽ¾Š³f’fD ‘æ103‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïi‰¡•lj4ŒŽ, 2006 “ú–{“à‰ÈŠw‰ïŽGŽ95i—ÕŽž‘Š§†j, 222, 2006
  33. £”ö—RL, ÎŒõ•qs, ‘O“c—TŽj, ŽÂŒ´i, “à“c´Žq, Î’Ã’qŽq, XŽR’¼Žq, “n•Óds, ÂÀ˜a—², ŽRŒû@›Ü: ‹}«‘O•ÇS‹Ø[Ç‚É‚¨‚¯‚éSë•”ŒŒð‚Ì‹K’èˆöŽqFƒRƒ“ƒgƒ‰ƒXƒgSƒGƒR[–@‚É‚æ‚錟“¢D “ú–{SƒGƒR[}Šw‰ïi‚³‚¢‚½‚܁j4ŒŽ, 2006
  34. ŽðŠª•¶Žq, £”ö—RL, Î’Ã’qŽq, ”Ñ“c“TŽq, ’†“‡‰pŽ÷, ˆî—t@•, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: Šg’£Œ^S‹ØÇ‚É‚¨‚¯‚éŽûkŠú‚¨‚æ‚ÑŠg’£Šú“¯Šú•s‘S‚ÆQRSŽžŠÔ‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä‚ÌŒŸ“¢D “ú–{SƒGƒR[}Šw‰ïi‚³‚¢‚½‚܁j4ŒŽ, 2006
  35. £”ö—RL, ÎŒõ•qs, “à“c´Žq, ŽÂŒ´@i, ‘O“c—TŽj, “¡“cŒ\Žj, ‹Tè‚•v, ÂÀ˜a—², ŽRŒû@›Ü: ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“FzŠÂŠí‚É‚¨‚¯‚é‰Á—î•Ï‰».‘m–X•Ù—֐ΊD‰»‚Æèò“®–¬d‰»Ç‚Æ‚ÌŠÖ˜AG”][ÇÇ—á‚É‚¨‚¯‚錟“¢. “ú–{’´‰¹”gˆãŠw‰ïi‘åãj5ŒŽ, 2006
  36. £”ö—RL, ÎŒõ•qs, Î’Ã’qŽq, XŽR’¼Žq, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—², ŽRŒû@›Ü: ƒJƒ‰[ƒhƒvƒ‰–@‚É‚æ‚é“`”d‘¬“xŒv‘ª–@•W€‰»‚Ì‚½‚ß‚Ì, ƒRƒ“ƒgƒ‰ƒXƒgSƒGƒR[–@‚ð—p‚¢‚½“`”d‘¬“x‚Ì•]‰¿. “ú–{’´‰¹”gˆãŠw‰ïi‘åãj5ŒŽ, 2006
  37. £”ö—RL, ÂÀ˜a—², ‹g“cŒ’‘¾˜Y, Î’Ã’qŽq, XŽR’¼Žq, ‰Í–ì@—¹, “n•Óds, ŽRŒû@›Ü: dÇS•s‘S‚É‚¨‚¯‚éŽûkŠg’£“¯Šú•s‘S‚ɑ΂·‚éÄ“¯Šú—Ö@‚ÌŒø‰ÊD “ú–{’´‰¹”gˆãŠw‰ïi‘åãj5ŒŽ, 2006
  38. Î’Ã’qŽq, £”ö—RL, XŽR’¼Žq, •ˆÀ–@”V, “n•Óds, ÂÀ˜a—², ŽRŒû@›Ü: Ž_‰»LDL‚ÆŒz“®–¬ƒGƒR[ŠŒ©‚ÌŠÖ˜AD ‘æ79‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‘åãj5ŒŽ, 2006
  39. –{ŠÔ@Šo, ‰F–ìŠó¢Žq, ˆÀ”{‘å•ã, ’†¼Œ[‘¾, ²“¡–L”ü, ‰«@–¾“T, ²“¡‰Á“ÞŽq, Šp“c@”£, ‹gì—T”V, ŽRŒû@›Ü: •wl‰ÈŽèp‚ÌŽüpŠú‚É‚¨‚¯‚éÃ–¬ŒŒðÇðÇ‚Ì—\–h‘΍ô. ‘æ79‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‘åãj5ŒŽ, 2006
  40. ‰F–ìŠó¢Žq, –{ŠÔ@Šo, ˆÀ”{‘å•ã, ’†¼Œ[‘¾, ŽRŒû@›Ü, à_“c—m”ü, ‹gì—T”V: ŽüŽYŠú‚É‚¨‚¯‚錌ŠÇ’´‰¹”gŒŸ¸ŠŒ©‚̈Ӌ`|ŒŒ‰t‹ÃŒÅˆöŽq‚Æ‚ÌŠÖ˜A|D ‘æ79‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi‘åãj5ŒŽ, 2006
  41. ÂÀ˜a—²: S‹ØÇ‚É‚Æ‚à‚È‚¤•s®–¬‚Ì”ñ–ò•¨—Ö@‚̐V‚½‚ÈŽŽ‚݁D ‘æ41‰ñ—˜_S“d}Œ¤‹†‰ïi“Œ‹žj5ŒŽ, 2006
  42. •ˆÀ–@”V, “n•Óds, £”ö—RL, ‘ŠŒ´‰p–¾, ¯@’q–ç, –Ø‘º‘׎O, ‰Í–ì@—¹, ‘å’Ë’è“¿, ŽRŒû@›Ü: Vein-covered Cypher ƒXƒeƒ“ƒg‚ð—p‚¢‚½Š¥“®–¬áŽ‚ɑ΂·‚éPCI‚̈ê—áD ‘æ28‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Ȗ؁j5ŒŽ, 2006 ‘æ28‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠÖ“ŒbM‰z’n•û‰ï´˜^W, 42, 2006
  43. ‹g“cŒ’‘¾˜Y, ÂÀ˜a—², “cã˜aK, •–ØŒ’Žu, ‹g“cˆè—Y, ’†¼Œ[‘¾, ‹à–{@“s, —é–؏͍O, ‰““¡—DŽ}, ‹v‰êŒ\—S, ŽRŒû@›Ü, –ìãº•F, —é–Ø•¶’j: ‹t“`“±‚Ì‚Ý‚ð—L‚·‚é•›–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[‚É‚æ‚éS–[•p”‚̈ê—á. ‘æ36‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žj5ŒŽ, 2006
  44. ì‘º@—´, •ˆÀ–@”V, ŽRè@_, •–ØŒ’Žu, ’¬–ì@‹B, £”ö—RL, ‰Í–ì@—¹, “n•Óds, ÂÀ˜a—²: CypherƒXƒeƒ“ƒgÄ‹·ó‚É“ÁˆÙ‚È•a•ÏŒ`‘Ô‚ð”F‚ß‚½“§ÍÇ—áD ‘æ20‰ñˆïéŒ§PCIŒ¤‹†‰ï…ŒËƒvƒ‰ƒUƒzƒeƒ‹i…ŒËj6ŒŽ, 2006 ‘æ20‰ñˆïéŒ§PCIŒ¤‹†‰ï´˜^W, 4, 2006
  45. –Ø‘º‘׎O, •ˆÀ–@”V, “n•Óds, ‘å’Ë’è“¿, ¯@’q–ç, ‘ŠŒ´‰p–¾, ”üè¹Žq, ÂÀ˜a—², ŽRŒû@›Ü: ‰EŠ¥“®–¬‚É“ÁˆÙ‚È‹·óŒ`‘Ô‚ð”F‚ß‚½PCI‚̈ê—áD ‘æ200‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj6ŒŽ, 2006 Circ J 70 (Suppl III), 1198, 2006
  46. •ˆÀ–@”V, “n•Óds, £”ö—RL, ¯@’q–ç, –Ø‘º‘׎O, ŽRŒû@›Ü: Hagging and kissing stenting with DES to LMT and LAD, LCx bifurcation lesion. ‘æ15‰ï“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi•Ÿ‰ªj6ŒŽ, 2006 “ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŽ21 (Suppl I), 318, 2006
  47. ÂÀ˜a—²: Meet the ExpertF‚—îŽÒ‚É‚¨‚¯‚éS–[×“®‚̍ŐVŽ¡—ÃUp to DateD ‘æ48‰ñ“ú–{˜V”NˆãŠw‰ïŠwpW‰ïi‹à‘òj6ŒŽ, 2006
  48. ‰ÆŒõ‘fs, ‘O“c´Ži, ‘å’΁@‹B, ›Œ´@‡, “c•Ó@ , S.ƒWƒFƒXƒ~ƒ“, ‹v–안–ç, éˍ◲ˆê, ‹{“à@‘ì, ¼“cŒõ¶: ’†‚—îŽÒ‚É‚¨‚¯‚é‰^“®KŠµ‚Æ“®–¬L“W«‚ÌŠÖŒW‚ɃGƒ“ƒhƒZƒŠƒ“ŠÖ˜Aˆâ“`Žq‘½Œ^‚ª‰e‹¿‚·‚éD ‘æ6‰ñ—Տ°ŒŒˆ³–¬”gŒ¤‹†‰ïi“Œ‹žj6ŒŽ, 2006 PWV‚ÆAI (Augmentation Index)‚ÌŠî‘b‚©‚ç—Տ°E—\–hˆãŠw‚ւ̉ž—p, 31, 2006
  49. £”ö—RL, ÂÀ˜a—², ‹g“cŒ’‘¾˜Y, “cã˜aK, ’¬–ì@‹B, •–ØŒ’Žu, ŽRè@_, ì‘º@—´, ‰Í–ì@—¹, “n•Óds, ŽRŒû@›Ü: SŽºŠÔ˜A‘±ƒy[ƒVƒ“ƒO‚É‚æ‚éSŽºÄ“¯Šú—Ö@‚Ì—LŒø«. ‘æ9‰ñˆïéS‘ŸŒŒŠÇŒ¤‹†‰ïi‚‚­‚΁j6ŒŽ, 2006
  50. –Ø‘º‘׎O, •ˆÀ–@”V, ”üè¹Žq, ‘å’Ë’è“¿, £”ö—RL, “n•Óds, ÂÀ˜a—²: ŒŒð‚ªŠÖ—^‚µ‚½“ÁˆÙ‚ȉEŠ¥“®–¬‹·óŒ`‘Ô‚Ì1—áD ‘æ9‰ñˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ïi‚‚­‚΁j7ŒŽ, 2006 ‘æ9‰ñˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï´˜^W, 4, 2006
  51. £”ö—RL, “n•Óds, •ˆÀ–@”VCÎ’Ã’qŽq, XŽR’¼ŽqCÂÀ˜a—², ŽRŒû@›Ü: Š¥“®–¬Ž¾Š³‚É‚¨‚¯‚éŒz“®–¬ŠŸŽî«ó‚Æ“®–¬d‰»Žä‹NˆöŽq‚ÌŠÖ˜A‚ɂ‚¢‚Ä‚ÌŒŸ“¢D ‘æ9‰ñˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ïi‚‚­‚΁j7ŒŽ, 2006 ‘æ9‰ñˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï´˜^WF5, 2006
  52. £”ö—RL, “n•Óds, •ˆÀ–@”VCÎ’Ã’qŽq, XŽR’¼ŽqCÂÀ˜a—², ŽRŒû@›Ü: Œz“®–¬ƒGƒR[ŠŒ©‚ÆŽ_‰»LDL‚¨‚æ‚Ñhs-CRP‚ÌŠÖ˜AD The 6th symposium of meet the professor in cardiovascular diseasei“Œ‹žj7ŒŽ, 2006
  53. ‘ŠàVŸŽ¡, ‰ÆŒõ‘fs, ‘O“c´Ži, ‘å’΁@‹B, ‹{“à@‘ì, –ڍè@“o: ˆê‰ß«‰^“®‚É‚æ‚鍜Ši‹Ø‚̐«ƒzƒ‹ƒ‚ƒ“‡¬y‘f‚Ì”­Œ»‚Ɛ«·D ‘æ14‰ñ“ú–{‰^“®¶—Šw‰ïiL“‡j7ŒŽ, 2006 ‘æ14‰ñ“ú–{‰^“®¶—Šw‰ïƒvƒƒOƒ‰ƒ€E´˜^W, 77, 2006
  54. ‰ÆŒõ‘fs, ‘O“c´Ži, ‘å’΁@‹B, ‹{“à@‘ì: ƒgƒŒ[ƒjƒ“ƒO‚¨‚æ‚шê‰ß«‰^“®‚É‚æ‚éS‘Ÿ‚ÌMAPKƒVƒOƒiƒ‹Šˆ«‚ÌŒoŽž“I•Ï“®D ‘æ14‰ñ“ú–{‰^“®¶—Šw‰ïiL“‡j7ŒŽ, 2006 ‘æ14‰ñ“ú–{‰^“®¶—Šw‰ïƒvƒƒOƒ‰ƒ€E´˜^W, 73, 2006
  55. ŠÖŒûK•v, ŽR“àNÆ, ‰Ã”[Š°l, ‘åŽR–¾Žq, ‹v²–ÎŽ÷, ‚‘ºç’q, ”óŒûWŽi, —é–؁@“Ä, ‹{–{‹M—f, ”ö—с@“O, ’O‰H–¾”Ž, ÂÀ˜a—², ˆé•”ŒõÍ: ‚—îŽÒ‚É‚¨‚¯‚é”xÃ–¬Šu—£pD ‘æ21‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi“Œ‹žj7ŒŽ, 2006
  56. —é–؏͍O, ‹v‰êŒ\—S, ‰““¡—DŽ}, ‹g“cŒ’‘¾˜Y, ‹à–{@“s, “cã˜aK, •–ØŒ’Žu, ŽRè@_, ÂÀ˜a—², ŽRŒû@›Ü: ‚Žü”gƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚ɃÔg‚ÌŒ¸­‚ª”F‚ß‚ç‚ꂽ•s®–¬Œ¹«‰EŽºˆÙŒ`¬Ç‚Ì1—áD ‘æ21‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi“Œ‹žj7ŒŽ, 2006
  57. ŽRè@_, ÂÀ˜a—², ‹g“cŒ’‘¾˜Y, “cã˜aK, •–ØŒ’Žu, ‹à–{@“s, —é–؏͍O, ‰““¡—DŽ}, ‹v‰êŒ\—S, ŽRŒû@›Ü, ŽR“àNÆ, ‰¡ŽR‘לA, ‚‹´@~: ‰EŽº—¬o˜H‹NŒ¹SŽº•p”‚ɑ΂·‚鍂Žü”gƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚¨‚¯‚éelectroanatomical mapping system‚Ì—L—p«D ‘æ21‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi“Œ‹žj7ŒŽ, 2006
  58. ‰““¡—DŽ}, ‹g“cŒ’‘¾˜Y, “cã˜aK, —é–؏͍O, ‹v‰êŒ\—S, ÂÀ˜a—², ŽRŒû@›Ü: ‘½Ê‚È•s®–¬‚É‚Ä”­Ç‚µ, ƒXƒeƒƒCƒh—Ö@‚ª’˜Œø‚µ‚½SƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì3Ç—áD ‘æ21‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi“Œ‹žj7ŒŽ, 2006
  59. •–ØŒ’Žu, ÂÀ˜a—², ‹g“cŒ’‘¾˜Y, “cã˜aK, ŽRè@_, ‹à–{@“s, £”ö—RL, —é–؏͍O, ‰““¡—DŽ}, ‹v‰êŒ\—S, ŽRŒû@›Ü: FallotŽl”÷ÇªŽ¡pŒã‚̐S–[•p”‚ɑ΂·‚éCARTO system‚ð—p‚¢‚½ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“D ‘æ21‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi“Œ‹žj7ŒŽ, 2006
  60. ÂÀ˜a—²: mƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[nD Real Time Magnetic Resonance Guided Electrophysiology Intervention. ‘æ21‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi“Œ‹žj7ŒŽ, 2006
  61. ‰¡ŽR‘לA, ‚‹´@~, ‹{èW‰î, ¬–x“ÖŽu, ŒKŒ´‘åŽu, ÂÀ˜a—², ‰Æâ‹`l: –«S–[×“®‚ɑ΂·‚é8mmƒ`ƒbƒvƒAƒuƒŒ[ƒVƒ‡ƒ“ƒJƒe[ƒeƒ‹‚ð—p‚¢‚½¶‰º”xÃ–¬|‘m–X•Ù—Ö‹¬•”ÄŽÜ‚Ì—L—p«, ˆÀ‘S«‚ÉŠÖ‚·‚錟“¢D ‘æ21‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi“Œ‹žj7ŒŽ, 2006
  62. ÂÀ˜a—²: mDebate?@Protagonistn@CRT‚Ì‘Šú“±“ü‚͐¥‚©”ñ‚©D ‘æ21‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi“Œ‹žj7ŒŽ, 2006
  63. Watanabe S: ƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€uWorld trend of magnetocardiographyv Diagnosis of ischemic heart disease using 64-channel MCG system. ‘æ21‰ñ“ú–{•s®–¬Šw‰ï/‘æ23‰ñ“ú–{S“dŠw‰ï‡“¯ŠwpW‰ïi“Œ‹žj7ŒŽ, 2006
  64. •ˆÀ–@”V, “n•Óds, £”ö—RL: CypherƒXƒeƒ“ƒg—¯’uŒãÄ‹·ó‚ðŒJ‚è•Ô‚·Ç—áD ‘æ26‰ñ‚‚­‚΃Cƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ƒVƒlƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‚‚­‚΁j7ŒŽ, 2006 ‘æ26‰ñ‚‚­‚΃Cƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ƒVƒlƒJƒ“ƒtƒ@ƒŒƒ“ƒX´˜^W, 7, 2006
  65. “yŠò_‰î, –{ŠÔ^l, ‹v‰êŒ\—S, “n•Óds, ÂÀ˜a—², Žæ‹v”ü, ‘–ìˆê•x, ŽRŒû@›Ü, K“cK’¼: CYP2D6ˆâ“`Žq‘½Œ^‰ðÍ‚ÉŠî‚­ƒtƒŒƒJƒCƒjƒh‚Ì•êW’c–ò•¨“®‘Ô‰ðÍD ‘æ23‰ñ“ú–{TDMŠw‰ïi“Œ‹žj7ŒŽ, 2006
  66. éˍ◲ˆê, ‘ºã°, ‘O“c´Ži, ‹v–안–ç, “c’†Šì‘㎟, “n•Óds, ÂÀ˜a—², ŽRŒû@›Ü, ‘å’΁@‹B, ‰ÆŒõ‘fs, ‘]ª”Žm: ’†‚—îŽÒ‚É‚¨‚¯‚鍂Š´“xCRP‚Ɖ^“®‘Ï—e”\‚ÌŠÖ˜A‚¨‚æ‚щ^“®ƒgƒŒ[ƒjƒ“ƒOŒø‰ÊD ‘æ56‰ñzŠÂŠí•‰‰×Œ¤‹†‰ïi“Œ‹žj8ŒŽ, 2006 ‘æ56‰ñzŠÂŠí•‰‰×Œ¤‹†‰ï´˜^W, 6, 2006
  67. £”ö—RL, ÂÀ˜a—², ‹g“cŒ’‘¾˜Y, “cã˜aK, ‰Í–ì@—¹, “n•Óds, ŽRŒû@›Ü: ¶Žº“¯Šú•s‘S—á‚É‚¨‚¯‚éƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚éŽûkÅ‘ŠúŽž‘Š‚ÉŠÖ‚·‚錟“¢D ‘æ4‰ñæiSŒŒŠÇƒGƒR[Œ¤‹†‰ïi‘åãj8ŒŽ, 2006
  68. –{ŠÔ@Šo: zŠÂŠíŽ¾Š³‚Æèò“®–¬ƒGƒR[D ‘æ4‰ñŠÖ“ŒbM‰z‘Šú“®–¬d‰»Œ¤‹†‰ïi“Œ‹žj8ŒŽ, 2006
  69. ‘ŠàVŸŽ¡, ‰ÆŒõ‘fs, ‘O“c´Ži, ‘å’΁@‹B, ‹{“à@‘ì, –ڍè@“o: œŠi‹Ø‚͐«ƒzƒ‹ƒ‚ƒ“‚ðŽY¶‚·‚éD ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï‘å‰ïi_ŒËj9ŒŽ, 2006 ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï—\eW, 259, 2006
  70. ‹gàV–rŽq, ›Œ´@‡, ¬•ôG•F, —эvˆê˜Y, ‰¡ˆäFŽu, ‘å’΁@‹B, ‰ºžŠMˆÐ, ‹{“à@‘ì, ‘O“c´Ži: ’†‚—îŽÒ‚É‚æ‚é—LŽ_‘f«‰^“®ƒgƒŒ[ƒjƒ“ƒO‚ª‰ºŽˆ‚ÌŒðŠ´_Œo«ŒŒŠÇŽûk‚É‹y‚Ú‚·‰e‹¿D ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï‘å‰ïi_ŒËj9ŒŽ, 2006 ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï—\eW, 332, 2006
  71. ‰ÆŒõ‘fs, ‘O“c´Ži, ‘å’΁@‹B, ›Œ´@‡, “c•Ó@ , ‹v–안–ç, éˍ◲ˆê, ‹{“à@‘ì, ¼“cŒõ¶: ’†‚—îŽÒ‚É‚¨‚¯‚é“®–¬stiffness‚̉^“®Œø‰Ê‚ɃGƒ“ƒhƒZƒŠƒ“ŠÖ˜Aˆâ“`Žq‘½Œ^‚ª‰e‹¿‚·‚é |SATƒvƒƒWƒFƒNƒg191|D ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï‘å‰ï i_ŒËj9ŒŽ, 2006 ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï—\eW, 281, 2006
  72. ‘å’΁@‹B, ‘O“c´Ži, ‰ÆŒõ‘fs, Ä“¡—zŽq, ’J‘º—SŽq, éˍ◲ˆê, ‹{“à@‘ì: “®–¬ƒRƒ“ƒvƒ‰ƒCƒAƒ“ƒX‚Ì“®–¬ƒGƒ‰ƒXƒ^ƒ“ƒX‚ɑ΂·‚évŒ£“x‚͉^“®Žž‚É‘‘å‚·‚éD ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï‘å‰ïi_ŒËj9ŒŽ, 2006 ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï—\eW, 282, 2006
  73. —эvˆê˜Y, ‘O“c´Ži, ‰ÆŒõ‘fs, ‘å’΁@‹B, ›Œ´@‡, “c•Ó@ , ‹{“à@‘ì, ‹v–안–ç, éˍ◲ˆê, –ڍè@“o, ¼“cŒõ¶: ƒGƒXƒgƒƒQƒ“Žó—e‘̃¿ˆâ“`Žq‘½Œ^‚͐g‘ÌŠˆ“®ƒŒƒxƒ‹‚Æ“®–¬stiffness‚ÌŠÖŒW‚ɉe‹¿‚·‚é |SATƒvƒƒWƒFƒNƒg192|D ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï‘å‰ïi_ŒËj9ŒŽ, 2006 ‘æ61‰ñ“ú–{‘̗͈ãŠw‰ï—\eW, 397, 2006
  74. â‘q—f‰î, ‹v‰êŒ\—S, ‰Í–ì@—¹, —é–؏͍O, ‹g“cŒ’‘¾˜Y, “cã˜aK, •–ØŒ’Žu, ŽRè@_, ì‘º@—´, ’¬–ì@‹B, ÂÀ˜a—², ŽRŒû@›Ü: ƒtƒ@ƒ[Žl”÷ÇªŽ¡pŒãS–[•p”‚ªoŒ»‚µICD‚̐ݒè‚É‹ê—¶‚µƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðs‚Á‚½Ç—áD ‘æ201‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj9ŒŽ, 2006
  75. ÂÀ˜a—²: ƒRƒ“ƒgƒƒo[ƒV[2FƒŠƒYƒ€ƒRƒ“ƒgƒ[ƒ‹FƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—§ê‚©‚çD ‘æ54‰ñ“ú–{S‘Ÿ•aŠw‰ïiŽ­Ž™“‡j9ŒŽ, 2006
  76. XŽR’¼Žq, £”ö—RL, Î’Ã’qŽq, ‰Í–ì@—¹, ÎŒõ•qs, “n•Óds, ÂÀ˜a—², ŽRŒû@›Ü: S•s‘S—\Œã—\‘ª‚É‚¨‚¯‚éƒhƒvƒ‰¶Žº—¬“ü‘¬”gŒ`‰ðÍ‚Ì—L—p«FBNP’l‚Æ‚Ì”äŠrŒŸ“¢D ‘æ54‰ñ“ú–{S‘Ÿ•aŠw‰ïiŽ­Ž™“‡j9ŒŽ, 2006 J Cardiol 48 (Suppl. I), 440, 2006
  77. •–ØŒ’Žu, ’¬–ì@‹B, ŽRè@_, ì‘º@—´, “cã˜aK, ‹g“cŒ’‘¾˜Y, ‹à–{@“s, —é–؏͍O, ‰““¡—DŽ}, ‹v‰êŒ\—S, ÂÀ˜a—², ŽRŒû@›Ü: FallotŽl’¥ÇªŽ¡pŒã‚ɐ¶‚¶‚½ãŽº«•p”‚ɑ΂µ, ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½5Ç—á‚ɂ‚¢‚Ä‚Ì•ñD ‘æ54‰ñ“ú–{S‘Ÿ•aŠw‰ïiŽ­Ž™“‡j 9ŒŽ, 2006
  78. “cã˜aK, •–ØŒ’Žu, ’¬–ì@‹B, ŽRè@_, ì‘º@—´, ‹g“cŒ’‘¾˜Y, ‹à–{@“s, —é–؏͍O, ‰““¡—DŽ}, ‹v‰êŒ\—S, ÂÀ˜a—², ŽRŒû@›Ü: •s®–¬Œ¹«‰EŽºˆÙŒ`¬ÇiARVCj‡•¹‚̐SŽº•p”‚ɑ΂·‚éCARTO sytem‚ð—p‚¢‚½ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“D ‘æ54‰ñ“ú–{S‘Ÿ•aŠw‰ïiŽ­Ž™“‡j9ŒŽ, 2006
  79. ŽRè@_, •–ØŒ’Žu, ’¬–ì@‹B, ì‘º@—´, “cã˜aK, ‹g“cŒ’‘¾˜Y, ‹à–{@“s, —é–؏͍O, ‰““¡—DŽ}, ‹v‰êŒ\—S, ÂÀ˜a—², ŽRŒû@›Ü: ‰E‘¤‹¹•”—U“±iV1j‚ÅQSŒ^‚ð’æ‚·‚錰«WPWÇŒóŒQ‚Å, ‹ts«‘å“®–¬ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚荪Ž¡‚µ‚¦‚½3—áD ‘æ54‰ñ“ú–{S‘Ÿ•aŠw‰ïiŽ­Ž™“‡j9ŒŽ, 2006
  80. £”ö—RL, ‘å’Ë’è“¿, ¬‘îN”V, ÂÀ˜a—², “c’†—D”üŽq, “ì@Šw, V“¡@‰ëŽi, •½–ì—Y“ñ, H“¡”ŽK, –Ø‘º—Y‰î: ãk–§‚ÈŠiŽqƒ‚ƒfƒ‹‚ð—p‚¢‚½S‘ŸMRI ƒ^ƒMƒ“ƒO–@‚ÌŠJ”­D ‘æ34‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ïi‚‚­‚΁j9ŒŽ, 2006
  81. ŽÂŒ´@i, £”ö—RL, –ìŒû–¾Žq, “c‘ºˆ»Žq, “à“c´Žq, ’–£—R”üŽq, ‰“ŽR‘ì–¾, —Lì—Ç“ñ, ‘O“c—TŽj: ‹}«Š¥ÇŒóŒQ‚É‚¨‚¯‚éŒz“®–¬’´‰¹”g‘œ‚Ì“Á’¥D ‘æ55‰ñ“ú–{”_‘ºˆãŠw‰ïŠwpW‰ïi–¼ŒÃ‰®j10ŒŽ, 2006
  82. ”Ñ“c“TŽq, £”ö—RL, Žsì—¢”ü, ŽðŠª•¶Žq, ’†“‡‰pŽ÷, ˆî—t@•, ÂÀ˜a—², åŒ´@Œª: Žq‹{Ã–¬‚©‚çS‘Ÿ‚܂ŐL“W‚µ‚½Ã–¬“à•½ŠŠ‹ØŽî‚Ì1Ç—áD “ú–{’´‰¹”gˆãŠw‰ï@ŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj10ŒŽ, 2006
  83. ’†“‡‰pŽ÷, £”ö—RL, Î’Ã’qŽq, Žsì—¢”ü, ŽðŠª•¶Žq, ”Ñ“c“TŽq, ˆî—t@•, ÂÀ˜a—²: ƒy[ƒXƒ[ƒJƒŠ[ƒh‚É‚æ‚éŽOë•Ù•Â½•s‘S‚̐f’fF3DSƒGƒR[}–@‚Ì—L—p«‚ÉŠÖ‚·‚錟“¢D “ú–{’´‰¹”gˆãŠw‰ï@ŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj10ŒŽ, 2006
  84. ÂÀ˜a—²: m‹³ˆçu‰‰nS•s‘S‚Æ“Ë‘RŽ€D ‘æ10‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi“Œ‹žj10ŒŽ, 2006
  85. ŽR–{­], ‹v‰êŒ\—S, Î’Ã’qŽq, ‹g“cOŽq, •½“cŽO‘ãŽq, ŒÜ“‡—mŽq, X@ŒcŽq, ¼ˆä—TŽj, ‘å’ː·’j: ‚Ž‰ŒŒÇ‚𔺂¤‹³Eˆõ‚É‚¨‚¯‚éèò“®–¬’´‰¹”gŒŸ¸‚̐¶ŠˆKŠµ‰ü‘P‚Ì“®‹@‚¯‚ɑ΂·‚é—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢D ‘æ44‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ¤‹†W‰ïi“Œ‹žj10ŒŽ, 2006
  86. ‹v‰êŒ\—S, Î’Ã’qŽq, ¼ˆä—TŽj, X@ŒcŽq, ŽR–{­], •½“cŽO‘ãŽq, ŒÜ“‡—mŽq, ‹ß“¡¬D, ‘å’ː·’j: ‘åŠw¶‚É‚¨‚¯‚éSŽºŠúŠOŽûk‚ÌŽÀ‘ԁD ‘æ44‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ¤‹†W‰ïi“Œ‹žj10ŒŽ, 2006
  87. óì“N–ç, –]ŒŽ@~, ¼‘º‘‰À, ŽR“àNÆ, ‚‹´@~, ÂÀ˜a—²: ‰º‘åÃ–¬•ÂÇÇ—á‚ɍ‡•¹‚µ‚½’ʏíŒ^S–[‘e“®‚ɑ΂µƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½1—áD ‘æ18‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi“Œ‹žj11ŒŽ, 2006
  88. ŽRè@_, •–ØŒ’Žu, “cã˜aK, ‹g“cŒ’‘¾˜Y, —é–؏͍O, ‰““¡—DŽ}, ‹v‰êŒ\—S, ÂÀ˜a—², ŽRŒû@›Ü: FallotŽl”÷ÇªŽ¡pŒã‚̐S–[•p”‚É‚æ‚èŽä‹N‚³‚ê‚éፍ­ŽüˆÍ‚𗼕ûŒü«‚ɐù‰ñ‚·‚é2Ží‚̐SŽº•p”D ‘æ18‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi“Œ‹žj11ŒŽ, 2006
  89. —é–؁@“Ä, ŽR“àNÆ, ŠÖŒûK•v, ”óŒûWŽi, ‹v²–ÎŽ÷, ‘åŽR–¾Žq, ‚‘ºç’q, ‰Ã”[Š°l, ‹{–{‹M—f, ”ö—с@“O, ’O‰H–¾”Ž, —é–Ø•¶’j, –I’J@m, •½”öŒ©ŽO, ˆé•ÓŒõÍ, ÂÀ˜a—²: ‰E–[’†Šu‚Ìfocal ablation ‚ɂčªŽ¡‚µ‚½limbus fossa ovalis‹NŒ¹”­ì«S–[×“®‚Ì1—áD ‘æ18‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi“Œ‹žj11ŒŽ, 2006
  90. ŽÄ“c—ÏŽq, •–ØŒ’Žu, “n•Óds, ’¬–ì@‹B, ŽRè@_, ì‘º@—´, £”ö—RL, •ˆÀ–@”V, ÂÀ˜a—², ŽRŒû@›Ü, •½ŽR@‹Å, ’ç@–¾l: Blue toe syndrome‚ɑ΂µ, ƒXƒeƒƒCƒhƒZƒ~ƒpƒ‹ƒX—Ö@‚¨‚æ‚Ñ‘½—Ê“à•žˆÛŽ“Š—^‚ª‘tŒ÷‚µ‚½ˆê—á. ‘æ14‰ñˆïézŠÂŠíŒ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2006 ‘æ14‰ñˆïézŠÂŠíŒ¤‹†‰ï´˜^WF3, 2006
  91. •–ØŒ’Žu, “n•Óds, ’¬–ì@‹B, ŽRè@_, ì‘º@—´, £”ö—RL, •ˆÀ–@”V, ÂÀ˜a—², ŽRŒû@›Ü, •½ŽR@‹Å, ’ç@–¾l: ƒRƒŒƒXƒeƒ[ƒ‹ÇðÇ‚ɑ΂µ, ƒXƒeƒƒCƒhƒZƒ~ƒpƒ‹ƒX—Ö@‚¨‚æ‚Ñ‘½—Ê“à•žˆÛŽ“Š—^‚ª‘tŒ÷‚µ‚½ˆê—áD ‘æ202‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj12ŒŽ, 2006 Circ J 71 (Suppl II), 872, 2007
  92. ²“¡“¡•v, …’J‘¾˜Y, ã‘º˜a–ç, X“‡—TŽq, ‚‹´L“ñ, •ˆÀ–@”V, –{ŠÔ–žŽq, “n•Ó‰ë•F, “n•Óds: “–‰@‚É‚¨‚¯‚éS”x‘h¶–@•W€‰»‚Ö‚ÌŽæ‚è‘g‚݁|CPRƒNƒŠƒeƒBƒJƒ‹ƒpƒX‚Ì“±“ü|D “ú–{‘h¶Šw‰ï‘æ25‰ñ‘å‰ïi•l¼j12ŒŽ, 2006
  93. £”ö—RL, ÎŒõ•qs, Î’Ã’qŽq, ‰F–ìŠó¢Žq, XŽR’¼Žq, ‰Í–ì@—¹, ÂÀ˜a—²: S•s‘S—\Œã”»’è‚É‚¨‚¯‚éE/A”ä‚Ì—L—p«Fƒhƒvƒ‰•¡‡Žw•W‚ƍ¶–[ˆ³‚ÌŠÖ˜A‚ÉŠî‚­ŒŸ“¢D ‘æ25‰ñ’´‰¹”gŒŒ—¬Œ¤‹†‰ïi“Œ‹žj12ŒŽ, 2006

@@@¡ ‚»‚Ì‘¼

  1. ÂÀ˜a—²: “«’vŽ€«SŽº«•s®–¬‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Ã. ‘æ21‰ñÔézŠÂŠíƒtƒH[ƒ‰ƒ€i‘O‹´j1ŒŽ, 2006
  2. ÂÀ˜a—²: S–[×“®‚ÌŽ¡—ÃUp to Date@|V‚½‚È–ò•¨ƒRƒ“ƒrƒl[ƒVƒ‡ƒ“Ž¡—©‚çƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Â܂Ł|D ¼”Z”öƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ïi–¼ŒÃ‰®j2ŒŽ, 2006
  3. ÂÀ˜a—²: S–[×“®‚̍ŐVŽ¡—ÁD é‹ÊS‘Ÿ•a’k˜b‰ïi‚³‚¢‚½‚܁j2ŒŽ, 2006
  4. –{ŠÔ@Šo: ŒŒðÇ‚ɂ‚¢‚āD –‡•ûEŒð–ìEQ‰®ìzŠÂŠíŒ¤‹†‰ïi‘åãj2ŒŽ, 2006
  5. ŽRŒû@›Ü: ¶ŠˆKŠµ•a|‚ ‚È‚½‚Ì“w—Í‚ÅŒ’N’·Žõ|u‹·SÇ, S‹Ø[Ç‚É‚È‚ç‚È‚¢‚½‚߂ɁvD ‘æ5‰ñˆïéŒ§ˆãŽt‰ïŒ§–¯Œ’NƒtƒH[ƒ‰ƒ€i—F•”j3ŒŽ, 2006
  6. ÂÀ˜a—²: Šî‘bSŽ¾Š³‚ð—L‚µ‚½SŽº•p”‚ɑ΂·‚éƒTƒuƒXƒŒ[ƒgƒ}ƒbƒsƒ“ƒO‚É‚æ‚éƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—L—p«D ‘æ35‰ñ_“ސìS‘Ÿƒy[ƒVƒ“ƒO“d‹C¶—Œ¤‹†‰ïi_“ސìj3ŒŽ, 2006
  7. ÂÀ˜a—²: —¬o˜HSŽº•p”F•”ˆÊf’f‚ÆŽ¡—Ð헪D ‘æ17‰ñã_ƒAƒuƒŒ[ƒVƒ‡ƒ““d‹C¶—Œ¤‹†‰ïi‹ž“sj4ŒŽ, 2006
  8. ÂÀ˜a—²: 21¢‹I‚É‚¨‚¯‚é•s®–¬Ž¡—Á@|‚±‚ê‚©‚ç‚Ì•ûŒü«|D Œ§“ì’n‹æˆãŽt‰ïŠwpu‰‰‰ïi‚‚­‚΁j4ŒŽ, 2006
  9. ŽRŒû@›Ü: uzŠÂŠíŒn‚̐VŽ¡—¨‚æ‚Ñ’nˆæ•af˜AŒg‚ɂ‚¢‚āvD ^•ÇˆãŽt‰ï÷ìŽx•”‘æ1‰ñŠwpu‰‰‰ïi÷ìj5ŒŽ, 2006
  10. ÂÀ˜a—²: ƒuƒ‹ƒKƒ_ÇŒóŒQ‚ÌŒ»ó‚Æ‚»‚ÌŽ¡—ÁD ‹ß‹ESŒŒŠÇƒWƒ‡ƒCƒ“ƒgƒ‰ƒCƒu2006i‹ž“sj5ŒŽ, 2006
  11. •ˆÀ–@”V: ‚ŒŒˆ³E‚Ž‰ŒŒÇ‚̃Rƒ“ƒgƒ[ƒ‹‚ɂ‚¢‚āD ˆïé¶ŠˆKŠµ•aƒtƒH[ƒ‰ƒ€i‚‚­‚΁j5ŒŽ, 2006
  12. “n•Óds: •s®–¬‚ÆŽ¸_‚¨‚æ‚ÑŽ©“®ŽÔ‚̉^“]‚ɂ‚¢‚āD ‘S‘ŒxŽ@ŠwZ‰^“]“K«‘Š’kê‰È ŠÖ“ŒŠÇ‹æŒxŽ@ŠwZi¬•½j5ŒŽ, 2006
  13. ÂÀ˜a—²: ”x“®–¬Šu—£p‘OŒã‚É‚¨‚¯‚é‘Ì•\–ÊP”g‰ÁŽZ•½‹ÏS“d}•]‰¿‚̈Ӌ`D ˆïéŒ§•a‰@–òÜŽt‰ï/ˆïéŒ§–òÜŽt‰ïŠwpu‰‰‰ïi…ŒËj6ŒŽ, 2006
  14. ÂÀ˜a—²: S–[×“®‚̍ŐVŽ¡—Á@|–ò•¨—Ö@‚©‚çƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚܂Ł|D Ã‰ªƒAƒuƒŒ[ƒVƒ‡ƒ“•×‹­‰ïiÃ‰ªj 6ŒŽ, 2006
  15. “cã˜aK, ‹g“cŒ’‘¾˜Y, ì‘º@—´, ŽRè@_, •–ØŒ’Žu, ’¬–ì@‹B, ÂÀ˜a—², ŽRŒû@›Ü: u‹•ŒŒ«SŽ¾Š³‚Ì—\–h‚ÆŽ¡—ÁvD ‘æ11‰ñ_“ސì—Տ°•s®–¬ƒtƒH[ƒ‰ƒ€i‰¡•lj6ŒŽ, 2006
  16. £”ö—RL, ÂÀ˜a—², ‹g“cŒ’‘¾˜Y, “cã˜aK, ‰Í–ì@—¹, ŽRŒû@›Ü: S–[×“®‚̍ŐVŽ¡—ÁD ‘æ63‰ñˆïéS‘ŸŒŒŠÇŒ¤‹†‰ïi‚‚­‚΁j6ŒŽ, 2006
  17. ÂÀ˜a—²: ŠîŽ¿SŽ¾Š³‚ð—L‚·‚鈫«SŽº«•s®–¬‚ɑ΂·‚éV‚½‚ÈŽ¡—Ð헪D ‘æ19‰ñ‰¡{‰êzŠÂŠíƒOƒ‹[ƒv•af˜AŒgŒ¤‹†‰ïi‰¡{‰êj6ŒŽ, 2006
  18. ÂÀ˜a—²: S–[×“®‚ɑ΂·‚錻Ý‚ÌŽ¡—Á@|ƒAƒbƒvƒXƒgƒŠ[ƒ€Ž¡—Ã, ƒ_ƒEƒ“ƒXƒgƒŠ[ƒ€Ž¡—Ã, ‚»‚µ‚ăJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚܂Ł|D ‘æ15‰ñêt–¾S‘ŸƒtƒH[ƒ‰ƒ€iŽ­Ž™“‡j6ŒŽ, 2006
  19. ŽRŒû@›Ü: ‚—îŽÒ‚̐S–[×“®D ‘æ5‰ñuHCN…ŒËvŒ¤‹†‰ïi…ŒËj7ŒŽ, 2006
  20. ÂÀ˜a—²: S–[×“®‚̍ŐVŽ¡—ÁD ‘æ9‰ñŽOdzŠÂŠíƒtƒH[ƒ‰ƒ€iŽOdj7ŒŽ, 2006
  21. ÂÀ˜a—²: S–[×“®‚̍ŐVŽ¡—Á@|Up To Date|D ‘æ12‰ñŽR‚̏ãzŠÂŠíƒZƒ~ƒi[i“Œ‹žj7ŒŽ, 2006
  22. ÂÀ˜a—²: ŽÀ’n—Տ°‚É‚¨‚¯‚é‹•ŒŒ«SŽ¾Š³‚̐f’fEŽ¡—ÁD ‰¡{‰êŽsˆãŽt‰ïŠwpu‰‰‰ïi‰¡{‰êj7ŒŽ, 2006
  23. ÂÀ˜a—²: S”ì‘匤‹†‚̐V‚½‚È‚é“WŠJD Meet the Clinical Expert 2006i‘åãj7ŒŽ, 2006
  24. ÂÀ˜a—²: “úíf—Âɖ𗧂ŋ߂̐S•s‘S‚̘b‘èD Œ§“ì’n‹æˆãŽt‰ïŠwpu‰‰‰ïi‚‚­‚΁j7ŒŽ, 2006
  25. ÂÀ˜a—²: S–[×“®‚ɑ΂·‚éÅ‹ßŽ¡—ÁD ^•ÇˆãŽt‰ïŠwpu‰‰‰ïi’}¼Žsj7ŒŽ, 2006
  26. “n•Óds: SŽºÄ“¯Šú—Ö@‚Ì“K‰ž‚ÆŽè‹Z, ‚»‚µ‚ĐV‚½‚È“WŠJD ^•ÇˆãŽt‰ïŠwpu‰‰‰ïi’}¼Žsj7ŒŽ, 2006
  27. Žðˆä@r: ”x‚ŒŒˆ³‚ɑ΂·‚é–ò•¨Ž¡—Â̐i•àD zŠÂŠí“à‰ÈŠwpu‰‰‰ïi‚‚­‚΁j7ŒŽ, 2006
  28. ‰Í–ì@—¹: “®–¬EÃ–¬ŒŒðÇ‚̗Տ°D S•s‘SŠwpu‰‰‰ïi‚‚­‚΁j7ŒŽ, 2006
  29. ‰Í–ì@—¹: •s®–¬‚̐f’fŠw‚ÌŒüã‚ÆŽ¡—Êw‚ÌŠm—§D Î‰ª–òÜŽt‰ïŠwpu‰‰‰ïiÎ‰ªŽsj7ŒŽ, 2006
  30. ÂÀ˜a—²: ’vŽ€«•s®–¬‚ɑ΂·‚éICDESRT-DŽ¡—ÁD ‘æ86‰ñ’}¼zŠÂŠíuK‰ïi’}¼Žsj9ŒŽ, 2006
  31. £”ö—RL, ÂÀ˜a—²: S–[×“®@|‰uŠw‚©‚玡—Â܂Ł|D —Տ°MEê–å”F’èŽmuK‰ïi“Œ‹žj9ŒŽ, 2006
  32. –{ŠÔ@Šo: S•s‘S‚Ì“Ë‘RŽ€‚ÆCRT‚Ì“K‰žD Pulmonary HypertensionƒZƒ~ƒi[i–ì“cj9ŒŽ, 2006
  33. –{ŠÔ@Šo: S‘Ÿ•a‚Ƃ́@•s®–¬‚Æ‚¢‚í‚ꂽ‚ç@S‹Ø[Ç‚É‚È‚ç‚È‚¢‚½‚߂ɁD ‘æ86‰ñ’}¼zŠÂŠíuK‰ïi’}¼j10ŒŽ, 2006
  34. ÂÀ˜a—²: S‹Ø[Ç‚É‚È‚ç‚È‚¢‚½‚߂ɁD ‘æ4‰ñé‹ÊƒAƒ~ƒIƒ_ƒƒ“ƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‚³‚¢‚½‚܁j10ŒŽ, 2006
  35. ÂÀ˜a—²: S‘Ÿ•aŽ¡—ÁEH¶ŠˆE‰^“®‚ɂ‚¢‚āD ç—t•s®–¬ƒVƒ“ƒ|ƒWƒEƒ€iç—tj10ŒŽ, 2006
  36. ÂÀ˜a—²: SŽº«•s®–¬‚̐f’f‚ÆŽ¡—ÁD ƒ‘ƒŽsˆãŽt‰ïŠwpu‰‰‰ïi‚³‚¢‚½‚܁j10ŒŽ, 2006
  37. ÂÀ˜a—²: S–[×“®‚ÌŽ¡—ÃUp to Date@|V‚½‚È–ò•¨ƒRƒ“ƒrƒl[ƒVƒ‡ƒ“Ž¡—©‚çƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Â܂Ł|D ‘æ3‰ñHF/CRTƒZƒ~ƒi[i“Œ‹žj10ŒŽ, 2006
  38. ÂÀ˜a—²: Œz“®–¬ƒGƒR[‚ÌŽÀ‘H‚ƃGƒrƒfƒ“ƒXD ‘æ13‰ñŒ§–¯‚Ì‚½‚ß‚ÌŒ’NŠÇ—uÀi“y‰Yj10ŒŽ, 2006
  39. “n•Óds: CRT‚ÌŠT”O‚Æ—LŒø«, “K‰žŠî€D ‘æ13‰ñŒ§–¯‚Ì‚½‚ß‚ÌŒ’NŠÇ—uÀi“y‰Yj10ŒŽ, 2006
  40. •ˆÀ–@”V: Œz“®–¬ƒGƒR[‚ÌŽÀ‘H‚ƃGƒrƒfƒ“ƒXD ‘æ13‰ñŒ§–¯‚Ì‚½‚ß‚ÌŒ’NŠÇ—uÀi“y‰Yj10ŒŽ, 2006
  41. ÂÀ˜a—²: ‹}«S•s‘SŽ¡—Âɂ¨‚¯‚éHANP‚̈ʒu‚¯D Medical TribunezŠÂŠíƒZƒ~ƒi[u•s®–¬‚̃vƒ‰ƒCƒ}ƒŠEƒPƒAvi‹{éj10ŒŽ, 2006
  42. ÂÀ˜a—²: S–[×“®‚̍ŐVŽ¡—Á@|ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚©‚ç–ò•¨•¹—p—Ö@‚܂Ł|D ‘æ1‰ñé–kƒAƒ~ƒIƒ_ƒƒ“§˜b‰ïi“Œ‹žj10ŒŽ, 2006
  43. £”ö—RL: S–[×“®‚ÌŽ¡—ÃUp to Date@|–ò•¨•¹—p—Ö@‚©‚çƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚܂Ł|D —Տ°ŒŒŠÇáŠQƒtƒH[ƒ‰ƒ€i‚‚­‚΁j10ŒŽ, 2006
  44. £”ö—RL: zŠÂŠí“à‰Èˆã‚©‚猩‚½‹}«S•s‘SŽ¡—Ð헪D ƒy[ƒVƒ“ƒO‚É‚æ‚éS•s‘SŽ¡—ÃŒ¤CƒZƒ~ƒi[i“Œ‹žj 10ŒŽ, 2006
  45. £”ö—RL: S“d}Šî‘bƒZƒ~ƒi[D —Տ°ŒŒŠÇáŠQƒtƒH[ƒ‰ƒ€i…ŒËj10ŒŽ, 2006
  46. ‰Í–ì@—¹: Ï‹É“IŽ‰Ž¿’ቺ—Ö@‚̈Ӌ`D HANP FORUM in TSUKUBAi‚‚­‚΁j10ŒŽ, 2006
  47. •ˆÀ–@”V: ƒCƒ“ƒVƒfƒ“ƒg@ƒIƒJƒŒƒ“ƒX•ñ‚Æ“dŽq‰»‚̉e‹¿D ˆïéŒ§JELISu‰‰‰ïi‚‚­‚΁j10ŒŽ, 2006
  48. ÂÀ˜a—²: “dŽq‰»‚ªƒCƒ“ƒVƒfƒ“ƒg, ƒIƒJƒŒƒ“ƒX•ñŒ”‚Æ•ñŽžŠÔ‚É—^‚¦‚é‰e‹¿D ‘æ22‰ñ–k‹ãB—Տ°•s®–¬Œ¤‹†‰ïi¬‘qj11ŒŽ, 2006
  49. ÂÀ˜a—²: zŠÂŠíf—ÂƐϋɓIŽ‰Ž¿’ቺ—Ö@‚̈Ӌ`D ‘æ12‰ñ’·è—Տ°•s®–¬’k˜b‰ïi’·èj11ŒŽ, 2006
  50. ‰Í–ì@—¹: S–[×“®‚̍ŐVŽ¡—ÁD ƒAƒXƒeƒ‰ƒX»–òŽÐ“àu‰‰‰ïi‚‚­‚΁j11ŒŽ, 2006
  51. “n•Óds: S•s‘S‚ɑ΂·‚éSŽºÄ“¯Šú—Ö@‚ÌŒ»ŽÀ‚Æ–¢—ˆD ‘æ4‰ñŒÄ‹zEzŠÂƒZƒ~ƒi[IN TSUKUBAi‚‚­‚΁j11ŒŽ, 2006
  52. “n•Óds: S–[×“®‚̍ŐV‚ÌŽ¡—ÁD uÏ‹É“IŽ‰Ž¿’ቺ—Ö@‚̈Ӌ`vu‰‰‰ïi–kˆïéŽsj11ŒŽ, 2006
  53. ‚—œ“TŽq, –{ŠÔ@Šo, ‹àŽq“¹•v: S•s‘SŽ¡—Á@|Å‹ß‚̍l‚¦•û|D ˆã—Â̎¿EˆÀ‘SŠw‰ï‘æ1‰ñŠwpW‰ïi“Œ‹žj11ŒŽ, 2006
  54. ‚—œ“TŽq, –{ŠÔ@Šo, ‹àŽq“¹•v: S–[×“®‚̍ŐVŽ¡—ÁD ‘æ2‰ñˆïéŒ§ˆã—ÃŽ–ŒÌ–hŽ~Œ¤‹†‰ïi‚‚­‚΁j11ŒŽ, 2006
  55. “n•Óds: S‹Ø”ì‘å‚Ì•ªŽq×–EŠw“IƒƒJƒjƒYƒ€D —ˆã‚̉ïu‰‰‰ïi‚‚­‚΁j12ŒŽ, 2006
  56. ÂÀ˜a—²: Granulocyte colony-stimulating factor prevents progression of monocrotaline-induced pulmonary arterial hypertension in rats. …‹½ˆãŽt‰ïŠwpW‰ïis•ûj12ŒŽ, 2006
  57. ÂÀ˜a—²: In vivo electropharmacological effects of amiodarone and candesartan on atria of chronic atrioventricular block dogs. SeminarFCARDIOLOGY 2006i“Œ‹žj12ŒŽ, 2006
  58. ÂÀ˜a—²: Tissue factor expression as a possible determinant of thromboembolism in ovarian Cancer. •½¬18”N‚È‚ß‚ª‚½’nˆæ‘‡•a‰@Šwpu‰‰‰ïis•ûj12ŒŽ, 2006
  59. ÂÀ˜a—²: Postexercise heart rate recovery accelerates in strength-trained athletes. ‘æ281‰ñŒ§“ìzŠÂŠíŒ¤‹†‰ï“Á•Êu‰‰‰ïi“y‰Yj12ŒŽ, 2006
  60. ÂÀ˜a—²: Expression of steroidgenic enzymes and synthesis of sex steroid hormones from DHEA in skeletal mustle of rats. ‘æ1‰ñŠâŽè•s®–¬Ž¡—ͧ˜b‰ïiŠâŽèj12ŒŽ, 2006
  61. Žðˆä@r: Vascular endothelium-derived factors and arterial stiffness in strength-and endurance-trained men. ‘æ1‰ñTsukuba Cardiovascular Research Seminari‚‚­‚΁j12ŒŽ, 2006

@2005”N“xi2005”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. •ˆÀ –@”VC“n•Ó dsC‹v‰ê Œ\—SCÂÀ ˜a—²CŽRŒû ›ÜF ƒzƒ‹ƒ^[S“d}‚É‚¨‚¢‚Ä‹Ø“d}¬“ü‚ª—L—p‚ȏŠŒ©‚Å‚ ‚Á‚½2Ç—áD ‘æ39‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïŠwpW‰ïi“Œ‹žjC1ŒŽC2005
  2. ‹v‰ê Œ\—SC‰““¡ —D]Cm•Û •¶•½C—é–Ø ÍOC‹à–{ “sC‹g“cŒ’‘¾˜YCÂÀ ˜a—²C‘å’Ë ·’jCŽRŒû ›ÜF V‚µ‚¢~ˆ³Œø‰Ê‚ÌŽw•W‚Å‚ ‚ég~ˆ³—͉¿Hypovaric equivalentsh‚É‚æ‚éŠeŽí~ˆ³–ò‚̍~ˆ³Œø‰Ê‚Ì’è—Ê“I”äŠr–@‚ÌŽŽ‚݁D ‘æ39‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïŠwpW‰ïi“Œ‹žjC1ŒŽC2005
  3. ‘Œ© ’qŽqCˆÀ”{ ‘å•ãCd“c Ž¡C‰Í–ì —¹C“n•Ó dsCŽRŒû ›ÜF ‰ES•s‘SÇó‚Å”­Ç‚µ‚½–«‘å“®–¬‰ð—£‚Ì1—áD ‘æ39‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïŠwpW‰ïi“Œ‹žjC1ŒŽC2005
  4. ‘å’Ë ’è“¿F •úŽËŒõ‚ð—p‚¢‚½ŒoÃ–¬Š¥“®–¬‘¢‰eD ‘æ1‰ñ¬Œ^ƒ‰ƒCƒiƒbƒNˆã—Éž—pŒ¤‹†‰ïi“ŒŠCjC1ŒŽC2005
  5. —é–Ø GrC‰¡ŽR ‘לAC”Ñ“c Œ[‘¾C“c’† ‘׏́CˆÉ“¡ —S•ãC¬–x “ÖŽuC–ì—¢ ŽõŽjCŒKŒ´ ‘åŽuC²“¡ –¾C‚‹´ ~CÂÀ ˜a—²C•½”ö Œ©ŽOCˆé•” ŒõÍF ƒAƒ~ƒIƒ_ƒƒ“•s‘ϐ«‚̒፶S‹@”\Š³ŽÒ‚ɑ΂µ‚ĉ–Ž_ƒxƒvƒŠƒWƒ‹EƒJƒ‹ƒxƒWƒ[ƒ‹•¹—p“Š—^‚ª—L—p‚Å‚ ‚Á‚½ˆêÇ—áD ‘æ195‰ñ“ú–{zŠÂŠí•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC2ŒŽC2005
  6. ‹g“cŒ’‘¾˜YCÂÀ ˜a—²C”üè ¹ŽqCŒj–Ø —eŽqC£”ö —RLC‰Í–ì —¹C‘å’Ë ’è“¿C•ˆÀ –@”VC“n•Ó dsC‹v‰ê Œ\—SCŽRŒû ›ÜF PCIŒã‚ÉŽ‘±«’PŒ^«SŽº•p”‚̃Xƒg[ƒ€‚Æ‚È‚è‹Ù‹}ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚荪Ž¡‚µ“¾‚½’‹Œ«S‹Ø[Ç‚Ì1—áD ‘æ195‰ñ“ú–{zŠÂŠí•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC2ŒŽC2005
  7. ì‘º —´C“’ì –¾˜aC“n•Ó NŽuC—é–Ø ÍOC“c’†Šì”ü•vC“n•Ó dsCŽRŒû ›ÜF ƒ¿ŽÕ’f–ò‚ª—LŒø‚¾‚Á‚½‘½Ü’ïR«‰^“®—U”­«Š¥¹k«‹·SÇ‚Ì1—áD ‘æ195‰ñ“ú–{zŠÂŠí•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC2ŒŽC2005
  8. ‘ŠŒ´ ‰p–¾CÂÀ ˜a—²C‹g“cŒ’‘¾˜YC”üè ¹ŽqC‹v‰ê Œ\—SCŽRŒû ›ÜC‰““¡ „C–x F•¶C’©“c —²F ŽOŠÂŒnR‚¤‚–ò“Š—^’†‚Éáz¹‚𔺂¤ˆÓŽ¯ÁŽ¸”­ì‚𐶂¶‚½BrugadaÇŒóŒQ‚̈ê—áD ‘æ3‰ñ“Á”­«SŽº×“®Œ¤‹†‰ïi“Œ‹žjC2ŒŽC2005
  9. ‹{“à ‘ìF S•s‘SE”x‚ŒŒˆ³‚ƃGƒ“ƒhƒZƒŠƒ“‚¨‚æ‚ÑŽó—e‘ÌŽÕ’f–òD _ŒË‘åŠw‘åŠw‰@“Á•Êu‰‰i_ŒËjC2ŒŽC2005
  10. Suzuki H., Takahashi A., Yokoyama Y., Kuwahara T., Kobori A., Yamauchi Y., Handa K., Tanaka Y., Itoh Y., Nozato T., Sato A., Nogami A., Abe R., Aonuma K., Iesaka Y., Isobe M.F Clinical Predictor of Atrial Fibrillation Recurrence after Initial Procedure of Extensive Encircling Isolation of Ipsilateral Pulmonary Veins. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  11. Handa K., Takahashi A., Yokoyama Y., Kuwahara T., Kobori A., Yamauchi Y., Suzuki H., Tanaka Y., Itoh Y., Nozato T., Sato A., Nogami A., Aonuma K., Iesaka Y., Isobe M.F Evaluation of Anatomical Relationship between Esophagus and Heart Using Esophagram: Implications for Pulmonary Vein Isolation in Atrial Fibrillation Patient. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  12. Yokoyama Y., Aonuma K., Seo Y., Yamauchi Y., Sato A., Nozato T., Suzuki H., Hanada K., Tanaka Y., Itoh Y., Kobori A., Kuwahara T., Takahashi A., Hirao K., Yamaguchi I., Isobe M.F Efficacy of Novel Tri-ventricular Pacing to Cardiac Resynchronization in Patients with Congrestive Heart Failure. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  13. Ohtsuka S., Oyake Y., Yamazaki A., Yamaguchi I.F Comparison between the Effects of AT1-Blocker and Calcium Antagonist on Foream Vascular Function in Essential Hypertensive Patients. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  14. Aihara H., Watanabe S., On K., Yamada S., Takeyasu N., Suzuki D., Ogata K., Kandori A., Miyashita T., Tsukada K., Yamaguchi I.F Detection of the Patients with Coronary Stenosis by High-Tc-SQUID Magnetocardiogram. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  15. Kobori A., Takahashi A., Yokoyama Y., Kuwahara T., Yamauchi Y., Handa K., Suzuki H., Tanaka Y., Itoh Y., Nozato T., Sato A., Nogami A., Aonuma K., Iesaka Y., Isobe M.F Evaluation of the Safety Techniques in Electrical Isolation of Superior Vena Cava. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  16. Misaki M., Aonuma K., Yoshida K., Yamauchi Y., Yokoyama Y., Suzuki Y., Endo M., Kuga K., Takahashi A., Yamaguchi I.F The Long Term Clinical Outcome after the Complete Cration of a Cavo-tricuspid Isthmus Blokline in Patients with Common Atrial Flutter. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  17. Yokoyama Y., Takahashi A., Aonuma K., Yamauchi Y., Suzuki H., Handa K., Itoh Y., Kobori A., Sekiguchi Y., Nozato T., Hachiya H., Kuwahara T., Sato A., Hirao K., Iesaka Y., Isobe M.F Cause of Recurrence after the Initial Procedure of Extensive Encircling Ipsilateral Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  18. Takahashi A., Yokoyama Y., Kuwahara T., Kobori A., Yamauchi Y., Handa K., Suzuki H., Tanaka Y., Itoh Y., Nozato T., Sato A., Nogami A., Aonuma K., Iesaka Y., Isobe M.F Feasibility and Efficacy of Extensive Isolation Including Pulmonary Veins and Entire Posterior Left Atrium in Patients with Permanent Atrial Fibrillation. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  19. Takahashi A., Yokoyama Y., Kuwahara T., Kobori A., Yamauchi Y., Handa K., Suzuki H., Tanaka Y., Itoh Y., Nozato T., Sato A., Nogami A., Aonuma K., Iesaka Y, Isobe M.F Mechanism of Atrial Fibrillation Resistant to Electrical Cardioversion: Evaluation by Extensive Ipsilateral Pulmonary Vein Ablation in Patients with Atrial Fibrillation. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  20. Takahashi A., okoyama Y., Kuwahara T., Kobori A., Yamauchi Y., Handa K., Suzuki H., Tanaka Y., Itoh Y., Nozato T., Sato A., Nogami A., Aonuma K., Iesaka Y., Isobe M.F Efficacy of Continuous Isoproterenol Infusion during Extensive Ablation Encircling Ipsilateral Pulmonary Veins in Patients with Paroxysmal Atrial Fibrillation. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  21. Aonuma K., Yokoyama Y., Seo Y., Ohtuka S., Kawano S., Sato A., Murakoshi N., Yoshida I., Hoshi T., Kuga K., Takahashi A., Yamaguchi I.F Tri-ventricular Pacing : A Novel Concept of Resynchronization Therapy for Left Ventricular Performance in End-stage Heart Failue. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  22. Ohtsuka S., Ishikawa K., Shibata H., Masuda N., Kamohara M., Takesaki J., Hisano S., Yamaguchi I.F Increased Expression of Cysteinyl Leukotriene Receptor, CysLT-R2 in Injured Coronary Artery of Pigs. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  23. Murakoshi N., Aonuma K., Tanaka Y., Yokoyama Y., Suzuki A., Yamauchi Y., Yoshida K., Endo M., Kuga K., Takahashi A., Yamaguchi I.F Characteristics of Induced Ventricular Tachyarrhythmias before Degeneratig into Ventricular Fibrillation in Brugada Syndrome. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  24. Kuwahara T., Takahashi A., Yokoyama Y., Kobori A., Yamauchi Y., Handa K., Suzuki H., Tanaka Y., Itoh Y., Nozato T., Sato A., Nogami A., Aonuma K., Iesaka Y., Isobe M.F Evaluation of Rapid and Irregular Atrial Tachycardia (Pseudo-Atrial Flutter) Occurring After Pulmonary Vein Isolation in Patients with Atrial Fibrillation. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  25. Uno K., Honma S., Nakanishi K., Abe D., Hamada H., Yamaguchi I.F Coagulofibrynolytic Factors Activation is well Correlated with Moya-Moya Echo Severity of Limb Vein in Preganant Women. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  26. Tanaka Y., Yokoyama Y., Suzuki H., Handa K., Itoh Y., Kobori A., Nozato T., Kuwahara T., Sato A., Takahashi A., Yamauchi Y., Aonuma K., Isobe M.F The Efficacy and the Safety of Epicardial Cryothermal Ablation Using Subxyphoidal Centesis Approach; Comparison of Cryothermal Versus Radiofrequency Ablation. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  27. Kumagai K., Otomo J., Wakayama Y., Watanabe J., Shirato Y., Takahashi A., Yokoyama Y., Yamauchi Y., Aonuma K., Yamaguchi I.F Tow Ttypes of Origin refractory to Ablate from Endocardium of Idiopathic Left Vwntricular Tachyarrythmia from the Mitral Annulus. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  28. Kobori A., Takahashi A., Yokoyama Y., Kuwahara T., Yamauchi Y., Handa K., Suzuki H., Tanaka Y., Itoh Y., Nozato T., Sato A., Nogami A., Aonuma K., Iesaka Y., Isobe M.F Anatomical Location of the Course of the Phrenic Nerve-Implications for Ablation of the Superior Vena Cava and Pulmonary Veins. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  29. Tanaka Y., Yokoyama Y., Suzuki H., Handa K., Itoh Y., Kobori A., Nozato T., Kuwahara T., Sato A., Takahashi A., Aonuma K., Yamaguchi I., Isobe M.F Clinical Implication of Ventricular Tachycadia Induction Test after Positive Pilsicainide Provocation Test in Patients with Brugada Syndrome. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  30. Iemitsu M., Maeda S., Miyauchi T., Matsuda M., Yamaguchi I.F Gene Expression Profiling of Exercise Training-induced Physioligical Cardiac Hypertrophy in the Rats. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  31. Seo Y., Aonuma K., Ohtsuka S., Kawano S., Ishizu T., Kuga K., Ishmitsu T., Yokoyama Y., Sato A., Takahashi A., Watanabe S., Yamaguchi I.F Implication of Analysis of Strain Distribution on Left Ventricular Performance in Cardiac Resynchronzation Therapy. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  32. Nozato T., Sato A., Abe R., Suzuki H., Handa K., Tanaka Y., Itoh Y., Kobori A., Kuwahara T., Yokoyama Y., Isobe M., Aonuma K., Takahashi A.F Transesophageal Echocardiographic Predictors for Relapse of Atrial Fibrillation after Pulmonary Vein Isolation. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  33. Seo Y., Ishimitsu T., Ishizu T., Sakane M., Maeda H., Watanabe S., Yamaguchi I.F Peak C-reactive Protein Level is a Useful Marker for Left Ventricular Thrombus in Patients with First Anterior Acute Myocardial Infarction. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  34. Kuwahara T., Takahashi A., Yokoyama Y., Kobori A., Yamauchi Y., Handa K., Suzuki H., Tanaka Y., Itoh Y., Nozato T., Sato A., Nogami A., Aonuma K., Iesaka Y.,Isobe M.F Novel Method to Search Residual Conduction Gaps Through the Ablation Lines Encircling Ipsilateral Pulmonary Veins in Patients with Atrial Fibrillation. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  35. Yamauchi Y., Takahashi A., Kumagai K., Yokoyama Y., Kurihara K., Sato A., Aonuma K., Niwa J., Nogami A., Iesaka Y., Hirao K., Isobe M., Yamaguchi I.F Anatomical Linear Ablation during Sinus Rhythm for Verapamil-sensitive Idiopathic Left Ventricular Tachycardia. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  36. Takeyasu N., Watanabe S., Aihara H., Saitoh T., Toyama M., Sakane M., Eda K., Ishiyama M., Nishina H., Shintomi Y., Morimoto T., Ajisaka R., Yamanouchi T., Arai E., Takeda T., Yamaguchi I.F Clinical Singnificance of the Lung Uptake of Tc-99m Tetrofosmin in Patients with Coronary Artery Disease. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  37. Aihara H., Takeyasu N., Watanabe S., Saitoh T., Toyama M., Sakamoto K., Eda K., Ishiyama M., Nishina H., Shintomi Y., Morimoto T., Ajisaka R., Yamanouchi T., Arai E., Takeda T., Yamaguchi I.F Changes of Left Ventricular Systolic and Diastolic Functions after ATP Stress Assessed by Stress/rest 99m-Tc MIBI Gated SPECT. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  38. Takeyasu N., Watanabe S., Miyauchi T., Sakai S., Ogata T., Shimojyoh N., Aihara H., Saitoh T., Toyama M., Sakamoto K., Eda K., Ishiyama M., Nishina H., Shintomi Y., Morimoto T., Ajisaka R., Yamanouchi T., Arai E., Yamaguchi I.F In vivo Direct Nitric Oxide(NO) Measurement in the Ret Abdominal Aorta Using Novel Clinically Practicable NO Sensor-tipped Catheter. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  39. Yoshida K., Aonuma K., Yamauchi Y., Yokoyama Y., Suzuki A., Endo M., Kuga K., Takahashi A., Yamaguchi I.F Characteristics of Antegarde Slow Pathway Conduction Befor and After Catheter Ablation in Patients with Fast-slow Uncommon Atrioventricular Nodal Reentrant Tachycardia. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  40. Yoshida K., Aonuma K., Yamauchi Y., Yokoyama Y., Suzuki A., Endoh M., Kuga K., Takahashi A., Yamaguchi I.F Sinus Rhythm High-Density Substrate Mapping Accurately Detects Critical Isthmus of Ventricular Tachycardia Reentry Circit in Patients with Underlying Heart Disease. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  41. Itoh Y., Yokoyama Y., Sato A., Nozato T., Suzuki H., Handa K., Tanaka Y., Kobori A., Kuwahara T., Takahashi A., Hirao K., Isobe M., Aonuma K., Hiroe M.F Iodine-123-MIBG Imaging Findings in Patients with Refractory Heart Failure Treated Using Nocturnal Home Oxygen Therapy. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  42. Kumagai K., Otomo J., Watanabe J., Shirato K., Takahashi A., Yokoyama Y., Yamauchi Y., Aonuma K., Yamaguchi I.F Observation of Electrical Conduction of Right Atrium Related with the Crista Terminalis and Sinus Venosa Region in Patients with AFL. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  43. Watanabe Y., Suzuki A., Tanaka K., Takei Y., Ejiri N., Yamaguchi I., Yukawa A.F Termisaltan Produced Regression of Left Ventricular Hypertrophy with the Improvement of Myocardial Perfusion and Fatty Acid Metabolism. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  44. Ishikawa K., Ohtsuka S., Shibata H., Masuda N., Kamohara M., Takasaki J., Hisano S., Yamaguchi I.F Cardiac Cysteiny Leukotriene Receptors and Their Contribution to Coronary Vasoconstriction in Intact Pig Heart. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  45. Maruyama H., Otsu M., Watanabe S., Yamaguchi I., Onodera M.F VEGF-transduced Rat Fibroblast Cells Using Retrovirus Produces Functioning Amount of VEGF for a Prolonged Prolonged Period and Induces Angiogenesis. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  46. Sato A., Aonuma K., Suzuki H., Handa K., Itoh Y., Tanaka Y., Nozato T., Kobori A., Kuwahara T., Yokoyama Y., Takahashi A., Kanoh H., Isobe M., Misumi K.F Clinical Profiles and Long-term Outcomes of Severely Calcified Coronary Lesions in Hemodialysis Patients Treated by Rotational Athrectomy. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  47. Kumagai K., Otomo J., Watanabe J., Shirato K., Takahashi A., Yokoyama Y., Yamauchi Y., Aonuma K., Yamaguchi I.F Similarity of Delta-like Wave of Idiopathic Left Ventricular Tachyarrhythmia Arising from Mitral Annulus to Full-preexcited Delta Wave of WPW syndrome. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  48. Sato A., Hiroe M., Imanaka-Yoshida K., Suzuki H., Handa K., Tanaka Y., Itoh Y., Kobori A, Nozato T., Kuwahara T., Yokoyama Y., Takahashi A., Isobe M., Aonuma K.F Prognostic Significance of Serum Tenascin-C Levels in Patients With Acute Myocardial Infarction. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  49. Koshino Y., Kawano S., Takeyasu N., Watanabe S., Morimoto T., Noguchi Y., Uchida K., Sato Y., Takano R., Kurachi S., Kurachi Y., Yamaguchi I.F Proteome Analysis of Plasma from Coronary Artery in Patients with Acute Coronary Syndrome Using SELDI-TOF-MS. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  50. Iemitsu M., Maeda S., Matsuda M., Miyauchi T., Yamaguchi I.F Time-course Change of MAPK Signaling Pathways in the Heart during Exercise and Post-exercise. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  51. Itoh Y., Takahashi A., Yokoyama Y., Kuwahara T., Kobori A., Yamauchi Y., Suzuki H., Handa K., Tanaka Y., Nozato T., Satoh A., Nogami A., Aonuma K., Iesaka Y., Isobe M.F Clinical Usefulness of I-123 MIBG Imaging to Predict the Genesis of Fatal Arrhythmias in Patients with an Implantable Cardioverter Defibrillator. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  52. Sekiguchi Y, Yamauchi Y, Sasaki T, Kusa S, Onishi K, Higuchi K, Miyamoto T, Obayashi T, Niwa A, Nitta J, Takahashi A, Aonuma K., Isobe M.F Importance of Power Settings for Applications of Radiofrequency Energy undergoing Extensive Circumferential Pulmonary Vein Ablation in Patients with Atrial Fibrillation. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  53. Kuga K., Watanabe S., Aonuma K., Yamaguchi I., Doki K., Homma M., Katori K., Kohda Y.F Metabolization of Flecainide is Affected by Gender. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  54. Maeda S., Iemitsu M., Miyauchi T., Yamaguchi I., Matsuda M.F Aortic Stiffness and Habitual Exercise:Molecular Mechanistic Insight. ‘æ69‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi‰¡•ljC3ŒŽC2005
  55. ƒWƒFƒXƒ~ƒ“ ƒTƒuƒŠƒiC•ž•” —TˆêC‹{“à ‘ìF Ž“«ƒ}ƒEƒX‚É‚¨‚¯‚éS‘Ÿ‚ÌŠ¥ŒŒŠÇŒ`¬‹@\‚ÉŠÖ—^‚·‚éƒGƒXƒgƒƒQƒ“Žó—e‘̃Tƒuƒ^ƒCƒv‚̃mƒbƒNƒAƒEƒgƒ}ƒEƒX‚ð—p‚¢‚½“¯’èD ‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ï (‰¡•l)C3ŒŽC2005
  56. ŒKŒ´ ‘åŽuC‚‹´ ~C¬–x “ÖŽuC‰¡ŽR ‘לAC”Ñ“c Œ[‘¾C—é–Ø GrC“c’† ‘׏́CˆÉ“¡ —S•ãC–ì—¢ ŽõŽjC²“¡ –¾C¥‰i ³‹`CÂÀ ˜a—²Cˆé•” ŒõÍF “d‹C“I”xÃ–¬Šu—£Ap‚É‚æ‚éH“¹áŠQ—\–h‚Ì‚½‚߂̐H“¹‰·‘ª’è‚Ì—L—p«‚ÌŒŸ“¢D ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  57. ŒF’J _ŽiC‘å—F ~CŽáŽR —SŽiC“n•Ó ~CŽR“à NÆC‚‹´ ~C‰¡ŽR ‘לACÂÀ ˜a—²F S“à–Œ‚©‚ç‚̏Ď܍¢“ï‚È‘m–X•Ù—Ö•”—R—ˆ“Á”­«SŽº•p”‚Ì‹NŒ¹‚ÌŒŸ“¢D ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  58. ŠÖŒû K•vCŽR“à NÆC²X–Ø‹BC”óŒû WŽiC‹v² –ÎŽ÷C‘吼Œ’‘¾˜YC‹{–{ ‹M—fC”ö—Ñ “OC’O‰H –¾”ŽCV“c ‡ˆêCÂÀ ˜a—²Cˆé•” ŒõÍF ”­ì«S–[×“®‚ɑ΂µÓ”C‘¤”x“®–¬‚Ì‚ÝŠu—£‚ðŽ{s‚µ‚½Ç—á‚̗Տ°¬ÑD ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  59. ¬–x “ÖŽuC‚‹´ ~C‰¡ŽR ‘לACŒKŒ´ ‘åŽuC”Ñ“c Œ[‘¾C—é–Ø GrC“c’† ‘׏́CˆÉ“¡ —S•ãC–ì—¢ ŽõŽjC²“¡ –¾Cˆé•” ŒõÍCÂÀ ˜a—²F ã‘åÃ–¬‚É‚¨‚¯‚é“d‹CŠˆ“®«S–[‹Ø‘gD‚Ì“Á’¥-3D electro-anatomical mapping‚ð—p‚¢‚½S–[×“®‚Ì—L–³‚É‚æ‚鍷ˆÙŒŸ“¢-D ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  60. ‹g“cŒ’‘¾˜YCÂÀ ˜a—²C£”ö —RLC‰Í–ì —¹C‘å’Ë ’è“¿C‹v‰ê Œ\—SCŽRŒû ›ÜC‰¡ŽR ‘לAC‚‹´ ~F dÇS•s‘SŠ³ŽÒ‚É‚¨‚¯‚éSŽº3“_“¯Žžƒy[ƒVƒ“ƒO‚É‚æ‚éS‹@”\‰ü‘P‚̗Տ°“IŒ¤‹†D ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  61. ÂÀ ˜a—²C‹g“cŒ’‘¾˜YC‹v‰ê Œ\—SCŽRŒû ›ÜCŽR“à NÆC‚‹´ ~F Šî‘bSŽ¾Š³‚ð—L‚·‚郊ƒGƒ“ƒgƒŠ[«SŽº•p”‚ɑ΂·‚é“´’²—¥Žž‚–§“xƒ}ƒbƒsƒ“ƒO ˆÙí“dˆÊ”÷×ƒ}ƒbƒsƒ“ƒO‚ÉŠî‚­ÄŽÜƒ‰ƒCƒ“Œˆ’è‚É‚æ‚é•p”‚̍ªŽ¡D ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  62. ŽR“à NÆCŠÖŒû K•vC²X–Ø ‹BC”óŒû WŽiC‹v² –ÎŽ÷C‘吼Œ’‘¾˜YC‹{–{ ‹M—fC”ö—Ñ “OC’O‰H –¾”ŽC‰¡ŽR ‘לAC‚‹´ ~CV“c ‡ˆêC–ìã º•FC‰Æâ ‹`lC•½”ö Œ©ŽOCˆé•” ŒõÍCŽRŒû ›ÜCÂÀ ˜a—²F ‘½Œ¹«‚Ì“Á”­«SŽº«ŠúŠOŽûk‚ɑ΂·‚éƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ÁD ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  63. ŽR“à NÆCŠÖŒû K•vC²X–Ø ‹BC”óŒû WŽiC‹v² –ÎŽ÷C‘吼Œ’‘¾˜YC‹{–{ ‹M—fC”ö—Ñ “OC’O‰H –¾”ŽC‰¡ŽR ‘לAC‚‹´ ~CV“c ‡ˆêC–ìã º•FC‰Æâ ‹`lC•½”ö Œ©ŽOCˆé•” ŒõÍCŽRŒû ›ÜCÂÀ ˜a—²F ”xÃ–¬Šu—£p‚É‚¨‚¯‚éS–[×“®‚̃gƒŠƒK[‚Ì—U”­«‚Æ‘½‹É“d‹Éƒ}ƒbƒsƒ“ƒO‚É‚æ‚é‹NŒ¹‚Ì“¯’è‚̈Ӌ`D ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  64. ŽR“à NÆCŠÖŒû K•vC²X–Ø ‹BC”óŒû WŽiC‹v² –ÎŽ÷C‘吼Œ’‘¾˜YC‹{–{ ‹M—fC”ö—Ñ “OC’O‰H –¾”ŽC‰¡ŽR ‘לAC‚‹´ ~CV“c ‡ˆêC–ìã º•FC‰Æâ ‹`lC•½”ö Œ©ŽOCˆé•” ŒõÍCŽRŒû ›ÜCÂÀ ˜a—²F Extensive ipsilateral pulmonary vein isolation ‚Æ segmental ostial pulmonary vein isolation ‚ÌŽ¡—ЬÑ‚Ì”äŠrŒŸ“¢D ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  65. óì “N–çC–]ŒŽ ~C¼‘º ‘‰ÀCŽR“à NÆC‚‹´ ~CÂÀ ˜a—²CŽRŒû ›ÜF ƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚ɐ¬Œ÷‚µ‚½ƒqƒX‘©‹ß–T‰EŽº—¬“ü˜H‹NŒ¹“Á”­«SŽº•p”‚Ì1—áD ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  66. ‹g“cŒ’‘¾˜YCÂÀ ˜a—²C‘º‰z LsC”üè ¹ŽqC‘ŠŒ´ ‰p–¾C£”ö —RLC‹v‰ê Œ\—SCŽRŒû ›ÜCV“c ‡ˆêF VDDƒy[ƒXƒ[ƒJAž‚ÝŒã‚̉ES•s‘S VDD—pƒVƒ“ƒOƒ‹ƒŠ[ƒh‚É‚æ‚éŽOë•Ùˆ³”r‚ªAŒ°’˜‚ÈŽOë•Ù•Â½•s‘S‚ðŽä‹N‚µ‚½Š®‘S–[ŽºƒuƒƒbƒN‚Ì1—áD ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  67. ‘º‰z LsCÂÀ ˜a—²C‹g“cŒ’‘¾˜YC‹v‰ê Œ\—SCŽRŒû ›ÜCç“c GŽiC’JŒû ‘ׁCƒs[ƒ^[ƒ`ƒFƒ“F ’´‰¹”gƒoƒ‹[ƒ“ƒJƒe[ƒeƒ‹‚É‚æ‚éÃ–¬ŠJŒû•”‚ɑ΂·‚é“d‹C“IŠu—£‚ÉŠÖ‚·‚éŽÀŒ±“IŒŸ“¢D ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  68. ‘ŠŒ´ ‰p–¾CÂÀ ˜a—²C‹g“cŒ’‘¾˜YC”üè ¹ŽqC‰Í–ì —¹CŽRŒû ›ÜF ‹Ø‹Ù’£«ƒWƒXƒgƒƒtƒB[‚ɍ‡•¹‚µ‚½¶Žº‹@”\•s‘S‚ɑ΂·‚éSŽºÄ“¯Šú—Ö@‚ÌŒø‰ÊD ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  69. ”üè ¹ŽqCÂÀ ˜a—²C‹g“cŒ’‘¾˜YC‰Í–ì —¹C‹v‰ê Œ\—SC‘ŠŒ´ ‰p–¾CŽRŒû ›ÜC•ˆä GMC“¿‰i ‹BF ¶Žºãk–§‰»áŠQ‚É‚æ‚é––Šú¶S•s‘S‚ɑ΂·‚éSŽº3“_“¯Žžƒy[ƒVƒ“ƒO‚ÌŒø‰ÊD ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  70. “n•Ó dsC‹v‰ê Œ\—SCÂÀ ˜a—²CŽRŒû ›ÜF •s®–¬Š³ŽÒ‚ÌŽ©“®ŽÔ‰^“]‚Ì–@§ã‚ÌŒ»‹µD ‘æ20‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwp‘å‰ïi•ó’ˁjC5ŒŽC2005
  71. £”ö —RLCÎŒõ •qsCÎ’à ’qŽqCXŽR ’¼ŽqC‘O“c —TŽjC“n•Ó dsCŽRŒû ›ÜF ‹}«Š¥ÇŒóŒQ‚É‚¨‚¯‚éŒz“®–¬’´‰¹”g‘œ‚Ì“Á’¥D “ú–{’´‰¹”gˆãŠw‰ïi“Œ‹žjC5ŒŽC2005
  72. ¬‘î N”VC‘å’Ë ’è“¿CŽRŒû ›ÜF ‚ŒŒˆ³Š³ŽÒ‚̐S‘ŸMRIŠŒ©D ‘æ30‰ñˆïéŒ§‚ŒŒˆ³Œ¤‹†‰ïi‚‚­‚΁jC5ŒŽC2005
  73. ‘å’Î ‹BC‘O“c ´ŽiC‰ÆŒõ ‘fsCÄ“¡ —zŽqC’J‘º —SŽqCéˍ⠗²ˆêC‹{“à ‘ìF Žá”NŽÒ‚É‚¨‚¯‚é‰^“®ƒgƒŒ[ƒjƒ“ƒO—lŽ®‚̈Ⴂ‚ª“®–¬L“W«‚É‹y‚Ú‚·‰e‹¿D ‘æ5‰ñ—Տ°“®–¬”gŒ¤‹†‰ïi“Œ‹žjC5ŒŽC2005
  74. ‘ŠŒ´ ‰p–¾C•ˆÀ –@”VC“n•Ó dsC‹g“cŒ’‘¾˜YCÂÀ ˜a—²CŽRŒû ›ÜF Sƒv[ƒ‹ƒVƒ“ƒ`ƒOƒ‰ƒtƒB‚É‚æ‚éS‘ŸÄ“¯Šú—Ö@‚Ì•]‰¿D ‘æ27‰ñS‘ŸŠjˆãŠw’k˜b‰ïi“Œ‹žjC 6ŒŽC2005
  75. ‹g“cŒ’‘¾˜YCÂÀ ˜a—²CŽRè _C–Ø‘º ‘׎OC¯ ’q–çC‘ŠŒ´ ‰p–¾C—é–Ø ÍOC‰““¡ —DŽ}C‹v‰ê Œ\—SCŽRŒû ›ÜC‘O“c —TŽjF “Á”­«¶–[ƒ}ƒNƒƒŠƒGƒ“ƒgƒŠ[S–[•p”‚Ì1—áD ‘æ13‰ñŠÖ“ŒƒAƒuƒŒ[ƒVƒ‡ƒ“EƒZƒ~ƒi[ 2005i‚‚­‚΁jC6ŒŽC2005
  76. –Ø‘º ‘׎OC¯ ’q–çC‘ŠŒ´ ‰p–¾C‹g“cŒ’‘¾˜YC”üè ¹ŽqC£”ö —RLC•ˆÀ –@”VC‘å’Ë ’è“¿C“n•Ó dsCŽRŒû ›ÜF ‰EŠ¥“®–¬‚É“ÁˆÙ‚È‹·óŒ`‘Ô‚ð”F‚ß‚½PCI‚Ì1—áD ‘æ19‰ñˆïéŒ§PCIŒ¤‹†‰ïi“y‰YjC6ŒŽC2005
  77. ‹g“cŒ’‘¾˜YCÂÀ ˜a—²C‹v‰ê Œ\—SC‰““¡ —DŽ}Cm•Û •¶•½C—é–Ø ÍOC‹à–{ “sCŽRŒû ›ÜCŠÖŒû K•vCŽR“à NÆF Ú×‚ÈEntrainment Mapping‚É‚æ‚è•p”‰ñ˜H‚Ì“¯’肪‰Â”\‚Å‚ ‚Á‚½Lower Loop Reentry‚Ì1—áD ‘æ35‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi‹ž“sjC6ŒŽC2005
  78. ŽR“à NÆCŠÖŒû K•vC²X–Ø ‹BC”óŒû WŽiC‘吼Œ’‘¾˜YC‹v² –ÎŽ÷C‹{–{ ‹M—fC”ö—Ñ “OC’O‰H –¾”ŽCÂÀ ˜a—²F Ú×‚ÈEntrainment Mapping‚É‚æ‚è•p”‰ñ˜H‚Ì“¯’肪‰Â”\‚Å‚ ‚Á‚½Lower Loop Reentry‚Ì1—áD ‘æ35‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi‹ž“sjC6ŒŽC2005
  79. ŒF’J _ŽiC‘å—F ~CŽáŽR —TŽiC”nê Œb•vC•Ÿ“c _“ñC›ˆä ‹`®CŽÂè ‹BC“n•Ó ~C”’“y –M’jCÂÀ ˜a—²CŽRŒû ›ÜF QRS”gŒ`‚ª—ÞŽ—‚µ‚éAorto-mitral Continuity‚Æ‘å“®–¬•ÙŠ¥ë•”‹NŒ¹‚Ì“Á”­«¶Žº—¬o˜HŒ¹«ŠëŠQŽûk‚Ì2—áD ‘æ35‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi‹ž“sjC6ŒŽC2005
  80. ‰F–ìŠó¢ŽqC–{ŠÔ ŠoCˆÀ”{ ‘å•ãC’†¼ Œ[‘¾Cà_“c —mŽÀCŽRŒû ›ÜF ”DPŒo‰ß‚É”º‚¤ŒŒŠÇ’´‰¹”gŠŒ©‚ÆŒŒ‰t‹ÃŒÅˆöŽq‚̐„ˆÚD ‘æ25‰ñ“ú–{Ã–¬Šw‰ï‘‰ïi–¼ŒÃ‰®jC7ŒŽC2005
  81. ‹g“cŒ’‘¾˜YCÂÀ ˜a—²C‚‹´ ~C‰¡ŽR ‘לAC‹v‰ê Œ\—SCŽRŒû ›ÜF ’‹Œ«S‹Ø[Ç‚ɍ‡•¹‚µ‚½SŽº•p”‚ɑ΂·‚é“´’²—¥Žž‚–§“xƒ}ƒbƒsƒ“ƒO‚Ì—L—p«D ‘æ10‰ñ_“ސì—Տ°•s®–¬ƒtƒH[ƒ‰ƒ€i‰¡•ljC7ŒŽC2005
  82. “n•Ó dsC‰· ŒiC‘ŠŒ´ ‰p–¾C•ˆÀ –@”VCŽR“c‚³‚‚«C—é–Ø ‘å‰îC¬Œ` –MbC_’¹ –¾•FC‹{‰º ‹C’Ë“c Œ[“ñCŽRŒû ›ÜF SŽ¥}‚É‚æ‚éS‹Ø‹•ŒŒ‚Ì•]‰¿D ‘æ20‰ñ“ú–{¶‘ÌŽ¥‹CŠw‰ï‘å‰ïi‘åãjC7ŒŽC2005
  83. ‘O“c ´ŽiCƒWƒFƒXƒ~ƒ“ ƒTƒuƒŠƒiC‰ÆŒõ ‘fsC‘å’Î ‹BC’†“c —R•vC“c’†Šì‘㎟C‹{“à ‘ìF ”ì–žŽÒ‚ÌŒŒŠÇ‹@”\áŠQ‚ÌŒ¸—Ê‚É‚æ‚é‰ü‘PƒƒJƒjƒYƒ€‚̉𖾁FƒGƒ“ƒhƒZƒŠƒ“‚Æ nitric oxide‚ÌŒŒ’†”Z“x‚ÌŒŸ“¢D ‘æ13‰ñ“ú–{‰^“®¶—Šw‰ï‘å‰ïi“Œ‹žjC7ŒŽC2005
  84. ‰ÆŒõ ‘fsC‘O“c ´ŽiC‹{“à ‘ìF ˜V—îŠú‚Ì–«‰^“®‚É‚æ‚éS‘Ÿ‚Ì—LŽ_‘fƒGƒlƒ‹ƒM[‘ãŽÓ”\‰ü‘P‚ÉPGC-1ƒ¿‚ð‰î‚µ‚½•ªŽq’²ß‚ªŠÖ—^‚·‚éD ‘æ13‰ñ“ú–{‰^“®¶—Šw‰ï‘å‰ïi“Œ‹žjC7ŒŽC2005
  85. ‘å’Î ‹BC‘O“c ´ŽiC‰ÆŒõ ‘fsCâV“¡ —zŽqC’J‘º —SŽqCéˍ⠗²ˆêC‹{“à ‘ìF ’ïR«‰^“®’b˜BŽÒ‚͈ê‰ß«‰^“®Œã‚̐S‘Ÿ•›ŒðŠ´_ŒoŒnŠˆ“®‚̉ñ•œ‰ž“š‚ª‘‚­‚È‚éD ‘æ13‰ñ“ú–{‰^“®¶—Šw‰ï‘å‰ïi“Œ‹žjC7ŒŽ30“úC2005
  86. ƒWƒFƒXƒ~ƒ“ ƒTƒuƒŠƒiC‰ºžŠ MˆÐC‹{“à ‘ìF ‚ŒŒˆ³S‚Æ“œ”A•aS‚ɑ΂·‚éƒGƒ“ƒhƒZƒŠƒ“ŽÕ’f–ò‚ÌŒø‰ÊFƒŒƒjƒ“EƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn‚Ƃ̃NƒƒXƒg[ƒND Cardiovascular Medicine 21 / ‘æ5‰ñƒtƒH[ƒ‰ƒ€i“Œ‹žjC7ŒŽC2005
  87. X–{ —²ŽjC“n•Ó dsCéˍ⠗²ˆêC•ˆÀ –@”VC‘ŠŒ´ ‰p–¾C–Ø‘º ‘׎OCm‰È G’CVˆä Œb”üCÎŽR ŽÀŽ÷C]“c ˆê•FCâ–{ ˜a•FCŠOŽR ¹OCÄ“¡ ICŽRŒû ›ÜCˆî—t •F ƒJƒ‹ƒVƒEƒ€hR–òbenidipine‚ÌŒŒŠÇ‹@”\‹y‚щ^“®‘Ï—e”\‚ɑ΂·‚éŒø‰ÊD ‘æ55‰ñzŠÂŠí•‰‰×Œ¤‹†‰ïi“Œ‹žjC8ŒŽC2005
  88. £”ö —RLC“n•Ó dsC•ˆÀ –@”VCÂÀ ˜a—²CŽRŒû ›ÜF ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚𔺂Á‚½Š¥“®–¬Ž¾Š³Ç—á‚É‚¨‚¯‚éèò“®–¬ƒGƒR[‚Ì“Á’¥D ‘æ46‰ñ˜ZbƒJƒ‹ƒfƒBƒAƒbƒNƒZƒ~ƒi[i‘åãjC8ŒŽC2005
  89. ƒWƒFƒXƒ~ƒ“ ƒTƒuƒŠƒiC‹{“à ‘ìC‰ºžŠ MˆÐCŒã“¡ Ÿ”NCŽRŒû ›ÜF ‚ŒŒˆ³S‚Æ“œ”A•aS‚̐S‘ŸƒŠƒ‚ƒfƒŠƒ“ƒO‚ɑ΂·‚éƒGƒ“ƒhƒZƒŠƒ“ŽÕ’f–ò‚ÌŒø‰ÊFƒŒƒjƒ“EƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn‚Ƃ̃NƒƒXƒg[ƒND ‘æ8‰ñÅæ’[zŠÂŠíƒtƒH[ƒ‰ƒ€ i“Œ‹žjC8ŒŽC2005
  90. £”ö —RLC‰Í–ì —¹C”üè ¹ŽqC¯ ’q–çC¼ Œ÷C‹v‰ê Œ\—SCÂÀ ˜a—²C“n•Ó dsCŽRŒû ›ÜF S•s‘S–ò•¨—Ö@D ‘æ10‰ñƒAƒ~ƒIƒ_ƒƒ“u‰‰‰ïƒVƒ“ƒ|ƒWƒEƒ€i“Œ‹žjC9ŒŽC2005
  91. ÂÀ ˜a—²C‰Í–ì —¹C£”ö —RLC‹g“cŒ’‘¾˜YC“cã ˜aKC‰““¡ —DŽ}C‹v‰ê Œ\—SC“n•Ó dsCŽRŒû ›ÜC‰¡ŽR NœAC‚‹´ ~C²“¡ –¾F CRT—Ö@D ‘æ10‰ñƒAƒ~ƒIƒ_ƒƒ“u‰‰‰ïƒVƒ“ƒ|ƒWƒEƒ€i“Œ‹žjC9ŒŽC2005
  92. £”ö —RLCÂÀ ˜a—²C‹g“cŒ’‘¾˜YC‰Í–ì —¹C“n•Ó dsCŽRŒû ›ÜC‰¡ŽR NœAC²“¡ –¾C‚‹´ ~F 3“_ƒy[ƒVƒ“ƒOÄ“¯Šú—Ö@‚̍¶ŽºŠg’£‹@”\‰ü‘PŒø‰ÊD ‘æ53‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi‘åãjC9ŒŽC2005
  93. ¯ ’q–çC‰Í–ì —¹C¼ Œ÷C‘Œ© ’qŽqC”üè ¹ŽqC•“c “OC“n•Ó dsCŽRŒû ›ÜF –«S•s‘SŠ³ŽÒ‚É‚¨‚¯‚éŒðŠ´_Œo‹@”\Šˆ«‚ÆQTc Dispersion‚ɑ΂·‚éƒJƒ‹ƒxƒWƒ[ƒ‹‚ÌŒø‰ÊD ‘æ53‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi‘åãjC9ŒŽC2005
  94. ‘ŠàV ŸŽ¡C‘O“c ´ŽiC‰ÆŒõ ‘fsC‘å’Î ‹BCƒWƒFƒXƒ~ƒ“ ƒTƒuƒŠƒiC—Ñ vˆê˜YC‹{“à ‘ìC–Úè “oF œŠi‹Ø‚ɐ«ƒXƒeƒƒCƒhƒzƒ‹ƒ‚ƒ“‡¬Œo˜H‚̍y‘f‚ª”­Œ»‚·‚éD ‘æ60‰ñ“ú–{‘̗͈ãŠw‰ï i‰ªŽRjC9ŒŽC20055
  95. ‰ÆŒõ ‘fsC‘O“c ´ŽiC‹{“à ‘ìF ‰^“®‚É‚æ‚éS‘Ÿ‚̈â“`Žq”­Œ»‚Æ“]ŽÊ’²ßD ‘æ60‰ñ“ú–{‘̗͈ãŠw‰ï i‰ªŽRjC9ŒŽC2005
  96. ‘å’Î ‹BC‘O“c ´ŽiC‰ÆŒõ ‘fsCÄ“¡ —zŽqC’J‘º —SŽqCéˍ⠗²ˆêC‹{“à ‘ìF —LŽ_‘f«‰^“®‹£‹ZŽÒ‚¨‚æ‚Ñ’ïR«‰^“®‹£‹ZŽÒ‚É‚¨‚¯‚錌Ÿ÷ƒGƒ“ƒhƒZƒŠƒ“[1”Z“x‚Æ“®–¬L“W«D ‘æ60‰ñ“ú–{‘̗͈ãŠw‰ï i‰ªŽRjC9ŒŽC2005
  97. —Ñ vˆê˜YC‘O“c ´ŽiC‰ÆŒõ ‘fsC‘å’Î ‹BC›Œ´ ‡C“c•Ó  C‹{“à ‘ìC‹v–ì •ˆ–çCéˍ⠗²ˆêC‰¡ˆä FŽuC–Úè “oC¼“c Œõ¶F ƒGƒXƒgƒƒQƒ“Žó—e‘̃¿ˆâ“`Žq‘½Œ^‚Í’†‚—îŽÒ‚Ì“®–¬stiffness‚ɉe‹¿‚·‚é : SATƒvƒƒWƒFƒNƒg179D ‘æ60‰ñ“ú–{‘̗͈ãŠw‰ï i‰ªŽRjC9ŒŽC2005
  98. ‰ÆŒõ ‘fsC‘O“c ´ŽiCƒWƒFƒXƒ~ƒ“ ƒTƒuƒŠƒiC‹{“à ‘ìF ˜V—îŠú‚©‚ç‚̉^“®ƒgƒŒ[ƒjƒ“ƒO‚É‚æ‚éS‘Ÿ‚̖э׌ŒŠÇ”’ቺ‚̉ü‘P‚ÉVascular Endothelial Growth Factor (VEGF)‚É‚æ‚镪ŽqƒŒƒxƒ‹‚̉ü‘P‚ªŠÖ—^‚·‚éD ‘æ60‰ñ“ú–{‘̗͈ãŠw‰ï i‰ªŽRjC9ŒŽC2005
  99. ‘å‹v•ÛŠ°”VC’†“c —R•vC‰ÆŒõ ‘fsC‹{“à ‘ìC‘O“c ´ŽiC“c’†Šì‘㎟F ‰^“®‚ƍœŠÖ˜Aˆâ“`Žq‚ªœ‹­“x‚É‹y‚Ú‚·‰e‹¿D ‘æ60‰ñ“ú–{‘̗͈ãŠw‰ï i‰ªŽRjC9ŒŽC2005
  100. ‹à–{ “sCŽRè _C‰–’Ë “ñCX–{ —²ŽjC•¶‘  —DŽqCÎì ŒölC–ìŒû —SˆêC’r“c W•FC²X–؏º’¨CŽ²‰® ’qºC“n•Ó dsCŽRŒû ›ÜF p‘O‚ɃXƒeƒƒCƒhŽ¡—Âðs‚¢—ǍD‚ÈŒo‰ß‚𓾂½Š¥“®–¬‹·ó‚Æ‘å“®–¬•Ù•Â½•s‘S‚𔺂¤‘å“®–¬‰ŠÇŒóŒQ‚Ì1—áD ‘æ197‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj C10ŒŽC2005
  101. “n•Ó NŽuC“’ì –¾˜aCì‘º —´C—é–Ø ÍOC“c’†Šì”ü•vC“n•Ó dsCŽRŒû ›ÜC“‡“c ŒbŽOF ‹~‹}‘àˆõ‚É‚æ‚éAED‚ɂĈꎟ‹~–½‚µ‚¦‚½6—á‚ɂ‚¢‚Ä‚ÌŒŸ“¢D ‘æ197‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC10ŒŽC2005
  102. •ˆä MGC•ˆÀ –@”VC¯ ’q–çC‘ŠŒ´ ‰p–¾C–Ø‘º ‘׎OC‹g“cŒ’‘¾˜YC“n•Ó dsCŽRŒû ›ÜF ãˆô“ªŽîᇂÌ1Çó‚Æ‚µ‚Ä•p‰ñ‚ÌNeurally mediated syncope‚ð”F‚ß‚½Ç—áD ‘æ197‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC10ŒŽC2005
  103. “cã ˜aKCÂÀ ˜a—²C‹g“cŒ’‘¾˜YC‘ŠŒ´ ‰p–¾C¯ ’q–çC‰Í–ì —¹C“n•Ó dsCŽRŒû ›ÜF •s®–¬Œ¹«‰EŽºS‹ØÇiARVCj‚̐f’fEŽ¡—Âɂ¨‚¯‚éCARTO system‚Ì—L—p«D ‘æ197‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC10ŒŽC2005
  104. “n•Ó NŽuC“’ì –¾˜aC—é–Ø ÍOC“c’†Šì”ü•vC“n•Ó dsCŽRŒû ›ÜF SŽ¥}‚É‚æ‚è‘ÙŽ™‚ÌQT‰„’·‚ªf’f‚³‚ꂽöÝ«QT‰„’·ÇŒóŒQ‚Ì1—áD ‘æ197‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC10ŒŽC2005
  105. Miyauchi T.F Futur Directions of Treatment of Diastolic Heart Failure. ‘æ9‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‰ºŠÖjC10ŒŽC2005
  106. Seo Y., Aonuma K., Yoshida K., Kawano S., Watanabe S., Yamaguchi I.F Improvements of Diastolic Dysfunction by the Triple Site Cardiac Resynchronization Therapy: a Comparative Study with Dual Site Resynchronization Therapy. ‘æ9‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‰ºŠÖjC10ŒŽC2005
  107. Aihara H., Takeyasu N., Watanabe S., Kimura T., Yoshida K., Aonuma K., Kuga K., Yamaguchi I., Takeda T.,F Radionuclide Ventriculographic Evaluation of the Effect Cardiac Resynchronization Therary. ‘æ9‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‰ºŠÖjC10ŒŽC2005
  108. ”üè ¹ŽqC‰Í–ì —¹C‹g“c ˆè—YC‹g“cŒ’‘¾˜YC¯ ’q–çC£”ö —RLCÂÀ ˜a—²C“n•Ó dsCŽRŒû ›ÜF ”’ŒŒ•a‚ɑ΂·‚鉻Šw—Ö@Œã‚Ì—¼S•s‘S‚ɐS‘ŸÄ“¯Šú—Ö@‚ª—LŒø‚Å‚ ‚Á‚½1—áD ‘æ9‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‰ºŠÖjC10ŒŽC2005
  109. ‰F–ìŠó¢ŽqC–{ŠÔ ŠoCˆÀ”{ ‘å•ãC’†¼ Œ[‘¾CŽRŒû ›ÜC²“¡ –L”üC‰« –¾“TC²“¡‰Á“ÞŽqCŠp“c ”£C‹gì —T”VF •wl‰ÈŽèp‚É‚¨‚¯‚éŽüpŠú‚̐Ö¬ŒŒðÇðÇD ˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï‘æ8‰ñ”­•\‰ï i‚‚­‚΁jC10ŒŽC2005
  110. ²“¡ ˆò”VCŽÄ“c –õCŠÛ“‡ ˆ¤Ž÷C¼‘º –¾Cd“c Ž¡C–{ŠÔ ŠoC‚‹´ L“ñF Ò‘ŠïŒ`Žíp’¼Œã‚É”x[Ç‚ð‡•¹‚µAWŠw“IŽ¡—Âɂæ‚è‰ñ•œ‚µ‚½ˆê—áD ˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï‘æ8‰ñ”­•\‰ï i‚‚­‚΁jC10ŒŽC2005
  111. ŽðŠª •¶ŽqCˆî—t •CÎ’à ’qŽqC£”ö —RLC•½¼ —SŽiF ‘å“®–¬“ñë•Ù‚É•ÙŒ`¬p‚ªŽ{s‚³‚ꂽˆêÇ—áD “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï i‰¡•ljC10ŒŽC2005
  112. ŽÂŒ´ iC£”ö —RLC’–£—R”üŽqC“à“c ´ŽqC–ìŒû –¾ŽqC—Lì —Ç“ñC‘O“c —TŽjF ƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚É‚¨‚¯‚éŒz“®–¬ƒGƒR[‘œ‚Ì“Á’¥F”]ƒhƒbƒNŽóf—á‚É‚¨‚¯‚錟“¢D “ú–{’´‰¹”gˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï i‰¡•ljC10ŒŽ22“úC2005
  113. óì “N–çC–]ŒŽ ~C‘º¼ ‘‰ÀCŽR“à NÆC‚‹´ ~CÂÀ ˜a—²CŽRŒû ›ÜF ƒqƒX‘©‹L˜^•”ˆÊ‚ªŠ¥Ã–¬“´“üŒû•”‚æ‚è‚à’èˆÊ’u‚É‘¶Ý‚µ2Ží—Þ‚ÌLong RP'Œ^•p”‚ª—U”­‚³‚ꂽÇ—á‚ɑ΂µƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½1—áD ‘æ17‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi‚‚­‚΁jC10ŒŽC2005
  114. •–Ø Œ’ŽuCŒË“c ’¼C²“¡ ’‹§CŽOŒË ªmCŽR”ö G“ñC¬¼ é•vC–p‘ò ‰p¬C™ ³•¶C–ûˆä –žCŽsŒ´ —˜ŸC“cã ˜aKC‹g“cŒ’‘¾˜YCÂÀ ˜a—²F ‘å“®–¬•Ù¶Š¥ë‚ōªŽ¡‚ɐ¬Œ÷‚µ‚½¶Žº—¬o˜H‹NŒ¹“Á”­«SŽº•p”‚Ì1—áD ‘æ17‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi‚‚­‚΁jC10ŒŽC2005
  115. ŒF’J _ŽiCŽáŽR —TŽiC•Ÿ“c _“ñC›ˆä ‹`®C‰ºì G–¾CÂÀ ˜a—²F ‘å“®–¬•Ù’uŠ·pŒãCICD•p‰ñì“®‚·‚é–òÜ’ïR«‚̍¶SŽºáŽ‹NŒ¹SŽº•p”‚ɃAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚½1—áD ‘æ17‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi‚‚­‚΁jC10ŒŽC2005
  116. “cã ˜aKCÂÀ ˜a—²C‹g“cŒ’‘¾˜YC‘ŠŒ´ ‰p–¾C¯ ’q–çC‰Í–ì —¹C“n•Ó dsCŽRŒû ›ÜF f’f‚ÉCARTO system ‚ª—L—p‚Å‚ ‚Á‚½•s®–¬Œ¹«‰EŽºS‹ØÇiARVCj‚̈ê—áD ˆïézŠÂŠíŒ¤‹†‰ïi…ŒËjC11ŒŽC2005
  117. ‰ÆŒõ ‘fsC‘O“c ´ŽiC‹{“à ‘ìF ˜V—îŠú‚©‚ç‚̉^“®ƒgƒŒ[ƒjƒ“ƒO‚͉Á—î‚É‚æ‚蘴i‚µ‚½S‘Ÿ‚̃Aƒ|ƒg[ƒVƒXi×–EŽ€j‚ð‰ü‘P‚³‚¹‚éD “ú–{‘̈çŠw‰ï‘æ56‰ñ‘å‰ïi‚‚­‚΁jC11ŒŽC2005
  118. ‘ŠàV ŸŽ¡C‘O“c ´ŽiC‰ÆŒõ ‘fsC‘å’Î ‹BC‹{“à ‘ìC–Úè “oF ‰^“®‚͍œ”Ջ؋ǏŠ‚̐«ƒXƒeƒƒCƒhƒzƒ‹ƒ‚ƒ“‘ãŽÓŠÖ˜Ay‘f‚ðŠˆ«‰»‚³‚¹‚éD “ú–{‘̈çŠw‰ï‘æ56‰ñ‘å‰ïi‚‚­‚΁jC11ŒŽC2005
  119. ‘å’Î ‹BC‘O“c ´ŽiC‰ÆŒõ ‘fsCÄ“¡ —zŽqC’J‘º —SŽqCéˍ⠗²ˆêC‹{“à ‘ìF Â”NŠú‚É‚¨‚¯‚é—LŽ_‘f«‚¨‚æ‚Ñ’ïR«‚̉^“®‹£‹ZŒp‘±”N”‚Æ“®–¬L“W«‚¨‚æ‚э¶SŽº‚ÌŒ`‘Ô“I“K‰žD “ú–{‘̈çŠw‰ï‘æ56‰ñ‘å‰ïi‚‚­‚΁jC11ŒŽC2005
  120. ‰F–ìŠó¢ŽqC–{ŠÔ ŠoCˆÀ”{ ‘å•ãC’†¼ Œ[‘¾CŽRŒû ›ÜC²“¡ –L”üC‰« –¾“TCŠp“c ”£C‹gì —T”VF p‘O‚Ì—‘‘ƒŠàŠ³ŽÒ‚É‚Ý‚ç‚ꂽÃ–¬ŒŒðÇ‚ÌŒŒŠÇ’´‰¹”gŠŒ©D ‘æ46‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ï i‘åãjC12ŒŽC2005
  121. ‰¡ŽR ‘לACÂÀ ˜a—²C‹{è W‰îC¬–x “ÖŽuCŒIŒ´ ‘åŽuC‚‹´ ~CŽRŒû ›ÜF ICDŠ³ŽÒ‚ւ̃Aƒ~ƒIƒ_ƒƒ“Bd,1-ƒ\ƒ^ƒ[ƒ‹“Š—^‚ÉŠÖ‚·‚錟“¢D ‘æ32‰ñR•s®–¬–ò•¹—p—Ö@Œ¤‹†‰ïi“Œ‹žjC12ŒŽC2005

@@@¡ Œ¤‹†•ñ

  1. ¯ ’q–çC‰Í–ì —¹C¼ Œ÷C‘Œ© ’qŽqC”üè ¹ŽqC‹{“à ‘ìC•“c “OC“n•Ó dsCŽRŒû ›ÜF –«S•s‘SŠ³ŽÒ‚É‚¨‚¯‚éŒðŠ·_Œo‹@”\Šˆ«‚ÆQTc dispersion‚ɑ΂·‚éƒJƒ‹ƒxƒWƒ[ƒ‹‚ÌŒø‰ÊD Œú¶˜J“­È‰ÈŠwŒ¤‹†“«Ž¾Š³Ž•žŒ¤‹†Ž–‹Æ“Á”­«S‹ØÇ‚ÉŠÖ‚·‚é’²¸Œ¤‹†”Ç Œú¶˜J“­È‰ÈŠwŒ¤‹†“«Ž¾Š³Ž•žŒ¤‹†Ž–‹Æ“Á”­«S‹ØÇ‚ÉŠÖ‚·‚é’²¸Œ¤‹†”Ç •½¬16”N“x‘æ2‰ñ”ljï‹cƒvƒƒOƒ‰ƒ€E´˜^WF24C2005
  2. ’†àV ½CŽRŒû ›ÜC‰Í–ì —¹C•ˆÀ –@”V ‘¼F zŠÂŠí•a‚̐f’f‚ÆŽ¡—ÂɊւ·‚éƒKƒCƒhƒ‰ƒCƒ“i2003-2004”N“x‡“¯Œ¤‹†”Ç•ñjD SŽ¾Š³ Circ J 69(Suppl IV)F1267-1342C2005
  3. ‘å’Ë ’è“¿F •úŽËŒõ‚ð—p‚¢‚½ŒoÃ–¬Š¥“®–¬‘¢‰e‚É‚æ‚é‰^“®Žž‚ÌŠ¥“®–¬Œ`‘Ô‚Ì•]‰¿D •½¬14”N“x •½¬16”N“x‰ÈŠwŒ¤‹†”ï•â•‹àiŠî”ÕŒ¤‹†(C)(2)j
  4. ‘å’Ë ’è“¿CŽRŒû ›ÜCŒà ™¤C•“c “OC•º“¡ ˆêsCˆÀ“¡ ³ŠCF •úŽËŒõ‚ð—p‚¢‚½ŒoÃ–¬Š¥“®–¬‘¢‰e‚̗Տ°‰ž—pD 2004PF§’k‰ïƒOƒ‹[ƒvuˆãŠw—˜—pvCSPring-8 —˜—pŽÒ§’k‰ïƒTƒuƒOƒ‹[ƒv
  5. ‘ŠàV ‹`–[Cˆäã ”ŽC‘å] “§C¬ì ‘C‰œ‘º ŒªC‰Á“¡ ‹M—YCŠ™‘q Žj˜YCŒÃ‰ê ‹`‘¥CŒ´“c Œ¤‰îC–x] –«C¼è ‰v“¿CŽOè ‘ñ˜YCŽO“c‘ºG—YCŽRŒû ›ÜC‹g‰i ³•vC’r“c —²“¿CˆÉ“¡ ½C]X “N˜NC‹v‰ê Œ\—SCŽ™‹Ê ˆí—YC²X–ؐ^ŒáC´… º•FC´… ÂCZ—F ’¼•ûC‚ŒŽ ½ŽiF S‘Ÿ“Ë‘RŽ€‚Ì—\’m‚Æ—\–h–@‚̃KƒCƒhƒ‰ƒCƒ“D Circ J 69:1209-1265C10ŒŽC2005

@@@¡ ‚»‚Ì‘¼

  1. ŽRŒû ›ÜF S–[×“®‚ÌŽ¡—ÁD ‘æ39‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ï“Á•Êu‰‰i“Œ‹žjC1ŒŽ9“úC2005
  2. ‘å’Ë ’è“¿F ‚ŒŒˆ³ƒKƒCƒhƒ‰ƒCƒ“D ‰ºŠÙŽsˆãŽt‰ïzŠÂŠíuK‰ïi‰ºŠÙjC1ŒŽ12“úC2005
  3. –{ŠÔ ŠoF –«“®–¬•ÂÇÇ‚ÌŒŒŠÇ—\Œã‚Ɛ¶–½—\Œã[RŒŒ¬”–ò‚Ì–ðŠ„D …‹½ˆãŽt‰ïŠwpu‰‰‰ïi–ƒ¶jC1ŒŽ20“úC2005
  4. ŽRŒû ›ÜF S–[×“®Ž¡—Â̖â‘è“_D ‚Ђ½‚¿‚È‚©ŽsˆãŽt‰ïŠwpu‰‰‰ïi‚Ђ½‚¿‚È‚©jC2ŒŽC2005
  5. £”ö —RLF Ï‹É“IŽ‰Ž¿’ቺ—Ö@‚ƃvƒ‰[ƒN•Ï‰»D ‰Ž“‡ŒSˆãŽt‰ïu‰‰‰ïiŒÃ‰êjC2ŒŽC2005
  6. ÂÀ ˜a—²F S–[×“®Ž¡—ÂÌUP TO DATE -V‚½‚È–ò•¨ƒRƒ“ƒrƒl[ƒVƒ‡ƒ“Ž¡—©‚çƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Â܂Å-D ‘啪ƒAƒ~ƒIƒ_ƒƒ“‚̉ïi‘啪jC2ŒŽ25“úC2005
  7. ŽRŒû ›ÜF zŠÂŠíŽ¾Š³‚̐f’f‚ÆŽ¡—Âɔº‚¤ƒŠƒXƒN‚ɂ‚¢‚āD …ŒË’nÙŒ¤C‰ïi…ŒËjC3ŒŽC2005
  8. ‰Í–ì —¹F S‹ØŠg’£áŠQ‚̐S“d}ŠŒ©E•s®–¬D ‘æ8‰ñ—Տ°S‘Ÿ•aƒtƒH[ƒ‰ƒ€i‰¡•ljC3ŒŽ20“úC2005
  9. ‘å’Ë ’è“¿F ‹•ŒŒ«SŽ¾Š³‚Ì‚³‚ç‚È‚éf’fEŽ¡—Âð‚ß‚´‚µ‚āD 21ˆïézŠÂŠíƒtƒH[ƒ‰ƒ€i‚‚­‚΁jC3ŒŽ31“úC2005
  10. ‘å’Ë ’è“¿F ‚ŒŒˆ³Ž¡—Ã2004ƒKƒCƒhƒ‰ƒCƒ“D ŽæŽèˆãŽt‰ïŠwpW‰ïŽæŽèiŽæŽèjC4ŒŽ26“úC2005
  11. ÂÀ ˜a—²F High resolution substrate Mapping for better cure of ischemic VT. Asia Nightiƒjƒ…[ƒIƒŠƒ“ƒYjC5ŒŽ6“úC2005
  12. ÂÀ ˜a—²F S–[×“®‚̍ŐVŽ¡—à -–ò•¨Ž¡—©”ñ–ò•¨Ž¡—©H-D ‘æ2‰ñ“ú—§S‘Ÿ§˜b‰ïi“ú—§jC5ŒŽ18“úC2005
  13. “n•Ó dsF ‰ž—pƒR[ƒX ICDÇ—á‚̎Љï“I–â‘èi‰^“]EA˜JjD ‘æ11‰ñAž‚ÝŒ^™×“®ŠíiICDjŒ¤CƒZƒ~ƒi[i•ó’ˁjC5ŒŽ29“úC2005
  14. ŽRŒû ›ÜF S‘Ÿ•a‚Æ‚Í ‚ŒŒˆ³E•s®–¬‚ÆŒ¾‚í‚ꂽ‚ç S‹Ø[Ç‚É‚È‚ç‚È‚¢‚½‚ß‚É S‘Ÿ•aŽ¡—ÁEH¶ŠˆE‰^“®‚ɂ‚¢‚āD ‘æ9‰ñŒ§–¯‚Ì‚½‚ß‚ÌŒ’NŠÇ—uÀi“ú—§jC6ŒŽC2005
  15. ÂÀ ˜a—²F ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Up to Date gS–[×“®‚©‚çSŽº•p”‚܂Łh-ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚̍ŐVŽè‹Z-D ‘æ5‰ñ…ŒËE“ú—§CCUƒlƒbƒgƒ[ƒNŒ¤‹†‰ïi…ŒËjC6ŒŽ9“úC2005
  16. ‰Í–ì —¹F ‚ŒŒˆ³Ž¡—Âɂ¨‚¯‚éCahR–ò‚Ì–ðŠ„D ‹¦˜a”®yH‹ÆŠ”Ž®‰ïŽÐŽÐ“àŒ¤C‰ïi‚‚­‚΁jC6ŒŽ9“úC2005
  17. £”ö —RLF zŠÂŠíŽ¾Š³‚É‚¨‚¯‚éèò“®–¬ƒGƒR[‚Ì—L—p«‚ɂ‚¢‚āD ‚ŒŒˆ³Ž¡—ÂƑŸŠí•ÛŒìŒ¤‹†‰ï ˆïéNOƒtƒH[ƒ‰ƒ€i‚‚­‚΁jC6ŒŽ10“úC2005
  18. ÂÀ ˜a—²F S–[×“®Ž¡—Â̍ŋ߂̓®Œü‚ɂ‚¢‚āD ‘æ93‰ñ“ú–{zŠÂŠíŠw‰ï–kŠC“¹’n•û‰ï‹³ˆçƒZƒbƒVƒ‡ƒ“i–kŠC“¹jC6ŒŽ11“úC2005
  19. ‹v‰ê Œ\—SF ‰Ä‹x‚Ý‚ðŠy‚µ‚­‰ß‚²‚·‚½‚߂ɁD ‚‚­‚ÎStudents 560:6-6C6ŒŽ16“úC2005
  20. ‘å’Ë ’è“¿F JSH‚ŒŒˆ³Ž¡—ÃKƒCƒhƒ‰ƒCƒ“2004‚ɂ‚¢‚āD Î‰ª–òÜŽt‰ïW‡Œ¤C‰ïiÎ‰ªjC6ŒŽ21“úC2005
  21. ÂÀ ˜a—²F S–[×“®Ž¡—ÂÌDP to DateF-V‚½‚È–ò•¨ƒRƒ“ƒrƒl[ƒVƒ‡ƒ“Ž¡—©‚çƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Â܂Å-D ŽRŒ`•s®–¬Ž¡—ͧe‰ïiŽRŒ`j6ŒŽ24“úC2005
  22. ‹g“cŒ’‘¾˜YCÂÀ ˜a—²CŽRè _C–Ø‘º ‘׎OC¯ ’q–çC‘ŠŒ´ ‰p–¾C—é–Ø ÍOC‰““¡ —DŽ}C‹v‰ê Œ\—SCŽRŒû ›ÜC‘O“c —SŽjF “Á”­«¶–[ƒ}ƒNƒƒŠƒGƒ“ƒgƒŠ[‚Ì1—áD ‘æ13‰ñŠÖ“ŒƒAƒuƒŒ[ƒVƒ‡ƒ“EƒZƒ~ƒi[i‚‚­‚΁j6ŒŽ24“úC2005
  23. ŽRŒû ›ÜF Ž„‹¤‚Ì”ñ–ò•¨“I—Տ°Œ¤‹†‚ɂ‚¢‚āD ‚݂ȂƏzŠÂŠí•af˜AŒgƒZƒ~ƒi[i“Œ‹žjC7ŒŽC2005
  24. ÂÀ ˜a—²F CRTiS‘ŸÄ“¯Šú—Ö@j‚Ì“K‰ž‚©‚玡—Â܂ŠADATARA Live Demonstration 2005D ƒ‚[ƒjƒ“ƒOƒZƒbƒVƒ‡ƒ“iŒSŽRjC7ŒŽ8“úC2005
  25. ÂÀ ˜a—²F ’vŽ€«SŽº•p”‚̍ŐVŽ¡—à -–ò•¨—Ö@‚©‚ç”ñ–ò•¨—Ö@‚Ü‚Å-D H“cƒAƒ~ƒIƒ_ƒƒ“u‰‰‰ïiH“cjC7ŒŽ15“úC2005
  26. “n•Ó dsF ŽY‹Æˆã‚̐搶‚ɖ𗧂A‰^“®•‰‰×ŽŽŒ±–@‚Ɖ^“®—Ö@D •½¬17”N“x‘æ2‰ñˆïéŒ§ˆãŽt‰ïŽY‹ÆˆãŒ¤C‰ïi‚‚­‚΁jC7ŒŽ16“úC2005
  27. ÂÀ ˜a—²F S–[×“®‚̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ -V‚½‚Ȃ鍪Ž¡‚ÌŽŽ‚Ý-D •s®–¬Šwpu‰‰‰ïi¬‘qjC7ŒŽ22“úC2005
  28. ÂÀ ˜a—²F ’vŽ€«QŽº•p”‚̍ŐVŽ¡—à -–ò•¨—Ö@‚©‚ç”ñ–ò•¨—Ö@‚Ü‚Å-D ˆïéƒAƒ~ƒIƒ_ƒƒ“u‰‰‰ïi‚‚­‚΁j7ŒŽ30“úC2005
  29. ÂÀ ˜a—²F 21¢‹I•s®–¬‚Í‚±‚±‚Ü‚ÅŽ¡‚éD ˆî•~ˆãŽt‰ïŠwpu‰‰‰ïiˆî•~ŽsjC8ŒŽ8“úC2005
  30. ÂÀ ˜a—²F S•s‘S‚É‚¨‚¯‚éÅVŽ¡—à -–ò•¨Ž¡—©‚ç”ñ–ò•¨Ž¡—Â܂Å-D —Տ°Œ¤‹†‰ïi‚‚­‚΁jC9ŒŽ3“úC2005
  31. •ˆÀ –@”VF V‚µ‚¢’mŒ©‚ÉŠî‚¢‚½CahR–ò‚̈ʒu•t‚¯D Î‰ªŽsˆãŽt‰ïŠwpu‰‰‰ïiÎ‰ªjC9ŒŽ9“úC2005
  32. ‰Í–ì —¹F S•s‘S‚ɂ‚¢‚āD ‹»˜aŠ”Ž®‰ïŽÐŽÐ“àŒ¤C‰ïi‚‚­‚΁jC9ŒŽ27“úC2005
  33. ÂÀ ˜a—²F ƒP[ƒXƒXƒ^ƒfƒB “ú–{S•s‘SŠw‰ïC“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C®—‰ïD uƒy[ƒVƒ“ƒO‚É‚æ‚éS•s‘SŽ¡—ÁvŒ¤CƒZƒ~ƒi[i‰ºŠÖjC10ŒŽ20“úC2005
  34. £”ö —RLF ƒhƒbƒvƒ‰[ƒGƒR[‚ð—p‚¢‚½S‹@”\‚̐V‚µ‚¢•]‰¿–@D ‘æ2‰ñEX Open Conferencei‚‚­‚΁jC10ŒŽ26“úC2005
  35. ŽRŒû ›ÜF ‹•ŒŒ«SŽ¾Š³‚̐f’f‚ÆŽ¡—ÁD ‰¡{‰êƒ[ƒ^ƒŠ[ƒNƒ‰ƒuu‰‰‰ïi‰¡{‰êjC11ŒŽC2005
  36. ŽRŒû ›ÜF ‹•ŒŒ«SŽ¾Š³‚̐f’f‚ÆŽ¡—ÁD “úˆã¶ŠU‹³ˆç‹¦—͍uÀƒZƒ~ƒi[u”]ESŒŒŠÇŽ¾Š³uÀvi…ŒËjC11ŒŽC2005
  37. ‰Í–ì —¹F SƒGƒR[ŽÀ‹ZŒ¤CEŠî–{“I‘ª’荀–Ú‚Æ‚»‚ُ̈í2D ‰ºŠÙzŠÂŠíu‰‰‰ïi‰ºŠÙjC11ŒŽ9“úC2005
  38. “n•Ó dsF S“d}Šî‘bƒZƒ~ƒi[ S“d}Œ©•ûE•s®–¬‚ÌŠî‘bD ‘æ3‰ñŒÄ‹zEzŠÂƒZƒ~ƒi[i¬“cjC11ŒŽ23“úC2005
  39. ‰Í–ì —¹F AED‚Á‚ĉ½‚Å‚·‚©-Chain of Survival ‘Šúœ×“®‚ɂ‚¢‚āD “y‰Y–òÜŽt‰ï–òÜŽtW‡Œ¤C‰ïi“y‰Yj
  40. ÂÀ ˜a—²F S–[×“®‚̍ŐVŽ¡—ÁD “Œ‹ž•ÛŒ¯ˆã‹¦‰ï‘æ319‰ñzŠÂŠíŒ¤‹†‰ïi“Œ‹žjC12ŒŽ21“úC2005
  41. ‰Í–ì —¹F Å‹ß‚̐S•s‘S‚̘b‘èD “c•Ó»–òŠ”Ž®‰ïŽÐŽÐ“àŒ¤C‰ïi‚‚­‚΁jC12ŒŽ27“úC2005

@2004”N“xi2004”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. ŽRŒû ›ÜF ‰ï’·u‰‰uŽüpŠú‚ƏzŠÂŠíŽ¾Š³FŠO‰È‚ɖ𗧂zŠÂŠíŽ¾Š³‚̐f’f‚ÆŽ¡—ÁvD ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  2. —é–Ø ËŽiC”Ñ“c Œ[Ž¡C‹g“c ³C¬ŠÖ iŽqC‘º‰z LsCÝŠy²‘ãŽqCm•Û •¶•½C‰|–{ ‹­ŽuC¬ŠÖ 猁C‰Í–ì —¹C“n•Ó dsCŽRŒû ›ÜF lŠÔƒhƒbƒN‚̐S“d}‚Å‹•ŒŒ«SŽ¾Š³‚Ì‹^‚¢‚Ɉڍs‚µ‚½Ç—á‚Ì‹K’èˆöŽq‚ÌŒŸ“¢D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  3. ¬‘î N”VC‘å’Ë ’è“¿CŽRè –¾CŽRŒû ›ÜF S‹@”\’ቺ—á‚É‚¨‚¯‚éS‘ŸŽ©—¥_ŒoŠˆ“® -“ü—‚É”º‚¤S”•Ï“®‚̕ω»‚©‚ç‚ÌŒŸ“¢-D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  4. “n•Ó dsCÎˆä’qŽqCˆ±â —²ˆêC•ˆÀ –@”VCVˆä Œb”üCX–{ —²ŽjCV•y ‹`CÄ“¡ IC]“c ˆê•FCâ–{ ˜a•FCÎŽR ŽÀŽ÷Cm‰È G’CŽRŒû ›ÜF ‹ßÔŠOü•ªŒõ–@‚É‚æ‚é‰^“®‹ØŒŒŠÇŠg’£‚Ì”ñNP“I‘ª’è–@D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  5. V•y ‹`ŒòC“n•Ó dsCˆ±â —²ˆêC•ˆÀ –@”VC]“c ˆê•FCâ–{ ˜a•FCm‰È GCX–{ —²ŽjCŽRŒû ›ÜF ‰^“®•‰‰×S“d}‚É‚¨‚¢‚ÄSTã¸‚ðŽ¦‚·—á‚̗Տ°”wŒiD ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  6. ¯ ’q–çC£”ö —RLCâª‚Ý‚¿ŽqC‘O“c —TŽjC“n•Ó dsCŽRŒû ›ÜF ƒgƒƒ|ƒjƒ“T—z«AH FABP‰A«‚ðŽ¦‚·‹}«Š¥ÇŒóŒQ‚ÌŒŸ“¢D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  7. Î’à ’qŽqCÎŒõ •qsC–ö ‹vŽqC¬Œ´ Œ’ˆêCXŽR ’¼ŽqC£”ö —RLCŽRŒû ›ÜF ¬Ž™‚É‚¨‚¯‚éèò“®–¬“à–Œ’†–ŒŒú‚̉Á—•Ï‰»‚ÌŒŸ“¢D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  8. ŽR“à F‹`C¬‘î N”VC“n•Ó dsCˆ±â —²ˆêCŽRŒû ›ÜF ¶ŠˆKŠµ•aŠ³ŽÒ‚ɑ΂·‚é‰^“®—Ö@‚ÌŒø‰Ê‚ÌŒŸ“¢D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  9. ˆ±â —²ˆêC‹v–ì •ˆ–çC¼“c Œõ¶C“n•Ó dsCŽRŒû ›ÜF ’†‚—îŽÒ‚É‚¨‚¯‚鉺ŽˆƒŒƒWƒXƒ^ƒ“ƒX‰^“®‚̐SŒŒŠÇŒn‚©‚ç‚Ý‚½ˆÀ‘S« -SATƒvƒƒWƒFƒNƒg136-D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  10. ”üè ¹ŽqC‰Í–ì —¹C”Ñ“c Œ[Ž¡C–{ŠÔ ŠoC“n•Ó dsCŽRŒû ›ÜF ƒNƒŠƒjƒJƒ‹ƒJƒ“ƒtƒ@ƒŒƒ“ƒXu‚¤‚ÁŒŒ«S•s‘S‚ðŒJ‚è•Ô‚·“Á”­«Šg’£Œ^S‹ØÇ‚ɍ‡•¹‚µ‚½ãs‘å’°ŠàÇ—á‚ɑ΂µ‚Ä‚ÌŽèp—Ö@‚Ì“K‰žvD ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  11. £”ö —RLC‘O“c —TŽjCâª‚Ý‚¿ŽqC“¡“c ŒjŽjC‹Tè ‚•vCÎ’à ’qŽqCÎŒõ •qsC“n•Ó dsCŽRŒû ›ÜF ”][Ç‚É‚¨‚¯‚é‘m–X•Ù—֐ΒY‰»‚̈Ӌ`‚ɂ‚¢‚Ä‚ÌŒŸ“¢D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  12. X–{ —²ŽjC–ìŒû —SˆêCÎì ŒölC‹à–{ “sC•¶‘  —DŽqC•ˆÀ –@”VC“n•Ó dsCŽRŒû ›ÜF ƒXƒeƒ“ƒgƒfƒUƒCƒ“‚͍ċ·ó‚ɉe‹¿‚ð—^‚¦‚é‚©HBX velocity stent‚ÆMultilink tristar stent‚É‚æ‚é–³ìˆ×‰»”äŠrŽŽŒ±D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  13. —é–Ø ÍOC‘ŠŒ´ ‰p–¾C“’ì –¾˜aC“n•Ó NŽuC“c’†Šì”ü•vC•ˆä ‘וFC]K ¬ºC“n•Ó dsCŽRŒû ›ÜF S‹•ŒŒƒCƒxƒ“ƒg‚Ì•aŒ^‚É‚æ‚éÓ”C•a•Ï‚ÌŒŒŠÇ‘¢‰eŠŒ©‚Ì“Á’¥‚ɂ‚¢‚āD ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  14. “n•Ó NŽuC—é–Ø ÍOC•ˆä ‘וFC“c’†Šì”ü•vC“n•Ó dsCŽRŒû ›ÜF ƒRƒŒƒXƒeƒ[ƒ‹³í’l‚ÌŠ¥“®–¬ƒXƒeƒ“ƒg—¯’uŒãŠ³ŽÒ‚É‚¨‚¯‚éƒAƒgƒ‹ƒoƒXƒ^ƒ`ƒ“‚̍ċ·ó—\–h‚ɑ΂·‚é—LŒø«‚ÌŒŸ“¢D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  15. ¬Œ` ŠxŠ°C‹{“à ‘ìC‰ºžŠ MˆÐC‚—œ ³ŸC‘àV _ˆêCŽRŒû ›ÜF DOCA-salt‚ŒŒˆ³«ƒ‰ƒbƒgS‘Ÿ‚É‚¨‚¯‚éAPPARƒ¿ŽhŒƒ–ò‚É‚æ‚éS‹ØüˆÛ‰»—}§Œø‰Ê‚ÆŠg’£‹@”\‘ˆ«—}§Œø‰Ê ]NF-kB—}§‚É‚æ‚éR‰ŠÇì—p‚©‚ç‚ÌŒŸ“¢-D ‘æ38‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2004
  16. ‘å’Ë ’è“¿CŽRŒû ›ÜCŒà ™¤C•“c “OC”Âˆä —I“ñCŠÛ‹´ WC•º“¡ ˆêsCˆÀ“¡ ³ŠCF •úŽËŒõ‚ð—p‚¢‚½Š¥“®–¬“®‰æ‘¢‰e‚̗Տ°‰ž—pD ‘æ17‰ñ“ú–{•úŽËŒõŠw‰ï”N‰ïE•úŽËŒõ‰ÈŠw‡“¯ƒVƒ“ƒ|ƒWƒEƒ€ i‚‚­‚΁jC1ŒŽC2004
  17. ‹g“cŒ’‘¾˜YC‹v‰ê Œ\—SC‚‹´ ”ü•äC–x•Ä mŽuC¼ˆä —zCd“c Ž¡CåŒ´ ŒªCˆé•” „ŽuCŽR‰º ³•vCŽRŒû ›ÜF –ƒŒ“±“ü‚ŐSŽº×“®‚ð‚«‚½‚µAŒã•ûŽ‹“I‚ÉBrugadaÇŒóŒQ—lS“d}‚ð’悵‚Ä‚¢‚½‘å“®–¬kóÇD ‘æ2‰ñ“Á”­«SŽº×“®Œ¤‹†‰ïi“Œ‹žjC2ŒŽC2004.
  18. •ˆÀ –@”VC“n•Ó dsC‹g“cŒ’‘¾˜YC‹g“c ˆè—YCˆÀ”{ ‘å•ãC‰Í–ì —¹C–{ŠÔ ŠoCŽRŒû ›ÜF ’˜‚µ‚¢ƒAƒR[ƒfƒBƒIƒ“Œ»Û‚𗈂µ‚½LITAƒoƒCƒpƒXƒOƒ‰ƒtƒg‚ɑ΂µ‚ă_ƒCƒhƒƒCƒ„[‹È‚°ƒeƒNƒjƒbƒN‚ð—p‚¢‚ÄPCI‚ðŽ{s‚µ“¾‚½Ç—áD ‘æ24‰ñ’}”gƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ƒVƒlƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‚‚­‚΁jC2ŒŽC2004
  19. ˆÀ”{ ‘å•ãC–{ŠÔ ŠoCX–{ —²ŽjC‰F–ìŠó¢ŽqC’†¼ Œ[‘¾C“n•Ó dsCŽRŒû ›ÜCˆÀ“¡ ‘¾ŽOF –«”xŒŒðÇðÇ‚ɑ΂µ‚Ä”x“®–¬ŒŒð“à–Œ“Eœp‚ªŽ{s‚³‚ꂽ1—áD ‘æ191‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žj2ŒŽC2004
  20. X–{ —²ŽjC“n•Ó dsC•ˆÀ –@”VCÄ“¡ ICŠOŽR ¹OCâ–{ ˜a•FC]“c ˆê•FCÎŽR ŽÀŽ÷Cm‰È G’CV•y ‹`ŒòCVˆä Œb”üCÎˆä’qŽqCŽRŒû ›ÜCˆ±â —²ˆêC•“c “OF ŒðŠ´_ŒoŠˆ«‚Ɖ^“®‘Ï—e”\‚ÌŠÖ˜AD ‘æ31‰ñˆïéŒ§—Տ°ŠjˆãŠwŒ¤‹†‰ïi…ŒËjC2ŒŽC2004
  21. ‹{“à ‘ìCŒã“¡ Ÿ”NF ƒGƒ“ƒhƒZƒŠƒ“‚ƐS‘ŸƒŠƒ‚ƒfƒŠƒ“ƒOE•s‘SS‚̐i“WD ‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïi‘åãj3ŒŽC2004
  22. Jesmin S., Sakuma I., Miyauchi T., Hattori Y.F ƒCƒ“ƒXƒŠƒ“’ïR«“œ”A•aƒ‰ƒbƒgS‘Ÿ‚É‚¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“BŽó—e‘̃VƒOƒiƒŠƒ“ƒOŒn‚̕ω»FSƒ‚ƒfƒŠƒ“ƒOŒ`¬‚É‚¨‚¯‚é–ðŠ„D ‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïi‘åãj3ŒŽC2004
  23. Ajisaka R., Matsuda M., Maeda S., Kuno S., Watanabe S., Yamaguchi I.F Tptal Plasma Homocysteine, Exercise Hyperemia, and Aerobic Exersise Capacity in the Middle aged or Elderly People. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  24. Ohtsuka S., Sohara Y., Yamaguchi I.F The Relation of Diurnal Variation of Forearm Vascular Resistance to Nocturnal Blood Pressure in Patients with Essential Hypertension. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  25. Seo Y., Ishimitsu T., Ishizu T., Moriyama N., Obara K., Sakane M., Maeda H., Watanabe S., Yamaguchi I.F Comparison of Clinical Implication between the Echolucent Cardiotid Plaques and Plaque Score in Patients with Acute Coronary Syndrome. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  26. Suzuki S., Iida K., Koseki Y., Murakoshi N., Niho B., Enomoto T., Koseki S., Watanabe S., Yamaguchi I.F What clinical characteristics of normal subjects can predict that they will have ischemic heart disease two years later. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  27. Jesmin S., Sakuma I., Hattori Y., Kitabatake A., Miyauchi T.F Endothelin and its Signaling Pathway is Upregulated in a Type? Diabetic Rat Heart :Potential Reversal by Calcium Channel Antagonism. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  28. Oyake Y., Ohtsuka S., Yamazaki A., Yamaguchi I.F Comprarison of the Effects of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker on Vascular Function and Autonomic Activity in Heart Failure. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  29. Hoshi T., Kawano S., Misaki M., Masumi T., Iida K., Watanabe S., Yamaguchi I., Nishi I.F Cardeivilol Has an Effect on QT dispersion in Patients of DCM. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  30. Kanemoto M., Suzuki K., Goya M., Nagata Y., Yonetsu T., Kuboyama O., Kimura S., Kakuta T., Fujiwara H., Noguchi Y., Kuga K., Yamagchi I., Iesaka Y.F Modification of Autonomic Nervous System by Extensive Encircling Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrllation. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  31. Arai E., Watanabe S., Takeyasu N., Ajisaka R., Nishina H., Aihara H., Saitoh T., Toyama M., Sakamoto K., Eda K., Ishiyama M., Shintomi Y., Morimoto T., Yamanouchi T., Yamaguchi I.F Relation between Muscl Function and Early Dyynamics of Oxygen Uptake the Ouset of Constant Workload Exercise. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  32. Ishiyama M., Watanabe S., Takeyasu N., Ajisaka R., Saitoh T., Toyama M., Sakamoto K., Eda K., Nishina H., Morimoto T., Shintomi Y., Aihara H., Yamanouchi T., Yamaguchi I.F The mechanism of lactate production during execise in patients with cardiac disease. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  33. Yoshida I., Ohtsuka S., Ishikawa K.,Yamaguchi I.F Inhibitory Effects of Ticlopidine on the Coronary Vascular Remodeling of the Artifically Damaged Pig Coronary Moedl. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  34. Watanabe S., On K., Yamada S., Tsukada K., Miyashita T., Ogata K., Yamaguchi I.F Multiple current vector diagram of magnetocardiolography is highly sensitive to coronary stenosis : A novel technique to evaluate the inhomogeneity of myocardial repolarization. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  35. Ishizu T., Ishimitsu T., Yanagi H., Seo Y., Obara K., Moriyama N., Watanabe S., Yamaguchi I.F Current parental smoking and irregularities of the carotid arterialintima media thickness in healthy children. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  36. On K., Watanabe S., Yamada S., Yamaguchi I., Miyashita T., Tsukada K., Ogata K.F Multiple current vector diagram of magnetocardiogram (MCG) is high sensitive to coronary stenosis and its abnormality persists after coronary revascularization. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  37. On K., Watanabe S., Yamada S., Yamaguchi I., Miyashita T., Tsukada K., Ogata K.F Integral Value of JT Interval in Magnetocardiogram is Sensitive to Coronary Stenosis, and It Improves Early after Successful Coronary Revascularization. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  38. Takeyasu N., Watanabe S., Aihara H., Saitoh T., Toyama M., Sakamoto K., Eda K., Ishiyama M., Nishina H., Shintomi Y., Morimoto T., Ajisaka R., Yamanouchi T., Arai E., Yamaguchi I.F Tetrahydrobiopterin (BH4) improves the early dynamics of oxygen uptake at the onset of exercise in patients with coronary artery disease. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  39. Jesmin S., Sakuma I., Togashi H., Yoshioka M., Hattori Y., Kitabatake A., Miyaudhi T.F Long term Endothelin Antagonism Reveres the Hypertnsion-induced Neurovascular Remodeling in the Frontal Cortex of SHR-SP. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  40. Suzuki A., Yukawa A., Watanabe Y., Tanaka K., Takei Y., Ejiri N., Kawagoe K., Kuga K., Watanabe S., Yamaguchi I.F Homogeneous washout pattern of 123I-MIBG images before beta-blocker therapy may predict the clinical outcome in patients with chronic heart failure. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  41. Kuga K., Endo M., Niho B., Suzuki A., Enomoto M., Kanemoto M., Yoshida K., Yamaguchi I.F Evaluation of Potency of Aniti Hypertensive Drugs by a Novel Index-"Hypobaric Potency"-. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  42. Morimoto T., Watanabe S., Yamanouchi T., Saitoh T., Toyama M., Takeyasu N., Sakamoto K., Eda K., Ishiyama M., Nishina H., Shintomi Y., Aihara H., Arai E., Ajisaka R., Yamaguchi I.F Tetrahydrobiopterin Improves Exercise Tolerance and Endothelium Dependent Vasodilation in Patients with Coronary Artery Disease(CAD). ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  43. Kuga K., Watanabe S., Yamaguchi I., Doki K., Katori K., Homma M., Kohda Y.F Relationship Between the Activity of p450-CYP2D6 and Serum Level of Fecainide. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  44. Kawano S., Ohtsuka S., Misaki M., Hoshi T., Masumi T., Iida K., Watanabe S., Yamaguchi I.F Transcardiac Gradient of Cyclic GMP befor and after ANP Infusion in Patients with Chronic Heart Failure. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  45. Iemitsu M., Miyauchi T., Shimojo N., Irukayama-Tomobe Y., Maeda S., Ohkubo T., Tanaka Y., Yamaguchi I.F Effects of Medium-chain Triglycerde(MCT) Application to SHR on Myocardial Energy Metabolic Capacity, Cardiac Function, and Cardiac Hypertrophy. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  46. Takanashi M., Miyauchi T., Yamaguchi I.F Hypoxia Inducible Factor (HIF)-1ƒ¿ Overexpression Greatly Induces Endothelin(ET)-1 mRNA and Endothelin Converting Enzyme mRNA in Cultured Cardiomyocytes. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  47. Ogata T., Miyauchi T., Takanashi M., Simojyoh N., Sakai S., Yamaguchi I.F The PPAR-ƒ¿ Activator Fenofibrate Inhibits Myocardial Fibrosis with Improving Diastolic Function in DOCA-salt Hypertensive Rats, Partly via Suppressing Endothelin-1 Expression. ‘æ68‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi“Œ‹žjC3ŒŽC2004
  48. “yŠò _‰îC–{ŠÔ ^lC‹v‰ê Œ\—SC“n•Ó dsCŽæ ‹v”üCŽRŒû ›ÜCK“c K’¼F •p–¬«•s®–¬Š³ŽÒ‚É‚¨‚¯‚錌’†ƒtƒŒƒJƒCƒjƒh‚¨‚æ‚Ñ‚»‚Ì‘ãŽÓ•¨‚Ì“¯Žž’è—ʁD ‘æ124‰ñ“ú–{–òŠw‰ïi‘åãjC3ŒŽC2004
  49. ‘å’Ë ’è“¿CŽRŒû ›ÜCŒà ™¤C•“c “OC”Âˆä —I“ñCŠÛ‹´ WC•º“¡ ˆêsCˆÀ“¡ ³ŠCF ƒVƒ“ƒ|ƒWƒEƒ€uƒr[ƒ€‚̈ãŠw—˜—pv•úŽËŒõ‚ð—p‚¢‚½ŒoÃ–¬Š¥“®–¬‘¢‰e‚ÌŒ»ó‚Æ“W–]D “ú–{•¨—Šw‰ï‘æ59‰ñ”NŽŸ‘å‰ï i•Ÿ‰ªj C3ŒŽC2004
  50. •ˆÀ –@”VC“n•Ó dsCm‰È G’CV•y ‹`ŒòCÎŽR ŽÀŽ÷C]“c ˆê•FCŠOŽR ¹OC‹v‰ê Œ\—SCéˍ⠗²ˆêCŽRŒû ›ÜF Œã•ÇS‹Ø‹•ŒŒ‚̐S“d}f’fD ‘æ101‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïi“Œ‹žjC4ŒŽC2004
  51. ‰Í–ì —¹C‘å’Ë ’è“¿C”üè ¹ŽqC¯ ’q–çC‘Œ© ’qŽqC”Ñ“c Œ[Ž¡C“n•Ó dsCŽRŒû ›ÜF –«S•s‘S‚É‚¨‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“iILj 18ŽY¶‚̈Ӌ`D ‘æ101‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïi“Œ‹žjC4ŒŽC2004
  52. •ˆÀ –@”VC“n•Ó dsC‹g“cŒ’‘¾˜YC‹g“c ˆè—YCˆÀ”{ ‘å•ãC‰Í–ì —¹C–{ŠÔ ŠoCŽRŒû ›ÜF ’˜‚µ‚¢ƒAƒR[ƒfƒBƒIƒ“Œ»Û‚𗈂µ‚½LITAƒoƒCƒpƒXƒOƒ‰ƒtƒg‚ɑ΂µ‚ă_ƒCƒhƒƒCƒ„[‹È‚°ƒeƒNƒjƒbƒN‚ð—p‚¢‚ÄPCI‚ðŽ{s‚µ1—áD ’í24‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠÖ“ŒbM‰z’n•û‰ïib•{jC5ŒŽC2004
  53. ŽR“à NÆC‚‹´ ~C‰¡ŽR ‘לACŒF’J _ŽiC“c’† ‘׏́CŒIŒ´ Œ°C²“¡ –¾CÂÀ ˜a—²C–ìã º•FC‰Æâ ‹`lC•½”ö Œ©ŽOCˆé•” ŒõÍF ƒVƒ“ƒ|ƒWƒEƒ€Eu–«S–[×“®‚ɑ΂·‚éƒAƒ~ƒIƒ_ƒƒ“‚Æ”xÃ–¬Šu—£p‚̃nƒCƒuƒŠƒbƒgŽ¡—ÂɊւ·‚錟“¢vD ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  54. ‚‹´ ~CŽR“à NÆC‰¡ŽR ‘לACŒF’J _ŽiC²“¡ –¾CŒIŒ´ Œ°C“c’† ‘׏́CÂÀ ˜a—²C‡‰® ‰ë•FC‰Æâ ‹`lCˆé•” ŒõÍF ƒVƒ“ƒ|ƒWƒEƒ€EuŽ‘±«‚¨‚æ‚Ñ–«S–[×“®‚ɑ΂·‚é“d‹C“I”xÃ–¬Šu—£ÄŽÜiL”͈͓¯‘¤”xÃ–¬“¯ŽžŠu—£–@j‚Ì—L—p«‚ÌŒŸ“¢vD ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  55. ŒF’J _ŽiC‚‹´ ~CŽR“à NÆC‰¡ŽR NœAC“c’† ‘׏́CŒIŒ´ Œ°C²“¡ –¾CÂÀ ˜a—²C‰Æâ‹`lF Aorto-mitral continuity‹NŒ¹‚̐SŽº•p” -ÄŽÜ•”ˆÊ•Êi‘å“®–¬•Ùó‚¨‚æ‚Ñ•Ù‰ºj‚̐S“d}Šw“I“Á’¥-D ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  56. ŒF’J _ŽiC‚‹´ ~CŽR“à NÆC‰¡ŽR NœAC“c’† ‘׏́CŒIŒ´ Œ°C²“¡ –¾CÂÀ ˜a—²C‰Æâ ‹`lF ‘m–X•Ù—Ö•”‹NŒ¹‚Ìidiopathic repetitive ventricular premature beats‚Ìdelta-like wave‚ÆWPWÇŒóŒQ‚Ìfull preexcited delta wave‚ÌŒŸ“¢D ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  57. ŽR“à NÆC‚‹´ ~C‰¡ŽR ‘לACŒF’J _ŽiC“c’† ‘׏́CŒIŒ´ Œ°C²“¡ –¾CÂÀ ˜a—²C–ìã º•FC‰Æâ ‹`lC•½”ö Œ©ŽOCˆé•” ŒõÍF ‘å“®–¬Š¥ë‚©‚ç‚Ì’Ê“d‚ɂčªŽ¡‰Â”\‚ȍ¶Žº—¬o˜H‹NŒ¹SŽº•p”‚É‚¨‚¯‚鋹•”ˆÚ€‘тɂ‚¢‚Ä‚ÌŒŸ“¢D ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  58. Œ´“c ’q—YC˜e–{ ”Ž•¶C’†‘ò Œ‰C’r“c ‹¿ŽqCŠÝ —ÇŽ¦C‚–Ø –¾•FC’·“c Œ\ŽOC“c’† CC²X–؏r—YC…–ì KˆêC÷ˆä N°CŽO‘î —Ç•FCÂÀ ˜a—²C—é–Ø •¶’jF SŽº—¬o˜HƒŠƒGƒ“ƒgƒŠ[«•p”‚É‚¨‚¯‚éƒoƒ‹ƒUƒŒƒo“´‚ðŠÜ‚ފɏ™“`“±˜H‚Ì“¯’è‚ƃJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“¬Œ÷•”ˆÊD ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  59. ŠÖŒû K•vCV“c ‡ˆêC²X–Ø ‹BC‘吼Œ’‘¾˜YC”óŒû WŽiC‘吼 —²sC‹{–{ ‹M—fC”ö—Ñ “OC’O”g –¾”ŽC‚‹´ ~CÂÀ ˜a—²C‰Æâ ‹`lCˆé•” ŒõÍF ’·ŠúŠÔ‚̐S–[×“®‚ð—L‚·‚鍂“xS‹@”\’ቺŒ^‚É‚¨‚¯‚éS–[’†Šuƒy[ƒVƒ“ƒO‚ƃAƒ~ƒIƒ_ƒƒ“•¹—p“Š—^‚Ì—L—p«D ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  60. “n•Ó dsF ƒtƒ@ƒCƒAƒTƒCƒhƒVƒ“ƒ|ƒWƒEƒ€Iu•s®–¬Š³ŽÒ‚̉^“]‹–‰Â‚ÉŠÖ‚·‚鏔–â‘èv•s®–¬‚É‹Nˆö‚·‚鎸_—á‚̉^“]–Æ‹–Žæ“¾„Ÿ‚킪‘‚̍‡“¯ŒŸ“¢ˆÏˆõ‰ï‚̍l‚¦•û„ŸD ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  61. “n•Ó dsC‰· ŒiC‹v‰ê Œ\—SCŽR“c‚³‚‚«CŽRŒû ›ÜC•û –MbC‹{‰º ‹C’Ë“c Œ[“ñC_’¹ –¾•FF ‹•ŒŒ«SŽ¾Š³‚̐f’f‚É‚¨‚¯‚éSŽ¥}Ï•ª’l‚Ì—L—p«‚ÌŒŸ“¢D ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  62. –ìŠÔ ”üC¼‰º¹”V•C•½¼ —SŽiCåŒ´ ŒªC‹v‰ê Œ\—SCŽ²‰® ’qºF ‰ESŽº“à‚Å‚h‚b‚cƒŠ[ƒh’fü‚ð”F‚ß‚½ —á|’¿‚µ‚¢ƒŠ[ƒh’fü|D ‘æ19‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïŠwpW‰ïiVŠƒjC5ŒŽC2004
  63. ‹g“c ˆè—YC–{ŠÔ ŠoCˆÀ•”ˆä½lC‘º‰z LsC¯ ’q–çC‰F–ìŠó¢ŽqC‘å’Ë ’è“¿CŽRŒû ›ÜF ŠÌ‘Ÿ“à‚É‘½”­«Žîᎂð—L‚·‚鍂“x”x‚ŒŒˆ³Ç‚̏ǗáD ‘æ6‰ñ”x‚ŒŒˆ³Ž¡—ÃŒ¤‹†‰ïi“Œ‹žjC5ŒŽC2004
  64. ‰F–ìŠó¢ŽqC–{ŠÔ ŠoCˆÀ”{ ‘å•ãC’†¼ Œ[‘¾CŠÛŽR G˜aC•“c “OCåŒ´ ŒªCŽRŒû ›ÜF [•”Ã–¬ŒŒðÇ‚Ì’´‰¹”gŠŒ©[RI ŒŸ¸‚Ƃ̈Ⴂ[D ‘æ24‰ñ“ú–{Ã–¬Šw‰ï‘‰ïiŽOdjC6ŒŽC2004
  65. “n•Ó dsC‰· ŒiC‹v‰ê Œ\—SCŽR“c‚³‚‚«C•ˆÀ –@”VC‹{‰º ‹C•û –MbC_’¹ –¾•FCŽRŒû ›ÜF ƒVƒ“ƒ|ƒWƒEƒ€1uS‘ŸŽ¥ŠEŒv‘ª„ŸÅ‹ß‚̐i•àvSŽ¥ƒ}ƒ‹ƒ`“d—¬ƒxƒNƒgƒ‹ƒ_ƒCƒAƒOƒ‰ƒ€–@ Multi-current-vector Diagram Method ‚É‚æ‚é‹•ŒŒ«SŽ¾Š³•]‰¿D ‘æ19‰ñ“ú–{¶‘ÌŽ¥‹CŠw‰ï‘å‰ïi“¿“‡jC6ŒŽC2004
  66. ”üè ¹ŽqC‰Í–ì —¹C‹g“cŒ’‘¾˜YC’†¼ Œ[‘¾C“n•Ó dsCŽRŒû ›ÜF “¯–E‚É”­Ç‚µ‚½ŽYåñS‹ØÇ‚Ì“ñÇ—áD ‘æ192‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC6ŒŽC2004
  67. ì‘º —´C“n•Ó NŽuC“’ì –¾˜aC—é–Ø ÍOC“c’†Šì”ü•vCŽRŒû ›ÜF •Û‘¶“IŽ¡—ÂɂČy‰õ‚µ‚½ŽYåñS‹ØÇ‚Ì“ñ—áD ‘æ192‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC6ŒŽC2004
  68. V•y ‹`ŒòCì“ˆ Í_C›’J ’‰KC•x‘ò IŽ¡C“n•Ó dsCŽRŒû ›ÜF uL‰»ƒWƒXƒ`ƒOƒ~ƒ“iƒEƒuƒŒƒ`ƒhj‚É‚æ‚éƒRƒŠƒ“ì“®«ƒNƒŠ[ƒ[v‚Ɓu‚½‚±‚‚ڌ^S‹ØÇv‚ð‡•¹‚µ‚½ˆê—áD ‘æ192‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC6ŒŽC2004
  69. ‹{“à ‘ìF ”x‚ŒŒˆ³ES•s‘S‚ƃGƒ“ƒhƒZƒŠƒ“D ‘æ19‰ñŽ ‰êS•s‘SŒ¤‹†‰ïiŽ ‰êjC6ŒŽC2004
  70. ‹g“cŒ’‘¾˜YC‹v‰ê Œ\—SC‰““¡ —DŽ}Cm•Û •¶•½C—é–Ø ÍOC‹à–{ “sC‰|–{ ^”üCŽRŒû ›ÜC‡‰® ‰ë•FC‰Æâ ‹`lF ƒtƒ@ƒ[Žl’¥ÇpŒã‚Ì dual loop reentry‚ɑ΂·‚éØŠJüፍ­|ŽOë•Ù—֊Ԃ̐üóÄŽÜ‚Å‚Í’âŽ~‚¹‚¸AŽOë•Ù—ց|‰º‘åÃ–¬‹¬•”‚¨‚æ‚ѐ؊Jü|‰º‘åÃ–¬ŠÔ‚̐üóÄŽÜ‚É‚æ‚荪Ž¡‚µ‚½Ç—áD ‘æ34‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi“Œ‹žjC6ŒŽC2004
  71. ‘]Œ´ ‹`Œ°C‘å’Ë ’è“¿CŽRŒû ›ÜF ‚ŒŒˆ³Š³ŽÒ‚ÌŒŒˆ³“ú“à•Ï“®‚Æ‘O˜rŒŒŠÇ’ïR‚Ì“ú“à•Ï“®‚Æ‚ÌŠÖ˜A«D ‘æ28‰ñˆïéŒ§‚ŒŒˆ³Œ¤‹†‰ïi‚‚­‚΁j C6ŒŽC2004
  72. “n•Ó NŽuC“’ì –¾˜aC—é–Ø ÍOC“c’†Šì”ü•vC“n•Ó dsCŽRŒû ›ÜF –³Çó‚̏‰‰ñPCIŒãŠ³ŽÒ‚ɑ΂·‚閝«ŠúCAG‚Ì—L—p«D ‘æ13‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi–¼ŒÃ‰®jC7ŒŽC2004
  73. £”ö —RLC‘O“c —TŽjCâª‚Ý‚¿ŽqC“n•Ó dsCŽRŒû ›ÜF ‹}«Š¥ÇŒóŒQ‚É‚¨‚¯‚éRadius stent ‚Ì—L—p«D ‘æ13‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi–¼ŒÃ‰®jC7ŒŽC2004
  74. ‹v‰ê Œ\—SC‰““¡ —DŽ}C—é–Ø ÍOC‹g“cŒ’‘¾˜YCÂÀ ˜a—²CŽRŒû ›ÜF SŽº•p”^SŽº×“®‚ɑ΂·‚éƒAƒ~ƒIƒ_ƒƒ“‚ÌŒø‰ÊD ‘æ3‰ñƒjƒtƒFƒJƒ‰ƒ“ƒgŒ¤‹†‰ïi“Œ‹žjC7ŒŽC2004
  75. ‹g“cŒ’‘¾˜YC‹g“c ˆè—YC—é–Ø ÍOC‰““¡ —DŽ}C‹v‰ê Œ\—SCÂÀ ˜a—²CŽRŒû ›ÜF Ú×‚Èsubstrate-mapping‚ª•p”‚̍ªŽ¡‚É—L—p‚Å‚ ‚Á‚½ pleomorphic VT‚𔺂Á‚½Šg’£Œ^S‹ØÇ‚̈ê—áD ‘æ12‰ñŠÖ“ŒƒAƒuƒŒ[ƒVƒ‡ƒ“EƒZƒ~ƒi[i“Œ‹žjC7ŒŽC2004
  76. ‰ÆŒõ ‘fsC‘O“c ´ŽiC‹{“à ‘ìF ƒXƒ|[ƒcS‘Ÿ‚ÌŒ`¬‰ß’ö‚É‚¨‚¯‚éS‘Ÿ‚̃Gƒ“ƒhƒZƒŠƒ“ŽY¶‚Ì•Ï“®D ‘æ131‰ñ“ú–{‘̗͈ãŠw‰ïŠÖ“Œ’n•û‰ïi“Œ‹žjC7ŒŽC2004
  77. ‰ÆŒõ ‘fsC‘O“c ´ŽiC‹{“à ‘ìF ˆê‰ß«‰^“®‚É‚æ‚éS‘Ÿ‚Ìimmediate early genes‚ÌŒoŽž“I•Ï‰»D ‘æ12‰ñ“ú–{‰^“®¶—Šw‰ï‘å‰ïi¬“cjC7ŒŽC2004
  78. ˆ±â —²ˆêC‘åX ”£C‹v–ì •ˆ–çCŸ“c –΁CˆÀ“c rLCì“ˆ Ž‡”TC‘å’Î ‹BC‘O“c ´ŽiC¼“c Œõ¶C“n•Ó dsCŽRŒû ›ÜF ŒãŠú‚—îŽÒ‚̉^“®•‰‰×„ŸˆÀ‘S«‚¨‚æ‚щ^“®‘ϐ«D ‘æ54‰ñzŠÂŠí•‰‰×Œ¤‹†‰ïi“Œ‹žj8ŒŽC2004
  79. ‰ÆŒõ ‘fsC‹{“à ‘ìC‰ºžŠ MˆÐC‘O“c ´ŽiC“üŽ­ŽR—eŽqC‘å‹v•Û „C“c’† K‹vCŽRŒû ›ÜF SHR ‚ɑ΂·‚émedium-chain triglyceride(MCT) ‚Ì’·Šú“Š—^‚ÍPPAR- ƒ¿ activation ‚ð‰î‚µ‚ĐVƒGƒlƒ‹ƒM[‘ãŽÓES‹@”\ES”ì‘å‚ð‰ü‘P‚·‚éD Cardiovasucular Medicine 21 ‘æ4‰ñƒtƒH[ƒ‰ƒ€i“Œ‹žjC8ŒŽC2004
  80. –{ŠÔ ŠoF ’´‰¹”g–@‚É‚æ‚錌ŠÇ‚ÆŒŒ—¬‚Ì’è—Ê“IŒv‘ª[ƒfƒWƒ^ƒ‹Žž‘ã‚ÌŒŒŠÇƒGƒR[ŒŸ¸[D ‘æ1‰ñŠÖ“ŒbM‰z‘Šú“®–¬d‰»Œ¤‹†‰ïu‰‰‰ïi“Œ‹žjC8ŒŽC2004
  81. •ˆÀ –@”VC“n•Ó dsC¯ ’q–çC‹g“c ˆè—YC‘º‰z LsC£”ö —RLC‰Í–ì —¹C–{ŠÔ ŠoCŽRŒû ›ÜF ‰EŠ¥“®–¬‚Ö‚ÌPCI’†‚ɉEŠ¥“®–¬‹ßˆÊ•”‚É‹ts«‰ð—£‚𐶂¶A‰ð—£‚ª‘å“®–¬•Ç‚É‚¨‚æ‚ñ‚¾1—áD ‘æ25‰ñ’}”gƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ƒVƒlƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‚‚­‚΁jC8ŒŽC2004
  82. ‘å’Î ‹BC‹Cå—LŽÀŽqC›Œ´ ‡C‰¡ŽR “TŽqC“c•Ó  C‹{“à ‘ìC‘O“c ´ŽiC‹v–ì •ˆ–çCéˍ⠗²ˆêC¼“c Œõ¶F “®–¬L“W«‚ª’ቺ‚·‚é‚Ɖ^“®Žž‚̐S‹ØŽ_‘fÛŽæ—Ê‚Í‘‘å‚·‚éD ‘æ59‰ñ“ú–{‘̗͈ãŠw‰ï‘å‰ïi‘å‹{jC9ŒŽC2004
  83. ‘O“c ´ŽiC‰ÆŒõ ‘fsC›Œ´ ‡C‹{“à ‘ìF 8TŠÔ‚̋ؗ̓gƒŒ[ƒjƒ“ƒO‚ªƒqƒgŒŒ’†ƒGƒ“ƒhƒZƒŠƒ“”Z“x‚É‹y‚Ú‚·‰e‹¿D ‘æ59‰ñ“ú–{‘̗͈ãŠw‰ï‘å‰ïi‘å‹{jC9ŒŽC2004
  84. ‰ÆŒõ ‘fsC‘O“c ´ŽiC‹{“à ‘ìF ˆê‰ß«‰^“®‚É‚æ‚éS‘Ÿ‚Ìmitogen-activated protein kinaseŠˆ«‚ÌŒoŽž“I•Ï‰»D ‘æ59‰ñ“ú–{‘̗͈ãŠw‰ï‘å‰ïi‘å‹{jC9ŒŽC2004
  85. ‹v‰ê Œ\—SCŽRŒû ›ÜF ƒpƒlƒ‹EƒfƒBƒXƒJƒbƒVƒ‡ƒ“ ’vŽ€«•s®–¬‚ɑ΂·‚é”ñ–ò•¨—Ö@‚¨‚æ‚Ñ–ò•¨—Ö@‚̍őOü-ICDAƒAƒ~ƒIƒ_ƒƒ“‚Í“Ë‘RŽ€‚ðŒ¸‚ç‚µ‚½‚©ƒAƒ~ƒIƒ_ƒƒ“AICD‚ÌŒ÷ßD ‘æ62‰ï“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi‹ž“sjC9ŒŽC2004
  86. £”ö —RLC‘O“c —TŽjC¯ ’q–çCâª‚Ý‚¿ŽqC“n•Ó dsCŽRŒû ›ÜF ƒgƒƒ|ƒjƒ“T—z«AƒqƒgS‘ŸŒ^Ž‰–bŽ_Œ‹‡’`”’iH-FABPj‰A«‚ðŽ¦‚·‹}«Š¥ÇŒóŒQ‚ÌŒŸ“¢D ‘æ52‰ï“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi‹ž“sjC9ŒŽC2004
  87. ‹g“cŒ’‘¾˜YC‹v‰ê Œ\—SC‰““¡ —DŽ}Cm•Û •¶•½C—é–Ø ÍOC‹à–{ “sC‰|–{ ^”üCÂÀ ˜a—²CŽRŒû ›ÜF ‰EŽº—¬o˜H‹NŒ¹SŽºŠúŠOŽûk‚ɑ΂·‚鍂Žü”gƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚¨‚¯‚éƒoƒXƒPƒbƒgƒJƒe[ƒeƒ‹‚Ì—L—p«D ‘æ21‰ñ“ú–{S“dŠw‰ïi‹ž“sjC9ŒŽC2004
  88. ¬‘î N”VC‘å’Ë ’è“¿C“c’†—D”üŽqC‹g“c ˆè—YCŒã“¡ “TŽqCV“¡ ‰ëŽiC“ì ŠwCŽRŒû ›ÜF ‹·SÇŠ³ŽÒ‚ÆŒ’íŽÒ‚É‚¨‚¯‚éMRI‚ð—p‚¢‚½ŠeŽíS‹ØŠÁ—¬Žw•W‚Ì”äŠrD ‘æ52‰ï“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi‹ž“sjC9ŒŽC2004
  89. “n•Ó dsC‹v‰ê Œ\—SCŽRŒû ›ÜF ‘æ52‰ñ“ú–{S‘Ÿ•aŠw‰ïE‘æ21‰ñ“ú–{S“dŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€u•s®–¬Ž¡—ÂƂ»‚ÌŒø‰Ê -QOL‚Æ—\Œã‚̉ü‘P‚ð‚ß‚´‚µ‚Ä v•s®–¬Ž¡—ÂƎԂ̉^“]D ‘æ52‰ï“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi‹ž“sjC9ŒŽC2004
  90. ‹v‰ê Œ\—SCŽRŒû ›ÜF ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“u’vŽ€«•s®–¬‚ɑ΂·‚é”ñ–ò•¨—Ö@‚¨‚æ‚Ñ–ò•¨—Ö@‚̍őOü| ICDAƒAƒ~ƒIƒ_ƒƒ“‚Í“Ë‘RŽ€‚ðŒ¸‚ç‚µ‚½‚©|uƒAƒ~ƒIƒ_ƒƒ“AICD‚ÌŒ÷ß‚ɂ‚¢‚āvD ‘æ52‰ï“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi‹ž“sjC9ŒŽC2004
  91. ¬Œ` ŠxŠ°C‹{“à ‘ìC‰ºžŠ MˆÐC‘àV _ˆêCŽRŒû ›ÜF PPAR-ƒ¿ŽhŒƒ–ò‚Å‚ ‚éfenofibrate ‚ÍDOCA-salt ‚ŒŒˆ³«ƒ‰ƒbƒgS‘Ÿ‚É‚¨‚¢‚ĐS‹ØüˆÛ‰»‚ÆŠg’£”\‘žˆ«‚ð—}§‚·‚éD ‘æ7‰ñÅæ’[zŠÂŠíƒtƒH[ƒ‰ƒ€i’W˜HjC9ŒŽC2004
  92. ‘å’Î ‹BC‘ºã °C“c•Ó  C‹{“à ‘ìC‘O“c ´ŽiC‹v–ì •ˆ–çC¼“c Œõ¶F 70‘ã‚̍‚—îŽÒ‚É‚¨‚¯‚é’á‹­“x‚Ì—LŽ_‘f«ƒgƒŒ[ƒjƒ“ƒO‚ª“®–¬ŒnƒRƒ“ƒvƒ‰ƒCƒAƒ“ƒX‚É‹y‚Ú‚·‰e‹¿D “ú–{‘̈çŠw‰ï‘æ55‰ñ‘å‰ïi’·–ìjC9ŒŽC2004
  93. ‘O“c ´ŽiC‰ÆŒõ ‘fsC‹{“à ‘ìC“c•Ó  C‹v–ì •ˆ–çC¼“c Œõ¶F ˆê‰ß«‰^“®‚Æ‘å“®–¬‚É‚¨‚¯‚éˆâ“`Žqƒvƒƒtƒ@ƒCƒŠƒ“ƒOD “ú–{‘̈çŠw‰ï‘æ55‰ñ‘å‰ïi’·–ìjC9ŒŽC2004
  94. ‰ÆŒõ ‘fsC‘O“c ´ŽiC‹{“à ‘ìC“c•Ó  C¼“c Œõ¶F ˆê‰ß«‰^“®‚É‚¨‚¯‚éS‘Ÿ‚̈â“`Žqƒvƒƒtƒ@ƒCƒŠƒ“ƒOD “ú–{‘̈çŠw‰ï‘æ55‰ñ‘å‰ïi’·–ìjC9ŒŽC2004
  95. ²“¡ —zŽqC“n•Ó dsC”üè ¹ŽqC•ˆÀ –@”VC‰Í–ì —¹C‘å’Ë ’è“¿CŽRŒû ›ÜF Š¥“®–¬‘¢‰e’†‚É”­Œ©‚³‚ꂽŠ¥“®–¬“àŒŒð‰e‚ªƒwƒpƒŠƒ““Š—^‚É‚æ‚è’ZŽžŠÔ‚ŏÁŽ¸‚µ‚½ˆê—áD ‘æ193‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC9ŒŽC2004
  96. “c’† ‘׏́C‰¡ŽR ‘לAC”Ñ“c Œ[‘¾C—é–Ø GrCˆÉ“¡ —S•ãC–ì—¢ ŽõŽjC¬–x “ÖŽuCŒKŒ´ ‘åŽuC²“¡ –¾C‚‹´ ~CœA] “¹ºCÂÀ ˜a—²Cˆé•” ŒõÍF ‘½Ê‚ȐS‹@”\áŠQ‚𓯎ž‚ɒ悵‚½SƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈êÇ—áD ‘æ193‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC9ŒŽC2004
  97. ÂÀ ˜a—²C‹v‰ê Œ\—SCŽRŒû ›ÜC‚‹´ ~C‰¡ŽR ‘לACŠÖŒû K•vCŽR“à NÆCV“c ‡ˆêF ƒVƒ“ƒ|ƒWƒEƒ€uƒAƒ~ƒIƒ_ƒƒ“‚Æ”xÃ–¬ƒAƒuƒŒ[ƒVƒ‡ƒ“‚̃nƒCƒuƒŠƒbƒhŽ¡—Âɂæ‚閝«S–[×“®‚ÌŽ¡—ÁvD ‘æ9‰ñƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ïi“Œ‹žjC9ŒŽC2004
  98. ¯ ’q–çC‰Í–ì —¹C”üè ¹ŽqC”Ñ“c Œ[Ž¡C“n•Ó dsCŽRŒû ›ÜF ‰º‚‘ÌŽîᇓEop‚ƃÀŽÕ’f–ò‚ª‘tŒ÷‚µ‚½––’[”ì‘åÇ‚É”º‚¤“ñŽŸ«S‹ØÇ‚̈êÇ—áD ‘æ8‰ñ“ú–{S•s‘SŠw‰ï iŠò•ŒjC10ŒŽC2004
  99. Ishikawa K., Ohtsuka S., Yamaguchi I.F Effect of mibefradil, a T-type calcium channel blocker in pigs with heart failure: comparison with amlodipine, a L-type calcium channel blocker. ‘æ8‰ñ“ú–{S•s‘SŠw‰ï iŠò•ŒjC10ŒŽC2004
  100. ‘ŠŒ´ ‰p–¾C•ˆÀ –@”VC“n•Ó dsCÄ“¡ IC]“c ˆê•FCÎŽR ŽÀŽ÷Cm‰È G’CV•y ‹`ŒòCX–{ —²ŽjCˆ±â —²ˆêCŽRŒû ›ÜC•“c “OF ATP•‰‰×Žž‚É”F‚ß‚ç‚ê‚鍶ŽºŽûk”\EŠg’£”\áŠQ‚ÌŒŸ“¢D ‘æ32‰ñˆïéŒ§—Տ°ŠjˆãŠwŒ¤‹†‰ïi“y‰Yj10ŒŽC2004
  101. ƒWƒFƒXƒ~ƒ“ ƒTƒuƒŠƒiC²‹vŠÔˆê˜YC•xŠ~ œAŽqC‹g‰ª [OC•ž•” —TˆêCŒã“¡ Ÿ”NC‹{“à ‘ìF ƒGƒ“ƒhƒZƒŠƒ“Žó—e‘ÌŽÕ’f–ò‚́A”]‘²’†ˆÕ”­¶‚ŒŒˆ³ƒ‰ƒbƒg‚̐S‘Ÿ‚É‚¨‚¯‚éD Renin-Angiotension Œn‚ÌŠeƒRƒ“ƒ|[ƒlƒ“ƒg‚Ì”­Œ»‚Ì’˜–¾‚È‘‘å‚𐳏퉻‚·‚é
  102. ƒWƒFƒXƒ~ƒ“ ƒTƒuƒŠƒiC²‹vŠÔˆê˜YC•xŠ~ œAŽqC‹g‰ª [OC•ž•” —TˆêCŒã“¡ Ÿ”NC‹{“à ‘ìF ‚ŒŒˆ³‚É‚æ‚Á‚Ĉø‚«‹N‚±‚³‚ê‚é‘O“ª—t‚ł̐_ŒoŒŒŠÇŒnƒŠƒ‚ƒfƒŠƒ“ƒO‚ɑ΂µ‚āAƒGƒ“ƒhƒZƒŠƒ“Žó—e‘ÌŽÕ’f–ò‚͉ü‘PŒø‰Ê‚ðŽ¦‚· [”]‘²’†ˆÕ”­Ç‚ŒŒˆ³ƒ‰ƒbƒg‚Å‚ÌŒŸ“¢[D ‘æ111‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ïi‚‚­‚΁jC10ŒŽC2004
  103. ‰F–ìŠó¢ŽqC–{ŠÔ ŠoCˆÀ”{ ‘å•ãC’†¼ Œ[‘¾C•“c “OCd“c Ž¡CåŒ´ ŒªCŽRŒû ›ÜF ”xŒŒðÇðÇ‚É‚¨‚¯‚éÇðŒ¹‚Æ‚µ‚Ă̐[•”Ã–¬ŒŒðÇ‚ÌŒŸ“¢D ‘æ45‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïiŽD–yjC10ŒŽC2004
  104. ‘å’Ë ’è“¿CŽRŒû ›ÜF u•úŽËŒõ‚̗Տ°‰ž—pFŒoÃ–¬Š¥“®–¬‘¢‰ev‚o‚e§’k‰ïƒOƒ‹[ƒvuˆãŠw—˜—pvCSpring-8—˜—pŽÒ§’k‰ïƒTƒuƒOƒ‹[ƒvD uˆãŠw—˜—pv ‡“¯Œ¤‹†‰ï i‚‚­‚΁jC10ŒŽC2004
  105. ƒWƒFƒXƒ~ƒ“ ƒTƒuƒŠƒiC²‹vŠÔˆê˜YC•xŠ~ œAŽqC‹g‰ª [OC•ž•” —TˆêC‹{“à ‘ìCŒã“¡ Ÿ”NF ƒGƒ“ƒhƒZƒŠƒ“Žó—e‘ÌŽÕ’f–ò‚́A”]‘²’†ˆÕ”­¶‚ŒŒˆ³ƒ‰ƒbƒg‚Ì”ì‘åS‚É‚Ä’˜–¾‚É‘‘債‚½Renin-Angiotension Œn‚ÌŠeƒRƒ“ƒ|[ƒlƒ“ƒg‚Ì”­Œ»‚𐳏퉻‚·‚éD ‘æ14‰ñ“ú–{zŠÂ–ò—Šw‰ïiÃ‰ªjC11ŒŽC2004
  106. X–{ —²ŽjC•ˆÀ –@”VC“n•Ó dsC‘ŠŒ´ ‰p–¾CÎŽR ŽÀŽ÷Cm‰È G’CV•y ‹`ŒòCŽRŒû ›ÜF Ž¡—ÃŒø‰Ê‚Ì”»’è‚ɉ^“®•‰‰×SPECT‚ª—L—p‚Å‚ ‚Á‚½‘Sg«d‰»Ç‚̈ê—áD ‘æ12‰ñ“ú–{S‘ŸŠjˆãŠw‰ï‘‰ïEŠwp‘å‰ïi‹ž“sjC11ŒŽC2004
  107. ‹{“à ‘ìC‘O“c ´ŽiF ƒGƒ“ƒhƒZƒŠƒ“D ‘æ8‰ñ“ú–{SŒŒŠÇ“à•ª”å‘ãŽÓŠw‰ïŠwp‘‰ïi‹{èjC11ŒŽC2004
  108. ”üè ¹ŽqC‹g“cŒ’‘¾˜YC‰Í–ì —¹C“n•Ó dsCŽRŒû ›ÜF Ž¡—Âɓïa‚µ‚½Ž©ŒÈ–Ɖu«S‹Ø‰Š‚̈ê—áD ‘æ12‰ñˆïézŠÂŠíŒ¤‹†‰ïi“y‰Yj11ŒŽC2004
  109. V•y ‹`ŒòC•x‘ò IŽ¡CˆÀ”{ ‘å•ãC“n•Ó dsCŽRŒû ›ÜF Hairy cell”’ŒŒ•aŽ¡—Ã’†ƒŠƒcƒLƒVƒ}ƒu“Š—^‚É‚æ‚è”­Ç‚µ‚½‘ûšâŒ^S‹ØÇ‚̈ê—áD ‘æ194‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC12ŒŽC2004
  110. “’ì –¾˜aC“n•Ó NŽuC—é–Ø ÍOC“c’†Šì”ü•vC¬‘î N”VCŽR“à F‹`CŽRŒû ›ÜF PCI‚É‚æ‚銥“®–¬úEŒã‚ÉŒ`¬‚³‚ꂽ‰¼«“®–¬áŽŽ©‘R•ÂÇ‚µ‚½ˆê—áD ‘æ194‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC12ŒŽC2004
  111. ‹g“c ˆè—YC¯ ’q–çC‘º‰z LsC“n•Ó dsC•ˆÀ –@”VC£”ö —RLCÂÀ ˜a—²C‹v‰ê Œ\—SCŽRŒû ›ÜF ¶‘O‰ºsŽ}‹·ó‚É”º‚¤‹•ŒŒ”­ì‚ɍۂµCŠ®‘S–[ŽºƒuƒƒbƒNES’âŽ~‚Æ‚È‚Á‚½ˆê—áD ‘æ194‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC12ŒŽC2004
  112. ‹gè ²C–x ‘וFCà_ ‹`”VC’·‹´ ’B˜YC‚“c ”Ž”VCÂÀ ˜a—²C‚‹´ ~F ”­ì«S–[×“®‚ɑ΂·‚铯‘¤”xÃ–¬ˆêŠ‡ÄŽÜŠu—£p‚ðŽ{sŒã‚É–ƒáƒ«ˆÝŠg’£‚𗈂µ‚½ˆê—áD ‘æ194‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC12ŒŽC2004
  113. ‹g“cŒ’‘¾˜YC‹v‰ê Œ\—SCÂÀ ˜a—²F “´’²—¥Žž‚É‚¨‚¯‚éÚ×‚Èsubstrate-mapping‚É‚æ‚è•p”‰ñ˜H‚Ì“¯’肪‚ ‚ç‚©‚¶‚߉”\‚Å‚ ‚Á‚½Šg’£Œ^S‹ØÇ‚ɍ‡•¹‚µ‚½Ž‘±«SŽº•p”‚̈ê—áD ‘æ3‰ñ•½‰ª•s®–¬Œ¤‹†‰ïi”MŠCjC12ŒŽC2004

@@@¡ Œ¤‹†•ñ

  1. ¯ ’q–çC‰Í–ì —¹C¼ Œ÷C”üè ¹ŽqC”Ñ“c Œ[Ž¡C“n•Ó dsCŽRŒû ›ÜF Šg’£Œ^S‹ØÇ‚É‚¨‚¢‚ăJƒ‹ƒxƒWƒ[ƒ‹‚ªQT dispersion‚É‹y‚Ú‚·‰e‹¿D “Á”­«S‹ØÇ‚ÉŠÖ‚·‚é’²¸Œ¤‹†”Ç•½¬15”N“x‘æ2‰ñ”ljï‹ciŽD–yjC2ŒŽC2004
  2. ŽRŒû ›ÜC¬Œ` ŠxŠ°C‰ºžŠ MˆÐC‘àV _ˆêC‰Í–ì —¹C‹{“à ‘ìF in vivo ‚ŒŒˆ³”ì‘åS‚É‚¨‚¯‚éPPARƒ¿ŽhŒƒ–òifenofibrate)‚̐S‹ØüˆÛ‰»‚ƍ¶ŽºŠg’£”\‚ɑ΂·‚錟“¢D Œú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹ài“«Ž¾Š³Ž•žŒ¤‹†Ž–‹Æj•ª’SŒ¤‹†•ñ pp63-65C3ŒŽC2004
  3. ŽRŒû ›ÜF “dŽ¥}‚ð—p‚¢‚½”ñŠÏŒŒ“IƒqƒX‘©“dˆÊ‹L˜^•û‚ÉŠÖ‚·‚錤‹† Œú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹àŒø‰Ê“Iˆã—ËZp‚ÌŠm—§„i—Տ°Œ¤‹†Ž–‹ÆD •s®–¬Ž€‚Ì—\’m‚Æ—\–hƒKƒCƒhƒ‰ƒCƒ“ì¬‚ÉŠÖ‚·‚錤‹†i‰Û‘è”ԍ†H15-S‹Ø-06j•½¬15”N“x‘Š‡Œ¤‹†•ñ‘ pp.12-14C3ŒŽC2004
  4. ¬Œ` ŠxŠ°C‹{“à ‘ìC‰ºžŠ MˆÐC‘àV _ˆêCŽRŒû ›ÜF in vivo ‚ŒŒˆ³”ì‘åS‚É‚¨‚¯‚éPPARƒ¿ ŽhŒƒ–ò(fenofibrate)‚̐S‹ØüˆÛ‰»‚ƍ¶ŽºŠg’£”\‚ɑ΂·‚錟“¢D “Á”­«S‹ØÇ‚ÉŠÖ‚·‚é’²¸Œ¤‹†”Ç•½¬16”N“x‘æ1‰ñ”ljï‹ciŽD–yjC10ŒŽC2004

@@@¡ ‚»‚Ì‘¼

  1. ‹v‰ê Œ\—SF Šw¶’èŠúŒ’Nf’fFS“d}‚ÌŒ‹‰ÊD •½¬14”N“x•ÛŒ’ŠÇ—ƒZƒ“ƒ^[‹Æ–±•ñ‘F22|22C1ŒŽC2004
  2. ÎŒõ •qsF zŠÂŠíf—ÂƍRŒŒ¬”—Ö@D …‹½ˆãŽt‰ïŠwpu‰‰‰ïi–ƒ¶jC1ŒŽ21“úC2004
  3. ‰Í–ì —¹F ”]ESEtŽ¾Š³‚ð—L‚·‚鍂ŒŒˆ³ÇŽ¡—Â̂±‚D ‰ºŠÙzŠÂŠíuK‰ïi‰ºŠÙjC2ŒŽ4“úC2004
  4. ŽRŒû ›ÜF S‘Ÿ•a‚Ƃ́D ‘æ‚T‰ñŒ§–¯‚Ì‚½‚ß‚ÌŒ’NŠÇ—uÀi‰ºŠÙjC2ŒŽ26“úC2004
  5. “n•Ó dsF S‹Ø[Ç‚É‚È‚ç‚È‚¢‚½‚߂ɁD ‘æ‚T‰ñŒ§–¯‚Ì‚½‚ß‚ÌŒ’NŠÇ—uÀi‰ºŠÙjC2ŒŽ26“úC2004
  6. ‘å’Ë ’è“¿ F ‚ŒŒˆ³‚Æ‚¢‚í‚ꂽ‚çD ‘æ‚T‰ñŒ§–¯‚Ì‚½‚ß‚ÌŒ’NŠÇ—uÀi‰ºŠÙjC2ŒŽ26“úC2004
  7. ‹v‰ê Œ\—SF ŒÃ‚­‚ĐV‚µ‚¢•a‹CuŠ´õÇvD ‚‚­‚ÎStudents 546:6|6C2004
  8. ‰Í–ì —¹F •a‹C‚ª‚Ý‚¦‚é Vol2 zŠÂŠíŽ¾Š³D ¬l•ai¶ŠˆKŠµ•ajƒjƒ…[ƒXƒŒƒ^[ vol3(3) F6C3ŒŽC2004
  9. ŽRŒû ›ÜF S–[×“®Ž¡—Â̖â‘è“_D ‘æ1‰ñ“ú—§S‘Ÿ•a§˜b‰ïi“ú—§jC5ŒŽ14“úC2004
  10. ŽRŒû ›ÜF “ú–{‚Ì•s®–¬D ‘æ1‰ñ“ú’†‘å˜A•a‰@‰ï‘‰ïi“Œ‹žjC5ŒŽ16“úC2004
  11. ŽRŒû ›ÜF ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[uSŽ¥}‚É‚æ‚é‹•ŒŒ«SŽ¾Š³‚Æ•s®–¬‚̐f’fvD ‘æ43‰ñ“ú–{ƒGƒ€EƒC[Šw‰ï‘å‰ïi‹à‘òjC5ŒŽ21“úC2004
  12. ŽRŒû ›ÜF S–[×“®‚É‚¨‚¯‚éÅ‹ß‚ÌŽ¡—Â̍l‚¦•ûD “ú–{ˆã‘匧¼ ¥‚‚­‚Ίwpu‰‰‰ïi‚‚­‚΁jC6ŒŽ19“úC2004
  13. ÂÀ ˜a—²F ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[uRoles of Multi-Channel Blocker Therapy for Atrial Fibrillation vD The 31st International Congress on Electroclogy i‹ž“sjC6ŒŽ28“úC2004
  14. “n•Ó dsF SŽ¾Š³‹y‚Ñ“®–¬d‰»«Ž¾Š³‚ɑ΂·‚é‰^“®—Ö@‚ÌŒø‰Ê‚ÆŽÀÛ‚ɂ‚¢‚āD ^•ÇŒSŽsˆãŽt‰ïŠwpu‰‰‰ïi‰ºŠÙjC6Œú29“úC2004
  15. ‰Í–ì —¹F ‘æ98‰ñÄŒ»ˆãŽt‘‰ÆŽŽŒ±–â‘è‰ðàFzŠÂŠí@98‰ñÄŒ»ˆãŽt‘‰ÆŽŽŒ±–â‘è‰ðà‘D ˆãŠw•]˜_ŽÐi“Œ‹žjC6ŒŽ30“úC2004
  16. ‰Í–ì —¹F SƒGƒR[‚ð—p‚¢‚½Šg’£”\‚ÌŒv‘ª‚ɂ‚¢‚āD ‘æ4‰ñ Symposium of Meet the Professor in Cardiovascular Disease i“Œ‹žjC7ŒŽ10“úC2004
  17. ‹{“à ‘ìF S•s‘SŽ¡—Â̐V‚µ‚¢“WŠJD ‰ºŠÙzŠÂŠíuK‰ïi‰ºŠÙjC7ŒŽ14“úC2004
  18. ÂÀ ˜a—²F S–[×“®‚̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ -V‚½‚Ȃ鍪Ž¡‚ÌŽŽ‚Ý-D •s®–¬Šwpu‰‰‰ïi–k‹ãBjC7ŒŽ22“úC2004
  19. “n•Ó dsF •s®–¬‚ÆŽ¸_A‚¨‚æ‚ÑŽ©“®ŽÔ‚̉^“]‚ɂ‚¢‚āD ‘S‘ŒxŽ@ŠwZ‰^“]“K³‘Š’kê‰Èi‘åãjC7ŒŽ27“úC2004
  20. ŽRŒû ›ÜF ŽüpŠú‚É‚¨‚¯‚éSŽ¾Š³‚ւ̑Ήž‚ɂ‚¢‚āD ‘æ13‰ñ‰¡{‰êzŠÂŠíƒOƒ‹[ƒv•af˜AŒgŒ¤‹†‰ïi‰¡{‰êjC8ŒŽ10“úC2004
  21. ŽRŒû ›ÜF •s®–¬‚Ì”ñ–ò•¨Ž¡—ÁF‚¢‚A‚ǂ̏Ǘá‚ÉEPS-Ablation‚ðŽwŽ¦‚·‚é‚©H ‘æ31‰ñu•s®–¬‚̐f’f‚ÆŽ¡—Áv“n•”ƒZƒ~ƒi[i“Œ‹žjC8ŒŽ21“úC2004
  22. •ˆÀ –@”VF ACS‚ÌŽ¡—ÂƗ\–hD ‰ºŠÙzŠÂŠíuK‰ïi‰ºŠÙjC9ŒŽ8“úC2004
  23. –{ŠÔ ŠoF •a‰@‚É‚¨‚¯‚éˆã—ÈÀ‘S‚ÌŠî‘b“IŽ–€D ˆã—ÈÀ‘S‚ÉŠÖ‚·‚éu‰‰‰ïF’}”g‹L”O•a‰@ i‚‚­‚΁jC9ŒŽ17“úC2004
  24. ÂÀ ˜a—²F Eˆæ‚É‚¨‚¯‚é•s®–¬‘΍ô-“Á‚ɐSŽº×“®‚É‚¨‚¯‚鎩“®‘ΊOŽ®œ×“®Ší‚Ì—L—p«‚ɂ‚¢‚Ä-D •½¬16”N“xˆïéŒ§ˆãŽt‰ïŽY‹ÆˆãŒ¤C‰ïi…ŒËjC10ŒŽ2“úC2004
  25. ‰Í–ì —¹C“n•Ó dsF Eˆæ‚É‚¨‚¯‚é•s®–¬‘΍ô-ACLS(“ñŽŸ‹~–½ˆ’u)‚ÌŒ»ó‚ɂ‚¢‚Ä-D •½¬16”N“xˆïéŒ§ˆãŽt‰ïŽY‹ÆˆãŒ¤C‰ïi…ŒËjC10ŒŽ2“úC2004
  26. ‹v‰ê Œ\—SF Eˆæ‚É‚¨‚¯‚é•s®–¬‘΍ô|“Á‚ɐSŽº×“®‚É‚¨‚¯‚鎩“®‘ÌŠOœ×“®Ší‚Ì—L—p«‚ɂ‚¢‚ā|D •½¬16”N“xˆïéŒ§ˆãŽt‰ïŽY‹ÆˆãŒ¤C‰ïi…ŒËjC10ŒŽ2“úC2004
  27. “n•Ó dsF S“d}Šî‘bƒZƒ~ƒi[D ‘æ2‰ñŒÄ‹zEzŠÂƒZƒ~ƒi[i‚‚­‚΁jC10ŒŽ3“úC2004
  28. •ˆÀ –@”VF ƒzƒ‹ƒ^[S“d}‚Ì”»“ǁD ‘æ2‰ñŒÄ‹zEzŠÂƒZƒ~ƒi[i‚‚­‚΁jC10ŒŽ3“úC2004
  29. ‰Í–ì —¹F S•s‘S‚̐f’f‚ÆŽ¡—ÁD ^•ÇŒSŽsˆãŽt‰ïŠwpu‰‰‰ïi‰ºŠÙjC10ŒŽ28“úC2004
  30. ÂÀ ˜a—²F S–[×“®Ž¡—ÂÌUp to DateF - V‚½‚È–ò•¨ƒRƒ“ƒrƒl[ƒVƒ‡ƒ“Ž¡—©‚çƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ü‚Å-D ‰«“êƒAƒ~ƒIƒ_ƒƒ“u‰‰‰ïi‰«“êjC11ŒŽ2“úC2004
  31. “n•Ó dsF uSŽ¥Œvv‚Á‚ĉ½H “úŠ§ƒQƒ“ƒ_ƒCi“úŠ§Œ»‘ãF“Œ‹žjC11ŒŽ9“úC2004
  32. ŽRŒû ›ÜF •s®–¬Ž¡—ÍőOü \–ò•¨Ž¡—©‚ç”ñ–ò•¨Ž¡—Âց\D ‘æ11‰ñHealth & Science 20-20i“Œ‹žjC11ŒŽ25“úC2004
  33. ‘å’Ë ’è“¿ F ‚ŒŒˆ³Ž¡—ÂɊւ·‚éu‰‰‰ïD ‹‹vŽsE—´ƒ–èŽsˆãŽt‰ïŠwpu‰‰‰ï i—´ƒ–èj C11ŒŽ26“úC2004
  34. ‹v‰ê Œ\—SF BLS‚É‚¨‚¯‚éAED‚Ì–ðŠ„‚ÆŽg—p–@D …ŒËÏ¶‰ï•a‰@Œ¤C‰ïi…ŒËjC12ŒŽ12“úC2004

@2003”N“xi2003”N1ŒŽ`12ŒŽj


@@@¡ Šw‰ï”­•\

  1. ‘å’Ë’è“¿CŽRŒû ›ÜCŒà ™¤C•“c “OC”ˆä—I“ñCŠÛ‹´ WC•º“¡ˆêsCˆÀ“¡³ŠCF ‚ƒGƒlƒ‹ƒM[‰Á‘¬ŠíŒ¤‹†‹@\‚É‚¨‚¯‚é•úŽËŒõŠ¥“®–¬‘¢‰e‚ÌŒ»óD ‘æ8‰ñ•úŽËŒõˆãŠwŒ¤‹†‰ïu‰‰‰ïi•P˜HjC1ŒŽC2003
  2. ‰Í–ì —¹C”Ñ“c Œ[Ž¡C¼ Œ÷C‘Œ© ’qŽqC”üè ¹ŽqC“n•Ó dsCŽRŒû ›ÜF –«S•s‘S‚ɑ΂·‚éƒÀŽÕ’f–ò—Ö@“±“üŽž‚ɉʂ½‚·BNP‘«’ê‚̈Ӌ`D ‘æ37‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïi“Œ‹žjC1ŒŽC2003 ‘æ37‰ñ“ú–{¬l•ai¶ŠˆKŠµ•ajŠw‰ïƒvƒƒOƒ‰ƒ€E´˜^WF45C2003
  3. Ohtsuka S., Yamaguchi I., Jin W., Takeda T., Itai Y., Maruhashi A., Hyodo K., Ando M.F Ongoing IVCAG Clinical Program in Japan. ‘æ2‰ñ‹ãB•úŽËŒõˆãŠw—˜—pƒVƒ“ƒ|ƒWƒEƒ€i•Ÿ‰ªjC1ŒŽC2003
  4. …’J ‘¾˜YC‚‹´ L“ñC–L‰ª GŒPC–{ŠÔ ŠoC“›ˆä ’B•vF ƒxƒ“ƒgƒiƒCƒgŒœ‘÷‰t‹CŠÇ“à’“ü‚É‚æ‚éV‚µ‚¢–³‹C”xƒ‚ƒfƒ‹ì¬‚ÌŽŽ‚݁D ‘æ30‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï‘‰ïiŽD–yjC2ŒŽC2003
  5. ‹Ñˆä G˜aC‘å’Ë ’è“¿CV•y ‹`ŒòCŽRŒû ›ÜC–{ŠÔ ŠoC…’J ‘¾˜YF “ÁˆÙ‚ÈŒo‰ß‚ðŽ¦‚µ‚½”x‰Š‹…‹Û‚É‚æ‚éARDS‚̈ꐬl—áD ‘æ30‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï‘‰ïiŽD–yjC2ŒŽC2003
  6. ‰F–ìŠó¢ŽqC‹v‰ê Œ\—SC¼”ö ŒhŽqCˆÀ•” ‘å•ãCV•y ‹`ŒòCX–{ —²ŽjCŠÛŽR G˜aC“n•Ó dsCŽRŒû ›ÜCŒ´ ®lF ƒJƒeƒRƒ‰ƒ~ƒ“S‹ØÇ‚É‚æ‚éS•s‘S‚É‚æ‚è”­Œ©‚³‚ꂽŠŒF×–EŽî‚̈ê—áD ‘æ187‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi‰¡•ljC2ŒŽC2003
  7. Î’à ’qŽqCÎŒõ •qsC£”ö —RLCXŽR ’¼ŽqC¬Œ´ Œ’ˆêC‰Í–ì —¹CŽRŒû ›ÜF ‹U³í‰»Œ^‘m–X•ÙŒŒ—¬‘¬“x”gŒ`‚ð’æ‚·‚éŠg’£Œ^S‹ØÇ‚É‚¨‚¯‚éŠg’£‘Šú¶Žº“àŒŒ—¬‚Ì“Á’¥ ‘¢‰eSƒGƒR[–@‚ð—p‚¢‚½ŒŸ“¢D ‘æ25‰ñƒRƒ“ƒgƒ‰ƒXƒgƒGƒR[Œ¤‹†‰ïi‘åãjC2ŒŽC2003
  8. “yŠò _‰îC–{ŠÔ ^lC‹v‰ê Œ\—SC“n•Ó dsCŽæ ‹v”üCŽRŒû ›ÜCK“c K’¼F •p–¬«•s®–¬Š³ŽÒ‚É‚¨‚¯‚錌’†ƒtƒŒƒJƒCƒjƒh‚¨‚æ‚Ñ‚»‚Ì‘ãŽÓ•¨‚Ì“¯Žž’è—ʁD ‘æ124‰ñ“ú–{–òŠw‰ïi‘åãjC3ŒŽC2003
  9. Takanashi M., Miyauchi T., Irukayama-Tomobe Y., Sakai S., Kasuya Y., Ogata T., Iemitsu M., Sudo T., Goto K., Yamaguchi I.F ET-1-induced cardiac hypertrophy is inhibited by activation of PPAR-ƒ¿ via blockade of Jun NH-terminal kinase pathway. ‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïi•Ÿ‰ªjC3ŒŽC2003 J Pharmacological Sciences 91 (Suppl.?)F104, 2003
  10. Miyauchi T., Yamauchi-Kohno R., Kobayashi T., Sakai S., Aihara H., Yabana H., Murata S., Goto K., Yamaguchi I.F Poor Survival of Cardiomyopathic Hamsuters with CHF Is Greatly Improvend by Combined Treatment with Endothelin(ET)-A Receptor Antagonist and ACE Inhibitor. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F94C2003
  11. Yamazaki A., Ohtsuka S., Oyake Y., Yamaguchi I.F Long-Term Treatment with Nitrates Aggravates Vascular Endothelial Function in Patients with Lschemic Heart Disease. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F167C2003
  12. Kakinuma Y., Miyauchi T., Yamaguchi I.F Anti-ER Stress Action of HIF-1 Alpha in Compensation of Impairment of Energy Matabolism Due to Cellular Stress. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F501C2003
  13. On K., Yamada S., Tsukada K., Miyashita T., Watanabe S., Kuga K., Yamaguchi I.F Reversible Myocardial Ishemia in Asymptomatic Phase Can Be Diagnosed by Magnetocardiograms. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F429C2003
  14. Iemitsu M., Miyauchi T., Maeda S., Tanabe T., Matsuda M., Yamaguchi I.F Exercise Training Improves the Aging-Induced Decrease in Molecular Regulatory System of Mitochondrial Respiratory Function in the Rat Heart. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F522C2003
  15. Ogata T., Miyauchi T., Sakai S., Yamaguchi I.F A PPAR- ƒ¿ Activator Inhibits Cardiac Fibrosis by Inhiditing of Fibroblast Proliferation and Collagenesis in Cultured Fibroblasts and DOCA-Salt Hypertensive Rats. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F516C2003
  16. Abe D., Homma S., Nakanishi K., Uno K., Kawano S., Watanabe S., Yamaguchi I.F Frequent Saturation Dips at Daytime Observed in SpO2 Night-Dippers. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F547C2003
  17. Iemitsu M., Miyauchi T., Maeda S., Yamaguchi I.F Acute Exercise Induces Activation of Mitogen-Activated Protein Kinase(MAPK) Pathway in the Heart of Rats. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F318C2003
  18. Kuga K., Yamaguchi I., Ohtsuka M.F Currents Status and Problems of Cardiovascular Health Administration in University. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F43C2003
  19. Yamada S., Tsukada K., Miyashita T., Kuga K., Yamaguchi I.F Initiation and Persistence of Atrial Flutter Visualized by Magnetocardiographic Animations. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F133C2003
  20. Iida K., Kawano S., Homma S., Nishi I., Masumi T., Misaki M., Yamaguchi I.F Heterogeneity of Expression of Messenger RNA in Failing Hearts. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F227C2003
  21. Oyake Y., Ohtsuka S., Yamazaki A., Yamaguchi I.F Increased Sympathetic Nerve Activity Relates to Vascular Endothelial Dysfunction in Patients with Essential Hypertension. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F229C2003
  22. Suzuki A., Watanabe Y., Takei Y., Tanaka K., Kawagoe K., Ejiri N., Kuga K., Watanabe S.CYamaguchi I., Yanagita Y.F Distributional Heterogeneity of Washout-Rate by MIBG Images May Be New Predictor for Serious Adverse Cardiac Events with Chronic Heart Failure. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F235C2003
  23. Seo Y., Ishimitsu T., Ishizu T., Obara K., Moriyama N., Maeda Y., Watanabe S., Yamaguchi I.F Relation between Mitral Annular Calcification and Severity of Carotid Arterosclerosis in Stroke Patients. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F223C2003
  24. Oyake Y., Ohtsuka S., Yamazaki A., Yamaguchi I.F Relation of Left Ventricular Diastolic Function to Vascular Endothelial Function in Patients with Essential Hypertension. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F575C2003
  25. Yamada S., Yakmaguchi I.F Efficacy, Safety, and Limitations of Amiodarone Therapy. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F71C2003
  26. Yamada S., Tsukada K., Miyashita T., On K., Kuga K., Yamaguchi I.F Magnetocardiograms Detect the Right Atrial Conduction Delay in Paroxysmal Atrial Fibrillation. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F250C2003
  27. Sakai S., Miyauchi T., Irukayama-Tomobe Y., Ogata T., Takanashi M., Iemitsu M., Goto K., Yamaguchi I.F Stimulation of Peroxisome Proliferator-Activated Receptor- ƒ¿ (PPAR- ƒ¿ ) Attenuates Endothelin-1-lnduced Cardiac Hypertrophy Partly via Inhibition of c-Jun NH2 Terminal Kinase(JNK) Pathway. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F145C2003
  28. Miyauchi T., Sakai S., Maeda S., Iemitsu M., Fujimori A., Shikama H., Takanashi M., Tanabe T., Matsuda M., Goto K., Yamaguchi I.F Decreases in Exercise Capacity, Myocardial Energy Metabolism, and Survival in Rats with CHF AreGreatly Improved by Endothelin-A Receptor Antagonist. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F156C2003
  29. Watanabe S., Ajisaka R., Ishii C., Morimoto T., Shintomi Y., Takeyasu N., Saitoh T., Toyama M., Sakamoto K., Eda K., Ishiyama M., Nishina H., Arai E., Yamaguchi I.F The Contributions of Muscle Vasodilation and Cardiac Function to the Exercise Performance in Patients with Left Ventricular Dysfunction. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F475C2003
  30. Seo Y., Ishimitu T., Ishizu T., Obara K., Moriyama N., Kawano S., Watanabe S., Yamaguchi I.F A Novel Echocardiographc Classificaton of Left Ventricular Diastolic Dysfunction in Patients with Preserved Systolic Function. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F482C2003
  31. Takanashi M., Miyauchi T., Yamaguchi I.F Establishiment of Hypoxia Inducible Factor(HIF)-1 ƒ¿ Overexpressing Cells; Useful Model for Analyzing the Mechanisms of Hypoxia-Induced Cellular Pathophysiology. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F376C2003
  32. Shintomi Y., Watanabe S., Ajisaka R., Ishii C., Morimoto T., Takeyasu N., Saitoh T., Toyama M., Sakamoto K., Eda K., Ishiyama M., Nishina H., Arai E., Yamaguchi I.F Stress-Induced Deep T Wave Inversion is a Marker of the Stenosis of Right Coronary(RCA) or Left Circumflex Coronary(LCX) Arteries. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F624C2003
  33. Maeda S., Miyauchi T., Iemitsu M., Tanabe T., Goto K., Yanaguchi I., Matsuda M.F An Endothelin-A/B Dual Receptor Antagonist Reverses the Exercise-Induced Redistribution of Tissue Blood Flow. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F627C2003
  34. Morimoto T., Watanabe S., Ajisaka R., Shintomi Y., Takeyasu N., Saitoh T., Toyama M.,Sakamoto K., Eda K., Ishiyama M., Nishina H., Arai E., Ishii C., Yamaguchi I.F Temporal Changes of Vascular Function and Exercise Tolerance in the Patients with Heart Disease. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F623C2003
  35. Meda S., Miyauchi T., Iemistu M., Tanabe T., Watabnabe M., Yamaguchi I.,Matsuda M.F Exercise Causes Upregulation of Renin-Angiotensisn System in Kidneys and Decreases Renal Blood Flow. ‘æ67‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi•Ÿ‰ªjC3ŒŽC2003 Circ J 67(Suppl.?)F634C2003
  36. –{ŠÔ ŠoC¼”ö ”āC‘Δn MŽqC—Ñ•x ‹M—YC–ìX–Ø GCŽRŒû ›ÜF “®–¬d‰»ŠëŒ¯ˆöŽq‚ð—L‚·‚銳ŽÒ‚ɑ΂·‚éRŒŒ¬”—Ö@‚ª’·Šú—\Œã‚É‹y‚Ú‚·‰e‹¿ \•ÂÇ«“®–¬d‰»Ç‚É‚¨‚¯‚錌ŠÇŒ`¬pŒã15”N‚ÌŒŸ“¢\D ‘æ100‰ñ“ú–{“à‰ÈŠw‰ï‘‰ï i•Ÿ‰ªjC4ŒŽC2003
  37. V•y ‹`ŒòC“n•Ó dsCX–{ —²ŽjCˆ±â —²ˆêC•ˆÀ –@”VCÄ“¡ ICŠOŽR ¹OCâ–{ ˜a•FC]“c ˆê•FCŽRŒû ›ÜF S“d}“¯ŠúS‹ØSPECT(gated SPECT) ‚É‚æ‚鍶ŽºŠg’£”\•]‰¿‚̑Ó–«‚Æ—L—p«D ‘æ100‰ñ“ú–{“à‰ÈŠw‰ï‘‰ï i•Ÿ‰ªjC4ŒŽC2003 “ú–{“à‰ÈŠw‰ïŽGŽ92(Suppl.?): 123C2003
  38. ‰F–ìŠó¢ŽqC–{ŠÔ ŠoCˆÀ”{ ‘å•ãC’†¼ Œ[‘¾CŠÛŽR G˜aCŽRŒû ›ÜF ŽlŽˆ‚Ì–¬”gŒv‘ª‚É‚æ‚é“®–¬d‰»«Ž¾Š³‚̐„‘ªD ˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï‘æ4‰ñ”­•\‰ï i‚‚­‚΁jC4ŒŽC2003
  39. ˆÀ”{ ‘å•ãC–{ŠÔ ŠoC’†¼ Œ[‘¾C‰F–ìŠó¢ŽqC‰Í–ì —¹C“n•Ó dsCŽRŒû ›ÜF zŠÂŠíŽ¾Š³‚É‚¨‚¢‚Ä’‹ŠÔ‚É‚àŠÏŽ@‚³‚ê‚é––½Ž_‘f–O˜a“x‚Ì”­ì“I’ቺ‚̈Ӌ`D ˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï‘æ4‰ñ”­•\‰ï i‚‚­‚΁jC4ŒŽC2003
  40. ‹g“cŒ’‘¾˜YC‹v‰ê Œ\—SC‰““¡ —DŽ}Cm•Û •¶•½C—é–Ø ÍOC‹à–{ “sC–ö“c —tŽqCŽRŒû ›ÜF ‰E‘O•Ç•›“`“±˜HƒAƒuƒŒ[ƒVƒ‡ƒ“5”NŒã‚ɁA¶Œã•Ç•›“`“±˜H“`“±‚𐶂¶‚½WPWÇŒóŒQ‚Ì1—áD ‘æ33‰ñ—Տ°S‘Ÿ“d‹C¶—Œ¤‹†‰ïi–¼ŒÃ‰®jC5ŒŽC2003
  41. ‹à–{ “sC‹v‰ê Œ\—SC‰““¡ —DŽ}Cm•Û •¶•½C—é–Ø ÍOC–ö“c —tŽqC‹g“cŒ’‘¾˜YCŽRŒû ›ÜF ‰EŽº—¬o˜H‹NŒ¹“Á”­«SŽº•p”‚É”F‚ß‚ç‚ê‚é—²‹N«\‘¢‚̈Ӌ`D ‘æ18‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïi‹ž“sjC5ŒŽC2003
  42. ‹v‰ê Œ\—SC‰““¡ —DŽ}Cm•Û •¶•½C—é–Ø ÍOC‹à–{ “sC–ö“c —tŽqC‹g“cŒ’‘¾˜YCŽRŒû ›ÜC–åŠÔ ³•FCÎì ‰‰”üF ŠjŽ¥‹C‹¤–‰摜‚̃Jƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“‚ɑ΂·‚鉞—p‚ÌŒŸ“¢D ‘æ18‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïi‹ž“sjC5ŒŽC2003
  43. “n•Ó dsC‹v‰ê Œ\—SCŽRŒû ›ÜF ICDAž‚ÝŠ³ŽÒ‚ÌŽ©“®ŽÔ‰^“]‚ÉŠÖ‚·‚é–@§ã‚̍l‚¦•ûD ‘æ18‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïi‹ž“sjC5ŒŽC2003
  44. —é–Ø ÍOC‹à–{ “sC‹g“cŒ’‘¾˜YC‰““¡ —DŽ}Cm•Û •¶•½C‹v‰ê Œ\—SCŽRŒû ›ÜC“n•Ó NŽuC•ˆä N•FC“c’†Šì”ü•vC]K ¬ºC‘O“c —TŽjF •ªŠE—ÅŽüˆÍ‚Ì“`“±—lŽ®‚ɂ‚¢‚Ä-•ªŠE—Å-‘åÃ–¬“´ŠÔ‚Å‚Ì“`“±’x‰„-D ‘æ18‰ñ“ú–{S‘Ÿƒy[ƒVƒ“ƒOE“d‹C¶—Šw‰ïi‹ž“sjC5ŒŽC2003
  45. X–{ —²ŽjC–{ŠÔ ŠoC‰F–ìŠó¢ŽqC’†¼ Œ[‘¾CˆÀ”{ ‘å•ãC“n•Ó dsCŽRŒû ›ÜF –«”xŒŒðÇðÇ‚ɑ΂µ‚ăNƒGƒ“Ž_ƒVƒ‹ƒfƒiƒtƒBƒ‹‚ðŠJŽn‚µ‚½1—áD ‘æ4‰ñ”x‚ŒŒˆ³Ž¡—ÃŒ¤‹†‰ïi“Œ‹žjC5ŒŽC2003
  46. ”üè ¹ŽqC‰Í–ì —¹CX–{ —²ŽjC‹{•› —ÁŽqC’†¼ Œ[‘¾C¬Œ´ Œ’ˆêC“n•Ó dsCŽRŒû ›ÜF ƒXƒeƒƒCƒhprednisolone“Š—^‚ª’˜Œø‚ðŽ¦‚µ‚½–«S•s‘S‚̈ê—áD ‘æ188‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC6ŒŽC2003 Circ J 67(Suppl. III): 924C2003
  47. “n•Ó dsCVˆä Œb”üC•ˆÀ –@”VC‘ŠŒ´ ‰p–¾Cˆ±â —²ˆêCX–{ —²ŽjCV•y ‹`ŒòCm‰ÈG’CŽRŒû ›ÜF ‰^“®‚¨‚æ‚щ^“®‘Ï—e”\‚ÆMIBGŠŒ©D ‘æ23‰ñS‘ŸŠjˆãŠw’k˜b‰ïi“Œ‹žjC6ŒŽC2003
  48. ’†¼ Œ[‘¾C“n•Ó dsC¬Œ´ Œ’ˆêCX–{ —²ŽjC‰Í–ì —¹C–{ŠÔ ŠoCŽ²‰® ’qºCåŒ´ ŒªCŽRŒû ›ÜF Stunned myocardium ‚©‚ç‚̉ñ•œ‚É’·ŽžŠÔ‚ð—v‚µ‚½1—áD ˆïéPTCAŒ¤‹†‰ïi“y‰YjC6ŒŽC2003
  49. ŽRŒû ›ÜF ŠO‰ÈŽèp‚ɖ𗧂zŠÂŠíŽ¾Š³‚̐f’f‚ÆŽ¡—ÁD ‘æ203‰ñˆïéŠO‰ÈŠw‰ïi‚‚­‚΁jC7ŒŽC2003
  50. ˆ±â —²ˆêC¼“c Œõ¶C“n•Ó dsCX–{ —²ŽjCV•y ‹`ŒòC•ˆÀ –@”VCŽRŒû ›ÜF ˆÀ’肵‚½‚—“®–¬Ž¾Š³Š³ŽÒ‚É‚¨‚¯‚鉺ŽˆƒŒƒWƒXƒ^ƒ“ƒX‰^“®‚̈À‘S«D ‘æ9‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïi“Œ‹žjC7ŒŽC2003 ‘æ9‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï´˜^W:63C2003
  51. “n•Ó dsC•ˆÀ –@”VCm‰È G’CVˆä Œb”üC‘ŠŒ´ ‰p–¾CÎŽR ŽÀŽ÷C]“c ˆê•FCâ–{ ˜a•FCŠOŽR ¹OCÄ“¡ ICŽR“à F‹`CŽRŒû ›ÜCˆ±â —²ˆêCˆî—t •CÎˆä’qŽqF ƒVƒ“ƒ|ƒWƒEƒ€u‰^“®‚ÆŒŒŠÇ‹@”\A––½zŠÂvSŽ¾Š³Š³ŽÒ‚É‚¨‚¯‚é“à”çˆË‘¶«‚¨‚æ‚Ñ“à”ç”ñˆË‘¶«ŒŒŠÇŠg’£”\‚Ɖ^“®‘Ï—e”\vD ‘æ53‰ñzŠÂŠí•‰‰×Œ¤‹†‰ïi“Œ‹žjC8ŒŽC2003 ‘æ53‰ñzŠÂŠí•‰‰×Œ¤‹†‰ï´˜^W: 21C2003
  52. ¬Œ` ŠxŠ°C‹{“à ‘ìC‰ºžŠ MˆÐC‚—œ ³ŸC‘àV _ˆêCŽRŒû ›ÜF DOCA-salt ‚ŒŒˆ³«ƒ‰ƒbƒgS‘Ÿ‚ł́APPARƒ¿ŽhŒƒ–ò‚É‚æ‚éS‹Ø‘@ˆÛ‰»—}§Œø‰Ê‚ÆŠg’£‹@”\‘ˆ«—}§Œø‰Ê\R‰ŠÇì—p‚©‚ç‚ÌŒŸ“¢\D Cardiovascular Medicine 21 ‘æ3‰ñƒtƒH[ƒ‰ƒ€i“Œ‹žj8ŒŽC2003 Cardiovascular Medicine 21 ‘æ3‰ñƒtƒH[ƒ‰ƒ€´˜^WF12-13C2003
  53. ‘º‰z LsC‹{“à ‘ìC–ö‘ò ³ŽjCŽRŒû ›ÜF “®–¬d‰»Ž¾Š³‚É‚¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“‚Ì–ðŠ„D ‘æ6‰ñÅæ’[zŠÂŠíƒtƒH[ƒ‰ƒ€i¬’Mj8ŒŽC2003
  54. •ˆÀ –@”VC“n•Ó dsC‹g“cŒ’‘¾˜YC’†¼ Œ[‘¾C”üè ¹ŽqC‰Í–ì —¹C–{ŠÔ ŠoCŽRŒû ›ÜF Ž¡—Ð헪‚É‹ê—¶‚µ‚½¶‘O‰ºsŽ}‹ßˆÊ•”Š®‘S•ÂÇ‚Ì1—áD ’í23‰ñ’}”gƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ƒVƒlƒJƒ“ƒtƒ@ƒŒƒ“ƒXi‚‚­‚΁jC8ŒŽC2003
  55. ‹v‰ê Œ\—SC‰““¡ —DŽ}Cm•Û •¶•½C—é–Ø ÍOC‹à–{ “sC‹g“cŒ’‘¾˜YCŽRŒû ›ÜC–åŠÔ ³•FCÎì ‰‰”üF ”ñŽ¥«ƒAƒuƒŒ[ƒVƒ‡ƒ“EƒJƒe[ƒeƒ‹‚ð—p‚¢‚½open MRI‰º‚É‚¨‚¯‚鍂Žü”gƒAƒuƒŒ[ƒVƒ‡ƒ“‚ÌŽÀŒ±D ‘æ20‰ñ“ú–{S“dŠw‰ïi“Œ‹žjC9ŒŽC2003
  56. ŽR“c‚³‚‚«CŽRŒû ›ÜF SŽ¥}‚ð—p‚¢‚½g’N‚É‚Å‚à‚í‚©‚é•s®–¬‚Ì‹NŒ¹E‹@˜f’fhD ‘æ51‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žjC9ŒŽC2003 ‘æ51‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï´˜^W J Cardiology :146C2003
  57. ‰““¡ —DŽ}C‹v‰ê Œ\—SCm•Û •¶•½C—é–Ø ÍOC‹à–{ “sC‹g“cŒ’‘¾˜YCŽRŒû ›ÜF ‹}«S‹Ø[Ç”­ÇŒã‚Ɂ¢”g‚ªÁŽ¸‚µ‚½WPWÇŒóŒQ‚Ì2Ç—áD ‘æ51‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi“Œ‹žjC9ŒŽC2003 ‘æ51‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï´˜^W J Cardiology :460C2003
  58. ¬Œ´ Œ’ˆêCŠOŽR ¹OC“n•Ó dsCŽRŒû ›ÜF ˆÙŒ^‹·SÇ‚Ì”­ì‚ɍDŽ_‹…‘‘½Ç‚ÌŠÖ—^‚ð”F‚߁AƒvƒŒƒhƒjƒ]ƒƒ“‚ª’˜Œø‚ðŽ¦‚µ‚½ˆê—áD ‘æ189‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC9ŒŽC2003
  59. ì‘º —´CÎì ŒölC•¶‘  —DŽqC–ìŒû —SˆêCˆî—¯ ª“TC•ˆÀ –@”VC“n•Ó dsCŽRŒû ›ÜF ‰ESŒn‚̏áŠQ‚ðŽå‘Ì‚Æ‚µ”ñ“ÁˆÙ“I‚ȏǏó‚Å”­ÇŒo‰ß‚µ‚½–«S‹Ø‰Š‚̈ê–UŒŸ—áD ‘æ189‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC9ŒŽC2003
  60. ¯ ’q–çC“n•Ó NŽuC—é–Ø ÍOC•ˆä ‘וFC“c’†Šì”ü•vC‰Í–ì —¹C“n•Ó dsCŽRŒû ›ÜF ”S‰tŽî‚ÆŒŒð‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚½¶–[“àŽîᎂ̈ê—áD ‘æ189‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC9ŒŽC2003
  61. —é–Ø ËŽiC”Ñ“c Œ[Ž¡C¬ŠÖ iŽqC‘º‰z LsCm•Û •¶•½C‰|–{ ‹­ŽuC¬ŠÖ 猁C“n•Ó dsCŽRŒû ›ÜF ‹•ŒŒ«SŽ¾Š³‚ð‡•¹‚µ‘½Ê‚È•s®–¬‚ð’悵‚½SƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—áD ‘æ189‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ïi“Œ‹žjC9ŒŽC2003
  62. ”üè ¹ŽqC‰Í–ì —¹C‘Œ© ’qŽqC¯ ’q–çC“n•Ó dsCŽRŒû ›ÜF ¶Žº‹@”\•s‘S‚ɑ΂·‚éƒAƒ~ƒIƒ_ƒƒ“Ž¡—Â̌ø‰Ê—\‘ªˆöŽq‚ɂ‚¢‚Ä‚ÌŒã‚ëŒü‚«ŒŸ“¢D ‘æ8‰ñƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ïi“Œ‹žjC9ŒŽC2003 ‘æ8‰ñƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ï´˜^Wp. 13
  63. –{ŠÔ ^lC‹v‰ê Œ\—SCŽæ ‹v”üC“yŠò _‰îC‘–ì ˆê•yC“n•Ó dsCŽRŒû ›ÜCK“c K’¼F ƒtƒŒƒJƒCƒjƒh‚ÌŒŒ’†”Z“x‚É‹y‚Ú‚·CYP2D6ˆâ“`Žq‘½Œ^‚̉e‹¿D ‘æ18‰ñ“ú–{–ò•¨“®‘ÔŠw‰ïiŽD–yjC10ŒŽC2003
  64. ’†¼ Œ[‘¾C“n•Ó dsC¬Œ´ Œ’ˆêCX–{ —²ŽjC‰Í–ì —¹C–{ŠÔ ŠoCŽ²‰® ’qºCåŒ´ ŒªCŽRŒû ›ÜF Stunned myocardium ‚©‚ç‚̉ñ•œ‚É’·ŽžŠÔ‚ð—v‚µ‚½Ç—áD ‘æ7‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi‘åâjC10ŒŽC2003 ‘æ7‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï Abstracts:78C2003
  65. –x•Ä mŽuCåŒ´ ŒªCd“c Ž¡C‹v‰ê Œ\—SCŽRŒû ›ÜCˆé•” „ŽuCŽR‰º ³•vC‚‹´ ŽÀ•äC¼ˆä —zF –ƒŒ“±“ü‚ŐSŽº×“®‚ð‚«‚½‚µAŒã•ûŽ‹“I‚ÉBrugadaÇŒóŒQ—lS“d}‚ð’悵‚Ä‚¢‚½‘å“®–¬kóÇD ‘æ7‰ñ“ú–{¬Ž™S“dŠwŒ¤‹†‰ïi_ŒËjC11ŒŽC2003
  66. ‰F–ìŠó¢ŽqC–{ŠÔ ŠoCˆÀ”{ ‘å•ãC’†¼ Œ[‘¾C”Ñ“c Œ[Ž¡CŽRŒû ›ÜF ŽlŽˆ‚Ì–¬”gŒv‘ª‚É‚æ‚é“®–¬d‰»«Ž¾Š³‚̐„‘ªD ‘æ44‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi•Ÿ‰ªjC11ŒŽC2003
  67. X–{ —²ŽjC“n•Ó dsC¯ ’q–çCŠ`À —R•FC¬Œ´ Œ’ˆêC’†¼ Œ[‘¾CŽRŒû ›ÜF ‹•ŒŒ«SŽ¾Š³‚ª‹^‚í‚êNifedipin ‚ª’˜Œø‚ðŽ¦‚µ‚½‘Sg«d‰»Ç‚̈ê—áD ˆïézŠÂŠíŒ¤‹†‰ïiˆïéjC11ŒŽC2003 ˆïézŠÂŠíŒ¤‹†‰ïŽGŽ 10F21-24C2003
  68. ‹g“cŒ’‘¾˜YC‹v‰ê Œ\—SC‰““¡ —DŽ}Cm•Û •¶•½C—é–Ø ÍOC‹à–{ “sCŽRŒû ›ÜF CARTO system‚Ìcycle lengthŠî€‚É‚æ‚émapping‚ªƒAƒuƒŒ[ƒVƒ‡ƒ“‚É—L—p‚Å‚ ‚Á‚½¶‘¤•Ç‹NŒ¹‚̐SŽºŠúŠOŽûk‚Ì1—áD ‘æ15‰ñƒJƒe[ƒeƒ‹EƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ¤‹†‰ïi“Œ‹žjC11ŒŽC2003
  69. âV“¡ ‹MŽuA–x•Ä mŽuAŠâè M–¾A‰––ì “ÖŽqA‚‹´ ŽÀ•äA‹{“à ‘ìA¼ˆä —zF Damon•a‰ÆŒn‚ÌŒoŽž“IS“d}•Ï‰»D ‘æ8‰ñ “ú–{¬Ž™S“dŠwŒ¤‹†‰ïi“Œ‹žj11ŒŽC2003 ‘æ8‰ñ“ú–{¬Ž™S“dŠwŒ¤‹†‰ï´˜^C2003
  70. ˆÀ”{ ‘å•ãC–{ŠÔ ŠoCX–{ —²ŽjC‰F–ìŠó¢ŽqC’†¼ Œ[‘¾CˆÀ“¡ ‘¾ŽOC“n•Ó dsCŽRŒû ›ÜF AT IIIŒ‡–RÇ‚𔺂¤–«”xŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂µ”x“®–¬ŒŒð“à–Œ“Eœp‚ªŽ{s‚³‚ꂽÇ—áD ˆïéŒŒŠÇŽ¾Š³Œ¤‹†‰ï‘æ5‰ñ”­•\‰ïi‚‚­‚΁jC11ŒŽC2003
  71. ’†¼ Œ[‘¾C–{ŠÔ ŠoC”üè ¹ŽqC‹g“cŒ’‘¾˜YC•ˆÀ –@”VC‰Í–ì —¹C“n•Ó dsCŽRŒû ›ÜF ¶S‹@”\áŠQ‚ð‡•¹‚µ‚½‚ˆÀ“®–¬‰Š‚̏ǗáD “ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘æ190‰ñŠwpW‰ïi“Œ‹žjC12ŒŽC2003
  72. ‘å’Ë ’è“¿CŽRŒû ›ÜCŒà ™¤C•“c “OC”Âˆä —I“ñCŠÛ‹´ WC•º“¡ ˆêsCˆÀ“¡ ³ŠCF •úŽËŒõŒŒŠÇ‘¢‰eD ‰»Šw•úŽËüŽ¡—ÉȊwŒ¤‹†‰ïi“Œ‹žjC12ŒŽC2003

@@@¡ Œ¤‹†•ñ

  1. ŽRŒû ›ÜC‹{“à ‘ìCŽðˆä rC“üŽ­ŽR—eŽqC¬Œ` ŠxŠ°C‚—œ ³ŸC‰Í–ì —¹C”Ñ“c Œ[Ž¡CŒã“¡ Ÿ”NF S‘Ÿ‚É‚¨‚¯‚éƒGƒ“ƒhƒZƒŠƒ“ˆâ“`Žq‚Ì”­Œ»’²ß‚ÌŒ¤‹†D Œú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹ài“Á’莾Š³‘΍ôŒ¤‹†Ž–‹Æj•ª’SŒ¤‹†•ñ‘Cpp.74-77C2003
  2. ŽRŒû ›ÜC¼ Œ÷C‰Í–ì —¹C”üè ¹ŽqC‘Œ© ’qŽqC”Ñ“c Œ[Ž¡C“n•Ó dsF ‚ŒŒˆ³«S•s‘S‚É‚¨‚¯‚éACE‘jŠQ–ò‚ƍRƒAƒ‹ƒhƒXƒeƒƒ“–ò‚Ì•¹—pŒø‰Ê‚ÌŒŸ“¢D Œú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹ài“Á’莾Š³‘΍ôŒ¤‹†Ž–‹Æj•ª’SŒ¤‹†•ñ‘Cpp.78-82C2003
  3. ‹v‰ê Œ\—SF Šw¶’èŠúŒ’Nf’fFS“d}‚ÌŒ‹‰ÊD •½¬14”N“x•ÛŒ’ŠÇ—ƒZƒ“ƒ^[‹Æ–±•ñ‘Cpp.22C2003
  4. ‹v‰ê Œ\—SF “à‰È‚ÌŠˆ“®D •½¬14”N“x’}”g‘åŠwƒXƒ|[ƒcƒNƒŠƒjƒbƒN‹Æ–±EŒ¤‹†•ñCpp.12C2003
  5. ‹{“à ‘ìF ƒGƒ“ƒhƒZƒŠƒ“Œn‚ðƒ^[ƒQƒbƒg‚É‚µ‚½AS‹Ø•s‘S‚ɑ΂·‚éS‹Ø•ÛŒì—Ö@‚̗Տ°‰ž—p‚ÉŠÖ‚·‚錤‹†D •½¬14”N“xŒú¶˜J“­ÈzŠÂŠí•aŒ¤‹†ˆÏ‘õ”ï‚É‚æ‚錤‹†•ñWCpp.5C2003

@@@¡ ‚»‚Ì‘¼

  1. “n•Ó dsF uzŠÂŠí“à‰ÈEŠO‰È—̈æ‚̘b‘è‚Æ“W–]v‹ßÔŠOü•ªŒõ–@‚É‚æ‚鐶‘Ì‘gDŽ_‘f‘ãŽÓE¶‰»Šw‘g¬‚Ìin vivo ‘ª’è–@‚ÌŠJ”­D ‘æ6‰ñ ‚‚­‚Έã—ÃŽY‹Æ§’k‰ïi‚‚­‚΁jC1ŒŽ15“úC2003
  2. ‹{“à ‘ìF ŠO—ˆf—Âɂ¨‚¯‚éƒGƒrƒfƒ“ƒX‚ÉŠî‚¢‚½Ž¡—ÁE–òÜ‚Ì‘I‘ð-S•s‘S-D ‰ºŠÙˆãŽt‰ïzŠÂŠíuK‰ïi‰ºŠÙjC1ŒŽ15“úC2003
  3. ¯ ’q–çC‰Í–ì —¹F Key worduAEDvD ¬l•ai¶ŠˆKŠµ•ajƒjƒ…[ƒXƒŒƒ^[ l2(2):5C2ŒŽC2003
  4. ‘å’Ë ’è“¿F ‚ŒŒˆ³Ž¡—ÂƑŸŠí•ÛŒìD ^•ÇŒSŽsˆãŽt‰ïŠwpu‰‰‰ïi‰ºŠÙjC2ŒŽ17“úC2003
  5. ŽRŒû ›ÜF Plenary Session ?uHRT and cardiovascular Disease-Recent Clinical Trial Results and Their Implications for Clinical PracticevD AHA Highlights 2002:61-64C2ŒŽC2003
  6. “n•Ó dsF ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“ ALLHATŽŽŒ±‚ð‚Ç‚¤“ú–{‚̗Տ°‚ɐ¶‚©‚·‚©H ALLHATŠwpu‰‰‰ïi…ŒËjC3ŒŽ13“úC2003
  7. ‘å’Ë ’è“¿F uDiscussion on Hypertension Therapy in NORTH KANTO\ŽjãÅ‘å‹K–͂̃Gƒrƒfƒ“ƒXALLHAT‚ÌŒ‹‰Ê‚æ‚èvD À’k‰ïi‰F“s‹{jC4ŒŽ18“úC2003
  8. ŽRŒû ›ÜF R•s®–¬—Ö@‚ÌŒ»ó‚Æ“W–]D H“c‘åŠw‘æ2“à‰ÈuÀ‘n—§30Žü”N‹L”Ou‰‰iH“cjC4ŒŽ27“úC2003
  9. ‘å’Ë ’è“¿F ‘å‹K–͗Տ°ŽŽŒ±‚©‚ç‚Ý‚½ƒJƒ‹ƒVƒEƒ€hR–ò‚ÌŒø‰ÊD •½¬15”N“x‘æ1‰ñˆïéŒ§ˆãŽt‰ïŽY‹ÆˆãŒ¤C‰ïŠwpu‰‰‰ïi‚‚­‚΁jC5ŒŽ17“úC2003
  10. ‰Í–ì —¹F S•s‘S‚̍l‚¦•ûD äݗL»–òu‰‰‰ïi‚‚­‚΁jC5ŒŽ29“úC2003
  11. ‹v‰ê Œ\—SF •s®–¬‚É‚æ‚é“Ë‘RŽ€‚̐f’f‚ÆŽ¡—ÁD ‰ºŠÙˆãŽt‰ïzŠÂŠíuK‰ïi‰ºŠÙjC 6ŒŽ11“úC2003
  12. ‘å’Ë ’è“¿F ƒJƒ‹ƒVƒEƒ€hR–ò‚ÉŠÖ‚·‚é‘å‹K–͗Տ°ŽŽŒ±‚ɂ‚¢‚āD ‚«‚ʁEŽç’J•a‰@–òÜŽt‰ïŠwpu‰‰‰ïiŽç’JjC6ŒŽ19“úC2003
  13. ŽRŒû ›ÜF ƒAƒ~ƒIƒ_ƒƒ“‚Ì10”N‚Ì‹OÕD ‘æ3‰ñ–kŠC“¹ƒAƒ~ƒIƒ_ƒƒ“Ž¡—ͧ˜b‰ïi–kŠC“¹jC6ŒŽ28“úC2003
  14. ŽRŒû ›ÜF ŠO‰ÈŽèp‚ɖ𗧂zŠÂŠíŽ¾Š³‚̐f’f‚ÆŽ¡—ÁD ‘æ203‰ñˆïéŠO‰ÈŠw‰ïi‚‚­‚΁jC7ŒŽ5“úC2003
  15. •ˆÀ –@”VF ‹•ŒŒ«SŽ¾Š³‚Ì•a‘Ô‚ÆŽ¡—ÁD ‰ºŠÙˆãŽt‰ïzŠÂŠíuK‰ïi‰ºŠÙjC7ŒŽ9“úC2003
  16. ‰Í–ì —¹F ƒAƒ~ƒIƒ_ƒƒ“’·Šú“Š—^‚ª–«S•s‘SŠ³ŽÒ‚Ì—\ŒãES‹@”\‚É—^‚¦‚é‰e‹¿D The 3rd Symposium of Meet the Professor in Cardiovascular Diseasei“Œ‹žjC7ŒŽ19“úC2003
  17. “n•Ó dsF ŒŒŠÇ‹@”\‚Ɖ^“®‘Ï—e”\‚Æ‚ÌŠÖ˜AA‚¨‚æ‚Ñ‚»‚ê‚ç‚ɑ΂·‚é–òÜŒø‰Ê‚ɂ‚¢‚āD ‚ŒŒˆ³Ž¡—ÂƑŸŠí•ÛŒìŒ¤‹†‰ï ˆïéNOƒtƒH[ƒ‰ƒ€2003i‚‚­‚΁jC7ŒŽ19“úC2003
  18. ‰Í–ì —¹F “úíf—Âɖ𗧂S•s‘S‚Ì’mŽ¯D ˆïéŒ§^•ÇˆãŽt‰ïu‰‰‰ïi^•ÇjC8ŒŽ7“úC2003
  19. ŽRŒû ›ÜF Å‹ß‚Ì•s®–¬Ž¡—Â̓®ŒüD ‘æ217‰ñŒ§“ìSŽ¾Š³§˜b‰ïiH“cjC8ŒŽ29“úC2003
  20. “n•Ó dsF “®–¬d‰»‚ð–h‚®D NPO–@lŽs–¯‚Ì‚½‚ß‚ÌŒ’NEˆã—Ãlƒbƒgƒ[ƒNuŒ’N”üH‚ðŠy‚µ‚ނ‚ǂ¢vi‚‚­‚΁jC8ŒŽ31“úC2003
  21. •ˆÀ –@”VF ‹•ŒŒ«SŽ¾Š³‚̐f’f‚ÆŽ¡—ÁD ŒÃ‰ÍŽsˆãŽt‰ïŠwpu‰‰‰ïiŒÃ‰ÍjC9ŒŽ19“úC2003
  22. •ˆÀ –@”VF ‹~‹}ˆã—ÂƊjˆãŠwD ’í30‰ñˆïéŠjˆãŠwŒ¤‹†‰ïi“y‰YjC9ŒŽ27“úC2003
  23. ÎŒõ •qsF —Տ°Œ»ê‚ł̐S‹@”\•]‰¿ ¶ŽºEF‚¾‚¯‚ÅŽûk‹@”\‚Í‚í‚©‚é‚Ì‚©H “ú–{SƒGƒR[}Šw‰ï‘æ1‰ñHŠúu‰‰‰ïi“Œ‹žjC10ŒŽ11“úC2003
  24. ŽRŒû ›ÜF S•s‘S‚Æ•s®–¬‚ÌŠÖ˜AD ‘æ30‰ñé¼’n‹æzŠÂŠí•aŒ¤‹†‰ïi“Œ‹žjC10ŒŽ16“úC2003
  25. ŽR“c M”ŽA“n•Ó dsA¼“‡ ‹P•FA“cŒû CˆêA’x–ì ˆäŒ’F ŠëŒ¯ˆöŽq‚ɑΉž‚µ‚½Ï‹É“I‚ÈŽ‰Ž¿’ቺ—Ö@‚̈Ӌ` “ú–{“®–¬d‰»Šw‰ïƒKƒCƒhƒ‰ƒCƒ“‰ü’ù‚𓥂܂¦‚āD Nikkei Medical 10(ˆïé”Å)F1-8C10ŒŽC2003
  26. “n•Ó dsF ‚ŒŒˆ³‚Æ’°“à×‹ÛD ƒVƒŠ[ƒY Ž¾•a‚Æ’°“à×‹ÛC10ŒŽC2003
  27. ŽRŒû ›ÜF S•s‘S‚Æ•s®–¬‚ÌŠÖ˜AD “ú—§“à‰Èˆã‰ïŠwpu‰‰‰ïi“ú—§jC11ŒŽ18“úC2003
  28. ‰Í–ì —¹F SŽ¾Š³‚ðƒ^[ƒQƒbƒg‚É‚µ‚½‚ŒŒˆ³Ž¡—ÁD ‘æ9‰ñˆïéŒ§‚ŒŒˆ³ƒZƒ~ƒi[i‚‚­‚΁jC11ŒŽ27“úC2003
  29. “n•Ó dsF “®–¬d‰»‚ð–h‚¬AS‹Ø[Ç‚ð—\–h‚·‚邽‚߂ɁD ‚±‚Ý‚ã‚É‚Ä‚¡iNPO–@lŽs–¯‚Ì‚½‚ß‚ÌŒ’NEˆã—Ãlƒbƒgƒ[ƒNj1(2)F4C12ŒŽC2003

Copyright(C) Tsukuba University Hospital,All Rights Reserved